ELSEVIER

European Journal of Pharmacology

ejp

Master keyword index to volumes 317–339 (1997)

A23187
Auranofin; Prostaglandin E_2; 12-*O*-Tetradecanoylphorbol 13-acetate; Thapsigargin; Cyclooxygenase 2; Cyclooxygenase 1; Macrophage (Yamashita, M. (325) 221)

Endothelium; Nitric oxide (NO); Coronary small artery; Acetylcholine; Apamin; K^+ channel (Simonsen, U. (329) 153)

A-86929
Dopamine D_1 receptor; ABT-431; Hyperactivity; Seizure; Tolerance (Shiosaki, K. (317) 183)

AA-2414
Thromboxane; Smooth muscle, vascular; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; SQ 29,548; Daltroban; BM-13505; SQ 30,741 (Zhang, R. (317) 91)

Abdominal afferent vagus nerve activity
N-3389; 5-HT_3 receptor antagonist; 5-HT_4 receptor antagonist; Antiemetic effect; (Ferret) (Minami, M. (321) 333)

Abruquinone A
Neutrophil; Inositol phosphate; Phospholipase C; Ca^{2+} concentration, intracellular (Wang, J.-P. (319) 131)

Absence epilepsy
$GABA_B$ receptor antagonism; Cognition; GAERS (genetic absence epilepsy rat of Strasbourg) (Getova, D. (320) 9)

Absence seizure
$GABA_B$ receptor; GHB (γ-hydroxybutyric acid); G-protein-coupled receptor; GTP shift (Mathivet, P. (321) 67)

ABT 418
Epibatidine; Epiboxidine; Nicotinic receptor; Analgesia (Badio, B. (321) 189)

ABT-431
Dopamine D_1 receptor; A-86929; Hyperactivity; Seizure; Tolerance (Shiosaki, K. (317) 183)

ABT-491
PAF (platelet-activating factor); PAF receptor antagonist; Ca^{2+} flux; Superoxide anion; Vascular permeability; Degranulation; Endotoxemia (Albert, D.H. (325) 69)

Acamprosate
Ethanol withdrawal; Pentylenetetrazole; Hippocampus; Cerebellum; c-*fos* mRNA; Northern and dot blotting; In situ hybridization (Putzke, J. (317) 39)

ACEA 1021
Glycine; Psychotomimetic; Amnesia; Side effects; Glutamate (Kretschmer, B.D. (331) 109)

Aceclofenac
Cyclooxygenase; Prostaglandin E_2; Polymorphonuclear leukocyte; Monocyte; Synovial cell (Yamazaki, R. (329) 181)

Acetate
Anesthetic potency; Ethanol; Adenosine (Campisi, P. (325) 165)

Acetic acid test
Opioid analgesia; Amphibian; Intracerebroventricular (i.c.v.) administration; (*Rana pipiens*) (Stevens, C.W. (331) 15)

Acetylcholine
5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Galanin; Hypothermia; Muscarinic receptor (Patel, S. (317) 197)

Dopamine; Dopamine D_1 receptor; Dopamine D_2 receptor; Microdialysis; Neostigmine; Striatum (DeBoer, P. (317) 257)

$GABA_A$ receptor; Blood pressure; (Rat) (Tellioğlu, T. (317) 301)

D-Cycloserine; Glycine site; NMDA receptor; Hippocampus; Working memory (Ohno, M. (318) 267)

Coronary microvessel; Nitroglycerin; Heart failure; L-Arginine; Nitric oxide (NO) (Larosa, G. (318) 387)

Acetylcholinesterase activity; Adrenal homogenate; Nicotine-induced inward current; Physostigmine; Patch clamp (Sugawara, T. (319) 123)

Alzheimer's disease; Basal forebrain lesion; Cholinesterase inhibitor; Scopolamine; (Rat) (Itoh, A. (322) 11)

Tacrine; Cognex; Vacuous chew; Purposeless; Tremor; Parkinson's disease; Alzheimer's disease (Cousins, M.S. (322) 137)

Cannabinoid receptor; CP 55,940; SR 141716A; Brain slice (Gifford, A.N. (324) 187)

NGF (nerve growth factor); Locomotion; Nicotinic receptor; Dopamine receptor antagonist (Kobayashi, S. (326) 1)

Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Hippocampus; Cannabinoid (Gessa, G.L. (327) R1)

Endothelium; Nitric oxide (NO); Coronary small artery; A23187; Apamin; K^+ channel (Simonsen, U. (329) 153)

Clotrimazole; Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Nitric oxide (NO); Nitro-L-arginine (Fujimoto, S. (330) 177)

UMI

SHOULD READ INDEX (1996-1997)

european journal of pharmacology

an international journal

Master Author and Keyword Indexes, Volumes 317–339, 1997

EUROPEAN JOURNAL OF PHARMACOLOGY

INDEXES 1997

european journal of pharmacology

Author and Keyword Indexes, 1997
Volumes 317–339

ELSEVIER

AMSTERDAM — LAUSANNE — NEW YORK — OXFORD - SHANNON - TOKYO

Copyright © 1998 Elsevier Science B.V. All rights reserved.

ISSN 0014-2999/98/$19.00

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science B.V., and the following terms and conditions apply to their use:

Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

In the USA, users may clear permissions and make payment through the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; Tel. (508) 7508-400; Fax (508) 7504 744. In the UK, users may clear permissions and make payment through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP. In other countries where a local copyright clearance centre exists, please contact it for information on required permissions and payments.

Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution.

Permission of the publisher is required for all other derivative works, including compilations and translations.

Electronic Storage
Permission of the publisher is required to store electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Notice
No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

This journal is in the ADONIS Service, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to ADONIS B.V., P.O. Box 17005, 1001 JA Amsterdam, The Netherlands.

Publication information
European Journal of Pharmacology (ISSN 0014-2999). As of 1996 the journal is no longer divided into sections. For 1998, volumes 340–362 are scheduled for publication. Volume 340 appeared in 1997 but remain the first volumes of the 1998 subscription year.
Subscription prices are available upon request from the publisher. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where air delivery via SAL mail is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request.
Claims for missing issues must be made within six months of our publication (mailing) date.
For orders, claims, product enquiries (no manuscript enquiries) please contact the Customer Support Department at the Regional Sales Office nearest to you:
New York, Elsevier Science, P.O. Box 945, New York, NY 10159-0945, USA. Tel.: (1-212) 633-3730 (Toll Free number for North American Customers:1-888-4ES-INFO (437-4636)), Fax: (1-212) 633-3680; e-mail: usinfo-f@elsevier.com
Amsterdam, Elsevier Science, P.O. Box 211, 1000 AE Amsterdam, The Netherlands. Tel.: (1-212) 485-3757; Fax: (1-212) 485-3432; e-mail: nlinfo-f@elsevier.nl
Tokyo, Elsevier Science, 9-15, Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan. Tel.: (81-3) 5561-5033; Fax: (81-3) 5561-5047; e-mail: kyf04035@niftyserve.or.jp
Singapore, Elsevier Science, No. 1 Temasek Avenue, #17-01 Millenia Tower, Singapore 039192. Tel.: (+65) 434-3727; Fax: (+65) 337-2230; e-mail: asiainfo@elsevier.com.sg
All questions arising after acceptance of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publisher, Elsevier Science B.V., Log-in Department, P.O. Box 2759, 1000 CT Amsterdam, The Netherlands (Fax: (31-20) 485-3239). Address for courier service: Molenwerf 1, 1014 AG Amsterdam, The Netherlands.
In the U.S.A. and Canada: For further information on this and other Elsevier journals please contact: Elsevier Science Inc., Journal Information Center, 655 Avenue of the Americas, New York, NY 10010, U.S.A. (Tel.: 212-633-3750; Fax: 212-633-3764; Telex: 420.643 AEP UI).

Advertising information
Advertising orders and enquiries may be sent to:
International: Elsevier Science, Advertising Department, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK; Tel. (44-1865) 843-565; Fax (44-1865) 843-976.
USA & Canada: Weston Media Associates, Daniel Lipner, P.O. Box 1110, Greens Farms, CT 06436-1110, USA; Tel. (1-203) 261-2500; Fax: (1-203) 261- 0101.
Japan: Elsevier Science Japan, Marketing Services, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106, Japan; Tel. (81-3) 5561-5033; Fax (81-3) 5561-5047.

US mailing info – European Journal of Pharmacology (ISSN 0014-2999) is published weekly by Elsevier Science NL (P.O. Box 211, 1000 AE Amsterdam, The Netherlands). Annual subscription rate in the USA US$ 6431.00 (valid in North, Central and South America), including air speed delivery. Periodicals postage paid at Jamaica, NY 11431.
USA POSTMASTERS: Send address changes to *European Journal of Pharmacology*, Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003.
AIRFREIGHT AND MAILING in the USA by Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003.

Printed in The Netherlands

⊖ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

ELSEVIER

European Journal of Pharmacology

ejp

Master author index to volumes 317–339 (1997)

Abdel-Galil, A.-G.A., see El-Mas, M.M. (322) 201
Abdel-Galil, A.-G.A., see El-Mas, M.M. (337) 235
Abdi, A. and Johns, E.J.
The effect of angiotensin II receptor antagonists on kidney function in two-kidney, two-clip Goldblatt hypertensive rats (331) 185
Abdul-Ghani, A.-S., Attwell, P.J.E. and Bradford, H.F.
The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdala-kindled seizures (326) 7
Abe, I., see Ohya, Y. (330) 93
Abe, K., Horiuchi, M. and Yoshimura, K.
Potentiation by DSP-4 of EEG slowing and memory impairment in basal forebrain-lesioned rats (321) 149
Abercrombie, E.D., see DeBoer, P. (317) 257
Abi-Dargham, A., Zea-Ponce, Y., Terriere, D., Al-Tikriti, M., Baldwin, R.M., Hoffer, P., Charney, D., Leysen, J.E., Laruelle, M., Mertens, J. and Innis, R.B.
Preclinical evaluation of [^{123}I]R93274 as a SPECT radiotracer for imaging 5-HT_{2A} receptors (321) 285
Aboo Zar, M., see Iravani, M.M. (338) 75
Aceto, M.D., Harris, L.S. and Bowman, E.R.
Etorphines: μ-opioid receptor-selective antinociception and low physical dependence capacity (338) 215
Adachi-Akahane, S., see Kanda, S. (319) 101
Adachi-Akahane, S., see Kurokawa, J. (325) 229
Adachi, K., see Morizane, C. (328) 45
Adachi, N., see Ohya, Y. (330) 93
Adachi, Y., Hashimoto, K., Ono, N., Yoshida, M., Suzuki-Kusaba, M., Hisa, H. and Satoh, S.
Renal effects of a nitric oxide donor, NOC 7, in anesthetized rabbits (324) 223
Adams Jr., J.D., see Mukherjee, S.K. (330) 27
Adapa, I.D., see Gintzler, A.R. (325) 29
Adler-Graschinsky, E., see Feleder, E.C. (319) 229
Adner, M., see Möller, S. (329) 69
Advenier, C., see Magraner, J. (326) 211
Ågmo, A., see Belzung, C. (323) 133
Agulló, L. and García, A.
Ca^{2+}/calmodulin-dependent cyclic GMP phosphodiesterase activity in granule neurons and astrocytes from rat cerebellum (323) 119
Ahmad, S.
Angiotensin receptor antagonists delay nitric oxide-deficient stroke in stroke-prone rats (333) 39
Aimi, N., see Leewanich, P. (332) 321
Aimi, N., see Matsumoto, K. (317) 75
Aizenman, E., see Scanlon, J.M. (326) 67
Akaike, A., see Kaneda, K. (322) 259
Akaike, A., see Morizane, C. (328) 45
Akaike, N., see Uneyama, C. (319) 299
Akaike, N., see Westh-Hansen, S.E. (329) 253
Akera, T., see Temma, K. (322) 235
Åkerman, K.E.O., see Kukkonen, J.P. (335) 99
Akin, S., see Tellioğlu, T. (317) 301
Akiyama, K., see Moriyama, N. (331) 39
Akuta, K., see Manabe, H. (332) 97
Akwa, Y., see Brot, M.D. (325) 1
Al-Tikriti, M., see Abi-Dargham, A. (321) 285
Ala, Y., Morin, D., Mahé, E., Cotte, N., Mouillac, B., Jard, S., Barberis, C., Tribollet, E., Dreifuss, J.-J., Sawyer, W.H., Wo, N.C., Chan, W.Y., Kolodziejczyk, A.S., Cheng, L.L. and Manning, M.
Properties of a new radioiodinated antagonist for human vasopressin V_2 and V_{1a} receptors (331) 285
Albasanz, J.L., Ros, M. and Martín, M.
Characterization of metabotropic glutamate receptors in rat C6 glioma cells (326) 85
Albert, D.H., Magoc, T.J., Tapang, P., Luo, G., Morgan, D.W., Curtin, M., Sheppard, G.S., Xu, L., Heyman, H.R., Davidsen, S.K., Summers, J.B. and Carter, G.W.
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist (325) 69
Albrecht, D., Broser, M., Krüger, H. and Bader, M.
Effects of angiotensin II and IV on geniculate activity in nontransgenic and transgenic rats (332) 53
Alexander, B., see Browse, D.J. (320) 139
Alicke, B., see Bartolome, J.V. (331) 145
Allain, N., see Berdyshev, E.V. (330) 231
Allard, P., see Norlén, M. (332) 227
Almansa, C., see De Arriba, A.F. (318) 341
Almazan, G., see Liu, H.-N. (338) 277
Alonci, A., see Squadrito, F. (318) 153
Altan, V.M., see Öztürk, Y. (321) 59
Altavilla, D., see Squadrito, F. (318) 153
Altavilla, D., see Squadrito, F. (335) 185
Altura, B.M., Zhang, A. and Altura, B.T.
Exposure of piglet coronary arterial muscle cells to low concentrations of Mg^{2+} found in blood of ischemic heart disease patients result in rapid elevation of cytosolic Ca^{2+}: Relevance to sudden infant death syndrome (338) R7
Amandi-Burgermeister, E., Tibes, U., Kaiser, B.M., Friebe, W.G. and Scheuer, W.V.
Suppression of cytokine synthesis, integrin expression and chronic inflammation by inhibitors of cytosolic phospholipase A_2 (326) 237
Ambler, S.J., see O'Neill, M.J. (332) 121
Amemiya, N., Hatta, S. and Ohshika, H.
Effects of ondansetron on electrically evoked contraction in rat stomach fundus: Possible involvement of 5-HT_{2B} receptors (339) 173
Amemiya, N., Hatta, S., Takemura, H. and Ohshika, H.
Characterization of the contractile response induced by 5-methoxytryptamine in rat stomach fundus strips (318) 403
Amenta, F., see Barili, P. (338) 89
Ameri, A.
Inhibition of rat hippocampal excitability by the *Aconitum* alkaloid, 1-benzoylnapelline, but not by napelline (335) 145
Amico-Roxas, M., see Clementi, G. (332) 209
Ammendolia, L., see Squadrito, F. (318) 153
Andell, S., see Xu, X.-J. (318) 301
Anderson, G.P., see Bowden, J.J. (338) 83
Andersson, K.-E., see Nilvebrant, L. (327) 195
Andersson, R.G.G., see Johansson Rydberg, I.G.M. (329) 175

Andoh, T. and Kuraishi, Y.
Quantitative determination of endogenous nitric oxide in the mouse skin in vivo by microdialysis (332) 279
Ang, K.W., see Cassel, G. (332) 43
Angel, I., see Barras, M. (318) 425
Angel, I., see Goldhill, J. (323) 229
Angel, I., see Van der Graaf, P.H. (327) 25
Angelucci, L., see Patacchioli, F.R. (336) 159
Anger, J.-P., see Berdyshev, E.V. (330) 231
Angulo, J., see Peiró, C. (324) 257
Anselmi, E., see Magraner, J. (326) 211
Anselmi, E., see Pinto, F.M. (324) 125
Anthony, D.M., see Dickinson, K. (339) 69
Antkiewicz-Michaluk, L., Romańska, I. and Vetulani, J.
Ca^{2+} channel blockade prevents lysergic acid diethylamide-induced changes in dopamine and serotonin metabolism (332) 9
Antonakis, K., see Halmos, T. (318) 477
Antunes, E., see Costa, S.K.P. (339) 223
Antunes, E., see Zappellini, A. (317) 285
Antúnez, P., see Sardi, S.P. (321) 33
Anwyl, R., see Breakwell, N.A. (322) 173
Anwyl, R., see Hölscher, C. (322) 155
Anwyl, R., see Huang, L. (332) 161
Anwyl, R., see Xu, L. (323) 59
Aoba, A., see Miyamoto, S. (333) 279
Aoki, K., Ohmori, M., Takimoto, M., Ota, H. and Yoshida, T.
Cocaine-induced liver injury in mice is mediated by nitric oxide and reactive oxygen species (336) 43
Arai, Y., see Yatsu, T. (322) 45
Arakawa, T., see Sasaki, E. (338) 253
Araki, S.-i., see Togawa, M. (336) 291
Araki, T., see Ishizaki, K. (333) 207
Archer, S., see McLaughlin, J.P. (320) 121
Arcoraci, V., see Squadrito, F. (335) 185
Ardenghi, P., see Wolfman, C. (318) 23
Argiolas, A., see Melis, M.R. (328) 115
Arias-Montaño, J.-A., see Soria-Jasso, L.-E. (318) 185
Arias-Montaño, J.-A., see Trejo, F. (318) 175
Arita, J., Xue, Y.X., Aye, N.N., Fukuyama, K., Wakui, Y., Niitsu, K., Maruno, M., Siying, C. and Hashimoto, K.
Antiarrhythmic effects of an aconitine-like compound, TJN-505, on canine arrhythmia models (318) 333
Arm, J.P., see Gibbs, B.F. (327) 73
Armario, A., see Lahmame, A. (337) 115
Artuković, B., see Sikirić, P. (332) 23
Asai, T., see Matsushima, S. (333) 93
Asaka, T., see Inoue, H. (333) 231
Asakura, M., see Miyamoto, S. (333) 279
Asano, M., see Inamura, N. (333) 79
Asano, M., see Nakajima, T. (320) 81
Asano, M., see Yatsu, T. (322) 45
Asano, T., see Sugawara, T. (319) 123
Ashby Jr., C.R., see Gifford, A.N. (324) 187
Ashby Jr., C.R., see Morgan, A.E. (331) R1
Ashford, M.L.J., see Griffin, G. (339) 53
Ashworth, S., see Hume, S.P. (317) 67
Asin, K.E., see Shiosaki, K. (317) 183
Aslan, N., Gören, Z., Onat, F. and Oktay, Ş.
Carbachol-induced pressor responses and muscarinic M_1 receptors in the central nucleus of amygdala in conscious rats (333) 63
Assayag, P., see Besse, S. (338) 123
Assié, M.-B., Cosi, C. and Koek, W.
5-HT_{1A} receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine (334) 141
A. Teixeira, S., see Zappellini, A. (317) 285
Atgié, C., see Le Gouic, S. (339) 271
Attwell, P.J.E., see Abdul-Ghani, A.-S. (326) 7
Audinot-Bouchez, V., see Newman-Tancredi, A. (319) 379
Audinot, V., Lochon, S., Newman-Tancredi, A., Lavielle, G. and Millan, M.J.
Binding profile of the novel 5-$HT_{1B/1D}$ receptor antagonist, [^{3}H]GR 125,743, in guinea-pig brain: a comparison with [^{3}H]5-carboxamidotryptamine (327) 247
Aura, J., Sirviö, J. and Riekkinen Jr., P.
Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test (333) 129
Ausina, P., see Pinto, F.M. (324) 125
Autelitano, F., see Weill, C. (333) 269
Avenet, P., see Biton, B. (323) 277
Ayajiki, K., Okamura, T. and Toda, N.
Flunarizine, an anti-migraine agent, impairs nitroxidergic nerve function in cerebral arteries (329) 49
Aye, N.N., Xue, Y.X. and Hashimoto, K.
Antiarrhythmic effects of cariporide, a novel Na^+–H^+ exchange inhibitor, on reperfusion ventricular arrhythmias in rat hearts (339) 121
Aye, N.N., see Xue, Y.X. (317) 309

Baamonde, A., see Gutiérrez, M. (328) 99
Baamonde, A., see Menéndez, L. (335) 9
Baba, J., see Yamashita, N. (337) 95
Bach, F.H., see Stuhlmeier, K.M. (325) 209
Bachelet, M., see Bureau, M.F. (324) 89
Bäck, M., Wikström Jonsson, E. and Dahlén, S.-E.
The cysteinyl-leukotriene receptor antagonist BAY u9773 is a competitive antagonist of leukotriene C_4 in the guinea-pig ileum (317) 107
Baczkó, I., Leprán, I. and Papp, J.Gy.
K_{ATP} channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats (324) 77
Badio, B., Garraffo, H.M., Plummer, C.V., Padgett, W.L. and Daly, J.W.
Synthesis and nicotinic activity of epiboxidine: an isoxazole analogue of epibatidine (321) 189
Badran, S., Schmutz, M. and Olpe, H.-R.
Comparative in vivo and in vitro studies with the potent $GABA_B$ receptor antagonist, CGP 56999A (333) 135
Baffi, J.S., see Palkovits, M. (331) 53
Bagdy, G. and To, C.T.
Comparison of relative potencies of i.v. and i.c.v. administered 8-OH-DPAT gives evidence of different sites of action for hypothermia, lower lip retraction and tail flicks (323) 53
Bähr, M., Kolter, T., Seipke, G. and Eckel, J.
Growth promoting and metabolic activity of the human insulin analogue [Gly^{A21},Arg^{B31},Arg^{B32}]insulin (HOE 901) in muscle cells (320) 259
Bakthavachalam, V., see Kula, N.S. (331) 333
Balakrishnan, S.M., Gopalakrishnan, V. and McNeill, J.R.
Endothelin contributes to the hemodynamic effects of vasopressin in spontaneous hypertension (334) 55
Baldessarini, R.J., see Kula, N.S. (331) 333
Baldi, A., see Shayo, C.C. (324) 129
Baldoni, E., see Barili, P. (338) 89
Balducci, C., see Pulvirenti, L. (321) 279
Baldwin, R.M., see Abi-Dargham, A. (321) 285
Balfour, D.J.K., see Benwell, M.E.M. (325) 13
Bandarage, U.K., see Maisonneuve, I.M. (336) 123
Bar-Joseph, A., see Striem, S. (338) 205
Barberá, M., see Higueras, J. (326) 175
Barberis, C., see Ala, Y. (331) 285
Barili, P., Ricci, A., Baldoni, E., Mignini, F. and Amenta, F.
Pharmacological characterisation and autoradiographic localisation of a putative dopamine D_3 receptor in the rat kidney (338) 89

Barili, P., Sabbatini, M., Soares-da-Silva, P. and Amenta, F.
Dopamine D_2-like receptors in the rat kidney: Effect of denervation (334) 233
Barnes, N.M., see Ge, J. (332) 307
Barnes, P.J., see Nishikawa, M. (318) 123
Barnes, P.J., see Stone, R.A. (332) 201
Barnes, P.J., see Takahashi, T. (324) 219
Baron, B.M., Harrison, B.L., Kehne, J.H., Schmidt, C.J., Van Giersbergen, P.L.M., White, H.S., Siegel, B.W., Senyah, Y., McCloskey, T.C., Fadayel, G.M., Taylor, V.L., Murawsky, M.K., Nyce, P. and Salituro, F.G.
Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist (323) 181
Barrachina, M.D., see Magraner, J. (326) 211
Barras, M., Van der Graaf, P.H. and Angel, I.
Characterisation of the 5-HT receptor potentiating neurotransmission in rabbit bladder (318) 425
Bartfai, T., see Xu, X.-J. (318) 301
Bartolini, A., see Galeotti, N. (330) 15
Bartolini, A., see Ghelardini, C. (329) 1
Bartolini, L., see Scali, C. (325) 173
Bartolome, J.V., Alicke, B. and Bartolome, M.B.
Central administration of morphine inhibits brain and liver ornithine decarboxylase activity in neonatal rats: Involvement of transcription- and non-transcription-dependent mechanisms (331) 145
Barton, C.L., see Hutson, P.H. (326) 127
Bartoszyk, G.D., Hegenbart, R. and Ziegler, H.
EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT_{1A} receptor agonistic properties (322) 147
Basile, A.S., see Sei, Y. (325) 81
Bates, J.N., see Travis, M.D. (318) 47
Bateson, A.N., see Holt, R.A. (329) 129
Bath, C.P., see O'Neill, M.J. (332) 121
Battle, T., see N'Diaye, N. (321) 387
Baudet, C., see Canova, C. (319) 365
Bayer, B.M., see Flores, L.R. (318) 437
Bazzani, C., see Guarini, S. (336) 15
Beart, P.M., see Bunting, M.W. (337) 35
Beaujouan, J.-C., Saffroy, M., Torrens, Y. and Glowinski, J.
Potency and selectivity of the tachykinin NK_3 receptor antagonist SR 142801 (319) 307
Bednarz, L., see Shiosaki, K. (317) 183
Beer, M.S., see Stanton, J.A. (320) 267
Beitner, R., see Glass-Marmor, L. (328) 241
Bell, D., see McDermott, B.J. (336) 257
Bell, R.L., see Hulkower, K.I. (331) 79
Bellasio, R., see Calzi, F. (338) 185
Bellavite, P., see Conforti, A. (324) 241
Beltramo, M., see Calignano, A. (337) R1
Belvisi, M.G., see Takahashi, T. (324) 219
Belzung, C. and Ågmo, A.
Naloxone potentiates the effects of subeffective doses of anxiolytic agents in mice (323) 133
Benavides, J., see Debeir, T. (323) 111
Benedito, S., see Martínez, A.C. (326) 163
Benigni, F., see Ghezzi, P. (317) 369
Benjamin, I.S., see Browse, D.J. (320) 139
Bennett, G.W., see Thongsaard, W. (319) 157
Benton, D.C.H.
The effects of cetiedil and its congeners on levcromakalim-stimulated ^{86}Rb efflux from smooth and skeletal muscle (317) 329
Benwell, M.E.M. and Balfour, D.J.K.
Regional variation in the effects of nicotine on catecholamine overflow in rat brain (325) 13
Ber, E., see Rupniak, N.M.J. (326) 201
Berdeu, D., Puech, R., Ribes, G., Loubatières-Mariani, M.-M. and Bertrand, G.
Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs (324) 233
Berdyshev, E.V., Boichot, E., Germain, N., Allain, N., Anger, J.-P. and Lagente, V.
Influence of fatty acid ethanolamides and Δ^9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells (330) 231
Berkovitch, Y., see Striem, S. (338) 205
Berman, F.W., see Soderstrom, K. (338) 191
Bernareggi, M., see De Gennaro Colonna, V. (334) 201
Bernasconi, R., see Mathivet, P. (321) 67
Bernasconi, R., see Vergnes, M. (332) 245
Bernat, A., see Schaeffer, P. (323) 215
Bernauer, W.
Concerning the effect of the K^+ channel blocking agent glibenclamide on ischaemic and reperfusion arrhythmias (326) 147
Berthelot, P., see Ong, J. (329) 133
Berthiaume, N., Hess, F., Chen, A., Regoli, D. and D'Orléans-Juste, P.
Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B_2 knockout transgenic mice (333) 55
Berti, F., see Radice, S. (320) 43
Bertini, R., see Ghezzi, P. (317) 369
Berto, L., see Cortijo, J. (333) 69
Bertolini, A., see Guarini, S. (336) 15
Bertorelli, R., see Di Santo, E. (336) 197
Bertrand, G., see Berdeu, D. (324) 233
Berzsenyi, P., see Palkovits, M. (331) 53
Bespalov, A. and Zvartau, E.
NMDA receptor antagonists prevent conditioned activation of intracranial self-stimulation in rats (326) 109
Besse, S., Assayag, P., Latour, C., Janmot, C., Robert, V., Delcayre, C., Nahas, G. and Swynghedauw, B.
Molecular characteristics of cocaine-induced cardiomyopathy in rats (338) 123
Beubler, E. and Schirgi-Degen, A.
Nitric oxide counteracts 5-hydroxytryptamine- and cholera toxin-induced fluid secretion and enhances the effect of oral rehydration solution (326) 223
Beyeler, M.L., see Fleckenstein, A.E. (334) 111
Bhanot, S., see Verma, S. (322) R1
Bhargava, H.N., see Cao, Y.-J. (335) 161
Bian, J.-T., see Cao, Y.-J. (335) 161
Bianchi, L., see Boselli, C. (335) 23
Bianchi, L., see Grana, E. (319) 57
Bianchi, M., see Sacerdote, P. (319) 287
Bianchi, N., see Passadore, M. (319) 317
Bianco, I.D., see Correa, S.G. (319) 85
Bickel, M., see Wirth, K.J. (337) 45
Bidlack, J.M., see McLaughlin, J.P. (320) 121
Bidouard, J.-P., see Thollon, C. (339) 43
Biegon, A., see Striem, S. (338) 205
Bini, A., see Guarini, S. (336) 15
Biton, B., Godet, D., Granger, P. and Avenet, P.
R- and L-type Ca^{2+} channels are insensitive to eliprodil in rat cultured cerebellar granule neurons (323) 277
Bitran, M., Daniels, A.J. and Boric, M.P.
GW1229, a novel neuropeptide Y Y_1 receptor antagonist, inhibits the vasoconstrictor effect of neuropeptide Y in the hamster microcirculation (319) 43
Bittencourt, A.L. and Takahashi, R.N.
Mazindol and lidocaine are antinociceptives in the mouse formalin model: involvement of dopamine receptor (330) 109
Björkling, F., see García-Martínez, J.A. (325) 65
Björklund, M., see Jäkälä, P. (318) 239
Bjorn, H., see Martin, R.J. (322) 249
Black, M., Lanthorn, T., Small, D., Mealing, G., Lam, V. and Morley, P.
Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2 (317) 377

Blanco, I., see Rodriguez, F.J. (323) 283
Blandl, T., see Kardos, J. (337) 83
Blaskó, G., see Kardos, J. (337) 83
Bleakman, D., see O'Neill, M.J. (332) 121
Blomqvist, O., Ericson, M., Engel, J.A. and Söderpalm, B.
Accumbal dopamine overflow after ethanol: Localization of the antagonizing effect of mecamylamine (334) 149
Bodaiji, N., see Miyamoto, S. (333) 279
Boeckxstaens, G.E., see De Winter, B.Y. (339) 63
Boeckxstaens, G.E., see Michielsen, P.P. (329) 137
Boege, F., see Jahns, R. (334) 115
Boehrer, A., see Vergnes, M. (332) 245
Boev, K.K., see Duridanova, D.B. (333) 105
Boev, K.K., see Petkov, G.V. (318) 109
Boeynaems, J.-M., see Communi, D. (317) 383
Boeynaems, J.-M., see Robaye, B. (329) 231
Böhm, M., see Rosenkranz, S. (330) 35
Boichot, E., see Berdyshev, E.V. (330) 231
Boku, Y., see Takano, H. (323) 107
Bolanos, C.A., Garmsen, G.M., Clair, M.A. and McDougall, S.A.
Effects of the κ-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat (317) 1
Bone, H.-G., see Waurick, R. (333) 181
Boni, C., see Fabre, V. (337) 297
Bonnet, J., see Ghezzi, P. (317) 369
Bonnet, P.-A., see Pocock, T.M. (334) 75
Bonnet, P.-A., see Zurbonsen, K. (320) 215
Booke, M., see Waurick, R. (333) 181
Boot, J.R., see Tran, S. (335) 31
Borchard, U., see Dodel, R.C. (318) 395
Bordin, S., Carneiro, E.M., Bosqueiro, J.R. and Boschero, A.C.
Tetracaine stimulates extracellular Ca^{2+}-independent insulin release (327) 257
Boric, M.P., see Bitran, M. (319) 43
Börjesson, L., Nordgren, S. and Delbro, D.S.
DMPP causes relaxation of rat distal colon by a purinergic and a nitrergic mechanism (334) 223
Borowicz, K.K., Gasior, M., Kleinrok, Z. and Czuczwar, S.J.
Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice (323) 45
Borowicz, K.K., Kleinrok, Z. and Czuczwar, S.J.
N^6-2-(4-Aminophenyl)ethyl-adenosine enhances the anticonvulsive activity of antiepileptic drugs (327) 125
Borowicz, K.K., Kleinrok, Z. and Czuczwar, S.J.
Influence of 7-nitroindazole on the anticonvulsive action of conventional antiepileptic drugs (331) 127
Boschero, A.C., see Bordin, S. (327) 257
Boselli, C., Bianchi, L. and Grana, E.
Effect of cromakalim on the purinergic and cholinergic transmission in the rat detrusor muscle (335) 23
Bosker, F.J., Klompmakers, A. and Westenberg, H.G.M.
Postsynaptic 5-HT_{1A} receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe (333) 147
Bottlaender, M., Schmid, L., Fuseau, C., Fournier, D., Brouillet, E. and Mazière, M.
In vivo modulation of benzodiazepine receptor function after inhibition of endogenous γ-aminobutyric acid synthesis (321) 13
Bourin, M., see Redrobe, J.P. (318) 213
Bourin, M., see Redrobe, J.P. (325) 129
Bouvier, M., see Rousseau, G. (326) 75
Bouysset, F., see Vayssettes-Courchay, C. (320) 151
Bowden, J.J., Anderson, G.P., Lefevre, P.M., Sulakvelidze, I. and McDonald, D.M.
Characterization of tolerance to the anti-leakage effect of formoterol in rat airways (338) 83
Bowen, W., see Chien, C.-C. (321) 361
Bowery, N.G., see Getova, D. (320) 9
Bowman, C.J., see Tümer, N. (324) 57
Bowman, E.R., see Aceto, M.D. (338) 215
Brachet, P., see Canova, C. (319) 365
Bracke, M., see Charlier, C. (317) 413
Brackett, R.L., see Matsumoto, R.R. (338) 233
Bradford, H.F., see Abdul-Ghani, A.-S. (326) 7
Bradford, H.F., see Croucher, M.J. (319) 207
Bradley, K.J. and Headley, P.M.
Effect of agmatine on spinal nociceptive reflexes: Lack of interaction with α_2-adrenoceptor or μ-opioid receptor mechanisms (331) 133
Brailoiu, E., see Filipeanu, C.M. (332) 71
Brain, S.D., see Costa, S.K.P. (339) 223
Brambilla, L., see Palomba, L. (318) 167
Brandi, G., see Palomba, L. (318) 167
Branisteanu, D.D., see Filipeanu, C.M. (332) 71
Brattsand, R., see Larsson, S. (334) 265
Bratulić, M., see Sikirić, P. (332) 23
Bräuner-Osborne, H., Madsen, U., Mikiciuk-Olasik, E. and Curry, K.
New analogues of ACPD with selective activity for group II metabotropic glutamate receptors (332) 327
Bräuner-Osborne, H., Nielsen, B., Stensbøl, T.B., Johansen, T.N., Skjærbæk, N. and Krogsgaard-Larsen, P.
Molecular pharmacology of 4-substituted glutamic acid analogues at ionotropic and metabotropic excitatory amino acid receptors (335) R1
Breakwell, N.A., Huang, L.Q., Rowan, M.J. and Anwyl, R.
DCG-IV inhibits synaptic transmission by activation of NMDA receptors in area CA1 of rat hippocampus (322) 173
Bregonzio, C., see Cabrera, R.J. (317) 55
Breithecker, K., see Kretschmer, B.D. (331) 109
Breschi, M.C., see Nieri, P. (331) 205
Brezenoff, H.E., see Li, J. (337) 227
Briner, V.A., see Mühl, H. (317) 137
Brion, J.-D., see Ghezzi, P. (317) 369
Britton, D.R., see Shiosaki, K. (317) 183
Britton, K.T., see Brot, M.D. (325) 1
Brocco, M., see Millan, M.J. (321) R7
Brodie, M.J., see Sills, G.J. (325) 35
Brooks, E.N., see Mansbach, R.S. (323) 21
Broser, M., see Albrecht, D. (332) 53
Brot, M.D., Akwa, Y., Purdy, R.H., Koob, G.F. and Britton, K.T.
The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with $GABA_A$ receptors (325) 1
Brown, G.P., see Chien, C.-C. (321) 361
Brownhill, V.R., Hourani, S.M.O. and Kitchen, I.
Differential ontogeny of adenosine receptors in the longitudinal muscle and muscularis mucosae of the rat isolated duodenum (317) 321
Browning, R.A., Wood, A.V., Merrill, M.A., Dailey, J.W. and Jobe, P.C.
Enhancement of the anticonvulsant effect of fluoxetine following blockade of 5-HT_{1A} receptor (336) 1
Browse, D.J., Mathie, R.T., Benjamin, I.S. and Alexander, B.
The action of ATP on the hepatic arterial and portal venous vascular networks of the rabbit liver: the role of adenosine (320) 139
Bruggeman, R., Westerink, B.H.C. and Timmerman, W.
Effects of risperidone, clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons of the rat brain (324) 49
Brunet, J., see Taouil, K. (324) 289
Brunn, G., Hey, C., Wessler, I. and Racké, K.
Endogenous nitric oxide inhibits leukotriene B_4 release from rat alveolar macrophages (326) 53
Bruyneel, E., see Charlier, C. (317) 413
Bucharles, C., see Leroux, P. (337) 333
Buchkremer-Ratzmann, I. and Witte, O.W.
Pharmacological reduction of electrophysiological diaschisis after photothrombotic ischemia in rat neocortex (320) 103
Buéno, L., see Million, M. (334) 67

Buggé, C.J.L., see Kurz, M.A. (322) 211
Buller, A.L. and Monaghan, D.T.
Pharmacological heterogeneity of NMDA receptors: characterization of NR1a/NR2D heteromers expressed in *Xenopus* oocytes (320) 87
Bullough, D.A., see Kurz, M.A. (322) 211
Bullough, D.A., see Wang, J. (320) 241
Bunting, M.W., Beart, P.M. and Widdop, R.E.
Effects of the CCK_A receptor antagonists SR 27897B and PD140548 on baroreflex function in conscious rats (337) 35
Bureau, M.F., De Castro, C.M.B., Cortese, C., Bachelet, M. and Vargaftig, B.B.
5-Lipoxygenase and endotoxin-induced microvascular albumin exchanges and leucocyte recruitment in guinea-pig lungs (324) 89
Buritova, J., Chapman, V., Honoré, P. and Besson, J.-M.
The contribution of peripheral bradykinin B_2 receptors to carrageenan-evoked oedema and spinal c-Fos expression in rats (320) 73
Burkey, T.H., Quock, R.M., Consroe, P., Ehlert, F.J., Hosohata, Y., Roeske, W.R. and Yamamura, H.I.
Relative efficacies of cannabinoid CB_1 receptor agonists in the mouse brain (336) 295
Burkey, T.H., Quock, R.M., Consroe, P., Roeske, W.R. and Yamamura, H.I.
Δ^9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain (323) R3
Burkey, T.H., see Quock, R.M. (326) 101
Burlet, H., see Marchand, V. (336) 187
Burnett, J.P., see Gehlert, D.R. (318) 485
Burnstock, G., see Hill, B. (317) 275
Burnstock, G., see Ren, L.-M. (318) 411
Burnstock, G., see Ventura, S. (334) 87
Burrell, J.H. and Lumbers, E.R.
Angiotensin receptor subtypes in the uterine artery during ovine pregnancy (330) 257
Burvenich, C., see Hoeben, D. (332) 289
Butour, J.-L., Moisand, C., Mazarguil, H., Mollereau, C. and Meunier, J.-C.
Recognition and activation of the opioid receptor-like ORL1 receptor by nociceptin, nociceptin analogs and opioids (321) 97

Cabello, P., see González, P. (332) 257
Cabrera, R.J. and Bregonzio, C.
Turnover rate and stimulus-evoked release of dopamine by progesterone and *N*-methyl-D-aspartic acid in rat striatum during pregnancy (317) 55
Cabrini, D.A. and Calixto, J.B.
Characterization of des-Arg^9-bradykinin-induced contraction in guinea-pig gallbladder in vitro (331) 31
Cacciaguerra, S., see Ucar, H. (335) 267
Caddy, K.W.T. and Vožeh, F.
The effect of 3-acetylpyridine on inferior olivary neuron degeneration in Lurcher mutant and wild-type mice (330) 139
Cadène, A., Gross, R., Poucheret, P., Mongold, J.-J., Masiello, P., Roye, M., Ribes, G., Serrano, J.-J. and Cros, G.
Vanadyl sulphate differently influences insulin response to glucose in isolated pancreas of normal rats after in vivo or in vitro exposure (318) 145
Cain, J.C., see Ireland, L.M. (327) 79
Cainazzo, M.-M., see Guarini, S. (336) 15
Calapai, G., see Nava, F. (331) 267
Calignano, A., La Rana, G., Beltramo, M., Makriyannis, A. and Piomelli, D.
Potentiation of anandamide hypotension by the transport inhibitor, AM404 (337) R1
Calixto, J.B., see Saleh, T.S.F. (331) 43
Callado, L.F. and Meana, J.J.
Low-affinity conditions for agonists increase the binding of the antagonist [^{3}H]RX821002 to the $\alpha_{2B/C}$-adrenoceptor subtypes in human brain and rat kidney (332) 109
Calò, L., see Pontieri, F.E. (335) 133
Calvo, J.R., see Pozo, D. (321) 379
Calzi, F., Bellasio, R., Guiso, G., Caccia, S. and Tacconi, M.T.
Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo (338) 185
Cameron, N.E. and Cotter, M.A.
Neurovascular effects of L-carnitine treatment in diabetic rats (319) 239
Campisi, P., Carmichael, F.J.L., Crawford, M., Orrego, H. and Khanna, J.M.
Role of adenosine in the ethanol-induced potentiation of the effects of general anesthetics in rats (325) 165
Campo, G.M., see Squadrito, F. (335) 185
Canale, P., see Squadrito, F. (318) 153
Candenas, M.L., see Magraner, J. (326) 211
Candenas, M.L., see Pinto, F.M. (324) 125
Candiloros, H., see Muller, S. (337) 103
Canet, E., see Roussin, A. (322) 91
Cano, J., see De la Cruz, C.P. (327) 215
Canova, C., Baudet, C., Chevalier, G., Brachet, P. and Wion, D.
Noradrenaline inhibits the programmed cell death induced by 1,25-dihydroxyvitamin D_3 in glioma (319) 365
Cao, B.-J. and Rodgers, R.J.
Dopamine D_4 receptor and anxiety: Behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze (335) 117
Cao, Y.-J., Bian, J.-T. and Bhargava, H.N.
Effects of NMDA receptor antagonists on δ_1- and δ_2-opioid receptor agonists-induced changes in the mouse brain [^{3}H]DPDPE binding (335) 161
Capaccioli, S., see Ghelardini, C. (329) 1
Capasso, A. and Sorrentino, L.
Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum (330) 199
Capobianchi, M.R., see Noviello, L. (332) R1
Caputi, A.P., see Nava, F. (331) 267
Caputi, A.P., see Squadrito, F. (318) 153
Caputi, A.P., see Squadrito, F. (335) 185
Cardinali, D.P., see Esquifino, A.I. (319) 181
Carlson, E.J., see Rupniak, N.M.J. (326) 201
Carlsson, A., see Martin, P. (335) 107
Carlsson, M.L., see Martin, P. (335) 107
Carmeliet, E.E., see Van der Walt, J.J. (329) 201
Carmichael, F.J.L., see Campisi, P. (325) 165
Carneiro, E.M., see Bordin, S. (327) 257
Carnuccio, R., see D'Acquisto, F. (339) 87
Caron, N., see Kramp, R.A. (330) 165
Carón, R.W., see Salicioni, A.M. (332) 283
Carrasco, E., see Cortijo, J. (333) 69
Carriero, D.L., see Cousins, M.S. (322) 137
Carroll, F.I., see Chien, C.-C. (321) 361
Carroll, J., see Sehba, F. (339) 33
Carta, G., see Gessa, G.L. (327) R1
Carta, G., see Imperato, A. (317) 231
Carter, G.W., see Albert, D.H. (325) 69
Caruso, A., see Clementi, G. (332) 209
Casalotti, S.O., see Siripurkpong, P. (331) 227
Cascieri, M.A., Ber, E., Fong, T.M., Hale, J.J., Tang, F., Shiao, L.-L., Mills, S.G., MacCoss, M., Sadowski, S., Tota, M.R. and Strader, C.D.
Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK_1 receptor antagonist (325) 253
Cascieri, M.A., see Seabrook, G.R. (317) 129
Cash, D.J., see Kardos, J. (337) 83
Cassel, G., Karlsson, L., Waara, L., Ang, K.W. and Göransson-Nyberg, A.

Pharmacokinetics and effects of HI 6 in blood and brain of soman-intoxicated rats: A microdialysis study (332) 43
Casteilla, L., see Le Gouic, S. (339) 271
Castel, H., see Le Foll, F. (331) 303
Castrén, E., see Lindén, A.-M. (319) R1
Castrillón, P.O., see Esquifino, A.I. (319) 181
Castronovo, V., see Charlier, C. (317) 413
Casu, M.A., see Gessa, G.L. (327) R1
Casu, M.A., see Imperato, A. (317) 231
Casu, M.A., see Weiss, F. (337) 219
Catheline, G., Kayser, V., Idänpään-Heikkilä, J.J. and Guilbaud, G.
The antinociceptive activity of κ- but not δ-opioid receptor agonists is maintained in morphine-tolerant neuropathic rats (318) 273
Cattabeni, F., see Palomba, L. (318) 167
Cattaneo, M.G., see Vicentini, L.M. (318) 497
Cavalcanti, F., see De Arriba, A.F. (318) 341
Cazin, L., see Le Foll, F. (331) 303
Cechetto, D.F. and Kline, R.L.
Effect of rilmenidine on arterial pressure and urinary output in the spontaneously hypertensive rat (325) 47
Cellier, E., Fayolle, C., Hipskind, P.A., Iyengar, S. and Couture, R.
Peripheral effects of three novel non-peptide tachykinin NK_1 receptor antagonists in the anaesthetized rat (318) 377
Champion, H.C., Wang, R., Shenassa, B.B., Murphy, W.A., Coy, D.H., Hellstrom, W.J.G. and Kadowitz, P.J.
Adrenomedullin induces penile erection in the cat (319) 71
Chan, C.-C., Panneton, M., Taylor, A.M., Therien, M. and Rodger, I.W.
A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates (327) 221
Chan, K.W., Duttory, A. and Yoburn, B.C.
Magnitude of tolerance to fentanyl is independent of μ-opioid receptor density (319) 225
Chan, M.-H., Dwyer, T.M. and Farley, J.M.
Reduction in the bioelectric properties of swine tracheal submucosal gland cells in culture after daily short-term exposure to cocaine (334) 281
Chan, S.L.F., Pallett, A.L., Clews, J., Ramsden, C.A. and Morgan, N.G.
Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with σ receptors (323) 241
Chang, A., see King, M. (331) R5
Chang, Y.-C., see Tyan, S.-H. (321) 171
Chanussot, F., see Hajri, T. (320) 65
Chaouloff, F., Kulikov, A. and Mormède, P.
Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical $5\text{-}HT_{2A}$ receptors (334) 25
Chapman, V., see Buritova, J. (320) 73
Chariot, J., see Souli, A. (333) 87
Charlier, C., Bruyneel, E., Lechanteur, C., Bracke, M., Mareel, M. and Castronovo, V.
Enhancement of tamoxifen-induced E-cadherin function by Ca^{2+} channel antagonists in human breast cancer MCF7/6 cells (317) 413
Chebib, M., Vandenberg, R.J., Froestl, W. and Johnston, G.A.R.
Unsaturated phosphinic analogues of γ-aminobutyric acid as $GABA_C$ receptor antagonists (329) 223
Chen, A., see Berthiaume, N. (333) 55
Chen, B., see Sehba, F. (339) 33
Chen, M., Xiao, C.-Y., Hashizume, H. and Abiko, Y.
Differential effects of Ca^{2+} channel blockers on Ca^{2+} overload induced by lysophosphatidylcholine in cardiomyocytes (333) 261
Chen, N.-H., see Reith, M.E.A. (324) 1
Chen, Q.-m. and LaBella, F.S.
Inhibition of nitric oxide synthase by straight chain and cyclic alcohols (321) 355
Chen, Y.L., see Mansbach, R.S. (323) 21
Chenard, B., see Menniti, F. (331) 117
Cheng, L.L., see Ala, Y. (331) 285
Cheng, Y.-W. and Kang, J.-J.
Mechanism of vasorelaxation of thoracic aorta caused by xanthone (336) 23
Chevalier, G., see Canova, C. (319) 365
Chevillard, C., see Zurbonsen, K. (320) 215
Chiba, S. and Tsukada, M.
Mechanisms for histamine H_1 receptor-mediated vasodilation in isolated canine lingual arteries (329) 63
Chiba, S., see Haniuda, K. (333) 163
Chiba, S., see Hirose, M. (338) 35
Chiba, S., see Matsumoto, T. (334) 173
Chiba, S., see Yamazaki, K. (320) 21
Chidiac, P., see Rousseau, G. (326) 75
Chien, C.-C., Carroll, F.I., Brown, G.P., Pan, Y.-X., Bowen, W. and Pasternak, G.W.
Synthesis and characterization of $[^{125}I]3'$-(−)-iodopentazocine, a selective σ_1 receptor ligand (321) 361
Chindaduangratana, C., see Siripurkpong, P. (331) 227
Chintala, M., see Chiu, P.J.S. (321) 129
Chiu, P., see Pocock, T.M. (334) 75
Chiu, P.J.S., Tetzloff, G.G., Foster, C., Chintala, M. and Sybertz, E.J.
Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs (321) 129
Cho, S., Neff, N.H. and Hadjiconstantinou, M.
Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs (323) 149
Choi, R.T., see McPherson, G.A. (324) 193
Chojnacka-Wójcik, E., Tatarczyńska, E. and Pilc, A.
The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats (319) 153
Chopp, M., see Jiang, N. (320) 131
Chow, L., De Gasparo, M. and Levens, N.
Blockade of angiotensin converting enzyme but not of angiotensin AT_1 receptors improves glucose tolerance (319) 77
Christopoulos, A. and El-Fakahany, E.E.
Novel persistent activation of muscarinic M_1 receptors by xanomeline (334) R3
Christopoulos, A. and Mitchelson, F.
Pharmacological analysis of the mode of interaction of McN-A-343 at atrial muscarinic M_2 receptors (339) 153
Chugun, A., see Temma, K. (322) 235
Chung, K.F., see Stone, R.A. (332) 201
Cicatiello, L., see D'Acquisto, F. (339) 87
Cimino, M., Marini, P. and Cattabeni, F.
Interaction of thiocolchicoside with $[^3H]$strychnine binding sites in rat spinal cord and brainstem (318) 201
Clair, M.A., see Bolanos, C.A. (317) 1
Clark, D.A., see Ribbons, K.A. (323) 245
Clark, R.D., see Hume, S.P. (317) 67
Clayton, P., see Thomas, N.K. (338) 111
Clementi, G., Caruso, A., Cutuli, V.M.C., Prato, A., De Bernardis, E. and Amico-Roxas, M.
Effect of amylin in various experimental models of gastric ulcer (332) 209
Clincke, G., see Scheller, D.K.A. (338) 243
Cockcroft, V., see Kukkonen, J.P. (335) 99
Cohen, C., Perrault, G. and Sanger, D.J.
Effects of dihydropyridine Ca^{2+} channel blockers on the discriminative stimulus and the motor impairing effects of (±)-Bay K 8644 (336) 113
Collins, M., see Menniti, F. (331) 117
Collu, M., Poggiu, A.S., Devoto, P. and Serra, G.
Behavioural sensitization of mesolimbic dopamine D_2 receptors in chronic fluoxetine-treated rats (322) 123
Colville-Nash, P., see Papworth, J. (325) R1

Communi, D., Motte, S., Boeynaems, J.-M. and Pirotton, S.
Pharmacological characterization of the human P_{2Y4} receptor (317) 383
Compaan, J.C., Groenink, L., Van der Gugten, J., Maes, R.A.A. and Olivier, B.
Pretreatment with 5-HT_{1A} receptor agonist flesinoxan attenuates Fos protein in rat hypothalamus (324) 161
Conforti, A., Lussignoli, S., Bertani, S., Verlato, G., Ortolani, R., Bellavite, P. and Andrighetto, G.
Specific and long-lasting suppression of rat adjuvant arthritis by low-dose *Mycobacterium butyricum* (324) 241
Conroy, D.M., see Prié, S. (317) 343
Consroe, P., see Burkey, T.H. (323) R3
Consroe, P., see Burkey, T.H. (336) 295
Consroe, P., see Hosohata, Y. (321) R1
Consroe, P., see Landsman, R.S. (334) R1
Constantino, M.D., see Cunha, R.A. (323) 167
Conte, B., see Parlani, M. (318) 419
Conte Camerino, D., see Tricarico, D. (321) 369
Contreras, E., see González, P. (332) 257
Cook, S.J., see Lancaster, M.K. (339) 97
Cooney, G., see Qu, X. (338) 269
Copani, A., see Sureda, F. (338) R1
Corchero, J., Fuentes, J.A. and Manzanares, J.
Δ^9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus (323) 193
Correa, S.G., Riera, C.M., Spiess, J. and Bianco, I.D.
Modulation of the inflammatory response by corticotropin-releasing factor (319) 85
Cortijo, J., Martí-Cabrera, M., Berto, L., Antón, F., Carrasco, E., Grau, M. and Morcillo, E.J.
Pharmacological activity of PF-904 in guinea pig in vivo, and on human bronchus and neutrophils in vitro (333) 69
Cortijo, J., see Magraner, J. (326) 211
Cosi, C., see Assié, M.-B. (334) 141
Costa, G., see Martínez, A.C. (326) 163
Costa, S.K.P., De Nucci, G., Antunes, E. and Brain, S.D.
Phoneutria nigriventer spider venom induces oedema in rat skin by activation of capsaicin sensitive sensory nerves (339) 223
Costuleanu, A., see Filipeanu, C.M. (332) 71
Costuleanu, M., see Filipeanu, C.M. (332) 71
Cotte, N., see Ala, Y. (331) 285
Cotter, M.A., see Cameron, N.E. (319) 239
Cousins, M.S., Carriero, D.L. and Salamone, J.D.
Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs (322) 137
Cox, C., see McCoy, L. (318) 41
Coy, D.H., see Champion, H.C. (319) 71
Coy, D.H., see Ladenheim, E.E. (319) 245
Coy, D.H., see Rossowski, W.J. (336) 51
Crane, D.I., see Lewohl, J.M. (326) 265
Crawford, M., see Campisi, P. (325) 165
Cremers, B., see Rosenkranz, S. (330) 35
Crider, A.M., see Scheideler, M.A. (339) 261
Cros, G., see Cadène, A. (318) 145
Croucher, M.J., Ruffle, K.L. and Bradford, H.F.
The effects of focal *N*-methyl-D-aspartate pretreatment on the parameters of amygdaloid electrical kindling (319) 207
Crowe, R., see Hill, B. (317) 275
Crowley, W.R., see Parker, M.S. (318) 193
Crunelli, V., see Nyitrai, G. (318) 295
Cruse, S.F., see Scheideler, M.A. (339) 261
Cuadra, A.E. and El-Fakahany, E.E.
Enhancement of maximal activation of neuronal nitric oxide synthase at muscarinic M_1 receptors following prolonged agonist treatment (334) 107
Culver, K.E. and Szechtman, H.
Monoamine oxidase inhibitor sensitive site implicated in sensitization to quinpirole (339) 109
Cumberbatch, M.J., Hill, R.G. and Hargreaves, R.J.
Rizatriptan has central antinociceptive effects against durally evoked responses (328) 37
Cunha, R.A., Constantino, M.D. and Ribeiro, J.A.
Inhibition of [^{3}H]γ-aminobutyric acid release by kainate receptor activation in rat hippocampal synaptosomes (323) 167
Curtin, M., see Albert, D.H. (325) 69
Curzon, G., see Datla, K.P. (333) 27
Custers, F.G.J., Leysen, J.E., Stoof, J.C. and Herscheid, J.D.M.
Vesamicol and some of its derivatives: Questionable ligands for selectively labelling acetylcholine transporters in rat brain (338) 177
Cuzzocrea, S., see Nava, F. (331) 267
Czuczwar, S.J., see Borowicz, K.K. (323) 45
Czuczwar, S.J., see Borowicz, K.K. (327) 125
Czuczwar, S.J., see Borowicz, K.K. (331) 127
Czuczwar, S.J., see Przesmycki, K. (337) 11

Daabees, T.T., see El-Mas, M.M. (322) 201
Daabees, T.T., see El-Mas, M.M. (337) 235
D'Acquisto, F., Cicatiello, L., Iuvone, T., Ialenti, A., Ianaro, A., Esumi, H., Weisz, A. and Carnuccio, R.
Inhibition of inducible nitric oxide synthase gene expression by glucocorticoid-induced protein(s) in lipopolysaccharide-stimulated J774 cells (339) 87
Dahl, R., see Thirstrup, S. (333) 215
Dahl, S.G., see Langlois, A. (318) 141
Dahl, S.G., see Langlois, A. (324) 211
Dahlén, S.-E., see Bäck, M. (317) 107
Dailey, J.W., Reith, M.E.A., Yan, Q.-S., Li, M.-Y. and Jobe, P.C.
Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca^{2+} (328) 153
Daly, J.W., see Badio, B. (321) 189
Damaj, M.I.
Altered behavioral sensitivity of Ca^{2+}-modulating drugs after chronic nicotine administration in mice (322) 129
D'Amico, M., Rossi, F. and Warner, T.D.
Regulation of blood pressure by L-arginine-nitric oxide pathway within the superior colliculus of rats (328) 65
Daniele, E., Villani, G. and Lograno, M.D.
Effects of phorbol ester on carbachol-induced contraction in bovine ciliary muscle: possible involvement of protein kinase C (330) 247
Dannals, R.F., see Mochizuki, T. (338) 17
Danner, S. and Lohse, M.J.
Cell type-specific regulation of β_2-adrenoceptor mRNA by agonists (331) 73
D'Aquila, P.S., Collu, M., Gessa, G.L. and Serra, G.
Dizocilpine prevents the enhanced locomotor response to quinpirole induced by repeated electroconvulsive shock (330) 11
Da Silva, A., see Rousseau, G. (326) 75
Dassouli, A., see D'hahan, N. (328) 163
Datla, K.P. and Curzon, G.
The effect of D-fenfluramine on brain 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in male and female rats (333) 27
Davies, M.F., see Fang, F. (336) 137
Dawirs, R.R., Teuchert-Noodt, G. and Nossoll, M.
Pharmacologically induced neural plasticity in the prefrontal cortex of adult gerbils (*Meriones unguiculatus*) (327) 117
De Arriba, A.F., Gómez-Casajús, L.A., Cavalcanti, F., Almansa, C., García-Rafanell, J. and Forn, J.
In vitro pharmacological characterization of a new selective angiotensin AT_1 receptor antagonist, UR-7280 (318) 341
De Barry, J., see Mathivet, P. (321) 67
De Barry, J., see Schaffhauser, H. (334) 289

Debeir, T., Vigé, X. and Benavides, J.
Pharmacological characterization of protease-activated receptor (PAR-1) in rat astrocytes (323) 111
DeBoer, P., Heeringa, M.J. and Abercrombie, E.D.
Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D_2 receptors (317) 257
De Costa, B.R., see Zambon, A.C. (324) 39
De Gasparo, M., see Chow, L. (319) 77
De Gennaro Colonna, V., Rossoni, G., Bernareggi, M., Müller, E.E. and Berti, F.
Cardiac ischemia and impairment of vascular endothelium function in hearts from GH-deficient rats: Protection by hexarelin (334) 201
Deguchi, Y., see Taniguchi, Y. (330) 221
Deis, R.P., see Salicioni, A.M. (332) 283
De Jong, J.W., see De Jonge, R. (337) 41
De Jonge, R., Macleod, D.C., Suryapranata, H., Van Es, G.A., Friedman, J., Serruys, P.W. and De Jong, J.W.
Effect of acadesine on myocardial ischaemia in patients with coronary artery disease (337) 41
Deka, D.K., Raviprakash, V. and Mishra, S.K.
K_{ATP} channels do not mediate vasodilation by 3-morpholino-sydnonimine in goat coronary artery (330) 157
De la Cruz, C.P., Revilla, E., Rodríguez-Gómez, J.A., Vizuete, M.L., Cano, J. and Machado, A.
(−)-Deprenyl treatment restores serum insulin-like growth factor-I (IGF-I) levels in aged rats to young rat level (327) 215
Delaey, C. and Van de Voorde, J.
Heterogeneity of the inhibitory influence of sulfonylureas on prostanoid-induced smooth muscle contraction (325) 41
Delagrange, P., see Le Gouic, S. (339) 271
De la Lande, I.S., Stafford, I. and Horowitz, J.D.
Heterogeneity of glyceryl trinitrate response in isolated bovine coronary arteries (318) 65
Delaney, S.M., Blackburn, G.M. and Geiger, J.D.
Diadenosine polyphosphates inhibit adenosine kinase activity but decrease levels of endogenous adenosine in rat brain. (332) 35
De la Vega, M.-T., see Trejo, F. (318) 175
Delbro, D.S., see Börjesson, L. (334) 223
Delcayre, C., see Besse, S. (338) 123
Delchier, J.C., see Kiss, J. (336) 219
Delescluse, I., see Thollon, C. (339) 43
Delgado Hernandez, R., see Ghezzi, P. (317) 369
Dell, C.P., see O'Neill, M.J. (332) 121
Della Maggiore, V., see Esquifino, A.I. (319) 181
Delobette, S., Privat, A. and Maurice, T.
In vitro aggregation facilitates β-amyloid peptide-(25–35)-induced amnesia in the rat (319) 1
De Man, J.G., see De Winter, B.Y. (339) 63
Demirakça, S., see Dötsch, J. (331) 313
De Mol, N.J., see Fischer, M.J.E. (322) 97
Demura, H., see Seki, T. (331) 87
De Nadaï, J., see Roussin, A. (322) 91
Denet, S., see Muller, S. (337) 103
De Nucci, G., see Costa, S.K.P. (339) 223
De Nucci, G., see Faria, M.S. (323) 37
De Nucci, G., see Zappellini, A. (317) 285
De Oliveira, B., see Faria, M.S. (323) 37
Deplanne, V., see Van der Graaf, P.H. (327) 25
De Pont, J.J.H.H.M., see Smeets, R.L.L. (325) 93
Depoortere, I., see Van Assche, G. (337) 267
De Ryck, M., see Scheller, D.K.A. (338) 243
De Sarro, A., see De Sarro, G. (317) 239
De Sarro, A., see Nava, F. (331) 267
De Sarro, G., Donato Di Paola, E., Falconi, U., Ferreri, G. and De Sarro, A.
Repeated treatment with adenosine A_1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene (317) 239
Deveney, A.M. and Waddington, J.L.
Evidence for dopamine 'D_1-like' receptor subtypes in the behavioural effects of two new selective antagonists, LY 270411 and BW 737C (317) 175
De Vera, N., see Giménez-Llort, L. (318) 231
Devoto, P., see Collu, M. (322) 123
De Vry, J., see Xu, L. (323) 59
Dewar, K.M., Rompré, P.-P., Stewart, J. and Warren, R.A.
Excitotoxic lesions of the prefrontal cortex reduce dopamine D_1-like receptor in the ventral tegmental area (336) 155
De Wildt, D.J., see Van Bergen, P. (318) 357
De Wildt, D.J., see Van Buren, T. (318) 73
De Winter, B.Y., Boeckxstaens, G.E., De Man, J.G., Moreels, T.G., Herman, A.G. and Pelckmans, P.A.
Effects of μ- and κ-opioid receptors on postoperative ileus in rats (339) 63
D'hahan, N., Taouil, K., Dassouli, A. and Jean-Emile Morel,
Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6 (328) 163
Dhein, S., Gottwald, M., Gottwald, E., Hohlfeld, T., Salameh, A. and Klaus, W.
Acetylsalicylic acid enhances arrhythmogeneity in a model of local ischemia of isolated rabbit hearts (339) 129
Dias, H.B., see Faria, M.S. (323) 37
Diaz, A., Mayet, S. and Dickenson, A.H.
BU-224 produces spinal antinociception as an agonist at imidazoline I_2 receptors (333) 9
Dickenson, J.M. and Hill, S.J.
Transfected adenosine A_1 receptor-mediated modulation of thrombin-stimulated phospholipase C and phospholipase A_2 activity in CHO cells (321) 77
Dickinson, K., North, T.J., Sills, S., Anthony, D.M., Lock, J.I., Vowles, D.T. and Jones, R.B.
BTS 67 582 stimulates insulin secretion from perifused rat pancreatic islets (339) 69
Diéguez, G., Fernández, N., García, J.L., García-Villalón, A.L., Monge, L. and Gómez, B.
Role of nitric oxide in the effects of hypoglycemia on the cerebral circulation in awake goats (330) 185
Di Grezia, R., see Patacchioli, F.R. (336) 159
Di Grezia, R., see Pontieri, F.E. (335) 133
Di Iulio, J.L., Li, C.G. and Rand, M.J.
Determination of nitric oxide synthase activity in rat, pig and rabbit prostate glands (337) 245
Dimmeler, S., see Haendeler, J. (317) 407
Dinh, D.M., see Schlachter, S.K. (322) 283
Diop, L., see Langlois, A. (324) 211
Dirig, D.M., Konin, G.P., Isakson, P.C. and Yaksh, T.L.
Effect of spinal cyclooxygenase inhibitors in rat using the formalin test and in vitro prostaglandin E_2 release (331) 155
Dirsch, V.M., Kiemer, A.K., Wagner, H. and Vollmar, A.M.
The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophage (336) 211
Di Santo, E., Adami, M., Bertorelli, R. and Ghezzi, P.
Systemic interleukin 10 administration inhibits brain tumor necrosis factor production in mice (336) 197
Dittrich, P., see Graier, W.F. (322) 113
Dive, V., see Vincent, B. (334) 49
Dix, D., see Martin, D. (317) 247
Doak, G.J., see Sawynok, J. (333) 1
Dobolyi, A., see Juhász, G. (331) 139
Dobolyi, Á., see Nyitrai, G. (318) 295
Dobronyi, I., Hung, K.-S., Satchell, D.G. and Maguire, M.H.
Evidence for a novel P_{2X} purinoceptor in human placental chorionic surface arteries (320) 61
Docherty, J.R., see O'Rourke, M. (336) 37
Dodd, P.R., see Lewohl, J.M. (326) 265

Dodel, R.C., Hafner, D. and Borchard, U.
Characterization of histamine receptors in the ureter of the dog (318) 395
Domino, E.F., Ni, L., Zhang, H., Kohno, Y. and Sasa, M.
Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys (325) 137
Dondlinger, L.A., see Pieper, G.M. (317) 317
Donnelly, R., see Qu, X. (338) 269
Donner, M., see Muller, S. (337) 103
Donoso, M.V., see Racchi, H. (329) 79
D'Orléans-Juste, P., see Berthiaume, N. (333) 55
Dörnyei, G., see Kardos, J. (337) 83
Dosogne, H., see Hoeben, D. (332) 289
Dot, J., see Rodriguez, F.J. (323) 283
Dötsch, J., Hänze, J., Dittrich, K., Demirakça, S., Haberberger, R. and Rascher, W.
Stimulation of neuropeptide Y release in rat pheochromocytoma cells by nitric oxide (331) 313
Doudet, D.J., Chan, G.L.Y., Holden, J.E., Pate, B.D., Morrison, K.S., Calne, D.B. and Ruth, T.J.
Effects of monoamine oxidase and catechol-*O*-methyltransferase inhibition on dopamine turnover: A PET study with 6-[^{18}F]L-DOPA (334) 31
Dowell, F.J. and Martin, W.
The effects of peroxynitrite on rat aorta: interaction with glucose and related substances (338) 43
Dragsted, N., see Ipsen, M. (336) 29
Draguhn, A., Jungclaus, M., Sokolowa, S. and Heinemann, U.
Losigamone decreases spontaneous synaptic activity in cultured hippocampal neurons (325) 245
Dreifuss, J.-J., see Ala, Y. (331) 285
Dretchen, K.L., see Flores, L.R. (318) 437
Drouin, P., see Muller, S. (337) 103
Drukarch, B., Schepens, E., Stoof, J.C. and Langeveld, C.H.
Anethole dithiolethione prevents oxidative damage in glutathione-depleted astrocytes (329) 259
Duarte, J., Ocete, M.A., Pérez-Vizcaino, F., Zarzuelo, A. and Tamargo, J.
Effect of tyrosine kinase and tyrosine phosphatase inhibitors on aortic contraction and induction of nitric oxide synthase (338) 25
Ducat, M., see Menniti, F. (331) 117
Dumont, Y., see Pheng, L.H. (327) 163
Dumont, Y., see Trinh, T. (318) R1
Duncan, C.J., see Harding, R.J. (330) 47
Duncan, J.N., see Schlachter, S.K. (322) 283
Dupouy, V. and Zajac, J.-M.
Neuropeptide FF receptors control morphine-induced analgesia in the parafascicular nucleus and the dorsal raphe nucleus (330) 129
Durham, R.A., Eaton, M.J., Moore, K.E. and Lookingland, K.J.
Effects of selective activation of dopamine D_2 and D_3 receptors on prolactin secretion and the activity of tuberoinfundibular dopamine neurons (335) 37
Duridanova, D.B., Gagov, H.S. and Boev, K.K.
Two populations of smooth muscle cells in the guinea-pig gastric antrum (333) 105
Duttaroy, A., see Sehba, F. (339) 33
Duttory, A., see Chan, K.W. (319) 225
Duval, D., see Froissard, P. (326) 93
Dvorkin, B., see Makman, M.H. (338) 171
Dwyer, T.M., see Chan, M.-H. (334) 281
Dyer, D.C., see Hill, B.J.F. (339) 147
Dyer, D.C., see Hu, X.-Q. (322) 107
Dyer, D.C., see Hu, X.-Q. (324) 67
Dzieciuch, J.A., see Przesmycki, K. (337) 11
Dziedzicka-Wasylewska, M.
The effect of imipramine on the amount of mRNA coding for rat dopamine D_2 autoreceptors (337) 291
Ebendal, T., see Kobayashi, S. (326) 1
Ebert, B., Mikkelsen, S., Thorkildsen, C. and Borgbjerg, F.M.
Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord (333) 99
Ebert, U., Wlaź, P. and Löscher, W.
Anticonvulsant effects by combined treatment with a glycine$_B$ receptor antagonist and a polyamine site antagonist in amygdala-kindled rats (322) 179
Eckel, J., see Bähr, M. (320) 259
Eckly-Michel, A.E., Le Bec, A. and Lugnier, C.
Chelerythrine, a protein kinase C inhibitor, interacts with cyclic nucleotide phosphodiesterases (324) 85
Edwards, G., see Kirkup, A.J. (317) 165
Efange, S.M.N., see Staley, J.K. (338) 159
Ehlert, F.J., see Burkey, T.H. (336) 295
Eigler, A., see Siegmund, B. (321) 231
Ekblad, E. and Sundler, F.
Distinct receptors mediate pituitary adenylate cyclase-activating peptide- and vasoactive intestinal peptide-induced relaxation of rat ileal longitudinal muscle (334) 61
El-Fakahany, E.E., see Cuadra, A.E. (334) 107
El-Gowelli, H.M., see El-Mas, M.M. (322) 201
El-Gowelli, H.M., see El-Mas, M.M. (337) 235
El-Mas, M.M., Abdel-Galil, A.-G.A., El-Gowelli, H.M. and Daabees, T.T.
Short-term aortic barodenervation diminishes α_1-adrenoceptor reactivity in rat aortic smooth muscle (322) 201
El-Mas, M.M., Daabees, T.T., El-Gowelli, H.M. and Abdel-Galil, A.-G.A.
Enhanced endothelial nitric oxide activity contributes to the reduced responsiveness of vascular α_1-adrenoceptors following aortic barodenervation (337) 235
El-Metwally, M., Shafiee-Nick, R., Pyne, N.J. and Furman, B.L.
The effect of selective phosphodiesterase inhibitors on plasma insulin concentrations and insulin secretion in vitro in the rat (324) 227
Elger, B., Hornberger, W., Schwarz, M. and Seega, J.
MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats (336) 7
Eltze, M., König, H., Ullrich, B. and Grebe, T.
Contraction of guinea-pig gallbladder: muscarinic M_3 or M_4 receptors? (332) 77
Endo, T., see Minami, M. (321) 333
Endoh, M., see Zhu, Y. (332) 195
Endres, S., see Siegmund, B. (321) 231
Engel, J.A., see Blomqvist, O. (334) 149
Ercan, Z.S., see Sipahi (Yılmaz), E. (321) 45
Ericson, M., see Blomqvist, O. (334) 149
Escalante, B., see González-Castillo, C. (329) 245
Eschalier, A., see Mestre, C. (335) 1
Esclapez, M., see Khalilov, I. (319) R5
Espitia, S.A., see Hawkinson, J.E. (329) 213
Esquifino, A.I., Selgas, L., Della Maggiore, V., Castrillón, P.O. and Cardinali, D.P.
Diurnal changes in cyclosporine effect on ornithine decarboxylase and noradrenergic and cholinergic activities in submaxillary lymph nodes (319) 181
Eto, T., see Khan, A.I. (333) 187

Fabre, V., Boni, C., Mocaër, E., Lesourd, M., Hamon, M. and Laporte, A.-M.
[^{3}H]Alnespirone: A novel specific radioligand of 5-HT$_{1A}$ receptors in the rat brain (337) 297
Fadayel, G.M., see Baron, B.M. (323) 181
Falcón, J., Privat, K. and Ravault, J.-P.
Binding of an adenosine A_1 receptor agonist and adenosine A_1 receptor antagonist to sheep pineal membranes (337) 325
Fang, F., Guo, T.-Z., Davies, M.F. and Maze, M.

Opiate receptor in the periaqueductal gray mediate analgesic effect of nitrous oxide in rats (336) 137
Faria, M.S., Muscará, M.N., Moreno Jr., H., Teixeira, S.A., Dias, H.B., De Oliveira, B., Graeff, F.G. and De Nucci, G.
Acute inhibition of nitric oxide synthesis induces anxiolysis in the plus maze test (323) 37
Fatehi-Hassanabad, Z. and Parratt, J.R.
Genistein, an inhibitor of tyrosine kinase, prevents the antiarrhythmic effects of preconditioning (338) 67
Fawzi, A.B., Zhang, H., Weig, B., Hawes, B. and Graziano, M.P.
Nociceptin activation of the human ORL_1 receptor expressed in Chinese hamster ovary cell: Functional homology with opioid receptor (336) 233
Fekete, M.I.K., Horváth, K., Kedves, R., Máté, I., Székely, J.I. and Szentkuti, E.
Selective interaction of homophtalazine derivatives with morphine (331) 175
Feleder, E.C. and Adler-Graschinsky, E.
Endothelium-mediated and N^{ω}-nitro-L-arginine methyl ester-sensitive responses to cromakalim and diazoxide in the rat mesenteric bed (319) 229
Fendt, M., Koch, M. and Schnitzler, H.-U.
NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response (318) 1
Fenu, S., Pinna, A., Ongini, E. and Morelli, M.
Adenosine A_{2A} receptor antagonism potentiates L-DOPA-induced turning behaviour and c-*fos* expression in 6-hydroxydopamine-lesioned rats (321) 143
Férézou, J., see Hajri, T. (320) 65
Feriotto, G., see Passadore, M. (319) 317
Fernández, A.G., see Silvestre, J.S. (318) 257
Fernández, F., see Hirata, H. (321) 217
Fernández, N., see Diéguez, G. (330) 185
Fernández, N., see Monge, L. (338) 135
Fernando, S.R., see Griffin, G. (339) 53
Ferrara, M., see Tirelli, E. (328) 103
Ferré, S., see Giménez-Llort, L. (318) 231
Ferreira, S.H., see Tonussi, C.R. (326) 61
Ferreri, G., see De Sarro, G. (317) 239
Fertel, R.H., see Xia, Y. (320) 95
Fesce, R., see Vicentini, L.M. (318) 497
Fibiger, H.C., see Zernig, G. (337) 1
Fiedeldey, D., see Rice, W. (327) 227
Field, M.J., see Singh, L. (321) 209
Filipeanu, C.M., Brailoiu, E., Costuleanu, M., Costuleanu, A., Toma, C.P. and Branisteanu, D.D.
Vasorelaxant properties of brefeldin A in rat aorta (332) 71
Filipeanu, C.M., De Zeeuw, D. and Nelemans, S.A.
Δ^9-Tetrahydrocannabinol activates $[Ca^{2+}]_i$ increases partly sensitive to capacitative store refilling (336) R1
Finberg, J.P.M., see Shachar, D.B. (332) 237
Fink-Jensen, A., see Scheideler, M.A. (339) 261
Fink, J.S., see Peterfreund, R.A. (336) 71
Finkel, M.S., see Oddis, C.V. (320) 167
Finklestein, S.P., see Ren, J.M. (327) 11
Fioramonti, J., see McLean, P.G. (337) 279
Fioramonti, J., see Million, M. (334) 67
Fiorella, D., see Johnson, R.G. (329) 99
Firestein, G.S., see Wang, J. (320) 241
Fischer, M.J.E., Paulussen, J.J.C., Kok-Van Esterik, J.A.E., Van der Heijden, V.S., De Mol, N.J. and Janssen, L.H.M.
Effects of the anti-allergics astemizole and norastemizole on FcεRI receptor-mediated signal transduction processes (322) 97
Fisher, L. and Pennefather, J.N.
Potencies of agonists acting at tachykinin receptors in the oestrogen-primed rat uterus: Effects of peptidase inhibitors (335) 221
Fleckenstein, A.E., Beyeler, M.L., Jackson, J.C., Wilkins, D.G., Gibb, J.W. and Hanson, G.R.
Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters (324) 179
Fleckenstein, A.E., Metzger, R.R., Beyeler, M.L., Gibb, J.W. and Hanson, G.R.
Oxygen radicals diminish dopamine transporter function in rat striatum (334) 111
Fleckenstein, A.E., Metzger, R.R., Gibb, J.W. and Hanson, G.R.
A rapid and reversible change in dopamine transporters induced by methamphetamine (323) R7
Fleckenstein, A.E.
Effect of methamphetamine on tryptophan hydroxylase activity: Role of hyperthermia (332) 263
Fletcher, P.J., see Sills, T.L. (337) 161
Flores, L.R., Dretchen, K.L. and Bayer, B.M.
Potential role of the autonomic nervous system in the immunosuppressive effects of acute morphine administration (318) 437
Florin, S., Suaudeau, C., Meunier, J.-C. and Costentin, J.
Nociceptin stimulates locomotion and exploratory behaviour in mice (317) 9
Foga, I.O., Geiger, J.D. and Parkinson, F.E.
Nucleoside transporter-mediated uptake and release of [^{3}H]L-adenosine in DDT_1 MF-2 smooth muscle cells (318) 455
Fong, T.M., see Cascieri, M.A. (325) 253
Fontana, D.J., see Hunter, J.C. (324) 153
Fontenot, H.J., see Wang, S.-N. (321) 39
Forn, J., see De Arriba, A.F. (318) 341
Forrest, G., see Sills, G.J. (325) 35
Forster, C.
Interaction of 5-methyl-urapidil with α_1-adrenoceptors in canine blood vessels: impact of pacing-induced heart failure (318) 55
Forster, C., see Le Tran, Y. (336) 177
Förster, R., see Vollmar, A.M. (319) 279
Foster, C., see Chiu, P.J.S. (321) 129
Foster, R.W., see Pocock, T.M. (334) 75
Fournié-Zaluski, M.-C., see Hernando, F. (318) 221
Fournier, A., see Pheng, L.H. (327) 163
Fournier, A., see Pheng, L.H. (333) R3
Fournier, D., see Bottlaender, M. (321) 13
Fradin, A., see Ghezzi, P. (317) 369
Franco-Cereceda, A., see Holm, P. (323) 83
Franco, M., see González-Castillo, C. (329) 245
Franková, D., see Zídek, Z. (331) 245
Franqueza, L., see Valenzuela, C. (326) 257
Frantz, K.J., see Gendreau, P.L. (337) 147
Fraser, C.M., see Sills, G.J. (325) 35
Fredholm, B.B., see Jin, S. (329) 107
Frey, K., Kilbourn, M. and Robinson, T.
Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine (334) 273
Friedman, J., see De Jonge, R. (337) 41
Friese, J., Gleitz, J., Gutser, U.T., Heubach, J.F., Matthiesen, T., Wilffert, B. and Selve, N.
Aconitum sp. alkaloids: the modulation of voltage-dependent Na^+ channels, toxicity and antinociceptive properties (337) 165
Froestl, W., see Chebib, M. (329) 223
Froissard, P., Monrocq, H. and Duval, D.
Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal-like PC12 cells (326) 93
Fuchey, C., see Marchand, V. (336) 187
Fuchigami, J.-i., see Ikegami, K. (328) 75
Fuentes, J.A., see Corchero, J. (323) 193
Fuentes, J.A., see Hernando, F. (318) 221
Fuentes, J.A., see Reche, I. (318) 11

Fuhlendorff, J., see Ladrière, L. (335) 227
Fujii, A., see Nishio, H. (321) 27
Fujii, E., see Irie, K. (339) 289
Fujii, E., see Uchida, Y. (335) 235
Fujii, M., see Takeuchi, H. (329) 27
Fujii, S., Sekino, Y., Kuroda, Y., Sasaki, H., Ito, K.-I. and Kato, H.
8-Cyclopentyltheophylline, an adenosine A_1 receptor antagonist, inhibits the reversal of long-term potentiation in hippocampal CA1 neurons (331) 9
Fujiki, H., see Hirano, T. (324) 201
Fujimori, A., see Shibasaki, M. (335) 167
Fujimori, A., see Shibasaki, M. (335) 175
Fujimoto, J., see Ho, B.Y. (319) 109
Fujimoto, S. and Itoh, T.
Role of nitric oxide and nitric oxide-independent relaxing factor in contraction and relaxation of rabbit blood vessels (330) 177
Fujimura, M., Kita, T., Myou, S., Tachibana, H. and Matsuda, T.
Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo (327) 57
Fujioka, T. and Tsujita, Y.
Effects of single administration of pravastatin sodium on hepatic cholesterol metabolism in rats (323) 223
Fujioka, T., Tsujita, Y. and Shimotsu, H.
Induction of fatty acid synthesis by pravastatin sodium in rat liver and primary hepatocytes (328) 235
Fujishima, M., see Ohya, Y. (330) 93
Fujita, H., see Kageyama, M. (333) 223
Fujita, K., see Matsumura, Y. (319) 65
Fujita, N., see Ikeda, M. (324) 283
Fujita, Y., see Morizane, C. (328) 45
Fujiwara, T., see Inamura, N. (333) 79
Fujiwara, Y., see Sasaki, E. (338) 253
Fukamauchi, F., Wang, Y.-J., Mataga, N. and Kusakabe, M.
Paradoxical behavioral response to apomorphine in tenascin-gene knockout mouse (338) 7
Fukuda, H., see Shiroshita, Y. (339) 183
Fukuda, T., see Sasaki, E. (338) 253
Fukunaga, K., see Sugimura, M. (336) 99
Fukunari, A., Miyai, H., Shinagawa, K., Kawahara, K. and Nakajima, T.
Y-26763 protects the canine heart from a stunning injury through opening of the K_{ATP} channels (323) 197
Fukushi, Y., Ozawa, T., Kanno, T. and Wakui, M.
Na^+-dependent release of intracellular Ca^{2+} induced by purinoceptor in parotid acinar cell of the rat (336) 89
Fukuuchi, Y., see Kobari, M. (317) 269
Fukuyama, J., Ichikawa, K., Hamano, S. and Shibata, N.
Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet (318) 327
Fukuzaki, K., see Kohno, Y. (319) 197
Funada, M., see Sora, I. (324) R1
Furman, B.L., see El-Metwally, M. (324) 227
Furukawa, H., see Kitaichi, K. (318) 205
Furukawa, H., see Kitaichi, K. (318) 7
Furukawa, H., see Noda, Y. (324) 135
Furukawa, K., see Taniguchi, Y. (330) 221
Furukawa, T. and Morishita, H.
Existence of dopamine D_3 receptor on the sympathetic nerve endings in the guinea-pig vas deferens (328) 229
Furukawa, Y., Takei, M., Narita, M., Karasawa, Y., Tada, A., Zenda, H. and Chiba, S.
Different sympathetic–parasympathetic interactions on sinus rate and atrioventricular conduction in dog hearts (334) 191
Furukawa, Y., see Yamazaki, K. (320) 21
Furuse, M., Matsumoto, M., Saito, N., Sugahara, K. and Hasegawa, S.
The central corticotropin-releasing factor and glucagon-like peptide-1 in food intake of the neonatal chick (339) 211
Fuseau, C., see Bottlaender, M. (321) 13
Gackenheimer, S.L., see Gehlert, D.R. (318) 485
Gackenheimer, S.L., see Schober, D.A. (318) 307
Gadski, R., see Gehlert, D.R. (318) 485
Gagov, H.S., see Duridanova, D.B. (333) 105
Galeotti, N., Ghelardini, C., Capaccioli, S., Quattrone, A., Nicolin, A. and Bartolini, A.
Blockade of clomipramine and amitriptyline analgesia by an antisense oligonucleotide to mKv1.1, a mouse *Shaker*-like K^+ channel (330) 15
Gallagher, K.P., see Ignasiak, D.P. (321) 295
Galloway, M.P., see Koch, S. (319) 173
Galloway, M.P., see Norton, C.S. (318) 323
Gambari, R., see Passadore, M. (319) 317
Ganapathy, V., see Prasad, P.D. (325) 85
Gandía, L., Vitale, M.L., Villarroya, M., Ramirez-Lavergne, C., García, A.G. and Trifaró, J.-M.
Differential effects of forskolin and 1,9-dideoxy-forskolin on nicotinic receptor- and K^+-induced responses in chromaffin cells (329) 189
Gandía, L., see Villarroya, M. (320) 249
Gandolfo, P., Patte, C., Leprince, J., Thoumas, J.-L., Vaudry, H. and Tonon, M.-C.
The stimulatory effect of the octadecaneuropeptide (ODN) on cytosolic Ca^{2+} in rat astrocytes is not mediated through classical benzodiazepine receptors (322) 275
Ganten, D., see Rosenkranz, S. (330) 35
Gao, W., see Tang, L. (318) 349
Garattini, S., see Ghezzi, P. (317) 369
Garay, R.P., see Taouil, K. (324) 289
García, A., see Agulló, L. (323) 119
García, A.G., see Gandía, L. (329) 189
García, A.G., see Hirata, H. (321) 217
García, A.G., see Lara, B. (325) 109
García, A.G., see Montiel, C. (332) 183
García, A.G., see Villarroya, M. (320) 249
García, J.L., see Diéguez, G. (330) 185
García, J.L., see Monge, L. (338) 135
García-Martínez, J.A., Villanueva-Peñacarrillo, M.L., Valverde, I., Björkling, F. and Malaisse, W.J.
Potentiation of the insulinotropic and hypoglycemic action of gliquidone by succinic acid esters (325) 65
García-Rafanell, J., see De Arriba, A.F. (318) 341
García-Sacristán, A., see Martínez, A.C. (326) 163
García-Sacristán, A., see Simonsen, U. (329) 153
Garcia, V., see Pavía, J. (320) 209
García-Villalón, A.L., see Diéguez, G. (330) 185
García-Villalón, Á.L., see Monge, L. (338) 135
Garcia-Villar, R., see McLean, P.G. (337) 279
Gariépy, J.-L., see Gendreau, P.L. (337) 147
Garland, C.J., see Waldron, G.J. (318) 89
Garmsen, G.M., see Bolanos, C.A. (317) 1
Garraffo, H.M., see Badio, B. (321) 189
Gartside, S.E., see Sharp, T. (320) 15
Gasior, M., see Borowicz, K.K. (323) 45
Gaster, L., see Hagan, J.J. (331) 169
Gatley, S.J., see Gifford, A.N. (324) 187
Gavin, K. and Docherty, J.R.
Investigation of the subtype of α_2-adrenoceptor mediating pressor responses in the pithed rat (318) 81
Gay, P., see Valenzuela, C. (326) 257
Ge, J., Barnes, J.M., Towers, P. and Barnes, N.M.
Distribution of *S*(−)-zacopride-insensitive [^{125}I]*R*(+)-zacopride binding sites in the rat brain and peripheral tissues (332) 307
Gehlert, D.R., Gackenheimer, S.L., Schober, D.A., Beavers, L., Gadski, R., Burnett, J.P., Mayne, N., Lundell, I. and Larhammar, D.
The neuropeptide Y Y_1 receptor selective radioligand, [^{125}I][Leu^{31},Pro^{34}]peptide YY, is also a high affinity radioligand for human pancreatic polypeptide 1 receptors (318) 485

Gehlert, D.R., see Statnick, M.A. (332) 299
Geiger, J.D., see Delaney, S.M. (332) 35
Geiger, J.D., see Foga, I.O. (318) 455
Genard, J., see Kramp, R.A. (330) 165
Gendreau, P.L., Petitto, J.M., Schnauss, R., Frantz, K.J., Van Hartesveldt, C., Gariépy, J.-L. and Lewis, M.H.
Effects of the putative dopamine D_3 receptor antagonist PNU 99194A on motor behavior and emotional reactivity in C57BL/6J mice (337) 147
Gerhardt, C.C. and Van Heerikhuizen, H.
Functional characteristics of heterologously expressed 5-HT receptors (334) 1
Germany, A., see González, P. (332) 257
Germonpré, P.R., Joos, G.F., Mekeirele, K. and Pauwels, R.A.
Role of the 5-HT receptor in neurogenic inflammation in Fisher 344 rat airways (324) 249
Gerrits, M.A.F.M., see Kuzmin, A.V. (321) 265
Gessa, G.L., Mascia, M.S., Casu, M.A. and Carta, G.
Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A (327) R1
Gessa, G.L., see Imperato, A. (317) 231
Gessa, G.L., see Weiss, F. (337) 219
Getova, D., Bowery, N.G. and Spassov, V.
Effects of $GABA_B$ receptor antagonists on learning and memory retention in a rat model of absence epilepsy (320) 9
Ghelardini, C., Galeotti, N., Pecori Vettori, A., Capaccioli, S., Quattrone, A. and Bartolini, A.
Effect of K^+ channel modulation on mouse feeding behaviour (329) 1
Ghezzi, P., Garattini, S., Mennini, T., Bertini, R., Delgado Hernandez, R., Benigni, F., Sacco, S., Skorupska, M., Mengozzi, M., Latini, R., Kurosaki, M., Lombet, A., Fradin, A., Bonnet, J., Rolland, Y. and Brion, J.-D.
Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice (317) 3 /9
Ghosh, A.K., see Mandhane, S.N. (328) 135
Ghosh, D., see Scheideler, M.A. (339) 261
Gianoulakis, C., see Guillaume, P. (319) 215
Giardina, W.J., see Shiosaki, K. (317) 183
Gibb, J.W., see Fleckenstein, A.E. (323) R7
Gibb, J.W., see Fleckenstein, A.E. (324) 179
Gibb, J.W., see Fleckenstein, A.E. (334) 111
Gibbs, B.F., Arm, J.P., Gibson, K., Lee, T.H. and Pearce, F.L.
Human lung mast cells release small amounts of interleukin-4 and tumour necrosis factor-α in response to stimulation by anti-IgE and stem cell factor (327) 73
Gies, E.K., see Peterfreund, R.A. (336) 71
Gifford, A.N., Samiian, L., Gatley, S.J. and Ashby Jr., C.R.
Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices (324) 187
Gilmore, J., see O'Neill, M.J. (332) 121
Giménez-Llort, L., Ferré, S., De Vera, N. and Martínez, E.
Motor depressant effects of systemically administered polyamines in mice: involvement of central NMDA receptors (318) 231
Gintzler, A.R., Adapa, I.D., Toll, L., Medina, V.M. and Wang, L.
Modulation of enkephalin release by nociceptin (orphanin FQ) (325) 29
Giordano, J. and Sacks, S.M.
Sub-anesthetic doses of bupivacaine or lidocaine increase peripheral ICS-205 930-induced analgesia against inflammatory pain in rats (334) 39
Giraldo, J., see Pardo, L. (335) 73
Gispen, W.H., see Van Buren, T. (318) 73
Giuliani, G., see Nava, F. (331) 267
Giuliani, S. and Maggi, C.A.
Prejunctional modulation by nociceptin of nerve-mediated inotropic responses in guinea-pig left atrium (332) 231
Giuliani, S., Tramontana, M., Lecci, A. and Maggi, C.A.
Effect of nociceptin on heart rate and blood pressure in anaesthetized rats (333) 177
Gjerstad, J., Tjølsen, A. and Hole, K.
A dual effect of 5-HT_{1B} receptor stimulation on nociceptive dorsal horn neurones in rats (335) 127
Gjerstad, J., Tjølsen, A. and Hole, K.
The effect of 5-HT_{1A} receptor stimulation on nociceptive dorsal horn neurones in rats (318) 315
Glass-Marmor, L. and Beitner, R.
Detachment of glycolytic enzymes from cytoskeleton of melanoma cells induced by calmodulin antagonists (328) 241
Gleitz, J. and Peters, M.
Influence of extracellular K^+ concentration on the time-course of Na^+/K^+-ATPase inhibition by cardiac glycosides with fast and low binding kinetics (335) 89
Glez-Correa, J.A., see Pavía, J. (320) 209
Glick, S.D., see Maisonneuve, I.M. (336) 123
Glowinski, J., see Beaujouan, J.-C. (319) 307
Gobert, A., see Newman-Tancredi, A. (319) 379
Goda, Y., see Nakamura, T. (322) 83
Godet, D., see Biton, B. (323) 277
Goeldner, M., see Weill, C. (333) 269
Gogas, K.R., see Hunter, J.C. (324) 153
Gold, L.H., see Roberts, A.J. (326) 119
Goldbach, J.-M., Roth, J., Störr, B. and Zeisberger, E.
Changes of abdominal temperature and circulating levels of cortisol and interleukin-6 in response to intra-arterial infusions of tumor necrosis factor-α or tumor necrosis factor-β in guinea pigs (334) 249
Goldbach, J.-M., Roth, J., Störr, B. and Zeisberger, E.
Influence of pentoxifylline on fevers induced by bacterial lipopolysaccharide and tumor necrosis factor-α in guinea pigs (319) 273
Goldhill, J., Porquet, M.-F. and Angel, I.
Post-synaptic 5-HT_4 receptor modulation of tachykinergic excitation of rat oesophageal tunica muscularis mucosae (323) 229
Goldstein, M., see Tsuda, K. (321) 5
Gombos, G., see Schaffhauser, H. (334) 289
Gomes, P., Serrão, M.P., Vieira-Coelho, M.A. and Soares-da-Silva, P.
Competitive and non-competitive inhibition of L-3,4-dihydroxyphenylalanine uptake in Opossum kidney cells (332) 219
Gómez, B., see Monge, L. (338) 135
Gómez-Casajús, L.A., see De Arriba, A.F. (318) 341
Gomeza, J., see Mary, S. (335) 65
Gomita, Y., see Suemaru, K. (335) 139
Gommans, J., see King, C.M.F. (325) 121
González, A.A. and Puig, M.M.
Ondansetron facilitates neuromuscular transmission in the guinea-pig ileum (328) 201
González-Castillo, C., Franco, M., Quintana, A., Escalante, B. and Martínez, F.
Indomethacin and piroxicam inhibit Na^+-adenosine transport in rat renal brush-border membranes (329) 245
González, P., Cabello, P., Germany, A., Norris, B. and Contreras, E.
Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists (332) 257
Göransson-Nyberg, A., see Cassel, G. (332) 43
Gordon, F.J., see Patterson, A.B. (333) 47
Gören, Z., see Aslan, N. (333) 63
Gören, Z., see Tellioğlu, T. (336) 163
Gori, E., see Sala, M. (328) 143
Goto, K., see Wei, S. (321) 307
Goto, M., see Inagaki, N. (336) 225
Goto, S., see Takahashi, W. (339) 165
Goto, W., see Kageyama, M. (333) 223
Gotoh, Y., see Kagitani, F. (332) 89
Gottwald, E., see Dhein, S. (339) 129
Gottwald, M., see Dhein, S. (339) 129

Gottwald, M., see Müller, A. (327) 65
Gozlan, H., see Lanfumey, L. (323) 137
Grabarević, Ž., see Sikirić, P. (332) 23
Graeff, F.G., see Faria, M.S. (323) 37
Graier, W.F., Simecek, S., Hoebel, B.G., Wascher, T.C., Dittrich, P. and Kostner, G.M.
Antioxidants prevent high-D-glucose-enhanced endothelial Ca^{2+}/cGMP response by scavenging superoxide anions (322) 113
Grana, E., Boselli, C. and Bianchi, L.
Cromakalim blocks the purinergic response evoked in rat vas deferens by single-pulse electrical stimulation (319) 57
Granger, P., see Biton, B. (323) 277
Grau, M., see Cortijo, J. (333) 69
Gray, A.M., see Phan, T.A. (323) R5
Graziano, M.P., see Fawzi, A.B. (336) 233
Grebe, T., see Eltze, M. (332) 77
Green, M.E., see Kirkup, A.J. (317) 165
Grenegård, M., see Johansson Rydberg, I.G.M. (329) 175
Gressier, H., see Millan, M.J. (321) R7
Greten, T.F., see Siegmund, B. (321) 231
Griffin, G., Fernando, S.R., Ross, R.A., McKay, N.G., Ashford, M.L.J., Shire, D., Huffman, J.W., Yu, S., Lainton, J.A.H. and Pertwee, R.G.
Evidence for the presence of CB_2-like cannabinoid receptors on peripheral nerve terminals (339) 53
Groenink, L., see Compaan, J.C. (324) 161
Gross, R., see Cadêne, A. (318) 145
Grosser, T., Zucker, T.-P., Weber, A.-A., Schulte, K., Sachinidis, A., Vetter, H. and Schrör, K.
Thromboxane A_2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen (319) 327
Guardiola-Lemaitre, B., see Le Gouic, S. (339) 271
Guarini, S., Bini, A., Bazzani, C., Ricigliano, G.M., Cainazzo, M.-M., Tomasi, A. and Bertolini, A.
Adrenocorticotropin normalizes the blood levels of nitric oxide in hemorrhage-shocked rats (336) 15
Guédin, D., see N'Diaye, N. (321) 387
Guenet, C., see Weill, C. (333) 269
Guerrero, J.M., see Pozo, D. (321) 379
Guilbaud, G., see Catheline, G. (318) 273
Guilbaud, G., see Idänpään-Heikkilä, J.J. (325) 155
Guilbault, N., see Rousseau, G. (326) 75
Guillaume, P., Gutkowska, J. and Gianoulakis, C.
Alterations in brain levels of atrial and C-type natriuretic peptides after chronic moderate ethanol consumption in spontaneously hypertensive rats (319) 215
Guiso, G., see Calzi, F. (338) 185
Guitteny, A.-F. and Herbert, J.-M.
Failure of heparin to inhibit the expression of the thrombin receptor following endothelial injury of the rabbit carotid artery (327) 157
Gully, D., see Schaeffer, P. (323) 215
Günzler, V., see Wirth, K.J. (337) 45
Guo, T.-Z., see Fang, F. (336) 137
Guo, Y., Mochizuki, T., Morii, E., Kitamura, Y. and Maeyama, K.
Role of mast cell histamine in the formation of rat paw edema: A microdialysis study (331) 237
Guth, P.H., see Király, Á. (334) 241
Gutiérrez, M., Menéndez, L., Ruiz-Gayo, M., Hidalgo, A. and Baamonde, A.
Cyproterone acetate displaces opiate binding in mouse brain (328) 99
Gutser, U.T., see Friese, J. (337) 165
Guzmán, S., see Racchi, H. (329) 79
György, K., see Vegh, A. (333) 33

Haapalinna, A., see Yavich, L. (339) 113
Haberberger, R., see Dütsch, J. (331) 313
Hadjiconstantinou, M., see Cho, S. (323) 149
Haendeler, J., Zeiher, A.M. and Dimmeler, S.
Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax (317) 407
Haensel, S.M. and Slob, A.K.
Flesinoxan: a prosexual drug for male rats (330) 1
Hagan, J.J., Slade, P.D., Gaster, L., Jeffrey, P., Hatcher, J.P. and Middlemiss, D.N.
Stimulation of 5-HT_{1B} receptors causes hypothermia in the guinea pig (331) 169
Hagiwara, H., see Seki, T. (331) 87
Hagiwara, K., see Yano, T. (323) 99
Hahn, E.G., see Konturek, P.Ch. (322) 73
Hahn, S.-J., see Sim, S.-S. (324) 205
Haj-Dahmane, S., see Lanfumey, L. (323) 137
Hajri, T., Chanussot, F., Férézou, J., Riottot, M., Lafont, H., Laruelle, C. and Lutton, C.
Reduced cholesterol absorption in hamsters by crilvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (320) 65
Hale, J.J., see Rupniak, N.M.J. (326) 201
Hall, J.M., see Hourani, S.M.O. (334) 95
Hallak, H., see Ignasiak, D.P. (321) 295
Halmos, T., Santarromana, M., Antonakis, K. and Scherman, D.
Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter (318) 477
Hamada, N. and Nagase, M.
In vivo effect of OPC15161, a superoxide scavenger, on anti-Thy1 nephritis (317) 123
Hamaguchi, A., Kim, S., Wanibuchi, H. and Iwao, H.
Imidapril inhibits increased transforming growth factor-β1 expression in remnant kidney model (331) 27
Hamano, S., see Fukuyama, J. (318) 327
Hamaue, N., see Minami, M. (321) 333
Hamel, E., see Petty, M.A. (336) 127
Hammer, R., see Walland, A. (330) 213
Hamon, M., see Fabre, V. (337) 297
Hamon, M., see Lanfumey, L. (323) 137
Han, C., see Ipsen, M. (336) 29
Han, C., see Zhu, W. (329) 55
Hancock, A.A., see Ireland, L.M. (327) 79
Haneda, M., see Togawa, M. (336) 291
Haniuda, K., Nakane, T. and Chiba, S.
Different contributions of ATP and noradrenaline to neurotransmission in the isolated canine intermediate auricular artery (333) 163
Hänninen, V., see Virtanen, K.A. (332) 215
Hanoun, N., see Le Gouic, S. (339) 271
Hansen, C.A., see Wenham, D. (339) 77
Hanson, G.R., see Fleckenstein, A.E. (323) R7
Hanson, G.R., see Fleckenstein, A.E. (324) 179
Hanson, G.R., see Fleckenstein, A.E. (334) 111
Hanson, G.R., see Huang, W. (332) 15
Hänze, J., Worgall, S. and Rascher, W.
Monitoring of antisense effects of oligonucleotides targeted to the neuropeptide Y Y_1 receptor gene (330) 87
Hanževački, M., see Sikirić, P. (332) 23
Hara, T., see Hotta, N. (326) 45
Hara, Y. and Nakaya, H.
Dual effects of extracellular ATP on the muscarinic acetylcholine receptor-operated K^+ current in guinea-pig atrial cells (324) 295
Hara, Y., see Watanabe, Y. (338) 71
Harding, R.J. and Duncan, C.J.
Protection against cellular damage in the perfused rat heart by lowered pH (330) 47
Hargreaves, K.M., see Richardson, J.D. (319) R3
Hargreaves, R.J., see Cumberbatch, M.J. (328) 37
Hargreaves, R.J., see Rupniak, N.M.J. (326) 201
Hargreaves, R.J., see Seabrook, G.R. (317) 129
Hargreaves, R.J., see Williamson, D.J. (328) 61
Harnyuttanakorn, P., see Siripurkpong, P. (331) 227

Harris, L.S., see Aceto, M.D. (338) 215
Harris, L.S., see Martin, T.J. (324) 141
Harris, R.A., see Minami, K. (339) 237
Harrison, B.L., see Baron, B.M. (323) 181
Harrison, T., see Seabrook, G.R. (317) 129
Harro, J., see Kask, A. (317) R3
Hartman, H.B., see Kongsamut, S. (317) 417
Hartmann, G., see Siegmund, B. (321) 231
Hasegawa, S., see Furuse, M. (339) 211
Hasegawa, T., see Itoh, A. (322) 11
Hasegawa, T., see Itoh, A. (332) 113
Hasegawa, T., see Kitaichi, K. (318) 205
Hasegawa, T., see Kitaichi, K. (318) 7
Hashimoto, K., see Adachi, Y. (324) 223
Hashimoto, K., see Arita, J. (318) 333
Hashimoto, K., see Aye, N.N. (339) 121
Hashimoto, K., see Xue, Y.X. (317) 309
Hashimoto, N., see Matsumura, Y. (319) 65
Hashimoto, S., see Yamazaki, R. (329) 181
Hashizume, H., see Chen, M. (333) 261
Haskó, G., see Németh, Z.H. (339) 215
Hastrup, S., see Westh-Hansen, S.E. (329) 253
Hata, H., see Ikegami, K. (328) 75
Hata, Y., Kawabe, T., Hiraishi, H., Ota, S., Terano, A. and Ivey, K.J.
Antioxidant defenses of cultured colonic epithelial cells against reactive oxygen metabolites (321) 113
Hatcher, J.P., see Hagan, J.J. (331) 169
Hätönen, T., see Mustanoja, S.M. (326) 229
Hatori, C., see Inamura, N. (333) 79
Hatta, S., see Amemiya, N. (318) 403
Hatta, S., see Amemiya, N. (339) 173
Hattori, H., see Takeuchi, H. (329) 27
Hattori, Y. and Kanno, M.
Involvement of α_{1B}-adrenoceptors in the positive inotropic effect of endogenous noradrenaline in rabbit myocardium (329) 165
Hatzoglou, A., see Kampa, M. (335) 255
Hauber, W. and Münkle, M.
Motor depressant effects mediated by dopamine D_2 and adenosine A_{2A} receptors in the nucleus accumbens and the caudate-putamen (323) 127
Hawes, B., see Fawzi, A.B. (336) 233
Hawkinson, J.E. and Espitia, S.A.
Effects of thiocyanate and AMPA receptor ligands on (*S*)-5-fluorowillardiine, (*S*)-AMPA and (*R,S*)-AMPA binding (329) 213
Hawkinson, J.E., Acosta-Burruel, M., Ta, N.D. and Wood, P.L.
Novel phosphoserine phosphatase inhibitors (337) 315
Hayashi, S., see Suma, C. (336) 283
Hayward, R., Nossuli, T.O., Scalia, R. and Lefer, A.M.
Cardioprotective effect of interleukin-10 in murine myocardial ischemia-reperfusion (334) 157
He, S. and Walls, A.F.
Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation (328) 89
He, Y. and Tabrizchi, R.
Effects of niflumic acid on α_1-adrenoceptor-induced vasoconstriction in mesenteric artery in vitro and in vivo in two-kidney one-clip hypertensive rats (328) 191
Heal, D.J., see Phillips, I. (337) 189
Heal, D.J., see Prow, M.R. (317) 21
Hedley, L.R., see Hunter, J.C. (324) 153
Heeringa, M.J., see DeBoer, P. (317) 257
Hegenbart, R., see Bartoszyk, G.D. (322) 147
Heidari, M.-R., see Zarrindast, M.-R. (338) 11
Heikki Vapaatalo, see Li, L. (331) 221
Heinemann, U., see Draguhn, A. (325) 245
Heitsch, H., see Wirth, K.J. (337) 45
Heitz, F., see Weill, C. (333) 269
Heitz, M.-P., see Schaffhauser, H. (334) 289
Hellewell, P.G., see Teixeira, M.M. (323) 255
Hellstrom, W.J.G., see Champion, H.C. (319) 71
Helyes, Z., see Pintér, E. (325) 57
Hemsén, A., Modin, A., Wanecek, M., Malmström, R.E. and Weitzberg, E.
Effects of Ro 47-0203 and PD155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig (318) 369
Herbert, J.-M., see Guitteny, A.-F. (327) 157
Herbert, J.-M., see Schaeffer, P. (323) 215
Herman, A., see Kramp, R.A. (330) 165
Herman, A.G., see De Winter, B.Y. (339) 63
Herman, A.G., see Michielsen, P.P. (329) 137
Herman, A.G., see Zamora, R. (321) 87
Hermsen, H.P.H., see Smeets, R.L.L. (325) 93
Hernández, A., see Mestre, C. (335) 1
Hernando, F., Fuentes, J.A., Fournié-Zaluski, M.-C., Roques, B.P. and Ruiz-Gayo, M.
Antidepressant-like effects of CCK_B receptor antagonists: involvement of the opioid system (318) 221
Herrero, C.J., see Montiel, C. (332) 183
Herscheid, J.D.M., see Custers, F.G.J. (338) 177
Hess, F., see Berthiaume, N. (333) 55
Heubach, J.F., see Friese, J. (337) 165
Heuer, H.O., Wenz, B., Jennewein, H.-M. and Urich, K.
Characterisation of a novel airway late phase model in the sensitized guinea pig which uses silica and *Bordetella pertussis* as adjuvant for sensitization (317) 361
Heyman, H.R., see Albert, D.H. (325) 69
Heyneman, R., see Hoeben, D. (332) 289
Hibert, M., see Petty, M.A. (336) 127
Hicks, C.A., see O'Neill, M.J. (332) 121
Hidaka, H., see Mori, Y. (320) 183
Hidaka, H., see Mori, Y. (330) 195
Hidaka, H., see Togawa, M. (336) 291
Hidalgo, A., see Gutiérrez, M. (328) 99
Hidalgo, A., see Menéndez, L. (335) 9
Higashi, M., see Yamaguchi, Y. (329) 37
Higashi, Y., see Shinguh, Y. (337) 63
Higashiyama, K., see Kamei, J. (337) 223
Higgins, G.A., see Varty, G.B. (339) 101
Higgins, M.J. and Stone, T.W.
The contribution of adenosine to paired-pulse inhibition in the normal and disinhibited hippocampal slice (317) 215
Higuchi, H. and Satoh, T.
Endothelin-1 induces vasoconstriction and nitric oxide release via endothelin ET_B receptors in isolated perfused rat liver (328) 175
Higueras, J., Sarriá, B., Ortiz, J.L., Cortijo, J., Maruenda, A., Barberá, M. and Morcillo, E.J.
Halothane inhibits endothelium-dependent relaxation elicited by acetylcholine in human isolated pulmonary arteries (326) 175
Hikosaka, O., see Horikawa, H.P.M. (326) 15
Hilaire, G., Bou, C. and Monteau, R.
Serotonergic modulation of central respiratory activity in the neonatal mouse: an in vitro study (329) 115
Hill, B., Ralevic, V., Crowe, R. and Burnstock, G.
Innervation and nitric oxide modulation of mesenteric arteries of the Golden hamster (317) 275
Hill, B.J.F. and Dyer, D.C.
Pharmacological characterization of α-adrenoceptors in the bovine median caudal artery (339) 147
Hill, R.G., see Rupniak, N.M.J. (326) 201
Hill, R.G., see Seabrook, G.R. (317) 129
Hill, R.G., see Williamson, D.J. (328) 61
Hill, S.J., see Dickenson, J.M. (321) 77
Hinz, V., see Scali, C. (325) 173
Hipskind, P.A., see Cellier, E. (318) 377

Hirabayashi, N., see Ishizaki, K. (333) 207
Hirafuji, M., see Minami, M. (321) 333
Hiraishi, H., see Hata, Y. (321) 113
Hirano, T., Ohura, M., Orito, K., Fujiki, H., Miyakoda, G. and Mori, T.
Venodilator effects of pranidipine, a 1,4-dihydropyridine Ca^{2+} channel antagonist, in rats: comparison with nifedipine and amlodipine (324) 201
Hirata, H., Albillos, A., Fernández, F., Medrano, J., Jurkiewicz, A. and García, A.G.
ω-Conotoxins block neurotransmission in the rat vas deferens by binding to different presynaptic sites on the N-type Ca^{2+} channel (321) 217
Hirobe, M., see Satoh, M. (327) 175
Hirose, M., Furukawa, Y., Nagashima, Y., Lakhe, M., Miyashita, Y. and Chiba, S.
PACAP-27 causes negative and positive dromotropic effects in anesthetized dogs (338) 35
Hirose, S., see Seki, T. (331) 87
Hirosumi, J., see Inamura, N. (333) 79
Hisa, H., see Adachi, Y. (324) 223
Hisa, H., see Nagayama, T. (327) 135
Hisa, H., see Yoshida, K. (338) 131
Hisamichi, N., see Suzuki, K.-i. (336) 169
Hitoshi Hongo, see Takano, H. (323) 107
Hitosugi, H., see Kamei, J. (326) 31
Hiyama, H., see Inagaki, N. (336) 225
Hjalmarson, Å., see Skomedal, T. (333) 169
Ho, B.Y., Holmes, B.B., Zhao, J. and Fujimoto, J.
Determination of δ-opioid receptors in NG108-15 cells (319) 109
Ho, I.H.M., see Huang, Y. (327) 209
Hodgson, W.C., see James, G.M. (322) 55
Hodoğlugil, U., see Sipahi (Yılmaz), E. (321) 45
Hoebeke, J., see Skomedal, T. (333) 169
Hoebel, B.G., see Graier, W.F. (322) 113
Hoeben, D., Dosogne, H., Heyneman, R. and Burvenich, C.
Effect of antibiotics on the phagocytotic and respiratory burst activity of bovine granulocytes (332) 289
Hoffmann, S., see Rosenkranz, S. (330) 35
Hohlfeld, T., see Dhein, S. (339) 129
Hohlweg, R., see Scheideler, M.A. (339) 261
Holden, J.E., see Doudet, D.J. (334) 31
Hole, K., see Gjerstad, J. (318) 315
Hole, K., see Gjerstad, J. (335) 127
Holm, P., Liska, J. and Franco-Cereceda, A.
The endothelin ET_B receptor antagonist BQ-788 reduces the pulmonary vasodilator effect of endothelin-1 during acute hypoxia in pigs (323) 83
Holsboer, F., see Schöbitz, B. (331) 97
Hölscher, C., Anwyl, R. and Rowan, M.J.
Activation of group-II metabotropic glutamate receptors blocks induction of long-term potentiation and depotentiation in area CA1 of the rat in vivo (322) 155
Holt, R.A., Bateson, A.N. and Martin, I.L.
Chronic zolpidem treatment alters $GABA_A$ receptor mRNA levels in the rat cortex (329) 129
Holtzman, S.G., see Patterson, A.B. (333) 47
Holý, A., see Zídek, Z. (331) 245
Homaidan, F.R., Tripodi, J., Zhao, L. and Burakoff, R.
Regulation of ion transport by histamine in mouse cecum (331) 199
Homey, B., Schuppe, H.-C., Assmann, T., Vohr, H.-W., Lauerma, A.I., Ruzicka, T. and Lehmann, P.
A local lymph node assay to analyse immunosuppressive effects of topically applied drugs (325) 199
Honda, K., see Yatsu, T. (322) 45
Honda, Y., see Kaneda, K. (322) 259
Honda, Y., see Morizane, C. (328) 45
Honoré, P., see Buritova, J. (320) 73
Hoppe, J., see Zeevalk, G.D. (320) 111
Horan, B., see Morgan, A.E. (331) R1
Horikawa, H.P.M., Nakazato, T. and Hikosaka, O.
Duration of catalepsy correlates with increased intrastriatal sulpiride (326) 15
Horiuchi, M., see Abe, K. (321) 149
Hornberger, W., see Elger, B. (336) 7
Horowitz, J.D., see De la Lande, I.S. (318) 65
Horváth, E.J., see Palkovits, M. (331) 53
Horváth, K., see Fekete, M.I.K. (331) 175
Hoshino, M., see Kakuyama, H. (329) 85
Hosohata, K., see Hosohata, Y. (321) R1
Hosohata, K., see Quock, R.M. (326) 101
Hosohata, Y., Quock, R.M., Hosohata, K., Makriyannis, A., Consroe, P., Roeske, W.R. and Yamamura, H.I.
AM630 antagonism of cannabinoid-stimulated [^{35}S]GTPγS binding in the mouse brain (321) R1
Hosohata, Y., see Quock, R.M. (326) 101
Hotta, H., see Messlinger, K. (332) 173
Hotta, N., Koh, N., Sakakibara, F., Nakamura, J., Hara, T., Hamada, Y., Fukasawa, H., Kakuta, H. and Sakamoto, N.
Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats (326) 45
Hou, W.-Y., Shyu, B.-C., Chen, T.-M., Lee, J.-W., Shieh, J.-Y. and Sun, W.-Z.
Intrathecally administered *c-fos* antisense oligodeoxynucleotide decreases formalin-induced nociceptive behavior in adult rats (329) 17
Hourani, S.M.O., Smith, N.C., Nettell, J.J. and Hall, J.M.
Relaxation of the ovine isolated iris sphincter by adenosine receptor agonists: Lack of effect of adenosine A_1 and A_2 receptor antagonists (334) 95
Hourani, S.M.O., see Nicholls, J. (338) 143
Hourani, S.M.O., see Prentice, D.J. (323) 103
Hoyle, C.H.V., Pintor, J., Gualix, J. and Miras-Portugal, M.T.
Antagonism of P2X receptors in guinea-pig vas deferens by diinosine pentaphosphate (333) R1
Hropot, M., see Wirth, K.J. (337) 45
Hruby, V.J., see Quock, R.M. (326) 101
Hsu, M.-F., see Wang, J.-P. (319) 131
Hu, S. and Kim, H.S.
On the mechanism of the differential effects of NS004 and NS1608 in smooth muscle cells from guinea pig bladder (318) 461
Hu, S., Kim, H.S., Savage, P. and Jeng, A.Y.
Activation of BK_{Ca} channel via endothelin ET_A receptors in porcine coronary artery smooth muscle cells (324) 277
Hu, X.-Q. and Dyer, D.C.
5-Hydroxytryptamine stimulates phosphoinositide hydrolysis and contraction in the ovine umbilical artery (322) 107
Hu, X.-Q. and Dyer, D.C.
Heterogeneity and complexity of α_1-adrenoceptors in the ovine uterine artery and umbilical vein (324) 67
Huang, L., Breakwell, N.A., Rowan, M.J. and Anwyl, R.
PCCG-IV inhibits the induction of long-term potentiation in the dentate gyrus in vitro (332) 161
Huang, W. and Hanson, G.R.
Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems (332) 15
Huang, Y. and Cheung, K.-K.
Endothelium-dependent rhythmic contractions induced by cyclopiazonic acid in rat mesenteric artery (332) 167
Huang, Y., Lau, C.-W. and Ho, I.H.M.
NS 1619 activates Ca^{2+}-activated K^+ currents in rat vas deferens (325) 21
Huang, Y., Lau, C.W. and Ho, I.H.M.
Involvement of ATP-sensitive K^+ channels in the inhibitory effect of calcitonin gene-related peptide on neurotransmission in rat vas deferens (327) 209

Huang, Y.
Inhibition of contractions by tricyclic antidepressants and xylamine in rat vas deferens (327) 41
Huang, Y.-H., Tsai, S.-J., Huang, H.-J. and Sim, C.-B.
Effects of amphetamine challenge on local cerebral glucose utilization after chronic dopamine D_1 and D_2 receptor agonist administration to rats (338) 117
Huchet-Cadiou, C., see Talon, S. (327) 33
Huffman, J.W., see Griffin, G. (339) 53
Hughes, J., see Panegyres, P.K. (328) 31
Hughes, J., see Singh, L. (321) 209
Hughes, Z.A. and Stanford, S.C.
Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex (317) 83
Huifang, G., see Kukkonen, J.P. (335) 99
Hulkower, K.I., Otis, E.R., Wernimont, A.K. and Bell, R.L.
Stimulus dependence of non-steroidal antiinflammatory drug potency in a cellular assay of prostaglandin H synthase-2 (331) 79
Hume, S.P., Ashworth, S., Lammertsma, A.A., Opacka-Juffry, J., Law, M.P., McCarron, J.A., Clark, R.D., Nutt, D.J. and Pike, V.W.
Evaluation in rat of RS-79948-197 as a potential PET ligand for central α_2-adrenoceptors (317) 67
Hung, W.-C., see Sheu, J.-R. (318) 469
Hunt, T., see Ye, J.H. (337) 87
Hunter, J.C., Gogas, K.R., Hedley, L.R., Jacobson, L.O., Kassotakis, L., Thompson, J. and Fontana, D.J.
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain (324) 153
Hurley, M.J., Stubbs, C.M., Jenner, P. and Marsden, C.D.
Dopamine D_3 receptors are not involved in the induction of c-*fos* mRNA by neuroleptic drugs: comparison of the dopamine D_3 receptor antagonist GR103691 with typical and atypical neuroleptics (318) 283
Hussain, S.N.A., see Kristof, A.S. (328) 69
Hussain, T., Abdul-Wahab, R. and Lokhandwala, M.F.
Bromocriptine stimulates Na^+,K^+-ATPase in renal proximal tubules via the cAMP pathway (321) 259
Hutson, P.H. and Barton, C.L.
L-701,324, a glycine/NMDA receptor antagonist, blocks the increase of cortical dopamine metabolism by stress and DMCM (326) 127
Huupponen, R., see Savontaus, E. (328) 207
Huupponen, R., see Virtanen, K.A. (332) 215
Hwang, T.-L., see Wu, S.-N. (327) 233

Ialenti, A., see D'Acquisto, F. (339) 87
Ianaro, A., see D'Acquisto, F. (339) 87
Iannucci, U., see Melis, M.R. (328) 115
Ibarra, M., Terrón, J.A., López-Guerrero, J.J. and Villalobos-Molina, R.
Evidence for an age-dependent functional expression of α_{1D}-adrenoceptors in the rat vasculature (322) 221
Ibarra, M., see Villalobos-Molina, R. (322) 225
Ichihara, T., see Nanaumi, K. (327) 239
Ichikawa, K., see Fukuyama, J. (318) 327
Ichikawa, T., see Yano, T. (323) 99
Ichimaru, Y., see Imanishi, T. (321) 273
Ichimura, M., see Manabe, H. (332) 97
Ichino, T., see Koike, K. (334) 217
Idänpään-Heikkilä, J.J., Perrot, S., Guilbaud, G. and Kayser, V.
In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK_B receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics (325) 155
Igawa, Y., see Nishizawa, S. (335) 211
Ignasiak, D.P., McClanahan, T.B., Saganek, L.J., Potoczak, R.E., Hallak, H. and Gallagher, K.P.
Effects of endothelin ET_A receptor antagonism with PD 156707 on hemodynamics and renal vascular resistance in rabbits (321) 295
Ihara, T., Ikeda, U., Ishibashi, S. and Shimada, K.
Tranilast inhibits contraction of rat aortic smooth muscle (329) 43
Iida, R., see Itoh, A. (332) 113
Ijzerman, A.P., see Lorenzen, A. (334) 299
Ijzerman, A.P., see Smeets, R.L.L. (325) 93
Ikeda, M., Ikeda, U., Shimada, K., Fujita, N., Okada, K., Saito, T., Minota, S. and Kano, S.
Tranilast inhibits the growth of rat mesangial cells (324) 283
Ikeda, U., see Ikeda, M. (324) 283
Ikeda, U., see Shimpo, M. (338) 97
Ikegami, K., Hata, H., Fuchigami, J.-i., Tanaka, K., Kohjimoto, Y., Uchida, S. and Tasaka, K.
Apafant (a PAF receptor antagonist) suppresses the early and late airway responses in guinea pigs: a comparison with antiasthmatic drugs (328) 75
Ilhan, M., see Iskit, A.B. (326) 183
Ilien, B., see Weill, C. (333) 269
Illes, P., see Poelchen, W. (332) 267
Ilyin, V.I., see Whittemore, E.R. (337) 197
Imafuku, J., see Miyamoto, S. (333) 279
Imai, K., see Shinguh, Y. (337) 63
Imai, S., see Kawada, T. (323) 75
Imaizumi, Y., see Ishii, Y. (331) 295
Imaki, T., see Seki, T. (331) 87
Imanishi, T., Sawa, A., Ichimaru, Y., Miyashiro, M., Kato, S., Yamamoto, T. and Ueki, S.
Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents (321) 273
Imperato, A., Obinu, M.C., Carta, G., Mascia, M.S., Casu, M.A. and Gessa, G.L.
Reduction of dopamine release and synthesis by repeated amphetamine treatment: Role in behavioral sensitization (317) 231
Inada, H., see Matsushima, S. (333) 93
Inada, Y., see Ojima, M. (319) 137
Inadome, A., see Takahashi, W. (339) 165
Inagaki, C., see Tanabe, T. (321) 137
Inagaki, N., Kawasaki, H., Hiyama, H., Goto, M., Matsuo, A. and Nagai, H.
Inhibitory mechanisms of β-adrenoceptor agonists for immunoglobulin E-mediated experimental allergic reactions in rats (336) 225
Inagaki, O., see Shibasaki, M. (335) 175
Inagaki, O., see Suzuki, K.-i. (336) 169
Inagaki, O., see Yatsu, T. (322) 45
Inamura, N., Asano, M., Hatori, C., Sawai, H., Hirosumi, J., Fujiwara, T., Kayakiri, H., Satoh, S., Abe, Y., Inoue, T., Sawada, Y., Oku, T. and Nakahara, K.
Pharmacological characterization of a novel, orally active, nonpeptide bradykinin B_2 receptor antagonist, FR167344 (333) 79
Inatomi, N., see Sato, F. (322) 63
Innis, R.B., see Abi-Dargham, A. (321) 285
Inoue, A., Miki, S., Seto, M., Kikuchi, T., Morita, S., Ueda, H., Misu, Y. and Nakata, Y.
Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D_2 receptor following repeated treatment in the rat striatum (321) 105
Inoue, H., Asaka, T., Nagata, N. and Koshihara, Y.
Mechanism of mustard oil-induced skin inflammation in mice (333) 231
Inoue, K., see Nakazawa, K. (337) 309
Inoue, T., see Inamura, N. (333) 79
Inui, K., see Taniguchi, Y. (330) 221
Ioculano, M., see Squadrito, F. (318) 153
Ipsen, M., Zhang, Y., Dragsted, N., Han, C. and Mulvany, M.J.
The antipsychotic drug sertindole is a specific inhibitor of α_{1A}-adrenoceptor in rat mesenteric small arteries (336) 29
Iravani, M.M. and Aboo Zar, M.

The presence and the effects of neuropeptide Y in rat anococcygeus muscle (338) 75
Ireland, L.M., Cain, J.C., Rotert, G., Thomas, S., Shoghi, S., Hancock, A.A. and Kerwin Jr., J.F.
[^{3}H]*R*-Terazosin binds selectively to α_1-adrenoceptors over α_2-adrenoceptors – comparison with racemic [^{3}H]terazosin and [^{3}H]prazosin (327) 79
Irie, K., Tsukahara, F., Fujii, E., Uchida, Y., Yoshioka, T., He, W.-R., Shitashige, M., Murota, S.-i. and Muraki, T.
Cationic amino acid transporter-2 mRNA induction by tumor necrosis factor-α in vascular endothelial cells (339) 289
Isa, M., see Ucar, H. (335) 267
Isaac, L.M., see Pocock, T.M. (334) 75
Isakson, P.C., see Dirig, D.M. (331) 155
Ischiropoulos, H., see Zingarelli, B. (338) 55
Ishibashi, S., see Ihara, T. (329) 43
Ishida, N., see Moriyama, N. (331) 39
Ishiguro, I., see Nishida, K. (333) 289
Ishii, K., see Masumoto, N. (330) 55
Ishii, Y., Muraki, K., Kurihara, A., Imaizumi, Y. and Watanabe, M.
Effects of sematilide, a novel class III antiarrhythmic agent, on membrane currents in rabbit atrial myocytes (331) 295
Ishikane, T., Kusumi, I., Matsubara, R., Matsubara, S. and Koyama, T.
Effects of serotonergic agents on the up-regulation of dopamine D_2 receptors induced by haloperidol in rat striatum (321) 163
Ishima, T., see Shimidzu, T. (338) 225
Ishine, T., see Sun, M.-H. (334) 165
Ishiyama, Y., see Khan, A.I. (333) 187
Ishizaki, K., Kinbara, S., Miyazawa, N., Takeuchi, Y., Hirabayashi, N., Kasai, H. and Araki, T.
Effect of sodium tauroursodeoxycholate (UR-906) on liver dysfunction in bile duct-ligated rats (333) 207
Iskander, M.N., see McPherson, G.A. (324) 193
Iskit, A.B., Guc, M.O. and Ilhan, M.
L-Canavanine and dexamethasone attenuate endotoxin-induced suppression of ischaemia-reperfusion arrhythmias (326) 183
Isohama, Y., see Takahama, K. (329) 93
Isono, M., see Togawa, M. (336) 291
Ito, H., see Kiso, T. (320) 187
Ito, H., see Nagakura, Y. (321) 53
Ito, H., see Nagakura, Y. (327) 189
Ito, K.-I., see Fujii, S. (331) 9
Ito, S., see Otsuguro, K.-i. (317) 97
Ito, S., see Sugawara, T. (319) 123
Ito, Y., see Oike, M. (319) 291
Itogawa, E., Kurosawa, H., Yabana, H. and Murata, S.
Protective effect of *l*-cis-diltiazem on hypercontracture of rat myocytes induced by veratridine (317) 401
Itoh, A., Nitta, A., Katono, Y., Usui, M., Naruhashi, K., Iida, R., Hasegawa, T. and Nabeshima, T.
Corrigendum to "Effects of metrifonate on memory impairment and cholinergic dysfunction in rats" [Eur. J. Pharmacol. 322 (1997) 11–19] (332) 113
Itoh, A., Nitta, A., Katono, Y., Usui, M., Naruhashi, K., Iida, R., Hasegawa, T. and Nabeshima, T.
Effects of metrifonate on memory impairment and cholinergic dysfunction in rats (322) 11
Itoh, Y., see Masuda, Y. (325) 263
Itoh, Y., see Shimidzu, T. (338) 225
Itoh, Z., see Sato, F. (322) 63
Iuvone, T., see D'Acquisto, F. (339) 87
Iversen, H.H., Wiklund, N.P., Olgart, C. and Gustafsson, L.E.
Nerve stimulation-induced nitric oxide release as a consequence of muscarinic M_1 receptor activation (331) 213
Iwao, H., see Hamaguchi, A. (331) 27
Iwao, H., see Takaori, K. (322) 59
Iwasawa, K., see Nakajima, T. (320) 81
Iyengar, S., see Cellier, E. (318) 377
Iyengar, S., see Pheng, L.H. (333) R3
Izquierdo, I., see Wolfman, C. (318) 23
Izzo, A.A., Sautebin, L., Rombolà, L. and Capasso, F.
The role of constitutive and inducible nitric oxide synthase in senna- and cascara-induced diarrhoea in the rat (323) 93

Jacobson, L.O., see Hunter, J.C. (324) 153
Jager, L.P., De Graaf, G.J. and Widjaja-Greefkes, H.C.A.
Differential effects of nitrofurans on the production/release of steroid hormones by porcine adrenocortical cells in vitro (331) 325
Jahns, R., Siegmund, C., Jahns, V., Reiländer, H., Maidhof, A., Müller-Esterl, W., Lohse, M.J. and Boege, F.
Probing human β_1- and β_2-adrenoceptors with domain-specific fusion protein antibodies (334) 115
Jäkälä, P., Riekkinen, M., Björklund, M., Koivisto, E., Schmidt, B. and Riekkinen Jr., P.
Effects of combined nimodipine and metrifonate on rat cognition and cortical EEG (318) 239
James, G.M. and Hodgson, W.C.
A role for protein kinase C in the attenuated response to 5-hydroxytryptamine in aortas from streptozotocin-diabetic rats (322) 55
Jane, D.E., see Tang, E. (327) 109
Jane, D.E., see Thomas, N.K. (338) 111
Janmot, C., see Besse, S. (338) 123
Janssen, L.H.M., see Fischer, M.J.E. (322) 97
Janssens, J.J., see Van Assche, G. (337) 267
Jansson, C.C., see Kukkonen, J.P. (335) 99
Jansson, C.C., see Pohjanoksa, K. (335) 53
Jansson, C.C., see Virolainen, S. (338) 293
Jard, S., see Ala, Y. (331) 285
Jarrott, B., see Lawrence, A.J. (328) 83
Jean-Emile Morel, see D'hahan, N. (328) 163
Jeffrey, P., see Hagan, J.J. (331) 169
Jelovac, N., see Slobodnjak, Z. (332) 23
Jeng, A.Y., see Hu, S. (324) 277
Jenner, P., see Hurley, M.J. (318) 283
Jennewein, H.-M., see Heuer, H.O. (317) 361
Jensen, R.T., see Ladenheim, E.E. (319) 245
Jiang, N., Kowaluk, E.A., Lee, C.-H., Mazdiyasni, H. and Chopp, M.
Adenosine kinase inhibition protects brain against transient focal ischemia in rats (320) 131
Jiménez, E., see Pavía, J. (320) 209
Jin, H., Zastawny, R., George, S.R. and O'Dowd, B.F.
Elimination of palmitoylation sites in the human dopamine D_1 receptor does not affect receptor-G protein interaction (324) 109
Jin, J., Yamamoto, T. and Watanabe, S.
The involvement of σ receptors in the choice reaction performance deficits induced by phencyclidine (319) 147
Jin, S. and Fredholm, B.B.
Adenosine A_1 receptors mediate hypoxia-induced inhibition of electrically evoked transmitter release from rat striatal slices (329) 107
Jo, Y.-H., see Sim, S.-S. (324) 205
Jobe, P.C., see Browning, R.A. (336) 1
Jobe, P.C., see Dailey, J.W. (328) 153
Joëls, M., see Karst, H. (339) 17
Johansen, T.N., see Bräuner-Osborne, H. (335) R1
Johansson-Alila, A., see Mustanoja, S.M. (326) 229
Johansson Rydberg, I.G.M., Andersson, R.G.G. and Grenegård, M.
Effects of the nitric oxide-donor, GEA 3175, on guinea-pig airways (329) 175
Johns, E.J., see Abdi, A. (331) 185
Johnson, M.P., see Petty, M.A. (336) 127
Johnson, R.A., see Kozma, F. (323) R1
Johnson, R.G., Fiorella, D., Winter, J.C. and Rabin, R.A.
[^{3}H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe (329) 99

Jolkkonen, M., see Wang, J.Q. (334) 43
Jones, B.J., see Roberts, C. (326) 23
Jones, R.B., see Dickinson, K. (339) 69
Jones, S.L.
Dipyrone into the nucleus raphe magnus inhibits the rat nociceptive tail-flick reflex (318) 37
Joos, G.F., Lefebvre, R.A., Bullock, G.R. and Pauwels, R.A.
Role of 5-hydroxytryptamine and mast cells in the tachykinin-induced contraction of rat trachea in vitro (338) 259
Juhász, G., Kékesi, K.A., Nyitrai, G., Dobolyi, A., Krogsgaard-Larsen, P. and Schousboe, A.
Differential effects of nipecotic acid and 4,5,6,7-tetrahydroisoxazolo[4,5-*c*]pyridin-3-ol on extracellular γ-aminobutyrate levels in rat thalamus (331) 139
Jungclaus, M., see Draguhn, A. (325) 245
Junien, J.-L., see Langlois, A. (324) 211
Junien, J.L., see Langlois, A. (318) 141
Jurina, L., see Sikirić, P. (332) 23
Jurkiewicz, A., see Hirata, H. (321) 217

Kaan, S.K., Mei, Q.B. and Cho, C.H.
A mechanistic study of β-adrenoceptor antagonists on ethanol-induced gastric damage (317) 115
Kadowitz, P.J., see Champion, H.C. (319) 71
Kageyama, M., Fujita, H., Goto, W., Nakata, K., Shirasawa, E. and Kanai, A.
FK506-binding proteins regulate smooth muscle contractility by altering neurotransmitter release (333) 223
Kagitani, F., Gotoh, Y., Kimura, A., Nakayama, H. and Sato, A.
Central effects of (5*RS*, 1′*SR*)-5-benzyl-3-(3′-morpholino-1′-phenylpropyl)-1, 3-oxazolidin-2-one monofumarate on the function of the bladder and periurethral skeletal muscle in anesthetized rats (332) 89
Kaise, T., see Sakurai, T. (334) 255
Kaiser, B.M., see Amandi-Burgermeister, E. (326) 237
Kaku, S., Umemura, K., Mizuno, A., Kawasaki, T. and Nakashima, M.
Evaluation of the disintegrin, triflavin, in a rat middle cerebral artery thrombosis model (321) 301
Kakuta, H., see Hotta, N. (326) 45
Kakuyama, H., Kuwahara, A., Mochizuki, T., Hoshino, M. and Yanaihara, N.
Role of N-terminal active sites of galanin in neurally evoked circular muscle contractions in the guinea-pig ileum (329) 85
Kamei, H., Noda, Y., Kameyama, T. and Nabeshima, T.
Role of (+)-SKF-10,047-sensitive sub-population of σ_1 receptors in amelioration of conditioned fear stress in rats: association with mesolimbic dopaminergic systems (319) 165
Kamei, J. and Ohsawa, M.
Effects of diabetes on methamphetamine-induced place preference in mice (318) 251
Kamei, J., Kashiwazaki, T., Hitosugi, H. and Nagase, H.
The role of spinal δ_1-opioid receptors in inhibiting the formalin-induced nociceptive response in diabetic mice (326) 31
Kamei, J., Kawai, K., Mizusuna, A., Saitoh, A., Morita, K., Narita, M., Tseng, L.F. and Nagase, H.
Supraspinal δ_1-opioid receptor-mediated antinociceptive properties of (−)-TAN-67 in diabetic mice (322) 27
Kamei, J., Ohsawa, M., Suzuki, T. and Nagase, H.
Modification of morphine-induced place preference by diabetes (337) 137
Kamei, J., Xiao, P., Ohsawa, M., Kubo, H., Higashiyama, K., Takahashi, H., Li, J., Nagase, H. and Ohmiya, S.
Antinociceptive effects of (+)-matrine in mice (337) 223
Kameyama, T., see Kamei, H. (319) 165
Kameyama, T., see Ukai, M. (324) 147
Kameyama, T., see Ukai, M. (338) 1
Kaminuma, O., see Matsubara, S. (337) 259
Kampa, M., Bakogeorgou, E., Hatzoglou, A., Damianaki, A., Martin, P.-M. and Castanas, E.
Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors (335) 255
Kanda, S., Kurokawa, J., Adachi-Akahane, S. and Nagao, T.
Diltiazem derivatives modulate the dihydropyridine-binding to intact rat ventricular myocytes (319) 101
Kaneda, K., Kikuchi, M., Kashii, S., Honda, Y., Maeda, T., Kaneko, S. and Akaike, A.
Effects of B vitamins on glutamate-induced neurotoxicity in retinal cultures (322) 259
Kaneko, S., see Kaneda, K. (322) 259
Kaneko, S., see Okada, M. (321) 181
Kang, J.-J., see Cheng, Y.-W. (336) 23
Kangawa, K., see Khan, A.I. (333) 187
Kankaanranta, H., see Kosonen, O. (337) 55
Kankaanranta, H., see Li, L. (331) 221
Kanno, M., see Hattori, Y. (329) 165
Kanno, M., see Tomita, F. (326) 157
Kanno, T., see Fukushi, Y. (336) 89
Kano, S., see Ikeda, M. (324) 283
Kanthasamy, A.G., see Matsumoto, R.R. (338) 233
Kanthasamy, A.G., see Zambon, A.C. (324) 39
Kanyonyo, M., see Ucar, H. (335) 267
Kappelle, A.C., see Van Buren, T. (318) 73
Karaki, H., see Takizawa, S. (330) 143
Karasawa, Y., see Furukawa, Y. (334) 191
Kardos, J., Kovács, I., Blandl, T., Cash, D.J., Simon-Trompler, E., Luyen, N.D., Dörnyei, G., Simonyi, M., Blaskó, G. and Szántay, C.
Inhibition of γ-aminobutyric acid uptake by bicuculline analogues (337) 83
Karlsson, L., see Cassel, G. (332) 43
Karst, H., De Kloet, E.R. and Joëls, M.
Effect of ORG 34116, a corticosteroid receptor antagonist, on hippocampal Ca^{2+} currents (339) 17
Kasai-Nakagawa, C., see Yatsu, T. (322) 45
Kasbergen, C.M., see Van Bergen, P. (318) 357
Kasbergen, C.M., see Van Buren, T. (318) 73
Kase, H., see Manabe, H. (332) 97
Kashii, S., see Kaneda, K. (322) 259
Kashii, S., see Morizane, C. (328) 45
Kashiwagi, A., see Togawa, M. (336) 291
Kashiwazaki, T., see Kamei, J. (326) 31
Kask, A., Rägo, L. and Harro, J.
Anxiogenic-like effect of the neuropeptide Y Y_1 receptor antagonist BIBP3226: antagonism with diazepam (317) R3
Kasuya, Y., see Wei, S. (321) 307
Kaszala, K., Végh, Á., Papp, J.Gy. and Parratt, J.R.
Modification by bradykinin B_2 receptor blockade of protection by pacing against ischaemia-induced arrhythmias (328) 51
Kato, A., see Rahman, F. (317) 293
Kato, H., see Fujii, S. (331) 9
Kato, J., see Khan, A.I. (333) 187
Kato, S., see Imanishi, T. (321) 273
Katono, Y., see Itoh, A. (322) 11
Katono, Y., see Itoh, A. (332) 113
Katsube, Y., Yokoshiki, H., Nguyen, L. and Sperelakis, N.
Differences in isoproterenol stimulation of Ca^{2+} current of rat ventricular myocytes in neonatal compared to adult (317) 391
Katsuki, H., Nakanishi, C., Saito, H. and Matsuki, N.
Biphasic effect of hydrogen peroxide on field potentials in rat hippocampal slices (337) 213
Kaur, S., Özer, H. and Starr, M.
MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain (332) 153
Kawabe, T., see Hata, Y. (321) 113

Kawada, N., see Sasaki, E. (338) 253
Kawada, T., Toyosato, A., Islam, Md.O., Yoshida, Y. and Imai, S.
cGMP-kinase mediates cGMP- and cAMP-induced Ca^{2+} desensitization of skinned rat artery (323) 75
Kawahara, K., see Rahman, F. (317) 293
Kawai, K., see Kamei, J. (322) 27
Kawai, S., see Yamazaki, R. (329) 181
Kawakita, T., see Manabe, H. (332) 97
Kawasaki, H., see Inagaki, N. (336) 225
Kawasaki, H., see Manabe, H. (332) 97
Kawasaki, H., see Suemaru, K. (335) 139
Kawasaki, T., see Kaku, S. (321) 301
Kawasaki, T., see Sato, K. (339) 141
Kawasaki, T., see Suzuki, K.-i. (336) 169
Kawata, Y., see Okada, M. (321) 181
Kawikova, I., see Takahashi, T. (324) 219
Kayakiri, H., see Inamura, N. (333) 79
Kayser, V., see Catheline, G. (318) 273
Kayser, V., see Idänpään-Heikkilä, J.J. (325) 155
Kebabian, J.W., see Kula, N.S. (331) 333
Kedves, R., see Fekete, M.I.K. (331) 175
Kedves, R., see Székely, J.I. (336) 143
Kehne, J.H., see Baron, B.M. (323) 181
Kékesi, K.A., see Juhász, G. (331) 139
Kékesi, K.A., see Nyitrai, G. (318) 295
Kekuda, R., see Prasad, P.D. (325) 85
Keller, H., see Niggli, V. (324) 99
Keller, H., see Niggli, V. (335) 43
Kellerman, T.S., see Van der Walt, J.J. (329) 201
Kelley, A., see Tümer, N. (324) 57
Kendall, D.A., see Randall, M.D. (333) 191
Kendall, D.A., see Randall, M.D. (335) 205
Kendall, D.A., see Thongsaard, W. (319) 157
Kendig, J.J., see Wong, S.M.E. (329) 121
Kennedy, C., see Westfall, T.D. (329) 169
Kennedy, R.H., see Wang, S.-N. (321) 39
Kerman, L.L., see Kongsamut, S. (317) 417
Kerr, D.I.B., see Ong, J. (329) 133
Kerwin Jr., J.F., see Ireland, L.M. (327) 79
Khalilov, I., Khazipov, R., Esclapez, M. and Ben-Ari, Y.
Bicuculline induces ictal seizures in the intact hippocampus recorded in vitro (319) R5
Khan, A.I., Kato, J., Ishiyama, Y., Kitamura, K., Kangawa, K. and Eto, T.
Effect of chronically infused adrenomedullin in two-kidney, one-clip hypertensive rats (333) 187
Khare, A.B., see Staley, J.K. (338) 159
Khawaja, A.M., see Perez, A.C. (330) 241
Khazipov, R., see Khalilov, I. (319) R5
Kiang, J.G.
Corticotropin-releasing factor-like peptides increase cytosolic $[Ca^{2+}]$ in human epidermoid A-431 cells (329) 237
Kikkawa, H., see Matsubara, S. (337) 259
Kikkawa, R., see Togawa, M. (336) 291
Kikuchi, M., see Kaneda, K. (322) 259
Kikuchi, T., see Inoue, A. (321) 105
Kikuchi, T., see Masuda, Y. (325) 263
Kilbourn, M. and Sherman, P.
In vivo binding of (+)-α-[^{3}H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies (331) 161
Kim, H.S., see Hu, S. (318) 461
Kim, H.S., see Hu, S. (324) 277
Kim, K.-T., see Song, S.-K. (322) 265
Kim, M.-S., see Sim, S.-S. (324) 205
Kim, S., see Hamaguchi, A. (331) 27
Kim, S., see Takaori, K. (322) 59
Kim, S.A., see Martin, T.J. (324) 141
Kimes, A.S., see Vaupel, D.B. (324) 11
Kimura, A., see Kagitani, F. (332) 89
Kimura, I., Okazaki, M. and Nojima, H.
Mutual dependence of calcitonin-gene related peptide and acetylcholine release in neuromuscular preparations (330) 123
Kimura, K., see Suma, C. (336) 283
Kimura, K., see Taniguchi, N. (318) 117
Kimura, M. and Ogihara, M.
Density-dependent proliferation of adult rat hepatocytes in primary culture induced by epidermal growth factor is potentiated by cAMP-elevating agents (324) 267
Kimura, M. and Ogihara, M.
Proliferation of adult rat hepatocytes in primary culture induced by insulin is potentiated by cAMP-elevating agents (327) 87
Kimura, T., see Nagayama, T. (327) 135
Kinbara, S., see Ishizaki, K. (333) 207
Kindgen-Milles, D. and Holthusen, H.
Nociception from blood vessels is independent of the sympathetic nervous system under physiological conditions in humans (328) 41
King, C.M.F., Gommans, J., Joordens, R.J.E., Hijzen, T.H., Maes, R.A.A. and Olivier, B.
Effects of 5-HT_{1A} receptor ligands in a modified Geller-Seifter conflict model in the rat (325) 121
King, M., Pan, Y.-X., Mei, J., Chang, A., Xu, J. and Pasternak, G.W.
Enhanced κ-opioid receptor-mediated analgesia by antisense targeting the σ_1 receptor (331) R5
Kiniwa, M., see Taniguchi, H. (321) 397
Kinoshita, M., Saito, N. and Tamaki, H.
Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats (321) 325
Kinzler, N., see Witte, K. (334) 209
Király, Á., Süto, G., Guth, P.H. and Taché, Y.
Ketotifen prevents gastric hyperemia induced by intracisternal thyrotropin-releasing hormone at a low dose (334) 241
Kirkup, A.J., Edwards, G., Green, M.E., Miller, M., Walker, S.D. and Weston, A.H.
Modulation of membrane currents and mechanical activity by niflumic acid in rat vascular smooth muscle (317) 165
Kishimoto, Y., see Suzuki, T. (324) 21
Kiso, T., Ito, H. and Miyata, K.
Effect of ramosetron on short-circuit current response in rat colonic mucosa (320) 187
Kiss, J., Lamarque, D., Delchier, J.C. and Whittle, B.J.R.
Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats (336) 219
Kitabatake, A., see Tomita, F. (326) 157
Kitagaki, K., Nagai, H., Hayashi, S. and Totsuka, T.
Facilitation of apoptosis by cyclosporins A and H, but not FK506 in mouse bronchial eosinophils (337) 283
Kitaichi, K., Noda, Y., Hasegawa, T., Furukawa, H. and Nabeshima, T.
Acute phencyclidine induces aversion, but repeated phencyclidine induces preference in the place conditioning test in rats (318) 7
Kitaichi, K., Noda, Y., Hasegawa, T., Furukawa, H. and Nabeshima, T.
In vivo functional interaction between phencyclidine binding sites and σ receptors to produce head-weaving behavior in rats (318) 205
Kitamura, S., see Manabe, H. (332) 97
Kitamura, Y., see Guo, Y. (331) 237
Kitamura, Y., see Takao, K. (333) 123
Kitchen, I., see Brownhill, V.R. (317) 321
Klaidman, L.K., see Mukherjee, S.K. (330) 27
Klaus, W., see Dhein, S. (339) 129
Klaus, W., see Müller, A. (327) 65
Klein, E., see Shachar, D.B. (332) 237
Kleinrok, Z., see Borowicz, K.K. (323) 45
Kleinrok, Z., see Borowicz, K.K. (327) 125

Kleinrok, Z., see Borowicz, K.K. (331) 127
Kleinrok, Z., see Przesmycki, K. (337) 11
Kleven, M.S. and Koek, W.
Dopamine D_2 receptors play a role in the (−)-apomorphine-like discriminative stimulus effects of (+)-PD 128907 (321) 1
Klompmakers, A., see Bosker, F.J. (333) 147
Knapp, R.J., see Quock, R.M. (326) 101
Knight, D.A., Stewart, G.A. and Thompson, P.J.
Histamine-induced contraction of human isolated bronchus is enhanced by endogenous prostaglandin $F_{2\alpha}$ and activation of TP receptors (319) 261
Knight, K.R., Zhang, B., Morrison, W.A. and Stewart, A.G.
Ischaemia-reperfusion injury in mouse skeletal muscle is reduced by N^{ω}-nitro-L-arginine methyl ester and dexamethasone (332) 273
Knudsen, L.B. and Pridal, L.
Glucagon-like peptide-1-(9–36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor (318) 429
Kobari, M., Tomita, M., Tanahashi, N., Yokoyama, M., Takao, M. and Fukuuchi, Y.
Intravascular substance P dilates cerebral parenchymal vessels through a specific tachykinin NK_1 receptor in cats (317) 269
Kobayashi, K., see Sasaki, E. (338) 253
Kobayashi, S., Ögren, S.O., Ebendal, T. and Olson, L.
Dopamine receptor antagonists block nerve growth factor-induced hyperactivity (326) 1
Kobayashi, T., Strobeck, M., Schwartz, A. and Mori, Y.
Inhibitory effects of a new neuroprotective diltiazem analogue, T-477, on cloned brain Ca^{2+} channels expressed in *Xenopus* oocytes (332) 313
Koch, M., see Kretschmer, B.D. (331) 109
Koch, S., Piercey, M.F., Galloway, M.P. and Svensson, K.A.
Interactions between cocaine and (−)-DS 121: studies with 2-deoxyglucose autoradiography and microdialysis in the rat brain (319) 173
Kocić, I.
Pretreatment with rimalkalim changes the adrenergic responsiveness of isolated guinea pig papillary muscle (332) 65
Koda, A., see Taniguchi, H. (321) 397
Koek, W., see Assié, M.-B. (334) 141
Koek, W., see Kleven, M.S. (321) 1
Koga, T., see Shiroshita, Y. (339) 183
Koh, N., see Hotta, N. (326) 45
Kohjimoto, Y., see Ikegami, K. (328) 75
Kohmoto, O., Shimizu, T., Sugishita, K., Kinugawa, K.-i., Takahashi, T. and Serizawa, T.
Selectivity of felodipine for depolarized ventricular myocytes: a study at the single-cell level (319) 355
Kohno, Y., Fukuzaki, K., Kitahara, K. and Koja, T.
Anti-tremor activity of talipexole produced by selective dopamine D_2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum (319) 197
Kohya, T., see Tomita, F. (326) 157
Koidl, B., Miyawaki, N. and Tritthart, H.A.
A novel benzothiazine Ca^{2+} channel antagonist, semotiadil, inhibits cardiac L-type Ca^{2+} currents (322) 243
Koike, K., Takayanagi, I., Ichino, T., Koshikawa, H. and Nagatomo, T.
β_3-adrenoceptors mediate relaxation of guinea pig taenia caecum by BRL37344A and BRL35135A (334) 217
Koja, T., see Kohno, Y. (319) 197
Kojda, G., Kottenberg, K. and Noack, E.
Inhibition of nitric oxide synthase and soluble guanylate cyclase induces cardiodepressive effects in normal rat hearts (334) 181
Kolb, J., see Scheller, D.K.A. (338) 243
Koley, B., see Koley, J. (325) 181
Koley, J., Basak, A.K., Das, M., Sinha, S. and Koley, B.
Rectal response of cardiac origin in the cat: involvement of nitric oxide and acetylcholine (325) 181
Koller, M.-E., Berg, A., Rodt, S.Å., Westerberg, E. and Reed, R.K.
α-Trinositol prevents increased negativity of interstitial fluid pressure in rat skin and trachea induced by dextran anaphylaxis (331) 259
Kołodziejczyk, K., see Maj, J. (324) 31
Kolter, T., see Bähr, M. (320) 259
Komurasaki, T., see Sasaki, E. (338) 253
Kondo, H., see Temma, K. (322) 235
Kondo, K., see Shimazawa, M. (328) 183
Kondo, M., see Takano, H. (323) 107
Kong, D.C.M., see McPherson, G.A. (324) 193
Kongsamut, S., Roehr, J.E., Cai, J., Hartman, H.B., Weissensee, P., Kerman, L.L., Tang, L. and Sandrasagra, A.
Iloperidone binding to human and rat dopamine and 5-HT receptors (317) 417
König, H., see Eltze, M. (332) 77
Konin, G.P., see Dirig, D.M. (331) 155
Konishi, C., Naito, Y., Saito, Y., Ohara, N. and Ono, H.
Age-related differences and roles of endothelial nitric oxide and prostanoids in angiotensin II responses of isolated, perfused mesenteric arteries and veins of rats (320) 175
Konkoy, C.S., see Whittemore, E.R. (337) 197
Konturek, P.Ch., Konturek, S.J., Majka, J., Zembala, M. and Hahn, E.G.
Melatonin affords protection against gastric lesions induced by ischemia-reperfusion possibly due to its antioxidant and mucosal microcirculatory effects (322) 73
Koob, G.F., see Brot, M.D. (325) 1
Koob, G.F., see Pulvirenti, L. (321) 279
Környei, J.L., Vértes, Z., Oszter, A., Kovács, S. and Vértes, M.
Opioid peptides inhibit the estradiol-induced proliferation of cultured rat uterine cell (336) 65
Korsgaard, N., see Scheideler, M.A. (339) 261
Koshihara, Y., see Inoue, H. (333) 231
Koshika, T., see Nagayama, T. (327) 135
Koshikawa, H., see Koike, K. (334) 217
Koshino, T., see Yamazaki, R. (329) 181
Koshio, H., see Sato, K. (339) 141
Koshiya, K., see Takeuchi, H. (329) 27
Kosonen, O., Kankaanranta, H., Vuorinen, P. and Moilanen, E.
Inhibition of human lymphocyte proliferation by nitric oxide-releasing oxatriazole derivatives (337) 55
Koss, M.C.
Effect of N^{G}-nitro-L-arginine methyl ester on functionally characterized muscarinic receptors in anesthetized cats (335) 199
Kotchabhakdi, N., see Siripurkpong, P. (331) 227
Kotlinska, J. and Liljequist, S.
The NMDA/glycine receptor antagonist, L-701,324, produces discriminative stimuli similar to those of ethanol (332) 1
Koulu, M., see Savontaus, E. (328) 207
Koulu, M., see Virtanen, K.A. (332) 215
Kovács, A.D. and Szabó, G.
GYKI 53655, a 2,3-benzodiazepine, non-competitively protects cultured neurones against AMPA toxicity (331) 93
Kovács, K.J. and Larson, A.A.
Zn^{2+} inhibition of [^{3}H]MK-801 binding is different in mouse brain and spinal cord: effect of glycine and glutamate (324) 117
Kowalski, J.
Effect of enkephalins and endorphins on cytotoxic activity of natural killer cells and macrophages/monocytes in mice (326) 251
Koyama, T., see Ishikane, T. (321) 163
Kozlik-Feldmann, R., see Reithmann, C. (330) 79
Kozma, F., Johnson, R.A. and Nasjletti, A.
Role of carbon monoxide in heme-induced vasodilation (323) R1
Kramp, R.A., Caron, N., Genard, J., Lejeune, C., Gulbis, E. and Herman, A.

Differential effects of sulindac on renal hemodynamics and function in the rat (330) 165
Krause, T., see Rosenkranz, S. (330) 35
Krause, W., Michael, N., Lübke, C., Livett, B.G. and Oehme, P.
Substance P and epibatidine-evoked catecholamine release from fractionated chromaffin cells (328) 249
Kretschmer, B.D., Kratzer, U., Breithecker, K. and Koch, M.
ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats (331) 109
Kristof, A.S., Noorhosseini, H. and Hussain, S.N.A.
Attenuation of endothelium-dependent hyperpolarizing factor by bacterial lipopolysaccharides (328) 69
Krogsgaard-Larsen, P., see Juhász, G. (331) 139
Krstew, E., see Lawrence, A.J. (328) 83
Krüger, H., see Albrecht, D. (332) 53
Kubo, H., see Kamei, J. (337) 223
Kubo, K., see Ojima, M. (319) 137
Kubová, H., Világi, I., Mikulecká, A. and Mareš, P.
Non-NMDA receptor antagonist GYKI 52466 suppresses cortical afterdischarges in immature rats (333) 17
Kuitunen, J., see Riekkinen, M. (322) 1
Kukkonen, J.P., Huifang, G., Jansson, C.C., Wurster, S., Cockcroft, V., Savola, J.-M. and Åkerman, K.E.O.
Different apparent modes of inhibition of α_{2A}-adrenoceptor by α_2-adrenoceptor antagonists (335) 99
Kula, N.S., Baldessarini, R.J., Kebabian, J.W., Bakthavachalam, V. and Xu, L.
RBI-257: A highly potent dopamine D_4 receptor-selective ligand (331) 333
Kulkarni, S.K., see Reddy, D.S. (337) 19
Kunko, P.M., see Robinson, S.E. (319) 31
Kuo, B.-S., see Singh, L. (321) 209
Kuo, S.-C., see Teng, C.-M. (320) 161
Kuo, S.-C., see Wang, J.-P. (319) 131
Kuraishi, Y., see Andoh, T. (332) 279
Kurihara, A., see Ishii, Y. (331) 295
Kuroda, Y., see Fujii, S. (331) 9
Kurokawa, J., Adachi-Akahane, S. and Nagao, T.
Effects of a novel, potent benzothiazepine Ca^{2+} channel antagonist, DTZ323, on guinea-pig ventricular myocytes (325) 229
Kurosaki, K., see Shimpo, M. (338) 97
Kurosaki, M., see Ghezzi, P. (317) 369
Kurosawa, H., see Itogawa, E. (317) 401
Kurz, M.A., Bullough, D.A., Buggé, C.J.L., Mullane, K.M. and Young, M.A.
Cardioprotection with a novel adenosine regulating agent mediated by intravascular adenosine (322) 211
Kusayama, T., see Shibasaki, M. (335) 167
Kusayama, T., see Shibasaki, M. (335) 175
Kustova, Y., see Sei, Y. (325) 81
Kusumi, I., see Ishikane, T. (321) 163
Kuwahara, A., see Kakuyama, H. (329) 85
Kuzmin, A.V., Semenova, S., Gerrits, M.A.F.M., Zvartau, E.E. and Van Ree, J.M.
κ-Opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice (321) 265
Kwan, C.-Y., see Low, A.M. (339) 227
Kwan, C.-Y., see Wang, H.-X. (319) 115

La, M., Paisley, K., Martin, W. and Rand, M.J.
Effects of hydroxocobalamin on nitrergic transmission in rat anococcygeus and bovine retractor penis muscles: sensitivity to light (321) R5
Labadía, A., see Martínez, A.C. (326) 163
LaBella, F.S., see Chen, Q.-m. (321) 355
Lacerra, C., see Martijena, I.D. (330) 101
Lacour, M., see Tighilet, B. (330) 65
Ladenheim, E.E., Moore, K.A., Salorio, C.F., Manley, S.A., Taylor, J.E., Coy, D.H., Jensen, R.T. and Moran, T.H.
Characterization of bombesin binding sites in the rat stomach (319) 245
Ladrière, L., Malaisse-Lagae, F., Fuhlendorff, J. and Malaisse, W.J.
Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats (335) 227
Lagente, V., see Berdyshev, E.V. (330) 231
Laher, I., see Rahimian, R. (327) 143
Lahmame, A., Del Arco, C., Pazos, A., Yritia, M. and Armario, A.
Are Wistar-Kyoto rats a genetic animal model of depression resistant to antidepressants? (337) 115
Lajiness, M.E., see Schlachter, S.K. (322) 283
Lakhe, M., see Hirose, M. (338) 35
Lakoski, J.M., see Smith, J.E. (323) 69
Lam, V., see Black, M. (317) 377
Lamarque, D., see Kiss, J. (336) 219
Lammertsma, A.A., see Hume, S.P. (317) 67
Lampugnani, P., see Sala, M. (328) 143
Lancaster, M.K. and Cook, S.J.
The effects of levosimendan on $[Ca^{2+}]_i$ in guinea-pig isolated ventricular myocytes (339) 97
Landsman, R.S., Burkey, T.H., Consroe, P., Roeske, W.R. and Yamamura, H.I.
SR141716A is an inverse agonist at the human cannabinoid CB_1 receptor (334) R1
Lanfumey, L., Haj-Dahmane, S., Laporte, A.-M., Martin, P., Hamon, M. and Gozlan, H.
Effects of chronic diazepam treatment on pre- and postsynaptic 5-HT_{1A} receptors in the rat brain (323) 137
Langlois, A., Diop, L., Friese, N., Pascaud, X., Junien, J.-L., Dahl, S.G. and Rivière, P.J.M.
Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral κ-opioid receptors (324) 211
Langlois, A., Pascaud, X., Junien, J.L., Dahl, S.G. and Rivière, P.J.M.
Response heterogeneity of 5-HT_3 receptor antagonists in a rat visceral hypersensitivity model (318) 141
Lanzafame, A., Christopoulos, A. and Mitchelson, F.
Erratum to 'Interactions of agonists with an allosteric antagonist at muscarinic acetylcholine M_2 receptors' [Eur. J. Pharmacol. 316 (1996) 27–32] (321) 399
Laporte, A.-M., see Fabre, V. (337) 297
Laporte, A.-M., see Lanfumey, L. (323) 137
Lappalainen, R., see Yavich, L. (339) 113
Lara, B., Gandía, L., Torres, A., Olivares, R., Martínez-Sierra, R., García, A.G. and López, M.G.
'Wide-spectrum Ca^{2+} channel antagonists': lipophilicity, inhibition, and recovery of secretion in chromaffin cells (325) 109
Larhammar, D., see Gehlert, D.R. (318) 485
LaRochelle, J.S., see Tümer, N. (324) 57
Larosa, G. and Forster, C.
Altered vasodilator response of coronary microvasculature in pacing-induced congestive heart failure (318) 387
Larsen, P.J., see Scheideler, M.A. (339) 261
Larson, A.A., see Kovács, K.J. (324) 117
Larsson, M., see Schiöth, H.B. (319) 369
Larsson, S., Brattsand, R. and Linden, M.
Interleukin-2 and -4 induce resistance of granulocyte–macrophage colony-stimulating factor to corticosteroids (334) 265
Laruelle, M., see Abi-Dargham, A. (321) 285
László, F. and Whittle, B.J.R.
Actions of isoform-selective and non-selective nitric oxide synthase inhibitors on endotoxin-induced vascular leakage in rat colon (334) 99
László, F., Varga, C., Montoneri, C. and Drago, F.
Damaging actions of testosterone on cysteamine-induced gastroduodenal ulceration and vascular leakage in the rat (337) 275
Latour, C., see Besse, S. (338) 123

Lau, C.-W., see Huang, Y. (325) 21
Lau, C.W., see Huang, Y. (327) 209
Lau, S.S., see Miller, R.T. (323) 173
Laubie, M., see Vayssettes-Courchay, C. (320) 151
Lauerma, A.I., see Homey, B. (325) 199
Laurent, F., see Pocock, T.M. (334) 75
Lavielle, G., see Audinot, V. (327) 247
Lavielle, G., see Millan, M.J. (325) 9
Law, M.P., see Hume, S.P. (317) 67
Lawand, N.B., Willis, W.D. and Westlund, K.N.
Excitatory amino acid receptor involvement in peripheral nociceptive transmission in rats (324) 169
Lawrence, A.J., Krstew, E. and Jarrott, B.
Complex interactions between nitric oxide and adenosine receptors in the rat isolated nodose ganglion (328) 83
Lazzeri, N., see Nieri, P. (331) 205
Le, F., see Zeng, X.P. (321) 349
Leach, J.P., see Sills, G.J. (325) 35
Leander, J.D., see Wolff, M.C. (333) 113
Le Bec, A., see Eckly-Michel, A.E. (324) 85
Le Cabec, V., see Roussin, A. (322) 91
Lecci, A., see Giuliani, S. (333) 177
Lechanteur, C., see Charlier, C. (317) 413
Lee, C.-H., see Jiang, N. (320) 131
Lee, F.-Y., see Teng, C.-M. (320) 161
Lee, H., see Song, S.-K. (322) 265
Lee, H.-Z.
Inhibitory effect of 2-phenyl-4-quinolone on serotonin-mediated changes in the morphology and permeability of endothelial monolayers (335) 245
Lee, T.H., see Gibbs, B.F. (327) 73
Lee, T.J.-F., see Sun, M.-H. (334) 165
Lee, W.S., see Petty, M.A. (336) 127
Lee, Y.-M., see Sheu, J.-R. (318) 469
Leewanich, P., Tohda, M., Matsumoto, K., Subhadhirasakul, S., Takayama, H., Aimi, N. and Watanabe, H.
Inhibitory effects of corymine, an alkaloidal component from the leaves of *Hunteria zeylanica*, on glycine receptors expressed in *Xenopus* oocytes (332) 321
Lefebvre, R.A.
Influence of endotoxin on contractility in the rat gastric fundus (339) 201
Lefer, A.M., see Hayward, R. (334) 157
Lefevre, P.M., see Bowden, J.J. (338) 83
Le Foll, F., Louiset, E., Castel, H., Vaudry, H. and Cazin, L.
Electrophysiological effects of various neuroactive steroids on the $GABA_A$ receptor in pituitary melanotrope cells (331) 303
Le Gouic, S., Atgié, C., Viguerie-Bascands, N., Hanoun, N., Larrouy, D., Ambid, L., Raimbault, S., Ricquier, D., Delagrange, P., Guardiola-Lemaitre, B., Pénicaud, L. and Casteilla, L.
Characterization of a melatonin binding site in Siberian hamster brown adipose tissue (339) 271
Leibach, F.H., see Prasad, P.D. (325) 85
Leikola-Pelho, T., see Pietilä, K. (318) 17
Lejeune, C., see Kramp, R.A. (330) 165
Lemmer, B., see Witte, K. (334) 209
Lenz, O., see Rosenkranz, S. (330) 35
Leone, M.P., see Sala, M. (328) 143
Léoty, C., see Talon, S. (327) 33
Leprán, I., see Baczkó, I. (324) 77
Leprince, J., see Gandolfo, P. (322) 275
Leroux, P., Bucharles, C., Bologna, E. and Vaudry, H.
des-AA-^{1,2,5}[D-Trp^8, IAmp^9]Somatostatin-14 allows the identification of native rat somatostatin sst_1 receptor subtype (337) 333
Leslie, S.W., see Robichon, R. (328) 255
Lesourd, M., see Fabre, V. (337) 297
Lespy, L., see Schaeffer, P. (323) 215
Le Tran, Y. and Forster, C.
Chloroethylclonidine and α-adrenoceptor agonist interaction in blood vessel following heart failure (336) 177
Leung, Y.-M., Kwan, C.-Y. and Loh, T.-T.
Spontaneous Mn^{2+} entry is specifically inhibited by calyculin A in human leukemic HL-60 cells (331) 337
Lewis, M.H., see Gendreau, P.L. (337) 147
Lewis, S.J., see Travis, M.D. (318) 47
Lewis, S.J., see Travis, M.D. (328) R1
Lewohl, J.M., Crane, D.I. and Dodd, P.R.
Zolpidem binding sites on the $GABA_A$ receptor in brain from human cirrhotic and non-cirrhotic alcoholics (326) 265
Leysen, J.E., see Custers, F.G.J. (338) 177
Li, C.G., see Di Iulio, J.L. (337) 245
Li, C.G., see Najbar-Kaszkiel, A.T. (337) 251
Li, J., Brezenoff, H.E. and Tkacs, N.C.
Identification of pressor regions activated by central cholinergic stimulation in rat brain (337) 227
Li, L., Kankaanranta, H., Vaali, K., Paakkari, I. and Heikki Vapaatalo,
Econazole, miconazole and SK&F 96365 inhibit depolarization-induced and receptor-operated contraction of guinea-pig isolated trachea in vitro (331) 221
Liao, H.-Y., see Pan, W.H.T. (317) 205
Lieberman, E.M., see Olanrewaju, H.A. (322) 185
Liljequist, S., see Kotlinska, J. (332) 1
Liljequist, S., see Pokk, P. (317) 15
Lim, S.L., see Palacios, B. (327) 183
Lin, C.-N., see Wang, J.-P. (320) 201
Lin, C.-N., see Wang, J.-P. (336) 81
Lin, R.-H., see Liu, S.-H. (333) 241
Lin-Shiau, S.-Y., see Liu, S.-H. (333) 241
Lin, W.W.
Priming effects of lipopolysaccharide on UTP-induced arachidonic acid release in RAW 264.7 macrophages (321) 121
Lin, Y. and Long, J.B.
Acute or prolonged exposure to 1-aminocyclopropanecarboxylic acid protects spinal neurons against NMDA toxicity (318) 491
Lin, Y. and Long, J.B.
Prolonged pre-exposure to 1-aminocyclopropanecarboxylic acid protects against subsequent glutamate toxicity in vitro (338) 289
Lindeberg, G., see Schiöth, H.B. (319) 369
Lindefors, N., see Zachrisson, O. (319) 191
Lindén, A.-M., Väsäinen, J., Wong, G. and Castrén, E.
NMDA receptor 2C subunit is selectively decreased by MK-801 in the entorhinal cortex (319) R1
Lindsay, K.E., see Prior, C. (327) 103
Linke, W., see Müller, A. (327) 65
Linnik, M.D., see Petty, M.A. (336) 127
Liska, J., see Holm, P. (323) 83
Liu, H.-N., Molina-Holgado, E. and Almazan, G.
Glutamate-stimulated production of inositol phosphates is mediated by Ca^{2+} influx in oligodendrocyte progenitors (338) 277
Liu, M., see Nakazawa, K. (337) 309
Liu, S.-H., Sheu, Z.-J., Lin, R.-H. and Lin-Shiau, S.-Y.
The in vivo effect of lipopolysaccharide on neuromuscular transmission in the mouse (333) 241
Liu, X. and Songu-Mize, E.
Alterations in alpha subunit expression of cardiac Na^+,K^+-ATPase in spontaneously hypertensive rats: effect of antihypertensive therapy (327) 151
Liu, X., see Ribbons, K.A. (323) 245
Livett, B.G., see Krause, W. (328) 249
Llergo, J.L., see Peiró, C. (324) 257
Lluch, M., see Rodriguez, F.J. (323) 283
Lochon, S., see Audinot, V. (327) 247
Lock, J.I., see Dickinson, K. (339) 69
Loew, G.H., see Maguire, P.A. (318) 505

Lograno, M.D., see Daniele, E. (330) 247
Loh, T.-T., see Leung, Y.-M. (331) 337
Lohse, M.J., see Danner, S. (331) 73
Lohse, M.J., see Jahns, R. (334) 115
Lokhandwala, M.F., see Hussain, T. (321) 259
Lomax, R.B., see Montiel, C. (332) 183
Lombet, A., see Ghezzi, P. (317) 369
Lonchampt, M., see Roussin, A. (322) 91
London, E.D., see Vaupel, D.B. (324) 11
Long, J.B., see Lin, Y. (318) 491
Long, J.B., see Lin, Y. (338) 289
Loog, M., see Vincent, B. (334) 49
Lookingland, K.J., see Durham, R.A. (335) 37
López-Guerrero, J.J., see Ibarra, M. (322) 221
López-Guerrero, J.J., see Villalobos-Molina, R. (322) 225
Lopez, J.R., Linares, N., Brady, P.A. and Terzic, A.
Cardiac hypertrophy determines digitalis action on intracellular Ca^{2+} in human myocardium (339) 161
López, M.G., see Villarroya, M. (320) 249
López-Novoa, J.M., see Valdivielso, J.M. (335) 193
Lorenzen, A., Sebastião, A.M., Sellink, A., Vogt, H., Schwabe, U., Ribeiro, J.A. and IJzerman, A.P.
Biological activities of N^6,C8-disubstituted adenosine derivatives as partial agonists at rat brain adenosine A_1 receptors (334) 299
Löscher, W., see Richter, A. (332) 133
Loubatières-Mariani, M.-M., see Berdeu, D. (324) 233
Louiset, E., see Le Foll, F. (331) 303
Low, A.M., Sormaz, L., Kwan, C.-Y. and Daniel, E.E.
Mobilization of internal Ca^{2+} by vasoactive intestinal polypeptide in endothelial cells (339) 227
Lübke, C., see Krause, W. (328) 249
Ludvigsen, T.S., see Scheideler, M.A. (339) 261
Lugnier, C., see Eckly-Michel, A.E. (324) 85
Lumbers, E.R., see Burrell, J.H. (330) 257
Lum Min, S.A. and Tabrizchi, R.
Regulation of intracellular Ca^{2+} by 8-bromoguanosine 3′:5′-cyclic monophosphate, felodipine and ryanodine in rat caudal artery (318) 97
Lundstrom, K., Hawcock, A.B., Vargas, A., Ward, P., Thomas, P. and Naylor, A.
Effect of single point mutations of the human tachykinin NK_1 receptor on antagonist affinity (337) 73
Luomala, K., see Pohjanoksa, K. (335) 53
Lussignoli, S., see Conforti, A. (324) 241
Lutton, C., see Hajri, T. (320) 65
Luyen, N.D., see Kardos, J. (337) 83

Ma, Q.-P. and Woolf, C.J.
Tachykinin NK_1 receptor antagonist RP67580 attenuates progressive hypersensitivity of flexor reflex during experimental inflammation in rats (322) 165
Ma, T. and Zhu, X.
Interleukin-6 increases the levels of cyclic GMP and nitrite in rat hippocampal slices (321) 343
MacCoss, M., see Cascieri, M.A. (325) 253
MacCoss, M., see Rupniak, N.M.J. (326) 201
MacDonald, E., see Yavich, L. (339) 113
Machado, A., see De la Cruz, C.P. (327) 215
Macías, J.F., see Valdivielso, J.M. (335) 193
Macleod, D.C., see De Jonge, R. (337) 41
Macphail, E.M., see Nielsen, K.S. (326) 105
MacSweeney, C.P., see Redrobe, J.P. (318) 213
Madsen, U., see Bräuner-Osborne, H. (332) 327
Maeda, J., see Suzuki, T. (324) 21
Maeda, K., see Urabe, K. (321) 195
Maeda, S., see Murayama, T. (322) 21
Maeda, T., see Kaneda, K. (322) 259
Maeda, Y., see Shimpo, M. (338) 97
Maes, J.H.R. and Vossen, J.M.H.
Conditional control by midazolam and amphetamine in a rapid appetitive discrimination procedure (319) 5
Maes, R.A.A., see King, C.M.F. (325) 121
Maeyama, K., see Guo, Y. (331) 237
Maffre, M., see Valentin, J.-P. (317) 335
Maggi, C.A., see Giuliani, S. (332) 231
Maggi, C.A., see Giuliani, S. (333) 177
Magoc, T.J., see Albert, D.H. (325) 69
Magraner, J., Morcillo, E., Ausina, P., Pinto, F.M., Martín, J.D., Moreau, J., Anselmi, E., Barrachina, M.D., Cortijo, J., Advenier, C. and Candenas, M.L.
Effects of Mn^{2+} on the responses induced by different spasmogens in the oestrogen-primed rat uterus (326) 211
Maguire, M.H., see Dobronyi, I. (320) 61
Maguire, P.A. and Loew, G.H.
Thermodynamics of ligand binding to the cloned δ-opioid receptor (318) 505
Mahan, L., see Shiosaki, K. (317) 183
Mahé, E., see Ala, Y. (331) 285
Maher, J.R., see Robinson, S.E. (319) 31
Maidhof, A., see Jahns, R. (334) 115
Mailman, R.B., see Smith, H.P. (323) 27
Maisonneuve, I.M., Visker, K.E., Mann, G.L., Bandarage, U.K., Kuehne, M.E. and Glick, S.D.
Time-dependent interactions between iboga agents and cocaine (336) 123
Maj, J., Rogóż, Z., Skuza, G. and Kołodziejczyk, K.
The behavioural effects of pramipexole, a novel dopamine receptor agonist (324) 31
Mak, J.C.W., see Nishikawa, M. (318) 123
Makman, M.H. and Dvorkin, B.
Presence of nociceptin (orphanin FQ) receptors in rat retina: Comparison with receptors in striatum (338) 171
Makriyannis, A., see Hosohata, Y. (321) R1
Malaisse-Lagae, F., see Ladrière, L. (335) 227
Malaisse, W.J., see García-Martínez, J.A. (325) 65
Malaisse, W.J., see Ladrière, L. (335) 227
Malmström, R.E., see Hemsén, A. (318) 369
Mamiya, T., see Noda, Y. (324) 135
Manabe, H., Akuta, K., Sejimo, H., Kawasaki, H., Nukui, E., Ichimura, M., Kase, H., Kawakita, T., Suzuki, F., Kitamura, S., Sato, S. and Ohmori, K.
Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor (332) 97
Mandhane, S.N., Chopde, C.T. and Ghosh, A.K.
Adenosine A_2 receptors modulate haloperidol-induced catalepsy in rats (328) 135
Máñez, S., Recio, M.C., Giner, R.M. and Ríos, J.-L.
Effect of selected triterpenoids on chronic dermal inflammation (334) 103
Manning, M., see Ala, Y. (331) 285
Mansbach, R.S., Brooks, E.N. and Chen, Y.L.
Antidepressant-like effects of CP-154,526, a selective CRF_1 receptor antagonist (323) 21
Manzanares, J., see Corchero, J. (323) 193
Manzini, S., see Parlani, M. (318) 419
Manzino, L., see Zeevalk, G.D. (320) 111
Marchand, V., Tournier, J.-M., Polette, M., Nawrocki, B., Fuchey, C., Pierrot, D., Burlet, H. and Puchelle, E.
The elastase-induced expression of secretory leukocyte protease inhibitor is decreased in remodelled airway epithelium (336) 187
Mareel, M., see Charlier, C. (317) 413
Mareš, P., see Kubová, H. (333) 17
Marescaux, C., see Mathivet, P. (321) 67
Marescaux, C., see Vergnes, M. (332) 245

Maridonneau-Parini, I., see Roussin, A. (322) 91
Marini, P., see Cimino, M. (318) 201
Marjamäki, A., see Pohjanoksa, K. (335) 53
Markey, S.P., see Sei, Y. (325) 81
Marović, A., see Slobodnjak, Z. (332) 23
Marsden, C.A., see Thongsaard, W. (319) 157
Marsden, C.D., see Hurley, M.J. (318) 283
Martí-Cabrera, M., see Cortijo, J. (333) 69
Martijena, I.D., Lacerra, C. and Molina, V.A.
Carbamazepine normalizes the altered behavioral and neurochemical response to stress in benzodiazepine-withdrawn rats (330) 101
Martin, D., Miller, G., Cullen, T., Fischer, N., Dix, D. and Russell, D.
Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats (317) 247
Martin, J., see Scheideler, M.A. (339) 261
Martín, J.D., see Magraner, J. (326) 211
Martín, J.D., see Pinto, F.M. (324) 125
Martin, K.F., see Phillips, I. (337) 189
Martin, K.F., see Prow, M.R. (317) 21
Martín, M., see Albasanz, J.L. (326) 85
Martín, M.-L., see Morán, A. (330) 205
Martin, P., Waters, N.R., Waters, S.E., Carlsson, A. and Carlsson, M.L.
MK-801-induced hyperlocomotion: Differential effects of M100907, SDZ PSD 958 and raclopride (335) 107
Martin, P.-M., see Kampa, M. (335) 255
Martin, R.J., Robertson, A.P., Bjorn, H. and Sangster, N.C.
Heterogeneous levamisole receptors: a single-channel study of nicotinic acetylcholine receptors from *Oesophagostomum dentatum* (322) 249
Martin, T.J., Kim, S.A., Harris, L.S. and Smith, J.E.
Potent reinforcing effects of dihydroetorphine in rats (324) 141
Martin, W., see La, M. (321) R5
Martínez, A.C., Novella, S., Raposo, R., Recio, P., Labadía, A., Costa, G., García-Sacristán, A. and Benedito, S.
Histamine receptors in isolated bovine oviductal arteries (326) 163
Martínez, F., see González-Castillo, C. (329) 245
Martínez-Sierra, R., see Lara, B. (325) 109
Martinotti, E., see Nieri, P. (331) 205
Martos, F., see Pavía, J. (320) 209
Maruenda, A., see Higueras, J. (326) 175
Marui, S., see Sato, F. (322) 63
Maruno, M., see Arita, J. (318) 333
Maruta, E., see Yabuuchi, K. (334) 133
Mary, S., Stephan, D., Gomeza, J., Bockaert, J., Pruss, R.M. and Pin, J.-P.
The rat $mGlu_{1d}$ receptor splice variant shares functional properties with the other short isoforms of $mGlu_1$ receptor (335) 65
Mascia, M.S., see Gessa, G.L. (327) R1
Mascia, M.S., see Imperato, A. (317) 231
Mascia, M.S., see Weiss, F. (337) 219
Masereeuw, R., Moons, M.M. and Russel, F.G.M.
Rhodamine 123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system (321) 315
Mashino, T., see Satoh, M. (327) 175
Masiello, P., see Cadène, A. (318) 145
Masuda, Y., Sugo, T., Kikuchi, T., Satoh, M., Fujisawa, Y., Itoh, Y., Wakimasu, M. and Ohtaki, T.
Antagonist activity of [Thr^{18},γ-methylleucine^{19}]endothelin-1 in human endothelin receptors (325) 263
Masumiya, H., Tanaka, H. and Shigenobu, K.
Effects of Ca^{2+} channel antagonists on sinus node: Prolongation of late phase 4 depolarization by efonidipine (335) 15
Masumoto, N., Nakayama, K., Oyabe, A., Uchino, M., Ishii, K., Obara, K. and Tanabe, Y.
Specific attenuation of the pressure-induced contraction of rat cerebral artery by herbimycin A (330) 55
Masunaga, H., Ogawa, H., Uematsu, Y., Tomizuka, T., Yasuda, H. and Takeshita, Y.
Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs (339) 1
Mataga, N., see Fukamauchi, F. (338) 7
Máté, I., see Fekete, M.I.K. (331) 175
Máté, I., see Székely, J.I. (336) 143
Mathé, A.A., see Zachrisson, O. (319) 191
Mathie, R.T., see Browse, D.J. (320) 139
Mathieu, M.-N., see Zurbonsen, K. (320) 215
Mathivet, P., Bernasconi, R., De Barry, J., Marescaux, C. and Bittiger, H.
Binding characteristics of γ-hydroxybutyric acid as a weak but selective $GABA_B$ receptor agonist (321) 67
Matos, F.F., Korpinen, C. and Yocca, F.D.
5-HT_{1A} receptor agonist effects of BMY-14802 on serotonin release in dorsal raphe and hippocampus (317) 49
Matsubara, R., see Ishikane, T. (321) 163
Matsubara, S., Kikkawa, H., Kaminuma, O. and Ikezawa, K.
Angiotensin-converting enzyme inhibitors can potentiate ozone-induced airway hyperresponsiveness (337) 259
Matsuda, T., see Fujimura, M. (327) 57
Matsukawa, S., see Ohnishi, T. (319) 49
Matsuki, N., see Katsuki, H. (337) 213
Matsumoto, K., Mizowaki, M., Suchitra, T., Murakami, Y., Takayama, H., Sakai, S.-i., Aimi, N. and Watanabe, H.
Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems (317) 75
Matsumoto, M., see Furuse, M. (339) 211
Matsumoto, R.R., Brackett, R.L. and Kanthasamy, A.G.
Novel NMDA/glycine site antagonists attenuate cocaine-induced behavioral toxicity (338) 233
Matsumoto, T., Nakane, T. and Chiba, S.
Pharmacological analysis of responses to ATP in the isolated and perfused canine coronary artery (334) 173
Matsumura, Y., Hashimoto, N., Fujita, K. and Morimoto, S.
Ameliorating effect of an endothelin ET_A receptor antagonist on renal function of DOCA-salt hypertensive rats (319) 65
Matsuo, A., see Inagaki, N. (336) 225
Matsuo, K., see Satoh, M. (327) 175
Matsushima, S., Inada, H., Asai, T., Naka, M. and Tanaka, T.
Propiverine hydrochloride, an anti-pollakiuric agent, inhibits the activity of actomyosin ATPase from the urinary bladder (333) 93
Matsuura, N., see Taniguchi, H. (321) 397
Matsuzaki, T., see Yamazaki, R. (329) 181
Matthiesen, T., see Friese, J. (337) 165
Matthys, K.E., see Zamora, R. (321) 87
Matturri, L., see Sala, M. (328) 143
Maurice, T. and Privat, A.
SA4503, a novel cognitive enhancer with σ_1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice (328) 9
Mayet, S., see Diaz, A. (333) 9
Mayne, N., see Gehlert, D.R. (318) 485
Mazarguil, H., see Butour, J.-L. (321) 97
Mazdiyasni, H., see Jiang, N. (320) 131
Maze, M., see Fang, F. (336) 137
Mazière, M., see Bottlaender, M. (321) 13
McArdle, J.J., see Ye, J.H. (337) 87
McCarron, J.A., see Hume, S.P. (317) 67
McCarty, D.R., see Petty, M.A. (336) 127
McClanahan, T.B., see Ignasiak, D.P. (321) 295
McCloskey, T.C., see Baron, B.M. (323) 181
McCoy, L., Cox, C. and Richfield, E.K.
Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain (318) 41
McDermott, B.J., Millar, B.C., Dolan, F.M., Bell, D. and Balasubramaniam, A.

Evidence for Y_1 and Y_2 subtype of Neuropeptide Y receptor linked to opposing postjunctional effects observed in rat cardiac myocytes (336) 257
McDougall, S.A., see Bolanos, C.A. (317) 1
McGinty, J.F., see Wang, J.Q. (334) 43
McKay, N.G., see Griffin, G. (339) 53
McLarnon, J.G. and Xu, R.
Mixed blockade of K^+ and Na^+ currents in rat ventricular myocytes by the tedisamil analogue, KC8851 (339) 279
McLaughlin, J.P., Sebastian, A., Archer, S. and Bidlack, J.M.
14β-Chlorocinnamoylamino derivatives of metopon: long-term μ-opioid receptor antagonists (320) 121
McLean, P.G., Picard, C., Garcia-Villar, R., Moré, J., Fioramonti, J. and Buéno, L.
Effects of nematode infection on sensitivity to intestinal distension: Role of tachykinin NK_2 receptors (337) 279
McNeill, J.R., see Balakrishnan, S.M. (334) 55
McPherson, G.A., Choi, R.T., Kong, D.C.M. and Iskander, M.N.
The thromboxane A_2 and K_{ATP} channel antagonist actions of a series of sulphonylurea derivatives in the pig coronary artery (324) 193
Mealing, G., see Black, M. (317) 377
Meana, J.J., see Callado, L.F. (332) 109
Medeiros, Y.S., see Saleh, T.S.F. (331) 43
Medina, J.H., see Wolfman, C. (318) 23
Medina, V.M., see Gintzler, A.R. (325) 29
Medrano, J., see Hirata, H. (321) 217
Mei, J., see King, M. (331) R5
Mei, Q.B., see Kaan, S.K. (317) 115
Meißner, A., see Waurick, R. (333) 181
Mekeirele, K., see Germonpré, P.R. (324) 249
Meldrum, B.S., see Tang, E. (327) 109
Melis, M.R., Succu, S., Iannucci, U. and Argiolas, A.
N-Methyl-D-aspartic acid-induced penile erection and yawning: role of hypothalamic paraventricular nitric oxide (328) 115
Meltzger, G., see Sureda, F. (338) R1
Menéndez, L., Hidalgo, A. and Baamonde, A.
Spinal calmodulin inhibitors reduce *N*-methyl-D-aspartate- and septide-induced nociceptive behavior (335) 9
Mengozzi, M., see Ghezzi, P. (317) 369
Mennini, T., Mancini, L., Reggiani, A. and Trist, D.
GV 150526A, 7-Cl-kynurenic acid and HA 966 antagonize the glycine enhancement of *N*-methyl-D-aspartate-induced [^{3}H]noradrenaline and [^{3}H]dopamine release (336) 275
Menniti, F., Chenard, B., Collins, M., Ducat, M., Shalaby, I. and White, F.
CP-101,606, a potent neuroprotectant selective for forebrain neurons (331) 117
Mertens, J., see Abi-Dargham, A. (321) 285
Messlinger, K., Hotta, H., Pawlak, M. and Schmidt, R.F.
Effects of the 5-HT_1 receptor agonists, sumatriptan and CP 93,129, on dural arterial flow in the rat (332) 173
Mestre, C., Hernández, A., Eschalier, A. and Pelissier, T.
Effects of clomipramine and desipramine on a C-fiber reflex in rats (335) 1
Metzger, R.R., see Fleckenstein, A.E. (334) 111
Meunier, J.-C., see Butour, J.-L. (321) 97
Meunier, J.-C., see Florin, S. (317) 9
Meyer, J., see Waurick, R. (333) 181
Miao, L., Perreault, C.L., Travers, K.E. and Morgan, J.P.
Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium (321) 201
Michael, N., see Krause, W. (328) 249
Michel, A., see Pocock, T.M. (334) 75
Michel, A., see Zurbonsen, K. (320) 215
Michel, J.-B., see N'Diaye, N. (321) 387
Michielsen, P.P., Boeckxstaens, G.E., Sys, S.U., Herman, A.G. and Pelckmans, P.A.
Aminoguanidine reverses aortic hyporeactivity to noradrenaline in portal vein-ligated rats (329) 137
Michotte, Y., see Smolders, I. (319) 21
Middlemiss, D.N., see Hagan, J.J. (331) 169
Mignini, F., see Barili, P. (338) 89
Miki, S., see Inoue, A. (321) 105
Mikiciuk-Olasik, E., see Bräuner-Osborne, H. (332) 327
Mikkelsen, S., see Ebert, B. (333) 99
Miklić, P., see Sikirić, P. (332) 23
Mikulecká, A., see Kubová, H. (333) 17
Mikusa, J., see Shiosaki, K. (317) 183
Millan, M.J. and Perrin-Monneyron, S.
Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT_{1A} and 5-HT_{1B} receptors (321) R10
Millan, M.J., Gressier, H. and Brocco, M.
The dopamine D_3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats (321) R7
Millan, M.J., Peglion, J.-L., Lavielle, G. and Perrin-Monneyron, S.
5-HT_{2C} receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists (325) 9
Millan, M.J., see Newman-Tancredi, A. (319) 379
Millar, B.C., see McDermott, B.J. (336) 257
Miller, G., see Martin, D. (317) 247
Miller, M., see Kirkup, A.J. (317) 165
Miller, M.J.S., see Ribbons, K.A. (323) 245
Miller, R.T., Lau, S.S. and Monks, T.J.
2,5-*bis*-(Glutathion-*S*-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations (323) 173
Million, M., Fioramonti, J., Zajac, J.-M. and Buéno, L.
Effects of neuropeptide FF on intestinal motility and temperature changes induced by endotoxin and platelet-activating factor (334) 67
Mills, S.G., see Rupniak, N.M.J. (326) 201
Minami, K., Vanderah, T.W., Minami, M. and Harris, R.A.
Inhibitory effects of anesthetics and ethanol on muscarinic receptors expressed in *Xenopus* oocytes (339) 237
Minami, M., Endo, T., Tamakai, H., Ogawa, T., Hamaue, N., Hirafuji, M., Monma, Y., Yoshioka, M. and Hagihara, K.
Antiemetic effects of N-3389, a newly synthesized 5-HT_3 and 5-HT_4 receptor antagonist, in ferrets (321) 333
Minami, M., see Yabuuchi, K. (334) 133
Minota, S., see Ikeda, M. (324) 283
Minutoli, L., see Squadrito, F. (335) 185
Miras-Portugal, M.T., see Hoyle, C.H.V. (333) R1
Miras-Portugal, M.T., see Sistiaga, A. (321) 247
Misawa, M., see Suzuki, T. (324) 21
Misawa, M., see Suzuki, T. (331) 1
Misawa, M., see Tsuda, M. (324) 63
Mischiati, C., see Passadore, M. (319) 317
Miše, S., see Sikirić, P. (332) 23
Mishima, K., see Tanabe, T. (321) 137
Mishra, S.K., see Deka, D.K. (330) 157
Missale, C., see Sigala, S. (336) 107
Misu, Y., see Inoue, A. (321) 105
Mitchelson, F., see Christopoulos, A. (339) 153
Mitchelson, F., see Lanzafame, A. (321) 399
Miwa, Y., see Murayama, T. (322) 21
Miyabo, S., see Ohnishi, T. (319) 49
Miyai, H., see Fukunari, A. (323) 197
Miyakoda, G., see Hirano, T. (324) 201
Miyamoto, E., see Sugimura, M. (336) 99
Miyamoto, S., Asakura, M., Sasuga, Y., Osada, K., Bodaiji, N., Imafuku, J. and Aoba, A.
Effects of long-term treatment with desipramine on microtubule proteins in rat cerebral cortex (333) 279
Miyashita, Y., see Hirose, M. (338) 35
Miyata, K., see Kiso, T. (320) 187

Miyata, K., see Nagakura, Y. (321) 53
Miyata, K., see Nagakura, Y. (327) 189
Miyata, K., see Yamano, M. (317) 353
Miyata, T., see Takahama, K. (329) 93
Miyawaki, N., see Koidl, B. (322) 243
Miyazawa, N., see Ishizaki, K. (333) 207
Mizowaki, M., see Matsumoto, K. (317) 75
Mizuno, A., see Kaku, S. (321) 301
Mizuno, K., see Okada, M. (321) 181
Mizushima, Y., see Yamazaki, R. (329) 181
Mizusuna, A., see Kamei, J. (322) 27
Mladovan, A.G., see Shayo, C.C. (324) 129
Mo, Q., see Robinson, S.E. (319) 31
Mocaër, E., see Fabre, V. (337) 297
Mochizuki, T., Villemagne, V.L., Scheffel, U., Liu, X., Musachio, J.L., Dannals, R.F. and Wagner Jr., H.N.
A simple probe measures the pharmacokinetics of [^{125}I]RTI-55 in mouse brain in vivo (338) 17
Mochizuki, T., see Kakuyama, H. (329) 85
Modin, A., see Hemsén, A. (318) 369
Moeller, J., see Siegmund, B. (321) 231
Mohagheghi-Badi, M., see Zarrindast, M.-R. (338) 11
Moilanen, E., see Kosonen, O. (337) 55
Moisand, C., see Butour, J.-L. (321) 97
Molina-Holgado, E., see Liu, H.-N. (338) 277
Molina, V.A., see Martijena, I.D. (330) 101
Möller, S., Edvinsson, L. and Adner, M.
Transcriptional regulated plasticity of vascular contractile endothelin ET_B receptors after organ culture (329) 69
Monaghan, D.T., see Buller, A.L. (320) 87
Monge, L., García-Villalón, Á.L., Fernández, N., García, J.L., Gómez, B. and Diéguez, G.
In vitro relaxation of dog cerebral veins in response to histamine is mediated by histamine H_2 receptors (338) 135
Mongold, J.-J., see Cadène, A. (318) 145
Monks, T.J., see Miller, R.T. (323) 173
Monma, Y., see Minami, M. (321) 333
Monrocq, H., see Froissard, P. (326) 93
Monteau, R., see Hilaire, G. (329) 115
Montiel, C., Herrero, C.J., García-Palomero, E., Renart, J., García, A.G. and Lomax, R.B.
Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT_2 receptors (332) 183
Montoneri, C., see László, F. (337) 275
Moon, M.W., see Piercey, M.F. (317) 29
Moons, M.M., see Masereeuw, R. (321) 315
Moore, K.A., see Ladenheim, E.E. (319) 245
Moore, K.E., see Durham, R.A. (335) 37
Morán, A., Velasco, C., Martín, M.-L. and San Román, L.
Renal vasoconstrictor response to 5-hydroxytryptamine in the in situ autoperfused rat kidney: involvement of angiotensin II and the 5-HT_2 receptor activation (330) 205
Morcillo, E., see Magraner, J. (326) 211
Morcillo, E.J., see Cortijo, J. (333) 69
Morcillo, E.J., see Higueras, J. (326) 175
Moré, J., see McLean, P.G. (337) 279
Moreau, J., see Magraner, J. (326) 211
Moreels, T.G., see De Winter, B.Y. (339) 63
Moreira, E., see Weinberg, M.L.D. (320) 145
Moreland, S., see Zhang, R. (317) 91
Morelli, M., see Fenu, S. (321) 143
Morelli, M., see Pinna, A. (331) 23
Moreno Jr., H., see Faria, M.S. (323) 37
Morgan, A.E., Horan, B., Dewey, S.L. and Ashby Jr., C.R.
Repeated administration of 3,4-methylenedioxymethamphetamine augments cocaine's action on dopamine in the nucleus accumbens: A microdialysis study (331) R1
Morgan, J.P., see Miao, L. (321) 201
Morgan, N.G., see Chan, S.L.F. (323) 241
Mori, T., see Hirano, T. (324) 201
Mori, T., see Suzuki, T. (324) 21
Mori, T., see Suzuki, T. (331) 1
Mori, Y., Takayasu, M., Suzuki, Y., Shibuya, M., Yoshida, J. and Hidaka, H.
Effects of adrenomedullin on rat cerebral arterioles (330) 195
Mori, Y., Takayasu, M., Suzuki, Y., Shibuya, M., Yoshida, J. and Hidaka, H.
Vasodilator effects of C-type natriuretic peptide on cerebral arterioles in rats (320) 183
Morii, E., see Guo, Y. (331) 237
Morimoto, K., Sato, H., Sato, K., Sato, S. and Yamada, N.
BW1003C87, phenytoin and carbamazepine elevate seizure threshold in the rat amygdala-kindling model of epilepsy (339) 11
Morimoto, S., see Urabe, K. (321) 195
Morimoto, Y., see Nishio, H. (321) 27
Morin, D., see Ala, Y. (331) 285
Morisaki, I., see Murayama, T. (322) 21
Morishima, Y., see Sugimura, M. (336) 99
Morishita, H., see Furukawa, T. (328) 229
Morita, K., see Kamei, J. (322) 27
Morita, S., see Inoue, A. (321) 105
Moriyama, K., see Shimamura, K. (320) 37
Moriyama, N., Akiyama, K., Murata, S., Taniguchi, J., Ishida, N., Yamazaki, S. and Kawabe, K.
KMD-3213, a novel α_{1A}-adrenoceptor antagonist, potently inhibits the functional α_1-adrenoceptor in human prostate (331) 39
Morizane, C., Adachi, K., Furutani, I., Fujita, Y., Akaike, A., Kashii, S. and Honda, Y.
N^{ω}-Nitro-L-arginine methyl ester protects retinal neurons against *N*-methyl-D-aspartate-induced neurotoxicity in vivo (328) 45
Mormède, P., see Chaouloff, F. (334) 25
Morrison, K.S., see Doudet, D.J. (334) 31
Morrison, W.A., see Knight, K.R. (332) 273
Morse III, H.C., see Sei, Y. (325) 81
Moryl, E., see Papp, M. (317) 191
Mos, J., Van Hest, A., Van Drimmelen, M., Herremans, A.H.J. and Olivier, B.
The putative 5-HT_{1A} receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HT_{1A} receptor agonist flesinoxan in pigeons (325) 145
Mostofsky, D.I., see Yehuda, S. (328) 23
Motte, S., see Communi, D. (317) 383
Mouillac, B., see Ala, Y. (331) 285
Mouillac, B., see Rousseau, G. (326) 75
Moulds, R.F.W., see Tognarini, D.P. (322) 31
Mousa, S.A., see Schäfer, M. (323) 1
Mousseau, D.D., Rao, V.L.R. and Butterworth, R.F.
Vesicular dysfunction during experimental thiamine deficiency is indicated by alterations in dopamine metabolism (317) 263
Mue, S., see Niki, H. (320) 193
Mue, S., see Yamashita, M. (325) 221
Mue, S., see Yamashita, M. (338) 151
Mühl, H., Sandau, K., Brüne, B., Briner, V.A. and Pfeilschifter, J.
Nitric oxide donors induce apoptosis in glomerular mesangial cells, epithelial cells and endothelial cells (317) 137
Mukherjee, J. and Yang, Z.-Y.
Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): An in vitro and in vivo study (337) 111
Mukherjee, S.K., Klaidman, L.K., Yasharel, R. and Adams Jr., J.D.
Increased brain NAD prevents neuronal apoptosis in vivo (330) 27
Mulè, F. and Serio, R.
Mode and mechanism of neurotensin action in rat proximal colon (319) 269
Mullane, K.M., see Wang, J. (320) 241

Müller, A., Gottwald, M., Tudyka, T., Linke, W., Klaus, W. and Dhein, S.
Increase in gap junction conductance by an antiarrhythmic peptide (327) 65
Müller-Esterl, W., see Jahns, R. (334) 115
Muller, H., see Schaffhauser, H. (334) 289
Muller, S., Denet, S., Candiloros, H., Barrois, R., Wiernsperger, N., Donner, M. and Drouin, P.
Action of metformin on erythrocyte membrane fluidity in vitro and in vivo (337) 103
Mulvany, M.J., see Ipsen, M. (336) 29
Münkle, M., see Hauber, W. (323) 127
Muñoz, M., see Pavía, J. (320) 209
Murai, A., see Rho, M.-C. (319) 375
Murakami, A., see Yano, T. (323) 99
Murakami, J., see Ohtani, A. (330) 151
Murakami, Y., Yokotani, K., Okuma, Y. and Osumi, Y.
Nitric oxide mediates central activation of sympathetic outflow induced by interleukin-1β in rats (317) 61
Muraki, K., see Ishii, Y. (331) 295
Muraki, T., see Irie, K. (339) 289
Muraki, T., see Uchida, Y. (335) 235
Murata, S., see Itogawa, E. (317) 401
Murata, S., see Moriyama, N. (331) 39
Murawsky, M.K., see Baron, B.M. (323) 181
Murayama, T., Miwa, Y., Maeda, S., Morisaki, I. and Saito, K.
Effects of K^+ channel blockers and K^+ ionophore on isoprenaline-induced secretion of amylase from rat parotid acini (322) 21
Murota, S.-i., see Irie, K. (339) 289
Murphy, W.A., see Champion, H.C. (319) 71
Murray, T.F., see Soderstrom, K. (338) 191
Musachio, J.L., see Mochizuki, T. (338) 17
Muscará, M.N., see Faria, M.S. (323) 37
Muscará, M.N., see Zappellini, A. (317) 285
Musolino, C., see Squadrito, F. (318) 153
Mustafa, S.J., see Olanrewaju, H.A. (322) 185
Mustanoja, S.M., Hätönen, T., Johansson-Alila, A. and Laakso, M.-L.
Pineal melatonin in rats: suppression by the selective α_2-adrenoceptor agonist medetomidine (326) 229
Mutulis, F., see Schiöth, H.B. (319) 369
Myhrer, T. and Paulsen, R.E.
Infusion of D-cycloserine into temporal-hippocampal areas and restoration of mnemonic function in rats with disrupted glutamatergic temporal systems (328) 1

Nabekura, J., see Westh-Hansen, S.E. (329) 253
Nabeshima, T., see Itoh, A. (322) 11
Nabeshima, T., see Itoh, A. (332) 113
Nabeshima, T., see Kamei, H. (319) 165
Nabeshima, T., see Kitaichi, K. (318) 205
Nabeshima, T., see Kitaichi, K. (318) 7
Nabeshima, T., see Noda, Y. (324) 135
Nærum, L., see Scheideler, M.A. (339) 261
Nagahisa, A., see Nakamura, T. (322) 83
Nagai, H., see Inagaki, N. (336) 225
Nagai, H., see Kitagaki, K. (337) 283
Nagai, H., see Taniguchi, H. (318) 447
Nagai, H., see Taniguchi, H. (321) 397
Nagakura, Y., Ito, H., Kamato, T., Nishida, A. and Miyata, K.
Effect of a selective 5-HT_3 receptor agonist on gastric motility in fasted and fed dogs (327) 189
Nagakura, Y., Sohda, K.-y., Ito, H. and Miyata, K.
Gastrointestinal motor activity in conscious ferrets (321) 53
Nagao, T., see Kanda, S. (319) 101
Nagao, T., see Kurokawa, J. (325) 229
Nagase, H., see Kamei, J. (322) 27
Nagase, H., see Kamei, J. (326) 31
Nagase, H., see Kamei, J. (337) 137
Nagase, H., see Kamei, J. (337) 223
Nagase, H., see Quock, R.M. (326) 101
Nagase, H., see Suzuki, T. (324) 21
Nagase, H., see Suzuki, T. (331) 1
Nagase, M., see Hamada, N. (317) 123
Nagashima, Y., see Hirose, M. (338) 35
Nagata, N., see Inoue, H. (333) 231
Nagatani, T., see Takao, K. (333) 123
Nagatomo, T., see Koike, K. (334) 217
Nagayama, T., Koshika, T., Hisa, H., Kimura, T. and Satoh, S.
Apamin-sensitive SK_{Ca} channels modulate adrenal catecholamine release in anesthetized dogs (327) 135
Nahas, G., see Diesse, S. (338) 123
Naito, M., see Nanaumi, K. (327) 239
Naito, Y., see Konishi, C. (320) 175
Najbar-Kaszkiel, A.T., Di Iulio, J.L., Li, C.G. and Rand, M.J.
Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs (337) 251
Nakahara, K., see Inamura, N. (333) 79
Nakahara, K., see Yamamoto, N. (327) 169
Nakahashi, Y., see Takano, H. (323) 107
Nakahata, N., see Rho, M.-C. (319) 375
Nakai, T., see Ohnishi, T. (319) 49
Nakaike, S., see Nanaumi, K. (327) 239
Nakajima, T., Iwasawa, K., Hazama, H., Asano, M., Okuda, Y. and Omata, M.
Extracellular Mg^{2+} inhibits receptor-mediated Ca^{2+}-permeable non-selective cation currents in aortic smooth muscle cells (320) 81
Nakajima, T., see Rahman, F. (317) 293
Nakamura, A., see Nakamura, T. (322) 83
Nakamura, H., see Rho, M.-C. (319) 375
Nakamura, J., see Hotta, N. (326) 45
Nakamura, T., Ueno, Y., Goda, Y., Nakamura, A., Shinjo, K. and Nagahisa, A.
Efficacy of a selective histamine H_2 receptor agonist, dimaprit, in experimental models of endotoxin shock and hepatitis in mice (322) 83
Nakane, T., see Matsumoto, T. (334) 173
Nakanishi, C., see Katsuki, H. (337) 213
Nakashima, M., see Kaku, S. (321) 301
Nakashima, M., see Shimazawa, M. (328) 183
Nakata, K., see Kageyama, M. (333) 223
Nakata, Y., see Inoue, A. (321) 105
Nakata, Y., see Nishio, H. (321) 27
Nakato, K., see Takeuchi, H. (329) 27
Nakaya, H., see Hara, Y. (324) 295
Nakaya, H., see Watanabe, Y. (338) 71
Nakayama, H., see Kagitani, F. (332) 89
Nakayama, K., see Masumoto, N. (330) 55
Nakayama, W., see Sugimura, M. (336) 99
Nakazato, T., see Horikawa, H.P.M. (326) 15
Nakazato, Y., see Otsuguro, K.-i. (317) 97
Nakazato, Y., see Sugawara, T. (319) 123
Nakazawa, K. and Ohno, Y.
Effects of neuroamines and divalent cations on cloned and mutated ATP-gated channels (325) 101
Nakazawa, K., Liu, M., Inoue, K. and Ohno, Y.
Potent inhibition by trivalent cations of ATP-gated channels (325) 237
Nakazawa, K., Liu, M., Inoue, K. and Ohno, Y.
pH dependence of facilitation by neurotransmitters and divalent cations of $P2X_2$ purinoceptor/channels (337) 309
Nanaumi, K., Tsuchida, K., Nakaike, S., Yamagishi, T., Ichihara, T., Takahashi, K., Watajima, H., Suzuki, Y., Naito, M. and Tsuruo, T.
Overcoming of multidrug resistance by VA-033, a novel derivative of apovincaminic acid ester (327) 239

Narita, M., see Furukawa, Y. (334) 191
Narita, M., see Kamei, J. (322) 27
Naruhashi, K., see Itoh, A. (322) 11
Naruhashi, K., see Itoh, A. (332) 113
Naruse, K., see Seki, T. (331) 87
Naruse, M., see Seki, T. (331) 87
Nascimento, J.H.M., see Suarez-Kurtz, G. (335) 153
Nasjletti, A., see Kozma, F. (323) R1
Nasu, T. and Shibata, A.
Na^+-independent glucose utilization during Mn^{2+}-induced contraction in ileal longitudinal smooth muscle (333) 199
Nava, F., Calapai, G., Facciolà, G., Cuzzocrea, S., Giuliani, G., De Sarro, A. and Caputi, A.P.
Melatonin effects on inhibition of thirst and fever induced by lipopolysaccharide in rat (331) 267
Nawrath, H., see Wegener, J.W. (326) 37
Nawrocki, B., see Marchand, V. (336) 187
Naylor, A., see Lundstrom, K. (337) 73
Naylor, R.J., see Rudd, J.A. (322) 79
Naylor, R.J., see Singh, L. (321) 209
N'Diaye, N., Pueyo, M.E., Battle, T., Ossart, C., Guédin, D. and Michel, J.-B.
Conversion of big-endothelin-1 elicits an endothelin ET_A receptor-mediated response in endothelial cells (321) 387
Negri, L., see Noviello, L. (332) R1
Neisewander, J.L., see Sussman, A.N. (337) 157
Nelemans, S.A., see Filipeanu, C.M. (336) R1
Németh, Z.H., Szabó, C., Haskó, G., Salzman, A.L. and Vizi, E.S.
Effect of the phosphodiesterase III inhibitor amrinone on cytokine and nitric oxide production in immunostimulated J774.1 macrophages (339) 215
Netz, H., see Reithmann, C. (330) 79
Neuenschwander, S. and Pliška, V.
Effects of neurohypophyseal hormone analogues on blood clotting factor VIII and fibrinolytic activity in sheep (323) 205
Newman-Tancredi, A., Audinot-Bouchez, V., Gobert, A. and Millan, M.J.
Noradrenaline and adrenaline are high affinity agonists at dopamine D_4 receptors (319) 379
Nguyen, B.Q.H., see Zambon, A.C. (324) 39
Nguyen, L., see Katsube, Y. (317) 391
Ni, L., see Domino, E.F. (325) 137
Nicholls, J. and Hourani, S.M.O.
Characterization of adenosine receptors on rat ileum, ileal longitudinal muscle and muscularis mucosae (338) 143
Nickenig, G., see Rosenkranz, S. (330) 35
Nicoletti, F., see Sureda, F. (338) R1
Nicolin, A., see Galeotti, N. (330) 15
Nieber, K., see Poelchen, W. (332) 267
Nielsen, B., see Bräuner-Osborne, H. (335) R1
Nielsen, K.S., Macphail, E.M. and Riedel, G.
Class I mGlu receptor antagonist 1-aminoindan-1,5-dicarboxylic acid blocks contextual but not cue conditioning in rats (326) 105
Nielsen-Kudsk, F., see Thirstrup, S. (333) 215
Nielsen-Kudsk, J.E., see Thirstrup, S. (319) 253
Nielsen, M., see Westh-Hansen, S.E. (329) 253
Nieri, P., Lazzeri, N., Martinotti, E. and Breschi, M.C.
Histaminic bronchospasm potentiated by adenosine: Investigation of the mechanisms (331) 205
Niggli, V. and Keller, H.
Low concentrations of the phosphatase inhibitor okadaic acid stop tumor cell locomotion (324) 99
Niggli, V. and Keller, H.
The phosphatidylinositol 3-kinase inhibitor wortmannin markedly reduces chemotactic peptide-induced locomotion and increases in cytoskeletal actin in human neutrophils (335) 43
Niki, H., Tominaga, Y., Watanabe-Kobayashi, M., Mue, S. and Ohuchi, K.
Possible participation of cyclooxygenase-2 in the recurrence of allergic inflammation in rats (320) 193
Niki, H., see Yamashita, M. (338) 151
Nikkel, A., see Shiosaki, K. (317) 183
Nilvebrant, L., Andersson, K.-E., Gillberg, P.-G., Stahl, M. and Sparf, B.
Tolterodine – a new bladder-selective antimuscarinic agent (327) 195
Nishida, K., Ohta, Y. and Ishiguro, I.
Glycine facilitates γ-glutamylcysteinylethyl ester-mediated increase in liver glutathione level (333) 289
Nishikawa, K., see Ojima, M. (319) 137
Nishikawa, M., Mak, J.C.W. and Barnes, P.J.
Effect of short- and long-acting β_2-adrenoceptor agonists on pulmonary β_2-adrenoceptor expression in human lung (318) 123
Nishio, E. and Watanabe, Y.
Nitric oxide donor-induced apoptosis in smooth muscle cells is modulated by protein kinase C and protein kinase A (339) 245
Nishio, E. and Watanabe, Y.
Role of the lipoxygenase pathway in phenylephrine-induced vascular smooth muscle cell proliferation and migration (336) 267
Nishio, H., Morimoto, Y., Nuibe, T., Fujii, A. and Nakata, Y.
Inhibitory effect of ethanol on the $5\text{-}HT_3$ receptor-mediated tachycardia in isolated guinea-pig atrium (321) 27
Nishiura, M., see Urabe, K. (321) 195
Nishiyori, A., see Yabuuchi, K. (334) 133
Nishizawa, S., Igawa, Y., Okada, N. and Ohhashi, T.
Capsaicin-induced nitric-oxide-dependent relaxation in isolated dog urethra (335) 211
Nitta, A., see Itoh, A. (332) 113
Niwa, M., see Sakurai-Yamashita, Y. (338) 199
Noack, E., see Kojda, G. (334) 181
Noble, F., see Vincent, B. (334) 49
Noda, K., see Taniguchi, Y. (330) 221
Noda, Y., Mamiya, T., Furukawa, H. and Nabeshima, T.
Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice (324) 135
Noda, Y., see Kitaichi, K. (318) 205
Noda, Y., see Kitaichi, K. (318) 7
Noguchi, K., see Westh-Hansen, S.E. (329) 253
Nojima, H., see Kimura, I. (330) 123
Nomura, Y., see Oda, H. (339) 253
Noorhosseini, H., see Kristof, A.S. (328) 69
Nordgren, S., see Börjesson, L. (334) 223
Norlén, M. and Allard, P.
[^{3}H]GBR 12935 binding in platelets: A possible association with cytochrome P-450IID6? (332) 227
North, T.J., see Dickinson, K. (339) 69
Norton, C.S. and Galloway, M.P.
Repeated cocaine exposure attenuates the ability of 5-hydroxytryptamine to release striatal dopamine in vivo (318) 323
Nossuli, T.O., see Hayward, R. (334) 157
Novella, S., see Martínez, A.C. (326) 163
Noviello, L., Papadia, S., Capobianchi, M.R. and Negri, L.
Immunomodulatory responses to δ-opioid receptor ligands in human lymphocytes (332) R1
Nukui, E., see Manabe, H. (332) 97
Nutt, D.J., see Hume, S.P. (317) 67
Nyce, J.W., see Phan, T.A. (323) R5
Nyce, P., see Baron, B.M. (323) 181
Nyitrai, G., Emri, Z., Crunelli, V., Kékesi, K.A., Dobolyi, Á. and Juhász, G.
In vivo blockade of thalamic $GABA_B$ receptors increases excitatory amino-acid levels (318) 295

Obana, M., see Sakurai-Yamashita, Y. (338) 199
Obara, K., see Masumoto, N. (330) 55
Obermeier, H., Wehmeyer, A. and Schulz, R.
Expression of μ-, δ- and κ-opioid receptors in baculovirus-infected insect cells (318) 161

Ocete, M.A., see Duarte, J. (338) 25
Oda, H., Murayama, T., Sasaki, Y., Okada, T. and Nomura, Y.
Endothelin enhances lipopolysaccharide-induced expression of inducible nitric oxide synthase in rat glial cells (339) 253
Oddis, C.V. and Finkel, M.S.
Cytokines and nitric oxide synthase inhibitor as mediators of adrenergic refractoriness in cardiac myocytes (320) 167
Oehme, P., see Krause, W. (328) 249
Ogasawara, T., see Taniguchi, N. (318) 117
Ogawa, A., see Uchida, Y. (335) 235
Ogawa, H., see Masunaga, H. (339) 1
Ogawa, R., see Tanabe, T. (321) 137
Ogawa, T., see Minami, M. (321) 333
Ogihara, M., see Kimura, M. (324) 267
Ogihara, M., see Kimura, M. (327) 87
Ogletree, M.L., see Zhang, R. (317) 91
Ögren, S.O., see Kobayashi, S. (326) 1
Ohara, N., see Konishi, C. (320) 175
Ohba, K.-i., see Uchida, Y. (335) 235
Ohhashi, T., see Nishizawa, S. (335) 211
Ohizumi, Y., see Rho, M.-C. (319) 375
Ohmiya, S., see Kamei, J. (337) 223
Ohmori, K., see Manabe, H. (332) 97
Ohmori, M., see Aoki, K. (336) 43
Ohnishi, T., Ishizaki, T., Sasaki, F., Ameshima, S., Nakai, T., Miyabo, S. and Matsukawa, S.
The effect of Cu^{2+} on rat pulmonary arterial rings (319) 49
Ohno, M. and Watanabe, S.
D-Cycloserine, a glycine site agonist, reverses working memory failure by hippocampal muscarinic receptor blockade in rats (318) 267
Ohno, Y., see Nakazawa, K. (325) 237
Ohno, Y., see Nakazawa, K. (337) 309
Ohsawa, M. and Kamei, J.
Possible involvement of protein kinase C in the attenuation of [D-Ala^2, NMePhe^4, Gly-ol^5]enkephalin-induced antinociception in diabetic mice (339) 27
Ohsawa, M., see Kamei, J. (337) 137
Ohsawa, M., see Kamei, J. (337) 223
Ohsawa, M., see Yoshino, S. (336) 203
Ohshika, H., see Amemiya, N. (318) 403
Ohshika, H., see Amemiya, N. (339) 173
Ohta, K., see Takaori, K. (322) 59
Ohta, T., see Otsuguro, K.-i. (317) 97
Ohta, T., see Sugawara, T. (319) 123
Ohta, Y., see Nishida, K. (333) 289
Ohtaki, T., see Masuda, Y. (325) 263
Ohtani, A., Murakami, J. and Hirano-Wakimoto, A.
T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats (330) 151
Ohuchi, K., see Yamashita, M. (325) 221
Ohuchi, K., see Yamashita, M. (338) 151
Ohura, M., see Hirano, T. (324) 201
Ohwada, K., see Taniguchi, H. (318) 447
Ohwada, K., see Taniguchi, H. (321) 397
Ohya, Y., Adachi, N., Setoguchi, M., Abe, I. and Fujishima, M.
Effects of CP-060S on membrane channels in vascular smooth muscle cells from guinea pig (330) 93
Oikawa, T. and Shimamura, M.
Potent inhibition of angiogenesis by wortmannin, a fungal metabolite (318) 93
Oike, M. and Ito, Y.
Dynamic regulation of intracellular Ca^{2+} concentration in aortic endothelial cells (319) 291
Ojima, M., Inada, Y., Shibouta, Y., Wada, T., Sanada, T., Kubo, K. and Nishikawa, K.
Candesartan (CV-11974) dissociates slowly from the angiotensin AT_1 receptor (319) 137
Okabe, E., see Wada, S. (320) 51
Okada, K., see Ikeda, M. (324) 283
Okada, K., see Shimpo, M. (338) 97
Okada, M., Kiryu, K., Kawata, Y., Mizuno, K., Wada, K., Tasaki, H. and Kaneko, S.
Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis (321) 181
Okada, T., see Oda, H. (339) 253
Okamoto, R., see Yamazaki, R. (329) 181
Okamura, T., see Ayajiki, K. (329) 49
Okamura, T., see Uchiyama, M. (321) 19
Okazaki, M., see Kimura, I. (330) 123
Okazaki, T., see Shibasaki, M. (335) 167
Okazaki, T., see Shibasaki, M. (335) 175
Oktay, Ş., see Aslan, N. (333) 63
Oktay, Ş., see Tellioğlu, T. (336) 163
Oktay, Ş., see Tellioğlu, T. (317) 301
Oku, T., see Inamura, N. (333) 79
Okuda, Y., see Nakajima, T. (320) 81
Okuhara, M., see Yamamoto, N. (327) 169
Okuma, Y., see Murakami, Y. (317) 61
Olanrewaju, H.A., Hargittai, P.T., Lieberman, E.M. and Mustafa, S.J.
Effect of ouabain on adenosine receptor-mediated hyperpolarization in porcine coronary artery smooth muscle (322) 185
Olbrich, H.-G., see Witte, K. (334) 209
Olgart, C., see Iversen, H.H. (321) 213
Olivares, R., see Lara, B. (325) 109
Olivier, B., see Compaan, J.C. (324) 161
Olivier, B., see King, C.M.F. (325) 121
Olivier, B., see Mos, J. (325) 145
Olpe, H.-R., see Badran, S. (333) 135
Olson, L., see Kobayashi, S. (326) 1
Omata, M., see Nakajima, T. (320) 81
Omitsu, M., see Sugimura, M. (336) 99
Ōmura, S., see Sato, F. (322) 63
Onat, F., see Aslan, N. (333) 63
Onat, F., see Tellioğlu, T. (336) 163
Onat, F., see Tellioğlu, T. (317) 301
Ondeyka, J.G., see Suarez-Kurtz, G. (335) 153
O'Neill, M.F., see Silvestre, J.S. (318) 257
O'Neill, M.J., Bath, C.P., Dell, C.P., Hicks, C.A., Gilmore, J., Ambler, S.J., Ward, M.A. and Bleakman, D.
Effects of Ca^{2+} and Na^+ channel inhibitors in vitro and in global cerebral ischaemia in vivo (332) 121
Ong, J., Kerr, D.I.B., Vaccher, C. and Berthelot, P.
Actions of thienyl analogs of baclofen at $GABA_B$ receptors in rat neocortical slices (329) 133
Ono, H., see Konishi, C. (320) 175
Ono, N., see Adachi, Y. (324) 223
Ono, T., see Shinguh, Y. (337) 63
Opacka-Juffry, J., see Hume, S.P. (317) 67
Ophorst, O.J.A.E., see Smeets, R.L.L. (325) 93
Oriani, G., see Radice, S. (320) 43
Orito, K., see Hirano, T. (324) 201
O'Rourke, M., Gavin, K. and Docherty, J.R.
Further investigation of the α-adrenoceptor-mediated actions of chloroethylclonidine in rat aorta (336) 37
Ortiz, J.L., see Higueras, J. (326) 175
Ortolani, R., see Conforti, A. (324) 241
Orzi, F., see Patacchioli, F.R. (336) 159
Orzi, F., see Pontieri, F.E. (335) 133
Osada, K., see Miyamoto, S. (333) 279
Osnes, J.-B., see Skomedal, T. (333) 169
Osnes, J.-B., see Viko, H. (323) 269
Ossart, C., see N'Diaye, N. (321) 387
Osumi, Y., see Murakami, Y. (317) 61
Oszter, A., see Környei, J.L. (336) 65

Ota, H., see Aoki, K. (336) 43
Ota, S., see Hata, Y. (321) 113
Otani, H., see Tanabe, T. (321) 137
Otani, S. and Connor, J.A.
Rapid dendritic Ca^{2+} influx is associated with induction of homosynaptic long-term depression in adult rat hippocampus (318) R5
Otsuguro, K.-i., Ito, S., Ohta, T. and Nakazato, Y.
Influence of purines and pyrimidines on circular muscle of the rat proximal stomach (317) 97
Oveisi, M.-R., see Zarrindast, M.-R. (321) 157
Owen, S., see Rupniak, N.M.J. (326) 201
Oyabe, A., see Masumoto, N. (330) 55
Ozaki, H., see Takizawa, S. (330) 143
Ozawa, T., see Fukushi, Y. (336) 89
Ozawa, Y., see Sakitama, K. (337) 175
Özçelikay, A.T., see Öztürk, Y. (321) 59
Özer, H., see Kaur, S. (332) 153
Özkutlu, U., see Tellioğlu, T. (317) 301
Öztürk, Y., Aydın, S., Özçelikay, A.T., Altan, V.M. and Yıldızoğlu-Arı, N.
Calmodulin content and in vitro contractility of duodenum from streptozotocin-induced diabetic rats: effects of insulin therapy and calmodulin antagonism (321) 59

Padgett, W.L., see Badio, B. (321) 189
Page, C.P., see Perez, A.C. (330) 241
Paisley, K., see La, M. (321) R5
Palacios, B., Lim, S.L. and Pang, C.C.Y.
Effects of endothelin-1 on arterial and venous resistances in anaesthetized rats (327) 183
Paladini, A.C., see Wolfman, C. (318) 23
Palkovits, M., Baffi, J.S., Berzsenyi, P. and Horváth, E.J.
Anxiolytic homophthalazines increase Fos-like immunoreactivity in selected brain areas of the rat (331) 53
Palluk, R., see Walland, A. (330) 213
Palomba, L., Brambilla, L., Brandi, G., Sestili, P., Cattabeni, F. and Cantoni, O.
Low levels of hydrogen peroxide and L-histidine induce DNA double-strand breakage and apoptosis (318) 167
Pan, W.H.T., Chen, N.-H., Tsai, F.-Y. and Liao, H.-Y.
Intrategmental infusion of cocaine decreases dopamine release and enhances norepinephrine release in the medial prefrontal cortex (317) 205
Pan, Y.-X., see King, M. (331) R5
Panegyres, P.K. and Hughes, J.
Activation of c-*fos* mRNA in the brain by the κ-opioid receptor agonist enadoline and the NMDA receptor antagonist dizocilpine (328) 31
Pang, C.C.Y., see Palacios, B. (327) 183
Pang, L. and Hoult, J.R.S.
Induction of cyclooxygenase and nitric oxide synthase in endotoxin-activated J774 macrophages is differentially regulated by indomethacin: Enhanced cyclooxygenase-2 protein expression but reduction of inducible nitric oxide synthase (317) 151
Pansu, D., see Volant, K. (328) 217
Papadia, S., see Noviello, L. (332) R1
Papp, J.G., see Vegh, A. (333) 33
Papp, J.Gy., see Baczkó, I. (324) 77
Papp, J.Gy., see Kaszala, K. (328) 51
Papp, M., Moryl, E. and Maccecchini, M.-L.
Differential effects of agents acting at various sites of the NMDA receptor complex in a place preference conditioning model (317) 191
Papworth, J., Colville-Nash, P., Alam, C., Seed, M. and Willoughby, D.
The depletion of substance P by diclofenac in the mouse (325) R1
Pardo, L., Campillo, M. and Giraldo, J.
The effect of the molecular mechanism of G protein-coupled receptor activation on the process of signal transduction (335) 73
Park, P.D.S. and Henry, J.L.
Receptor subtypes mediating spinal cardiovascular effects of angiotensin II in rat using losartan and PD 123319 (326) 139
Parker, M.S., Crowley, W.R. and Parker, S.L.
Differences in cation sensitivity of ligand binding to Y_1 and Y_2 subtype of neuropeptide Y receptor of rat brain (318) 193
Parkinson, F.E., see Foga, I.O. (318) 455
Parlani, M., Conte, B., Cirillo, R. and Manzini, S.
Characterization of tachykinin NK_2 receptor on dog proximal colon. Antagonism by MEN 10,627 and SR 48,968 (318) 419
Paronis, C.A. and Woods, J.H.
Clocinnamox dose-dependently antagonizes morphine-analgesia and [^{3}H]DAMGO binding in rats (337) 27
Parratt, J.R., see Kaszala, K. (328) 51
Parratt, J.R., see Vegh, A. (333) 33
Parsons, S.M., see Staley, J.K. (338) 159
Pascaud, X., see Langlois, A. (318) 141
Pascaud, X., see Langlois, A. (324) 211
Passadore, M., Bianchi, N., Feriotto, G., Mischiati, C., Rutigliano, C. and Gambari, R.
In vitro and in vivo binding of a CC-1065 analogue to human gene sequences: a polymerase-chain reaction study (319) 317
Pasternak, G.W., see Chien, C.-C. (321) 361
Pasternak, G.W., see King, M. (331) R5
Patacchioli, F.R., Pontieri, F.E., Di Grezia, R., Colangelo, V., Angelucci, L. and Orzi, F.
Increased functional response to cocaine challenge following recovery from chronic corticosterone in the rat (336) 159
Patel, D.R. and Croucher, M.J.
Evidence for a role of presynaptic AMPA receptors in the control of neuronal glutamate release in the rat forebrain (332) 143
Patel, S. and Hutson, P.H.
Effects of galanin on 8-OH-DPAT induced decrease in body temperature and brain 5-hydroxytryptamine metabolism in the mouse (317) 197
Patte, C., see Gandolfo, P. (322) 275
Patterson, A.B., Gordon, F.J. and Holtzman, S.G.
Naltrindole, a selective δ-opioid receptor antagonist, potentiates the lethal effects of cocaine by a central mechanism of action (333) 47
Paulsen, R.E., see Myhrer, T. (328) 1
Paulussen, J.J.C., see Fischer, M.J.E. (322) 97
Pauwels, R.A., see Germonpré, P.R. (324) 249
Pauwels, R.A., see Joos, G.F. (338) 259
Pavía, J., Muñoz, M., Jiménez, E., Martos, F., Glez-Correa, J.A., De la Cruz, J.P., Garcia, V. and Sanchez de la Cuesta, F.
Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes (320) 209
Pazos, A., see Lahmame, A. (337) 115
Pearce, F.L., see Gibbs, B.F. (327) 73
Pecori Vettori, A., see Ghelardini, C. (329) 1
Peeters, T.L., see Van Assche, G. (337) 267
Peglion, J.-L., see Millan, M.J. (325) 9
Peglion, J.-L., see Thollon, C. (339) 43
Peiró, C., Angulo, J., Regadera, J., Llergo, J.L., Sánchez-Ferrer, A., Rodríguez-Mañas, L. and Sánchez-Ferrer, C.F.
Nifedipine, losartan and captopril effects on hyperplasia of vascular smooth muscle from Ren-2 transgenic rats (324) 257
Pelckmans, P.A., see Michielsen, P.P. (329) 137
Pelissier, T., see Mestre, C. (335) 1
Pencheva, N.
Dependence of γ-aminobutyric acid modulation of cholinergic transmission on nitric oxide and purines in cat terminal ileum (339) 193
Pennefather, J.N., see Fisher, L. (335) 221
Pennline, K., see Ribbons, K.A. (323) 245
Pepeu, G., see Scali, C. (325) 173
Perez, A.C., Khawaja, A.M., Page, C.P. and Paul, W.

Persistence of effects of nitric oxide synthase inhibitors: Comparisons on blood flow and plasma exudation in guinea pig skin (330) 241
Pérez, H., see Sardi, S.P. (321) 33
Pérez-Vizcaino, F., see Duarte, J. (338) 25
Pergande, G., see Perovic, S. (317) 157
Pergande, G., see Schmidt, W.J. (327) 1
Perović, D., see Sikirić, P. (332) 23
Perovic, S., Pialoglou, P., Schröder, H.C., Pergande, G. and Müller, W.E.G.
Flupirtine increases the levels of glutathione and Bcl-2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect (317) 157
Perreault, C.L., see Miao, L. (321) 201
Perretti, M., see Wheller, S.K. (331) 65
Perrin-Monneyron, S., see Millan, M.J. (321) R10
Perrin-Monneyron, S., see Millan, M.J. (325) 9
Perrot, S., see Idänpään-Heikkilä, J.J. (325) 155
Pertwee, R.G., see Griffin, G. (339) 53
Pesonen, U., see Savontaus, E. (328) 207
Petek, M., see Sikirić, P. (332) 23
Peterfreund, R.A., Gies, E.K. and Fink, J.S.
Protein kinase C regulates adenosine A2a receptor mRNA expression in SH-SY5Y cell (336) 71
Pethő, G., see Pintér, E. (325) 57
Petitto, J.M., see Gendreau, P.L. (337) 147
Petkov, G.V. and Boev, K.K.
Cyclopiazonic acid-induced changes in contractile activity of smooth muscle strips isolated from cat and guinea-pig stomach (318) 109
Petty, M.A., Elands, J., Johnson, M.P., Linnik, M.D., Hamel, E., Moskowitz, M.A., Lee, W.S., McCarty, D.R., Hibert, M. and Baron, B.M.
The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine (336) 127
Pèzzola, A., see Popoli, P. (333) 143
Pfeilschifter, J., see Mühl, H. (317) 137
Phan, T.A., Gray, A.M. and Nyce, J.W.
Intrastriatal adenosine A_1 receptor antisense oligodeoxynucleotide blocks ethanol-induced motor incoordination (323) R5
Pheng, L.H., Fournier, A., Dumont, Y., Quirion, R. and Regoli, D.
The dog saphenous vein: a sensitive and selective preparation for the Y_2 receptor of neuropeptide Y (327) 163
Pheng, L.H., Quirion, R., Iyengar, S., Fournier, A. and Regoli, D.
The rabbit ileum: A sensitive and selective preparation for the neuropeptide Y Y_4 receptor (333) R3
Phillips, I., Martin, K.F., Thompson, K.S.J. and Heal, D.J.
Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine (337) 189
Picard, C., see McLean, P.G. (337) 279
Piekarska, A.E. and McPherson, G.A.
Structure–activity relationship of quaternary ion antagonism of levcromakalim-induced relaxation in pig coronary artery (322) 37
Pieper, G.M., Siebeneich, W. and Dondlinger, L.A.
Short-term oral administration of L-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes (317) 317
Piercey, M.F., Moon, M.W., Sethy, V.H., Schreur, P.J.K.D., Smith, M.W., Tang, A.H. and VonVoigtlander, P.F.
Pharmacology of U-91356A, an agonist for the dopamine D_2 receptor subtype (317) 29
Pierrot, D., see Marchand, V. (336) 187
Pietilä, K., Salminen, O., Leikola-Pelho, T. and Ahtee, L.
Tolerance to nicotine's effects on striatal dopamine metabolism in nicotine. -withdrawn mice (318) 17
Pilc, A., see Chojnacka-Wójcik, E. (319) 153
Pilz, G., see Reithmann, C. (330) 79
Pin, J.-P., see Mary, S. (335) 65
Piña, E., see Saldaña-Balmori, Y. (317) 225
Pinna, A., Morelli, M., Drukarch, B. and Stoof, J.C.
Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D_1 receptor-dependent cyclic AMP production in striatal tissue (331) 23
Pintér, E., Helyes, Z., Pethő, G. and Szolcsányi, J.
Noradrenergic and peptidergic sympathetic regulation of cutaneous microcirculation in the rat (325) 57
Pinto, F.M., Magraner, J., Ausina, P., Anselmi, E., Martín, J.D. and Candenas, M.L.
Regulation by oestrogens of tachykinin NK_3 receptor expression in the rat uterus (324) 125
Pintor, J., see Hoyle, C.H.V. (333) R1
Pionnelli, D., see Calignano, A. (337) R1
Pirotton, S., see Communi, D. (317) 383
Pitsikas, N. and Borsini, F.
The adenosine A_1 receptor antagonist BHP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat (328) 19
Pittner, R.A.
Lack of effect of calcitonin gene-related peptide and amylin on major markers of glucose metabolism in hepatocytes (325) 189
Plummer, C.V., see Badio, B. (321) 189
Pocock, T.M., Laurent, F., Isaac, L.M., Chiu, P., Elliott, K.R.F., Foster, R.W., Michel, A., Bonnet, P.-A. and Small, R.C.
Effects of SCA40 on bovine trachealis muscle and on cyclic nucleotide phosphodiesterases (334) 75
Poelchen, W., Nieber, K. and Illes, P.
Tolerance to inhibition by ethanol of *N*-methyl-D-aspartate-induced depolarization in rat locus coeruleus neurons in vitro (332) 267
Pohjanoksa, K., Jansson, C.C., Luomala, K., Marjamäki, A., Savola, J.-M. and Scheinin, M.
α_2-Adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase (335) 53
Pokk, P., Liljequist, S. and Zharkovsky, A.
Ro 15-4513 potentiates, instead of antagonizes, ethanol-induced sleep in mice exposed to small platform stress (317) 15
Polgar, W.E., see Toll, L. (323) 261
Poli, E. and Pozzoli, C.
Histamine H_3 receptors do not modulate reflex-evoked peristaltic motility in the isolated guinea-pig ileum (327) 49
Pomés, A., see Vale, C. (319) 343
Pongsakorn, S., see Thongsaard, W. (319) 157
Pontieri, F.E., Calò, L., Di Grezia, R., Orzi, F. and Passarelli, F.
Functional correlates of heroin sensitization in the rat brain (335) 133
Popoli, P., Reggio, R. and Pèzzola, A.
Adenosine A_1 and A_2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats (333) 143
Porreca, F., see Quock, R.M. (326) 101
Potoczak, R.E., see Ignasiak, D.P. (321) 295
Poucheret, P., see Cadène, A. (318) 145
Poupaert, J.H., see Ucar, H. (335) 267
Pozo, D., Montilla, M.L., Guerrero, J.M. and Calvo, J.R.
Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages (321) 379
Prabonnaud, V., see Schaeffer, P. (323) 215
Prasad, P.D., Torres-Zamorano, V., Kekuda, R., Leibach, F.H. and Ganapathy, V.
Functional link between tyrosine phosphorylation and human serotonin transporter gene expression (325) 85
Prentice, D.J. and Hourani, S.M.O.
Adenosine analogues relax guinea-pig taenia caeci via an adenosine A_{2B} receptor and a xanthine-resistant site (323) 103
Price, G.W., see Roberts, C. (326) 23

Prickaerts, J., Steinbusch, H.W.M., Smits, J.F.M. and De Vente, J.
Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effects of 7-nitroindazole and zaprinast (337) 125
Prié, S., Conroy, D.M., Gleich, G.J. and Sirois, P.
Eosinophils and neutrophils modify arachidonic acid-induced relaxation of guinea-pig trachea (317) 343
Prieto, D., see Simonsen, U. (329) 153
Prior, C., Breadon, E.L. and Lindsay, K.E.
Modulation by presynaptic adenosine A_1 receptors of nicotinic receptor antagonist-induced neuromuscular block in the mouse (327) 103
Privat, A., see Maurice, T. (328) 9
Privat, K., see Falcón, J. (337) 325
Probst, J.C., see Schöbitz, B. (331) 97
Prosperi, C., see Scali, C. (325) 173
Prow, M.R., Martin, K.F. and Heal, D.J.
8-OH-DPAT-induced mydriasis in mice: A pharmacological characterisation (317) 21
Pruss, R.M., see Mary, S. (335) 65
Przesmycki, K., Dzieciuch, J.A., Czuczwar, S.J. and Kleinrok, Z.
Isobolographic analysis of interaction between intrathecal morphine and clonidine in the formalin test in rats (337) 11
Puech, R., see Berdeu, D. (324) 233
Pueyo, M.E., see N'Diaye, N. (321) 387
Puig, M.M., see González, A.A. (328) 201
Pulvirenti, L., Balducci, C. and Koob, G.F.
Dextromethorphan reduces intravenous cocaine self-administration in the rat (321) 279
Putzke, J., Spanagel, R., Tölle, T.R. and Zieglgänsberger, W.
The anti-craving drug acamprosate reduces c-*fos* expression in rats undergoing ethanol withdrawal (317) 39

Qu, X., Cooney, G. and Donnelly, R.
Short-term metabolic and haemodynamic effects of GR79236 in normal and fructose-fed rats (338) 269
Quattrone, A., see Ghelardini, C. (329) 1
Quintana, A., see González-Castillo, C. (329) 245
Quirion, R., see Pheng, L.H. (327) 163
Quirion, R., see Pheng, L.H. (333) R3
Quirion, R., see Trinh, T. (318) R1
Quock, R.M., Hosohata, Y., Knapp, R.J., Burkey, T.H., Hosohata, K., Zhang, X., Rice, K.C., Nagase, H., Hruby, V.J., Porreca, F., Roeske, W.R. and Yamamura, H.I.
Relative efficacies of δ-opioid receptor agonists at the cloned human δ-opioid receptor (326) 101
Quock, R.M., see Burkey, T.H. (336) 295
Quock, R.M., see Hosohata, Y. (321) R1

Raasmaja, A., see Savontaus, E. (328) 207
Rabin, R.A., see Johnson, R.G. (329) 99
Rabinovitz, S., see Yehuda, S. (328) 23
Racchi, H., Schliem, A.J., Donoso, M.V., Rahmer, A., Zúñiga, Á., Guzmán, S., Rudolf, K. and Huidobro-Toro, J.P.
Neuropeptide Y Y_1 receptors are involved in the vasoconstriction caused by human sympathetic nerve stimulation (329) 79
Radice, S., Rossoni, G., Oriani, G., Michael, M., Chiesara, E. and Berti, F.
Hyperbaric oxygen worsens myocardial low flow ischemia-reperfusion injury in isolated rat heart (320) 43
Rahimian, R., Van Breemen, C., Karkan, D., Dube, G. and Laher, I.
Estrogen augments cyclopiazonic acid-mediated, endothelium-dependent vasodilation (327) 143
Rahman, F., Kato, A., Kawahara, K. and Nakajima, T.
Y-26763 protects the working rat myocardium from ischemia/reperfusion injury through opening of K_{ATP} channels (317) 293
Rahmatullah, R.J., see Wenham, D. (339) 77
Rahmer, A., see Racchi, H. (329) 79
Raimbault, S., see Le Gouic, S. (339) 271
Ralevic, V., see Hill, B. (317) 275
Ramirez-Lavergne, C., see Gandía, L. (329) 189
Ramsden, C.A., see Chan, S.L.F. (323) 241
Rand, M.J., see Di Iulio, J.L. (337) 245
Rand, M.J., see La, M. (321) R5
Rand, M.J., see Najbar-Kaszkiel, A.T. (337) 251
Randall, M.D. and Kendall, D.A.
Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation (335) 205
Randall, M.D., McCulloch, A.I. and Kendall, D.A.
Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery (333) 191
Rao, V.L.R., see Mousseau, D.D. (317) 263
Rao, V.S.N., see Santos, F.A. (331) 253
Raposo, R., see Martínez, A.C. (326) 163
Rascher, W., see Dötsch, J. (331) 313
Rascher, W., see Hänze, J. (330) 87
Rasmussen, J.S., see Scheideler, M.A. (339) 261
Rasmussen, P.B., see Westh-Hansen, S.E. (329) 253
Raung, S.-L., see Wang, J.-P. (320) 201
Raung, S.-L., see Wang, J.-P. (336) 81
Ravault, J.-P., see Falcón, J. (337) 325
Raviprakash, V., see Deka, D.K. (330) 157
Reber, D., see Reithmann, C. (330) 79
Reche, I., Fuentes, J.A. and Ruiz-Gayo, M.
Potentiation of Δ^9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and κ-opioid receptors (318) 11
Recio, P., see Martínez, A.C. (326) 163
Reddy, D.S. and Kulkarni, S.K.
Chronic neurosteroid treatment prevents the development of morphine tolerance and attenuates abstinence behavior in mice (337) 19
Redrobe, J.P. and Bourin, M.
Partial role of 5-HT_2 and 5-HT_3 receptors in the activity of antidepressants in the mouse forced swimming test (325) 129
Redrobe, J.P., MacSweeney, C.P. and Bourin, M.
The role of 5-HT_{1A} and 5-HT_{1B} receptors in antidepressant drug actions in the mouse forced swimming test (318) 213
Rees, S.A., see Schlachter, S.K. (322) 283
Regadera, J., see Peiró, C. (324) 257
Reggiani, A., see Mennini, T. (336) 275
Reggio, R., see Popoli, P. (333) 143
Regoli, D., see Berthiaume, N. (333) 55
Regoli, D., see Pheng, L.H. (327) 163
Regoli, D., see Pheng, L.H. (333) R3
Reid, A., see Sawynok, J. (330) 115
Reid, A.R., see Sawynok, J. (333) 1
Reid, J.J., see Way, K.J. (318) 101
Reiländer, H., see Jahns, R. (334) 115
Reith, M.E.A., Xu, C. and Chen, N.-H.
Pharmacology and regulation of the neuronal dopamine transporter (324) 1
Reithmann, C., Reber, D., Kozlik-Feldmann, R., Netz, H., Pilz, G., Welz, A. and Werdan, K.
A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease (330) 79
Ren, J.M. and Finklestein, S.P.
Time window of infarct reduction by intravenous basic fibroblast growth factor in focal cerebral ischemia (327) 11
Ren, L.-M., Hoyle, C.H.V. and Burnstock, G.
Developmental changes in sympathetic contraction of the circular muscle layer in the guinea-pig vas deferens (318) 411
Reul, J.M.H.M., see Schöbitz, B. (331) 97
Reure, H., see Thollon, C. (339) 43
Revilla, E., see De la Cruz, C.P. (327) 215
Reynolds, I.J., see Scanlon, J.M. (326) 67
Rhie, D.-J., see Sim, S.-S. (324) 205
Rho, M.-C., Nakahata, N., Nakamura, H., Murai, A. and Ohizumi, Y.

Tyrphostin 23 blocks phosphorylation of p42 but not p38 mitogen-activated protein kinase by zooxanthellatoxin-A (319) 375
Ribbons, K.A., Thompson, J.H., Liu, X., Pennline, K., Clark, D.A. and Miller, M.J.S.
Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis (323) 245
Ribeiro, J.A., see Lorenzen, A. (334) 299
Ribes, G., see Berdeu, D. (324) 233
Ribes, G., see Cadène, A. (318) 145
Ricci, A., see Barili, P. (338) 89
Rice, K.C., see Quock, R.M. (326) 101
Rice, W., Shannon, J.M., Burton, F. and Fiedeldey, D.
Expression of a brain-type cannabinoid receptor (CB_1) in alveolar Type II cells in the lung: regulation by hydrocortisone (327) 227
Richardson, J.D., Aanonsen, L. and Hargreaves, K.M.
SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice (319) R3
Richfield, E.K., see McCoy, L. (318) 41
Richter, A., Gernert, M. and Löscher, W.
Prodystonic effects of riluzole in an animal model of idiopathic dystonia related to decreased total power in the red nucleus? (332) 133
Ricquier, D., see Le Gouic, S. (339) 271
Riedel, G., see Nielsen, K.S. (326) 105
Riekkinen, M., Schmidt, B., Kuitunen, J. and Riekkinen Jr, P.
Effects of combined chronic nimodipine and acute metrifonate treatment on spatial and avoidance behavior (322) 1
Riekkinen, M., Schmidt, B.H. and Riekkinen Jr., P.
Subchronic treatment increases the duration of the cognitive enhancement induced by metrifonate (338) 105
Riekkinen, M., see Riekkinen Jr., P. (323) 11
Riekkinen Jr., P., Schmidt, B. and Riekkinen, M.
Behavioral characterization of metrifonate-improved acquisition of spatial information in medial septum-lesioned rats (323) 11
Riekkinen Jr., P., see Aura, J. (333) 129
Riekkinen Jr., P., see Jäkälä, P. (318) 239
Riekkinen Jr., P., see Riekkinen, M. (338) 105
Riera, C.M., see Correa, S.G. (319) 85
Rigby, M., see Seabrook, G.R. (317) 129
Ríos, J.-L., see Máñez, S. (334) 103
Riottot, M., see Hajri, T. (320) 65
Rivière, P.J.M., see Langlois, A. (318) 141
Rivière, P.J.M., see Langlois, A. (324) 211
Roach, A.G., see Waldron, G.J. (318) 89
Robaye, B., Boeynaems, J.-M. and Communi, D.
Slow desensitization of the human $P2Y_6$ receptor (329) 231
Roberts, A.J., Polis, I.Y. and Gold, L.H.
Intravenous self-administration of heroin, cocaine, and the combination in Balb/c mice (326) 119
Roberts, C., Price, G.W. and Jones, B.J.
The role of $5\text{-}HT_{1B/1D}$ receptors in the modulation of 5-hydroxytryptamine levels in the frontal cortex of the conscious guinea pig (326) 23
Robichon, R., Randall, P.K. and Leslie, S.W.
A partial agonist model used in the allosteric modulation of the NMDA receptor (328) 255
Robinson, S.E., Kunko, P.M., Smith, J.A., Wallace, M.J., Mo, Q. and Maher, J.R.
Extracellular aspartate concentration increases in nucleus accumbens after cocaine sensitization (319) 31
Robishaw, J.D., see Wenham, D. (339) 77
Rocha-Hernández, A., see Saldaña-Balmori, Y. (317) 225
Rodger, I.W., see Chan, C.-C. (327) 221
Rodgers, R.J., see Cao, B.-J. (335) 117
Rodriguez-Alvarez, J., see Rodriguez, F.J. (323) 283
Rodríguez-Farré, E., see Vale, C. (319) 343
Rodriguez, F.J., Lluch, M., Dot, J., Blanco, I. and Rodriguez-Alvarez, J.
Histamine modulation of glutamate release from hippocampal synaptosomes (323) 283
Rodríguez-Mañas, L., see Peiró, C. (324) 257
Rodríguez-Puyol, D., see Ruiz-Ginés, J.A. (336) 251
Rodríguez-Puyol, M., see Ruiz-Ginés, J.A. (336) 251
Rodt, S.Å., see Koller, M.-E. (331) 259
Roehr, J.E., see Kongsamut, S. (317) 417
Roeske, W.R., see Burkey, T.H. (323) R3
Roeske, W.R., see Burkey, T.H. (336) 295
Roeske, W.R., see Hosohata, Y. (321) R1
Roeske, W.R., see Landsman, R.S. (334) R1
Roeske, W.R., see Quock, R.M. (326) 101
Roffel, A.F., see Ten Berge, R.E.J. (318) 131
Rogóż, Z., see Maj, J. (324) 31
Rolland, Y., see Ghezzi, P. (317) 369
Rollema, H., Lu, Y., Schmidt, A.W. and Zorn, S.H.
Clozapine increases dopamine release in prefrontal cortex by $5\text{-}HT_{1A}$ receptor activation (338) R3
Rombolà, L., see Izzo, A.A. (323) 93
Romero, A.G., see Schlachter, S.K. (322) 283
Rompré, P.-P.
Repeated activation of neurotensin receptors sensitizes to the stimulant effect of amphetamine (328) 131
Roques, B., see Vincent, B. (334) 49
Roques, B.P., see Hernando, F. (318) 221
Ros, M., see Albasanz, J.L. (326) 85
Rosenkranz, S., Nickenig, G., Flesch, M., Cremers, B., Schnabel, P., Lenz, O., Krause, T., Ganten, D., Hoffmann, S. and Böhm, M.
Cardiac angiotensin II receptors: studies on functional coupling in Sprague-Dawley rats and TGR(αMHC-hAT_1) transgenic rats (330) 35
Rossi, F., see D'Amico, M. (328) 65
Rossi, F., see Squadrito, F. (318) 153
Rossoni, G., see De Gennaro Colonna, V. (334) 201
Rossoni, G., see Radice, S. (320) 43
Rossowski, W.J., Jiang, N.-Y. and Coy, D.H.
Adrenomedullin, amylin, calcitonin gene-related peptide and their fragments are potent inhibitor of gastric acid secretion in rats (336) 51
Roth, J., see Goldbach, J.-M. (319) 273
Roth, J., see Goldbach, J.-M. (334) 249
Rothe, K.S., see Stevens, C.W. (331) 15
Rothlin, R.P., see Sardi, S.P. (321) 33
Rotkvić, I., see Sikirić, P. (332) 23
Rouru, J., see Savontaus, E. (328) 207
Rouru, J., see Virtanen, K.A. (332) 215
Rousseau, G., Guilbault, N., Da Silva, A., Mouillac, B., Chidiac, P. and Bouvier, M.
Influence of receptor density on the patterns of β_2-adrenoceptor desensitization (326) 75
Roussin, A., Le Cabec, V., Lonchampt, M., De Nadaï, J., Canet, E. and Maridonneau-Parini, I.
Neutrophil-associated inflammatory responses in rats are inhibited by phenylarsine oxide (322) 91
Rowan, M.J., see Breakwell, N.A. (322) 173
Rowan, M.J., see Hölscher, C. (322) 155
Rowan, M.J., see Huang, L. (332) 161
Rowan, M.J., see Xu, L. (323) 59
Roye, M., see Cadène, A. (318) 145
Rozé, C., see Souli, A. (333) 87
Ručman, R., see Sikirić, P. (332) 23
Rudd, J.A. and Naylor, R.J.
The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret (322) 79
Ruffle, K.L., see Croucher, M.J. (319) 207
Ruiz-Gayo, M., see Gutiérrez, M. (328) 99
Ruiz-Gayo, M., see Hernando, F. (318) 221
Ruiz-Gayo, M., see Reche, I. (318) 11

Ruiz-Ginés, J.A., Pérez-Caballero, C., O'Valle, F., Rodríguez-Puyol, M. and Rodríguez-Puyol, D.
Captopril inhibits pp60^{c-src} tyrosine phosphorylation in cultured human mesangial cell (336) 251
Ruiz-Ortega, J.A. and Ugedo, L.
Activation of 5-HT$_{1A}$ receptors potentiates the clonidine inhibitory effect in the locus coeruleus (333) 159
Rundfeldt, C.
The new anticonvulsant retigabine (D-23129) acts as an opener of K^+ channels in neuronal cell (336) 243
Rupniak, N.M.J., Tattersall, F.D., Williams, A.R., Rycroft, W., Carlson, E.J., Cascieri, M.A., Sadowski, S., Ber, E., Hale, J.J., Mills, S.G., MacCoss, M., Seward, E., Huscroft, I., Owen, S., Swain, C.J., Hill, R.G. and Hargreaves, R.J.
In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK$_1$ receptor antagonists (326) 201
Russel, F.G.M., see Masereeuw, R. (321) 315
Russell, D., see Martin, D. (317) 247
Ruth, T.J., see Doudet, D.J. (334) 31
Rutigliano, C., see Passadore, M. (319) 317
Ruzicka, T., see Homey, B. (325) 199
Rycroft, W., see Rupniak, N.M.J. (326) 201

Sabbatini, M., see Barili, P. (334) 233
Sacco, S., see Ghezzi, P. (317) 369
Sacerdote, P., Bianchi, M. and Panerai, A.E.
In vivo and in vitro clomipramine treatment decreases the migration of macrophages in the rat (319) 287
Sacks, S.M., see Giordano, J. (334) 39
Sadowski, S., see Cascieri, M.A. (325) 253
Sadowski, S., see Rupniak, N.M.J. (326) 201
Saffroy, M., see Beaujouan, J.-C. (319) 307
Saganek, L.J., see Ignasiak, D.P. (321) 295
Saito, H., see Katsuki, H. (337) 213
Saito, K., see Murayama, T. (322) 21
Saito, N., see Furuse, M. (339) 211
Saito, N., see Kinoshita, M. (321) 325
Saito, T., see Ikeda, M. (324) 283
Saito, T., see Shimpo, M. (338) 97
Saito, Y., see Konishi, C. (320) 175
Saitoh, A., see Kamei, J. (322) 27
Saitta, A., see Squadrito, F. (318) 153
Saitta, A., see Squadrito, F. (335) 185
Sajjadi, F., see Wang, J. (320) 241
Sakai, F., see Yamamoto, N. (327) 169
Sakai, S.-i., see Matsumoto, K. (317) 75
Sakai, Y., see Suzuki, K.-i. (336) 169
Sakakibara, F., see Hotta, N. (326) 45
Sakamoto, N., see Hotta, N. (326) 45
Sakitama, K., Ozawa, Y., Aoto, N., Tomita, H. and Ishikawa, M.
Effects of a new centrally acting muscle relaxant, NK433 (lanperisone hydrochloride) on spinal reflexes (337) 175
Sakurai, T., Kaise, T., Yadomae, T. and Matsubara, C.
Different role of serum components and cytokines on alveolar macrophage activation by soluble fungal (1 → 3)-β-D-glucan (334) 255
Sakurai-Yamashita, Y., Yamashita, K., Yoshida, A., Obana, M., Takada, K., Shibaguchi, H., Shigematsu, K., Niwa, M. and Taniyama, K.
Rat peritoneal macrophages express endothelin ET$_B$ but not endothelin ET$_A$ receptors (338) 199
Sala, M., Leone, M.P., Lampugnani, P., Matturri, L. and Gori, E.
Polydeoxyribonucleotide (defibrotide) protects against post-ischemic behavioral, electroencephalographic and neuronal damage in the gerbil (328) 143
Salamone, J.D., see Cousins, M.S. (322) 137
Saldaña-Balmori, Y., Zentella de Piña, M., Guinzberg, R., Rocha-Hernández, A. and Piña, E.
Piroxicam modifies the effects of ethanol on isolated rat hepatocytes (317) 225
Saleh, T.S.F., Calixto, J.B. and Medeiros, Y.S.
Pro-inflammatory effects induced by bradykinin in a murine model of pleurisy (331) 43
Salicioni, A.M., Carón, R.W. and Deis, R.P.
Participation of both adrenergic and opioidergic systems in the negative feedback of adrenal progesterone on LH secretion (332) 283
Salituro, F.G., see Wu, H.-Q. (319) 13
Salminen, O., see Pietilä, K. (318) 17
Salorio, C.F., see Ladenheim, E.E. (319) 245
Salzman, A.L., see Németh, Z.H. (339) 215
Salzman, A.L., see Zingarelli, B. (338) 55
Sam, E., Sarre, S., Michotte, Y. and Verbeke, N.
Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid (329) 9
Sanada, T., see Ojima, M. (319) 137
Sànchez, C.
Interaction studies of 5-HT$_{1A}$ receptor antagonists and selective 5-HT reuptake inhibitors in isolated aggressive mice (334) 127
Sánchez-Ferrer, C.F., see Peiró, C. (324) 257
Sánchez-Prieto, J., see Sistiaga, A. (321) 247
Sanchez de la Cuesta, F., see Pavía, J. (320) 209
Sandau, K., see Mühl, H. (317) 137
Sandnes, D., see Viko, H. (323) 269
Sandrasagra, A., see Kongsamut, S. (317) 417
Sanger, D.J., see Cohen, C. (336) 113
Sangster, N.C., see Martin, R.J. (322) 249
San Román, L., see Morán, A. (330) 205
Santarromana, M., see Halmos, T. (318) 477
Santos, F.A. and Rao, V.S.N.
Mast cell involvement in the rat paw oedema response to 1,8-cineole, the main constituent of eucalyptus and rosemary oils (331) 253
Sardi, S.P., Pérez, H., Antúnez, P. and Rothlin, R.P.
Bradykinin B$_1$ receptors in human umbilical vein (321) 33
Sarriá, B., see Higueras, J. (326) 175
Sasa, M., see Domino, E.F. (325) 137
Sasaki, E., Arakawa, T., Fujiwara, Y., Kawada, N., Fukuda, T., Higuchi, K., Komurasaki, T. and Kobayashi, K.
Epiregulin stimulates proliferation of rabbit gastric cells in primary culture through autophosphorylation of the epidermal growth factor receptor (338) 253
Sasaki, H., see Fujii, S. (331) 9
Sasaki, M., see Tomita, F. (326) 157
Sasaki, T., see Temma, K. (322) 235
Sasaki, Y., see Oda, H. (339) 253
Sasaki, Y., see Ukai, M. (338) 1
Sasuga, Y., see Miyamoto, S. (333) 279
Satake, N., Shibata, M. and Shibata, S.
Endothelium- and cytochrome P-450-dependent relaxation induced by isoproterenol in rat aortic rings (319) 37
Sato, A., see Kagitani, F. (332) 89
Sato, F., Sekiguchi, M., Marui, S., Inatomi, N., Shino, A., Itoh, Z. and Ōmura, S.
EM574, an erythromycin derivative, is a motilin receptor agonist in the rabbit (322) 63
Sato, K., Kawasaki, T., Taniuchi, Y., Hirayama, F., Koshio, H. and Matsumoto, Y.
YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time (339) 141
Sato, K., see Suzuki, K.-i. (336) 169
Sato, N., see Yamamoto, N. (327) 169
Sato, S., see Manabe, H. (332) 97
Sato, S., see Morimoto, K. (339) 11
Sato, T., see Sugimura, M. (336) 99
Satoh, M., Matsuo, K., Kiriya, H., Mashino, T., Nagano, T., Hirobe, M. and Takayanagi, I.

Inhibitory effects of a fullerene derivative, dimalonic acid C_{60}, on nitric oxide-induced relaxation of rabbit aorta (327) 175
Satoh, M., see Yabuuchi, K. (334) 133
Satoh, S., see Adachi, Y. (324) 223
Satoh, S., see Inamura, N. (333) 79
Satoh, S., see Nagayama, T. (327) 135
Satoh, S., see Yoshida, K. (338) 131
Satoh, T., see Higuchi, H. (328) 175
Satoh, Y., see Shibasaki, M. (335) 167
Satoh, Y., see Shibasaki, M. (335) 175
Sautebin, L., see Izzo, A.A. (323) 93
Savage, P., see Hu, S. (324) 277
Savola, J.-M., see Kukkonen, J.P. (335) 99
Savola, J.-M., see Pohjanoksa, K. (335) 53
Savola, J.-M., see Savontaus, E. (328) 207
Savontaus, E., Raasmaja, A., Rouru, J., Koulu, M., Pesonen, U., Virtanen, R., Savola, J.-M. and Huupponen, R.
Anti-obesity effect of MPV-1743 AIII, a novel imidazoline derivative, in genetic obesity (328) 207
Sawa, A., see Imanishi, T. (321) 273
Sawa, A., see Yamashita, N. (337) 95
Sawada, Y., see Inamura, N. (333) 79
Sawai, H., see Inamura, N. (333) 79
Sawyer, W.H., see Ala, Y. (331) 285
Sawynok, J. and Reid, A.
Peripheral adenosine 5′-triphosphate enhances nociception in the formalin test via activation of a purinergic P_{2X} receptor (330) 115
Sawynok, J., Zarrindast, M.-R., Reid, A.R. and Doak, G.J.
Adenosine A_3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine (333) 1
Scali, C., Giovannini, M.G., Bartolini, L., Prosperi, C., Hinz, V., Schmidt, B. and Pepeu, G.
Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats (325) 173
Scanlon, J.M., Aizenman, E. and Reynolds, I.J.
Effects of pyrroloquinoline quinone on glutamate-induced production of reactive oxygen species in neurons (326) 67
Schaeffer, P., Laplace, M.-C., Prabonnaud, V., Bernat, A., Gully, D., Lespy, L. and Herbert, J.-M.
Neurotensin induces the release of prostacyclin from human umbilical vein endothelial cells in vitro and increases plasma prostacyclin levels in the rat (323) 215
Schäfer, M., Mousa, S.A. and Stein, C.
Corticotropin-releasing factor in antinociception and inflammation (323) 1
Schaffhauser, H., De Barry, J., Muller, H., Heitz, M.-P., Gombos, G. and Mutel, V.
Involvement of a cyclic-AMP pathway in group I metabotropic glutamate receptor responses in neonatal rat cortex (334) 289
Schechter, M.D.
Discrete versus cumulative dosing in dose–response discrimination studies (326) 113
Schechter, M.D.
Discrimination of cocaethylene in rats trained to discriminate between its components (320) 1
Scheideler, M.A., Martin, J., Hohlweg, R., Rasmussen, J.S., Nærum, L., Ludvigsen, T.S., Larsen, P.J., Korsgaard, N., Crider, A.M., Ghosh, D., Cruse, S.F. and Fink-Jensen, A.
The preferential dopamine D_3 receptor agonist *cis*-8-OH-PBZI induces limbic *Fos* expression in rat brain (339) 261
Scheinin, M., see Virolainen, S. (338) 293
Scheller, D.K.A., De Ryck, M., Kolb, J., Szathmary, S., Van Reempts, J., Clincke, G. and Tegtmeier, F.
Lubeluzole blocks increases in extracellular glutamate and taurine in the peri-infarct zone in rats (338) 243
Scherman, D., see Halmos, T. (318) 477
Scheuer, W.V., see Amandi-Burgermeister, E. (326) 237
Schiander, I.G., see Skomedal, T. (333) 169
Schiöth, H.B., Muceniece, R., Larsson, M., Mutulis, F., Szardenings, M., Prusis, P., Lindeberg, G. and Wikberg, J.E.S.
Binding of cyclic and linear MSH core peptides to the melanocortin receptor subtypes (319) 369
Schlachter, S.K., Poel, T.J., Lawson, C.F., Dinh, D.M., Lajiness, M.E., Romero, A.G., Rees, S.A., Duncan, J.N. and Smith, M.W.
Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D_4 receptor (322) 283
Schmid, L., see Bottlaender, M. (321) 13
Schmidt, A.W., see Rollema, H. (338) R3
Schmidt, B., see Jäkälä, P. (318) 239
Schmidt, B., see Riekkinen Jr., P. (323) 11
Schmidt, B., see Riekkinen, M. (322) 1
Schmidt, B., see Scali, C. (325) 173
Schmidt, B.H., see Riekkinen, M. (338) 105
Schmidt, C.J., see Baron, B.M. (323) 181
Schmidt, R.F., see Messlinger, K. (332) 173
Schmidt, W.J., Schuster, G., Wacker, E. and Pergande, G.
Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs (327) 1
Schnabel, P., see Rosenkranz, S. (330) 35
Schnauss, R., see Gendreau, P.L. (337) 147
Schnecko, A., see Witte, K. (334) 209
Schneider, A.S., Nagel, J.E. and Mah, S.J.
Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release (317) R1
Schober, D.A., Gackenheimer, S.L. and Gehlert, D.R.
Pharmacological characterization of neuropeptide Y-(2–36) binding to neuropeptide Y Y_1 and Y_2 receptors (318) 307
Schober, D.A., see Statnick, M.A. (332) 299
Schöbitz, B., Pezeshki, G., Probst, J.C., Reul, J.M.H.M., Skutella, T., Stöhr, T., Holsboer, F. and Spanagel, R.
Centrally administered oligodeoxynucleotides in rats: occurrence of non-specific effects (331) 97
Schousboe, A., see Juhász, G. (331) 139
Schreur, P.J.K.D., see Piercey, M.F. (317) 29
Schröder, H.C., see Perovic, S. (317) 157
Schrör, K., see Grosser, T. (319) 327
Schulte, K., see Grosser, T. (319) 327
Schulz, R., see Obermeier, H. (318) 161
Schulz, R., see Vollmar, A.M. (319) 279
Schuppe, H.-C., see Homey, B. (325) 199
Schuster, G., see Schmidt, W.J. (327) 1
Schwabe, U., see Lorenzen, A. (334) 299
Schwarcz, R., see Wu, H.-Q. (319) 13
Schwartz, A., see Kobayashi, T. (332) 313
Schwarz, M., see Elger, B. (336) 7
Seabrook, G.R., Shepheard, S.L., Williamson, D.J., Tyrer, P., Rigby, M., Cascieri, M.A., Harrison, T., Hargreaves, R.J. and Hill, R.G.
L-733,060, a novel tachykinin NK_1 receptor antagonist: effects in $[Ca^{2+}]_i$ mobilisation, cardiovascular and dural extravasation assays (317) 129
Sebastião, A.M., see Lorenzen, A. (334) 299
Seed, M., see Papworth, J. (325) R1
Seega, J., see Elger, B. (336) 7
Sehba, F., Duttaroy, A., Shah, S., Chen, B., Carroll, J. and Yoburn, B.C.
In vivo homologous regulation of μ-opioid receptor gene expression in the mouse (339) 33
Sei, Y., Nishida, K., Kustova, Y., Markey, S.P., Morse III, H.C. and Basile, A.S.
Pentoxifylline decreases brain levels of platelet activating factor in murine AIDS (325) 81
Seiwerth, S., see Sikirić, P. (332) 23
Sejimo, H., see Manabe, H. (332) 97
Seki, T., Naruse, M., Naruse, K., Yoshimoto, T., Tanabe, A., Imaki, T., Hagiwara, H., Hirose, S. and Demura, H.

Interrelation between nitric oxide synthase and heme oxygenase in rat endothelial cells (331) 87
Sekiguchi, M., see Sato, F. (322) 63
Sekino, Y., see Fujii, S. (331) 9
Selgas, L., see Esquifino, A.I. (319) 181
Sellink, A., see Lorenzen, A. (334) 299
Selve, N., see Friese, J. (337) 165
Semenova, S., see Kuzmin, A.V. (321) 265
Senyah, Y., see Baron, B.M. (323) 181
Šeparović, J., see Sikirić, P. (332) 23
Serio, R., see Mulè, F. (319) 269
Serizawa, T., see Kohmoto, O. (319) 355
Serra, G., see Collu, M. (322) 123
Serra, G., see D'Aquila, P.S. (330) 11
Serrano, J.-J., see Cadène, A. (318) 145
Serrano, M., see Squadrito, F. (335) 185
Serrão, M.P., see Gomes, P. (332) 219
Serruys, P.W., see De Jonge, R. (337) 41
Sestili, P., see Palomba, L. (318) 167
Sethy, V.H., see Piercey, M.F. (317) 29
Seto, M., see Inoue, A. (321) 105
Setoguchi, M., see Ohya, Y. (330) 93
Seward, E., see Rupniak, N.M.J. (326) 201
Shachar, D.B., Klein, E., Tabak, A. and Finberg, J.P.M.
Effect of single and repeated administration of fluvoxamine on noradrenaline release in rat brain (332) 237
Shah, S., see Sehba, F. (339) 33
Shalaby, I., see Menniti, F. (331) 117
Shannon, J.M., see Rice, W. (327) 227
Sharp, T., Gartside, S.E. and Umbers, V.
Effects of co-administration of a monoamine oxidase inhibitor and a 5-HT_{1A} receptor antagonist on 5-hydroxytryptamine cell firing and release (320) 15
Shayo, C.C., Mladovan, A.G. and Baldi, A.
Differentiating agents modulate topoisomerase I activity in U-937 promonocytic cells (324) 129
Sheardown, M.J.
The triggering of spreading depression in the chick retina by nicotinic receptor agonists (337) 209
Sheng, J.-Z., see Wang, H.-X. (319) 91
Shepheard, S.L., see Seabrook, G.R. (317) 129
Shepheard, S.L., see Williamson, D.J. (328) 61
Sheppard, G.S., see Albert, D.H. (325) 69
Sherman, P., see Kilbourn, M. (331) 161
Sheu, J.-R., Hung, W.-C., Lee, Y.-M. and Yen, M.-H.
Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from *Evodia rutaecarpa* (318) 469
Shiao, L.-L., see Cascieri, M.A. (325) 253
Shibaguchi, H., see Sakurai-Yamashita, Y. (338) 199
Shibasaki, M., Fujimori, A., Kusayama, T., Tokioka, T., Satoh, Y., Okazaki, T., Uchida, W., Inagaki, O. and Yanagisawa, I.
Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs (335) 175
Shibasaki, M., Fujimori, A., Takanashi, M., Kusayama, T., Tokioka, T., Satoh, Y., Okazaki, T., Uchida, W., Inagaki, O. and Yanagisawa, I.
Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist (335) 167
Shibata, M., see Satake, N. (319) 37
Shibata, N., see Fukuyama, J. (318) 327
Shibata, S., see Satake, N. (319) 37
Shibouta, Y., see Ojima, M. (319) 137
Shibuya, I., Kongsamut, S. and Douglas, W.W.
Both $GABA_A$ and $GABA_B$ receptors participate in suppression of $[Ca^{2+}]_i$ pulsing in toad melanotrophs (321) 241
Shibuya, M., see Mori, Y. (330) 195
Shieh, J.-Y., see Hou, W.-Y. (329) 17
Shigematsu, K., see Sakurai-Yamashita, Y. (338) 199
Shigenobu, K., see Masumiya, H. (335) 15
Shima, I., see Shinguh, Y. (337) 63
Shimada, K., see Ihara, T. (329) 43
Shimada, K., see Ikeda, M. (324) 283
Shimada, K., see Shimpo, M. (338) 97
Shimamura, K., Zou, L.-B., Moriyama, K., Yamamoto, K., Sekiguchi, F. and Sunano, S.
Effects of amiloride on the neurally mediated contraction of rat mesenteric artery (320) 37
Shimazawa, M., Takiguchi, Y., Umemura, K., Kondo, K. and Nakashima, M.
Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022 (328) 183
Shimidzu, T., Itoh, Y., Oka, M., Ishima, T., Ukai, Y., Yoshikuni, Y. and Kimura, K.
Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: Possible involvement of $GABA_B$ receptor up-regulation after repeated treatment (338) 225
Shimotsu, H., see Fujioka, T. (328) 235
Shimpo, M., Ikeda, U., Maeda, Y., Kurosaki, K., Okada, K., Saito, T. and Shimada, K.
Serotonin inhibits nitric oxide synthesis in rat vascular smooth muscle cells stimulated with interleukin-1 (338) 97
Shinguh, Y., Imai, K., Yamazaki, A., Inamura, N., Shima, I., Wakabayashi, A., Higashi, Y. and Ono, T.
Biochemical and pharmacological characterization of FK706, a novel elastase inhibitor (337) 63
Shino, A., see Sato, F. (322) 63
Shiosaki, K., Asin, K.E., Britton, D.R., Giardina, W.J., Bednarz, L., Mahan, L., Mikusa, J., Nikkel, A. and Wismer, C.
Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D_1 receptor agonists A-86929 and ABT-431 (317) 183
Shirasawa, E., see Kageyama, M. (333) 223
Shirayama, Y., Takahashi, K. and Nishikawa, T.
Uncompetitive inhibition of [^{3}H]1,3-di-*o*-tolyl-guanidine-defined σ binding sites by desipramine, propranolol and alprenolol in rat brain (331) 319
Shiroshita, Y., Koga, T. and Fukuda, H.
Capsaicin in the 4th ventricle abolishes retching and transmission of emetic vagal afferents to solitary nucleus neurons (339) 183
Shoghi, S., see Ireland, L.M. (327) 79
Shyu, B.-C., see Hou, W.-Y. (329) 17
Siebeneich, W., see Pieper, G.M. (317) 317
Siegel, B.W., see Baron, B.M. (323) 181
Siegmund, B., Eigler, A., Moeller, J., Greten, T.F., Hartmann, G. and Endres, S.
Suppression of tumor necrosis factor-α production by interleukin-10 is enhanced by cAMP-elevating agents (321) 231
Sigala, S., Missale, C. and Spano, P.
Opposite effects of dopamine D_2 and D_3 receptor on learning and memory in the rat (336) 107
Sikirić, P., Seiwerth, S., Grabarević, Ž., Ručman, R., Petek, M., Jagić, V., Turković, B., Rotkvić, I., Mišе, S., Zoričić, I., Konjevoda, P., Perović, D., Jurina, L., Šeparović, J., Hanževački, M., Artuković, B., Bratulić, M., Tišljar, M., Gjurašin, M., Miklić, P. and Stančić-Rokotov, D.
The influence of a novel pentadecapeptide, BPC 157, on N^G-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure (332) 23
Sills, G.J., Leach, J.P., Fraser, C.M., Forrest, G., Patsalos, P.N. and Brodie, M.J.
Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain (325) 35
Sills, T.L. and Fletcher, P.J.
Fluoxetine attenuates morphine-induced locomotion and blocks morphine-sensitization (337) 161

Silvestre, J.S., O'Neill, M.F., Fernández, A.G. and Palacios, J.M.
Effects of a range of dopamine receptor agonists and antagonists on ethanol intake in the rat (318) 257
Sim, S.-S., Baek, H.-J., Yoon, S.-H., Rhie, D.-J., Hahn, S.-J., Jo, Y.-H. and Kim, M.-S.
Regulation of protein kinases in steady-state contraction of cat gastric smooth muscle (324) 205
Simler, S., see Vergnes, M. (332) 245
Simon-Trompler, E., see Kardos, J. (337) 83
Simonsen, U., García-Sacristán, A. and Prieto, D.
Apamin-sensitive K^+ channels involved in the inhibition of acetylcholine-induced contractions in lamb coronary small arteries (329) 153
Singh, L., Field, M.J., Hughes, J., Kuo, B.-S., Suman-Chauhan, N., Tuladhar, B.R., Wright, D.S. and Naylor, R.J.
The tachykinin NK_1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret (321) 209
Sipahi (Yılmaz), E., Hodoğlugil, U., Üstün, H., Zengil, H., Türker, R.K. and Ercan, Z.S.
An unexpected interaction between N^G-nitro-L-arginine methyl ester and L-arginine in α-naphthylthiourea-induced pulmonary oedema in rats (321) 45
Siripurkpong, P., Harnyuttanakorn, P., Chindaduangratana, C., Kotchabhakdi, N., Wichyanuwat, P. and Casalotti, S.O.
Dexamethasone, but not stress, induce measurable changes of mitochondrial benzodiazepine receptor mRNA levels in rats (331) 227
Sirviö, J., see Aura, J. (333) 129
Sirviö, J., see Yavich, L. (339) 113
Sistiaga, A., Miras-Portugal, M.T. and Sánchez-Prieto, J.
Modulation of glutamate release by a nitric oxide/cyclic GMP-dependent pathway (321) 247
Skjærbæk, N., see Bräuner-Osborne, H. (335) R1
Skomedal, T., Fu, M.L.X., Hjalmarson, Å., Hoebeke, J., Schiander, I.G. and Osnes, J.-B.
Anti-M_2 muscarinic receptor antibodies inhibit β-adrenoceptor-mediated inotropic response in rat myocardium (333) 169
Skorupska, M., see Ghezzi, P. (317) 369
Skutella, T., see Schöbitz, B. (331) 97
Skuza, G., see Maj, J. (324) 31
Slade, P.D., see Hagan, J.J. (331) 169
Slob, A.K., see Haensel, S.M. (330) 1
Slobodnjak, Z., Jelovac, N. and Marović, A. (332) 23
Small, R.C., see Pocock, T.M. (334) 75
Smeets, R.L.L., IJzerman, A.P., Hermsen, H.P.H., Ophorst, O.J.A.E., Van Emst-de Vries, S.E., De Pont, J.J.H.H.M. and Willems, P.H.G.M.
Mutational analysis of the putative devazepide binding site of the CCK_A receptor (325) 93
Smith, H.P., Nichols, D.E., Mailman, R.B. and Lawler, C.P.
Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D_2 post-synaptic receptor agonist (323) 27
Smith, J.E. and Lakoski, J.M.
Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus (323) 69
Smith, M.W., see Piercey, M.F. (317) 29
Smith, M.W., see Schlachter, S.K. (322) 283
Smith, N.C., see Hourani, S.M.O. (334) 95
Smits, J.F.M., see Prickaerts, J. (337) 125
Smolders, I., Van Belle, K., Ebinger, G. and Michotte, Y.
Hippocampal and cerebellar extracellular amino acids during pilocarpine-induced seizures in freely moving rats (319) 21
Soares-da-Silva, P., see Barili, P. (334) 233
Soares-da-Silva, P., see Gomes, P. (332) 219
Söderpalm, B., see Blomqvist, O. (334) 149
Soderstrom, K., Choi, H., Berman, F.W., Aldrich, J.V. and Murray, T.F.
N-Alkylated derivatives of [D-Pro^{10}]dynorphin A-(1-11) are high affinity partial agonists at the cloned rat κ-opioid receptor (338) 191
Sokolowa, S., see Draguhn, A. (325) 245
Song, S.-K., Suh, B.-C., Lee, H. and Kim, K.-T.
Histamine inhibits ATP-induced $[Ca^{2+}]_i$ rise through the activation of protein kinase A in HL-60 cells (322) 265
Sonoda, R., see Takeuchi, H. (329) 27
Sonsalla, P., see Zeevalk, G.D. (320) 111
Sora, I., Funada, M. and Uhl, G.R.
The μ-opioid receptor is necessary for [D-Pen^2,D-Pen^5]enkephalin-induced analgesia (324) R1
Soria-Jasso, L.-E. and Arias-Montaño, J.-A.
Histamine H_1 receptor activation stimulates [^{3}H]GABA release from human astrocytoma U373 MG cells (318) 185
Sorrentino, L., see Capasso, A. (330) 199
Souli, A., Chariot, J., Presset, O., Tsocas, A. and Rozé, C.
Neural modulation of the antisecretory effect of peptide YY in the rat jejunum (333) 87
Spanagel, R., see Putzke, J. (317) 39
Spanagel, R., see Schöbitz, B. (331) 97
Spano, P., see Sigala, S. (336) 107
Sparf, B., see Nilvebrant, L. (327) 195
Spassov, V., see Getova, D. (320) 9
Sperelakis, N., see Katsube, Y. (317) 391
Sperelakis, N., see Yokoshiki, H. (333) 249
Spiess, J., see Correa, S.G. (319) 85
Squadrito, F., Altavilla, D., Ammendolia, L., Squadrito, G., Campo, G.M., Canale, P., Ioculano, M., Musolino, C., Alonci, A., Saitta, A., Rossi, F. and Caputi, A.P.
Leukocyte integrin very late antigen-4/vascular cell adhesion molecule-1 adhesion pathway in splanchnic artery occlusion shock (318) 153
Squadrito, F., Altavilla, D., Squadrito, G., Campo, G.M., Arlotta, M., Arcoraci, V., Minutoli, L., Serrano, M., Saitta, A. and Caputi, A.P.
17β-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat (335) 185
Squadrito, G., see Squadrito, F. (335) 185
Sredni, B., see Yehuda, S. (328) 23
Stafford, I., see De la Lande, I.S. (318) 65
Stahl, M., see Nilvebrant, L. (327) 195
Staley, J.K., Mash, D.C., Parsons, S.M., Khare, A.B. and Efange, S.M.N.
Pharmacological characterization of the vesamicol analogue (+)-[^{125}I]MIBT in primate brain (338) 159
Stanford, S.C., see Hughes, Z.A. (317) 83
Stanton, J.A. and Beer, M.S.
Characterisation of a cloned human 5-HT_{1A} receptor cell line using [^{35}S]GTP-γS binding (320) 267
Statnick, M.A., Schober, D.A. and Gehlert, D.R.
Identification of multiple neuropeptide Y receptor subtypes in the human frontal cortex (332) 299
Steinbusch, H.W.M., see Prickaerts, J. (337) 125
Stensbøl, T.B., see Bräuner-Osborne, H. (335) R1
Stephan, D., see Mary, S. (335) 65
Stevens, C.W. and Rothe, K.S.
Supraspinal administration of opioids with selectivity for μ-, δ- and κ-opioid receptors produces analgesia in amphibians (331) 15
Stewart, G.A., see Knight, D.A. (319) 261
Stewart, J., see Dewar, K.M. (336) 155
Stöhr, T., see Schöbitz, B. (331) 97
Stoll, L.L., see Travis, M.D. (318) 47
Stone, R.A., Barnes, P.J. and Chung, K.F.
Effect of 5-HT_{1A} receptor agonist, 8-OH-DPAT, on cough responses in the conscious guinea pig (332) 201
Stoof, J.C., see Custers, F.G.J. (338) 177
Stoof, J.C., see Drukarch, B. (329) 259
Stoof, J.C., see Pinna, A. (331) 23
Störr, B., see Goldbach, J.-M. (319) 273
Störr, B., see Goldbach, J.-M. (334) 249
Strader, C.D., see Cascieri, M.A. (325) 253

Striem, S., Bar-Joseph, A., Berkovitch, Y. and Biegon, A.
Interaction of Dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system (338) 205
Stubbs, C.M., see Hurley, M.J. (318) 283
Stuhlmeier, K.M., Tarn, C. and Bach, F.H.
The effect of 5,8,11,14-eicosatetraynoic acid on endothelial cell gene expression (325) 209
Suarez-Kurtz, G., Nascimento, J.H.M., Ondeyka, J.G. and Kaczorowski, G.J.
Ca^{2+}-entry blockade by CAF603, a carotane sesquiterpene isolated from *Trichoderma virens* (335) 153
Subhadhirasakul, S., see Leewanich, P. (332) 321
Succu, S., see Melis, M.R. (328) 115
Suchitra, T., see Matsumoto, K. (317) 75
Sudsuang, R., see Thongsaard, W. (319) 157
Sue, T.-Y., see Tyan, S.-H. (321) 171
Suemaru, K., Kawasaki, H., Gomita, Y. and Tanizaki, Y.
Involvement of nitric oxide in development of tail-tremor induced by repeated nicotine administration in rats (335) 139
Sugawara, T., Ohta, T., Asano, T., Ito, S. and Nakazato, Y.
Tacrine inhibits nicotinic secretory and current responses in adrenal chromaffin cells (319) 123
Sugimoto, Y., see Yamada, J. (323) 235
Sugimura, M., Sato, T., Nakayama, W., Morishima, Y., Fukunaga, K., Omitsu, M., Miyamoto, E. and Shirasaki, Y.
DY-9760e, a novel calmodulin antagonist with cytoprotective action (336) 99
Sugo, T., see Masuda, Y. (325) 263
Suh, B.-C., see Song, S.-K. (322) 265
Sulakvelidze, I., see Bowden, J.J. (338) 83
Suma, C., Hayashi, S., Ukai, Y., Yoshikuni, Y. and Kimura, K.
Na^+ and high-voltage-activated Ca^{2+} channel blocking actions of NS-7, a novel neuroprotective agent, in NG108-15 cell (336) 283
Summers, J.B., see Albert, D.H. (325) 69
Sun, M.-H., Ishine, T. and Lee, T.J.-F.
Dopamine constricts porcine pial veins (334) 165
Sun, X., Wei, S., Szabo, C. and Dusting, G.J.
Depression of the inotropic action of isoprenaline by nitric oxide synthase induction in rat isolated hearts (320) 29
Sunano, S., see Shimamura, K. (320) 37
Sundler, F., see Ekblad, E. (334) 61
Suñol, C., see Vale, C. (319) 343
Sureda, F., Copani, A., Bruno, V., Knöpfel, T., Meltzger, G. and Nicoletti, F.
Metabotropic glutamate receptor agonists stimulate polyphosphoinositide hydrolysis in primary cultures of rat hepatocytes (338) R1
Sussman, A.N., Tran-Nguyen, L.T.L. and Neisewander, J.L.
Acute reserpine administration elicits long-term spontaneous oral dyskinesia (337) 157
Suzuki, F., see Manabe, H. (332) 97
Suzuki, K.-i., Sakai, Y., Hisamichi, N., Taniuchi, Y., Sato, K., Terazaki, C., Kaku, S., Kawasaki, T., Yano, S., Inagaki, O. and Masuho, Y.
Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys (336) 169
Suzuki-Kusaba, M., see Yoshida, K. (338) 131
Suzuki, T., Mori, T., Tsuji, M., Maeda, J., Kishimoto, Y., Misawa, M. and Nagase, H.
Differential effects of μ-, δ- and κ-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats (324) 21
Suzuki, T., Mori, T., Tsuji, M., Misawa, M. and Nagase, H.
The role of δ-opioid receptors in the discriminative stimulus properties of a low dose of methamphetamine (331) 1
Suzuki, T., see Tsuda, M. (324) 63
Suzuki, Y., see Mori, Y. (320) 183
Suzuki, Y., see Mori, Y. (330) 195
Suzuki, Y., see Nanaumi, K. (327) 239
Svensson, K.A., see Koch, S. (319) 173
Swain, C.J., see Rupniak, N.M.J. (326) 201
Swynghedauw, B., see Besse, S. (338) 123
Sybertz, E.J., see Chiu, P.J.S. (321) 129
Sys, S.U., see Michielsen, P.P. (329) 137
Szabo, C., see Sun, X. (320) 29
Szabó, C., see Németh, Z.H. (339) 215
Szabó, C., see Zingarelli, B. (338) 55
Szabó, G., see Kovács, A.D. (331) 93
Szántay, C., see Kardos, J. (337) 83
Szardenings, M., see Schiöth, H.B. (319) 369
Szathmary, S., see Scheller, D.K.A. (338) 243
Szechtman, H., see Culver, K.E. (339) 109
Székely, J.I., Kedves, R., Máté, I., Török, K. and Tarnawa, I.
Apparent antinociceptive and anti-inflammatory effects of GYKI 52466 (336) 143
Szentkuti, E., see Fekete, M.I.K. (331) 175
Szolcsányi, J., see Pintér, E. (325) 57

Ta, N.D., see Hawkinson, J.E. (337) 315
Tabak, A., see Shachar, D.B. (332) 237
Tabrizchi, R., see He, Y. (328) 191
Tabrizchi, R., see Lum Min, S.A. (318) 97
Tacconi, M.T., see Calzi, F. (338) 185
Taché, Y., see Király, Á. (334) 241
Tachibana, H., see Fujimura, M. (327) 57
Tada, A., see Furukawa, Y. (334) 191
Tahara, A., see Yatsu, T. (321) 225
Takada, A., see Ukai, M. (338) 1
Takada, K., see Sakurai-Yamashita, Y. (338) 199
Takahama, K., Wakuda, I., Fukushima, H., Isohama, Y., Kai, H. and Miyata, T.
Differential effect of codeine on coughs caused by mechanical stimulation of two different sites in the airway of guinea pigs (329) 93
Takahashi, K., see Nanaumi, K. (327) 239
Takahashi, K., see Shirayama, Y. (331) 319
Takahashi, K., see Takahashi, T. (331) 193
Takahashi, M., see Uneyama, C. (319) 299
Takahashi, R.N., see Bittencourt, A.L. (330) 109
Takahashi, T., Barnes, P.J., Kawikova, I., Yacoub, M.H., Warner, T.D. and Belvisi, M.G.
Contraction of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan (324) 219
Takahashi, T., Tanikawa, S. and Takahashi, K.
Protective effects of CD-832 on organ damage in stroke-prone spontaneously hypertensive rats (331) 193
Takahashi, W., Yoshida, M., Wada, Y., Goto, S., Inadome, A., Yono, M. and Ueda, S.
Effect of estrogen on nitric oxide-induced relaxation of the rabbit urethra (339) 165
Takanashi, M., see Shibasaki, M. (335) 167
Takanashi, M., see Yatsu, T. (322) 45
Takano, H., Yoshikawa, T., Yamaguchi, T., Hitoshi Hongo, Fujii, T., Boku, Y., Yoshida, N., Yamamoto, H., Nakahashi, Y., Yanagisawa, R. and Kondo, M.
Effects of aminoguanidine on systemic inflammatory response syndrome induced by platelet activating factor and by lipopolysaccharide in rats (323) 107
Takao, K., Nagatani, T., Kitamura, Y. and Yamawaki, S.
Effects of corticosterone on 5-HT_{1A} and 5-HT_2 receptor binding and on the receptor-mediated behavioral responses of rats (333) 123
Takaori, K., Kim, S., Ohta, K., Hamaguchi, A., Yagi, K. and Iwao, H.
Inhibition of nitric oxide synthase causes cardiac phenotypic modulation in rat (322) 59
Takayama, H., see Matsumoto, K. (317) 75
Takayanagi, I., see Koike, K. (334) 217
Takayanagi, I., see Satoh, M. (327) 175
Takayasu, M., see Mori, Y. (320) 183

Takayasu, M., see Mori, Y. (330) 195
Takei, M., see Furukawa, Y. (334) 191
Takemura, H., see Amemiya, N. (318) 403
Takenaka, T., see Yatsu, T. (321) 225
Takenaka, T., see Yatsu, T. (322) 45
Takeshita, Y., see Masunaga, H. (339) 1
Takeuchi, H., Yatsugi, S.-i., Hatanaka, K.-i., Nakato, K., Hattori, H., Sonoda, R., Koshiya, K., Fujii, M. and Yamaguchi, T.
Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT_{2A} receptor antagonistic activity (329) 27
Takiguchi, Y., see Shimazawa, M. (328) 183
Takimoto, M., see Aoki, K. (336) 43
Takizawa, K., see Yatsu, T. (322) 45
Takizawa, S., Ozaki, H. and Karaki, H.
Interleukin-1β-induced, nitric oxide-dependent and -independent inhibition of vascular smooth muscle contraction (330) 143
Talon, S., Huchet-Cadiou, C. and Léoty, C.
Negative inotropic effect of heparin on tension development in rat skinned skeletal muscle fibres (327) 33
Tamakai, H., see Minami, M. (321) 333
Tamaki, H., see Kinoshita, M. (321) 325
Tamargo, J., see Duarte, J. (338) 25
Tamargo, J., see Valenzuela, C. (326) 257
Tanabe, A., see Seki, T. (331) 87
Tanabe, T., Otani, H., Zeng, X.-T., Mishima, K., Ogawa, R. and Inagaki, C.
Inhibitory effects of calcitonin gene-related peptide on substance-P-induced superoxide production in human neutrophils [Eur. J. Pharmacol. 314 (1996) 175–183] (321) 137
Tanahashi, N., see Kobari, M. (317) 269
Tanaka, A., see Yatsu, T. (321) 225
Tanaka, A., see Yatsu, T. (322) 45
Tanaka, H., see Masumiya, H. (335) 15
Tanaka, K., see Ikegami, K. (328) 75
Tanaka, T., see Matsushima, S. (333) 93
Tanaka, T., see Ukai, M. (324) 147
Tang, A.H., see Piercey, M.F. (317) 29
Tang, E., Yip, P.K., Chapman, A.G., Jane, D.E. and Meldrum, B.S.
Prolonged anticonvulsant action of glutamate metabotropic receptor agonists in inferior colliculus of genetically epilepsy-prone rats (327) 109
Tang, L., Gao, W. and Taylor, P.B.
Force-frequency response in isoproterenol-induced hypertrophied rat heart (318) 349
Taniguchi, H., Togawa, M., Ohwada, K., Kiniwa, M., Matsuura, N., Nagai, H. and Koda, A.
Corrigendum to 'Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs' [Eur. J. Pharmacol. 318 (1996) 447–454] [1] (321) 397
Taniguchi, H., Togawa, M., Ohwada, K., Kiniwa, M., Matsuura, N., Nagai, H. and Koda, A.
Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs (318) 447
Taniguchi, N., Hamada, K., Ogasawara, T., Ukai, Y., Yoshikuni, Y. and Kimura, K.
NS-49, an α_{1A}-adrenoceptor agonist, selectively increases intraurethral pressure in dogs (318) 117
Taniguchi, Y., Yokoyama, K., Inui, K., Deguchi, Y., Furukawa, K. and Noda, K.
Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide (330) 221
Taniuchi, Y., see Sato, K. (339) 141
Taniuchi, Y., see Suzuki, K.-i. (336) 169
Taniyama, K., see Sakurai-Yamashita, Y. (338) 199
Tanizaki, Y., see Suemaru, K. (335) 139
Taouil, K., Féray, J.-C., Brunet, J., Christen, M.-O., Garay, R.P. and Hannaert, P.
Inhibition by xipamide of amiloride-induced acidification in cultured rat cardiocytes (324) 289
Tapang, P., see Albert, D.H. (325) 69
Tarn, C., see Stuhlmeier, K.M. (325) 209
Tarnawa, I., see Székely, J.I. (336) 143
Tasaka, K., see Ikegami, K. (328) 75
Tasaki, H., see Okada, M. (321) 181
Tatarczyńska, E., see Chojnacka-Wójcik, E. (319) 153
Tattersall, F.D., see Rupniak, N.M.J. (326) 201
Tauck, D.L., see Wong, S.M.E. (329) 121
Taylor, A.M., see Chan, C.-C. (327) 221
Taylor, J.E., see Ladenheim, E.E. (319) 245
Taylor, P.B., see Tang, L. (318) 349
Taylor, V.L., see Baron, B.M. (323) 181
Tegtmeier, F., see Scheller, D.K.A. (338) 243
Teirmaa, T., see Virtanen, K.A. (332) 215
Teisman, A.C.H., see Ten Berge, R.E.J. (318) 131
Teixeira, M.M. and Hellewell, P.G.
Evidence that the eosinophil is a cellular target for the inhibitory action of salmeterol on eosinophil recruitment in vivo (323) 255
Tellioğlu, T., Aslan, N., Gören, Z., Onat, F. and Oktay, Ş.
Role of the AV3V region in the pressor responses induced by amygdala stimulation (336) 163
Tellioğlu, T., Akin, S., Özkutlu, U., Oktay, Ş. and Onat, F.
The role of brain acetylcholine in $GABA_A$ receptor antagonist-induced blood-pressure changes in rat (317) 301
Temma, K., Chugun, A., Akera, T., Hara, Y., Sasaki, T. and Kondo, H.
Ca^{2+} overloading causes the negative inotropic effect of doxorubicin in myocytes isolated from guinea-pig hearts (322) 235
Ten Berge, R.E.J., Krikke, M., Teisman, A.C.H., Roffel, A.F. and Zaagsma, J.
Dysfunctional muscarinic M_2 autoreceptors in vagally induced bronchoconstriction of conscious guinea pigs after the early allergic reaction (318) 131
Teng, C.-M., Wu, C.-C., Ko, F.-N., Lee, F.-Y. and Kuo, S.-C.
YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice (320) 161
Terano, A., see Hata, Y. (321) 113
Terazaki, C., see Suzuki, K.-i. (336) 169
Terriere, D., see Abi-Dargham, A. (321) 285
Terrón, J.A., see Ibarra, M. (322) 221
Terzic, A., see Lopez, J.R. (339) 161
Tetzloff, G.G., see Chiu, P.J.S. (321) 129
Teuchert-Noodt, G., see Dawirs, R.R. (327) 117
Therien, M., see Chan, C.-C. (327) 221
Thijs, T., see Van Assche, G. (337) 267
Thirstrup, S., Dahl, R. and Nielsen-Kudsk, F.
Interaction between prostaglandins and selective phosphodiesterase inhibitors in isolated guinea-pig trachea in vitro (333) 215
Thirstrup, S., Nielsen-Kudsk, F. and Dahl, R.
In vitro studies on the interactions of β_2-adrenoceptor agonists, methylxanthines, Ca^{2+}-channel blockers, K^+-channel openers and other airway smooth muscle relaxants in isolated guinea-pig trachea (326) 191
Thirstrup, S., Nielsen-Kudsk, J.E. and Mellemkjær, S.
Involvement of K^+ channels in the relaxant effect of vasoactive intestinal peptide and atrial natriuretic peptide in isolated guinea-pig trachea (319) 253
Thollon, C., Bidouard, J.-P., Cambarrat, C., Lesage, L., Reure, H., Delescluse, I., Vian, J., Peglion, J.-L. and Vilaine, J.-P.
Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257 (339) 43
Thomas, N.K., Clayton, P. and Jane, D.E.
Dicarboxyphenylglycines antagonize AMPA- but not kainate-induced depolarizations in neonatal rat motoneurones (338) 111
Thomas, S., see Ireland, L.M. (327) 79
Thompson, J., see Hunter, J.C. (324) 153
Thompson, J.H., see Ribbons, K.A. (323) 245

Thompson, K.S.J., see Phillips, I. (337) 189
Thompson, P.J., see Knight, D.A. (319) 261
Thongsaard, W., Pongsakorn, S., Sudsuang, R., Bennett, G.W., Kendall, D.A. and Marsden, C.A.
Barakol, a natural anxiolytic, inhibits striatal dopamine release but not uptake in vitro (319) 157
Thoumas, J.-L., see Gandolfo, P. (322) 275
Tibes, U., see Amandi-Burgermeister, E. (326) 237
Tighilet, B. and Lacour, M.
Histamine immunoreactivity changes in vestibular-lesioned and histaminergic-treated cats (330) 65
Tirelli, E. and Ferrara, M.
Neonatal and preweanling rats are able to express short-term behavioral sensitization to cocaine (328) 103
Tjølsen, A., see Gjerstad, J. (318) 315
Tjølsen, A., see Gjerstad, J. (335) 127
Tkacs, N.C., see Li, J. (337) 227
To, C.T., see Bagdy, G. (323) 53
Toda, N., see Ayajiki, K. (329) 49
Toda, N., see Uchiyama, M. (321) 19
Togawa, M., Haneda, M., Araki, S.-i., Sugimoto, T., Isono, M., Hidaka, H., Yasuda, H., Kashiwagi, A. and Kikkawa, R.
Beraprost sodium, an analogue of prostacyclin, induces the expression of mitogen-activated protein kinase phosphatase and inhibits the proliferation of cultured mesangial cell (336) 291
Togawa, M., see Taniguchi, H. (321) 397
Tognarini, D.P. and Moulds, R.F.W.
Intracellular Ca^{2+} and contractile responses to α_1-adrenoceptor subtype activation in rat aortic vascular smooth muscle (322) 31
Tokioka, T., see Shibasaki, M. (335) 167
Tokioka, T., see Shibasaki, M. (335) 175
Toll, L., Polgar, W.E. and Auh, J.S.
Characterization of the δ-opioid receptor found in SH-SY5Y neuroblastoma cells (323) 261
Tölle, T.R., see Putzke, J. (317) 39
Toma, C.P., see Filipeanu, C.M. (332) 71
Tomasi, A., see Guarini, S. (336) 15
Tominaga, Y., see Niki, H. (320) 193
Tomita, F., Hattori, Y., Kanno, M., Kohya, T., Sasaki, M. and Kitabatake, A.
Different regulation of myofilament Ca^{2+} sensitivity in β-escin-skinned cardiac and vascular smooth muscles (326) 157
Tomita, M., see Kobari, M. (317) 269
Tomizuka, T., see Masunaga, H. (339) 1
Tomlinson, D.R., see Vo, P.A. (329) 147
Tomura, Y., see Yatsu, T. (321) 225
Tomura, Y., see Yoshida, K. (338) 131
Tonon, M.-C., see Gandolfo, P. (322) 275
Tonussi, C.R. and Ferreira, S.H.
Bradykinin-induced knee joint incapacitation involves bradykinin B_2 receptor mediated hyperalgesia and bradykinin B_1 receptor-mediated nociception (326) 61
Torrens, Y., see Beaujouan, J.-C. (319) 307
Torres, A., see Lara, B. (325) 109
Torres-Zamorano, V., see Prasad, P.D. (325) 85
Tota, M.R., see Cascieri, M.A. (325) 253
Totsuka, T., see Kitagaki, K. (337) 283
Tournier, J.-M., see Marchand, V. (336) 187
Towers, P., see Ge, J. (332) 307
Toyosato, A., see Kawada, T. (323) 75
Tramontana, M., see Giuliani, S. (333) 177
Tran-Nguyen, L.T.L., see Sussman, A.N. (337) 157
Tran, S. and Boot, J.R.
Differential effects of voltage-dependent Ca^{2+} channels on low and high frequency mediated neurotransmission in guinea-pig ileum and rat vas deferens (335) 31
Travis, M.D., Stoll, L.L., Bates, J.N. and Lewis, S.J.
L- and D-*S*-nitroso-β,β-dimethylcysteine differentially increase cGMP in cultured vascular smooth muscle cells (318) 47
Travis, M.D., Whalen, E.J. and Lewis, S.J.
Heterologous desensitization of β-adrenoceptor signal transduction in vivo (328) R1
Trejo, F., De la Vega, M.-T. and Arias-Montaño, J.-A.
Functional characterisation of α_1-adrenoceptor subtypes mediating noradrenaline-induced inositol phosphate formation in rat thalamus slices (318) 175
Tricarico, D., Petruzzi, R. and Conte Camerino, D.
Different sulfonylurea and ATP sensitivity characterizes the juvenile and the adult form of K_{ATP} channel complex of rat skeletal muscle (321) 369
Trinh, T., Dumont, Y. and Quirion, R.
High levels of specific neuropeptide Y/pancreatic polypeptide receptors in the rat hypothalamus and brainstem (318) R1
Trist, D., see Mennini, T. (336) 275
Tritthart, H.A., see Koidl, B. (322) 243
Tsai, F.-Y., see Pan, W.H.T. (317) 205
Tsai, S.-J., see Huang, Y.-H. (338) 117
Tsao, L.-T., see Wang, J.-P. (320) 201
Tsao, L.-T., see Wang, J.-P. (336) 81
Tseng, C.-J., see Wu, S.-N. (327) 233
Tseng, L.F., see Kamei, J. (322) 27
Tsocas, A., see Souli, A. (333) 87
Tsuchida, K., see Nanaumi, K. (327) 239
Tsuda, K., Tsuda, S., Nishio, I., Goldstein, M. and Masuyama, Y.
Modulation of [^{3}H]dopamine release by neuropeptide Y in rat striatal slices (321) 5
Tsuda, M., Suzuki, T. and Misawa, M.
Recovery of decreased seizure threshold for pentylenetetrazole during diazepam withdrawal by NMDA receptor antagonists (324) 63
Tsuji, M., see Suzuki, T. (324) 21
Tsuji, M., see Suzuki, T. (331) 1
Tsujita, Y., see Fujioka, T. (323) 223
Tsujita, Y., see Fujioka, T. (328) 235
Tsukada, J., see Yatsu, T. (321) 225
Tsukada, M., see Chiba, S. (329) 63
Tsukahara, F., see Irie, K. (339) 289
Tsukahara, F., see Uchida, Y. (335) 235
Tsuruo, T., see Nanaumi, K. (327) 239
Tudyka, T., see Müller, A. (327) 65
Tuladhar, B.R., see Singh, L. (321) 209
Tümer, N., Bowman, C.J., LaRochelle, J.S., Kelley, A. and Scarpace, P.J.
Induction of tyrosine hydroxylase by forskolin: modulation with age (324) 57
Turković, B., see Sikirić, P. (332) 23
Tyan, S.-H., Sue, T.-Y., Hon, Y.-S., Gean, P.-W. and Chang, Y.-C.
A novel NMDA receptor antagonist protects against *N*-methyl-D-aspartate- and glutamate-induced neurotoxicity in the goldfish retina (321) 171

Ucar, H., Cacciaguerra, S., Spampinato, S., Van derpoorten, K., Isa, M., Kanyonyo, M. and Poupaert, J.H.
2(*3H*)-benzoxazolone and 2(*3H*)-benzothiazolone derivatives: Novel, potent and selective σ_1 receptor ligands (335) 267
Uchida, S., see Ikegami, K. (328) 75
Uchida, W., see Shibasaki, M. (335) 167
Uchida, W., see Shibasaki, M. (335) 175
Uchida, W., see Yatsu, T. (321) 225
Uchida, W., see Yatsu, T. (322) 45
Uchida, Y., Tsukahara, F., Ohba, K.-i., Ogawa, A., Irie, K., Fujii, E., Yoshimoto, T., Yoshioka, T. and Muraki, T.
Nitric oxide mediates down regulation of lipoprotein lipase activity induced by tumor necrosis factor-α in brown adipocytes (335) 235
Uchino, M., see Masumoto, N. (330) 55
Uchiyama, M., Okamura, T., Uehara, M. and Toda, N.

Analysis of the vasodilator nerve function by nicotine in isolated dog skin artery (321) 19
Ueda, S., see Takahashi, W. (339) 165
Uehara, M., see Uchiyama, M. (321) 19
Ueki, S., see Imanishi, T. (321) 273
Uematsu, Y., see Masunaga, H. (339) 1
Ueno, Y., see Nakamura, T. (322) 83
Ugedo, L., see Ruiz-Ortega, J.A. (333) 159
Uhl, G.R., see Sora, I. (324) R1
Ukai, M., Takada, A., Sasaki, Y. and Kameyama, T.
Stimulation of δ_1- and δ_2-opioid receptors produces amnesia in mice (338) 1
Ukai, M., Tanaka, T. and Kameyama, T.
Effects of the dopamine D_3 receptor agonist, *R*(+)-7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin, on memory processes in mice (324) 147
Ukai, Y., see Suma, C. (336) 283
Ukai, Y., see Taniguchi, N. (318) 117
Ullrich, B., see Eltze, M. (332) 77
Umbers, V., see Sharp, T. (320) 15
Umemura, K., see Kaku, S. (321) 301
Umemura, K., see Shimazawa, M. (328) 183
Uneyama, C., Uneyama, H., Narisawa, K., Takahashi, M. and Akaike, N.
Kinetic characteristics of thrombin receptor-mediated responses in rat megakaryocytes (319) 299
Unterwald, E.M., Fillmore, J. and Kreek, M.J.
Chronic repeated cocaine administration increases dopamine D_1 receptor-mediated signal transduction (318) 31
Urabe, K., Matsumura, Y., Nishiura, M., Maeda, K. and Morimoto, S.
Renal hemodynamic and excretory responses in anesthetized rats to FK409, a novel nitric oxide donor (321) 195
Üstün, H., see Sipahi (Yılmaz), E. (321) 45
Usui, M., see Itoh, A. (322) 11
Usui, M., see Itoh, A. (332) 113

Vaali, K., see Li, L. (331) 221
Vaccher, C., see Ong, J. (329) 133
Valdivielso, J.M., Macías, J.F. and López-Novoa, J.M.
Cardiovascular effects of elgodipine and nifedipine compared in anaesthetized rats (335) 193
Vale, C., Pomés, A., Rodríguez-Farré, E. and Suñol, C.
Allosteric interactions between γ-aminobutyric acid, benzodiazepine and picrotoxinin binding sites in primary cultures of cerebellar granule cells. Differential effects induced by γ- and δ-hexachlorocyclohexane (319) 343
Valentin, J.-P., Bessac, A.-M., Maffre, M. and John, G.W.
Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat (317) 335
Valenzuela, C., Delpón, E., Franqueza, L., Gay, P., Vicente, J. and Tamargo, J.
Comparative effects of nonsedating histamine H_1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels (326) 257
Van Aken, H., see Waurick, R. (333) 181
Van Assche, G., Depoortere, I., Thijs, T., Janssens, J.J. and Peeters, T.L.
Concentration-dependent stimulation of cholinergic motor nerves or smooth muscle by [Nle^{13}]motilin in the isolated rabbit gastric antrum (337) 267
Van Bergen, P., Van Der Vaart, J.G.M., Kasbergen, C.M., Versteeg, D.H.G. and De Wildt, D.J.
Structure-activity analysis for the effects of γ-MSH/ACTH-like peptides on cerebral hemodynamics in rats (318) 357
Van Buren, T., Kappelle, A.C., Kasbergen, C.M., Gispen, W.H. and De Wildt, D.J.
A disturbed macrocirculatory supply as a determinant for a reduced sciatic nerve blood flow in diabetic rats (318) 73
Van den Buuse, M.
Pretreatment with quinpirole inhibits the central antihypertensive effects of rilmenidine and α-methyldopa in conscious rats (322) 191
Van der Graaf, P.H., Deplanne, V., Duquenne, C. and Angel, I.
Analysis of α_1-adrenoceptors in rabbit lower urinary tract and mesenteric artery (327) 25
Van der Gugten, J., see Compaan, J.C. (324) 161
Van der Heijden, V.S., see Fischer, M.J.E. (322) 97
Vanderheyden, P.M.L., Van Liefde, I., De Backer, J.-P. and Vauquelin, G.
Non-competitive binding of the nonpeptide antagonist BIBP3226 to rat forebrain neuropeptide Y_1 receptors (331) 275
Van Der Vaart, J.G.M., see Van Bergen, P. (318) 357
Van der Walt, J.J., Van Rooyen, J.M., Kellerman, T.S., Carmeliet, E.E. and Verdonck, F.
Neurospecificity of phyto-bufadienolides is not related to differences in Na^+/K^+ pump inhibition (329) 201
Van Drimmelen, M., see Mos, J. (325) 145
Van Emst-de Vries, S.E., see Smeets, R.L.L. (325) 93
Van Es, G.A., see De Jonge, R. (337) 41
Van Giersbergen, P.L.M., see Baron, B.M. (323) 181
Van Hartesveldt, C., see Gendreau, P.L. (337) 147
Van Heerikhuizen, H., see Gerhardt, C.C. (334) 1
Van Hest, A., see Mos, J. (325) 145
Van Hooft, J.A. and Vijverberg, H.P.M.
RS-056812-198: partial agonist on native and antagonist on cloned 5-HT_3 receptors (322) 229
Vanover, K.E.
Discriminative stimulus effects of the endogenous neuroactive steroid pregnanolone (327) 97
Vanover, K.E.
Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion (332) 115
Van Reempts, J., see Scheller, D.K.A. (338) 243
Van Rooyen, J.M., see Van der Walt, J.J. (329) 201
Varga, C., see László, F. (337) 275
Vargaftig, B.B., see Bureau, M.F. (324) 89
Vargas, A., see Lundstrom, K. (337) 73
Varty, G.B. and Higgins, G.A.
Investigations into the nature of a 7-OH-DPAT discriminative cue: Comparison with D-amphetamine (339) 101
Vaudry, H., see Gandolfo, P. (322) 275
Vaudry, H., see Le Foll, F. (331) 303
Vaudry, H., see Leroux, P. (337) 333
Vaupel, D.B., Kimes, A.S. and London, E.D.
Further in vivo studies on attenuating morphine withdrawal: isoform-selective nitric oxide synthase inhibitors differ in efficacy (324) 11
Vayssettes-Courchay, C., Bouysset, F., Laubie, M. and Verbeuren, T.J.
The central sympatho-inhibitory effect of 5,6-dihydroxy-2-dimethylaminotetralin (M7) is mediated by α_2-adrenoceptors (320) 151
Vegh, A., Papp, J.G., György, K., Kaszala, K. and Parratt, J.R.
Does the opening of ATP-sensitive K^+ channels modify ischaemia-induced ventricular arrhythmias in anaesthetised dogs? (333) 33
Velasco, C., see Morán, A. (330) 205
Venter, D.P.
Efficacy I: a new method for estimating relative efficacy of full agonists via a newly defined efficacy related parameter (320) 223
Venter, D.P.
Efficacy II. Estimation of a newly defined efficacy related parameter (320) 233
Ventura, S. and Burnstock, G.
Evidence against nitrergic neuromodulation in the rat vas deferens (334) 87
Verbeuren, T.J., see Vayssettes-Courchay, C. (320) 151
Verdonck, F., see Van der Walt, J.J. (329) 201
Vergnes, M., Boehrer, A., Simler, S., Bernasconi, R. and Marescaux, C.
Opposite effects of $GABA_B$ receptor antagonists on absences and convulsive seizures (332) 245
Verma, S., Bhanot, S., Yao, L. and McNeill, J.H.
Vascular insulin resistance in fructose-hypertensive rats (322) R1

Vértes, M., see Környei, J.L. (336) 65
Vértes, Z., see Környei, J.L. (336) 65
Vetter, H., see Grosser, T. (319) 327
Vetulani, J., see Antkiewicz-Michaluk, L. (332) 9
Vian, J., see Thollon, C. (339) 43
Vicente, J., see Valenzuela, C. (326) 257
Vicentini, L.M., Cattaneo, M.G. and Fesce, R.
Evidence for receptor subtype cross-talk in the mitogenic action of serotonin on human small-cell lung carcinoma cells (318) 497
Vigé, X., see Debeir, T. (323) 111
Viguerie-Bascands, N., see Le Gouic, S. (339) 271
Vijverberg, H.P.M., see Van Hooft, J.A. (322) 229
Viko, H., Osnes, J.-B., Sandnes, D. and Skomedal, T.
α_1-Adrenoceptor subtypes involved in increased $^{86}Rb^+$ influx rate and inositol 1,4,5-trisphosphate mass in adult rat cardiomyocytes (323) 269
Vilaine, J.-P., see Thollon, C. (339) 43
Villalobos-Molina, R. and Ibarra, M.
Corrigendum to 'α_1-Adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the α_{1D} and α_{1A} subtypes' [Eur. J. Pharmacol. 298 (1996) 257–263] (318) 511
Villalobos-Molina, R., López-Guerrero, J.J. and Ibarra, M.
α_{1D}- and α_{1A}-adrenoceptors mediate contraction in rat renal artery (322) 225
Villani, G., see Daniele, E. (330) 247
Villanueva-Peñacarrillo, M.L., see García-Martínez, J.A. (325) 65
Villarroya, M., De la Fuente, M.-T., López, M.G., Gandía, L. and García, A.G.
Distinct effects of ω-toxins and various groups of Ca^{2+}-entry inhibitors on nicotinic acetylcholine receptor and Ca^{2+} channels of chromaffin cells (320) 249
Villemagne, V.L., see Mochizuki, T. (338) 17
Vincent, B., Jiracek, J., Noble, F., Loog, M., Roques, B., Dive, V., Vincent, J.-P. and Checler, F.
Contribution of endopeptidase 3.4.24.15 to central neurotensin inactivation (334) 49
Viola, H., see Wolfman, C. (318) 23
Virolainen, S., Jansson, C.C. and Scheinin, M.
Assessment of α_2-adrenoceptor antagonist potency with GTPase assay (338) 293
Virtanen, K.A., Rouru, J., Hänninen, V., Savontaus, E., Rouvari, T., Teirmaa, T., Koulu, M. and Huupponen, R.
Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism (332) 215
Visker, K.E., see Maisonneuve, I.M. (336) 123
Vitale, M.L., see Gandía, L. (329) 189
Vizi, E.S., see Németh, Z.H. (339) 215
Vizuete, M.L., see De la Cruz, C.P. (327) 215
Vo, P.A. and Tomlinson, D.R.
Effects of adrenergic stimulation on sciatic nerve blood flow in diabetic and control rats (329) 147
Vohr, H.-W., see Homey, B. (325) 199
Volant, K., Grishina, O., Descroix-Vagne, M. and Pansu, D.
Guanylin-, heat-stable enterotoxin of *Escherichia coli*- and vasoactive intestinal peptide-induced water and ion secretion in the rat intestine in vivo (328) 217
Vollmar, A.M., Förster, R. and Schulz, R.
Effects of atrial natriuretic peptide on phagocytosis and respiratory burst in murine macrophages (319) 279
VonVoigtlander, P.F., see Piercey, M.F. (317) 29
Vossen, J.M.H., see Maes, J.H.R. (319) 5
Vowles, D.T., see Dickinson, K. (339) 69
Vožeh, F., see Caddy, K.W.T. (330) 139
Vuorinen, P., see Kosonen, O. (337) 55

Waara, L., see Cassel, G. (332) 43
Wacker, E., see Schmidt, W.J. (327) 1
Wada, K., see Okada, M. (321) 181
Wada, K.-i., see Yatsu, T. (321) 225
Wada, S. and Okabe, E.
Susceptibility of caffeine- and Ins(1,4,5)P_3-induced contractions to oxidants in permeabilized vascular smooth muscle (320) 51
Wada, Y., see Takahashi, W. (339) 165
Waddington, J.L., see Deveney, A.M. (317) 175
Wagner, H., see Dirsch, V.M. (336) 211
Wagner Jr., H.N., see Mochizuki, T. (338) 17
Wakabayashi, A., see Shinguh, Y. (337) 63
Wakimasu, M., see Masuda, Y. (325) 263
Wakuda, I., see Takahama, K. (329) 93
Wakui, M., see Fukushi, Y. (336) 89
Wakui, Y., see Arita, J. (318) 333
Wakulich, C.A. and Tepperman, B.L.
Role of glutathione in nitric oxide-mediated injury to rat gastric mucosal cells (319) 333
Waldron, G.J., Roach, A.G. and Garland, C.J.
Lack of endothelin ET_B receptor-mediated smooth muscle hyperpolarization in rat mesenteric resistance arteries (318) 89
Wallace, M.J., see Robinson, S.E. (319) 31
Walland, A., Palluk, R., Burkard, S. and Hammer, R.
Compensation of muscarinic bronchial effects of talsaclidine by concomitant sympathetic activation in guinea pigs (330) 213
Wanecek, M., see Hemsén, A. (318) 369
Wang, H.-X., Kwan, C.-Y. and Wong, T.-M.
Tetrandrine inhibits electrically induced $[Ca^{2+}]_i$ transient in the isolated single rat cardiomyocyte (319) 115
Wang, H.-X., Zhang, W.-M., Sheng, J.-Z. and Wong, T.-M.
High carbachol increases the electrically induced $[Ca^{2+}]_i$ transient in the single isolated ventricular myocyte of rats (319) 91
Wang, J., Drake, L., Sajjadi, F., Firestein, G.S., Mullane, K.M. and Bullough, D.A.
Dual activation of adenosine A_1 and A_3 receptors mediates preconditioning of isolated cardiac myocytes (320) 241
Wang, J.-P., Hsu, M.-F. and Kuo, S.-C.
Inhibition by abruquinone A of phosphoinositide-specific phospholipase C activation in rat neutrophils (319) 131
Wang, J.-P., Raung, S.-L., Tsao, L.-T. and Lin, C.-N.
Evidence for the involvement of protein kinase C inhibition by norathyriol in the reduction of phorbol ester-induced neutrophil superoxide anion generation and aggregation (336) 81
Wang, J.-P., Tsao, L.-T., Raung, S.-L. and Lin, C.-N.
Investigation of the inhibitory effect of broussochalcone A on respiratory burst in neutrophils (320) 201
Wang, J.Q., Jolkkonen, M. and McGinty, J.F.
The muscarinic toxin 3 augments neuropeptide mRNA in rat striatum in vivo (334) 43
Wang, R., see Champion, H.C. (319) 71
Wang, S.-N., Fontenot, H.J. and Kennedy, R.H.
α_{1D}-Adrenoceptors play little role in the positive inotropic action of phenylephrine (321) 39
Wanibuchi, H., see Hamaguchi, A. (331) 27
Ward, M.A., see O'Neill, M.J. (332) 121
Ward, P., see Lundstrom, K. (337) 73
Warner, T.D., see D'Amico, M. (328) 65
Warner, T.D., see Takahashi, T. (324) 219
Warren, R.A., see Dewar, K.M. (336) 155
Wascher, T.C., see Graier, W.F. (322) 113
Wasowski, C., see Wolfman, C. (318) 23
Watajima, H., see Nanaumi, K. (327) 239
Watanabe, H., see Leewanich, P. (332) 321
Watanabe, H., see Matsumoto, K. (317) 75
Watanabe-Kobayashi, M., see Niki, H. (320) 193
Watanabe-Kobayashi, M., see Yamashita, M. (325) 221
Watanabe, M., see Ishii, Y. (331) 295
Watanabe, S., see Jin, J. (319) 147
Watanabe, S., see Ohno, M. (318) 267

Watanabe, Y., Hara, Y., Tamagawa, M. and Nakaya, H.
Pirmenol inhibits muscarinic acetylcholine receptor-operated K^+ current in the guinea pig heart (338) 71
Watanabe, Y., see Nishio, E. (339) 245
Waters, N.R., see Martin, P. (335) 107
Waters, S.E., see Martin, P. (335) 107
Waurick, R., Bone, H.-G., Meyer, J., Booke, M., Meißner, A., Prien, T. and Van Aken, H.
Haemodynamic effects of dopexamine and nitric oxide synthase inhibition in healthy and endotoxaemic sheep (333) 181
Way, K.J. and Reid, J.J.
The aldose reductase inhibitor sorbinil does not prevent the impairment in nitric oxide-mediated neurotransmission in anococcygeus muscle from diabetic rats (318) 101
Weatherspoon, J.K., Gonzalez-Alvear, G.M. and Werling, L.L.
Regulation of [^{3}H]norepinephrine release from guinea pig hippocampus by σ_2 receptors (326) 133
Wegener, J.W. and Nawrath, H.
Cardiac effects of isoliquiritigenin (326) 37
Wegener, J.W. and Nawrath, H.
Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle (323) 89
Wei, S., Kasuya, Y., Yanagisawa, M., Kimura, S., Masaki, T. and Goto, K.
Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery (321) 307
Weig, B., see Fawzi, A.B. (336) 233
Weill, C., Autelitano, F., Guenet, C., Heitz, F., Goeldner, M. and Ilien, B.
Pharmacological and structural integrity of muscarinic M_2 acetylcholine receptors produced in Sf9 insect cells (333) 269
Weinberg, M.L.D., Moreira, E. and Weinberg, J.
Arachidonic acid products-mediated contraction induced by bradykinin in relaxed mesenteric arterial rings from Holtzman rats (320) 145
Weiss, F., Imperato, A., Casu, M.A., Mascia, M.S. and Gessa, G.L.
Opposite effects of stress on dopamine release in the limbic system of drug-naive and chronically amphetamine-treated rats (337) 219
Weisz, A., see D'Acquisto, F. (339) 87
Weitzberg, E., see Hemsén, A. (318) 369
Welz, A., see Reithmann, C. (330) 79
Wenham, D., Rahmatullah, R.J., Rahmatullah, M., Hansen, C.A. and Robishaw, J.D.
Differential coupling of α_1-adrenoreceptor subtypes to phospholipase C and mitogen activated protein kinase in neonatal rat cardiac myocytes (339) 77
Werdan, K., see Reithmann, C. (330) 79
Werling, L.L., see Weatherspoon, J.K. (326) 133
Wernimont, A.K., see Hulkower, K.I. (331) 79
Wessler, I., see Brunn, G. (326) 53
Westenberg, H.G.M., see Bosker, F.J. (333) 147
Westerberg, E., see Koller, M.-E. (331) 259
Westerink, B.H.C., see Bruggeman, R. (324) 49
Westfall, T.D., Kennedy, C. and Sneddon, P.
The ecto-ATPase inhibitor ARL 67156 enhances parasympathetic neurotransmission in the guinea-pig urinary bladder (329) 169
Westh-Hansen, S.E., Rasmussen, P.B., Hastrup, S., Nabekura, J., Noguchi, K., Akaike, N., Witt, M.-R. and Nielsen, M.
Decreased agonist sensitivity of human $GABA_A$ receptors by an amino acid variant, isoleucine to valine, in the α_1 subunit (329) 253
Weston, A.H., see Kirkup, A.J. (317) 165
Whalen, E.J., see Travis, M.D. (328) R1
Wheller, S.K. and Perretti, M.
Dexamethasone inhibits cytokine-induced intercellular adhesion molecule-1 up-regulation on endothelial cell lines (331) 65
White, H.S., see Baron, B.M. (323) 181
White, R. and Hiley, C.R.
Endothelium and cannabinoid receptor involvement in levcromakalim vasorelaxation (339) 157
Whittemore, E.R., Ilyin, V.I., Konkoy, C.S. and Woodward, R.M.
Subtype-selective antagonism of NMDA receptors by nylidrin (337) 197
Whittle, B.J.R., see László, F. (334) 99
Wichyanuwat, P., see Siripurkpong, P. (331) 227
Widdop, R.E., see Bunting, M.W. (337) 35
Widjaja-Greefkes, H.C.A., see Jager, L.P. (331) 325
Wiernsperger, N., see Muller, S. (337) 103
Wiesenfeld-Hallin, Z., see Xu, X.-J. (318) 301
Wikberg, J.E.S., see Schiöth, H.B. (319) 369
Wiklund, N.P., see Iversen, H.H. (331) 213
Wikström Jonsson, E., see Bäck, M. (317) 107
Wiley, J.L., Golden, K.M. and Bowen, S.E.
Effects of modulation of nitric oxide on acoustic startle responding and prepulse inhibition in rats (328) 125
Wilkins, D.G., see Fleckenstein, A.E. (324) 179
Willems, P.H.G.M., see Smeets, R.L.L. (325) 93
Williams, A.R., see Rupniak, N.M.J. (326) 201
Williamson, D.J., Shepheard, S.L., Hill, R.G. and Hargreaves, R.J.
The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation (328) 61
Willis, W.D., see Lawand, N.B. (324) 169
Willoughby, D., see Papworth, J. (325) R1
Winter, J.C., see Johnson, R.G. (329) 99
Wion, D., see Canova, C. (319) 365
Wirth, K.J., Bickel, M., Hropot, M., Günzler, V., Heitsch, H., Ruppert, D. and Schölkens, B.A.
The bradykinin B_2 receptor antagonist Icatibant (HOE 140) corrects avid Na^+ retention in rats with CCl_4-induced liver cirrhosis: possible role of enhanced microvascular leakage (337) 45
Witt, M.-R., see Westh-Hansen, S.E. (329) 253
Witte, K., Kinzler, N., Schnecko, A., Olbrich, H.-G. and Lemmer, B.
Effects of β-adrenoceptor blockade on β-adrenergic signal transduction in cardiomyopathic hamster (BIO 8262) hearts (334) 209
Wlaź, P., see Ebert, U. (322) 179
Wo, N.C., see Ala, Y. (331) 285
Wolff, M.C. and Leander, J.D.
Differentiation of 5-HT_{1A} receptor ligands by drug discrimination (333) 113
Wolfman, C., Viola, H., Marder, M., Wasowski, C., Ardenghi, P., Izquierdo, I., Paladini, A.C. and Medina, J.H.
Anxioselective properties of 6,3′-dinitroflavone, a high-affinity benzodiazepine receptor ligand (318) 23
Wong, S.M.E., Fong, E., Tauck, D.L. and Kendig, J.J.
Ethanol as a general anesthetic: actions in spinal cord (329) 121
Wong, T.-M., see Wang, H.-X. (319) 91
Wood, A.V., see Browning, R.A. (336) 1
Wood, J.D., see Xia, Y. (320) 95
Wood, P.L., see Hawkinson, J.E. (337) 315
Woods, J.H., see Paronis, C.A. (337) 27
Woodward, R.M., see Whittemore, E.R. (337) 197
Woolf, C.J., see Ma, Q.-P. (322) 165
Worgall, S., see Hänze, J. (330) 87
Wright, D.S., see Singh, L. (321) 209
Wu, C.-C. and Yen, M.-H.
Beneficial effects of dantrolene on lipopolysaccharide-induced haemodynamic alterations in rats and mortality in mice (327) 17
Wu, H.-Q., Salituro, F.G. and Schwarcz, R.
Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo (319) 13
Wu, S.-N., Hwang, T.-L., Jan, C.-R. and Tseng, C.-J.
Ionic mechanisms of tetrandrine in cultured rat aortic smooth muscle cells (327) 233
Wurster, S., see Kukkonen, J.P. (335) 99

Xia, Y., Fertel, R.H. and Wood, J.D.
Suppression of cAMP formation by adenosine in myenteric ganglia from guinea-pig small intestine (320) 95
Xiao, P., see Kamei, J. (337) 223

Xu, C., see Reith, M.E.A. (324) 1
Xu, J., see King, M. (331) R5
Xu, L., Anwyl, R., De Vry, J. and Rowan, M.J.
Effect of repeated ipsapirone treatment on hippocampal excitatory synaptic transmission in the freely behaving rat: role of 5-HT_{1A} receptors and relationship to anxiolytic effect (323) 59
Xu, L., see Kula, N.S. (331) 333
Xu, R., see McLarnon, J.G. (339) 279
Xu, X.-J., Andell, S., Bartfai, T. and Wiesenfeld-Hallin, Z.
Fragments of galanin message-associated peptide (GMAP) modulate the spinal flexor reflex in rat (318) 301
Xue, Y.X., Aye, N.N. and Hashimoto, K.
Antiarrhythmic effects of HOE642, a novel Na^+-H^+ exchange inhibitor, on ventricular arrhythmias in animal hearts (317) 309
Xue, Y.X., see Aye, N.N. (339) 121

Yabana, H., see Itogawa, E. (317) 401
Yabuuchi, K., Maruta, E., Yamamoto, J., Nishiyori, A., Takami, S., Minami, M. and Satoh, M.
Intracerebroventricular injection of isoproterenol produces its analgesic effect through interleukin-1β production (334) 133
Yadomae, T., see Sakurai, T. (334) 255
Yagi, K., see Takaori, K. (322) 59
Yaksh, T.L., see Dirig, D.M. (331) 155
Yamada, J., Sugimoto, Y., Yoshikawa, T. and Horisaka, K.
Hyperglycemia induced by the 5-HT receptor agonist, 5-methoxytryptamine, in rats: involvement of the peripheral 5-HT_{2A} receptor (323) 235
Yamada, M., see Yamashita, M. (338) 151
Yamada, N., see Morimoto, K. (339) 11
Yamagata, T., see Yoshida, K. (338) 131
Yamagishi, T., see Nanaumi, K. (327) 239
Yamaguchi, T., see Takano, H. (323) 107
Yamaguchi, T., see Takeuchi, H. (329) 27
Yamaguchi, Y., Higashi, M. and Kobayashi, H.
Effects of ginsenosides on maze performance and brain choline acetyltransferase activity in scopolamine-treated young rats and aged rats (329) 37
Yamamoto, J., see Yabuuchi, K. (334) 133
Yamamoto, K., see Shimamura, K. (320) 37
Yamamoto, N., Sakai, F., Yamazaki, H., Sato, N., Nakahara, K. and Okuhara, M.
FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shock (327) 169
Yamamoto, T., see Jin, J. (319) 147
Yamamura, H.I., see Burkey, T.H. (323) R3
Yamamura, H.I., see Burkey, T.H. (336) 295
Yamamura, H.I., see Hosohata, Y. (321) R1
Yamamura, H.I., see Landsman, R.S. (334) R1
Yamamura, H.I., see Quock, R.M. (326) 101
Yamano, M. and Miyata, K.
Investigation of 5-HT_3 receptor-mediated contraction in guinea-pig distal colon (317) 353
Yamashita, M., Niki, H., Yamada, M., Mue, S. and Ohuchi, K.
Induction of nitric oxide synthase by lipopolysaccharide and its inhibition by auranofin in RAW 264.7 cells (338) 151
Yamashita, M., Niki, H., Yamada, M., Watanabe-Kobayashi, M., Mue, S. and Ohuchi, K.
Dual effects of auranofin on prostaglandin E_2 production by rat peritoneal macrophages (325) 221
Yamashita, N., Yamauchi, M., Baba, J. and Sawa, A.
Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram (337) 95
Yamawaki, S., see Takao, K. (333) 123
Yamazaki, A., see Shinguh, Y. (337) 63
Yamazaki, H., see Yamamoto, N. (327) 169
Yamazaki, K., Furukawa, Y., Hirose, M. and Chiba, S.
Zatebradine inhibits tachycardia induced by bronchodilators without affecting respiratory resistance in dogs (320) 21
Yamazaki, R., Kawai, S., Matsuzaki, T., Kaneda, N., Hashimoto, S., Yokokura, T., Okamoto, R., Koshino, T. and Mizushima, Y.
Aceclofenac blocks prostaglandin E_2 production following its intracellular conversion into cyclooxygenase inhibitors (329) 181
Yan, Q.-S., see Dailey, J.W. (328) 153
Yanagisawa, I., see Shibasaki, M. (335) 167
Yanagisawa, I., see Shibasaki, M. (335) 175
Yanagisawa, M., see Wei, S. (321) 307
Yanagisawa, R., see Takano, H. (323) 107
Yanaihara, N., see Kakuyama, H. (329) 85
Yang, H.-T., see Zhu, Y. (332) 195
Yang, Z.-Y., see Mukherjee, J. (337) 111
Yano, S., see Suzuki, K.-i. (336) 169
Yano, T., Uchida, M., Yuasa, M., Murakami, A., Hagiwara, K. and Ichikawa, T.
The inhibitory effect of vitamin E on K-*ras* mutation at an early stage of lung carcinogenesis in mice (323) 99
Yasharel, R., see Mukherjee, S.K. (330) 27
Yasuda, H., see Masunaga, H. (339) 1
Yasuda, H., see Togawa, M. (336) 291
Yatsu, T., Arai, Y., Takizawa, K., Kasai-Nakagawa, C., Takanashi, M., Uchida, W., Inagaki, O., Tanaka, A., Asano, M., Honda, K. and Takenaka, T.
Renal effect of YM435, a new dopamine D_1 receptor agonist, in anesthetized dogs (322) 45
Yatsu, T., Tomura, Y., Tahara, A., Wada, K.-i., Tsukada, J., Uchida, W., Tanaka, A. and Takenaka, T.
Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V_{1A} and V_2 receptor antagonist, in dogs (321) 225
Yavich, L., Lappalainen, R., Sirviö, J., Haapalinna, A. and MacDonald, E.
α_2-Adrenergic control of dopamine overflow and metabolism in mouse striatum (339) 113
Ye, J.H., Hunt, T., Wu, W.-H. and McArdle, J.J.
Ondansetron modulates $GABA_A$ current of rat central nervous system neurons (337) 87
Yehuda, S., Rabinovitz, S., Mostofsky, D.I., Huberman, M. and Sredni, B.
Essential fatty acid preparation improves biochemical and cognitive functions in experimental allergic encephalomyelitis rats (328) 23
Yen, M.-H., see Wu, C.-C. (327) 17
Yıldızoğlu-Arı, N., see Öztürk, Y. (321) 59
Yip, P.K., see Tang, E. (327) 109
Yoburn, B.C., see Chan, K.W. (319) 225
Yoburn, B.C., see Sehba, F. (339) 33
Yocca, F.D., see Matos, F.F. (317) 49
Yokokura, T., see Yamazaki, R. (329) 181
Yokoshiki, H., Katsube, Y., Sunagawa, M. and Sperelakis, N.
Levosimendan, a novel Ca^{2+} sensitizer, activates the glibenclamide-sensitive K^+ channel in rat arterial myocytes (333) 249
Yokotani, K., see Murakami, Y. (317) 61
Yokoyama, K., see Taniguchi, Y. (330) 221
Yokoyama, M., see Kobari, M. (317) 269
Yono, M., see Takahashi, W. (339) 165
Yoon, S.-H., see Sim, S.-S. (324) 205
Yoshida, A., see Sakurai-Yamashita, Y. (338) 199
Yoshida, J., see Mori, Y. (320) 183
Yoshida, J., see Mori, Y. (330) 195
Yoshida, K., Yamagata, T., Tomura, Y., Suzuki-Kusaba, M., Yoshida, M., Hisa, H. and Satoh, S.
Effects of C-type natriuretic peptide on renal vasoconstriction in dogs (338) 131
Yoshida, M., see Takahashi, W. (339) 165
Yoshida, M., see Yoshida, K. (338) 131
Yoshida, N., see Takano, H. (323) 107

Yoshida, T., see Aoki, K. (336) 43
Yoshida, Y., see Kawada, T. (323) 75
Yoshikawa, T., see Takano, H. (323) 107
Yoshikawa, T., see Yamada, J. (323) 235
Yoshikuni, Y., see Shimidzu, T. (338) 225
Yoshikuni, Y., see Suma, C. (336) 283
Yoshikuni, Y., see Taniguchi, N. (318) 117
Yoshimoto, T., see Seki, T. (331) 87
Yoshimoto, T., see Uchida, Y. (335) 235
Yoshimura, K., see Abe, K. (321) 149
Yoshino, S. and Ohsawa, M.
Effect of a monoclonal antibody against interleukin-4 on the induction of oral tolerance in mice (336) 203
Yoshioka, T., see Irie, K. (339) 289
Yoshioka, T., see Uchida, Y. (335) 235
Young, M.A., see Kurz, M.A. (322) 211
Yritia, M., see Lahmame, A. (337) 115
Yu, S., see Griffin, G. (339) 53
Yuasa, M., see Yano, T. (323) 99

Zaagsma, J., see Ten Berge, R.E.J. (318) 131
Zachariou, V. and Goldstein, B.D.
Dynorphin-(1–8) inhibits the release of substance P-like immunoreactivity in the spinal cord of rats following a noxious mechanical stimulus (323) 159
Zachrisson, O., Mathé, A.A. and Lindefors, N.
Decreased levels of preprotachykinin-A and tachykinin NK_1 receptor mRNA in specific regions of the rat striatum after electroconvulsive stimuli (319) 191
Zajac, J.-M., see Million, M. (334) 67
Zambon, A.C., De Costa, B.R., Kanthasamy, A.G., Nguyen, B.Q.H. and Matsumoto, R.R.
Subchronic administration of *N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-(dimethylamino)ethylamine (BD1047) alters σ_1 receptor binding (324) 39
Zamora, R., Matthys, K.E. and Herman, A.G.
The protective role of thiols against nitric oxide-mediated cytotoxicity in murine macrophage J774 cells (321) 87
Zappellini, A., A. Teixeira, S., Muscará, M.N., Zatz, R., Antunes, E. and De Nucci, G.
In vivo inhibition of nitric oxide synthesis does not depend on renin-angiotensin system activation (317) 285
Zarrindast, M.-R. and Oveisi, M.-R.
Effects of monoamine receptor antagonists on nicotine-induced hypophagia in the rat (321) 157
Zarrindast, M.-R., Iraie, F., Heidari, M.-R. and Mohagheghi-Badi, M.
Effect of adenosine receptor agonists and antagonists on morphine-induced catalepsy in mice (338) 11
Zarzuelo, A., see Duarte, J. (338) 25
Zastawny, R., see Jin, H. (324) 109
Zatz, R., see Zappellini, A. (317) 285
Zea-Ponce, Y., see Abi-Dargham, A. (321) 285
Zeevalk, G.D., Manzino, L., Hoppe, J. and Sonsalla, P.
In vivo vulnerability of dopamine neurons to inhibition of energy metabolism (320) 111
Zeisberger, E., see Goldbach, J.-M. (319) 273
Zeisberger, E., see Goldbach, J.-M. (334) 249
Zembala, M., see Konturek, P.Ch. (322) 73
Zenda, H., see Furukawa, Y. (334) 191
Zeng, X.-T., see Tanabe, T. (321) 137
Zeng, X.P., Le, F. and Richelson, E.
Muscarinic m4 receptor activation by some atypical antipsychotic drugs (321) 349
Zentella de Piña, M., see Saldaña-Balmori, Y. (317) 225
Zernig, G., O'Laughlin, I.A. and Fibiger, H.C.
Nicotine and heroin augment cocaine-induced dopamine overflow in nucleus accumbens (337) 1
Zhang, B., see Knight, K.R. (332) 273
Zhang, H., see Domino, E.F. (325) 137
Zhang, H., see Fawzi, A.B. (336) 233
Zhang, R., Ogletree, M.L. and Moreland, S.
Characterization of thromboxane A_2/prostaglandin endoperoxide receptors in aorta (317) 91
Zhang, X., see Quock, R.M. (326) 101
Zhang, Y., see Ipsen, M. (336) 29
Zhang, Y., see Zhu, W. (329) 55
Zhao, J., see Ho, B.Y. (319) 109
Zhao, L., see Homaidan, F.R. (331) 199
Zharkovsky, A., see Pokk, P. (317) 15
Zhu, W., Zhang, Y. and Han, C.
Characterization of subtype of α_1-adrenoceptor mediating vasoconstriction in perfused rat hind limb (329) 55
Zhu, Y., Yang, H.-T. and Endoh, M.
Does nitric oxide contribute to the negative chronotropic and inotropic effects of endothelin-1 in the heart? (332) 195
Zídek, Z., Holý, A. and Franková, D.
Antiretroviral agent (R)-9-(2-phosphonomethoxypropyl)adenine stimulates cytokine and nitric oxide production (331) 245
Zieglgänsberger, W., see Putzke, J. (317) 39
Zingarelli, B., Ischiropoulos, H., Salzman, A.L. and Szabó, C.
Amelioration by mercaptoethylguanidine of the vascular and energetic failure in haemorrhagic shock in the anesthetised rat (338) 55
Zorn, S.H., see Rollema, H. (338) R3
Zou, L.-B., see Shimamura, K. (320) 37
Zucker, T.-P., see Grosser, T. (319) 327
Zúñiga, Á., see Racchi, H. (329) 79
Zurbonsen, K., Michel, A., Bonnet, P.-A., Gannoun-Zaki, L., Mathieu, M.-N. and Chevillard, C.
Apoptotic effects of imidazo[1,2-*a*]pyrazine derivatives in the human Dami cell line (320) 215
Zvartau, E.E., see Kuzmin, A.V. (321) 265

ELSEVIER

European Journal of Pharmacology

ejp

Master keyword index to volumes 317–339 (1997)

A23187
Auranofin; Prostaglandin E_2; 12-*O*-Tetradecanoylphorbol 13-acetate; Thapsigargin; Cyclooxygenase 2; Cyclooxygenase 1; Macrophage (Yamashita, M. (325) 221)

Endothelium; Nitric oxide (NO); Coronary small artery; Acetylcholine; Apamin; K^+ channel (Simonsen, U. (329) 153)

A-86929
Dopamine D_1 receptor; ABT-431; Hyperactivity; Seizure; Tolerance (Shiosaki, K. (317) 183)

AA-2414
Thromboxane; Smooth muscle, vascular; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; SQ 29,548; Daltroban; BM-13505; SQ 30,741 (Zhang, R. (317) 91)

Abdominal afferent vagus nerve activity
N-3389; 5-HT_3 receptor antagonist; 5-HT_4 receptor antagonist; Antiemetic effect; (Ferret) (Minami, M. (321) 333)

Abruquinone A
Neutrophil; Inositol phosphate; Phospholipase C; Ca^{2+} concentration, intracellular (Wang, J.-P. (319) 131)

Absence epilepsy
$GABA_B$ receptor antagonism; Cognition; GAERS (genetic absence epilepsy rat of Strasbourg) (Getova, D. (320) 9)

Absence seizure
$GABA_B$ receptor; GHB (γ-hydroxybutyric acid); G-protein-coupled receptor; GTP shift (Mathivet, P. (321) 67)

ABT 418
Epibatidine; Epiboxidine; Nicotinic receptor; Analgesia (Badio, B. (321) 189)

ABT-431
Dopamine D_1 receptor; A-86929; Hyperactivity; Seizure; Tolerance (Shiosaki, K. (317) 183)

ABT-491
PAF (platelet-activating factor); PAF receptor antagonist; Ca^{2+} flux; Superoxide anion; Vascular permeability; Degranulation; Endotoxemia (Albert, D.H. (325) 69)

Acamprosate
Ethanol withdrawal; Pentylenetetrazole; Hippocampus; Cerebellum; c-*fos* mRNA; Northern and dot blotting; In situ hybridization (Putzke, J. (317) 39)

ACEA 1021
Glycine; Psychotomimetic; Amnesia; Side effects; Glutamate (Kretschmer, B.D. (331) 109)

Aceclofenac
Cyclooxygenase; Prostaglandin E_2; Polymorphonuclear leukocyte; Monocyte; Synovial cell (Yamazaki, R. (329) 181)

Acetate
Anesthetic potency; Ethanol; Adenosine (Campisi, P. (325) 165)

Acetic acid test
Opioid analgesia; Amphibian; Intracerebroventricular (i.c.v.) administration; (*Rana pipiens*) (Stevens, C.W. (331) 15)

Acetylcholine
5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Galanin; Hypothermia; Muscarinic receptor (Patel, S. (317) 197)

Dopamine; Dopamine D_1 receptor; Dopamine D_2 receptor; Microdialysis; Neostigmine; Striatum (DeBoer, P. (317) 257)

$GABA_A$ receptor; Blood pressure; (Rat) (Tellioğlu, T. (317) 301)

D-Cycloserine; Glycine site; NMDA receptor; Hippocampus; Working memory (Ohno, M. (318) 267)

Coronary microvessel; Nitroglycerin; Heart failure; L-Arginine; Nitric oxide (NO) (Larosa, G. (318) 387)

Acetylcholinesterase activity; Adrenal homogenate; Nicotine-induced inward current; Physostigmine; Patch clamp (Sugawara, T. (319) 123)

Alzheimer's disease; Basal forebrain lesion; Cholinesterase inhibitor; Scopolamine; (Rat) (Itoh, A. (322) 11)

Tacrine; Cognex; Vacuous chew; Purposeless; Tremor; Parkinson's disease; Alzheimer's disease (Cousins, M.S. (322) 137)

Cannabinoid receptor; CP 55,940; SR 141716A; Brain slice (Gifford, A.N. (324) 187)

NGF (nerve growth factor); Locomotion; Nicotinic receptor; Dopamine receptor antagonist (Kobayashi, S. (326) 1)

Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Hippocampus; Cannabinoid (Gessa, G.L. (327) R1)

Endothelium; Nitric oxide (NO); Coronary small artery; A23187; Apamin; K^+ channel (Simonsen, U. (329) 153)

Clotrimazole; Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Nitric oxide (NO); Nitro-L-arginine (Fujimoto, S. (330) 177)

Cerebral blood flow; Cerebrovascular resistance; Cerebral vasodilatation; N^G-Nitro-L-arginine methyl ester (L-NAME) (Diéguez, G. (330) 185)

Dynorphin; Substance P; Enkephalin; Dopamine; Amphetamine; Nucleus accumbens; Caudoputamen; Behavior; Muscarinic receptor (Wang, J.Q. (334) 43)

Vesamicol receptor; Synaptic vesicle; Acetylcholine transporter, vesicular (Staley, J.K. (338) 159)

Acetylcholine esterase
Dopamine; HI 6; Microdialysis; Pharmacokinetics; Soman; (Rat) (Cassel, G. (332) 43)

Acetylcholine receptor antagonist
Nicotine; Dopamine receptor agonist; Adrenoceptor antagonist; 5-HT receptor antagonist; Anorexia; (Rat) (Zarrindast, M.-R. (321) 157)

Acetylcholine release
5-HT receptor; Stomach fundus, rat; Contractile response (Amemiya, N. (318) 403)

Aging; Metrifonate; Object recognition; Cholinesterase inhibitor (Scali, C. (327) 103)

Nicotinic receptor antagonist; Adenosine; Neuromuscular junction (Prior, C. (327) 103)

CGRP (calcitonin gene-related peptide) release; Neostigmine; Phrenic nerve-diaphragm muscle preparation (Kimura, I. (330) 123)

Ondansetron; Stomach fundus; Contractile response; (Rat) (Amemiya, N. (339) 173)

Acetylcholinesterase activity
Acetylcholine; Adrenal homogenate; Nicotine-induced inward current; Physostigmine; Patch clamp (Sugawara, T. (319) 123)

Acetylcholine synthesis
Cyclosporine chronopharmacology; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Ornithine decarboxylase; Norepinephrine uptake; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (319) 181)

Acetylcholine transporter
Vesamicol; AH5183; Alzheimer's disease; σ binding site; SPECT (Single-photon emission computed tomography) (Custers, F.G.J. (338) 177)

Acetylcholine transporter, vesicular
Vesamicol receptor; Acetylcholine; Synaptic vesicle (Staley, J.K. (338) 159)

***N*-Acetylcysteine**
Hyperbaric oxygen; Heart, rat; Ischemia, low flow; Defibrotide (Radice, S. (320) 43)

Nitric oxide (NO); Nitrosothiol; Glutathione; Glucose; Lipopolysaccharide; Cytotoxicity; Macrophage (Zamora, R. (321) 87)

6-Acetylmorphine
Fentanyl; Heroin; Morphine; Reinforcement (Martin, T.J. (324) 141)

3-Acetylpyridine
Inferior olivary neuron; Lurcher mutant mouse; NMDA (*N*-methyl-D-aspartate), inhibition; Niacinamide (Caddy, K.W.T. (330) 139)

Acetylsalicylic acid
Arrhythmia; Cardiac ischemia; Cardiac reperfusion; Electrophysiology; Electrocardiology; Epicardial mapping (Dhein, S. (339) 129)

Acidification rate
Dopamine D_1 receptor; Receptor binding; G protein; cAMP accumulation; *Fos* protein immunoreactivity (Scheideler, M.A. (339) 261)

Acid secretion
Gastric mucosal blood flow; Ketotifen; Mast cell; Mean arterial pressure; RX 77368; TRH (thyrotropin-releasing hormone); Vagus; Brain–gut (Király, Á. (334) 241)

Aconitine
TJN-505; Antiarrhythmic drug; Arrhythmia model, canine (Arita, J. (318) 333)

***Aconitum* alkaloid**
Hippocampus; Epileptiform activity (Ameri, A. (335) 145)

Na^+ channel; Toxicity; Antinociception (Friese, J. (337) 165)

Acoustic startle response
Anxiety; AP-5; Caudal pontine reticular formation; Fear; Glutamate receptor (Fendt, M. (318) 1)

ACPC (1-aminocyclopropanecarboxylic acid)
Conditioned preference; Reward; NMDA receptor; Glycine site; MK-801; CGP 37849; CGP 40116 (Papp, M. (317) 191)

Neuroprotection; NMDA receptor; Toxicity; Neuronal injury; Glycine; Excitatory amino acid (Lin, Y. (318) 491)

***trans*-ACPD**
Metabotropic glutamate receptor; C6 glioma cell; G-protein (Albasanz, J.L. (326) 85)

1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid)
Metabotropic glutamate receptor; Excitatory postsynaptic potential; Depotentiation; CA1 area; Hippocampus; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

ACTH (adrenocorticotropic hormone) fragment
γ-MSH (γ-melanocyte-stimulating hormone) fragment; Blood pressure; Heart rate; Cerebral blood flow; Structure-activity relationship; (Rat) (Van Bergen, P. (318) 357)

ACTH (adrenocorticotropin)
Hemorrhagic shock; Nitric oxide (NO); Electron spin resonance; Nitric oxide (NO) synthase, inducible (Guarini, S. (336) 15)

ACTH-(4–9) analogue
Streptozotocin-diabetic rat; Org 2766; Adrenergic responsiveness; Nerve blood flow; Macrocirculatory blood flow (Van Buren, T. (318) 73)

Actin, α-Actinin
Neutrophils; Cell locomotion; Wortmannin; Phosphatidylinositol 3-kinase (Niggli, V. (335) 43)

Action potential
Sinus node; Efonidipine; Chronotropism; Ca^{2+} channel antagonist; Ca^{2+} channel, T-type (Masumiya, H. (335) 15)

Action potential duration
ATP, extracellular; Muscarinic acetylcholine receptor-operated K^+ current; Atrial cell; Purinoceptor (Hara, Y. (324) 295)

Active metabolite
NK433; Muscle relaxant; Spinal reflex (Sakitama, K. (337) 175)

Active secretion
Renal clearance; Drug interaction; P-glycoprotein; Multidrug resistance; Organic cation carrier (Masereeuw, R. (321) 315)

Actomyosin ATPase activity
P-4 (1-methyl-4-piperidyl diphenylpropoxyacetate hydrochloride); Antipollakiuric agent; Urinary bladder; Smooth muscle; Calmodulin (Matsushima, S. (333) 93)

Acute-phase-response
TNF-α (tumor necrosis factor-α); TNF-β; Fever; Interleukin-6; Hypothalamic–pituitary–adrenal axis; Cortisol (Goldbach, J.-M. (334) 249)

Acyclic nucleotide analog
TNF-α (tumor necrosis factor α); IL-10 (interleukin-10); NO (nitric oxide); (R)-PMPA ((R)-9-(2-phosphonomethoxypropyl)adenine) (Zídek, Z. (331) 245)

Acyl coenzyme A:cholesterol acyltransferase
Cholesterol; Plasma; Liver; Bile; Gallstone; Cholesterol 7α-hydroxylase (Hajri, T. (320) 65)

Additivity
Cocaine; Dopamine; Heroin; Microdialysis; Nicotine; Nucleus accumbens; Speedball; Synergism; (Interaction) (Zernig, G. (337) 1)

Adenine nucleotide
Brain; Adenosine; Diadenosine polyphosphate; Microwave; (Rat) (Delaney, S.M. (332) 35)

Adenosine
Purine; (−)-Bicuculline; GABA (γ-aminobutyric acid); Paired-pulse inhibition; Inhibition; Hippocampus; Cyclopentyltheophylline (Higgins, M.J. (317) 215)

Nitrobenzylthioinosine; Nucleoside transport; L-Adenosine (Foga, I.O. (318) 455)

Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenylate cyclase; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Signal transduction (Xia, Y. (320) 95)

Hepatic circulation; Vasodilatation; 8-Phenyltheophylline; ATP; (Rat) (Browse, D.J. (320) 139)

Caffeine; Carbamazepine; Dopamine; Microdialysis (Okada, M. (321) 181)

Myocardial ischemia, myocardial stunning; Myocardial ischemia, reperfusion injury; Coronary vessel (Kurz, M.A. (322) 211)

Taenia caecum; Purinoceptor; Adenosine A_{2B} receptor; Adenosine A_3 receptor (Prentice, D.J. (323) 103)

Anesthetic potency; Ethanol; Acetate (Campisi, P. (325) 165)

Nicotinic receptor antagonist; Neuromuscular junction; Acetylcholine release (Prior, C. (327) 103)

Nodose ganglion; Nitric oxide (NO); Adenosine receptor; Electrophysiology (Lawrence, A.J. (328) 83)

Histamine; Airway; Lipooxygenase-products; NANC (non-adrenergic–non-cholinergic), inhibitory; (Guinea pig) (Nieri, P. (331) 205)

Brain; Diadenosine polyphosphate; Microwave; Adenine nucleotide; (Rat) (Delaney, S.M. (332) 35)

Coronary artery disease; Lactate; Myocardial ischaemia; Ventricular function (De Jonge, R. (337) 41)

$P2X_2$ purinoceptor; pH dependence; Neuroamine; Zn^{2+}; Cd^{2+} (Nakazawa, K. (337) 309)

Pineal; Adenosine receptor; Melatonin; (Sheep) (Falcón, J. (337) 325)

ATP; Cholinergic; GABA (γ-aminobutyric acid); Nitric oxide (NO); Ileum; Terminal (Pencheva, N. (339) 193)

L-Adenosine
Nitrobenzylthioinosine; Adenosine; Nucleoside transport (Foga, I.O. (318) 455)

Adenosine analog
Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

Adenosine A_1 receptor
Thrombin receptor; P_{2U} purinoceptor; Inositol phosphate; Arachidonic acid; CHO (Chinese hamster ovary) cell; Protein kinase C (Dickenson, J.M. (321) 77)

Striatum; Hypoxia; Xanthine; Purine; Transmitter release (Jin, S. (329) 107)

G protein; Excitatory postsynaptic potential; Hippocampus; Agonism, partial; Intrinsic activity (Lorenzen, A. (334) 299)

Adenosine A_{2A} receptor
Dopamine D_2 receptor; Striatum; Locomotion; Catalepsy; (Rat) (Hauber, W. (323) 127)

Adenosine A_{2B} receptor
Adenosine; Taenia caecum; Purinoceptor; Adenosine A_3 receptor (Prentice, D.J. (323) 103)

Adenosine A_3 receptor
Adenosine; Taenia caecum; Purinoceptor; Adenosine A_{2B} receptor (Prentice, D.J. (323) 103)

APNEA (N^6-2-(4-aminophenyl)ethyl-adenosine); Adenosine receptor; Maximal electroshock; Antiepileptic drug; Seizure (Borowicz, K.K. (327) 125)

Pain; Histamine; 5-HT (5-hydroxytryptamine, serotonin) (Sawynok, J. (333) 1)

Adenosine A_1 receptor agonist
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

Adenosine A_2 receptor agonist
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

Adenosine A_1 receptor antagonist
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

BIIP 20; Passive avoidance; Memory (Pitsikas, N. (328) 19)

Long-term potentiation; Depotentiation; 8-CPT (8-cyclopentyltheophylline); Synaptic plasticity, modulation of; Hippocampal CA1 neuron (Fujii, S. (331) 9)

Adenosine A_2 receptor antagonist
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

Adenosine A_1 receptor, pre-synaptic
2-Chloroadenosine; Electrical kindling; Seizure; Epileptogenesis; Amygdala (Abdul-Ghani, A.-S. (326) 7)

(Rp)-Adenosine-3′,5′-cyclic monophosphorothioate
cGMP-dependent protein kinase; cAMP-dependent protein kinase; (Rp)-8-Bromo-guanosine-3′,5′-cyclic monophosphorothioate; Ca^{2+} sensitivity; Smooth muscle, skinned, vascular (Kawada, T. (323) 75)

Adenosine kinase inhibitor
Cerebral ischemia; Neuronal damage (Jiang, N. (320) 131)

Adenosine receptor
Duodenum longitudinal muscle, rat; Duodenum muscularis mucosae, rat; P_1 purinoceptor; Development; Ontogeny (Brownhill, V.R. (317) 321)

Ischemic preconditioning; Cardiac myocyte, isolated (Wang, J. (320) 241)

Smooth muscle, vascular; *N*-Nitro-L-arginine methyl ester (L-NAME); Ouabain; Coronary circulation; EDHF (endothelium-derived hyperpolarizing factor) (Olanrewaju, H.A. (322) 185)

Motor coordination; Antisense oligodeoxynucleotide (Phan, T.A. (323) R5)

APNEA (N^6-2-(4-aminophenyl)ethyl-adenosine); Adenosine A_3 receptor; Maximal electroshock; Antiepileptic drug; Seizure (Borowicz, K.K. (327) 125)

Nodose ganglion; Nitric oxide (NO); Adenosine; Electrophysiology (Lawrence, A.J. (328) 83)

MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo-(a,d)cyclohepten-5,10-imine maleate); Electroencephalogram; (Rat) (Popoli, P. (333) 143)

Iris sphincter, ovine; Adenosine receptor antagonists; Relaxation (Hourani, S.M.O. (334) 95)

Phorbol ester; Protein kinase C; SH-SY5Y neuroblastoma cell; cAMP (Peterfreund, R.A. (336) 71)

Pineal; Adenosine; Melatonin; (Sheep) (Falcón, J. (337) 325)

Ileum, rat (Nicholls, J. (338) 143)

Adenosine receptor agonist
Haloperidol; Catalepsy; Theophylline; Adenosine receptor antagonist (Mandhane, S.N. (328) 135)

Morphine; Adenosine receptor antagonist; Naloxone; Catalepsy; (Mouse) (Zarrindast, M.-R. (338) 11)

Adenosine receptor antagonist
Haloperidol; Catalepsy; Theophylline; Adenosine receptor agonist (Mandhane, S.N. (328) 135)

Adenosine receptors; Iris sphincter, ovine; Relaxation (Hourani, S.M.O. (334) 95)

Morphine; Adenosine receptor agonist; Naloxone; Catalepsy; (Mouse) (Zarrindast, M.-R. (338) 11)

Adenosine release
Glibenclamide (glyburide); K^+_{ATP} channel; Myocardial ischemia; Cardiac arrhythmia (Bernauer, W. (326) 147)

Adenosine transport, Na^+-dependent
Brush-border membrane vesicle; Cyclooxygenase; Prostanoid; Nonsteroidal anti-inflammatory drug (NSAID) (González-Castillo, C. (329) 245)

Adenylate cyclase
Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Signal transduction (Xia, Y. (320) 95)

Adenylyl cyclase
Nucleus accumbens; Caudate putamen; SKF 82958; cAMP (Unterwald, E.M. (318) 31)

VIP (vasoactive intestinal peptide); Peritoneal macrophage; VIP receptor antagonist; VIP receptor; Propranolol; Isoproterenol; Neuroimmunobiology (Pozo, D. (321) 379)

Dopamine; Dopamine D_1 receptor; Palmitoylation; Desensitization (Jin, H. (324) 109)

Desensitization; β-Adrenoceptor; Protein kinase, cAMP dependent; Receptor density (Rousseau, G. (326) 75)

5-HT receptor; Phosphoinositide hydrolysis; Raphe nucleus, dorsal; Hippocampus; 5-HT_{1A} receptor (Johnson, R.G. (329) 99)

β-Adrenoceptor; Catalytic subunit; Congenital heart disease (Reithmann, C. (330) 79)

Cardiomyopathy; β-Adrenoceptor subtype; Coupling efficacy; Propranolol; Metoprolol; (Hamster) (Witte, K. (334) 209)

α_2-Adrenoceptor subtype; CHO cell; [^{3}H]RX821002 binding; cAMP (Pohjanoksa, K. (335) 53)

Adenylylcyclase, inhibition
[^{3}H]Nociceptin; Nociceptin receptor; Radioreceptor assay; Drug screening (Butour, J.-L. (321) 97)

Adhesion
Tamoxifen; MCF7/6; E-cadherin; Ca^{2+} channel antagonist (Charlier, C. (317) 413)

Adhesion molecule
ETYA (5,8,11,14-eicosatetraynoic acid); Endothelial cell activation; Polyunsaturated fatty acid; Gene regulation; Inhibition (Stuhlmeier, K.M. (325) 209)

Glucocorticoid; Inflammation; PECAM-1; Interleukin-1; TNF-α (Wheller, S.K. (331) 65)

Adjuvant arthritis
Cytokine; Immunoregulation (Conforti, A. (324) 241)

Adrenal catecholamine
K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Adrenal homogenate
Acetylcholine; Acetylcholinesterase activity; Nicotine-induced inward current; Physostigmine; Patch clamp (Sugawara, T. (319) 123)

Adrenaline
Dopamine D_4 receptor; L 745,870; Clozapine; Noradrenaline; [^{35}S]GTPγS (Newman-Tancredi, A. (319) 379)

Adrenaline release
Chromaffin cell; Epibatidine; Substance P; Noradrenaline release (Krause, W. (328) 249)

Adrenal medulla
Catecholamine synthesis; (F-344 rat) (Tümer, N. (324) 57)

Adrenergic nerve
Mesenteric artery; Contraction; Excitatory junctional potential; Amiloride (Shimamura, K. (320) 37)

Diabetes mellitus; Nerve blood flow; Noradrenaline; Sciatic nerve, rat (Vo, P.A. (329) 147)

Adrenergic responsiveness
Streptozotocin-diabetic rat; ACTH-(4–9) analogue; Org 2766; Nerve blood flow; Macrocirculatory blood flow (Van Buren, T. (318) 73)

Adrenergic transmission
Purinergic transmission; Contractile response; Circular muscle; Development; Vas deferens; (Guinea pig) (Ren, L.-M. (318) 411)

α-Adrenoceptor
β-Adrenoceptor; Myocardium; K^+ channel ATP-sensitive; Forskolin (Kocić, I. (332) 65)

Dissociation constant; Caudal artery; Tail artery; (Bovine) (Hill, B.J.F. (339) 147)

α_1-Adrenoceptor
Ventricular pacing, rapid; Heart failure; Dorsal pedal artery; Saphenous vein; 5-Methyl-urapidil (Forster, C. (318) 55)

Ca^{2+} efflux; Smooth muscle; Ca^{2+}, intracellular (Lum Min, S.A. (318) 97)

Thalamus; α_{1A}-Adrenoceptor; α_{1B}-Adrenoceptor; α_{1C}-Adrenoceptor; Inositol phosphate (Trejo, F. (318) 175)

Aortic barodenervation; Aorta; Sympathetic activity; Receptor desensitization (El-Mas, M.M. (322) 201)

Mesenteric artery; Prostate; Trigone; Urethra; (Rabbit) (Van der Graaf, P.H. (327) 25)

Terazosin; Prazosin; Radioligand assay (Ireland, L.M. (327) 79)

Chloride ion; Niflumic acid; Two-kidney one-clip hypertensive rat; Mesenteric blood vessel (He, Y. (328) 191)

Chloroethylclonidine; Prazosin; Aorta; Spleen; Submandibular gland; α_2-Adrenoceptor; (Rat) (O'Rourke, M. (336) 37)

Aortic barodenervation; Endothelium; Nitric oxide (NO) (El-Mas, M.M. (337) 235)

α_{1A}-Adrenoceptor
Thalamus; α_1-Adrenoceptor; α_{1B}-Adrenoceptor; α_{1C}-Adrenoceptor; Inositol phosphate (Trejo, F. (318) 175)

Hind limb, isolated perfused, rat (Zhu, W. (329) 55)

α_{1B}-Adrenoceptor
Thalamus; α_1-Adrenoceptor; α_{1A}-Adrenoceptor; α_{1C}-Adrenoceptor; Inositol phosphate (Trejo, F. (318) 175)

α_{1C}-Adrenoceptor
Thalamus; α_1-Adrenoceptor; α_{1A}-Adrenoceptor; α_{1B}-Adrenoceptor; Inositol phosphate (Trejo, F. (318) 175)

α_{1D}-Adrenoceptor
Renal artery; Contraction; BMY 7378; Chloroethylclonidine; 5-Methyl-urapidil (Villalobos-Molina, R. (322) 225)

α_2-Adrenoceptor
RS-79948-197; Brain; Radioligand; In vivo; PET (positron-emission tomography); (Rat) (Hume, S.P. (317) 67)

Mitragynine; Antinociception; Noradrenergic system; Serotonergic system; (Mouse) (Matsumoto, K. (317) 75)

Sympathetic nerve activity; Blood pressure; Ventrolateral medulla, rostral (Vayssettes-Courchay, C. (320) 151)

Pineal gland; Melatonin; Circadian rhythm; Medetomidine; Atipamezole (Mustanoja, S.M. (326) 229)

ATP; Neurotransmission; Dopamine D_1 receptor; Vas deferens, guinea-pig (Furukawa, T. (328) 229)

Agmatine; μ-Opioid receptor; Analgesia; Fentanyl; Spinal cord (Bradley, K.J. (331) 133)

Peptide YY; Intestinal secretion; VIP (vasoactive intestinal peptide); Intestinal nerve; σ Receptor; (Rat) (Souli, A. (333) 87)

Dopamine D_1 receptor; Dopamine D_2 receptor; Pial vein; (Constriction); (Porcine) (Sun, M.-H. (334) 165)

Ca^{2+} signaling; Fura-2; Receptor kinetics; Receptor binding (Kukkonen, J.P. (335) 99)

Chloroethylclonidine; Prazosin; Aorta; Spleen; Submandibular gland; α_1-Adrenoceptor; (Rat) (O'Rourke, M. (336) 37)

Antinociception; Nitric oxide (NO); Opiate receptor; Periaqueductal gray (Fang, F. (336) 137)

α_{2A}-Adrenoceptor
Locus coeruleus; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); ARC 239 (2-[2-[4-(*o*-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethyl-1,3(2H,4H)-isoquinolinedione); Chlorpromazine (Ruiz-Ortega, J.A. (333) 159)

α_{2D}-Adrenoceptor
α_2-Adrenoceptor, postjunctional; (Pithed rat) (Gavin, K. (318) 81)

β-Adrenoceptor
Heart, neonatal; Ca^{2+} current; G protein; Voltage clamp, whole cell (Katsube, Y. (317) 391)

Endotoxin; Nitric oxide (NO) synthase; Dexamethasone; Myocardial contractility; Mercaptoethylguanidine (Sun, X. (320) 29)

Desensitization; Adenylyl cyclase; Protein kinase, cAMP dependent; Receptor density (Rousseau, G. (326) 75)

Tachyphylaxis; Nitric oxide (NO) (Travis, M.D. (328) R1)

Adenylyl cyclase; Catalytic subunit; Congenital heart disease (Reithmann, C. (330) 79)

α-Adrenoceptor; Myocardium; K^+ channel ATP-sensitive; Forskolin (Kocić, I. (332) 65)

Isoproterenol; Interleukin-1β; Nociception, mechanical; (Rat) (Yabuuchi, K. (334) 133)

β_3-Adrenoceptor; BRL37344A, BRL35135A; Taenia caecum, guinea pig; Muscle relaxation (Koike, K. (334) 217)

Forced swimming test; Wistar-Kyoto rat; Brown Norway rat; Sprague-Dawley rat; Imipramine; 5-HT_1 receptor; 5-HT_2 receptor; Depression (Lahmame, A. (337) 115)

β_1-Adrenoceptor
Isoproterenol; β_2-Adrenoceptor; Endothelium; Relaxation; Cytochrome P450; Aortic ring, rat (Satake, N. (319) 37)

β_2-Adrenoceptor; Antibody; Fusion protein (Jahns, R. (334) 115)

β_2-Adrenoceptor
Down-regulation; Salbutamol; Salmeterol; Formoterol; Lung, human (Nishikawa, M. (318) 123)

Isoproterenol; β_1-Adrenoceptor; Endothelium; Relaxation; Cytochrome P450; Aortic ring, rat (Satake, N. (319) 37)

Receptor down-regulation; mRNA half-life (Danner, S. (331) 73)

β_1-Adrenoceptor; Antibody; Fusion protein (Jahns, R. (334) 115)

***β_3*-Adrenoceptor**
β-Adrenoceptor; BRL37344A, BRL35135A; Taenia caecum, guinea pig; Muscle relaxation (Koike, K. (334) 217)

***β_3*-Adrenoceptor agonism**
BRL 35135; Zucker (*fa/fa*) rat; Insulin sensitivity; Non-esterified fatty acid; Euglycaemic hyperinsulinaemic clamp (Virtanen, K.A. (332) 215)

α_1-Adrenoceptor agonist
Brown fat; Zucker rat; α_2-Adrenoceptor antagonist; Imidazoline derivative; Obesity, drug therapy (Savontaus, E. (328) 207)

β-Adrenoceptor agonist
EGF (epidermal growth factor); Forskolin; DNA synthesis; Hepatocyte proliferation (Kimura, M. (324) 267)

Insulin; Hepatocyte DNA synthesis; Hepatocyte proliferation; cAMP-elevating agent (Kimura, M. (327) 87)

Isoproterenol; Clenbuterol; Mast cell; Allergic reaction; Vascular permeability (Inagaki, N. (336) 225)

β_2-Adrenoceptor agonist
Salmeterol; Eosinophil; cAMP; Eosinophil aggregation (Teixeira, M.M. (323) 255)

Asthma; Drug combination; Interaction; Smooth muscle, airway; Trachea; Methylxanthine; K^+ channel opener; Sodium nitroprusside; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

Plasma leakage; Substance P; Trachea; Vascular permeability (Bowden, J.J. (338) 83)

Adrenoceptor antagonist
Nicotine; Dopamine receptor agonist; Acetylcholine receptor antagonist; 5-HT receptor antagonist; Anorexia; (Rat) (Zarrindast, M.-R. (321) 157)

Mifepristone; Progesterone; Oestrogen; LH (luteinizing hormone) (Salicioni, A.M. (332) 283)

α_1-Adrenoceptor antagonist
KMD-3213; Prostate; Benign prostatic hypertrophy; (Human) (Moriyama, N. (331) 39)

α_2-Adrenoceptor antagonist
Brown fat; Zucker rat; α_1-Adrenoceptor agonist; Imidazoline derivative; Obesity, drug therapy (Savontaus, E. (328) 207)

α_2-Adrenoceptor, postjunctional
α_{2D}-Adrenoceptor; (Pithed rat) (Gavin, K. (318) 81)

α_2-Adrenoceptor, postsynaptic
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)-induced mydriasis; 5-HT_{1A} receptor; Brain, mouse (Prow, M.R. (317) 21)

Adrenoceptor subtype
Antipsychotic; Small artery (Ipsen, M. (336) 29)

α-Adrenoceptor, subtype
Atrial muscle; Papillary muscle; BMY 7378; Contractility; (Rat) (Wang, S.-N. (321) 39)

α_1-Adrenoceptor, subtype
NS-49; Intraurethral pressure; Blood pressure (Taniguchi, N. (318) 117)

Ca^{2+} concentration, intracellular; Contraction; Smooth muscle, vascular; Fura-2 (Tognarini, D.P. (322) 31)

Aging; Blood pressure; BMY 7378; Pithed rat (Ibarra, M. (322) 221)

Chloroethylclonidine; 5-Methylurapidil; WB 4101; BMY 7378; $^{86}Rb^+$, influx rate; Inositol 1,4,5-trisphosphate (Viko, H. (323) 269)

Ca^{2+}; Uterine artery; Umbilical vein (Hu, X.-Q. (324) 67)

Endogenous noradrenaline; WB4101; Chloroethylclonidine; Positive inotropic action; Myocardium, rabbit (Hattori, Y. (329) 165)

Ventricular pacing, rapid; Heart failure; Blood vessel; Chloroethylclonidine (Le Tran, Y. (336) 177)

α_2-Adrenoceptor subtype
RX821002 (2-methoxyidazoxan); Gpp(NH)p; Na^+ (Callado, L.F. (332) 109)

CHO cell; [^{3}H]RX821002 binding; Adenylyl cyclase; cAMP (Pohjanoksa, K. (335) 53)

Antagonist potency; CHO cell; GTPase (Virolainen, S. (338) 293)

β-Adrenoceptor subtype
Cardiomyopathy; Coupling efficacy; Adenylyl cyclase; Propranolol; Metoprolol; (Hamster) (Witte, K. (334) 209)

Adrenocortical cell, in vitro, porcine
Steroid hormone; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-Hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Nitrofuran; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Adrenomedullin
Penile erection; Cavernosal pressure; (Cat) (Champion, H.C. (319) 71)

CGRP (calcitonin gene-related peptide); CGRP-(8–37); Amylin; Cerebral arteriole; Cerebral microcirculation (Mori, Y. (330) 195)

Blood pressure; Renovascular hypertension; Renin; Aldosterone; (Rat) (Khan, A.I. (333) 187)

Amylin; α-Calcitonin gene-related peptide; Gastric acid; (*N*-terminal cyclic octa-peptides); (C-terminal fragments); (Chronic fistulae equipped rat); (Rat); (Human) (Rossowski, W.J. (336) 51)

α_1-Adrenoreceptor subtype
Cardiac myocyte, rat, neonatal; Phosphatidylinositol hydrolysis; Mitogen activated protein kinase (Wenham, D. (339) 77)

AF-102B
Muscarinic receptor agonists; Salivary gland; Sjögren's syndrome (Masunaga, H. (339) 1)

Affinity label
σ Receptor; Benzomorphan (Chien, C.-C. (321) 361)

A-fiber
Codeine; Larynx; Trachea bifurcation; Mechanical stimulation; Cough, codeine-resistant; C-fiber (Takahama, K. (329) 93)

ω-Agatoxin IVA
Ca^{2+} channel; ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; Vas deferens; Purinergic neurotransmission (Hirata, H. (321) 217)

Ca^{2+} channel; Cerebellum; Granule neuron; ω-Conotoxin-GVIA; Eliprodil (Biton, B. (323) 277)

Ca^{2+} channel, voltage-dependent; ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Conotoxin SVIB; Neurotransmission (Tran, S. (335) 31)

Aged rat
Nimodipine, chronic; Metrifonate, acute; Water maze; Passive avoidance; Motor test; Washout; Medial septum-lesioned rat (Riekkinen, M. (322) 1)

Aggregation
Norathyriol; Neutrophil, rat; Respiratory burst; Protein kinase C; Phorbol 12-myristate 13-acetate; Translocation (Wang, J.-P. (336) 81)

Aging
Angiotensin II; EDRF (endothelium-derived relaxing factor); Prostanoid; Mesenteric artery; Mesenteric vein; Development (Konishi, C. (320) 175)

α_1-Adrenoceptor, subtype; Blood pressure; BMY 7378; Pithed rat (Ibarra, M. (322) 221)

Metrifonate; Object recognition; Acetylcholine, release; Cholinesterase inhibitor (Scali, C. (325) 173)

(−)-Deprenyl; IGF-I (insulin-like growth factor-I); Tyrosine hydroxylase; (Rat) (De la Cruz, C.P. (327) 215)

Agmatine
α_2-Adrenoceptor; μ-Opioid receptor; Analgesia; Fentanyl; Spinal cord (Bradley, K.J. (331) 133)

Agonism, partial
Adenosine A_1 receptor; G protein; Excitatory postsynaptic potential; Hippocampus; Intrinsic activity (Lorenzen, A. (334) 299)

Agonist affinity
Pharmacological method, new; Efficacy estimation; Carbachol; Salbutamol (Venter, D.P. (320) 233)

Agonist-antagonist combination
Efficacy, agonist; Efficacy, relative; Spare receptor; (New parameter) (Venter, D.P. (320) 223)

Agonist, inverse
Mesocortical dopamine neuron; Stress; Benzodiazepine/$GABA_A$ receptor agonist; Glycine/NMDA receptor antagonist (Hutson, P.H. (326) 127)

AH5183
Vesamicol; Alzheimer's disease; Acetylcholine transporter; σ binding site; SPECT (Single-photon emission computed tomography) (Custers, F.G.J. (338) 177)

AIDA (1-aminoindan-1,5-dicarboxylic acid)
Metabotropic glutamate (mGlu) receptor; Contextual conditioning (Nielsen, K.S. (326) 105)

AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid)
Metabotropic glutamate receptor; 1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitatory postsynaptic potential; Depotentiation; CA1 area; Hippocampus; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

AIDS (acquired immunodeficiency syndrome)
LP-BM5 murine leukemia virus; Encephalopathy; PAF (platelet-activating factor); Pentoxifylline; TNF-α (tumor necrosis factor-α) (Sei, Y. (325) 81)

Airway
Plasma protein extravasation; 5-HT receptor; Histamine receptor; Tachykinin; Capsaicin; (Fisher 344 rat) (Germonpré, P.R. (324) 249)

Adenosine; Histamine; Lipooxygenase-products; NANC (non-adrenergic–non-cholinergic), inhibitory; (Guinea pig) (Nieri, P. (331) 205)

PF-904; Airway, hyperreactivity; Eosinophil infiltration; Microvascular leakage; Bronchus, human, isolated; Phosphodiesterase activity; Neutrophils, human; Superoxide anion generation; (Guinea pig) (Cortijo, J. (333) 69)

Airway, human
Histamine; Prostaglandin $F_{2\alpha}$ (Knight, D.A. (319) 261)

Airway, hyperreactivity
PF-904; Airway; Eosinophil infiltration; Microvascular leakage; Bronchus, human, isolated; Phosphodiesterase activity; Neutrophils, human; Superoxide anion generation; (Guinea pig) (Cortijo, J. (333) 69)

Airway epithelium
Inflammation; Airway remodelling; Neutrophil elastase; Secretory leukocyte protease inhibitor (Marchand, V. (336) 187)

Airway hyperresponsiveness
Suplatast tosilate; Airway inflammation; Eosinophil; Lymphocyte; T cell (Taniguchi, H. (318) 447)

Suplaplast tosilate; Airway inflammation; Eosinophil; Lymphocyte; T cell (Taniguchi, H. (321) 397)

Imidapril; Enalapril; Captopril; Ozone; Angiotensin-converting enzyme (Matsubara, S. (337) 259)

Airway inflammation
Suplatast tosilate; Airway hyperresponsiveness; Eosinophil; Lymphocyte; T cell (Taniguchi, H. (318) 447)

Suplaplast tosilate; Airway hyperresponsiveness; Eosinophil; Lymphocyte; T cell (Taniguchi, H. (321) 397)

Airway remodelling
Airway epithelium; Inflammation; Neutrophil elastase; Secretory leukocyte protease inhibitor (Marchand, V. (336) 187)

Airway response, early
Apafant (WEB 2086 BS); Airway response, late (Ikegami, K. (328) 75)

Airway response, late
Apafant (WEB 2086 BS); Airway response, early (Ikegami, K. (328) 75)

Airway tone, spontaneous
Smooth muscle, airway; Phosphodiesterase inhibitor; Prostaglandin; (Guinea pig) (Thirstrup, S. (333) 215)

(+)-AJ76
Haloperidol; (+)-UH-232; (+)-PD 128907; (−)-Apomorphine; Discriminative stimulus effect; Dopamine D_3 receptor (Kleven, M.S. (321) 1)

Albumin leakage
Lipopolysaccharide; 5-Lipoxygenase; Leukocyte; Lung; Radioactive tracer (Bureau, M.F. (324) 89)

Alcohol
5-HT_3 receptor; Atrium; Tachycardia; Ethanol (Nishio, H. (321) 27)

Nitric oxide (NO) synthase; Brain, rat (Chen, Q.-m. (321) 355)

Aldose reductase
Anococcygeus muscle, rat; Diabetes; Nitrergic neurotransmission; Nitric oxide (NO); Sorbinil (Way, K.J. (318) 101)

Aldose reductase inhibitor
Electroretinogram; Sorbitol; Platelet aggregation; 2,3-Diphosphoglycerate; Diabetic retinopathy (Hotta, N. (326) 45)

Aldosterone
Steroid hormones; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Adrenomedullin; Blood pressure; Renovascular hypertension; Renin; (Rat) (Khan, A.I. (333) 187)

Alkaloid
Rutaecarpine; Platelet, human; cAMP; cGMP; Thromboxane A_2; Phosphoinositide (Sheu, J.-R. (318) 469)

Allergic inflammation, recurrence of
Granulation tissue; Prostaglandin E_2; Cyclooxygenase-1; Cyclooxygenase-2; NS-398; Indomethacin; Dexamethasone (Niki, H. (320) 193)

Allergic late phase
Methylprednisolone; (Guinea pig) (Heuer, H.O. (317) 361)

Allergic reaction
β-Adrenoceptor agonist; Isoproterenol; Clenbuterol; Mast cell; Vascular permeability (Inagaki, N. (336) 225)

Allergic reaction, early, late
Vagus nerve stimulation; Muscarinic M_2 receptor, prejunctional; Receptor dysfunction; Muscarinic receptor antagonist; Bronchial hyperresponsiveness; (Conscious, unrestrained guinea pig) (Ten Berge, R.E.J. (318) 131)

Allodynia
Hyperalgesia; Pain; Tachykinin; Flexor reflex (Ma, Q.-P. (322) 165)

Neuropathic pain; Antinociception; Tail-flick test; Behavior; Electroshock test, maximal; Lamotrigine; Felbamate; Gabapentin (Hunter, J.C. (324) 153)

NMDA receptor; Non-NMDA glutamate receptor; Nociception; Hyperalgesia; Inflammation; Pain (Lawand, N.B. (324) 169)

Allopregnanolone
Neurosteroids; Morphine; Pregnenolone sulfate; Progesterone; 4′-Chlordiazepam; Opiate tolerance; Opiate dependence (Reddy, D.S. (337) 19)

Allosteric antagonism
Glutamate receptor; *Xenopus* oocyte; Ifenprodil; CP 101,606; Ro 25-6981; Haloperidol (Whittemore, E.R. (337) 197)

Allosteric interaction
McN-A-343; Muscarinic receptors; Operational model (Christopoulos, A. (339) 153)

Allosteric modulation
[^{3}H]CGP-39653; Partial agonist; Binding (Robichon, R. (328) 255)

DL-Allylglycine
GABA (γ-aminobutyric acid); Benzodiazepine receptor, in vivo; Efficacy, intrinsic; Brain; (Non-human primate) (Bottlaender, M. (321) 13)

Alprenolol
DTG (1,3-di-*o*-tolylguanidine); σ Binding site; Desipramine; Propranolol; Cerebral cortex, rat (Shirayama, Y. (331) 319)

Alternative splicing
Metabotropic glutamate receptor; Constitutive activity; G-protein coupled receptor; Phospholipase C coupling (Mary, S. (335) 65)

Alveolar macrophage
Nitric oxide (NO); Lipoxygenase; Cyclooxygenase; Leukotriene B_4 (Brunn, G. (326) 53)

β-D-glucan; Serum component; Interferon γ; Nitric oxide (NO); β-D-glucan receptor (Sakurai, T. (334) 255)

Alzheimer's disease
Acetylcholine; Basal forebrain lesion; Cholinesterase inhibitor; Scopolamine; (Rat) (Itoh, A. (322) 11)

Tacrine; Cognex; Acetylcholine; Vacuous chew; Purposeless; Tremor; Parkinson's disease (Cousins, M.S. (322) 137)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; Scopolamine; Pirenzepine; Methoctramine; (Delay-dependent and -independent); (% correct choice) (Aura, J. (333) 129)

Xanomeline; Muscarinic receptors (Christopoulos, A. (334) R3)

Metrifonate; Spatial navigation; Cholinesterase inhibition; Medial septal-lesion (Riekkinen, M. (338) 105)

Vesamicol; AH5183; Acetylcholine transporter; σ binding site; SPECT (Single-photon emission computed tomography) (Custers, F.G.J. (338) 177)

AM630
Cannabinoid receptor antagonist; [^{35}S]GTPγS binding (Hosohata, Y. (321) R1)

Amiloride
Mesenteric artery; Adrenergic nerve; Contraction; Excitatory junctional potential (Shimamura, K. (320) 37)

Diuretic; Xipamide; Cardiocyte; H9c2 heart cell line; Cell membrane; (Rat, newborn) (Taouil, K. (324) 289)

Ca^{2+} paradox; O_2 paradox; Caffeine; pH; Heart damage (Harding, R.J. (330) 47)

Amino acid
Microdialysis; Hippocampus; Cerebellum; Pilocarpine; Epilepsy (Smolders, I. (319) 21)

***cis*-4-Aminocrotonic acid**
$GABA_C$ receptor; GABA (γ-aminobutyric acid); $GABA_B$ receptor agonist; $GABA_B$ receptor antagonist; *Xenopus* oocyte; *trans*-4-Aminocrotonic acid (Chebib, M. (329) 223)

***trans*-4-Aminocrotonic acid**
$GABA_C$ receptor; GABA (γ-aminobutyric acid); $GABA_B$ receptor agonist; $GABA_B$ receptor antagonist; *Xenopus* oocyte; *cis*-4-Aminocrotonic acid (Chebib, M. (329) 223)

1-Aminocyclopropanecarboxylic acid
Neuroprotection; Glutamate toxicity; Neuronal injury; Glycine receptor; NMDA receptor complex (Lin, Y. (338) 289)

Aminoguanidine
N^G-Nitro-L-arginine; PAF (platelet-activating factor); Lipopolysaccharide; Systemic inflammatory response syndrome; Nitric oxide (NO); (Rat) (Takano, H. (323) 107)

Morphine withdrawal; Blood pressure; Nitric oxide (NO) synthase inhibitor; 3-Bromo-7-nitro indazole; *S*-Methyl-L-thiocitrulline; 7-Nitro indazole; Nitric oxide (NO) (Vaupel, D.B. (324) 11)

Nitric oxide (NO); Nitric oxide (NO) synthase; Portal vein ligation, rat; Portal hypertension (Michielsen, P.P. (329) 137)

Aminophylline
Autonomic nervous system; Sympathetic-parasympathetic interaction; Sinus rate; Atrioventricular conduction (Furukawa, Y. (334) 191)

Aminopiperidine
Dopamine D_4 receptor, human; Receptor binding (Schlachter, S.K. (322) 283)

Aminotetralin
5-HT receptor pharmacology; Migraine models; Cerebrovascular regulation; Inflammation, neurogenic (Petty, M.A. (336) 127)

Amitriptyline
Noradrenaline uptake inhibitor; Protriptyline; Xylamine; Electric field stimulation; Contraction; Vas deferens, rat (Huang, Y. (327) 41)

Antisense oligonucleotide; K^+ channel; mKv1.1; Analgesia; Antinociception; Clomipramine; Tricyclic antidepressant; (Mouse) (Galeotti, N. (330) 15)

Amlodipine
Semotiadil; Diltiazem; Nifedipine; Ca^{2+} current; Ventricular myocyte (Koidl, B. (322) 243)

Amnesia
Glycine; ACEA 1021; Psychotomimetic; Side effects; Glutamate (Kretschmer, B.D. (331) 109)

cAMP
Nitric oxide synthase, inducible (NO); Cyclooxygenase-2; Western blot; Lipopolysaccharide; Indomethacin; Cytotoxicity (Pang, L. (317) 151)

Adenylyl cyclase; Nucleus accumbens; Caudate putamen; SKF 82958 (Unterwald, E.M. (318) 31)

Rutaecarpine; Alkaloid; Platelet, human; cGMP; Thromboxane A_2; Phosphoinositide (Sheu, J.-R. (318) 469)

Zatebradine; Tachycardia; Respiratory resistance (Yamazaki, K. (320) 21)

Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Histamine; Adenylate cyclase; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Signal transduction (Xia, Y. (320) 95)

Apoptosis; Imidazo[1,2-*a*]pyrazine derivative; Megakaryoblastic cell, human; Phosphodiesterase; Purinoceptor (Zurbonsen, K. (320) 215)

Na^+/Ca^{2+} exchange; Ca^{2+}, intracellular; Heart failure (Miao, L. (321) 201)

Rolipram; Learning; Memory; 3-Panel runway; Passive avoidance (Imanishi, T. (321) 273)

Clozapine; Muscariaic m4 receptor; Neuroleptic, atypical; Neuroleptics, typical; Chinese hamster ovary cell; Striatum, rat (Zeng, X.P. (321) 349)

Salmeterol; Eosinophil; β_2-Adrenoceptor agonist; Eosinophil aggregation (Teixeira, M.M. (323) 255)

Dopamine D_1 receptor; Dopamine D_2 receptor; Striatum; Parkinson's disease (Pinna, A. (331) 23)

Nitric oxide (NO); Endothelin-1 (Zhu, Y. (332) 195)

Ca^{2+} imaging; Cross talk; Phenylglycine (Schaffhauser, H. (334) 289)

α_2-Adrenoceptor subtype; CHO cell; [^{3}H]RX821002 binding; Adenylyl cyclase (Pohjanoksa, K. (335) 53)

2-Phenyl-4-quinolone; Endothelial cell, rat; 5-HT (5-hydroxytryptamine, serotonin); Gap formation; Permeability (Lee, H.-Z. (335) 245)

Thoracic aorta; Vasorelaxation; Norepinephrine; cGMP; Ca^{2+} channel blocker (Cheng, Y.-W. (336) 23)

Adenosine receptor; Phorbol ester; Protein kinase C; SH-SY5Y neuroblastoma cell (Peterfreund, R.A. (336) 71)

Beraprost sodium; Mitogen-activated protein kinase phosphatase 1 (MKP-1); Mesangial cell (Togawa, M. (336) 291)

Phosphodiesterase; Rolipram; Cortical neuron (Yamashita, N. (337) 95)

Lipopolysaccharide; cGMP; Phosphodiesterase III inhibitor; Monocyte; Macrophage; Interleukin-10; TNF-α (tumor necrosis factor-α); Nitric oxide (NO) (Németh, Z.H. (339) 215)

cAMP accumulation
5-HT_{1A} receptor; Antipsychotic; HA7 cell; 5-HT (extracellular concentration); Microdialysis (Assié, M.-B. (334) 141)

Dopamine D_3 receptor; Receptor binding; G protein; Acidification rate; *Fos* protein immunoreactivity (Scheideler, M.A. (339) 261)

cAMP-dependent protein kinase
cGMP-dependent protein kinase; (Rp)-8-Bromo-guanosine-3′,5′-cyclic monophosphorothioate; (Rp)-Adenosine-3′,5′-cyclic monophosphorothioate; Ca^{2+} sensitivity; Smooth muscle, skinned, vascular (Kawada, T. (323) 75)

cAMP-elevating agent
TNF-α (tumor necrosis factor-α); Interleukin-10 (Siegmund, B. (321) 231)

Insulin; Hepatocyte DNA synthesis; Hepatocyte proliferation; β-Adrenoceptor agonist (Kimura, M. (327) 87)

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
Ethanol; Spinal cord; Glutamate; GABA (γ-aminobutyric acid); NMDA (*N*-methyl-D-aspartate); Anesthesia (Wong, S.M.E. (329) 121)

Pain; Analgesia; Calmodulin inhibitor; Spinal cord; NMDA (*N*-methyl-D-aspartate); Septide (Menéndez, L. (335) 9)

[^{3}H]AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
Autoradiography; [^{3}H]CNQX (6-cyano-7-nitro-quinoxaline-2,3-dione); Antipsychotic drug (McCoy, L. (318) 41)

AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid)
Antipsychotic; Behavior; Dopamine; Schizophrenia; (Mouse) (Vanover, K.E. (332) 115)

AMPA receptor
Thiocyanate; (*S*)-5-Fluorowillardiine; (*S*)-AMPA ((*S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid); (*R,S*)-AMPA ((*R,S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) (Hawkinson, J.E. (329) 213)

AMPA receptor antagonism; Neuroprotection; GYKI 53655; NBQX (6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione) (Kovács, A.D. (331) 93)

Excitatory amino acids; Glutamate; [^{3}H]D-Aspartate release; Autoreceptor (Patel, D.R. (332) 143)

Extracellular calcium; Glutamate; Inositol phosphate; Oligodendrocyte (Liu, H.-N. (338) 277)

AMPA receptor antagonism
AMPA receptor; Neuroprotection; GYKI 53655; NBQX (6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione) (Kovács, A.D. (331) 93)

Amphetamine
Polyamine; Putrescine; Spermidine; Spermine; NMDA (*N*-methyl-D-aspartate); Motor activity; MK-801; Theophylline; (Mouse) (Giménez-Llort, L. (318) 231)

Appetitive discrimination; Occasion setting; Midazolam; Unconditioned drug effect; Conditioned drug effect (Maes, J.H.R. (319) 5)

[D-Tyr^{11}]Neurotensin; Neurotensin; Sensitization (Rompré, P.-P. (328) 131)

Dynorphin; Substance P; Enkephalin; Acetylcholine; Dopamine; Nucleus accumbens; Caudoputamen; Behavior; Muscarinic receptor (Wang, J.Q. (334) 43)

Vesicular monoamine transporter type-2 (VMAT2); Dopamine transporter, neuronal membrane; Methamphetamine; Dihydrotetrabenazine; WIN 35,428; Dopamine (Frey, K. (334) 273)

Dopamine; Stratium, ventral; Stress; Microdialysis; (Relapse) (Weiss, F. (337) 219)

Amphetamine, repeated
Microdialysis; Chronic transversal; Ventral striatum; Dopamine release; Dopamine synthesis; Behavioral sensitization (Imperato, A. (317) 231)

D-Amphetamine
Dopamine D_3 receptor; Drug discrimination; 7-OH-DPAT (7-hydroxy-2-(di-*N*-propylamino)-tetralin); (Rat) (Varty, G.B. (339) 101)

Amphetamine administration, chronic
Deoxyglucose; Sensitization; SKF 38393; Quinpirole (Huang, Y.-H. (338) 117)

Amphibian
Opioid analgesia; Acetic acid test; Intracerebroventricular (i.c.v.) administration; (*Rana pipiens*) (Stevens, C.W. (331) 15)

Amygdala
NMDA (*N*-methyl-D-aspartate); Kindling; Seizure; Epilepsy (Croucher, M.J. (319) 207)

2-Chloroadenosine; Electrical kindling; Seizure; Epileptogenesis; Adenosine A_1 receptor, pre-synaptic (Abdul-Ghani, A.-S. (326) 7)

AV3V region; Cholinergic hypertension; Carbachol; Blood pressure; Heart rate (Tellioğlu, T. (336) 163)

Amygdala, central
Immediate-early gene; Bed nucleus of the stria terminalis; Paraventricular nucleus of the hypothalamus; Corticosterone; CRH (corticotropin-releasing hormone) (Compaan, J.C. (324) 161)

Amygdala, central nucleus of
Muscarinic M_1 receptor; Carbachol; Blood pressure; (Rat) (Aslan, N. (333) 63)

Amygdala-kindling
BW1003C87; Phenytoin; Carbamazopine; Anticonvulsant effects; Seizure threshold (Morimoto, K. (339) 11)

Amylase secretion
K^+ channel; Parotid acini; Isoprenaline (Murayama, T. (322) 21)

Amylin
CGRP (calcitonin gene-related peptide); Hepatocyte; Glucose metabolism; Macrophage; Kupffer cell (Pittner, R.A. (325) 189)

Adrenomedullin; CGRP (calcitonin gene-related peptide); CGRP-(8–37); Cerebral arteriole; Cerebral microcirculation (Mori, Y. (330) 195)

Ulcer; CGRP (calcitonin gene-related peptide), human; Capsaicin; Domperidone; Neostigmine (Clementi, G. (332) 209)

Adrenomedullin; α-Calcitonin gene-related peptide; Gastric acid; (*N*-terminal cyclic octa-peptides); (C-terminal fragments); (Chronic fistulae equipped rat); (Rat); (Human) (Rossowski, W.J. (336) 51)

β-Amyloid peptide-(25–35)
Amyloid-type amnesia; Water-maze test (Delobette, S. (319) 1)

Amyloid-type amnesia
β-Amyloid peptide-(25–35); Water-maze test (Delobette, S. (319) 1)

Analgesia
Morphine; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Dynorphin; Nor-binaltorphimine; β-Funaltrexamine; DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly-ol^5]enkephalin) (Reche, I. (318) 11)

μ-Opioid receptor; Downregulation; Tolerance; Fentanyl; Clocinnamox; DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin) (Chan, K.W. (319) 225)

Morphine derivative; Cinnamoylamino group; β-Endorphin receptor; (Irreversible antagonist); (Mouse) (McLaughlin, J.P. (320) 121)

Epibatidine; Epiboxidine; ABT 418; Nicotinic receptor (Badio, B. (321) 189)

Pain; Opioid; Opioid receptor, peripheral; Stress (Schäfer, M. (323) 1)

Diclofenac; Substance P (Papworth, J. (325) R1)

Antisense oligonucleotide; K^+ channel; mKv1.1; Antinociception; Clomipramine; Amitriptyline; Tricyclic antidepressant; (Mouse) (Galeotti, N. (330) 15)

Agmatine; α_2-Adrenoceptor; μ-Opioid receptor; Fentanyl; Spinal cord (Bradley, K.J. (331) 133)

Opioid; σ Receptor (King, M. (331) R5)

Endopeptidase 3.4.24.15; Phosphinic inhibitor; Neurotensin; (Mouse) (Vincent, B. (334) 49)

Pain; C-fiber reflex; Clomipramine; Desipramine; Tricyclic antidepressant (Mestre, C. (335) 1)

Pain; Calmodulin inhibitor; Spinal cord; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Septide (Menéndez, L. (335) 9)

GYKI 52466; GYKI 53773; GYKI 53784; 2,3-Benzodiazepine; Anti-inflammatory drugs (Székely, J.I. (336) 143)

Morphine; Clocinnamox; [^{3}H]DAMGO ([^{3}H][D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]-enkephalin); Opioid receptor binding; (Rat) (Paronis, C.A. (337) 27)

μ-Opioid receptor; Regulation of mRNA; Etorphine; Receptor downregulation; Tolerance (Sehba, F. (339) 33)

Anandamide
Palmitoylethanolamide; Tetrahydrocannabinol; Cannabinoid receptors; Cytokines; Mononuclear cells; Immune response (Berdyshev, E.V. (330) 231)

Endothelium; EDHF (endothelium-derived hyperpolarizing factor); K^+ channel; Cytochrome *P*-450 inhibitor; Cannabinoid (Randall, M.D. (333) 191)

Endothelium; EDHF (endothelium-derived hyperpolarizing factor); SR141716A; Heart, rat; Cannabinoids (endocannabinoids), endogenous (Randall, M.D. (335) 205)

Cannabinoid; Vasculature (Calignano, A. (337) R1)

Anaphylaxis
Edema; α-Trinositol; Capillary permeability; Trachea; Skin (rat); Connective tissue; Inflammation (Koller, M.-E. (331) 259)

Ancrod
MRI (magnetic resonance imaging); Cerebral ischemia; Hypertensive rat; Fibrinogen; Middle cerebral artery occlusion; Therapeutic window; (Delayed therapy) (Elger, B. (336) 7)

Androstenedione
Steroid hormones; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Steroid biogenesis; Pregnenolone; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Anesthesia
Ethanol; Spinal cord; Glutamate; GABA (γ-aminobutyric acid); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); NMDA (*N*-methyl-D-aspartate) (Wong, S.M.E. (329) 121)

Anesthetic potency
Ethanol; Acetate; Adenosine (Campisi, P. (325) 165)

Anesthetized rat
Reperfusion arrhythmia; Pinacidil; Cromakalim; Glibenclamide (Baczkó, I. (324) 77)

Anethole dithiolethione
Glutathione; Hydrogen peroxide; Oxidative stress; Astrocyte; Neurodegeneration (Drukarch, B. (329) 259)

Angiogenesis, embryonic
Wortmannin; Phosphatidylinositol 3-kinase inhibitor; Anti-angiogenic activity; Chorioallantoic membrane (Oikawa, T. (318) 93)

Angioplasty
Tranilast; Muscle contraction; Restenosis (Ihara, T. (329) 43)

Angiotensin
Heart rate; Arterial pressure; Spinal cord; Cardiovascular control; Losartan; PD 123319 (Park, P.D.S. (326) 139)

Dorsal lateral geniculate nucleus; NMDA (*N*-methyl-D-aspartate); Kainate; Bicuculline; CGP 35348; Urethane; Unit activity; (Rat) (Albrecht, D. (332) 53)

Angiotensin AT_1 receptor
Angiotensin II; Binding; Losartan; Aorta, rabbit; UR-7280 (De Arriba, A.F. (318) 341)

Candesartan (CV-11974); [^{3}H]CV-11974; Losartan; Association rate constant; Dissociation rate constant (Ojima, M. (319) 137)

Angiotensin II; Contractile function; Cardiomyocyte, isolated; Transgenic rat (Rosenkranz, S. (330) 35)

Angiotensin AT_2 receptor; Losartan; PD-123319; Uterine artery; Pregnancy; (Sheep) (Burrell, J.H. (330) 257)

Angiotensin AT_2 receptor
Angiotensin AT_1 receptor; Losartan; PD-123319; Uterine artery; Pregnancy; (Sheep) (Burrell, J.H. (330) 257)

Angiotensin AT_1 receptor antagonist
Spontaneously hypertensive rat (SHR); Glucose tolerance; Blood pressure; Angiotensin-converting enzyme inhibitor; Valsartan (Chow, L. (319) 77)

Angiotensin II; YM358; Losartan (Shibasaki, M. (335) 167)

Angiotensin AT_1 receptor antagonists, non-peptide
Renovascular hypertension; Renal failure, acute; Angiotensin converting enzyme inhibition; Na^+ depletion (Abdi, A. (331) 185)

Angiotensin-converting enzyme
Imidapril; Enalapril; Captopril; Ozone; Airway hyperresponsiveness (Matsubara, S. (337) 259)

Angiotensin-converting enzyme inhibitor
Spontaneously hypertensive rat (SHR); Glucose tolerance; Blood pressure; Angiotensin AT_1 receptor antagonist; Valsartan (Chow, L. (319) 77)

TGF-β1 (transforming growth factor-β1); Extracellular matrix; Glomerulosclerosis; Gene expression (Hamaguchi, A. (331) 27)

Angiotensin converting enzyme inhibition
Renovascular hypertension; Renal failure, acute; Na^+ depletion; Angiotensin AT_1 receptor antagonists, non-peptide (Abdi, A. (331) 185)

Angiotensin II
Angiotensin AT_1 receptor; Binding; Losartan; Aorta, rabbit; UR-7280 (De Arriba, A.F. (318) 341)

EDRF (endothelium-derived relaxing factor); Prostanoid; Mesenteric artery; Mesenteric vein; Aging; Development (Konishi, C. (320) 175)

YM435; Dopamine D_1 receptor agonist; Renal vasodilator; Renal nerve stimulation; PAF (platelet-activating factor) (Yatsu, T. (322) 45)

Norepinephrine; NOC 7 (1-hydroxy-2-oxo-3-(*N*-methyl-3-aminopropyl)-3-methyl 1-triazene); Nitric oxide (NO); Kidney; (Rabbit) (Adachi, Y. (324) 223)

Angiotensin AT_1 receptor; Contractile function; Cardiomyocyte, isolated; Transgenic rat (Rosenkranz, S. (330) 35)

5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists; Renal blood flow; Kidney, autoperfused, rat (Morán, A. (330) 205)

Enalapril; L-nitro-arginine methyl ester (L-NAME); Nitric oxide (NO); Stroke (Ahmad, S. (333) 39)

Hexarelin; GH (growth hormone)-deficiency; Ischemia-reperfusion; Heart, rat; 6-keto-prostaglandin $F_{1\alpha}$ (De Gennaro Colonna, V. (334) 201)

Angiotensin AT_1 receptor antagonist; YM358; Losartan (Shibasaki, M. (335) 167)

Kidney; CNP (C-type natriuretic peptide); Norepinephrine; Vasoconstriction; (Dog) (Yoshida, K. (338) 131)

Angiotensin II-converting enzyme inhibitor
Mesangial cell; Proliferation; Captopril; Tyrosine phosphorylation; $pp60^{c\text{-}src}$ (Ruiz-Ginés, J.A. (336) 251)

Angiotensin II receptor antagonist
Antihypertensive activity; YM358 (Shibasaki, M. (335) 175)

Anococcygeus muscle
Drenergic transmission; Neuropeptide Y; NANC (non-adrenergic non-cholinergic) transmission (Iravani, M.M. (338) 75)

Anococcygeus muscle, rat
Aldose reductase; Diabetes; Nitrergic neurotransmission; Nitric oxide (NO); Sorbinil (Way, K.J. (318) 101)

Anorexia
Nicotine; Dopamine receptor agonist; Adrenoceptor antagonist; Acetylcholine receptor antagonist; 5-HT receptor antagonist; (Rat) (Zarrindast, M.-R. (321) 157)

ANP (atrial natriuretic peptide)
Ethanol; CNP (C-type natriuretic peptide); Hypertension (Guillaume, P. (319) 215)

Oxidative burst; Fluorescent latex bead; Dihydrorhodamine-123; Immune function; Flow cytometry (Vollmar, A.M. (319) 279)

CNP (C-type natriuretic peptide); BNP (brain natriuretic peptide); Cerebral arteriole (Mori, Y. (320) 183)

ANP (atrial natriuretic polypeptide)
VIP (vasoactive intestinal polypeptide); K^+ channel; Levcromakalim; Ca^{2+} channel blocker; Isradipine; Trachea; Smooth muscle, airway (Thirstrup, S. (319) 253)

Antagonism, pseudo-irreversible
Tachykinin NK_1 receptor antagonist (Cascieri, M.A. (325) 253)

Antagonist potency
α_2-Adrenoceptor subtype; CHO cell; GTPase (Virolainen, S. (338) 293)

Antazoline
Imidazoline; Insulin secretion; Somatostatin secretion; Glucose tolerance; Pancreas; (Rat); (Dog) (Berdeu, D. (324) 233)

Anthraquinone
Intestinal secretion; Nitric oxide (NO); Glucocorticoid; Laxative; Natural drug (Izzo, A.A. (323) 93)

Antiallergic effect
Phosphodiesterase I/IV inhibitor; Phosphodiesterase III inhibitor; Bronchodilator effect; (Guinea pig) (Fujimura, M. (327) 57)

Anti-angiogenic activity
Wortmannin; Phosphatidylinositol 3-kinase inhibitor; Angiogenesis, embryonic; Chorioallantoic membrane (Oikawa, T. (318) 93)

Antiarrhythmic agent
Sematilide; Atrium, rabbit; Membrane current (Ishii, Y. (331) 295)

Antiarrhythmic drug
TJN-505; Aconitine; Arrhythmia model, canine (Arita, J. (318) 333)

Antiarrhythmic peptide
Arrhythmia; Gap junction; Electrophysiology (Müller, A. (327) 65)

Antibiotics
Polymorphonuclear leukocyte; Respiratory burst; Phagocytosis (Hoeben, D. (332) 289)

Antibody
Muscarinic M_2 receptor; Peptide; Inotropic effect; Papillary muscle (Skomedal, T. (333) 169)

β_1-Adrenoceptor; β_2-Adrenoceptor; Fusion protein (Jahns, R. (334) 115)

Anticonvulsant
Excitatory amino acid; Anxiolytic; Dopamine; Psychosis (Baron, B.M. (323) 181)

σ Receptor; 2(*3H*)-Benzoxazolone; 2(*3H*)-Benzothiazolone; [^{3}H](+)-Pentazocine (Ucar, H. (335) 267)

Anticonvulsant action
GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzo-diazepine); Excitatory amino acid; Motor system; Flumazenil (Kubová, H. (333) 17)

Anticonvulsant effects
BW1003C87; Phenytoin; Carbamazopine; Amygdala-kindling; Seizure threshold (Morimoto, K. (339) 11)

Antidepressant
Forced swimming test; 5-HT_{1A} receptor; 5-HT_{1B} receptor (Redrobe, J.P. (318) 213)

Inflammation; Chemotaxis; Macrophage (Sacerdote, P. (319) 287)

5-HT_{2C} receptor; Fluoxetine (Millan, M.J. (321) R10)

Phencyclidine; Schizophrenia, negative symptom; Depression; 5-HT (5-hydroxytryptamine, serotonin); Forced swimming test; (Mouse) (Noda, Y. (324) 135)

Forced swimming test; 5-HT_2 receptor; 5-HT_3 receptor (Redrobe, J.P. (325) 129)

YM992; 5-HT (5-hydroxytryptamine, serotonin) re-uptake inhibition; 5-HT_{2A} receptor antagonistic activity; Tail suspension test; Olfactory bulbectomized rat (Takeuchi, H. (329) 27)

Desipramine; Microtubule-associated protein 2; Microtubule assembly; Phosphorylation (Miyamoto, S. (333) 279)

Forced swimming; Learned helplessness; $GABA_B$ receptor (Shimidzu, T. (338) 225)

Antidepressant drug
Dopamine receptor; Mesolimbic dopamine system; Fluoxetine; Chronic treatment (Collu, M. (322) 123)

Anti-emetic
Cisplatin; Ondansetron; Dexamethasone; (Acute and delayed) (Rudd, J.A. (322) 79)

Brain penetration (Rupniak, N.M.J. (326) 201)

Antiemetic effect
N-3389; 5-HT_3 receptor antagonist; 5-HT_4 receptor antagonist; Abdominal afferent vagus nerve activity; (Ferret) (Minami, M. (321) 333)

Antiepileptic
Dihydropyridine; Dantrolene; Electroshock, maximal; Seizure (Borowicz, K.K. (323) 45)

Membrane potential; Cromakalim; Glibenclamide; Patch-clamp electrophysiology; NG 108-15 cell; hNT neuron; Cortical neuron, mouse (Rundfeldt, C. (336) 243)

NMDA receptor; Non-NMDA receptor; Cortical wedge (Phillips, I. (337) 189)

Antiepileptic drug
Levetiracetam; GABA (γ-aminobutyric acid); Epilepsy (Sills, G.J. (325) 35)

APNEA (N^6-2-(4-aminophenyl)ethyl-adenosine); Adenosine receptor; Adenosine A_3 receptor; Maximal electroshock; Seizure (Borowicz, K.K. (327) 125)

Nitric oxide (NO); 7-Nitroindazole; Seizure (Borowicz, K.K. (331) 127)

Antihemophilic factor
Vasopressin; Oxytocin; Factor VIII (F-VIII); Blood clotting; Plasminogen activator; Neurohypophyseal hormone analog; Dose–response analysis; Time response; Non-monotonic profile (Neuenschwander, S. (323) 205)

Antihistaminic agent
Terfenadine; Ebastine; Carebastine; K^+ current; hKv1.5 channel (Valenzuela, C. (326) 257)

Antihypertensive activity
Angiotensin II receptor antagonist; YM358 (Shibasaki, M. (335) 175)

Anti-inflammatory drug
Neutrophil; NADPH oxidase; Phenylarsine oxide; Inflammation; NADPH oxidase inhibitor (Roussin, A. (322) 91)

Bradykinin; Pleurisy; Bradykinin receptor antagonist; Inflammatory mediator (Saleh, T.S.F. (331) 43)

GYKI 52466; GYKI 53773; GYKI 53784; 2,3-Benzodiazepine; Analgesia (Székely, J.I. (336) 143)

Antinociception
Mitragynine; Noradrenergic system; α_2-Adrenoceptor; Serotonergic system; (Mouse) (Matsumoto, K. (317) 75)

(−)-TAN-67; (+)-TAN-67; δ-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben, diabetes (Kamei, J. (322) 27)

Nicotine; Ca^{2+}; Ca^{2+} channel; Tolerance; Thapsigargin; (Intrathecal) (Damaj, M.I. (322) 129)

Opioid; Nor-binaltorphimine; κ-Opioid receptor; Dorsal horn; Tachykinin; Nociception; Pain (Zachariou, V. (323) 159)

Neuropathic pain; Allodynia; Tail-flick test; Behavior; Electroshock test, maximal; Lamotrigine; Felbamate; Gabapentin (Hunter, J.C. (324) 153)

Mononeuropathic rat; CCK_B receptor antagonist; L-365,260; Morphine; Naloxone; Vocalization threshold; Struggle latency (Idänpään-Heikkilä, J.J. (325) 155)

Antisense oligonucleotide; K^+ channel; mKv1.1; Analgesia; Clomipramine; Amitriptyline; Tricyclic antidepressant; (Mouse) (Galeotti, N. (330) 15)

Formalin test; Mazindol; Lidocaine; Dopamine; Opioid (Bittencourt, A.L. (330) 109)

α_2-Adrenoceptor; Nitric oxide (NO); Opiate receptor; Periaqueductal gray (Fang, F. (336) 137)

Aconitum alkaloid; Na^+ channel; Toxicity (Friese, J. (337) 165)

Matrine; κ-Opioid receptor; Pentazocine; Nor-binaltorphimine; (Mouse) (Kamei, J. (337) 223)

Dihydroetorphine; Etorphine; Physical dependence; (Rhesus monkey); (Mouse) (Aceto, M.D. (338) 215)

DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); Diabetes; Protein kinase C; Calphostin C; (Mouse) (Ohsawa, M. (339) 27)

Ileus; Gastrointestinal transit; Opioid; κ-Opioid receptor (De Winter, B.Y. (339) 63)

Antioxidant
Endotoxin; DNA fragmentation (Haendeler, J. (317) 407)

Antiparkinsonian potential activity
Pramipexole; Dopamine receptor agonist; Antipsychotic potential activity (Maj, J. (324) 31)

Anti-pollakiuric agent
P-4 (1-methyl-4-piperidyl diphenylpropoxyacetate hydrochloride); Urinary bladder; Smooth muscle; Actomyosin ATPase activity; Calmodulin (Matsushima, S. (333) 93)

Antipsychotic
Dopamine D_3 receptor; Catalepsy (Millan, M.J. (321) R7)

Substantia nigra reticulata; Schizophrenia; Basal ganglion; Electrophysiology; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Bruggeman, R. (324) 49)

AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid); Behavior; Dopamine; Schizophrenia; (Mouse) (Vanover, K.E. (332) 115)

$5\text{-}HT_{1A}$ receptor; cAMP accumulation; HA7 cell; 5-HT (extracellular concentration); Microdialysis (Assié, M.-B. (334) 141)

Adrenoceptor subtype; Small artery (Ipsen, M. (336) 29)

Antipsychotic agent
Dopamine receptor; 5-HT receptor; Schizophrenia; Psychotic disorder (Kongsamut, S. (317) 417)

Antipsychotic drug
Autoradiography; [^{3}H]AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); [^{3}H]CNQX (6-cyano-7-nitro-quinoxaline-2,3-dione) (McCoy, L. (318) 41)

Aripiprazole; Dopamine receptor; Striatum, rat; Ribonuclease protection assay (Inoue, A. (321) 105)

Homophthalazine; 2,3-benzodiazepine; Anxiolytic drug; c-*fos* expression; Striatum (Palkovits, M. (331) 53)

Antipsychotic drug, atypical
Up-regulation; Dopamine D_2 receptor; $5\text{-}HT_{2A}$ receptor; Striatum (Ishikane, T. (321) 163)

Antipsychotic potential activity
Pramipexole; Dopamine receptor agonist; Antiparkinsonian potential activity (Maj, J. (324) 31)

Antipyretic action
Nimesulide; Cyclooxygenase-2; Hypothalamus; Yeast-induced hyperthermia; RT-PCR (reverse transcription and polymerase chain reaction) (Taniguchi, Y. (330) 221)

Antisense oligodeoxynucleotide
Adenosine receptor; Motor coordination (Phan, T.A. (323) R5)

c-*fos*; Formalin test; Hyperalgesia; Nociception; (Intrathecal) (Hou, W.-Y. (329) 17)

Antisense oligodeoxyribonucleotide
K^+ channel; Food intake; K^+ channel opener; K^+ channel antagonist (Ghelardini, C. (329) 1)

Antisense oligonucleotide
K^+ channel; mKv1.1; Analgesia; Antinociception; Clomipramine; Amitriptyline; Tricyclic antidepressant; (Mouse) (Galeotti, N. (330) 15)

Neuropeptide Y Y_1 receptor; Binding; Gene expression; Electroporation (Hänze, J. (330) 87)

Antisense targeting
Oligodeoxynucleotides; Sickness behavior; Interleukin 6; Radiotelemetry; (Rat) (Schöbitz, B. (331) 97)

Antithrombotic effect
YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole); Tail bleeding time; Platelet aggregation; Profibrinolytic effect (Teng, C.-M. (320) 161)

Anti-Thy1 nephritis
Cytokine; OPC15161; Matrix index; Superoxide radical; Tubulointerstitial index (Hamada, N. (317) 123)

Anti-TNF strategy
Pentoxifylline; TNF-α (tumor necrosis factor-α); Lipopolysaccharide; Fever; TNF bioassay; Radiotelemetry; (Guinea pig) (Goldbach, J.-M. (319) 273)

Anti-tremor effect
Talipexole; Bromocriptine; Dopamine D_2 receptor agonist; Ventromedial tegmentum lesion; Parkinson's disease; (Cynomolgus monkey) (Kohno, Y. (319) 197)

Anxiety
Acoustic startle response; AP-5; Caudal pontine reticular formation; Fear; Glutamate receptor (Fendt, M. (318) 1)

Nitric oxide (NO); Plus maze, elevated; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Arterial blood pressure; Nitric oxide (NO) synthase; Brain (Faria, M.S. (323) 37)

Conflict; Neurosteroid; 3α-Hydroxy-5α-pregnan-20-one; $GABA_A$ receptor; Benzodiazepine (Brot, M.D. (325) 1)

$5\text{-}HT_{1A}$ receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Flesinoxan; WAY-100635; Geller-Seifter, conflict; (Rat) (King, C.M.F. (325) 121)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); SR 46349B; $5\text{-}HT_{2A}$ receptor; Elevated plus-maze; [^{3}H]Ketanserin binding; RHA and RLA (Roman high- and low-avoidance) rats (Chaouloff, F. (334) 25)

Elevated plus-maze; Clozapine; L-745,870; L-741,742; Dopamine D_4 receptor; Chlordiazepoxide; Mouse (Cao, B.-J. (335) 117)

Locomotion; Novelty; Fear (Gendreau, P.L. (337) 147)

Anxiolysis
Benzodiazepine receptor, central; Flavonoid; Autoradiography; (Partial agonist) (Wolfman, C. (318) 23)

Anxiolytic
5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; WAY-100635; *p*-Chlorophenylalanine; Hippocampus; Excitatory synaptic transmission; $5\text{-}HT_{1A}$ receptor; Excitatory postsynaptic potential; Ultrasonic vocalization (Xu, L. (323) 59)

Excitatory amino acid; Anticonvulsant; Dopamine; Psychosis (Baron, B.M. (323) 181)

Opioid; Signal transduction; Dopamine receptor antagonist; Benzodiazepine; Homophtalazine (2,3-benzodiazepine) (Fekete, M.I.K. (331) 175)

Anxiolytic drug
Homophthalazine; 2,3-benzodiazepine; Antipsychotic drug; c-*fos* expression; Striatum (Palkovits, M. (331) 53)

Aorta
Diabetes; 5-HT (5-hydroxytryptamine); Protein kinase C; Endothelin-1 (James, G.M. (322) 55)

Aortic barodenervation; α_1-Adrenoceptor; Sympathetic activity; Receptor desensitization (El-Mas, M.M. (322) 201)

Chloroethylclonidine; Prazosin; Spleen; Submandibular gland; α_1-Adrenoceptor; α_2-Adrenoceptor; (Rat) (O'Rourke, M. (336) 37)

Aorta, rabbit
Angiotensin AT_1 receptor; Angiotensin II; Binding; Losartan; UR-7280 (De Arriba, A.F. (318) 341)

Aorta, rat
cGMP; Relaxation; Nitric oxide (NO) synthase (Takizawa, S. (330) 143)

Lipopolysaccharide; Nitric oxide (NO) synthase, inducible; Genistein; Tyrphostin; Orthovanadate; Phenylarsine oxide (Duarte, J. (338) 25)

Aortic barodenervation
α_1-Adrenoceptor; Aorta; Sympathetic activity; Receptor desensitization (El-Mas, M.M. (322) 201)

α_1-Adrenoceptor; Endothelium; Nitric oxide (NO) (El-Mas, M.M. (337) 235)

Aortic ring, rat
Isoproterenol; β_1-Adrenoceptor; β_2-Adrenoceptor; Endothelium; Relaxation; Cytochrome P450 (Satake, N. (319) 37)

AP-5
Acoustic startle response; Anxiety; Caudal pontine reticular formation; Fear; Glutamate receptor (Fendt, M. (318) 1)

Apafant (WEB 2086 BS)
Airway response, early; Airway response, late (Ikegami, K. (328) 75)

Apamin
Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Charybdotoxin; Splanchnic nerve stimulation; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Endothelium; Nitric oxide (NO); Coronary small artery; Acetylcholine; A23187; K^+ channel (Simonsen, U. (329) 153)

Smooth muscle; K^+ channels; Ca^{2+} stores; Charybdotoxin; Pacemaker cells (Duridanova, D.B. (333) 105)

PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal peptide); PACAP receptor; VIP receptor; Neuropeptide Y; Motor effect; Gastro-intestinal tract (Ekblad, E. (334) 61)

Colon; DMPP (1,1-dimethyl-4-phenylpiperazinium iodide); Nitric oxide (NO); P_{2y} purinoceptor; Reactive blue 2; (Rat) (Börjesson, L. (334) 223)

AP5 (D-2-amino-5-phosphonopentanoic acid)
DCG-IV; Metabotropic glutamate receptor; NMDA receptor (Breakwell, N.A. (322) 173)

APNEA (N^6-2-(4-aminophenyl)ethyl-adenosine)
Adenosine receptor; Adenosine A_3 receptor; Maximal electroshock; Antiepileptic drug; Seizure (Borowicz, K.K. (327) 125)

(−)-Apomorphine
Haloperidol; (+)-AJ76; (+)-UH-232; (+)-PD 128907; Discriminative stimulus effect; Dopamine D_3 receptor (Kleven, M.S. (321) 1)

Apomorphine
Enantiomer; Biodistribution; Uptake, stereoselective, active (Sam, E. (329) 9)

Tenascin; Knockout mouse; Dopamine receptor (Fukamauchi, F. (338) 7)

Apoptosis
Nitric oxide (NO); Nitric oxide (NO) donor; Mesangial cell; Glomerular endothelial cell; Glomerular epithelial cell; Interleukin-1 (Mühl, H. (317) 137)

Flupirtine; Triamnopyridine; hNT neuron; Bcl-2; Neuroprotection; Glutathione (Perovic, S. (317) 157)

Hydrogen peroxide; L-Histidine; DNA double-strand breaks; Pulsed field gel electrophoresis; Necrosis (Palomba, L. (318) 167)

Vitamin D; Glioma; Noradrenaline (Canova, C. (319) 365)

Imidazo[1,2-*a*]pyrazine derivative; Megakaryoblastic cell, human; Phosphodiesterase; cAMP; Purinoceptor (Zurbonsen, K. (320) 215)

DNA fragmentation; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Nicotinamide (Mukherjee, S.K. (330) 27)

Cyclosporin A; Cyclosporin H; FK506; Eosinophil (Kitagaki, K. (337) 283)

Nitric oxide; Smooth muscle cell; Protein kinase C; Protein kinase A (Nishio, E. (339) 245)

Appetitive discrimination
Occasion setting; Midazolam; Amphetamine; Unconditioned drug effect; Conditioned drug effect (Maes, J.H.R. (319) 5)

Arachidonic acid
Tracheal epithelial cell, guinea pig; Eosinophil; Neutrophil (Prié, S. (317) 343)

CRF (corticotropin-releasing factor); Inflammation; Histamine (Correa, S.G. (319) 85)

Bradykinin; Thromboxane; Arterial ring, mesenteric; Smooth muscle, vascular (Weinberg, M.L.D. (320) 145)

Thrombin receptor; Adenosine A_1 receptor; P_{2U} purinoceptor; Inositol phosphate; CHO (Chinese hamster ovary) cell; Protein kinase C (Dickenson, J.M. (321) 77)

Lipopolysaccharide; Phospholipase A_2; Protein kinase; UTP; RAW 264.7 macrophage (Lin, W.W. (321) 121)

Dopamine transporter; WIN 35,428 binding; Protein kinase C; Parkinson's disease; Drug abuse (Reith, M.E.A. (324) 1)

Opioid; Withdrawal; Ileum (Capasso, A. (330) 199)

ARC 239 (2-[2-[4-(*o*-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethyl-1,3(2H,4H)-isoquinolinedione)
Locus coeruleus; α_{2A}-Adrenoceptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); Chlorpromazine (Ruiz-Ortega, J.A. (333) 159)

Arcuate nucleus
Δ^9-Tetrahydrocannabinol; Opioid; Proopiomelanocortin; mRNA (Corchero, J. (323) 193)

Arecoline
Talsaclidine; McN-A-343; Noradrenaline; Bronchospasm; Guinea pig (Walland, A. (330) 213)

Argatroban
YM-60828; Heparin; Dalteparin; Arterio–venous shunt; Bleeding time (Sato, K. (339) 141)

Arginase
L-Arginine; L-Citrulline; Nitric oxide (NO) synthase; Prostate; (Pig); (Rabbit); (Rat) (Di Iulio, J.L. (337) 245)

Arginine
Endothelium; Nitric oxide (NO); Diabetes mellitus (Pieper, G.M. (317) 317)

D-Arginine
α-Naphthylthiourea; Nitric oxide (NO); L-Arginine; N^G-Nitro-L-arginine methyl ester; Pulmonary oedema (Sipahi (Yılmaz), E. (321) 45)

L-Arginine
Coronary microvessel; Acetylcholine; Nitroglycerin; Heart failure; Nitric oxide (NO) (Larosa, G. (318) 387)

α-Naphthylthiourea; Nitric oxide (NO); D-Arginine; N^G-Nitro-L-arginine methyl ester; Pulmonary oedema (Sipahi (Yılmaz), E. (321) 45)

N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Superior colliculus; Blood pressure (D'Amico, M. (328) 65)

Pentadecapeptide BPC 157; Peptide BPC; Nitric oxide (NO); Gastrointestinal mucosal integrity; Blood pressure maintenance; Gastric lesion; Hypotension; N^G-Nitro-L-arginine methylester; Stomach mucosa (Slobodnjak, Z. (332) 23)

Vas deferens, rat; Nitric oxide (NO); Sodium nitroprusside; *N*-nitro-L-arginine methyl ester (L-NAME); (Neurotransmission) (Ventura, S. (334) 87)

Arginase; L-Citrulline; Nitric oxide (NO) synthase; Prostate; (Pig); (Rabbit); (Rat) (Di Iulio, J.L. (337) 245)

L-Arginine (L-Arg)
Myocardial ischemia; Nicotine; N^G-Nitro-L-arginine (LNNA) (Koley, J. (325) 181)

Aripiprazole
Antipsychotic drug; Dopamine receptor; Striatum, rat; Ribonuclease protection assay (Inoue, A. (321) 105)

ARL 67156
ATP; Ecto-ATPase; Purinergic; Urinary bladder (Westfall, T.D. (329) 169)

Aromatic L-amino acid decarboxylase
Tyrosine hydroxylase; Dopamine receptor; Striatum; Midbrain (Cho, S. (323) 149)

Arrhythmia
Gap junction; Electrophysiology; Antiarrhythmic peptide (Müller, A. (327) 65)

Ischaemia; K^+ channel activator; Levcromakalim; Reperfusion (Vegh, A. (333) 33)

Acetylsalicylic acid; Cardiac ischemia; Cardiac reperfusion; Electrophysiology; Electrocardiology; Epicardial mapping (Dhein, S. (339) 129)

Arrhythmia ischemia
HOE642; Na^+/H^+ exchange; Na^+/Ca^{2+} exchange; Arrhythmia reperfusion; Digitalis arrhythmia (Xue, Y.X. (317) 309)

Arrhythmia model, canine
TJN-505; Aconitine; Antiarrhythmic drug (Arita, J. (318) 333)

Arrhythmia reperfusion
HOE642; Na^+/H^+ exchange; Na^+/Ca^{2+} exchange; Arrhythmia ischemia; Digitalis arrhythmia (Xue, Y.X. (317) 309)

Arrhythmias
Cariporide (HOE642); Na^+–H^+ exchange; Ischemia; Reperfusion (Aye, N.N. (339) 121)

Arrhythmia, ventricular
Genistein; Preconditioning; Tyrosine kinase (Fatehi-Hassanabad, Z. (338) 67)

Arterial blood flow
Dura mater encephali; Neurogenic inflammation; 5-HT_1 receptor agonist; Migraine; Headache; (Rat) (Messlinger, K. (332) 173)

Arterial blood pressure
Nitric oxide (NO); Anxiety; Plus maze, elevated; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Nitric oxide (NO) synthase; Brain (Faria, M.S. (323) 37)

c-Fos; Cholinergic system, central; Neostigmine (Li, J. (337) 227)

Arterial injury
Thrombin receptor; In situ hybridization; Heparin (Guitteny, A.-F. (327) 157)

Arterial pressure
Angiotensin; Heart rate; Spinal cord; Cardiovascular control; Losartan; PD 123319 (Park, P.D.S. (326) 139)

Arterial resistance, systemic
Endothelin-1; Circulatory filling pressure, mean; Cardiac output; Venous resistance; Venous tone, body (Palacios, B. (327) 183)

Arterial ring, mesenteric
Bradykinin; Arachidonic acid; Thromboxane; Smooth muscle, vascular (Weinberg, M.L.D. (320) 145)

Arterial thrombosis
Cyclooxygenase; Thromboxane A_2; Platelet aggregation (Shimazawa, M. (328) 183)

Arterio–venous shunt
YM-60828; Argatroban; Heparin; Dalteparin; Bleeding time (Sato, K. (339) 141)

Artery
Sulfonylurea; Prostanoid; Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Tolazamide; Tolbutamide; Gliclazide; Glibenclamide; Bronchiole (Delaey, C. (325) 41)

Arthritis
Inflammation; Prostaglandin E_2; HOE-140; Des-Arg^9-bradykinin; (Rat) (Tonussi, C.R. (326) 61)

Aryldiazonium salt
Muscarinic receptor; Muscarinic receptor, m2 subtype; Sf9 cells; Covalent labelling (Weill, C. (333) 269)

Ascomycin
FK506-binding protein; Neurotransmitter release; Smooth muscle contraction; Tachykininergic nerve; Iris sphincter muscle, rabbit (Kageyama, M. (333) 223)

Aspartate
$GABA_B$ receptor; Microdialysis; Thalamus; Glutamate (Nyitrai, G. (318) 295)

Cocaine; Glutamate; Nucleus accumbens; Sensitization; (Rat) (Robinson, S.E. (319) 31)

[^{3}H]D-Aspartate release
Excitatory amino acids; AMPA receptor; Glutamate; Autoreceptor (Patel, D.R. (332) 143)

Association rate constant
Candesartan (CV-11974); [^{3}H]CV-11974; Losartan; Angiotensin AT_1 receptor; Dissociation rate constant (Ojima, M. (319) 137)

Astemizole
RBL-2H3; Membrane; Protein; Tyrosine; Phosphorylation; Ca^{2+}; Flux; Exocytosis (Fischer, M.J.E. (322) 97)

Asthma
Drug combination; Interaction; Smooth muscle, airway; Trachea; β_2-Adrenoceptor agonist; Methylxanthine; K^+ channel opener; Sodium nitroprusside; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

Eosinophil; Bronchodilator; Hyperreactivity; KF19514; Phosphodiesterase inhibitor (Manabe, H. (332) 97)

Steroid resistance; Corticosteroid; Cytokine; Mononuclear blood cell (Larsson, S. (334) 265)

Astrocyte
Excitotoxicity; Glycine site; NMDA receptor; Kynurenic acid; Neurodegenerative disorder; Quinolinic acid (Wu, H.-Q. (319) 13)

cGMP; Phosphodiesterase; Ca^{2+}; Granule cell (Agulló, L. (323) 119)

Anethole dithiolethione; Glutathione; Hydrogen peroxide; Oxidative stress; Neurodegeneration (Drukarch, B. (329) 259)

Astrocyte culture
Thrombin; Protease-activated receptor (Debeir, T. (323) 111)

Astrocytoma
Histamine; Histamine H_1 receptor; GABA (γ-aminobutyric acid); Glia; Ca^{2+} (Soria-Jasso, L.-E. (318) 185)

ATD (1,4,6-androstatriene-3,17-dione)
Sexual behavior; Ejaculation; Flesinoxan; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); (Wistar rat) (Haensel, S.M. (330) 1)

Atherosclerosis
Nitrite; Interleukin-1; Protein kinase C (Shimpo, M. (338) 97)

Atipamezole
α_2-Adrenoceptor; Pineal gland; Melatonin; Circadian rhythm; Medetomidine (Mustanoja, S.M. (326) 229)

Medetomidine; Dopamine overflow; Dopamine metabolisms; Voltammetry, in vivo; Mouse (Yavich, L. (339) 113)

ATP
UTP; Purinoceptor; Pyrimidinoceptor; Stomach, rat; Suramin (Otsuguro, K.-i. (317) 97)

Ca^{2+} release; Ca^{2+} entry; Endothelial cell; Thapsigargin (Oike, M. (319) 291)

Hepatic circulation; Vasodilatation; 8-Phenyltheophylline; Adenosine; (Rat) (Browse, D.J. (320) 139)

Purinoceptor P_{2X}; Ion channel; *Xenopus* oocyte; Site-directed mutagenesis (Nakazawa, K. (325) 101)

Purinoceptor P_{2X}; Trivalent cation; PC12 cell; *Xenopus* oocyte (Nakazawa, K. (325) 237)

Neurotransmission; Dopamine D_1 receptor; α_2-Adrenoceptor; Vas deferens, guinea-pig (Furukawa, T. (328) 229)

Ecto-ATPase; ARL 67156; Purinergic; Urinary bladder (Westfall, T.D. (329) 169)

α,β-methylene-ATP; Suramin; Nociception; Formalin test (Sawynok, J. (330) 115)

Diadenosine pentaphosphate; Diinosine pentaphosphate (Hoyle, C.H.V. (333) R1)

Coronary artery, canine; Vasoconstriction; Vasodilation; P2 purinoceptor; UTP; Suramin; Reactive blue 2 (Matsumoto, T. (334) 173)

Adenosine; Cholinergic; GABA (γ-aminobutyric acid); Nitric oxide (NO); Ileum; Terminal (Pencheva, N. (339) 193)

α,β-methylene-ATP
ATP; Suramin; Nociception; Formalin test (Sawynok, J. (330) 115)

ATP, extracellular
Histamine; $[Ca^{2+}]_i$; HL-60 cell (Song, S.-K. (322) 265)

Muscarinic acetylcholine receptor-operated K^+ current; Atrial cell; Purinoceptor; Action potential duration (Hara, Y. (324) 295)

ATP-sensitive K^+ channel
Y-26763; Myocardium, stunned; Ischemia; Reperfusion (Fukunari, A. (323) 197)

ATPase (Na^+, K^+)
Cardiac glycoside; α-Methyl-digitoxigenin-glucoside; Ouabain; Therapeutic index (Gleitz, J. (335) 89)

Atrial cell
ATP, extracellular; Muscarinic acetylcholine receptor-operated K^+ current; Purinoceptor; Action potential duration (Hara, Y. (324) 295)

Atrial fibrillation
K^+ current, muscarinic acetylcholine receptor-operated ($I_{K,ACh}$); Pirmenol; Disopyramide (Watanabe, Y. (338) 71)

Atrial muscle
α-Adrenoceptor, subtype; Papillary muscle; BMY 7378; Contractility; (Rat) (Wang, S.-N. (321) 39)

Atrial natriuretic factor
Cocaine; Molecular biology; Collagen; Myosin; Left ventricular hypertrophy; (Rat) (Besse, S. (338) 123)

Atrioventricular conduction
Autonomic nervous system; Sympathetic-parasympathetic interaction; Sinus rate; Aminophylline (Furukawa, Y. (334) 191)

PACAP (pituitary adenylate cyclase-activating polypeptide); Parasympathetic nerve; VIP (vasoactive intestinal peptide) (Hirose, M. (338) 35)

Atrium
5-HT_3 receptor; Tachycardia; Ethanol; Alcohol (Nishio, H. (321) 27)

Nociceptin; Capsaicin; Sensory nerve; Efferent function; (Guinea pig) (Giuliani, S. (332) 231)

Atrium, rabbit
Sematilide; Membrane current; Antiarrhythmic agent (Ishii, Y. (331) 295)

Atropine
Detrusor muscle, rat; Purinergic transmission; Cholinergic transmission; Cromakalim; Suramin; Nifedipine (Boselli, C. (335) 23)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; Muscarinic M_3 receptor; N^G-nitro-L-arginine methyl ester (L-NAME); N^G-nitro-L-arginine; Gallamine; Pirenzepine (Koss, M.C. (335) 199)

Attention
Choice reaction time; σ Receptor; Phencyclidine (Jin, J. (319) 147)

Audiogenic seizure
Adenosine analog; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

Auranofin
Prostaglandin E_2; 12-*O*-Tetradecanoylphorbol 13-acetate; Thapsigargin; A23187; Cyclooxygenase 2; Cyclooxygenase 1; Macrophage (Yamashita, M. (325) 221)

Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; Lipopolysaccharide; Aurothioglucose; Aurothiomalate; RAW 264.7 cell (Yamashita, M. (338) 151)

Auricular artery
Sympathetic nerve stimulation; Purinergic transmission; P_{2x} purinoceptor (Haniuda, K. (333) 163)

Aurothioglucose
Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; Lipopolysaccharide; Auranofin; Aurothiomalate; RAW 264.7 cell (Yamashita, M. (338) 151)

Aurothiomalate
Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; Lipopolysaccharide; Auranofin; Aurothioglucose; RAW 264.7 cell (Yamashita, M. (338) 151)

Autonomic nerves
Nitric oxide (NO); Enteric nervous system; Muscarinic receptor (Iversen, H.H. (331) 213)

Autonomic nervous system
Opioid; Immunity; Lymphocyte proliferation; Sympathetic division; Parasympathetic division; (Rat) (Flores, L.R. (318) 437)

Sympathetic-parasympathetic interaction; Sinus rate; Atrioventricular conduction; Aminophylline (Furukawa, Y. (334) 191)

Autoradiography
Benzodiazepine receptor, central; Anxiolysis; Flavonoid; (Partial agonist) (Wolfman, C. (318) 23)

[^{3}H]AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); [^{3}H]CNQX (6-cyano-7-nitro-quinoxaline-2,3-dione); Antipsychotic drug (McCoy, L. (318) 41)

Glycine receptor, strychnine-sensitive; [^{3}H]Strychnine binding; Spinal cord, rat; Thiocolchicoside; Myorelaxant agent (Cimino, M. (318) 201)

Neuropeptide Y; Neuropeptide Y-(2–36); SK-N-MC cell; SK-N-BE(2) cell (Schober, D.A. (318) 307)

Vasopressin V_2 receptor, human; Vasopressin receptor antagonist, iodinated (Ala, Y. (331) 285)

[^{125}I]*R*(+)-Zacopride; Radioligand binding; *R*(+)-site; Brain, rat; Peripheral tissue, rat (Ge, J. (332) 307)

Kidney; Dopamine; D_2-like receptor; Innervation; Radioligand binding assay; (Rat) (Barili, P. (334) 233)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Binding; Physicochemical parameter; [^{3}H]Alnespirone (Fabre, V. (337) 297)

Dopamine D_3 receptor; Kidney; Radioligand binding assay; Cortical tubule; Glomerulus (Barili, P. (338) 89)

Autoreceptor
Excitatory amino acids; AMPA receptor; Glutamate; [^{3}H]D-Aspartate release (Patel, D.R. (332) 143)

Autoreceptor antagonist
2-Deoxyglucose autoradiography; Microdialysis; Dopamine; Cocaine; Drug addiction (Koch, S. (319) 173)

AV3V region
Amygdala; Cholinergic hypertension; Carbachol; Blood pressure; Heart rate (Tellioğlu, T. (336) 163)

Baclofen
Melanotroph; $GABA_A$ receptor; Muscimol; $GABA_A$ receptor antagonist; Bicuculline; $GABA_B$ receptor; $GABA_B$ receptor antagonist; CGP 35348; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

$GABA_B$ receptor agonist; Thienyl baclofen analog; 2-Hydroxysaclofen; Neocortical slice, rat (Ong, J. (329) 133)

Baculovirus
Opioid receptor; 'High Five'; Sf9; Insect cell (Obermeier, H. (318) 161)

Balb/c mouse
Cocaine; Heroin; Self-administration, intravenous; Speedball; (Mouse) (Roberts, A.J. (326) 119)

Balloon injury
Tranilast; Hyperplasia, intimal; Cholesterol, high (Fukuyama, J. (318) 327)

Barakol
Cassia siamea; Striatum, rat; Dopamine release; Dopamine uptake, in vitro (Thongsaard, W. (319) 157)

Baroreflex
CCK (cholecystokinin); CCK_A receptor antagonist; Blood pressure; Heart rate; (Conscious rat) (Bunting, M.W. (337) 35)

Basal forebrain lesion
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Noradrenaline; EEG (electroencephalogram); Memory; Tetrahydroaminoacridine (Abe, K. (321) 149)

Alzheimer's disease; Acetylcholine; Cholinesterase inhibitor; Scopolamine; (Rat) (Itoh, A. (322) 11)

Basal ganglia
Succinate dehydrogenase, inhibition; Catecholamine; Toxicity; Energy metabolism (Zeevalk, G.D. (320) 111)

Heroin; Sensitization; Deoxyglucose; c-*fos* (Pontieri, F.E. (335) 133)

Basal ganglion
Substantia nigra reticulata; Antipsychotic; Schizophrenia; Electrophysiology; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Bruggeman, R. (324) 49)

BAY u9773
Cysteinyl-leukotriene receptor antagonist; Guinea pig; Ileum (Bäck, M. (317) 107)

BC 264
Cholecystokinin; CCK-8; CCK_B receptor antagonist; L-365,260; Devazepide; CCK_A receptor antagonist; Depression; Stress; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

Bcl-2
Flupirtine; Triamnopyridine; hNT neuron; Neuroprotection; Apoptosis; Glutathione (Perovic, S. (317) 157)

Bed nucleus of the stria terminalis
Immediate-early gene; Amygdala, central; Paraventricular nucleus of the hypothalamus; Corticosterone; CRH (corticotropin-releasing hormone) (Compaan, J.C. (324) 161)

Behavior
Body temperature; $5\text{-}HT_{1A}$ receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lower lip retraction; 5-HT (5-hydroxytryptamine, serotonin); Tail flick; (Intracerebroventricular administration) (Bagdy, G. (323) 53)

Neuropathic pain; Allodynia; Antinociception; Tail-flick test; Electroshock test, maximal; Lamotrigine; Felbamate; Gabapentin (Hunter, J.C. (324) 153)

Voltammetry, in vivo; Dopamine; Striatum; Dopamine D_2 receptor antagonist; (Rat) (Horikawa, H.P.M. (326) 15)

Pregnanolone; Neurosteroid; Neuroactive steroid; Drug discrimination (Vanover, K.E. (327) 97)

AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid); Antipsychotic; Dopamine; Schizophrenia; (Mouse) (Vanover, K.E. (332) 115)

Dynorphin; Substance P; Enkephalin; Acetylcholine; Dopamine; Amphetamine; Nucleus accumbens; Caudoputamen; Muscarinic receptor (Wang, J.Q. (334) 43)

Behavioral sensitization
Microdialysis; Chronic transversal; Amphetamine, repeated; Ventral striatum; Dopamine release; Dopamine synthesis (Imperato, A. (317) 231)

Cocaine; Development, ontogeny; Neonatal rat; Preweanling rat (Tirelli, E. (328) 103)

Benign prostatic hypertrophy
α_1-Adrenoceptor antagonist; KMD-3213; Prostate; (Human) (Moriyama, N. (331) 39)

Benzodiazepine
Opioid; Buspirone; Elevated plus-maze test; (Mouse) (Belzung, C. (323) 133)

Anxiety; Conflict; Neurosteroid; 3α-Hydroxy-5α-pregnan-20-one; $GABA_A$ receptor (Brot, M.D. (325) 1)

Opioid; Anxiolytics; Signal transduction; Dopamine receptor antagonist; Homophtalazine (2,3-benzodiazepine) (Fekete, M.I.K. (331) 175)

2,3-Benzodiazepine
Homophthalazine; Anxiolytic drug; Antipsychotic drug; c-*fos* expression; Striatum (Palkovits, M. (331) 53)

GYKI 52466; GYKI 53773; GYKI 53784; Analgesia; Anti-inflammatory drugs (Székely, J.I. (336) 143)

Benzodiazepine receptor
Endozepine; Octadecaneuropeptide (ODN); Diazepam-binding inhibitor; Glial cell; Ca^{2+} mobilization (Gandolfo, P. (322) 275)

Benzodiazepine receptor, central
Anxiolysis; Flavonoid; Autoradiography; (Partial agonist) (Wolfman, C. (318) 23)

Benzodiazepine receptor, in vivo
GABA (γ-aminobutyric acid); Efficacy, intrinsic; DL-Allylglycine; Brain; (Non-human primate) (Bottlaender, M. (321) 13)

Benzodiazepine / $GABA_A$ receptor agonist
Mesocortical dopamine neuron; Stress; Agonist, inverse; Glycine/NMDA receptor antagonist (Hutson, P.H. (326) 127)

Benzodiazepine tolerance
Gene expression; Coordinate gene regulation (Holt, R.A. (329) 129)

Benzodiazepine withdrawal
Stress; GABA (γ-aminobutyric acid)-gated Cl^- flux; Forced swim; Carbamazepine; Two-way avoidance (Martijena, I.D. (330) 101)

Benzomorphan
σ Receptor; Affinity label (Chien, C.-C. (321) 361)

Benzothiazepine
Diltiazem; Verapamil; Ca^{2+} channel antagonist; Ventricular myocyte; Ca^{2+} channel, L-type (Kurokawa, J. (325) 229)

2(*3H*)-Benzothiazolone
σ Receptor; 2(*3H*)-Benzoxazolone; Anticonvulsant; [^{3}H](+)-Pentazocine (Ucar, H. (335) 267)

2(*3H*)-Benzoxazolone
σ Receptor; 2(*3H*)-Benzothiazolone; Anticonvulsant; [^{3}H](+)-Pentazocine (Ucar, H. (335) 267)

7-Benzylidenenaltrexone
(−)-TAN-67; (+)-TAN-67; Antinociception; δ-Opioid receptor; Naltriben, diabetes (Kamei, J. (322) 27)

Nociception, formalin-induced; δ_1-Opioid receptor; Naltriben; Diabetes; (Mouse) (Kamei, J. (326) 31)

Beraprost sodium
Mitogen-activated protein kinase phosphatase 1 (MKP-1); Mesangial cell; cAMP (Togawa, M. (336) 291)

Betahistine
Histamine immunoreactivity; Vestibular nucleus; Tuberomammillary nucleus; Unilateral vestibular neurectomy; Thioperamide; (Cat) (Tighilet, B. (330) 65)

BIBP3226
Neuropeptide Y Y_1 receptor; Elevated plus-maze (Kask, A. (317) R3)

Neuropeptide Y receptor; Neuropeptide Y Y_1 receptor; Sympathetic stimulation; Mesenteric artery, human, inferior; Mesenteric vein, human, inferior (Racchi, H. (329) 79)

Neuropeptide Y, Neuropeptide Y Y_1 receptors; Rat brain; Radioligand binding (Vanderheyden, P.M.L. (331) 275)

(−)-Bicuculline
Adenosine; Purine; GABA (γ-aminobutyric acid); Paired-pulse inhibition; Inhibition; Hippocampus; Cyclopentyltheophylline (Higgins, M.J. (317) 215)

Bicuculline
Melanotroph; $GABA_A$ receptor; Muscimol; $GABA_A$ receptor antagonist; $GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; CGP 35348; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

Dorsal lateral geniculate nucleus; Angiotensin; NMDA (*N*-methyl-D-aspartate); Kainate; CGP 35348; Urethane; Unit activity; (Rat) (Albrecht, D. (332) 53)

Bicuculline analogue, enantiomer
[^{14}C]GABA ([^{14}C]γ-aminobutyric acid); Uptake, quench flow; Cortex, rat (Kardos, J. (337) 83)

BIIP 20
Adenosine A_1 receptor antagonist; Passive avoidance; Memory (Pitsikas, N. (328) 19)

Bile
Cholesterol; Plasma; Liver; Gallstone; Cholesterol 7α-hydroxylase; Acyl coenzyme A:cholesterol acyltransferase (Hajri, T. (320) 65)

Bile duct ligation
Sodium tauroursodeoxycholate (UR-906); Dehydrocholic acid; Blood coagulation factor; Cholestasis; (Rat) (Ishizaki, K. (333) 207)

BIMU-8
σ_2 Receptor; Norepinephrine; Hippocampus; (+)-Pentazocine (Weatherspoon, J.K. (326) 133)

Binding
Angiotensin AT_1 receptor; Angiotensin II; Losartan; Aorta, rabbit; UR-7280 (De Arriba, A.F. (318) 341)

Opioid; Steroid; Cyproterone acetate (Gutiérrez, M. (328) 99)

[^{3}H]CGP-39653; Partial agonist; Allosteric modulation (Robichon, R. (328) 255)

Neuropeptide Y Y_1 receptor; Gene expression; Antisense oligonucleotide; Electroporation (Hänze, J. (330) 87)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Autoradiography; Physicochemical parameter; [^{3}H]Alnespirone (Fabre, V. (337) 297)

Binding assays
Semliki Forest virus system; Tachykinin NK_1 receptor; Mutagenesis, site-directed; Functional coupling (Lundstrom, K. (337) 73)

σ Binding site
DTG (1,3-di-*o*-tolylguanidine); Desipramine; Propranolol; Alprenolol; Cerebral cortex, rat (Shirayama, Y. (331) 319)

Bioassay
Neuropeptide Y; Saphenous vein, dog; Neuropeptide Y Y_2 receptor (Pheng, L.H. (327) 163)

Biodistribution
Apomorphine; Enantiomer; Uptake, stereoselective, active (Sam, E. (329) 9)

Biogenic amine
LSD (lysergic acid diethylamide); Chronic treatment; Ca^{2+} channel; Nifedipine; Brain (Antkiewicz-Michaluk, L. (332) 9)

Bisquaternary allosteric antagonist
Muscarinic acetylcholine receptor agonist (Lanzafame, A. (321) 399)

BK_{Ca} channel
Bladder detrusor, guinea pig; Patch-clamp; Whole-cell recording; Inside-out single channel recording; Open-state probability (Hu, S. (318) 461)

Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

B_2 knockout mice
Vasodilation; Vasoconstriction; Bradykinin; Bradykinin receptor; Mesenteric bed (Berthiaume, N. (333) 55)

Bladder
Pelvic nerve; Micturition contraction; Periurethral muscle; Pudendal nerve; (Rat) (Kagitani, F. (332) 89)

Bladder detrusor, guinea pig
Patch-clamp; BK_{Ca} channel; Whole-cell recording; Inside-out single channel recording; Open-state probability (Hu, S. (318) 461)

Bleeding time
Glycoprotein IIb/IIIa; Monoclonal antibody; Platelet aggregation (Suzuki, K.-i. (336) 169)

YM-60828; Argatroban; Heparin; Dalteparin; Arterio–venous shunt (Sato, K. (339) 141)

Blood–brain barrier
GLUT1 transporter; Glucose; Chlorambucil; Erythrocyte (Halmos, T. (318) 477)

Blood clotting
Vasopressin; Oxytocin; Factor VIII (F-VIII); Antihemophilic factor; Plasminogen activator; Neurohypophyseal hormone analog; Dose–response analysis; Time response; Non-monotonic profile (Neuenschwander, S. (323) 205)

Blood coagulation factor
Bile duct ligation; Sodium tauroursodeoxycholate (UR-906); Dehydrocholic acid; Cholestasis; (Rat) (Ishizaki, K. (333) 207)

Blood flow
Nerve conduction; L-Carnitine; Nitric oxide (NO); Diabetic rat (Cameron, N.E. (319) 239)

NO synthase inhibitors; Plasma leakage; Bradykinin; Histamine (Perez, A.C. (330) 241)

Blood pressure
Nitric oxide (NO); Renin-angiotensin system; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Hoe 140; Enalapril (Zappellini, A. (317) 285)

$GABA_A$ receptor; Acetylcholine; (Rat) (Tellioğlu, T. (317) 301)

NS-49; α_1-Adrenoceptor, subtype; Intraurethral pressure (Taniguchi, N. (318) 117)

γ-MSH (γ-melanocyte-stimulating hormone) fragment; ACTH (adrenocorticotropic hormone) fragment; Heart rate; Cerebral blood flow; Structure-activity relationship; (Rat) (Van Bergen, P. (318) 357)

Tachykinin receptor antagonist; Substance P; Tachykinin NK_1 receptor; Salivation (Cellier, E. (318) 377)

Spontaneously hypertensive rat (SHR); Glucose tolerance; Angiotensin-converting enzyme inhibitor; Angiotensin AT_1 receptor antagonist; Valsartan (Chow, L. (319) 77)

α_2-Adrenoceptor; Sympathetic nerve activity; Ventrolateral medulla, rostral (Vayssettes-Courchay, C. (320) 151)

α_1-Adrenoceptor, subtype; Aging; BMY 7378; Pithed rat (Ibarra, M. (322) 221)

Morphine withdrawal; Nitric oxide (NO) synthase inhibitor; 3-Bromo-7-nitro indazole; Aminoguanidine; *S*-Methyl-L-thiocitrulline; 7-Nitro indazole; Nitric oxide (NO) (Vaupel, D.B. (324) 11)

N^{ω}-Nitro-L-arginine methyl ester (L-NAME); L-Arginine; Superior colliculus (D'Amico, M. (328) 65)

Opioid; Cocaine; Lethality; Cardiovascular; Seizure (Patterson, A.B. (333) 47)

Muscarinic M_1 receptor; Carbachol; Amygdala, central nucleus of; (Rat) (Aslan, N. (333) 63)

Nociceptin; Hypotension; Heart rate; Vagal bradycardia (Giuliani, S. (333) 177)

Adrenomedullin; Renovascular hypertension; Renin; Aldosterone; (Rat) (Khan, A.I. (333) 187)

Elgodipine; Tachycardia, reflex; Dihydropyridin (Valdivielso, J.M. (335) 193)

Amygdala; AV3V region; Cholinergic hypertension; Carbachol; Heart rate (Tellioğlu, T. (336) 163)

CCK (cholecystokinin); CCK_A receptor antagonist; Heart rate; Baroreflex; (Conscious rat) (Bunting, M.W. (337) 35)

Memory; Nitric oxide (NO); cGMP; 7-Nitroindazole; Zaprinast; (Rat) (Prickaerts, J. (337) 125)

Blood pressure maintenance
Pentadecapeptide BPC 157; Peptide BPC; Nitric oxide (NO); Gastrointestinal mucosal integrity; Gastric lesion; Hypotension; N^G-Nitro-L-arginine methylester; L-Arginine; Stomach mucosa (Slobodnjak, Z. (332) 23)

Blood vessel
Ventricular pacing, rapid; Heart failure; α_1-Adrenoceptor subtype; Chloroethylclonidine (Le Tran, Y. (336) 177)

BM-13505
Thromboxane; Smooth muscle, vascular; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; SQ 29,548; Daltroban; SQ 30,741; AA-2414 (Zhang, R. (317) 91)

BMS-180291
Thromboxane; Smooth muscle, vascular; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; SQ 29,548; Daltroban; BM-13505; SQ 30,741; AA-2414 (Zhang, R. (317) 91)

BMY 7378
α-Adrenoceptor, subtype; Atrial muscle; Papillary muscle; Contractility; (Rat) (Wang, S.-N. (321) 39)

α_1-Adrenoceptor, subtype; Aging; Blood pressure; Pithed rat (Ibarra, M. (322) 221)

α_{1D}-Adrenoceptor; Renal artery; Contraction; Chloroethylclonidine; 5-Methylurapidil (Villalobos-Molina, R. (322) 225)

α_1-Adrenoceptor, subtype; Chloroethylclonidine; 5-Methylurapidil; WB 4101; $^{86}Rb^+$, influx rate; Inositol 1,4,5-trisphosphate (Viko, H. (323) 269)

BMY-14802
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Dorsal raphe; Hippocampus; Microdialysis (Matos, F.F. (317) 49)

BNP (brain natriuretic peptide)
CNP (C-type natriuretic peptide); ANP (atrial natriuretic peptide); Cerebral arteriole (Mori, Y. (320) 183)

BNTX (7-benzylidenenaltrexone)
δ-Opioid receptor; NG108-15 cell; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin); Naltriben (Ho, B.Y. (319) 109)

Body temperature
Behavior; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lower lip retraction; 5-HT (5-hydroxytryptamine, serotonin); Tail flick; (Intracerebroventricular administration) (Bagdy, G. (323) 53)

Corticosterone; 5-HT_{1A} receptor; 5-HT_2 receptor; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Wet-dog shake (Takao, K. (333) 123)

Bosentan
Endothelin-1; Endothelin receptor antagonist; PD155080; Clearance; Half-life; Vascular effect (Hemsén, A. (318) 369)

Bosentan (4-tert-butyl-*N*-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2′-bipyrimidin-4-yl]-benzene sulfonamide)
Endothelin-1; IRL 1620 (Suc-[Glu^9,Ala^{11,15}]endothelin-1-(8–21)); FR 139317 ((*R*)2-[(*R*)-2-[(*S*)-2-[[1-(hexahydro-1*H*-azepinyl)]carbonyl] amino-4-methylpentanoil]amino-3-[3-(1-methyl-1*H*-indoyl)]propionyl]-amino-3-(2-pyridyl) propionic acid) (Takahashi, T. (324) 219)

BQ-788
Endothelin; Hypoxia; Pulmonary hypertension (Holm, P. (323) 83)

Bradycardic agent
S 16257; Stereospecificity; Transmembrane action potential; Heart rate; QT interval (Thollon, C. (339) 43)

Bradykinin
Carrageenan inflammation; c-Fos; Nociception; Spinal cord (Buritova, J. (320) 73)

Arachidonic acid; Thromboxane; Arterial ring, mesenteric; Smooth muscle, vascular (Weinberg, M.L.D. (320) 145)

Icatibant; Cardiac pacing, rapid; Ischemic preconditioning; Ventricular arrhythmia (Kaszala, K. (328) 51)

NO synthase inhibitors; Plasma leakage; Blood flow; Histamine (Perez, A.C. (330) 241)

Pleurisy; Anti-inflammatory drugs; Bradykinin receptor antagonist; Inflammatory mediator (Saleh, T.S.F. (331) 43)

Nitric oxide (NO); Microdialysis; Skin; Inflammatory hyperalgesia; N^G-nitro-L-arginine methyl ester; Bradykinin B_2 receptor (Andoh, T. (332) 279)

Vasodilation; Vasoconstriction; Bradykinin receptor; Mesenteric bed; B_2 knockout mice (Berthiaume, N. (333) 55)

Bradykinin receptor antagonist; FR167344; FR172357; Bradykinin B_2 receptor; Orally active (Inamura, N. (333) 79)

Bradykinin receptor
Vasodilation; Vasoconstriction; Bradykinin; Mesenteric bed; B_2 knockout mice (Berthiaume, N. (333) 55)

Bradykinin B_1 receptor
Des-Arg^9-bradykinin; Des-Arg^9-[Leu^8]bradykinin; Umbilical vein, human; Sensitization (Sardi, S.P. (321) 33)

Bradykinin B_2 receptor
Nitric oxide (NO); Microdialysis; Skin; Bradykinin; Inflammatory hyperalgesia; N^G-nitro-L-arginine methyl ester (Andoh, T. (332) 279)

Bradykinin; Bradykinin receptor antagonist; FR167344; FR172357; Orally active (Inamura, N. (333) 79)

Bradykinin receptor antagonist
Bradykinin; Pleurisy; Anti-inflammatory drugs; Inflammatory mediator (Saleh, T.S.F. (331) 43)

Bradykinin; FR167344; FR172357; Bradykinin B_2 receptor; Orally active (Inamura, N. (333) 79)

Bradykinin B_2 receptor antagonist
CCl_4-induced liver cirrhosis; Hepatorenal syndrome; Na^+ retention; Microvascular leakage; HOE 140 (Icatibant) (Wirth, K.J. (337) 45)

Bradykinin B_1 receptor-selective antagonist
Des-Arg^9-bradykinin; Gallbladder, guinea pig; Bradykinin B_2 receptor-selective antagonist; Prostanoid; Ca^{2+} (Cabrini, D.A. (331) 31)

Bradykinin B_2 receptor-selective antagonist
Des-Arg^9-bradykinin; Gallbladder, guinea pig; Bradykinin B_1 receptor-selective antagonist; Prostanoid; Ca^{2+} (Cabrini, D.A. (331) 31)

Brain
RS-79948-197; α_2-Adrenoceptor; Radioligand; In vivo; PET (positron-emission tomography); (Rat) (Hume, S.P. (317) 67)

Electroconvulsive stimuli; Hybridization, in situ; mRNA expression; Substance P; Tachykinin receptor; (Rat) (Zachrisson, O. (319) 191)

GABA (γ-aminobutyric acid); Benzodiazepine receptor, in vivo; Efficacy, intrinsic; DL-Allylglycine; (Non-human primate) (Bottlaender, M. (321) 13)

Nitric oxide (NO); Anxiety; Plus maze, elevated; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Arterial blood pressure; Nitric oxide (NO) synthase (Faria, M.S. (323) 37)

LSD (lysergic acid diethylamide); Chronic treatment; Biogenic amines; Ca^{2+} channel; Nifedipine (Antkiewicz-Michaluk, L. (332) 9)

Adenosine; Diadenosine polyphosphate; Microwave; Adenine nucleotide; (Rat) (Delaney, S.M. (332) 35)

TNF (tumor necrosis factor); Interleukin 10; Lipopolysaccharide (Di Santo, E. (336) 197)

Piribedil; Lipid peroxidation; Oxygen exposure, high (Calzi, F. (338) 185)

Brain, mouse
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)-induced mydriasis; α_2-Adrenoceptor, postsynaptic; 5-HT_{1A} receptor (Prow, M.R. (317) 21)

Δ^9-Tetrahydrocannabinol; G-protein (Burkey, T.H. (323) R3)

Cannabinoid; Cannabinoid receptor; Drug efficacy; Tetrahydrocannabinol; (Partial agonist) (Burkey, T.H. (336) 295)

Brain, rat
Alcohol; Nitric oxide (NO) synthase (Chen, Q.-m. (321) 355)

[^{125}I]*R*(+)-Zacopride; Autoradiography; Radioligand binding; *R*(+)-site; Peripheral tissue, rat (Ge, J. (332) 307)

Brain damage
Pathogenesis; Cerebral cortex; Receptor isoform; Receptor subtype; (Human) (Lewohl, J.M. (326) 265)

Brain–gut
Acid secretion; Gastric mucosal blood flow; Ketotifen; Mast cell; Mean arterial pressure; RX 77368; TRH (thyrotropin-releasing hormone); Vagus (Király, Á. (334) 241)

Brain penetration
Radioligand binding; Oral bioavailability; $t_{1/2}$; Vomiting; Retching; Nausea; Ondansetron (Singh, L. (321) 209)

Anti-emetic (Rupniak, N.M.J. (326) 201)

Brain slice
Cannabinoid receptor; CP 55,940; SR 141716A; Acetylcholine (Gifford, A.N. (324) 187)

$GABA_B$ receptors; CGP 56999A; Epilepsy (rat) (Badran, S. (333) 135)

Brefeldin A
Smooth muscle, vascular; Contraction; Ca^{2+} entry (Filipeanu, C.M. (332) 71)

BRL-15572
Hypothermia; 5-HT; Guinea pig; 5-HT_{1D} receptor; 5-HT_{1B} receptor; SKF-99101H; SB-216641A; SB-224289G (Hagan, J.J. (331) 169)

BRL 35135
β_3-adrenoceptor agonism; Zucker (*fa/fa*) rat; Insulin sensitivity; Non-esterified fatty acid; Euglycaemic hyperinsulinaemic clamp (Virtanen, K.A. (332) 215)

BRL37344A, BRL35135A
β-Adrenoceptor; β_3-Adrenoceptor; Taenia caecum, guinea pig; Muscle relaxation (Koike, K. (334) 217)

Bromocriptine
Talipexole; Dopamine D_2 receptor agonist; Anti-tremor effect; Ventromedial tegmentum lesion; Parkinson's disease; (Cynomolgus monkey) (Kohno, Y. (319) 197)

(Rp)-8-Bromo-guanosine-3′,5′-cyclic monophosphorothioate
cGMP-dependent protein kinase; cAMP-dependent protein kinase; (Rp)-Adenosine-3′,5′-cyclic monophosphorothioate; Ca^{2+} sensitivity; Smooth muscle, skinned, vascular (Kawada, T. (323) 75)

3-Bromo-7-nitro indazole
Morphine withdrawal; Blood pressure; Nitric oxide (NO) synthase inhibitor; Aminoguanidine; *S*-Methyl-L-thiocitrulline; 7-Nitro indazole; Nitric oxide (NO) (Vaupel, D.B. (324) 11)

Bronchial hyperresponsiveness
Vagus nerve stimulation; Muscarinic M_2 receptor, prejunctional; Receptor dysfunction; Muscarinic receptor antagonist; Allergic reaction, early, late; (Conscious, unrestrained guinea pig) (Ten Berge, R.E.J. (318) 131)

Bronchiole
Sulfonylurea; Prostanoid; Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Tolazamide; Tolbutamide; Gliclazide; Glibenclamide; Artery (Delaey, C. (325) 41)

Bronchoconstriction
Tachykinin; Substance P; Neurokinin A; Mast cell; 5-HT (5-hydroxytryptamine, serotonin); Tachykinin NK_1 receptor (Joos, G.F. (338) 259)

Bronchodilator
Asthma; Eosinophil; Hyperreactivity; KF19514; Phosphodiesterase inhibitor (Manabe, H. (332) 97)

Bronchodilator effect
Phosphodiesterase I/IV inhibitor; Phosphodiesterase III inhibitor; Anti-allergic effect; (Guinea pig) (Fujimura, M. (327) 57)

Bronchospasm
Talsaclidine; Arecoline; McN-A-343; Noradrenaline; Guinea pig (Walland, A. (330) 213)

Bronchus, human, isolated
PF-904; Airway; Airway, hyperreactivity; Eosinophil infiltration; Microvascular leakage; Phosphodiesterase activity; Neutrophils, human; Superoxide anion generation; (Guinea pig) (Cortijo, J. (333) 69)

Broussochalcone A
Neutrophil, rat; Respiratory burst; Inositol trisphosphate; Ca^{2+} concentration, intracellular; Protein kinase C; NADPH oxidase (Wang, J.-P. (320) 201)

Brown adipocyte
TMF-α (tumor necrosis factor-α); Nitric oxide (NO) synthase, inducible; Lipoprotein lipase; Guanosine 3′,5′-cyclic monophosphate (Uchida, Y. (335) 235)

Melatonin; Melatonin receptor; (Siberian hamster) (Le Gouic, S. (339) 271)

Brown fat
Zucker rat; α_1-Adrenoceptor agonist; α_2-Adrenoceptor antagonist; Imidazoline derivative; Obesity, drug therapy (Savontaus, E. (328) 207)

Brown Norway rat
Forced swimming test; Wistar-Kyoto rat; Sprague-Dawley rat; Imipramine; 5-HT_1 receptor; 5-HT_2 receptor; β-Adrenoceptor; Depression (Lahmame, A. (337) 115)

Brush-border membrane vesicle
Adenosine transport, Na^+-dependent; Cyclooxygenase; Prostanoid; Non-steroidal anti-inflammatory drug (NSAID) (González-Castillo, C. (329) 245)

BTS 67 582
Islets of Langerhans; Insulin release; Imidazoline receptor; Diabetes (Dickinson, K. (339) 69)

BU-224 (2-(4,5-dihydroimidazol-2yl)-quinoline hydrochloride))
Imidazoline receptor; Nociception; Spinal cord; (Rat) (Diaz, A. (333) 9)

Bufadienolide
Na^+/K^+ pump; Dorsal root ganglion cell; Cardiac cell; Na^+/K^+ ATPase isoform (Van der Walt, J.J. (329) 201)

Bupivacaine
5-HT_3 receptor; ICS-205 930; Lidocaine; Nociception inflammation (Giordano, J. (334) 39)

Buspirone
Opioid; Benzodiazepine; Elevated plus-maze test; (Mouse) (Belzung, C. (323) 133)

Butoxamine
Propranolol; Metoprolol; Neutrophil; Myeloperoxidase; Prostaglandin E_2 (Kaan, S.K. (317) 115)

BW 737C
Dopamine 'D_1-like' receptor; Dopamine 'D_2-like' receptor; D_1/D_2 interaction; LY 270411; SCH 23390; Grooming behavior; Vacuous chewing; Myoclonic jerking; (Rat) (Deveney, A.M. (317) 175)

BW1003C87
Phenytoin; Carbamazopine; Anticonvulsant effects; Amygdala-kindling; Seizure threshold (Morimoto, K. (339) 11)

c-Fos
Bradykinin; Carrageenan inflammation; Nociception; Spinal cord (Buritova, J. (320) 73)

Epilepsy; Cortex; Hippocampus; Thalamus; $GABA_B$ receptor antagonist (Vergnes, M. (332) 245)

Arterial blood pressure; Cholinergic system, central; Neostigmine (Li, J. (337) 227)

c-*fos* mRNA
Acamprosate; Ethanol withdrawal; Pentylenetetrazole; Hippocampus; Cerebellum; Northern and dot blotting; In situ hybridization (Putzke, J. (317) 39)

***Fos* protein immunoreactivity**
Dopamine D_3 receptor; Receptor binding; G protein; Acidification rate; cAMP accumulation (Scheideler, M.A. (339) 261)

Ca^{2+}
Histamine; Histamine H_1 receptor; Astrocytoma; GABA (γ-aminobutyric acid); Glia (Soria-Jasso, L.-E. (318) 185)

Isoproterenol; Cardiac hypertrophy; Force-frequency response; (Rat) (Tang, L. (318) 349)

Diabetic rat; Streptozotocin; Calmodulin; Calmidazolium; Insulin; Intestinal reactivity (Öztürk, Y. (321) 59)

RBL-2H3; Astemizole; Membrane; Protein; Tyrosine; Phosphorylation; Flux; Exocytosis (Fischer, M.J.E. (322) 97)

Nicotine; Antinociception; Ca^{2+} channel; Tolerance; Thapsigargin; (Intrathecal) (Damaj, M.I. (322) 129)

cGMP; Phosphodiesterase; Granule cell; Astrocyte (Agulló, L. (323) 119)

α_1-Adrenoceptor, subtype; Uterine artery; Umbilical vein (Hu, X.-Q. (324) 67)

Carbamazepine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Hippocampus; Electroshock seizure; Tetrodotoxin; (Rat) (Dailey, J.W. (328) 153)

Cardiomyopathy; Hypertrophy; Ischemia; Trimetazidine; Verapamil (D'hahan, N. (328) 163)

Sauvagine; Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Edema; Inositol trisphosphate; CRF receptor; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

Des-Arg^9-bradykinin; Gallbladder, guinea pig; Bradykinin B_1 receptor-selective antagonist; Bradykinin B_2 receptor-selective antagonist; Prostanoid (Cabrini, D.A. (331) 31)

Contraction; Trachea; Econazole; Miconazole; SK&F 96365; Nifedipine (Li, L. (331) 221)

NMDA receptor; Neuron; Uncompetitive; Neuroprotection; MK-801 (Black, M. (317) 377)

Ca^{2+}, cytosolic
Calyculin A; Mn^{2+}; Protein phosphatase; Protein phosphorylation; HL-60 cells (Leung, Y.-M. (331) 337)

Ca^{2+}, cytosolic, free
Mg^{2+}, extracellular; Ischemic heart disease (Altura, B.M. (338) R7)

Ca^{2+}, dendritic
Long-term depression; Metabotropic receptor (Otani, S. (318) R5)

Ca^{2+}, internal
VIP (vasoactive intestinal polypeptide); Endothelial cells; Ca^{2+} imaging; Fura-2 (Low, A.M. (339) 227)

Ca^{2+}, intracellular
Ca^{2+} efflux; Smooth muscle; α_1-Adrenoceptor (Lum Min, S.A. (318) 97)

Na^+/Ca^{2+} exchange; Heart failure; cAMP (Miao, L. (321) 201)

$[Ca^{2+}]_i$
Histamine; ATP, extracellular; HL-60 cell (Song, S.-K. (322) 265)

Pancreatic B-cell; Insulin secretion; Tetracaine (Bordin, S. (327) 257)

Δ^9-tetrahydrocannabinol; DDT_1MF-2 cell (Filipeanu, C.M. (336) R1)

Levosimendan; Myocyte; (Guinea pig) (Lancaster, M.K. (339) 97)

$[Ca^{2+}]_i$ transient
Muscarinic receptor; Electrical stimulation; Na^+-Ca^{2+} exchange; Carbachol (Wang, H.-X. (319) 91)

Tetrandrine; Heart muscle; Ca^{2+} antagonist; Ca^{2+} release; Cardiomyocyte (Wang, H.-X. (319) 115)

Ca^{2+}-activated
Adrenal catecholamine; K^+ channel; SK_{Ca} channel; BK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Ca^{2+}-activated K^+ channel
Ca^{2+}-entry block; Ca^{2+} current; Natural product; Excitation–contraction coupling (Suarez-Kurtz, G. (335) 153)

Ca^{2+}-activated K^+ current
Thrombin receptor; Megakaryocyte, rat; Patch clamp, perforated (Uneyama, C. (319) 299)

Ca^{2+} antagonist
Tetrandrine; $[Ca^{2+}]_i$ transient; Heart muscle; Ca^{2+} release; Cardiomyocyte (Wang, H.-X. (319) 115)

Ca^{2+}-ATPase
Cyclopiazonic acid; Sarcoplasmic reticulum; Smooth muscle; Stomach; Contraction (Petkov, G.V. (318) 109)

Ca^{2+} channel
ω-Toxin; Neuronal nicotinic receptor; Ca^{2+} channel antagonist; Chromaffin cell (Villarroya, M. (320) 249)

ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Agatoxin IVA; Vas deferens; Purinergic neurotransmission (Hirata, H. (321) 217)

Nicotine; Antinociception; Ca^{2+}; Tolerance; Thapsigargin; (Intrathecal) (Damaj, M.I. (322) 129)

Cerebellum; Granule neuron; ω-Conotoxin-GVIA; ω-Agatoxin-IVA; Eliprodil (Biton, B. (323) 277)

NS 1619; Charybdotoxin; Glibenclamide; K^+ channel, Ca^{2+}-activated; Vas deferens, rat (Huang, Y. (325) 21)

Nicotinic receptor; Forskolin; 1,9-Dideoxy-forskolin; Chromaffin cell (Gandía, L. (329) 189)

CP-060*S*; Smooth muscle, vascular; Electrophysiology; Voltage clamp; Ca^{2+} channel antagonist (Ohya, Y. (330) 93)

LSD (lysergic acid diethylamide); Chronic treatment; Biogenic amines; Nifedipine; Brain (Antkiewicz-Michaluk, L. (332) 9)

Dotarizine; 5-HT_2 receptor; *Xenopus* oocytes; Coronary artery (Montiel, C. (332) 183)

HEK293 cell; Na^+ channel; NNC 09-0026; CNS 1237; SB 201823-A; NS 649; Riluzole; Cerebral ischaemia (O'Neill, M.J. (332) 121)

Mn^{2+}; Ileum; Smooth muscle (Nasu, T. (333) 199)

Ca^{2+} channel, cloned
Ca^{2+} channel antagonist; Neuroprotective; T-477 ((*R*)-(+)-2-(4-chlorophenyl)-2,3-dihydro-4-diethylaminoacetyl-4H-1,4-benzothiazine); Oocyte; (*Xenopus*) (Kobayashi, T. (332) 313)

Ca^{2+} channel, L-type
Diltiazem; 1,4-Dihydropyridine; Ca^{2+} channel antagonist; Cardiac myocyte; Ventricular myocyte; (Rat) (Kanda, S. (319) 101)

Neurotensin; Colon; Mechanical activity (Mulè, F. (319) 269)

Felodipine; Ventricular cell, guinea pig; Voltage-dependent block; E-C (excitation-contraction) coupling (Kohmoto, O. (319) 355)

Benzothiazepine; Diltiazem; Verapamil; Ca^{2+} channel antagonist; Ventricular myocyte (Kurokawa, J. (325) 229)

Ca^{2+} channel, receptor-operated
Mn^{2+}; Uterus, rat (Magraner, J. (326) 211)

Dihydropyridine; Motor effects; Drug discrimination (Cohen, C. (336) 113)

Ca^{2+} channel, T-type
Sinus node; Efonidipine; Chronotropism; Action potential; Ca^{2+} channel antagonist (Masumiya, H. (335) 15)

Ca^{2+} channel, voltage-dependent
ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Conotoxin SVIB; ω-Agatoxin IVA; Neurotransmission (Tran, S. (335) 31)

Ca^{2+} channel antagonist
Tamoxifen; MCF7/6; E-cadherin; Adhesion (Charlier, C. (317) 413)

Diltiazem; 1,4-Dihydropyridine; Ca^{2+} channel, L-type; Cardiac myocyte; Ventricular myocyte; (Rat) (Kanda, S. (319) 101)

ω-Toxin; Ca^{2+} channel; Neuronal nicotinic receptor; Chromaffin cell (Villarroya, M. (320) 249)

Pranidipine (OPC-13340); Circulatory filling pressure, mean; Venodilator effect; (Rat) (Hirano, T. (324) 201)

Protein kinase C; Calmodulin; Tyrosine kinase; Smooth muscle contraction (Sim, S.-S. (324) 205)

Benzothiazepine; Diltiazem; Verapamil; Ventricular myocyte; Ca^{2+} channel, L-type (Kurokawa, J. (325) 229)

Ca^{2+} channel; CP-060*S*; Smooth muscle, vascular; Electrophysiology; Voltage clamp (Ohya, Y. (330) 93)

CD-832; Stroke-prone spontaneously hypertensive rats (SHRSPs); Renal lesion (Takahashi, T. (331) 193)

Ca^{2+} channel, cloned; Neuroprotective; T-477 ((*R*)-(+)-2-(4-chlorophenyl)-2,3-dihydro-4-diethylaminoacetyl-4H-1,4-benzothiazine); Oocyte; (*Xenopus*) (Kobayashi, T. (332) 313)

Sinus node; Efonidipine; Chronotropism; Action potential; Ca^{2+} channel, T-type (Masumiya, H. (335) 15)

Ca^{2+} channel antagonist, 'wide-spectrum'
Dotarizine; Flunarizine; Lubeluzole; Catecholamine release; Chromaffin cell (Lara, B. (325) 109)

Ca^{2+} channel blocker
ANP (atrial natriuretic polypeptide); VIP (vasoactive intestinal polypeptide); K^+ channel; Levcromakalim; Isradipine; Trachea; Smooth muscle, airway (Thirstrup, S. (319) 253)

Na^+,K^+-ATPase; Na^+,K^+-ATPase, α-subunit; Hypertension; Spontaneously hypertensive rat (SHR); Vasodilator (Liu, X. (327) 151)

Cardiomyocyte; Lysophosphatidylcholine; Ca^{2+} overload; Creatine kinase (Chen, M. (333) 261)

Thoracic aorta; Vasorelaxation; Norepinephrine; cAMP; cGMP (Cheng, Y.-W. (336) 23)

Ca^{2+} concentration, intracellular
Abruquinone A; Neutrophil; Inositol phosphate; Phospholipase C (Wang, J.-P. (319) 131)

Broussochalcone A; Neutrophil, rat; Respiratory burst; Inositol trisphosphate; Protein kinase C; NADPH oxidase (Wang, J.-P. (320) 201)

α_1-Adrenoceptor, subtype; Contraction; Smooth muscle, vascular; Fura-2 (Tognarini, D.P. (322) 31)

Doxorubicin; Cardiotoxicity; Cell contraction; Myocardial cell, single (Temma, K. (322) 235)

Ca^{2+} current
β-Adrenoceptor; Heart, neonatal; G protein; Voltage clamp, whole cell (Katsube, Y. (317) 391)

Semotiadil; Diltiazem; Amlodipine; Nifedipine; Ventricular myocyte (Koidl, B. (322) 243)

Smooth muscle cell, vascular; Tetrandrine (Wu, S.-N. (327) 233)

Chemotherapeutic; P-glycoprotein; Verapamil (Nanaumi, K. (327) 239)

Ca^{2+}-entry block; Ca^{2+}-activated K^+ channel; Natural product; Excitation–contraction coupling (Suarez-Kurtz, G. (335) 153)

Ca^{2+} current, L-type
Heart; Guanylyl cyclase; Phosphodiesterase; Force of contraction; Fura-2 (Wegener, J.W. (326) 37)

Ca^{2+} efflux
Smooth muscle; Ca^{2+}, intracellular; α_1-Adrenoceptor (Lum Min, S.A. (318) 97)

Ca^{2+} entry
Ca^{2+} release; Endothelial cell; ATP; Thapsigargin (Oike, M. (319) 291)

Brefeldin A; Smooth muscle, vascular; Contraction (Filipeanu, C.M. (332) 71)

Ca^{2+}-entry block
Ca^{2+} current; Ca^{2+}-activated K^+ channel; Natural product; Excitation–contraction coupling (Suarez-Kurtz, G. (335) 153)

Ca^{2+} flux
ABT-491; PAF (platelet-activating factor); PAF receptor antagonist; Superoxide anion; Vascular permeability; Degranulation; Endotoxemia (Albert, D.H. (325) 69)

Ca^{2+} imaging
Cross talk; cAMP; Phenylglycine (Schaffhauser, H. (334) 289)

Ca^{2+}, internal; VIP (vasoactive intestinal polypeptide); Endothelial cells; Fura-2 (Low, A.M. (339) 227)

Ca^{2+} level
Ventricular mass; Ion-selective microelectrode; Diastolic (Lopez, J.R. (339) 161)

Ca^{2+} mobilization
Endozepine; Octadecaneuropeptide (ODN); Diazepam-binding inhibitor; Benzodiazepine receptor; Glial cell (Gandolfo, P. (322) 275)

CHO (Chinese hamster ovary) cell; Cholecystokinin; CCK_A receptor; Devazepide; L-364,718; Cell recruitment; Receptor modelling (Smeets, R.L.L. (325) 93)

Ca^{2+} overload
l-cis-Diltiazem; *d-cis*-Diltiazem; Veratridine; Na^+ overload; Myocyte; (Rat) (Itogawa, E. (317) 401)

Cardiomyocyte; Lysophosphatidylcholine; Ca^{2+} channel blocker; Creatine kinase (Chen, M. (333) 261)

Ca^{2+} paradox
O_2 paradox; Caffeine; Amiloride; pH; Heart damage (Harding, R.J. (330) 47)

Ca^{2+}-permeable non-selective cation channel
Smooth muscle cell, vascular; Vasopressin; Endothelin-1; Mg^{2+}, extracellular (Nakajima, T. (320) 81)

Ca^{2+} release
Tetrandrine; $[Ca^{2+}]_i$ transient; Heart muscle; Ca^{2+} antagonist; Cardiomyocyte (Wang, H.-X. (319) 115)

Ca^{2+} entry; Endothelial cell; ATP; Thapsigargin (Oike, M. (319) 291)

Na^+, external; P_2 purinoceptor; Parotid acinar cell (Fukushi, Y. (336) 89)

Ca^{2+} sensitivity
cGMP-dependent protein kinase; cAMP-dependent protein kinase; (Rp)-8-Bromo-guanosine-3′,5′-cyclic monophosphorothioate; (Rp)-Adenosine-3′,5′-cyclic monophosphorothioate; Smooth muscle, skinned, vascular (Kawada, T. (323) 75)

G-protein; Protein kinase C; Pimobendan; β-Escin; Cardiac muscle; Smooth muscle, vascular (Tomita, F. (326) 157)

Ca^{2+} signaling
α_2-Adrenoceptor; Fura-2; Receptor kinetics; Receptor binding (Kukkonen, J.P. (335) 99)

Ca^{2+} store
Free radical; Smooth muscle, vascular (Wada, S. (320) 51)

Smooth muscle; K^+ channels; Charybdotoxin; Apamin; Pacemaker cells (Duridanova, D.B. (333) 105)

CA1 area
Metabotropic glutamate receptor; 1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitatory postsynaptic potential; Depotentiation; Hippocampus; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

Caffeine
Cl^--current; Niflumic acid; Noradrenaline; Glibenclamide; Smooth muscle (Kirkup, A.J. (317) 165)

Adenosine; Carbamazepine; Dopamine; Microdialysis (Okada, M. (321) 181)

Ca^{2+} paradox; O_2 paradox; Amiloride; pH; Heart damage (Harding, R.J. (330) 47)

Caffeine contracture
Heparin; Sarcoplasmic reticulum; Skinned fiber; Skeletal muscle, mammalian (Talon, S. (327) 33)

α-Calcitonin gene-related peptide
Adrenomedullin; Amylin; Gastric acid; (*N*-terminal cyclic octa-peptides); (C-terminal fragments); (Chronic fistulae equipped rat); (Rat); (Human) (Rossowski, W.J. (336) 51)

Calmidazolium
Diabetic rat; Streptozotocin; Ca^{2+}; Calmodulin; Insulin; Intestinal reactivity (Öztürk, Y. (321) 59)

Calmodulin
Diabetic rat; Streptozotocin; Ca^{2+}; Calmidazolium; Insulin; Intestinal reactivity (Öztürk, Y. (321) 59)

Ca^{2+} channel antagonist; Protein kinase C; Tyrosine kinase; Smooth muscle contraction (Sim, S.-S. (324) 205)

P-4 (1-methyl-4-piperidyl diphenylpropoxyacetate hydrochloride); Antipollakiuric agent; Urinary bladder; Smooth muscle; Actomyosin ATPase activity (Matsushima, S. (333) 93)

Calmodulin antagonist
Glycolysis; Cytoskeleton; Melanoma cell (Glass-Marmor, L. (328) 241)

DY-9760e; W-7; Cytotoxicity; Neuroprotection (Sugimura, M. (336) 99)

Calmodulin inhibitor
Pain; Analgesia; Spinal cord; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Septide (Menéndez, L. (335) 9)

Calphostin C
Antinociception; DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); Diabetes; Protein kinase C; (Mouse) (Ohsawa, M. (339) 27)

Calyculin A
Okadaic acid; Phosphatase; Tumor cell locomotion; Walker 256 carcinosarcoma cell; Vimentin (Niggli, V. (324) 99)

Ca^{2+}, cytosolic; Mn^{2+}; Protein phosphatase; Protein phosphorylation; HL-60 cells (Leung, Y.-M. (331) 337)

L-Canavanine
Ischemia-reperfusion arrhythmia; Endotoxin; Dexamethasone; Nitric oxide (NO) synthase, inducible (Iskit, A.B. (326) 183)

Candesartan (CV-11974)
[^{3}H]CV-11974; Losartan; Angiotensin AT_1 receptor; Association rate constant; Dissociation rate constant (Ojima, M. (319) 137)

Cannabinoid
Hyperalgesia; Pain (Richardson, J.D. (319) R3)

Lung; Type II cell; Ontogeny; Development; Steroid (Rice, W. (327) 227)

Hippocampus; Acetylcholine (Gessa, G.L. (327) R1)

Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Anandamide; K^+ channel; Cytochrome *P*-450 inhibitor (Randall, M.D. (333) 191)

Cannabinoid receptor; Drug efficacy; Brain, mouse; Tetrahydrocannabinol; (Partial agonist) (Burkey, T.H. (336) 295)

Anandamide; Vasculature (Calignano, A. (337) R1)

Cannabinoid CB_1 receptor; Cannabinoid CB_2 receptor; SR141716A; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation, guinea-pig small intestine (Griffin, G. (339) 53)

Cannabinoid CB_1 receptor
Cannabinoid; Cannabinoid CB_2 receptor; SR141716A; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation, guinea-pig small intestine (Griffin, G. (339) 53)

Cannabinoid CB_2 receptor
Cannabinoid; Cannabinoid CB_1 receptor; SR141716A; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation, guinea-pig small intestine (Griffin, G. (339) 53)

Cannabinoid receptor
CP 55,940; SR 141716A; Brain slice; Acetylcholine (Gifford, A.N. (324) 187)

Anandamide; Palmitoylethanolamide; Tetrahydrocannabinol; Cytokines; Mononuclear cells; Immune response (Berdyshev, E.V. (330) 231)

Cannabinoid; Drug efficacy; Brain, mouse; Tetrahydrocannabinol; (Partial agonist) (Burkey, T.H. (336) 295)

Levcromakalim; Endothelium (White, R. (339) 157)

Cannabinoid receptor antagonist
AM630; [^{35}S]GTPγS binding (Hosohata, Y. (321) R1)

Cannabinoid receptor, human
SR141716A; Inverse agonist (Landsman, R.S. (334) R1)

Cannabinoid (endocannabinoid), endogenous
Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Anandamide; SR141716A; Heart, rat (Randall, M.D. (335) 205)

Capillary permeability
Edema; α-Trinositol; Trachea; Skin (rat); Connective tissue; Inflammation; Anaphylaxis (Koller, M.-E. (331) 259)

Capsaicin
Plasma protein extravasation; 5-HT receptor; Histamine receptor; Tachykinin; Airways; (Fisher 344 rat) (Germonpré, P.R. (324) 249)

Amylin; Ulcer; CGRP (calcitonin gene-related peptide), human; Domperidone; Neostigmine (Clementi, G. (332) 209)

Nociceptin; Sensory nerve; Efferent function; Atrium; (Guinea pig) (Giuliani, S. (332) 231)

Mustard oil; Neurogenic inflammation; Plasma extravasation; Ear oedema; SR 140333 (Inoue, H. (333) 231)

Urethra, dog; Nitric oxide (NO); Smooth muscle relaxation (Nishizawa, S. (335) 211)

Vomiting; Resiniferatoxin; Solitary nucleus; Vagus nerve; (Dog) (Shiroshita, Y. (339) 183)

Sensory nerves; *Phoneutria nigriventer* venom; Neurogenic oedema; Tachykinin NK_1 receptor agonist (Costa, S.K.P. (339) 223)

Capsaicin-sensitive
Resiniferatoxin; Saphenous nerve; Neuropeptide Y; Vasoconstriction; Vasodilation; Laser-Doppler flowmetry (Pintér, E. (325) 57)

Captopril
Hyperplasia; Smooth muscle, vascular; Cell culture; Nifedipine; Losartan; Transgenic rat (Peiró, C. (324) 257)

Mesangial cell; Proliferation; Angiotensin II-converting enzyme inhibitor; Tyrosine phosphorylation; $pp60^{c\text{-}src}$ (Ruiz-Ginés, J.A. (336) 251)

Imidapril; Enalapril; Ozone; Angiotensin-converting enzyme; Airway hyperresponsiveness (Matsubara, S. (337) 259)

Carbachol
Muscarinic receptor; $[Ca^{2+}]_i$ transient; Electrical stimulation; Na^+-Ca^{2+} exchange (Wang, H.-X. (319) 91)

Pharmacological method, new; Efficacy estimation; Agonist affinity; Salbutamol (Venter, D.P. (320) 233)

Muscarinic M_1 receptor; Blood pressure; Amygdala, central nucleus of; (Rat) (Aslan, N. (333) 63)

Amygdala; AV3V region; Cholinergic hypertension; Blood pressure; Heart rate (Tellioğlu, T. (336) 163)

Carbamazepine
Adenosine; Caffeine; Dopamine; Microdialysis (Okada, M. (321) 181)

5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Hippocampus; Ca^{2+}; Electroshock seizure; Tetrodotoxin; (Rat) (Dailey, J.W. (328) 153)

Benzodiazepine withdrawal; Stress; GABA (γ-aminobutyric acid)-gated Cl^- flux; Forced swim; Two-way avoidance (Martijena, I.D. (330) 101)

Carbamazopine
BW1003C87; Phenytoin; Anticonvulsant effects; Amygdala-kindling; Seizure threshold (Morimoto, K. (339) 11)

Carbon monoxide
N^G-nitro-L-arginine; Zinc protoporphyrin IX; Nitric oxide (NO); Nitric oxide (NO) synthase; Heme oxygenase (Seki, T. (331) 87)

Cardiac arrhythmia
Glibenclamide (glyburide); K^+_{ATP} channel; Myocardial ischemia; Adenosine release (Bernauer, W. (326) 147)

Cardiac cell
Bufadienolide; Na^+/K^+ pump; Dorsal root ganglion cell; Na^+/K^+ ATPase isoform (Van der Walt, J.J. (329) 201)

Cardiac glycoside
ATPase (Na^+, K^+); α-Methyl-digitoxigenin-glucoside; Ouabain; Therapeutic index (Gleitz, J. (335) 89)

Cardiac hypertrophy
Isoproterenol; Force-frequency response; Ca^{2+}; (Rat) (Tang, L. (318) 349)

Cardiac ischemia
Arrhythmia; Acetylsalicylic acid; Cardiac reperfusion; Electrophysiology; Electrocardiology; Epicardial mapping (Dhein, S. (339) 129)

Cardiac muscle
Ca^{2+} sensitivity; G-protein; Protein kinase C; Pimobendan; β-Escin; Smooth muscle, vascular (Tomita, F. (326) 157)

Cardiac myocyte
Diltiazem; 1,4-Dihydropyridine; Ca^{2+} channel, L-type; Ca^{2+} channel antagonist; Ventricular myocyte; (Rat) (Kanda, S. (319) 101)**Cardiac myocyte, isolated**
Adenosine receptor; Ischemic preconditioning (Wang, J. (320) 241)

Cardiac myocyte, rat, neonatal
α_1-Adrenoreceptor subtype; Phosphatidylinositol hydrolysis; Mitogen activated protein kinase (Wenham, D. (339) 77)

Cardiac output
Endothelin-1; Circulatory filling pressure, mean; Arterial resistance, systemic; Venous resistance; Venous tone, body (Palacios, B. (327) 183)

Vasopressin; Endothelin; Spontaneously hypertensive rat (SHR); Hemodynamics; Radiotelemetry (Balakrishnan, S.M. (334) 55)

Cardiac pacing, rapid
Bradykinin; Icatibant; Ischemic preconditioning; Ventricular arrhythmia (Kaszala, K. (328) 51)

Cardiac remodeling
Nitric oxide (NO); Collagen; Myosin heavy chain (Takaori, K. (322) 59)

Cardiac reperfusion
Arrhythmia; Acetylsalicylic acid; Cardiac ischemia; Electrophysiology; Electrocardiology; Epicardial mapping (Dhein, S. (339) 129)

Cardiocyte
Diuretic; Xipamide; Amiloride; H9c2 heart cell line; Cell membrane; (Rat, newborn) (Taouil, K. (324) 289)

Cardiomyocyte
Tetrandrine; $[Ca^{2+}]_i$ transient; Heart muscle; Ca^{2+} antagonist; Ca^{2+} release (Wang, H.-X. (319) 115)

Insulin analog; Insulin; Mitogenic activity; Insulin-like growth factor receptor (Bähr, M. (320) 259)

Lysophosphatidylcholine; Ca^{2+} overload; Ca^{2+} channel blocker; Creatine kinase (Chen, M. (333) 261)

Cardiomyocyte, isolated
Angiotensin II; Angiotensin AT_1 receptor; Contractile function; Transgenic rat (Rosenkranz, S. (330) 35)

Cardiomyocyte, ventricular
Neuropeptide Y; Receptor subtype; Contraction (McDermott, B.J. (336) 257)

Cardiomyopathy
Ca^{2+}; Hypertrophy; Ischemia; Trimetazidine; Verapamil (D'hahan, N. (328) 163)

β-Adrenoceptor subtype; Coupling efficacy; Adenylyl cyclase; Propranolol; Metoprolol; (Hamster) (Witte, K. (334) 209)

Cardioprotection
Y-26763; K^+ channel opener; Glibenclamide; K^+ channel, ATP-sensitive (Rahman, F. (317) 293)

Cardiotoxicity
Doxorubicin; Cell contraction; Ca^{2+} concentration, intracellular; Myocardial cell, single (Temma, K. (322) 235)

Cardiovascular
Opioid; Cocaine; Lethality; Blood pressure; Seizure (Patterson, A.B. (333) 47)

Cardiovascular control
Angiotensin; Heart rate; Arterial pressure; Spinal cord; Losartan; PD 123319 (Park, P.D.S. (326) 139)

Carebastine
Antihistaminic agent; Terfenadine; Ebastine; K^+ current; hKv1.5 channel (Valenzuela, C. (326) 257)

CA1 region
Free radical; H_2O_2; Hippocampus; Synaptic plasticity (Katsuki, H. (337) 213)

Cariporide (HOE642)
Na^+–H^+ exchange; Arrhythmias; Ischemia; Reperfusion (Aye, N.N. (339) 121)

L-Carnitine
Nerve conduction; Blood flow; Nitric oxide (NO); Diabetic rat (Cameron, N.E. (319) 239)

Carrageenan inflammation
Bradykinin; c-Fos; Nociception; Spinal cord (Buritova, J. (320) 73)

Casein, bovine, human
Prostate cancer; Cell line, LNCaP, DU145, PC3; Cell proliferation; δ-Opioid receptor, μ-Opioid receptor, κ-Opioid receptor; Receptor subtype; Casomorphin (Kampa, M. (335) 255)

Casomorphin
Prostate cancer; Cell line, LNCaP, DU145, PC3; Cell proliferation; δ-Opioid receptor, μ-Opioid receptor, κ-Opioid receptor; Receptor subtype; Casein, bovine, human (Kampa, M. (335) 255)

Cassia siamea
Barakol; Striatum, rat; Dopamine release; Dopamine uptake, in vitro (Thongsaard, W. (319) 157)

Catalase
Oxygen metabolite, reactive; Superoxide dismutase; Glutathione redox cycle; Colonic epithelial cell (Hata, Y. (321) 113)

Catalepsy
Antipsychotic; Dopamine D_3 receptor (Millan, M.J. (321) R7)

Dopamine D_2 receptor; Adenosine A_{2A} receptor; Striatum; Locomotion; (Rat) (Hauber, W. (323) 127)

Flupirtine; NMDA receptor, antagonistic; Locomotion; L-DOPA (L-dihydroxyphenylalanine); Parkinson's disease (Schmidt, W.J. (327) 1)

Haloperidol; Theophylline; Adenosine receptor agonist; Adenosine receptor antagonist (Mandhane, S.N. (328) 135)

Haloperidol; Muscimol; MK 801 (Kaur, S. (332) 153)

Morphine; Adenosine receptor agonist; Adenosine receptor antagonist; Naloxone; (Mouse) (Zarrindast, M.-R. (338) 11)

HU-211; NMDA receptor antagonist; Dopamine receptor antagonist; Parkinson's disease (Striem, S. (338) 205)

Catalytic subunit
Adenylyl cyclase; β-Adrenoceptor; Congenital heart disease (Reithmann, C. (330) 79)

Catecholamine
Succinate dehydrogenase, inhibition; Toxicity; Energy metabolism; Basal ganglia (Zeevalk, G.D. (320) 111)

Catecholamine release
Ibogaine; Nicotinic acetylcholine receptor (Schneider, A.S. (317) R1)

Dotarizine; Flunarizine; Lubeluzole; Chromaffin cell; Ca^{2+} channel antagonist, 'wide-spectrum' (Lara, B. (325) 109)

Catecholamine synthesis
Adrenal medulla; (F-344 rat) (Tümer, N. (324) 57)

Catechol-*O*-methyltransferase inhibition
PET (positron emission tomography); 6-[^{18}F]L-DOPA (6-[^{18}F]L-3-4-dihydroxyphenylalanine); Monoamine oxidase inhibition; Dopamine turnover (Doudet, D.J. (334) 31)

Cationic amino acid transporter
Gene expression; TNF-α (tumor necrosis factor-α); Nitric oxide (NO); Umbilical vein endothelial cell; (Human) (Irie, K. (339) 289)

Cation regulation
Neuropeptide Y receptor, Y_1 subtype; Neuropeptide Y receptor, Y_2 subtype (Parker, M.S. (318) 193)

Caudal artery
α-Adrenoceptors; Dissociation constant; Tail artery; (Bovine) (Hill, B.J.F. (339) 147)

Caudal pontine reticular formation
Acoustic startle response; Anxiety; AP-5; Fear; Glutamate receptor (Fendt, M. (318) 1)

Caudate putamen
Adenylyl cyclase; Nucleus accumbens; SKF 82958; cAMP (Unterwald, E.M. (318) 31)

Caudoputamen
Dynorphin; Substance P; Enkephalin; Acetylcholine; Dopamine; Amphetamine; Nucleus accumbens; Behavior; Muscarinic receptor (Wang, J.Q. (334) 43)

Cavernosal pressure
Adrenomedullin, Penile erection; (Cat) (Champion, H.C. (319) 71)

CC-1065 analog
Gene sequence, human; PCR (polymerase-chain reaction) (Passadore, M. (319) 317)

CCK-8
Cholecystokinin; BC 264; CCK_B receptor antagonist; L-365,260; Devazepide; CCK_A receptor antagonist; Depression; Stress; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

CCK (cholecystokinin)
CCK_A receptor antagonist; Blood pressure; Heart rate; Baroreflex; (Conscious rat) (Bunting, M.W. (337) 35)

CCK_A receptor
CHO (Chinese hamster ovary) cell; Cholecystokinin; Devazepide; L-364,718; Ca^{2+} mobilization; Cell recruitment; Receptor modelling (Smeets, R.L.L. (325) 93)

CCK_A receptor antagonist
Cholecystokinin; CCK-8; BC 264; CCK_B receptor antagonist; L-365,260; Devazepide; Depression; Stress; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

CCK (cholecystokinin); Blood pressure; Heart rate; Baroreflex; (Conscious rat) (Bunting, M.W. (337) 35)

CCK_B receptor antagonist
Cholecystokinin; CCK-8; BC 264; L-365,260; Devazepide; CCK_A receptor antagonist; Depression; Stress; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

Antinociception; Mononeuropathic rat; L-365,260; Morphine; Naloxone; Vocalization threshold; Struggle latency (Idänpään-Heikkilä, J.J. (325) 155)

CCl_4-induced liver cirrhosis
Hepatorenal syndrome; Na^+ retention; Microvascular leakage; Bradykinin B_2 receptor antagonist; HOE 140 (Icatibant) (Wirth, K.J. (337) 45)

2-chloro-N^6-cyclopentyladenosine (CCPA)
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5'-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5'-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

CD-832
Ca^{2+} channel antagonist; Stroke-prone spontaneously hypertensive rats (SHRSPs); Renal lesion (Takahashi, T. (331) 193)

Cd^{2+}
$P2X_2$ purinoceptor; pH dependence; Neuroamine; Adenosine; Zn^{2+} (Nakazawa, K. (337) 309)

Cell contraction
Doxorubicin; Cardiotoxicity; Ca^{2+} concentration, intracellular; Myocardial cell, single (Temma, K. (322) 235)

Cell culture
Hyperplasia; Smooth muscle, vascular; Nifedipine; Captopril; Losartan; Transgenic rat (Peiró, C. (324) 257)

Epilepsy; Losigamone; IPSC (inhibitory postsynaptic current); EPSC (excitatory postsynaptic current) (Draguhn, A. (325) 245)

Opioid; Estradiol; Uterus; Proliferation; (Rat) (Környei, J.L. (336) 65)

Cell damage
Glutathione; Nitric oxide (NO); Oxidant; Gastric mucosa (Wakulich, C.A. (319) 333)

Cell line, LNCaP, DU145, PC3
Prostate cancer; Cell proliferation; δ-Opioid receptor, μ-Opioid receptor, κ-Opioid receptor; Receptor subtype; Casein, bovine, human; Casomorphin (Kampa, M. (335) 255)

Cell locomotion
Neutrophils; Wortmannin; Phosphatidylinositol 3-kinase; Actin, α-Actinin (Niggli, V. (335) 43)

Cell membrane
Diuretic; Xipamide; Amiloride; Cardiocyte; H9c2 heart cell line; (Rat, newborn) (Taouil, K. (324) 289)

Cell proliferation
Prostate cancer; Cell line, LNCaP, DU145, PC3; δ-Opioid receptor, μ-Opioid receptor, κ-Opioid receptor; Receptor subtype; Casein, bovine, human; Casomorphin (Kampa, M. (335) 255)

Epiregulin; Growth factor; Tyrosine phosphorylation; Epidermal growth factor; Epidermal growth factor receptor; Gastric cell (Sasaki, E. (338) 253)

Cell recruitment
CHO (Chinese hamster ovary) cell; Cholecystokinin; CCK_A receptor; Devazepide; L-364,718; Ca^{2+} mobilization; Receptor modelling (Smeets, R.L.L. (325) 93)

Cellular transport
OK (Opossum kidney) cell; L-DOPA (L-3,4-dihydroxyphenylalanine); L-5-HTP (L-5-hydroxytryptophan); Cyanine derivative (Gomes, P. (332) 219)

Central nervous system
Nitric oxide (NO); Interleukin-1β; Prostaglandin; Plasma noradrenaline (Murakami, Y. (317) 61)

Cerebellar granule cell, cultured
Hexachlorocyclohexane isomer; Lindane; $GABA_A$ receptor; Flunitrazepam binding; GABA (γ-aminobutyric acid) binding; TBPS (*t*-butylbicyclophosphorothionate) binding (Vale, C. (319) 343)

Cerebellar nucleus
Somatostatin binding site; CH-275; CH-288 (Leroux, P. (337) 333)

Cerebellum
Acamprosate; Ethanol withdrawal; Pentylenetetrazole; Hippocampus; *c-fos* mRNA; Northern and dot blotting; In situ hybridization (Putzke, J. (317) 39)

Microdialysis; Hippocampus; Pilocarpine; Epilepsy; Amino acid (Smolders, I. (319) 21)

Ca^{2+} channel; Granule neuron; ω-Conotoxin-GVIA; ω-Agatoxin-IVA; Eliprodil (Biton, B. (323) 277)

Cerebral arteriole
CNP (C-type natriuretic peptide); BNP (brain natriuretic peptide); ANP (atrial natriuretic peptide) (Mori, Y. (320) 183)

Adrenomedullin; CGRP (calcitonin gene-related peptide); CGRP-(8–37); Amylin; Cerebral microcirculation (Mori, Y. (330) 195)

Cerebral artery, rat
Myogenic response; Pressure-induced contraction; Tyrosine kinase inhibitor; Herbimycin A; Genistein (Masumoto, N. (330) 55)

Cerebral blood flow
γ-MSH (γ-melanocyte-stimulating hormone) fragment; ACTH (adrenocorticotropic hormone) fragment; Blood pressure; Heart rate; Structure-activity relationship; (Rat) (Van Bergen, P. (318) 357)

Cerebrovascular resistance; Cerebral vasodilatation; N^G-Nitro-L-arginine methyl ester (L-NAME); Acetylcholine (Diéguez, G. (330) 185)

Cerebral blood volume
Cerebral vessel; FK888; Photoelectric method; Substance P; Tachykinin NK_1 receptor antagonist (Kobari, M. (317) 269)

Cerebral cortex
Brain damage; Pathogenesis; Receptor isoform; Receptor subtype; (Human) (Lewohl, J.M. (326) 265)

Cerebral cortex, rat
DTG (1,3-di-*o*-tolylguanidine); σ Binding site; Desipramine; Propranolol; Alprenolol (Shirayama, Y. (331) 319)

Cerebral ischemia
Adenosine kinase inhibitor; Neuronal damage (Jiang, N. (320) 131)

Platelet aggregation; Thrombosis; (Rat) (Kaku, S. (321) 301)

Defibrotide; EEG (electroencephalographic) spectral power; Memory; Neuronal damage (Sala, M. (328) 143)

HEK293 cell; Ca^{2+} channel; Na^+ channel; NNC 09-0026; CNS 1237; SB 201823-A; NS 649; Riluzole (O'Neill, M.J. (332) 121)

MRI (magnetic resonance imaging); Ancrod; Hypertensive rat; Fibrinogen; Middle cerebral artery occlusion; Therapeutic window; (Delayed therapy) (Elger, B. (336) 7)

Cerebral ischemia, focal
bFGF (basic fibroblast growth factor) (Ren, J.M. (327) 11)

Cerebral microcirculation
Adrenomedullin; CGRP (calcitonin gene-related peptide); CGRP-(8–37); Amylin; Cerebral arteriole (Mori, Y. (330) 195)

Cerebral vasodilatation
Cerebral blood flow; Cerebrovascular resistance; N^G-Nitro-L-arginine methyl ester (L-NAME); Acetylcholine (Diéguez, G. (330) 185)

Cerebral vein
Histamine H_2 receptor; Venodilation; Endothelium; Nitric oxide (NO); Prostanoid (Monge, L. (338) 135)

Cerebral vessel
Cerebral blood volume; FK888; Photoelectric method; Substance P; Tachykinin NK_1 receptor antagonist (Kobari, M. (317) 269)

Cerebrovascular regulation
5-HT receptor pharmacology; Migraine models; Aminotetralin; Inflammation, neurogenic (Petty, M.A. (336) 127)

Cerebrovascular resistance
Cerebral blood flow; Cerebral vasodilatation; N^G-Nitro-L-arginine methyl ester (L-NAME); Acetylcholine (Diéguez, G. (330) 185)

Cetiedil
Levcromakalim; Smooth muscle; Skeletal muscle (Benton, D.C.H. (317) 329)

E-C (excitation-contraction) coupling
Felodipine; Ventricular cell, guinea pig; Ca^{2+} channel, L-type; Voltage-dependent block (Kohmoto, O. (319) 355)

C-fiber
Codeine; Larynx; Trachea bifurcation; Mechanical stimulation; Cough, codeine-resistant; A-fiber (Takahama, K. (329) 93)

C-fiber reflex
Pain; Analgesia; Clomipramine; Desipramine; Tricyclic antidepressant (Mestre, C. (335) 1)

c-fos
Dopamine D_1 receptor; Hybridization in situ; Neuroleptic; (Rat) (Hurley, M.J. (318) 283)

Formalin test; Hyperalgesia; Nociception; Antisense oligodeoxynucleotide; (Intrathecal) (Hou, W.-Y. (329) 17)

Heroin; Sensitization; Deoxyglucose; Basal ganglia (Pontieri, F.E. (335) 133)

***c-fos* expression**
Homophthalazine; 2,3-benzodiazepine; Anxiolytic drug; Antipsychotic drug; Striatum (Palkovits, M. (331) 53)

[^{14}C]GABA ([^{14}C]γ-aminobutyric acid)
Bicuculline analogue, enantiomer; Uptake, quench flow; Cortex, rat (Kardos, J. (337) 83)

C6 glioma cell
Metabotropic glutamate receptor; *trans*-ACPD; G-protein (Albasanz, J.L. (326) 85)

CGP 35348
Melanotroph; $GABA_A$ receptor; Muscimol; $GABA_A$ receptor antagonist; Bicuculline; $GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

Dorsal lateral geniculate nucleus; Angiotensin; NMDA (*N*-methyl-D-aspartate); Kainate; Bicuculline; Urethane; Unit activity; (Rat) (Albrecht, D. (332) 53)

CGP 37849
Conditioned preference; Reward; NMDA receptor; Glycine site; MK-801; CGP 40116; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (317) 191)

CGP 39551 (DL-(*E*)-2-amino-4-methyl-5-phosphonopentanoate carboxy-ethylester)
Morphine tolerance; Morphine dependence; Dizocilpine; Ketamine (González, P. (332) 257)

[^{3}H]CGP-39653
Partial agonist; Binding; Allosteric modulation (Robichon, R. (328) 255)

CGP 40116
Conditioned preference; Reward; NMDA receptor; Glycine site; MK-801; CGP 37849; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (317) 191)

CGP 56999A
$GABA_B$ receptors; Epilepsy (rat); brain slices (Badran, S. (333) 135)

CGRP-(8–37)
Adrenomedullin; CGRP (calcitonin gene-related peptide); Amylin; Cerebral arteriole; Cerebral microcirculation (Mori, Y. (330) 195)

CGRP (calcitonin gene-related peptide)
Nitric oxide (NO); Nitric oxide (NO) synthase containing nerve; Vasodilation (Uchiyama, M. (321) 19)

Substance P; Superoxide; Neutrophil (Tanabe, T. (321) 137)

Amylin; Hepatocyte; Glucose metabolism; Macrophage; Kupffer cell (Pittner, R.A. (325) 189)

Electric field stimulation; Glibenclamide; K^+ channel, ATP-sensitive; Neurotransmission; Vas deferens, rat (Huang, Y. (327) 209)

Rizatriptan; Microscopy, intravital; Meningeal artery, middle; Migraine (Williamson, D.J. (328) 61)

Adrenomedullin; CGRP-(8–37); Amylin; Cerebral arteriole; Cerebral microcirculation (Mori, Y. (330) 195)

CGRP (calcitonin gene-related peptide), human
Amylin; Ulcer; Capsaicin; Domperidone; Neostigmine (Clementi, G. (332) 209)

CGRP (calcitonin gene-related peptide) release
Acetylcholine release; Neostigmine; Phrenic nerve-diaphragm muscle preparation (Kimura, I. (330) 123)

CH-275
Somatostatin binding site; CH-288; Cerebellar nucleus (Leroux, P. (337) 333)

CH-288
Somatostatin binding site; CH-275; Cerebellar nucleus (Leroux, P. (337) 333)

Charybdotoxin
NS 1619; Glibenclamide; K^+ channel, Ca^{2+}-activated; Ca^{2+} channel; Vas deferens, rat (Huang, Y. (325) 21)

Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Apamin; Splanchnic nerve stimulation; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Smooth muscle; K^+ channels; Ca^{2+} stores; Apamin; Pacemaker cells (Duridanova, D.B. (333) 105)

Chelerythrine
Protein kinase C; Phosphodiesterase, cyclic nucleotide; Vasorelaxation; SK&F 94120; Isoprenaline (Eckly-Michel, A.E. (324) 85)

Chemoprevention
Lung cancer; K-*ras*; Proliferating cell nuclear antigen; Vitamin E (Yano, T. (323) 99)

Chemotaxis
Antidepressant; Inflammation; Macrophage (Sacerdote, P. (319) 287)

Chemotherapeutic
P-glycoprotein; Ca^{2+} current; Verapamil (Nanaumi, K. (327) 239)

Chinese hamster ovary cell
Clozapine; Muscarinic m4 receptor; Neuroleptic, atypical; Neuroleptics, typical; cAMP; Striatum, rat (Zeng, X.P. (321) 349)

Chloral hydrate
Microdialysis; (Rat) (Pan, W.H.T. (317) 205)

Chlorambucil
GLUT1 transporter; Glucose; Blood–brain barrier; Erythrocyte (Halmos, T. (318) 477)

4'-Chlordiazepam
Neurosteroids; Morphine; Pregnenolone sulfate; Allopregnanolone; Progesterone; Opiate tolerance; Opiate dependence (Reddy, D.S. (337) 19)

Chlordiazepoxide
Anxiety; Elevated plus-maze; Clozapine; L-745,870; L-741,742; Dopamine D_4 receptor; Mouse (Cao, B.-J. (335) 117)

Chlorethylclonidine
α_1-Adrenoceptor, subtype; Endogenous noradrenaline; WB4101; Positive inotropic action; Myocardium, rabbit (Hattori, Y. (329) 165)

Chloride ion
α_1-Adrenoceptor; Niflumic acid; Two-kidney one-clip hypertensive rat; Mesenteric blood vessel (He, Y. (328) 191)

2-Chloroadenosine
Electrical kindling; Seizure; Epileptogenesis; Amygdala; Adenosine A_1 receptor, pre-synaptic (Abdul-Ghani, A.-S. (326) 7)

Chloro-APB
Talipexole; Pramipexole; MPTP-induced hemiparkinsonism; SKF 82958; Dopamine D_1-like receptor agonist; Dopamine D_2-like receptor agonist; (Monkey) (Domino, E.F. (325) 137)

Chloroethylclonidine
α_{1D}-Adrenoceptor; Renal artery; Contraction; BMY 7378; 5-Methylurapidil (Villalobos-Molina, R. (322) 225)

α_1-Adrenoceptor, subtype; 5-Methylurapidil; WB 4101; BMY 7378; $^{86}Rb^+$, influx rate; Inositol 1,4,5-trisphosphate (Viko, H. (323) 269)

Prazosin; Aorta; Spleen; Submandibular gland; α_1-Adrenoceptor; α_2-Adrenoceptor; (Rat) (O'Rourke, M. (336) 37)

Ventricular pacing, rapid; Heart failure; Blood vessel; α_1-Adrenoceptor subtype (Le Tran, Y. (336) 177)

7-Chlorokynurenic acid
NMDA receptor; MK-801; Ifenprodil; Diazepam withdrawal; (Mouse) (Tsuda, M. (324) 63)

***p*-Chloromercuriphenylsulfonic acid**
Phosphoserine phosphatase; L-Serine; D-Serine; Glycerylphosphorylcholine; Phosphorylcholine; *N*-Ethylmaleimide (Hawkinson, J.E. (337) 315)

***p*-Chlorophenylalanine**
5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; WAY-100635; Hippocampus; Excitatory synaptic transmission; $5\text{-}HT_{1A}$ receptor; Excitatory postsynaptic potential; Ultrasonic vocalization; Anxiolytic (Xu, L. (323) 59)

***m*-Chlorophenylbiguanide**
$5\text{-}HT_3$ receptor; Gastric motility; Ramosetron; (Force transducer) (Nagakura, Y. (327) 189)

Chlorpromazine
TNF (tumor necrosis factor); Endotoxin (Ghezzi, P. (317) 369)

Locus coeruleus; α_{2A}-Adrenoceptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); ARC 239 (2-[2-[4-(*o*-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethyl-1,3(2H,4H)-isoquinolinedione) (Ruiz-Ortega, J.A. (333) 159)

CHO cell
α_2-Adrenoceptor subtype; [^{3}H]RX821002 binding; Adenylyl cyclase; cAMP (Pohjanoksa, K. (335) 53)

α_2-Adrenoceptor subtype; Antagonist potency; GTPase (Virolainen, S. (338) 293)

CHO (Chinese hamster ovary) cell
Thrombin receptor; Adenosine A_1 receptor; P_{2U} purinoceptor; Inositol phosphate; Arachidonic acid; Protein kinase C (Dickenson, J.M. (321) 77)

Cholecystokinin; CCK_A receptor; Devazepide; L-364,718; Ca^{2+} mobilization; Cell recruitment; Receptor modelling (Smeets, R.L.L. (325) 93)

Choice reaction time
Attention; σ Receptor; Phencyclidine (Jin, J. (319) 147)

Cholecystokinin
CCK-8; BC 264; CCK_B receptor antagonist; L-365,260; Devazepide; CCK_A receptor antagonist; Depression; Stress; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

CHO (Chinese hamster ovary) cell; CCK_A receptor; Devazepide; L-364,718; Ca^{2+} mobilization; Cell recruitment; Receptor modelling (Smeets, R.L.L. (325) 93)

Cholera toxin
Intestinal fluid transport; Nitric oxide (NO); 5-HT (5-hydroxytryptamine, serotonin); Oral rehydration solution (Beubler, E. (326) 223)

Cholestasis
Bile duct ligation; Sodium tauroursodeoxycholate (UR-906); Dehydrocholic acid; Blood coagulation factor; (Rat) (Ishizaki, K. (333) 207)

Cholesterol
Plasma; Liver; Bile; Gallstone; Cholesterol 7α-hydroxylase; Acyl coenzyme A:cholesterol acyltransferase (Hajri, T. (320) 65)

Cholesterol, high
Tranilast; Hyperplasia, intimal; Balloon injury (Fukuyama, J. (318) 327)

Cholesterol 7α-hydroxylase
Cholesterol; Plasma; Liver; Bile; Gallstone; Acyl coenzyme A:cholesterol acyltransferase (Hajri, T. (320) 65)

Pravastatin sodium; HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase; LDL (low-density lipoprotein) receptor; (Rat) (Fujioka, T. (323) 223)

Choline acetyltransferase
Ginsenoside; Scopolamine; Maze; Septum, medial (Yamaguchi, Y. (329) 37)

Cholinergic
Adenosine; ATP; GABA (γ-aminobutyric acid); Nitric oxide (NO); Ileum; Terminal (Pencheva, N. (339) 193)

Cholinergic hypertension
Amygdala; AV3V region; Carbachol; Blood pressure; Heart rate (Tellioğlu, T. (336) 163)

Cholinergic system, central
Arterial blood pressure; c-Fos; Neostigmine (Li, J. (337) 227)

Cholinergic transmission
Detrusor muscle, rat; Purinergic transmission; Cromakalim; Atropine; Suramin; Nifedipine (Boselli, C. (335) 23)

Cholinesterase inhibition
Metrifonate; Spatial navigation; Alzheimer's disease; Medial septal-lesion (Riekkinen, M. (338) 105)

Cholinesterase inhibitor
Alzheimer's disease; Acetylcholine; Basal forebrain lesion; Scopolamine; (Rat) (Itoh, A. (322) 11)

Aging; Metrifonate; Object recognition; Acetylcholine, release (Scali, C. (325) 173)

Chorda tympani
Cyclosporine chronopharmacology; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Ornithine decarboxylase; Norepinephrine uptake; Acetylcholine synthesis; Superior cervical ganglion (Esquifino, A.I. (319) 181)

Chorioallantoic membrane
Wortmannin; Phosphatidylinositol 3-kinase inhibitor; Anti-angiogenic activity; Angiogenesis, embryonic (Oikawa, T. (318) 93)

Choriocarcinoma cell, human
5-HT (5-hydroxytryptamine, serotonin) transporter; Tyrosine kinase inhibitor; Tyrosine phosphorylation; Transcription (Prasad, P.D. (325) 85)

Chorionic surface artery
P_{2X} purinoceptor; Placenta, human, term; α,β-Methylene-ATP; UTP receptor; Smooth muscle, vascular (Dobronyi, I. (320) 61)

S-4C3H-PG ((*S*)-4-carbonyl-3-hydroxyphenylglycine)
Metabotropic glutamate receptor; MSOP ((*RS*)-α-methylserine-*O*-phosphate); Drinking conflict test; Intrahippocampal injection (Chojnacka-Wójcik, E. (319) 153)

Chromaffin cell
ω-Toxin; Ca^{2+} channel; Neuronal nicotinic receptor; Ca^{2+} channel antagonist (Villarroya, M. (320) 249)

Dotarizine; Flunarizine; Lubeluzole; Catecholamine release; Ca^{2+} channel antagonist, 'wide-spectrum' (Lara, B. (325) 109)

Epibatidine; Substance P; Noradrenaline release; Adrenaline release (Krause, W. (328) 249)

Nicotinic receptor; Forskolin; 1,9-Dideoxy-forskolin; Ca^{2+} channel (Gandía, L. (329) 189)

Chromium mesoporphyrin
Vasomotor control; Heme-L-lysinate (Kozma, F. (323) R1)

Chronic administration
Nicotine; Tail-tremor; Nitric oxide (NO); NMDA receptor (Suemaru, K. (335) 139)

Chronic transversal
Microdialysis; Amphetamine, repeated; Ventral striatum; Dopamine release; Dopamine synthesis; Behavioral sensitization (Imperato, A. (317) 231)

Chronic treatment
Dopamine receptor; Mesolimbic dopamine system; Antidepressant drug; Fluoxetine (Collu, M. (322) 123)

LSD (lysergic acid diethylamide); Biogenic amines; Ca^{2+} channel; Nifedipine; Brain (Antkiewicz-Michaluk, L. (332) 9)

Chronotropism
Sinus node; Efonidipine; Action potential; Ca^{2+} channel antagonist; Ca^{2+} channel, T-type (Masumiya, H. (335) 15)

Ciliary muscle, bovine
Muscarinic receptor; Desensitization; Protein kinase C (Daniele, E. (330) 247)

1,8-cineole
Paw oedema; Mast cell; Compound 48/80; Ketotifen; Cyproheptadine; (Rat) (Santos, F.A. (331) 253)

Cinnamoylamino group
Morphine derivative; β-Endorphin receptor; Analgesia; (Irreversible antagonist); (Mouse) (McLaughlin, J.P. (320) 121)

Circadian rhythm
α_2-Adrenoceptor; Pineal gland; Melatonin; Medetomidine; Atipamezole (Mustanoja, S.M. (326) 229)

Circular muscle
5-HT_3 receptor; Colon, guinea pig; Longitudinal muscle; Tachykinin (Yamano, M. (317) 353)

Adrenergic transmission; Purinergic transmission; Contractile response; Development; Vas deferens; (Guinea pig) (Ren, L.-M. (318) 411)

Histamine H_3 receptor; Prejunctional receptor; Intramural reflex; Peristalsis; Ileum, guinea pig (Poli, E. (327) 49)

Circulation
Non-steroidal anti-inflammatory drug; Kidney; Prostanoid; Plasma renin activity; Cytochrome *P*-450 activity; Na^+ excretion (Kramp, R.A. (330) 165)

Circulatory filling pressure, mean
Pranidipine (OPC-13340); Ca^{2+} channel antagonist; Venodilator effect; (Rat) (Hirano, T. (324) 201)

Endothelin-1; Cardiac output; Arterial resistance, systemic; Venous resistance; Venous tone, body (Palacios, B. (327) 183)

Circumflex artery, right, pig
Levcromakalim; Quaternary ion; K^+ channel antagonist; Tetraphenylphosphonium; Triphenylphosphonium compound (Piekarska, A.E. (322) 37)

Cisapride
Gastrointestinal motility; Migrating motor complex; Force transducer; (Ferret) (Nagakura, Y. (321) 53)

Cisplatin
Anti-emetic; Ondansetron; Dexamethasone; (Acute and delayed) (Rudd, J.A. (322) 79)

Citric acid
Cough reflex; 5-HT (5-hydroxytryptamine, serotonin); Ketanserin; Methysergide (Stone, R.A. (332) 201)

L-Citrulline
Arginase; L-Arginine; Nitric oxide (NO) synthase; Prostate; (Pig); (Rabbit); (Rat) (Di Iulio, J.L. (337) 245)

Cl^- current
Niflumic acid; Noradrenaline; Caffeine; Glibenclamide; Smooth muscle (Kirkup, A.J. (317) 165)

Cl^- secretion
Cocaine; Short-circuit current; Trachea; Gland cell (Chan, M.-H. (334) 281)

$^{36}Cl^-$ uptake
Stress; Ethanol; Ro 15-4513; Plus-maze; Sleep; [^{3}H]Ro 15-4513 (Pokk, P. (317) 15)

Clearance
Endothelin-1; Endothelin receptor antagonist; Bosentan; PD155080; Half-life; Vascular effect (Hemsén, A. (318) 369)

Clenbuterol
β-Adrenoceptor agonist; Isoproterenol; Mast cell; Allergic reaction; Vascular permeability (Inagaki, N. (336) 225)

7-Cl-Kynurenic acid
Glycine receptor, strychnine-insensitive; NMDA receptor; [^{3}H]Dopamine release; [^{3}H]Noradrenaline release; Synaptosome; HA 966; GV 150526A (Mennini, T. (336) 275)

Clocinnamox
μ-Opioid receptor; Downregulation; Tolerance; Fentanyl; DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); Analgesia (Chan, K.W. (319) 225)

Analgesia; Morphine; [^{3}H]DAMGO ([^{3}H][D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]-enkephalin); Opioid receptor binding; (Rat) (Paronis, C.A. (337) 27)

Clomipramine
Antisense oligonucleotide; K^+ channel; mKv1.1; Analgesia; Antinociception; Amitriptyline; Tricyclic antidepressant; (Mouse) (Galeotti, N. (330) 15)

Pain; Analgesia; C-fiber reflex; Desipramine; Tricyclic antidepressant (Mestre, C. (335) 1)

Clonidine
Morphine; Nociception; Formalin test (Przesmycki, K. (337) 11)

Clorgyline
Locomotor sensitization; Dopamine receptor agonist; D_2/D_3 receptor (Culver, K.E. (339) 109)

Clotrimazole
Acetylcholine; Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Nitric oxide (NO); Nitro-L-arginine (Fujimoto, S. (330) 177)

Clozapine
Dopamine D_4 receptor; L 745,870; Noradrenaline; Adrenaline; [^{35}S]GTPγS (Newman-Tancredi, A. (319) 379)

Muscarinic m4 receptor; Neuroleptic, atypical; Neuroleptics, typical; cAMP; Chinese hamster ovary cell; Striatum, rat (Zeng, X.P. (321) 349)

Anxiety; Elevated plus-maze; L-745,870; L-741,742; Dopamine D_4 receptor; Chlordiazepoxide; Mouse (Cao, B.-J. (335) 117)

Cortical DA release; Serotonin 5-HT_{1A} receptor (Rollema, H. (338) R3)

CNP (C-type natriuretic peptide)
Ethanol; ANP (atrial natriuretic peptide); Hypertension (Guillaume, P. (319) 215)

BNP (brain natriuretic peptide); ANP (atrial natriuretic peptide); Cerebral arteriole (Mori, Y. (320) 183)

Kidney; Angiotensin II; Norepinephrine; Vasoconstriction; (Dog) (Yoshida, K. (338) 131)

CNS 1237
HEK293 cell; Ca^{2+} channel; Na^+ channel; NNC 09-0026; SB 201823-A; NS 649; Riluzole; Cerebral ischaemia (O'Neill, M.J. (332) 121)

[^{3}H]CNQX (6-cyano-7-nitro-quinoxaline-2,3-dione)
Autoradiography; [^{3}H]AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Antipsychotic drug (McCoy, L. (318) 41)

Cocaethylene drug–drug discrimination
Stimulus properties of drugs; Cocaine; Ethanol; (Dose–response); (Rat) (Schechter, M.D. (320) 1)

Cocaine
Microdialysis, brain; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Striatum (Norton, C.S. (318) 323)

Aspartate; Glutamate; Nucleus accumbens; Sensitization; (Rat) (Robinson, S.E. (319) 31)

2-Deoxyglucose autoradiography; Microdialysis; Dopamine; Autoreceptor antagonist; Drug addiction (Koch, S. (319) 173)

Stimulus properties of drugs; Ethanol; Cocaethylene drug–drug discrimination; (Dose–response); (Rat) (Schechter, M.D. (320) 1)

Drug self-administration; Morphine; κ-Opioid receptor; U50,488H; (Rat); (Mouse) (Kuzmin, A.V. (321) 265)

Dextromethorphan; Self-administration; NMDA receptor antagonist (Pulvirenti, L. (321) 279)

Opioid; Drug discrimination; Drug interaction (Suzuki, T. (324) 21)

Drug discrimination; MDMA (3,4-methylenedioxymethamphetamine); Dose response; Cumulative dosing; (Rat) (Schechter, M.D. (326) 113)

Balb/c mouse; Heroin; Self-administration, intravenous; Speedball; (Mouse) (Roberts, A.J. (326) 119)

Behavioral sensitization; Development, ontogeny; Neonatal rat; Preweanling rat (Tirelli, E. (328) 103)

MDMA (3,4-methylenedioxymethamphetamine); Dopamine (Morgan, A.E. (331) R1)

Opioid; Lethality; Cardiovascular; Blood pressure; Seizure (Patterson, A.B. (333) 47)

Cl^- secretion; Short-circuit current; Trachea; Gland cell (Chan, M.-H. (334) 281)

Hepatotoxicity; Nitric oxide (NO); Reactive oxygen species; (Mouse) (Aoki, K. (336) 43)

Ibogaine; Noribogaine; 18-Methoxycoronaridine; Motor activity (Maisonneuve, I.M. (336) 123)

Corticosterone; Deoxyglucose; (Rat) (Patacchioli, F.R. (336) 159)

Additivity; Dopamine; Heroin; Microdialysis; Nicotine; Nucleus accumbens; Speedball; Synergism; (Interaction) (Zernig, G. (337) 1)

Molecular biology; Collagen; Myosin; Atrial natriuretic factor; Left ventricular hypertrophy; (Rat) (Besse, S. (338) 123)

Convulsion; Lethality; NMDA receptor; Toxicity (Matsumoto, R.R. (338) 233)

Codeine
Larynx; Trachea bifurcation; Mechanical stimulation; Cough, codeine-resistant; C-fiber; A-fiber (Takahama, K. (329) 93)

Cognex
Tacrine; Acetylcholine; Vacuous chew; Purposeless; Tremor; Parkinson's disease; Alzheimer's disease (Cousins, M.S. (322) 137)

Cognition
$GABA_B$ receptor antagonism; GAERS (genetic absence epilepsy rat of Strasbourg); Absence epilepsy (Getova, D. (320) 9)

Cognitive function
Nimodipine; Metrifonate; EEG (electroencephalograph), cortical; (Rat) (Jäkälä, P. (318) 239)

Colitis
Interleukin-10; Inflammation; Nitric oxide (NO); TNF-α (tumor necrosis factor-α) (Ribbons, K.A. (323) 245)

Collagen
Cardiac remodeling; Nitric oxide (NO); Myosin heavy chain (Takaori, K. (322) 59)

Cocaine; Molecular biology; Myosin; Atrial natriuretic factor; Left ventricular hypertrophy; (Rat) (Besse, S. (338) 123)

Colon
Neurotensin; Ca^{2+} channel, L-type; Mechanical activity (Mulè, F. (319) 269)

Apamin; DMPP (1,1-dimethyl-4-phenylpiperazinium iodide); Nitric oxide (NO); P_{2y} purinoceptor; Reactive blue 2; (Rat) (Börjesson, L. (334) 223)

Nitric oxide (NO); N^G-nitro-L-arginine methyl ester (L-NAME); Inflammation; Nitric oxide (NO) synthase, constitutive; Nitric oxide (NO) synthase, inducible (Kiss, J. (336) 219)

Colon, distal
5-HT_3 receptor; Short-circuit current (I_{sc}); Ramosetron (YM060, (−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); (Rat) (Kiso, T. (320) 187)

Colon, guinea pig
5-HT_3 receptor; Longitudinal muscle; Circular muscle; Tachykinin (Yamano, M. (317) 353)

Colonic distension
5-HT_3 receptor antagonist; Visceral hypersensitivity; (Rat) (Langlois, A. (318) 141)

Colonic epithelial cell
Oxygen metabolite, reactive; Superoxide dismutase; Glutathione redox cycle; Catalase (Hata, Y. (321) 113)

Colonic hypersensitivity
Fedotozine; κ-Opioid receptor; μ-Opioid receptor; Visceral pain; (Colonic distension) (Langlois, A. (324) 211)

Complex partial seizure
Electrical kindling; Epilepsy; NMDA receptor (Ebert, U. (322) 179)

Compound 48/80
Microdialysis; Histamine; Paw edema; Mast cell deficient rat (Ws/Ws rat); Degranulation (Guo, Y. (331) 237)

1,8-cineole; Paw oedema; Mast cell; Ketotifen; Cyproheptadine; (Rat) (Santos, F.A. (331) 253)

Conditioned drug effect
Appetitive discrimination; Occasion setting; Midazolam; Amphetamine; Unconditioned drug effect (Maes, J.H.R. (319) 5)

Conditioned fear stress
σ Receptor; Dopaminergic system; Nucleus accumbens; Motor suppression; (Rat) (Kamei, H. (319) 165)

Conditioned place preference
Diabetes; Opioid receptor; Morphine; Naloxonazine; Reinforcement (Kamei, J. (337) 137)

Conditioned preference
Reward; NMDA receptor; Glycine site; MK-801; CGP 37849; CGP 40116; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (317) 191)

Conditioning
NMDA receptor antagonist; Electrical brain stimulation; Reward; (Rat) (Bespalov, A. (326) 109)

Conflict
Anxiety; Neurosteroid; 3α-Hydroxy-5α-pregnan-20-one; $GABA_A$ receptor; Benzodiazepine (Brot, M.D. (325) 1)

Conformational states, multiple
Signal transduction; Thermodynamic model; Ligand efficacy; Inverse agonist (Pardo, L. (335) 73)

Congenital heart disease
Adenylyl cyclase; β-Adrenoceptor; Catalytic subunit (Reithmann, C. (330) 79)

Connective tissue
Edema; α-Trinositol; Capillary permeability; Trachea; Skin (rat); Inflammation; Anaphylaxis (Koller, M.-E. (331) 259)

ω-Conotoxin GVIA
Ca^{2+} channel; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Agatoxin IVA; Vas deferens; Purinergic neurotransmission (Hirata, H. (321) 217)

Ca^{2+} channel; Cerebellum; Granule neuron; ω-Agatoxin-IVA; Eliprodil (Biton, B. (323) 277)

Ca^{2+} channel, voltage-dependent; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Conotoxin SVIB; ω-Agatoxin IVA; Neurotransmission (Tran, S. (335) 31)

ω-Conotoxin MVIIA
Ca^{2+} channel; ω-Conotoxin GVIA; ω-Conotoxin MVIIC; ω-Agatoxin IVA; Vas deferens; Purinergic neurotransmission (Hirata, H. (321) 217)

Ca^{2+} channel, voltage-dependent; ω-Conotoxin GVIA; ω-Conotoxin MVIIC; ω-Conotoxin SVIB; ω-Agatoxin IVA; Neurotransmission (Tran, S. (335) 31)

ω-Conotoxin MVIIC
Ca^{2+} channel; ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Agatoxin IVA; Vas deferens; Purinergic neurotransmission (Hirata, H. (321) 217)

Ca^{2+} channel, voltage-dependent; ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin SVIB; ω-Agatoxin IVA; Neurotransmission (Tran, S. (335) 31)

ω-Conotoxin SVIB
Ca^{2+} channel, voltage-dependent; ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Agatoxin IVA; Neurotransmission (Tran, S. (335) 31)

Constitutive activity
Metabotropic glutamate receptor; Alternative splicing; G-protein coupled receptor; Phospholipase C coupling (Mary, S. (335) 65)

Contextual conditioning
Metabotropic glutamate (mGlu) receptor; AIDA (1-aminoindan-1,5-dicarboxylic acid) (Nielsen, K.S. (326) 105)

Contractile function
Angiotensin II; Angiotensin AT_1 receptor; Cardiomyocyte, isolated; Transgenic rat (Rosenkranz, S. (330) 35)

Contractile response
5-HT receptor; Stomach fundus, rat; Acetylcholine release (Amemiya, N. (318) 403)

Adrenergic transmission; Purinergic transmission; Circular muscle; Development; Vas deferens; (Guinea pig) (Ren, L.-M. (318) 411)

Ondansetron; Stomach fundus; Acetylcholine release; (Rat) (Amemiya, N. (339) 173)

Contractility
α-Adrenoceptor, subtype; Atrial muscle; Papillary muscle; BMY 7378; (Rat) (Wang, S.-N. (321) 39)

N^{ω}-nitro-L-arginine; Nitric oxide (NO) donor; Heart muscle; Guanylate cyclase, soluble; Heart rate; (Rat) (Kojda, G. (334) 181)

Gastric fundus, rat; Endotoxin; Nitric oxide (NO); Prostaglandin $F_{2\alpha}$ (Lefebvre, R.A. (339) 201)

Contraction
Cyclopiazonic acid; Ca^{2+}-ATPase; Sarcoplasmic reticulum; Smooth muscle; Stomach (Petkov, G.V. (318) 109)

Mesenteric artery; Adrenergic nerve; Excitatory junctional potential; Amiloride (Shimamura, K. (320) 37)

α_1-Adrenoceptor, subtype; Ca^{2+} concentration, intracellular; Smooth muscle, vascular; Fura-2 (Tognarini, D.P. (322) 31)

α_{1D}-Adrenoceptor; Renal artery; BMY 7378; Chloroethylclonidine; 5-Methylurapidil (Villalobos-Molina, R. (322) 225)

Noradrenaline uptake inhibitor; Protriptyline; Amitriptyline; Xylamine; Electric field stimulation; Vas deferens, rat (Huang, Y. (327) 41)

Ca^{2+}; Trachea; Econazole; Miconazole; SK&F 96365; Nifedipine (Li, L. (331) 221)

Brefeldin A; Smooth muscle, vascular; Ca^{2+} entry (Filipeanu, C.M. (332) 71)

Neuropeptide Y; Receptor subtype; Cardiomyocyte, ventricular (McDermott, B.J. (336) 257)

Contraction, rhythmic
Cyclopiazonic acid; Nitric oxide (NO); Endothelium; K^+ channel; Mesenteric artery, rat (Huang, Y. (332) 167)

Convulsion
Cocaine; Lethality; NMDA receptor; Toxicity (Matsumoto, R.R. (338) 233)

Coordinate gene regulation
Benzodiazepine tolerance; Gene expression (Holt, R.A. (329) 129)

Coronary artery
SIN-1 (3-morpholinosydnonimine); Nitric oxide (NO); K_{ATP} channel; Vasodilation; Glibenclamide (Deka, D.K. (330) 157)

Dotarizine; $5\text{-}HT_2$ receptor; Ca^{2+} channels; *Xenopus* oocytes (Montiel, C. (332) 183)

Coronary artery, bovine
Vascular heterogeneity; Glyceryl trinitrate; *S*-Nitroso-*N*-acetylpenicillamine; Sodium nitroprusside; Isoprenaline (De la Lande, I.S. (318) 65)

Coronary artery, canine
Vasoconstriction; Vasodilation; P2 purinoceptor; ATP; UTP; Suramin; Reactive blue 2 (Matsumoto, T. (334) 173)

Coronary artery, pig
Sulphonylurea; Levcromakalim; Thromboxane A_2; U46619; Structure-activity relationship (McPherson, G.A. (324) 193)

Coronary artery disease
Adenosine; Lactate; Myocardial ischaemia; Ventricular function (De Jonge, R. (337) 41)

Coronary artery smooth muscle cell
Mitogenesis; Thromboxane A_2; PDGF (platelet-derived growth factor) (Grosser, T. (319) 327)

Coronary circulation
Smooth muscle, vascular; *N*-Nitro-L-arginine methyl ester (L-NAME); Ouabain; Adenosine receptor; EDHF (endothelium-derived hyperpolarizing factor) (Olanrewaju, H.A. (322) 185)

Coronary microvessel
Acetylcholine; Nitroglycerin; Heart failure; L-Arginine; Nitric oxide (NO) (Larosa, G. (318) 387)

Coronary small artery
Endothelium; Nitric oxide (NO); Acetylcholine; A23187; Apamin; K^+ channel (Simonsen, U. (329) 153)

Coronary vessel
Adenosine; Myocardial ischemia, myocardial stunning; Myocardial ischemia, reperfusion injury (Kurz, M.A. (322) 211)

Cortex
Epilepsy; Hippocampus; Thalamus; c-Fos; $GABA_B$ receptor antagonist (Vergnes, M. (332) 245)

Cortex, prefrontal
Methamphetamine; Synaptogenesis, reactive; GABA (γ-aminobutyric acid), innervation; (Gerbil) (Dawirs, R.R. (327) 117)

Cortex, rat
NMDA receptor antagonist, non-competitive; Electrophysiology; Spinal cord, rat; Enantiomer (Ebert, B. (333) 99)

Bicuculline analogue, enantiomer; [^{14}C]GABA ([^{14}C]γ-aminobutyric acid); Uptake, quench flow (Kardos, J. (337) 83)

Cortical DA release
Clozapine; Serotonin 5-HT_{1A} receptor (Rollema, H. (338) R3)

Cortical neuron
Phosphodiesterase; Rolipram; cAMP (Yamashita, N. (337) 95)

Cortical neuron, mouse
Membrane potential; Antiepileptics; Cromakalim; Glibenclamide; Patch-clamp electrophysiology; NG 108-15 cell; hNT neuron (Rundfeldt, C. (336) 243)

Cortical tubule
Dopamine D_3 receptor; Kidney; Radioligand binding assay; Autoradiography; Glomerulus (Barili, P. (338) 89)

Cortical wedge
NMDA receptor; Non-NMDA receptor; Antiepileptic (Phillips, I. (337) 189)

Corticoliberin
Sauvagine; Urotensin I; CRF (corticotropin-releasing factor); Epithelium; Edema; Ca^{2+}; Inositol trisphosphate; CRF receptor; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

Corticosteroid
Steroid resistance; Cytokine; Asthma; Mononuclear blood cell (Larsson, S. (334) 265)

Corticosterone
Immediate-early gene; Amygdala, central; Bed nucleus of the stria terminalis; Paraventricular nucleus of the hypothalamus; CRH (corticotropin-releasing hormone) (Compaan, J.C. (324) 161)

Steroid hormone; Aldosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cell, in vitro, porcine; Nitrofuran; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

5-HT_{1A} receptor; 5-HT_2 receptor; Body temperature; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Wet-dog shake (Takao, K. (333) 123)

Cocaine; Deoxyglucose; (Rat) (Patacchioli, F.R. (336) 159)

Cortisol
Steroid hormone; Aldosterone; Corticosterone; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cell, in vitro, porcine; Nitrofuran; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

TNF-α (tumor necrosis factor-α); TNF-β; Acute-phase-response; Fever; Interleukin-6; Hypothalamic–pituitary–adrenal axis (Goldbach, J.-M. (334) 249)

Corymine
Xenopus oocytes; $GABA_A$ receptor; Glycine receptor (Leewanich, P. (332) 321)

Cough, codeine-resistant
Codeine; Larynx; Trachea bifurcation; Mechanical stimulation; C-fiber; A-fiber (Takahama, K. (329) 93)

Cough reflex
Citric acid; 5-HT (5-hydroxytryptamine, serotonin); Ketanserin; Methysergide (Stone, R.A. (332) 201)

Coupling efficacy
Cardiomyopathy; β-Adrenoceptor subtype; Adenylyl cyclase; Propranolol; Metoprolol; (Hamster) (Witte, K. (334) 209)

Covalent labelling
Muscarinic receptor; Muscarinic receptor, m2 subtype; Sf9 cell; Aryldiazonium salt (Weill, C. (333) 269)

CP-060S
Ca^{2+} channel; Smooth muscle, vascular; Electrophysiology; Voltage clamp; Ca^{2+} channel antagonist (Ohya, Y. (330) 93)

CP 55,940
Cannabinoid receptor; SR 141716A; Brain slice; Acetylcholine (Gifford, A.N. (324) 187)

CP-93,129
Spinal cord; Nociception; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; Cyanopindolol; WAY100635 (Gjerstad, J. (335) 127)

CP 101,606
Glutamate receptor; Allosteric antagonism; *Xenopus* oocyte; Ifenprodil; Ro 25-6981; Haloperidol (Whittemore, E.R. (337) 197)

CP-154,526
CRF (Corticotropin-releasing factor); Depression; Learned helplessness; (Rat) (Mansbach, R.S. (323) 21)

3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene)
Adenosine analog; Audiogenic seizure; Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

8-CPT (8-cyclopentyltheophylline)
Long-term potentiation; Depotentiation; Adenosine A_1 receptor antagonist; Synaptic plasticity, modulation of; Hippocampal CA1 neuron (Fujii, S. (331) 9)

Creatine kinase
Cardiomyocyte; Lysophosphatidylcholine; Ca^{2+} overload; Ca^{2+} channel blocker (Chen, M. (333) 261)

Creatine kinase activity
Neutrophil adherence; Myeloperoxidase activity; Interleukin-1β; Neutrophil accumulation (Hayward, R. (334) 157)

CRF (corticotropin-releasing factor)
Inflammation; Histamine; Arachidonic acid (Correa, S.G. (319) 85)

Depression; Learned helplessness; CP-154,526; (Rat) (Mansbach, R.S. (323) 21)

Sauvagine; Urotensin I; Corticoliberin; Epithelium; Edema; Ca^{2+}; Inositol trisphosphate; CRF receptor; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

GLP-1 (glucagon-like peptide-1); Hypothalamic-pituitary-adrenal axis; Feeding behavior; (Chicken) (Furuse, M. (339) 211)

CRF receptor
Sauvagine; Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Edema; Ca^{2+}; Inositol trisphosphate; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

CRH (corticotropin-releasing hormone)
Immediate-early gene; Amygdala, central; Bed nucleus of the stria terminalis; Paraventricular nucleus of the hypothalamus; Corticosterone (Compaan, J.C. (324) 161)

Cromakalim
Vas deferens, rat; Purinergic transmission; Noradrenergic transmission; Prazosin; Suramin; Glibenclamide (Grana, E. (319) 57)

K^+ channel opener; Diazoxide; Mesenteric bed, rat; Endothelium; Nitric oxide (NO) (Feleder, E.C. (319) 229)

Reperfusion arrhythmia; Pinacidil; Glibenclamide; Anesthetized rat (Baczkó, I. (324) 77)

Detrusor muscle, rat; Purinergic transmission; Cholinergic transmission; Atropine; Suramin; Nifedipine (Boselli, C. (335) 23)

Membrane potential; Antiepileptic; Glibenclamide; Patch-clamp electrophysiology; NG 108-15 cell; hNT neuron; Cortical neuron, mouse (Rundfeldt, C. (336) 243)

Cross talk
Ca^{2+} imaging; cAMP; Phenylglycine (Schaffhauser, H. (334) 289)

[^{3}H]5-CT
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1D} receptor; [^{3}H]-GR 125,743; (Guinea pig) (Audinot, V. (327) 247)

Cu^{2+}
Nitric oxide (NO); cGMP; Nitric oxide (NO) donor (Ohnishi, T. (319) 49)

Culture
Vitamin B; Cytotoxicity; Glutamate; Retina (Kaneda, K. (322) 259)

Cumulative dosing
Drug discrimination; Cocaine; MDMA (3,4-methylenedioxymethamphetamine); Dose response; (Rat) (Schechter, M.D. (326) 113)

[^{3}H]CV-11974
Candesartan (CV-11974); Losartan; Angiotensin AT_1 receptor; Association rate constant; Dissociation rate constant (Ojima, M. (319) 137)

Cyanine derivative
OK (Opossum kidney) cell; L-DOPA (L-3,4-dihydroxyphenylalanine); L-5-HTP (L-5-hydroxytryptophan); Cellular transport (Gomes, P. (332) 219)

Cyanopindolol
Spinal cord; Nociception; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; CP-93,129; WAY100635 (Gjerstad, J. (335) 127)

Cyclooxygenase
Alveolar macrophage; Nitric oxide (NO); Lipoxygenase; Leukotriene B_4 (Brunn, G. (326) 53)

Arterial thrombosis; Thromboxane A_2; Platelet aggregation (Shimazawa, M. (328) 183)

Aceclofenac; Prostaglandin E_2; Polymorphonuclear leukocyte; Monocyte; Synovial cell (Yamazaki, R. (329) 181)

Adenosine transport, Na^+-dependent; Brush-border membrane vesicle; Prostanoid; Non-steroidal anti-inflammatory drug (NSAID) (González-Castillo, C. (329) 245)

Non-steroidal anti-inflammatory drug; Formalin; Release, in vitro; Spinal cord; Prostaglandin E_2; (Intrathecal) (Dirig, D.M. (331) 155)

Cyclooxygenase-1
Allergic inflammation, recurrence of; Granulation tissue; Prostaglandin E_2; Cyclooxygenase-2; NS-398; Indomethacin; Dexamethasone (Niki, H. (320) 193)

Auranofin; Prostaglandin E_2; 12-*O*-Tetradecanoylphorbol 13-acetate; Thapsigargin; A23187; Cyclooxygenase 2; Macrophage (Yamashita, M. (325) 221)

Cyclooxygenase-2
Nitric oxide synthase, inducible (NO); Western blot; Lipopolysaccharide; cAMP; Indomethacin; Cytotoxicity (Pang, L. (317) 151)

Allergic inflammation, recurrence of; Granulation tissue; Prostaglandin E_2; Cyclooxygenase-1; NS-398; Indomethacin; Dexamethasone (Niki, H. (320) 193)

Auranofin; Prostaglandin E_2; 12-*O*-Tetradecanoylphorbol 13-acetate; Thapsigargin; A23187; Cyclooxygenase 1; Macrophage (Yamashita, M. (325) 221)

Cyclooxygenase 2 inhibitor; Pyresis; Telemetry; (Squirrel monkey) (Chan, C.-C. (327) 221)

Nimesulide; Antipyretic action; Hypothalamus; Yeast-induced hyperthermia; RT-PCR (reverse transcription and polymerase chain reaction) (Taniguchi, Y. (330) 221)

Cyclooxygenase 2 inhibitor
Cyclooxygenase 2; Pyresis; Telemetry; (Squirrel monkey) (Chan, C.-C. (327) 221)

Cyclopentyltheophylline
Adenosine; Purine; (−)-Bicuculline; GABA (γ-aminobutyric acid); Paired-pulse inhibition; Inhibition; Hippocampus (Higgins, M.J. (317) 215)

Cyclopiazonic acid
Ca^{2+}-ATPase; Sarcoplasmic reticulum; Smooth muscle; Stomach; Contraction (Petkov, G.V. (318) 109)

Nitric oxide (NO); Endothelium; Vasodilation; N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Rahimian, R. (327) 143)

Nitric oxide (NO); Endothelium; K^+ channel; Contractions, rhythmic; Mesenteric artery, rat (Huang, Y. (332) 167)

D-Cycloserine
Glycine site; NMDA receptor; Acetylcholine; Hippocampus; Working memory (Ohno, M. (318) 267)

Memory impairment; Temporal cortex; Entorhinal cortex; Recovery of function; (Microinjection) (Myhrer, T. (328) 1)

Cyclosporin A
Cyclosporin H; FK506; Eosinophil; Apoptosis (Kitagaki, K. (337) 283)

Cyclosporine chronopharmacology
Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Ornithine decarboxylase; Norepinephrine uptake; Acetylcholine synthesis; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (319) 181)

Cyclosporin H
Cyclosporin A; FK506; Eosinophil; Apoptosis (Kitagaki, K. (337) 283)

Cyproheptadine
1,8-cineole; Paw oedema; Mast cell; Compound 48/80; Ketotifen; (Rat) (Santos, F.A. (331) 253)

Cyproterone acetate
Opioid; Steroid; Binding (Gutiérrez, M. (328) 99)

Cysteamine
Gastroduodenal ulceration; Gastroduodenal mucosa; Testosterone; Sexual dimorphism; Sexual steroid; Microcirculation; Microvascular leakage (László, F. (337) 275)

Cysteinyl-leukotriene receptor antagonist
Guinea pig; Ileum; BAY u9773 (Bäck, M. (317) 107)

Cytochrome P450
Isoproterenol; β_1-Adrenoceptor; β_2-Adrenoceptor; Endothelium; Relaxation; Aortic ring, rat (Satake, N. (319) 37)

Cytochrome *P*-450 activity
Non-steroidal anti-inflammatory drug; Kidney; Circulation; Prostanoid; Plasma renin activity; Na^+ excretion (Kramp, R.A. (330) 165)

Cytochrome P-450IID6
[^{3}H]GBR 12935 binding; Piperazine acceptor site; Platelet, human (Norlén, M. (332) 227)

Cytochrome *P*-450 inhibitor
Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Anandamide; K^+ channel; Cannabinoid (Randall, M.D. (333) 191)

Cytokine
Anti-Thy1 nephritis; OPC15161; Matrix index; Superoxide radical; Tubulointerstitial index (Hamada, N. (317) 123)

Adjuvant arthritis; Immunoregulation (Conforti, A. (324) 241)

Anandamide; Palmitoylethanolamide; Tetrahydrocannabinol; Cannabinoid receptors; Mononuclear cells; Immune response (Berdyshev, E.V. (330) 231)

Steroid resistance; Corticosteroid; Asthma; Mononuclear blood cell (Larsson, S. (334) 265)

Cytoprotection
Melatonin; Free radical; Ischemia-reperfusion; Gastric ulceration; Gastric blood flow (Konturek, P.Ch. (322) 73)

Cytoskeleton
Calmodulin antagonist; Glycolysis; Melanoma cell (Glass-Marmor, L. (328) 241)

Cytosolic free Ca^{2+}
Melanotroph; $GABA_A$ receptor; Muscimol; $GABA_A$ receptor antagonist; Bicuculline; $GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; CGP 35348; Fura-2 (Shibuya, I. (321) 241)

Cytotoxicity
Nitric oxide synthase, inducible (NO); Cyclooxygenase-2; Western blot; Lipopolysaccharide; cAMP; Indomethacin (Pang, L. (317) 151)

Nitric oxide (NO); Nitrosothiol; Glutathione; *N*-Acetylcysteine; Glucose; Lipopolysaccharide; Macrophage (Zamora, R. (321) 87)

Vitamin B; Culture; Glutamate; Retina (Kaneda, K. (322) 259)

σ Receptor; Regulation; Internalization; (+)-Pentazocine; Desensitization (Zambon, A.C. (324) 39)

Natural killer cell; Macrophage; Enkephalin; Endorphin (Kowalski, J. (326) 251)

DY-9760e; W-7; Calmodulin antagonist; Neuroprotection (Sugimura, M. (336) 99)

Dalteparin
YM-60828; Argatroban; Heparin; Arterio–venous shunt; Bleeding time (Sato, K. (339) 141)

Daltroban
Thromboxane; Smooth muscle, vascular; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; SQ 29,548; BM-13505; SQ 30,741; AA-2414 (Zhang, R. (317) 91)

DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly-ol^5]enkephalin)
Analgesia; Morphine; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Dynorphin; Nor-binaltorphimine; β-Funaltrexamine (Reche, I. (318) 11)

μ-Opioid receptor; Downregulation; Tolerance; Fentanyl; Clocinnamox; Analgesia (Chan, K.W. (319) 225)

Antinociception; Diabetes; Protein kinase C; Calphostin C; (Mouse) (Ohsawa, M. (339) 27)

[^{3}H]DAMGO ([^{3}H][D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]-enkephalin)
Analgesia; Morphine; Clocinnamox; Opioid receptor binding; (Rat) (Paronis, C.A. (337) 27)

Dantrolene
Dihydropyridine; Anti-epileptic; Electroshock, maximal; Seizure (Borowicz, K.K. (323) 45)

Nitric oxide (NO) synthase II; Lipopolysaccharide; Mortality; Hemodynamic alteration (Wu, C.-C. (327) 17)

DCG-IV
Metabotropic glutamate receptor; NMDA receptor; AP5 (D-2-amino-5-phosphonopentanoic acid) (Breakwell, N.A. (322) 173)

DDT$_1$MF-2 cell
Δ^9-tetrahydrocannabinol; $[Ca^{2+}]_i$ (Filipeanu, C.M. (336) R1)

Defibrotide
Hyperbaric oxygen; Heart, rat; Ischemia, low flow; *N*-Acetylcysteine (Radice, S. (320) 43)

Cerebral ischemia; EEG (electroencephalographic) spectral power; Memory; Neuronal damage (Sala, M. (328) 143)

Degranulation
ABT-491; PAF (platelet-activating factor); PAF receptor antagonist; Ca^{2+} flux; Superoxide anion; Vascular permeability; Endotoxemia (Albert, D.H. (325) 69)

Microdialysis; Histamine; Paw edema; Mast cell deficient rat (Ws/Ws rat); Compound 48/80 (Guo, Y. (331) 237)

Dehydrocholic acid
Bile duct ligation; Sodium tauroursodeoxycholate (UR-906); Blood coagulation factor; Cholestasis; (Rat) (Ishizaki, K. (333) 207)

Dehydroepiandrosterone
GABA (γ-aminobutyric acid); Pregnanolone; Tetrahydrodeoxycorticosterone; Pregnenolone sulfate; Neuroactive steroid; Pituitary melanotrope cell; Patch-clamp (Le Foll, F. (331) 303)

[D-Ala^2]Deltorphin II
[D-Pen^2,L-Pen^5]Enkephalin; Spontaneous alternation performance; Elevated plus-maze behavior; Passive avoidance learning; δ-Opioid receptor; (Mouse) (Ukai, M. (338) 1)

[D-Ala^2,Glu^4]Deltorphin II
DPDPE ([D-Pen^2,D-Pen^5]enkephalin); δ_1-/δ_2-opioid receptor agonist; NMDA receptor antagonist; MK-801, LY 235959 (Cao, Y.-J. (335) 161)

Deoxycortisol
Steroid hormone; Aldosterone; Corticosterone; Cortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cell, in vitro, porcine; Nitrofuran; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Deoxyglucose
Heroin; Sensitization; Basal ganglia; c-*fos* (Pontieri, F.E. (335) 133)

Corticosterone; Cocaine; (Rat) (Patacchioli, F.R. (336) 159)

Amphetamine administration, chronic; Sensitization; SKF 38393; Quinpirole (Huang, Y.-H. (338) 117)

2-Deoxyglucose autoradiography
Microdialysis; Dopamine; Autoreceptor antagonist; Cocaine; Drug addiction (Koch, S. (319) 173)

Depotentiation
Metabotropic glutamate receptor; 1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitatory postsynaptic potential; CA1 area; Hippocampus; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

Long-term potentiation; Adenosine A_1 receptor antagonist; 8-CPT (8-cyclopentyltheophylline); Synaptic plasticity, modulation of; Hippocampal CA1 neuron (Fujii, S. (331) 9)

(−)-Deprenyl
Aging; IGF-I (insulin-like growth factor-I); Tyrosine hydroxylase; (Rat) (De la Cruz, C.P. (327) 215)

Depression
Cholecystokinin; CCK-8; BC 264; CCK_B receptor antagonist; L-365,260; Devazepide; CCK_A receptor antagonist; Stress; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

CRF (Corticotropin-releasing factor); Learned helplessness; CP-154,526; (Rat) (Mansbach, R.S. (323) 21)

Phencyclidine; Antidepressant; Schizophrenia, negative symptom; 5-HT (5-hydroxytryptamine, serotonin); Forced swimming test; (Mouse) (Noda, Y. (324) 135)

Forced swimming test; Wistar-Kyoto rat; Brown Norway rat; Sprague-Dawley rat; Imipramine; 5-HT_1 receptor; 5-HT_2 receptor; β-Adrenoceptor (Lahmame, A. (337) 115)

Des-Arg^9-bradykinin
Des-Arg^9-[Leu^8]bradykinin; Umbilical vein, human; Bradykinin B_1 receptor; Sensitization (Sardi, S.P. (321) 33)

Inflammation; Arthritis; Prostaglandin E_2; HOE-140; (Rat) (Tonussi, C.R. (326) 61)

Gallbladder, guinea pig; Bradykinin B_1 receptor-selective antagonist; Bradykinin B_2 receptor-selective antagonist; Prostanoid; Ca^{2+} (Cabrini, D.A. (331) 31)

Des-Arg^9-[Leu^8]bradykinin
Des-Arg^9-bradykinin; Umbilical vein, human; Bradykinin B_1 receptor; Sensitization (Sardi, S.P. (321) 33)

Descending inhibition
Nociception; Non-steroidal anti-inflammatory drug; Raphe magnus (Jones, S.L. (318) 37)

Desensitization
σ Receptor; Cytotoxicity; Regulation; Internalization; (+)-Pentazocine (Zambon, A.C. (324) 39)

Dopamine; Dopamine D_1 receptor; Palmitoylation; Adenylyl cyclase (Jin, H. (324) 109)

β-Adrenoceptor; Adenylyl cyclase; Protein kinase, cAMP dependent; Receptor density (Rousseau, G. (326) 75)

Ciliary muscle, bovine; Muscarinic receptor; Protein kinase C (Daniele, E. (330) 247)

Desipramine
DTG (1,3-di-*o*-tolylguanidine); σ Binding site; Propranolol; Alprenolol; Cerebral cortex, rat (Shirayama, Y. (331) 319)

Antidepressant; Microtubule-associated protein 2; Microtubule assembly; Phosphorylation (Miyamoto, S. (333) 279)

Pain; Analgesia; C-fiber reflex; Clomipramine; Tricyclic antidepressant (Mestre, C. (335) 1)

Detrusor muscle, rat
Purinergic transmission; Cholinergic transmission; Cromakalim; Atropine; Suramin; Nifedipine (Boselli, C. (335) 23)

Devazepide
Cholecystokinin; CCK-8; BC 264; CCK_B receptor antagonist; L-365,260; CCK_A receptor antagonist; Depression; Stress; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

CHO (Chinese hamster ovary) cell; Cholecystokinin; CCK_A receptor; L-364,718; Ca^{2+} mobilization; Cell recruitment; Receptor modelling (Smeets, R.L.L. (325) 93)

Development
Duodenum longitudinal muscle, rat; Duodenum muscularis mucosae, rat; P_1 purinoceptor; Ontogeny; Adenosine receptor (Brownhill, V.R. (317) 321)

Adrenergic transmission; Purinergic transmission; Contractile response; Circular muscle; Vas deferens; (Guinea pig) (Ren, L.-M. (318) 411)

Angiotensin II; EDRF (endothelium-derived relaxing factor); Prostanoid; Mesenteric artery; Mesenteric vein; Aging (Konishi, C. (320) 175)

Cannabinoid; Lung; Type II cell; Ontogeny; Steroid (Rice, W. (327) 227)

Opiate; β-Endorphin; Insulin; Growth; Ornithine decarboxylase mRNA; Intracerebroventricular (Bartolome, J.V. (331) 145)

Development, ontogeny
Behavioral sensitization; Cocaine; Neonatal rat; Preweanling rat (Tirelli, E. (328) 103)

Dexamethasone
Endotoxin; Nitric oxide (NO) synthase; Myocardial contractility; β-Adrenoceptor; Mercaptoethylguanidine (Sun, X. (320) 29)

Allergic inflammation, recurrence of; Granulation tissue; Prostaglandin E_2; Cyclooxygenase-1; Cyclooxygenase-2; NS-398; Indomethacin (Niki, H. (320) 193)

Cisplatin; Anti-emetic; Ondansetron; (Acute and delayed) (Rudd, J.A. (322) 79)

Ischemia-reperfusion arrhythmia; Endotoxin; L-Canavanine; Nitric oxide (NO) synthase, inducible (Iskit, A.B. (326) 183)

Peripheral-type benzodiazepine receptor; RT-PCR (reverse transcriptase-polymerase chain reaction); GAPDH (glyceraldehyde-3-phosphate dehydrogenase); Stress (Siripurkpong, P. (331) 227)

Dextromethorphan
Cocaine; Self-administration; NMDA receptor antagonist (Pulvirenti, L. (321) 279)

Diabetes
Aldose reductase; Anococcygeus muscle, rat; Nitrergic neurotransmission; Nitric oxide (NO); Sorbinil (Way, K.J. (318) 101)

Methamphetamine; Place preference; Dopamine D_3 receptor; Mesolimbic dopamine system; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Kamei, J. (318) 251)

5-HT (5-hydroxytryptamine); Protein kinase C; Endothelin-1; Aorta (James, G.M. (322) 55)

Nociception, formalin-induced; δ_1-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben; (Mouse) (Kamei, J. (326) 31)

Conditioned place preference; Opioid receptor; Morphine; Naloxonazine; Reinforcement (Kamei, J. (337) 137)

Antinociception; DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); Protein kinase C; Calphostin C; (Mouse) (Ohsawa, M. (339) 27)

BTS 67 582; Islets of Langerhans; Insulin release; Imidazoline receptor (Dickinson, K. (339) 69)

Diabetes mellitus
Endothelium; Nitric oxide (NO); Arginine (Pieper, G.M. (317) 317)

Adrenergic nerve; Nerve blood flow; Noradrenaline; Sciatic nerve, rat (Vo, P.A. (329) 147)

Diabetes mellitus, non-insulin dependent
Metformin; Insulin; Erythrocyte membrane; Lipid fluidity (Muller, S. (337) 103)

Diabetic rat
Nerve conduction; Blood flow; L-Carnitine; Nitric oxide (NO) (Cameron, N.E. (319) 239)

Streptozotocin; Ca^{2+}; Calmodulin; Calmidazolium; Insulin; Intestinal reactivity (Öztürk, Y. (321) 59)

Diabetic retinopathy
Aldose reductase inhibitor; Electroretinogram; Sorbitol; Platelet aggregation; 2,3-Diphosphoglycerate (Hotta, N. (326) 45)

Diadenosine pentaphosphate
Diinosine pentaphosphate; ATP (Hoyle, C.H.V. (333) R1)

Diadenosine polyphosphate
Brain; Adenosine; Microwave; Adenine nucleotide; (Rat) (Delaney, S.M. (332) 35)

Diastolic
Ventricular mass; Ion-selective microelectrode; Ca^{2+} level (Lopez, J.R. (339) 161)

Diazepam
5-HT (5-hydroxytryptamine, serotonin); Withdrawal; $5\text{-}HT_{1A}$ receptor; Raphe nucleus, dorsal; Electrophysiological recording (Lanfumey, L. (323) 137)

Diazepam withdrawal
NMDA receptor; MK-801; 7-Chlorokynurenic acid, Ifenprodil; (Mouse) (Tsuda, M. (324) 63)

Diazepam-binding inhibitor
Endozepine; Octadecaneuropeptide (ODN); Benzodiazepine receptor; Glial cell; Ca^{2+} mobilization (Gandolfo, P. (322) 275)

Diazoxide
K^+ channel opener; Cromakalim; Mesenteric bed, rat; Endothelium; Nitric oxide (NO) (Feleder, E.C. (319) 229)

Diclofenac
Substance P; Analgesia (Papworth, J. (325) R1)

1,9-Dideoxy-forskolin
Nicotinic receptor; Forskolin; Chromaffin cell; Ca^{2+} channel (Gandía, L. (329) 189)

Differentiation
Topoisomerase I; U-937 cell (Shayo, C.C. (324) 129)

Digitalis arrhythmia
HOE642; Na^+/H^+ exchange; Na^+/Ca^{2+} exchange; Arrhythmia ischemia; Arrhythmia reperfusion (Xue, Y.X. (317) 309)

Dihydrexidine
Dopamine D_2 receptor; Locomotor activity; Sedation; Vacuous chewing; Yawning (Smith, H.P. (323) 27)

Dihydroethidium
Free radical; Glutamate; Pyrroloquinoline quinone; NMDA receptor; Redox modulatory site (Scanlon, J.M. (326) 67)

Dihydroetorphine
Etorphine; Antinociception; Physical dependence; (Rhesus monkey); (Mouse) (Aceto, M.D. (338) 215)

Dihydropyridin
Elgodipine; Blood pressure; Tachycardia, reflex (Valdivielso, J.M. (335) 193)

1,4-Dihydropyridine
Diltiazem; Ca^{2+} channel, L-type; Ca^{2+} channel antagonist; Cardiac myocyte; Ventricular myocyte; (Rat) (Kanda, S. (319) 101)

Dihydropyridine
Dantrolene; Anti-epileptic; Electroshock, maximal; Seizure (Borowicz, K.K. (323) 45)

Ca^{2+} channels; Motor effects; Drug discrimination (Cohen, C. (336) 113)

Dihydropyridine Ca^{2+} channel blocker
Asthma; Drug combination; Interaction; Smooth muscle, airway; Trachea; β_2-Adrenoceptor agonist; Methylxanthine; K^+ channel opener; Sodium nitroprusside (Thirstrup, S. (326) 191)

Dihydrorhodamine-123
Oxidative burst; ANP (atrial natriuretic peptide); Fluorescent latex bead; Immune function; Flow cytometry (Vollmar, A.M. (319) 279)

Dihydrotetrabenazine
Monoamine transporter, vesicular; Monoamine (Kilbourn, M. (331) 161)

Vesicular monoamine transporter type-2 (VMAT2); Dopamine transporter, neuronal membrane; Methamphetamine; Amphetamine; WIN 35,428; Dopamine (Frey, K. (334) 273)

Diinosine pentaphosphate
Diadenosine pentaphosphate; ATP (Hoyle, C.H.V. (333) R1)

Diltiazem
1,4-Dihydropyridine; Ca^{2+} channel, L-type; Ca^{2+} channel antagonist; Cardiac myocyte; Ventricular myocyte; (Rat) (Kanda, S. (319) 101)

Semotiadil; Amlodipine; Nifedipine; Ca^{2+} current; Ventricular myocyte (Koidl, B. (322) 243)

Benzothiazepine; Verapamil; Ca^{2+} channel antagonist; Ventricular myocyte; Ca^{2+} channel, L-type (Kurokawa, J. (325) 229)

***d-cis*-Diltiazem**
l-cis-Diltiazem; Veratridine; Ca^{2+} overload; Na^+ overload; Myocyte; (Rat) (Itogawa, E. (317) 401)

***l-cis*-Diltiazem**
d-cis-Diltiazem; Veratridine; Ca^{2+} overload; Na^+ overload; Myocyte; (Rat) (Itogawa, E. (317) 401)

Dimalonic acid C_{60}
Smooth muscle; Endothelium; Nitric oxide (NO); Superoxide dismutase (Satoh, M. (327) 175)

Dimaprit
Histamine H_2 receptor; TNF-α (tumor necrosis factor α); Hepatitis; Septic shock; Inflammation (Nakamura, T. (322) 83)

Lingual artery, dog; Histamine H_1 receptor; 2-Pyridylethylamine; (Cannula insertion method) (Chiba, S. (329) 63)

2,3-Diphosphoglycerate
Aldose reductase inhibitor; Electroretinogram; Sorbitol; Platelet aggregation; Diabetic retinopathy (Hotta, N. (326) 45)

Discriminative stimulus effect
Haloperidol; (+)-AJ76; (+)-UH-232; (+)-PD 128907; (−)-Apomorphine; Dopamine D_3 receptor (Kleven, M.S. (321) 1)

Disopyramide
K^+ current, muscarinic acetylcholine receptor-operated ($I_{K,ACh}$); Pirmenol; Atrial fibrillation (Watanabe, Y. (338) 71)

Dissociation constant
α-Adrenoceptors; Caudal artery; Tail artery; (Bovine) (Hill, B.J.F. (339) 147)

Dissociation rate constant
Candesartan (CV-11974); [^{3}H]CV-11974; Losartan; Angiotensin AT_1 receptor; Association rate constant (Ojima, M. (319) 137)

Diuretic
Xipamide; Amiloride; Cardiocyte; H9c2 heart cell line; Cell membrane; (Rat, newborn) (Taouil, K. (324) 289)

Dizocilpine
σ Receptor; Phencyclidine (PCP) receptor; Head-weaving behavior; (Rat) (Kitaichi, K. (318) 205)

Dopamine receptor; Electroconvulsive shock; NMDA receptor; Supersensitivity (D'Aquila, P.S. (330) 11)

Morphine tolerance; Morphine dependence; Ketamine; CGP 39551 (DL-(*E*)-2-amino-4-methyl-5-phosphonopentanoate carboxy-ethylester) (González, P. (332) 257)

Dizocilpine-induced amnesia
σ_1 Receptor; N^{ω}-Nitro-L-arginine methyl ester (L-NAME), induced amnesia; NMDA receptor; Learning (Maurice, T. (328) 9)

DMPP (1,1-dimethyl-4-phenyl-piperazinium)
Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; Acetylcholine; Muscarine (Nagayama, T. (327) 135)

DMPP (1,1-dimethyl-4-phenylpiperazinium iodide)
Apamin; Colon; Nitric oxide (NO); P_{2y} purinoceptor; Reactive blue 2; (Rat) (Börjesson, L. (334) 223)

DNA double-strand breaks
Hydrogen peroxide; L-Histidine; Pulsed field gel electrophoresis; Apoptosis; Necrosis (Palomba, L. (318) 167)

DNA fragmentation
Endotoxin; Antioxidant (Haendeler, J. (317) 407)

Apoptosis; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Nicotinamide (Mukherjee, S.K. (330) 27)

DNA synthesis
EGF (epidermal growth factor); β-Adrenoceptor agonist; Forskolin; Hepatocyte proliferation (Kimura, M. (324) 267)

DOCA (deoxycorticosterone acetate)-salt hypertension
Endothelin-1; Endothelin ET_A receptor; Renal function; Urine formation (Matsumura, Y. (319) 65)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
SR 46349B; 5-HT_{2A} receptor; Anxiety; Elevated plus-maze; [^{3}H]Ketanserin binding; RHA and RLA (Roman high- and low-avoidance) rats (Chaouloff, F. (334) 25)

Domoic acid
Kainate; Hippocampus; GABA (γ-aminobutyric acid) release; Glutamate; Synaptosome (Cunha, R.A. (323) 167)

Domperidone
Amylin; Ulcer; CGRP (calcitonin gene-related peptide), human; Capsaicin; Neostigmine (Clementi, G. (332) 209)

DOPAC (3,4-dihydroxyphenylal acetic acid)
Dopamine receptor agonist; PNU-95,666; PD128907; Median eminence (Durham, R.A. (335) 37)

L-DOPA (3,4-dihydroxyphenyl-L-alanine)
Striatum; Early gene; Parkinson's disease; Dopamine D_1 receptor; Dopamine D_2 receptor (Fenu, S. (321) 143)

L-DOPA (L-dihydroxyphenylalanine)
Flupirtine; NMDA receptor, antagonistic; Catalepsy; Locomotion; Parkinson's disease (Schmidt, W.J. (327) 1)

L-DOPA (L-3,4-dihydroxyphenylalanine)
OK (Opossum kidney) cell; L-5-HTP (L-5-hydroxytryptophan); Cyanine derivative; Cellular transport (Gomes, P. (332) 219)

6-[^{18}F]L-DOPA (6-[^{18}F]L-3-4-dihydroxyphenylalanine)
PET (positron emission tomography); Catechol-*O*-methyltransferase inhibition; Monoamine oxidase inhibition; Dopamine turnover (Doudet, D.J. (334) 31)

Dopamine
Striatum; Pregnancy; Progesterone; NMDA (*N*-methyl-D-aspartic acid); Glutamate (Cabrera, R.J. (317) 55)

GDNF (glial cell line-derived neurotrophic factor); Substantia nigra; Striatum; Parkinson's disease; Monoamine (Martin, D. (317) 247)

Acetylcholine; Dopamine D_1 receptor; Dopamine D_2 receptor; Microdialysis; Neostigmine; Striatum (DeBoer, P. (317) 257)

Ethanol preference; SKF 38393; Raclopride; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); Risperidone; SCH 23390; (Rat) (Silvestre, J.S. (318) 257)

Microdialysis, brain; Cocaine; 5-HT (5-hydroxytryptamine, serotonin); Striatum (Norton, C.S. (318) 323)

2-Deoxyglucose autoradiography; Microdialysis; Autoreceptor antagonist; Cocaine; Drug addiction (Koch, S. (319) 173)

Adenosine; Caffeine; Carbamazepine; Microdialysis (Okada, M. (321) 181)

Quinpirole; Dopamine D_2 receptor; Rilmenidine; α-Methyldopa; Hydralazine; Sympathetic nervous system; Vasopressin (Van den Buuse, M. (322) 191)

Excitatory amino acid; Anticonvulsant; Anxiolytic; Psychosis (Baron, B.M. (323) 181)

Substantia nigra reticulata; Antipsychotic; Schizophrenia; Basal ganglion; Electrophysiology; 5-HT (5-hydroxytryptamine, serotonin) (Bruggeman, R. (324) 49)

Dopamine D_1 receptor; Palmitoylation; Adenylyl cyclase; Desensitization (Jin, H. (324) 109)

Nicotine; Hippocampus, ventral; Nucleus accumbens; Striatum; Noradrenaline (Benwell, M.E.M. (325) 13)

Voltammetry, in vivo; Striatum; Dopamine D_2 receptor antagonist; Behavior; (Rat) (Horikawa, H.P.M. (326) 15)

NMDA (*N*-methyl-D-aspartate); Nitric oxide (NO); Oxytocin; Penile erection; Yawning; Paraventricular nucleus of the hypothalamus; (Rat) (Melis, M.R. (328) 115)

Formalin test; Mazindol; Lidocaine; Antinociception; Opioid (Bittencourt, A.L. (330) 109)

Dopamine D_4-receptors; RBI-257; U-101,958 (Kula, N.S. (331) 333)

MDMA (3,4-methylenedioxymethamphetamine); Cocaine (Morgan, A.E. (331) R1)

Neurotensin; Haloperidol; Striatum; Nucleus accumbens (Huang, W. (332) 15)

HI 6; Microdialysis; Pharmacokinetics; Acetylcholine esterase; Soman; (Rat) (Cassel, G. (332) 43)

AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid); Antipsychotic; Behavior; Schizophrenia; (Mouse) (Vanover, K.E. (332) 115)

Dynorphin; Substance P; Enkephalin; Acetylcholine; Amphetamine; Nucleus accumbens; Caudoputamen; Behavior; Muscarinic receptor (Wang, J.Q. (334) 43)

Ethanol; Hexamethonium; Microdialysis, in vivo; Mecamylamine; Nicotinic acetylcholine receptor (Blomqvist, O. (334) 149)

Kidney; D_2-like receptor; Innervation; Radioligand binding assay; Autoradiography; (Rat) (Barili, P. (334) 233)

Vesicular monoamine transporter type-2 (VMAT2); Dopamine transporter, neuronal membrane; Methamphetamine; Amphetamine; Dihydrotetrabenazine; WIN 35,428 (Frey, K. (334) 273)

Dopamine D_2 receptor; Dopamine D_3 receptor; Learning; Memory (Sigala, S. (336) 107)

Additivity; Cocaine; Heroin; Microdialysis; Nicotine; Nucleus accumbens; Speedball; Synergism; (Interaction) (Zernig, G. (337) 1)

Reserpine; Oral dyskinesia; Tongue protrusion; Tardive dyskinesia (Sussman, A.N. (337) 157)

Stratium, ventral; Amphetamine; Stress; Microdialysis; (Relapse) (Weiss, F. (337) 219)

Dopamine agonist
Dopamine D_2 receptor; Dopamine autoreceptor; Postsynaptic dopamine receptor (Piercey, M.F. (317) 29)

Dopamine autoreceptor
Dopamine D_2 receptor; Dopamine agonist; Postsynaptic dopamine receptor (Piercey, M.F. (317) 29)

Dopamine D_2 autoreceptor
Imipramine; mRNA; Ventral tegmental area; (Rat) (Dziedzicka-Wasylewska, M. (337) 291)

Dopamine D_1 / D_2 interaction
Dopamine 'D_1-like' receptor; Dopamine 'D_2-like' receptor; LY 270411; BW 737C; SCH 23390; Grooming behavior; Vacuous chewing; Myoclonic jerking; (Rat) (Deveney, A.M. (317) 175)

Dopamine 'D_1-like' receptor
Dopamine 'D_2-like' receptor; D_1/D_2 interaction; LY 270411; BW 737C; SCH 23390; Grooming behavior; Vacuous chewing; Myoclonic jerking; (Rat) (Deveney, A.M. (317) 175)

Dopamine 'D_2-like' receptor
Dopamine 'D_1-like' receptor; D_1/D_2 interaction; LY 270411; BW 737C; SCH 23390; Grooming behavior; Vacuous chewing; Myoclonic jerking; (Rat) (Deveney, A.M. (317) 175)

Na^+ pump; Proximal tubule; Kidney; (Rat) (Hussain, T. (321) 259)

Kidney; Dopamine; Innervation; Radioligand binding assay; Autoradiography; (Rat) (Barili, P. (334) 233)

Dopamine D_1-like receptor agonist
Talipexole; Pramipexole; Chloro-APB; MPTP-induced hemiparkinsonism; SKF 82958; Dopamine D_2-like receptor agonist; (Monkey) (Domino, E.F. (325) 137)

Dopamine D_2-like receptor agonist
Talipexole; Pramipexole; Chloro-APB; MPTP-induced hemiparkinsonism; SKF 82958; Dopamine D_1-like receptor agonist; (Monkey) (Domino, E.F. (325) 137)

Dopamine D_1 receptor
A-86929; ABT-431; Hyperactivity; Seizure; Tolerance (Shiosaki, K. (317) 183)

Acetylcholine; Dopamine; Dopamine D_2 receptor; Microdialysis; Neostigmine; Striatum (DeBoer, P. (317) 257)

L-DOPA (3,4-dihydroxyphenyl-L-alanine); Striatum; Early gene; Parkinson's disease; Dopamine D_2 receptor (Fenu, S. (321) 143)

Dopamine; Palmitoylation; Adenylyl cyclase; Desensitization (Jin, H. (324) 109)

ATP; Neurotransmission; α_2-Adrenoceptor; Vas deferens, guinea-pig (Furukawa, T. (328) 229)

cAMP; Dopamine D_2 receptor; Striatum; Parkinson's disease (Pinna, A. (331) 23)

Dopamine D_2 receptor; α_2-Adrenoceptor; Pial vein; (Constriction); (Porcine) (Sun, M.-H. (334) 165)

Medial prefrontal cortex; Substantia nigra; Ventral tegmental area (Dewar, K.M. (336) 155)

Dopamine D_2 receptor
Dopamine agonist; Dopamine autoreceptor; Postsynaptic dopamine receptor (Piercey, M.F. (317) 29)

Acetylcholine; Dopamine; Dopamine D_1 receptor; Microdialysis; Neostigmine; Striatum (DeBoer, P. (317) 257)

Neuropeptide Y; Dopamine release; G_i-protein; Striatum; Spontaneously hypertensive rat (SHR) (Tsuda, K. (321) 5)

L-DOPA (3,4-dihydroxyphenyl-L-alanine); Striatum; Early gene; Parkinson's disease; Dopamine D_1 receptor (Fenu, S. (321) 143)

Up-regulation; Antipsychotic drug, atypical; 5-HT_{2A} receptor; Striatum (Ishikane, T. (321) 163)

Quinpirole; Dopamine; Rilmenidine; α-Methyldopa; Hydralazine; Sympathetic nervous system; Vasopressin (Van den Buuse, M. (322) 191)

Dihydrexidine; Locomotor activity; Sedation; Vacuous chewing; Yawning (Smith, H.P. (323) 27)

Adenosine A_{2A} receptor; Striatum; Locomotion; Catalepsy; (Rat) (Hauber, W. (323) 127)

cAMP; Dopamine D_1 receptor; Striatum; Parkinson's disease (Pinna, A. (331) 23)

Dopamine D_1 receptor; α_2-Adrenoceptor; Pial vein; (Constriction); (Porcine) (Sun, M.-H. (334) 165)

Dopamine; Dopamine D_3 receptor; Learning; Memory (Sigala, S. (336) 107)

Dopamine D_2 / D_3 receptor
Locomotor sensitization; Dopamine receptor agonist; Clorgyline (Culver, K.E. (339) 109)

Dopamine D_3 receptor
Diabetes; Methamphetamine; Place preference; Mesolimbic dopamine system; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Kamei, J. (318) 251)

c-*fos*; Hybridization in situ; Neuroleptic; (Rat) (Hurley, M.J. (318) 283)

Haloperidol; (+)-AJ76; (+)-UH-232; (+)-PD 128907; (−)-Apomorphine; Discriminative stimulus effect (Kleven, M.S. (321) 1)

Antipsychotic; Catalepsy (Millan, M.J. (321) R7)

R-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-*N*,*N*-(di-*n*-propyl-2-amino)tetralin); Passive avoidance learning; Spontaneous locomotor activity; Memory; (Mouse) (Ukai, M. (324) 147)

Dopamine; Dopamine D_2 receptor; Learning; Memory (Sigala, S. (336) 107)

Kidney; Radioligand binding assay; Autoradiography; Cortical tubule; Glomerulus (Barili, P. (338) 89)

Drug discrimination; 7-OH-DPAT (7-hydroxy-2-(di-*N*-propylamino)-tetralin); D-Amphetamine; (Rat) (Varty, G.B. (339) 101)

Receptor binding; G protein; Acidification rate; cAMP accumulation; *Fos* protein immunoreactivity (Scheideler, M.A. (339) 261)

Dopamine D_4 receptor
L 745,870; Clozapine; Noradrenaline; Adrenaline; [^{35}S]GTPγS (Newman-Tancredi, A. (319) 379)

Dopamine; RBI-257; U-101,958 (Kula, N.S. (331) 333)

Dopamine D_1 receptor agonist
YM435; Renal vasodilator; Angiotensin II; Renal nerve stimulation; PAF (platelet-activating factor) (Yatsu, T. (322) 45)

Dopamine D_2 receptor agonist
Talipexole; Bromocriptine; Anti-tremor effect; Ventromedial tegmentum lesion; Parkinson's disease; (Cynomolgus monkey) (Kohno, Y. (319) 197)

Dopamine D_2 receptor antagonist
Voltammetry, in vivo; Dopamine; Striatum; Behavior; (Rat) (Horikawa, H.P.M. (326) 15)

Dopamine D_4 receptor, human
Receptor binding; Aminopiperidine (Schlachter, S.K. (322) 283)

Dopamine metabolism
Nicotine; Tolerance; Striatum, mouse; Dopamine receptor (Pietilä, K. (318) 17)

Atipamezole; Medetomidine; Dopamine overflow; Voltammetry, in vivo; Mouse (Yavich, L. (339) 113)

Dopamine overflow
Atipamezole; Medetomidine; Dopamine metabolisms; Voltammetry, in vivo; Mouse (Yavich, L. (339) 113)

Dopamine receptor
5-HT receptor; Schizophrenia; Psychotic disorder; Antipsychotic agent (Kongsamut, S. (317) 417)

Nicotine; Tolerance; Dopamine metabolism; Striatum, mouse (Pietilä, K. (318) 17)

Aripiprazole; Antipsychotic drug; Striatum, rat; Ribonuclease protection assay (Inoue, A. (321) 105)

Mesolimbic dopamine system; Antidepressant drug; Fluoxetine; Chronic treatment (Collu, M. (322) 123)

Tyrosine hydroxylase; Aromatic L-amino acid decarboxylase; Striatum; Midbrain (Cho, S. (323) 149)

Dizocilpine; Electroconvulsive shock; NMDA receptor; Supersensitivity (D'Aquila, P.S. (330) 11)

Tenascin; Knockout mouse; Apomorphine (Fukamauchi, F. (338) 7)

Dopamine receptor agonist
Nicotine; Adrenoceptor antagonist; Acetylcholine receptor antagonist; 5-HT receptor antagonist; Anorexia; (Rat) (Zarrindast, M.-R. (321) 157)

Pramipexole; Antipsychotic potential activity; Antiparkinsonian potential activity (Maj, J. (324) 31)

PNU-95,666; PD128907; DOPAC (3,4-dihydroxyphenylal acetic acid); Median eminence (Durham, R.A. (335) 37)

Locomotor sensitization; D_2/D_3 receptor; Clorgyline (Culver, K.E. (339) 109)

Dopamine receptor antagonist
NGF (nerve growth factor); Locomotion; Acetylcholine; Nicotinic receptor (Kobayashi, S. (326) 1)

Opioid; Anxiolytics; Signal transduction; Benzodiazepine; Homophtalazine (2,3-benzodiazepine) (Fekete, M.I.K. (331) 175)

MK-801; M100907; Locomotion; Schizophrenia; (Mouse) (Martin, P. (335) 107)

HU-211; NMDA receptor antagonist; Catalepsy; Parkinson's disease (Striem, S. (338) 205)

Dopamine release
Microdialysis; Chronic transversal; Amphetamine, repeated; Ventral striatum; Dopamine synthesis; Behavioral sensitization (Imperato, A. (317) 231)

Cassia siamea; Barakol; Striatum, rat; Dopamine uptake, in vitro (Thongsaard, W. (319) 157)

Neuropeptide Y; Dopamine D_2 receptor; G_i-protein; Striatum; Spontaneously hypertensive rat (SHR) (Tsuda, K. (321) 5)

[^{3}H]Dopamine release
Glycine receptor, strychnine-insensitive; NMDA receptor; [^{3}H]-Noradrenaline release; Synaptosome; 7-Cl-Kynurenic acid; HA 966; GV 150526A (Mennini, T. (336) 275)

Dopamine synthesis
Microdialysis; Chronic transversal; Amphetamine, repeated; Ventral striatum; Dopamine release; Behavioral sensitization (Imperato, A. (317) 231)

Dopamine transmission
Nociceptin; Locomotor activity; Exploratory behavior (Florin, S. (317) 9)

Dopamine transport
Methamphetamine; Hyperthermia; Fluoxetine; 5-HT (5-hydroxytryptamine, serotonin) (Fleckenstein, A.E. (324) 179)

Dopamine transporter
Methamphetamine; Free radical (Fleckenstein, A.E. (323) R7)

WIN 35,428 binding; Arachidonic acid; Protein kinase C; Parkinson's disease; Drug abuse (Reith, M.E.A. (324) 1)

Oxygen radical; Methamphetamine (Fleckenstein, A.E. (334) 111)

Single photon detection system; 5-HT (5-hydroxytryptamine, serotonin) transporter; GBR 12909; Paroxetine; RTI-55 (Mochizuki, T. (338) 17)

Dopamine transporter, neuronal membrane
Vesicular monoamine transporter type-2 (VMAT2); Methamphetamine; Amphetamine; Dihydrotetrabenazine; WIN 35,428; Dopamine (Frey, K. (334) 273)

Dopamine turnover
PET (positron emission tomography); 6-[^{18}F]L-DOPA (6-[^{18}F]L-3-4-dihydroxyphenylalanine); Catechol-*O*-methyltransferase inhibition; Monoamine oxidase inhibition (Doudet, D.J. (334) 31)

Dopamine uptake, in vitro
Cassia siamea; Barakol; Striatum, rat; Dopamine release (Thongsaard, W. (319) 157)

Dopaminergic system
Conditioned fear stress; σ Receptor; Nucleus accumbens; Motor suppression; (Rat) (Kamei, H. (319) 165)

Dopexamine
Endotoxaemia; Hyperdynamic circulation; Nitric oxide (NO) synthase inhibition (Waurick, R. (333) 181)

Dorsal horn
Opioid; Nor-binaltorphimine; κ-Opioid receptor; Antinociception; Tachykinin; Nociception; Pain (Zachariou, V. (323) 159)

Dorsal lateral geniculate nucleus
Angiotensin; NMDA (*N*-methyl-D-aspartate); Kainate; Bicuculline; CGP 35348; Urethane; Unit activity; (Rat) (Albrecht, D. (332) 53)

Dorsal pedal artery
Ventricular pacing, rapid; Heart failure; Saphenous vein; α_1-Adrenoceptor; 5-Methyl-urapidil (Forster, C. (318) 55)

Dorsal raphe
BMY-14802; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Hippocampus; Microdialysis (Matos, F.F. (317) 49)

Dorsal raphe nucleus
5-HT_{1A} receptor; WAY 100635; Monoamine oxidase inhibitor; Microdialysis; Extracellular recording (Sharp, T. (320) 15)

Neuropeptide FF; Receptors; Morphine-analgesia; Rat; Parafascicular nucleus; Serotonin (Dupouy, V. (330) 129)

Dorsal root ganglion cell
Bufadienolide; Na^+/K^+ pump; Cardiac cell; Na^+/K^+ ATPase isoform (Van der Walt, J.J. (329) 201)

Dose response
Drug discrimination; Cocaine; MDMA (3,4-methylenedioxymethamphetamine); Cumulative dosing; (Rat) (Schechter, M.D. (326) 113)

Dose–response analysis
Vasopressin; Oxytocin; Factor VIII (F-VIII); Antihemophilic factor; Blood clotting; Plasminogen activator; Neurohypophyseal hormone analog; Time response; Non-monotonic profile (Neuenschwander, S. (323) 205)

Dotarizine
Flunarizine; Lubeluzole; Catecholamine release; Chromaffin cell; Ca^{2+} channel antagonist, 'wide-spectrum' (Lara, B. (325) 109)

5-HT_2 receptor; Ca^{2+} channels; *Xenopus* oocytes; Coronary artery (Montiel, C. (332) 183)

Down-regulation
β_2-Adrenoceptor; Salbutamol; Salmeterol; Formoterol; Lung, human (Nishikawa, M. (318) 123)

Downregulation
μ-Opioid receptor; Tolerance; Fentanyl; Clocinnamox; DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); Analgesia (Chan, K.W. (319) 225)

Doxorubicin
Cardiotoxicity; Cell contraction; Ca^{2+} concentration, intracellular; Myocardial cell, single (Temma, K. (322) 235)

8-cyclopentyl-1,3 dipropylxanthine (DPCPX)
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin)
δ-Opioid receptor; NG108-15 cell; DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin); BNTX (7-benzylidenenaltrexone); Naltriben (Ho, B.Y. (319) 109)

δ-Opioid receptor; μ-Opioid receptor knockout mouse (Sora, I. (324) R1)

[D-Ala^2,Glu^4]Deltorphin II; δ_1-/δ_2-opioid receptor agonist; NMDA receptor antagonist; MK-801, LY 235959 (Cao, Y.-J. (335) 161)

Drenergic transmission
Anococcygeus muscle; Neuropeptide Y; NANC (non-adrenergic non-cholinergic) transmission (Iravani, M.M. (338) 75)

Drinking conflict test
Metabotropic glutamate receptor; S-4C3H-PG ((*S*)-4-carbonyl-3-hydroxyphenylglycine); MSOP ((*RS*)-α-methylserine-*O*-phosphate); Intrahippocampal injection (Chojnacka-Wójcik, E. (319) 153)

Drug abuse
Dopamine transporter; WIN 35,428 binding; Arachidonic acid; Protein kinase C; Parkinson's disease (Reith, M.E.A. (324) 1)

Drug addiction
2-Deoxyglucose autoradiography; Microdialysis; Dopamine; Autoreceptor antagonist; Cocaine (Koch, S. (319) 173)

Drug combination
Asthma; Interaction; Smooth muscle, airway; Trachea; β_2-Adrenoceptor agonist; Methylxanthine; K^+ channel opener; Sodium nitroprusside; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

Drug discrimination
Cocaine; Opioid; Drug interaction (Suzuki, T. (324) 21)

Flesinoxan; DU125530; 5-HT_{1A} receptor; (Pigeon) (Mos, J. (325) 145)

Cocaine; MDMA (3,4-methylenedioxymethamphetamine); Dose response; Cumulative dosing; (Rat) (Schechter, M.D. (326) 113)

Pregnanolone; Neurosteroid; Neuroactive steroid; Behavior (Vanover, K.E. (327) 97)

Methamphetamine; δ-Opioid receptor; TAN-67 (Suzuki, T. (331) 1)

Ethanol; NMDA/glycine receptor; L-701,324; MK-801; Eliprodil; (Rat) (Kotlinska, J. (332) 1)

5-HT_{1A} receptor; Efficacy; (Pigeon) (Wolff, M.C. (333) 113)

Ca^{2+} channels; Dihydropyridine; Motor effects (Cohen, C. (336) 113)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-2-(di-*N*-propylamino)-tetralin); D-Amphetamine; (Rat) (Varty, G.B. (339) 101)

Drug efficacy
Cannabinoid; Cannabinoid receptor; Brain, mouse; Tetrahydrocannabinol; (Partial agonist) (Burkey, T.H. (336) 295)

Drug interaction
Renal clearance; Active secretion; P-glycoprotein; Multidrug resistance; Organic cation carrier (Masereeuw, R. (321) 315)

Cocaine; Opioid; Drug discrimination (Suzuki, T. (324) 21)

Drug screening
[^{3}H]Nociceptin; Nociceptin receptor; Radioreceptor assay; Adenylylcyclase, inhibition (Butour, J.-L. (321) 97)

Drug self-administration
Cocaine; Morphine; κ-Opioid receptor; U50,488H; (Rat); (Mouse) (Kuzmin, A.V. (321) 265)

DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin)
δ-Opioid receptor; NG108-15 cell; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); BNTX (7-benzylidenenaltrexone); Naltriben (Ho, B.Y. (319) 109)

DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine)
Noradrenaline; EEG (electroencephalogram); Memory; Basal forebrain lesion; Tetrahydroaminoacridine (Abe, K. (321) 149)

DTG (1,3-di-*o*-tolylguanidine)
σ Binding site; Desipramine; Propranolol; Alprenolol; Cerebral cortex, rat (Shirayama, Y. (331) 319)

DU125530
Drug discrimination; Flesinoxan; 5-HT_{1A} receptor; (Pigeon) (Mos, J. (325) 145)

Duloxetine
Fluoxetine; Hippocampus; Raphe nucleus, dorsal; Electrophysiology, cellular (Smith, J.E. (323) 69)

Duodenum longitudinal muscle, rat
Duodenum muscularis mucosae, rat; P_1 purinoceptor; Development; Ontogeny; Adenosine receptor (Brownhill, V.R. (317) 321)

Duodenum muscularis mucosae, rat
Duodenum longitudinal muscle, rat; P_1 purinoceptor; Development; Ontogeny; Adenosine receptor (Brownhill, V.R. (317) 321)

Dura mater encephali
Arterial blood flow; Neurogenic inflammation; 5-HT_1 receptor agonist; Migraine; Headache; (Rat) (Messlinger, K. (332) 173)

DY-9760e
W-7; Calmodulin antagonist; Cytotoxicity; Neuroprotection (Sugimura, M. (336) 99)

Dynorphin
Analgesia; Morphine; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Nor-binaltorphimine; β-Funaltrexamine; DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly-ol^5]enkephalin) (Reche, I. (318) 11)

Substance P; Enkephalin; Acetylcholine; Dopamine; Amphetamine; Nucleus accumbens; Caudoputamen; Behavior; Muscarinic receptor (Wang, J.Q. (334) 43)

Partial agonism; Opioid (Soderstrom, K. (338) 191)

Dynorphin A
Nociceptin; Orphanin FQ; Retina; Striatum; Opioid (Makman, M.H. (338) 171)

Early gene
L-DOPA (3,4-dihydroxyphenyl-L-alanine); Striatum; Parkinson's disease; Dopamine D_1 receptor; Dopamine D_2 receptor (Fenu, S. (321) 143)

Ear oedema
Mustard oil; Neurogenic inflammation; Plasma extravasation; Capsaicin; SR 140333 (Inoue, H. (333) 231)

Ebastine
Antihistaminic agent; Terfenadine; Carebastine; K^+ current; hKv1.5 channel (Valenzuela, C. (326) 257)

E-cadherin
Tamoxifen; MCF7/6; Adhesion; Ca^{2+} channel antagonist (Charlier, C. (317) 413)

Econazole
Ca^{2+}; Contraction; Trachea; Miconazole; SK&F 96365; Nifedipine (Li, L. (331) 221)

Ecto-ATPase
ATP; ARL 67156; Purinergic; Urinary bladder (Westfall, T.D. (329) 169)

Edema
Sauvagine; Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Ca^{2+}; Inositol trisphosphate; CRF receptor; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

α-Trinositol; Capillary permeability; Trachea; Skin (rat); Connective tissue; Inflammation; Anaphylaxis (Koller, M.-E. (331) 259)

FK706; Elastase inhibitor; Neutrophil elastase; Pulmonary emphysema; Hemorrhage (Shinguh, Y. (337) 63)

EDHF (endothelium-dependent hyperpolarizing factor)
Endotoxin; Myocardium; Nitric oxide (NO) (Kristof, A.S. (328) 69)

EDHF (endothelium-derived hyperpolarizing factor)
Smooth muscle, vascular; *N*-Nitro-L-arginine methyl ester (L-NAME); Ouabain; Adenosine receptor; Coronary circulation (Olanrewaju, H.A. (322) 185)

Acetylcholine; Clotrimazole; Endothelium; Nitric oxide (NO); Nitro-L-arginine (Fujimoto, S. (330) 177)

Endothelium; Anandamide; K^+ channel; Cytochrome *P*-450 inhibitor; Cannabinoid (Randall, M.D. (333) 191)

Endothelium; Anandamide; SR141716A; Heart, rat; Cannabinoids (endocannabinoids), endogenous (Randall, M.D. (335) 205)

EDRF (endothelium-derived relaxing factor)
Angiotensin II; Prostanoid; Mesenteric artery; Mesenteric vein; Aging; Development (Konishi, C. (320) 175)

D-Glucose oxidation; Endothelial cell; Glutathione; Superoxide dismutase; Vitamin C; Vitamin E (Graier, W.F. (322) 113)

EEG (electroencephalogram)
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Noradrenaline; Memory; Basal forebrain lesion; Tetrahydroaminoacridine (Abe, K. (321) 149)

EEG (electroencephalograph), cortical
Nimodipine; Metrifonate; Cognitive function; (Rat) (Jäkälä, P. (318) 239)

EEG (electroencephalographic) spectral power
Defibrotide; Cerebral ischemia; Memory; Neuronal damage (Sala, M. (328) 143)

Efaroxan
Imidazoline receptor; σ Receptor; Insulin secretion; Phencyclidine; (+)-MK-801 (dizocilpine) (Chan, S.L.F. (323) 241)

Efferent function
Nociceptin; Capsaicin; Sensory nerve; Atrium; (Guinea pig) (Giuliani, S. (332) 231)

Efficacy
δ-Opioid receptor, human; Radioligand binding; δ-Opioid receptor agonist; [^{35}S]GTPγS binding (Quock, R.M. (326) 101)

5-HT_{1A} receptor; Drug discrimination; (Pigeon) (Wolff, M.C. (333) 113)

Efficacy, agonist
Efficacy, relative; Agonist-antagonist combination; Spare receptor; (New parameter) (Venter, D.P. (320) 223)

Efficacy, intrinsic
GABA (γ-aminobutyric acid); Benzodiazepine receptor, in vivo; DL-Allylglycine; Brain; (Non-human primate) (Bottlaender, M. (321) 13)

Efficacy, relative
Efficacy, agonist; Agonist-antagonist combination; Spare receptor; (New parameter) (Venter, D.P. (320) 223)

Efficacy estimation
Pharmacological method, new; Agonist affinity; Carbachol; Salbutamol (Venter, D.P. (320) 233)

Efonidipine
Sinus node; Chronotropism; Action potential; Ca^{2+} channel antagonist; Ca^{2+} channel, T-type (Masumiya, H. (335) 15)

EGF (epidermal growth factor)
β-Adrenoceptor agonist; Forskolin; DNA synthesis; Hepatocyte proliferation (Kimura, M. (324) 267)

Ejaculation
Sexual behavior; Flesinoxan; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); ATD (1,4,6-androstatriene-3,17-dione); (Wistar rat) (Haensel, S.M. (330) 1)

Elastase inhibitor
FK706; Neutrophil elastase; Pulmonary emphysema; Hemorrhage; Edema (Shinguh, Y. (337) 63)

Electrical brain stimulation
NMDA receptor antagonist; Conditioning; Reward; (Rat) (Bespalov, A. (326) 109)

Electrical field stimulation
5-HT (5-hydroxytryptamine, serotonin); 5-HT_3 receptor; Urinary bladder; (Rabbit) (Barras, M. (318) 425)

Electrical kindling
Complex partial seizure; Epilepsy; NMDA receptor (Ebert, U. (322) 179)

2-Chloroadenosine; Seizure; Epileptogenesis; Amygdala; Adenosine A_1 receptor, pre-synaptic (Abdul-Ghani, A.-S. (326) 7)

Electrical stimulation
Muscarinic receptor; $[Ca^{2+}]_i$ transient; Na^+-Ca^{2+} exchange; Carbachol (Wang, H.-X. (319) 91)

Electric field stimulation
Noradrenaline uptake inhibitor; Protriptyline; Amitriptyline; Xylamine; Contraction; Vas deferens, rat (Huang, Y. (327) 41)

CGRP (calcitonin gene-related peptide); Glibenclamide; K^+ channel, ATP-sensitive; Neurotransmission; Vas deferens, rat (Huang, Y. (327) 209)

Electrocardiology
Arrhythmia; Acetylsalicylic acid; Cardiac ischemia; Cardiac reperfusion; Electrophysiology; Epicardial mapping (Dhein, S. (339) 129)

Electroconvulsive shock
Dizocilpine; Dopamine receptor; NMDA receptor; Supersensitivity (D'Aquila, P.S. (330) 11)

Electroconvulsive stimuli
Brain; Hybridization, in situ; mRNA expression; Substance P; Tachykinin receptor; (Rat) (Zachrisson, O. (319) 191)

Electroencephalogram
Adenosine receptor; MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo-(a,d)cyclohepten-5,10-imine maleate); (Rat) (Popoli, P. (333) 143)

Electron spin resonance
Hemorrhagic shock; Nitric oxide (NO); ACTH (adrenocorticotropin); Nitric oxide (NO) synthase, inducible (Guarini, S. (336) 15)

Electrophysiological recording
5-HT (5-hydroxytryptamine, serotonin); Diazepam; Withdrawal; 5-HT_{1A} receptor; Raphe nucleus, dorsal (Lanfumey, L. (323) 137)

Electrophysiology
Substantia nigra reticulata; Antipsychotic; Schizophrenia; Basal ganglion; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Bruggeman, R. (324) 49)

Arrhythmia; Gap junction; Antiarrhythmic peptide (Müller, A. (327) 65)

$5\text{-HT}_{1B/1D}$ receptor agonist; Rizatriptan; Trigeminal nucleus caudalis; Migraine (Cumberbatch, M.J. (328) 37)

Nodose ganglion; Nitric oxide (NO); Adenosine; Adenosine receptor (Lawrence, A.J. (328) 83)

$GABA_A$ receptor; α_1 subunit; Mutation; Radioligand binding (Westh-Hansen, S.E. (329) 253)

Ca^{2+} channel; CP-060*S*; Smooth muscle, vascular; Voltage clamp; Ca^{2+} channel antagonist (Ohya, Y. (330) 93)

NMDA receptor antagonist, non-competitive; Cortex, rat; Spinal cord, rat; Enantiomer (Ebert, B. (333) 99)

SCA40; Trachealis, bovine; K^+-rich media; $^{86}Rb^+$ efflux; Phosphodiesterase isoenzyme (Pocock, T.M. (334) 75)

Arrhythmia; Acetylsalicylic acid; Cardiac ischemia; Cardiac reperfusion; Electrocardiology; Epicardial mapping (Dhein, S. (339) 129)

Electrophysiology, cellular
Duloxetine; Fluoxetine; Hippocampus; Raphe nucleus, dorsal (Smith, J.E. (323) 69)

Electroporation
Neuropeptide Y Y_1 receptor; Binding; Gene expression; Antisense oligonucleotide (Hänze, J. (330) 87)

Electroretinogram
Aldose reductase inhibitor; Sorbitol; Platelet aggregation; 2,3-Diphosphoglycerate; Diabetic retinopathy (Hotta, N. (326) 45)

Electroshock, maximal
Dihydropyridine; Dantrolene; Anti-epileptic; Seizure (Borowicz, K.K. (323) 45)

Electroshock seizure
Carbamazepine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Hippocampus; Ca^{2+}; Tetrodotoxin; (Rat) (Dailey, J.W. (328) 153)

Electroshock test, maximal
Neuropathic pain; Allodynia; Antinociception; Tail-flick test; Behavior; Lamotrigine; Felbamate; Gabapentin (Hunter, J.C. (324) 153)

Elevated plus-maze
Neuropeptide Y Y_1 receptor; BIBP3226 (Kask, A. (317) R3)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); SR 46349B; 5-HT_{2A} receptor; Anxiety; [^{3}H]Ketanserin binding; RHA and RLA (Roman high- and low-avoidance) rats (Chaouloff, F. (334) 25)

Anxiety; Clozapine; L-745,870; L-741,742; Dopamine D_4 receptor; Chlordiazepoxide; Mouse (Cao, B.-J. (335) 117)

Elevated plus-maze behavior
[D-Pen^2,L-Pen^5]Enkephalin; [D-Ala^2]Deltorphin II; Spontaneous alternation performance; Passive avoidance learning; δ-Opioid receptor; (Mouse) (Ukai, M. (338) 1)

Elevated plus-maze test
Opioid; Benzodiazepine; Buspirone; (Mouse) (Belzung, C. (323) 133)

Elgodipine
Blood pressure; Tachycardia, reflex; Dihydropyridin (Valdivielso, J.M. (335) 193)

Eliprodil
Ca^{2+} channel; Cerebellum; Granule neuron; ω-Conotoxin-GVIA; ω-Agatoxin-IVA (Biton, B. (323) 277)

Ethanol; NMDA/glycine receptor; L-701,324; MK-801; Drug discrimination; (Rat) (Kotlinska, J. (332) 1)

EM574
Erythromycin; Motilin; Receptor binding; (Rabbit) (Sato, F. (322) 63)

EMD 68843
5-HT_{1A} autoreceptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Fluoxetine; WAY 100635; Hypothermia; Ultrasonic vocalization; (Rat) (Bartoszyk, G.D. (322) 147)

Enalapril
Nitric oxide (NO); Renin-angiotensin system; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Hoe 140; Blood pressure (Zappellini, A. (317) 285)

Angiotensin II; L-nitro-arginine methyl ester (L-NAME); Nitric oxide (NO); Stroke (Ahmad, S. (333) 39)

Imidapril; Captopril; Ozone; Angiotensin-converting enzyme; Airway hyperresponsiveness (Matsubara, S. (337) 259)

Enantiomer
Apomorphine; Biodistribution; Uptake, stereoselective, active (Sam, E. (329) 9)

NMDA receptor antagonist, non-competitive; Electrophysiology; Cortex, rat; Spinal cord, rat (Ebert, B. (333) 99)

Encephalopathy
AIDS (acquired immunodeficiency syndrome); LP-BM5 murine leukemia virus; PAF (platelet-activating factor); Pentoxifylline; TNF-α (tumor necrosis factor-α) (Sei, Y. (325) 81)

Endocrine pancreas
Vanadyl sulphate; Insulin secretion; (Rat) (Cadène, A. (318) 145)

Endopeptidase 3.4.24.15
Phosphinic inhibitor; Neurotensin; Analgesia; (Mouse) (Vincent, B. (334) 49)

Endorphin
Nociceptin; Pain threshold; Opioid receptor (Gintzler, A.R. (325) 29)

Natural killer cell; Macrophage; Enkephalin; Cytotoxicity (Kowalski, J. (326) 251)

***β*-Endorphin**
Opiate; Insulin; Growth; Development; Ornithine decarboxylase mRNA; Intracerebroventricular (Bartolome, J.V. (331) 145)

β-Endorphin receptor
Morphine derivative; Cinnamoylamino group; Analgesia; (Irreversible antagonist); (Mouse) (McLaughlin, J.P. (320) 121)

Endothelial cell
Ca^{2+} release; Ca^{2+} entry; ATP; Thapsigargin (Oike, M. (319) 291)

D-Glucose oxidation; EDRF (endothelium-derived relaxing factor); Glutathione; Superoxide dismutase; Vitamin C; Vitamin E (Graier, W.F. (322) 113)

Ca^{2+}, internal; VIP (vasoactive intestinal polypeptide); Ca^{2+} imaging; Fura-2 (Low, A.M. (339) 227)

Endothelial cell activation
ETYA (5,8,11,14-eicosatetraynoic acid); Polyunsaturated fatty acid; Gene regulation; Inhibition; Adhesion molecule (Stuhlmeier, K.M. (325) 209)

Endothelial cell, rat
2-Phenyl-4-quinolone; 5-HT (5-hydroxytryptamine, serotonin); Gap formation; Permeability; cAMP (Lee, H.-Z. (335) 245)

Endothelin
Endothelium; Smooth muscle, vascular; Hyperpolarization (Waldron, G.J. (318) 89)

BQ-788; Hypoxia; Pulmonary hypertension (Holm, P. (323) 83)

Endothelin ET_A receptor; Endothelin ET_B receptor; Pressor effect; Nitric oxide (NO); Oxygen consumption; Liver (Higuchi, H. (328) 175)

Vasopressin; Spontaneously hypertensive rat (SHR); Hemodynamics; Cardiac output; Radiotelemetry (Balakrishnan, S.M. (334) 55)

Glial cell; Nitric oxide synthase, inducible; TNF-α (tumor necrosis factor-α); Protein kinase C; Endothelin ET_B receptor (Oda, H. (339) 253)

Endothelin-1
Endothelin receptor antagonist; Bosentan; PD155080; Clearance; Half-life; Vascular effect (Hemsén, A. (318) 369)

Endothelin ET_A receptor; DOCA (deoxycorticosterone acetate)-salt hypertension; Renal function; Urine formation (Matsumura, Y. (319) 65)

Smooth muscle cell, vascular; Ca^{2+}-permeable non-selective cation channel; Vasopressin; Mg^{2+}, extracellular (Nakajima, T. (320) 81)

Vascular resistance, renal; Endothelin ET_A receptor antagonist (Ignasiak, D.P. (321) 295)

Endothelin-converting enzyme; Phospholipase C; Phospholipase A_2; Phosphoramidon (N'Diaye, N. (321) 387)

Diabetes; 5-HT (5-hydroxytryptamine); Protein kinase C; Aorta (James, G.M. (322) 55)

Bosentan (4-tert-butyl-*N*-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2′-bipyrimidin-4-yl]-benzene sulfonamide); IRL 1620 (Suc-[Glu^9,Ala^{11,15}]endothelin-1-(8–21)); FR 139317 ((*R*)2-[(*R*)-2-[(*S*)-2-[[1-(hexahydro-1*H*-azepinyl)]carbonyl] amino-4-methylpentanoil]amino-3-[3-

(1-methyl-1*H*-indoyl)]propionyl]amino-3-(2-pyridyl) propionic acid) (Takahashi, T. (324) 219)

K^+ channel, Ca^{2+}-activated; Endothelin-3; Endothelin ET_A receptor; Patch-clamp (Hu, S. (324) 277)

Circulatory filling pressure, mean; Cardiac output; Arterial resistance, systemic; Venous resistance; Venous tone, body (Palacios, B. (327) 183)

Nitric oxide (NO); cAMP (Zhu, Y. (332) 195)

[Thr^{18},γ-methylleucine^{19}]Endothelin-1
Endothelin receptor antagonist (Masuda, Y. (325) 263)

Endothelin-3
K^+ channel, Ca^{2+}-activated; Endothelin-1; Endothelin ET_A receptor; Patch-clamp (Hu, S. (324) 277)

Endothelin-converting enzyme
Endothelin-1; Phospholipase C; Phospholipase A_2; Phosphoramidon (N'Diaye, N. (321) 387)

Endothelin ET_A receptor
Endothelin-1; DOCA (deoxycorticosterone acetate)-salt hypertension; Renal function; Urine formation (Matsumura, Y. (319) 65)

K^+ channel, Ca^{2+}-activated; Endothelin-1; Endothelin-3; Patch-clamp (Hu, S. (324) 277)

Endothelin; Endothelin ET_B receptor; Pressor effect; Nitric oxide (NO); Oxygen consumption; Liver (Higuchi, H. (328) 175)

Endothelin ET_B receptor; Organ culture; Reverse transcription-polymerase chain reaction; Up-regulation (Möller, S. (329) 69)

Endothelin ET_B receptor
Endothelin; Endothelin ET_A receptor; Pressor effect; Nitric oxide (NO); Oxygen consumption; Liver (Higuchi, H. (328) 175)

Endothelin ET_A receptor; Organ culture; Reverse transcription-polymerase chain reaction; Up-regulation (Möller, S. (329) 69)

Macrophage; RT-PCR (reverse transcription-polymerase chain reaction); Receptor autoradiography; (Rat) (Sakurai-Yamashita, Y. (338) 199)

Endothelin; Glial cell; Nitric oxide synthase, inducible; TNF-α (tumor necrosis factor-α); Protein kinase C (Oda, H. (339) 253)

Endothelin ET_A receptor antagonist
Endothelin-1; Vascular resistance, renal (Ignasiak, D.P. (321) 295)

Endothelin receptor antagonist
Endothelin-1; Bosentan; PD155080; Clearance; Half-life; Vascular effect (Hemsén, A. (318) 369)

[Thr^{18},γ-methylleucine^{19}]Endothelin-1 (Masuda, Y. (325) 263)

Endothelium
Mesenteric arterial bed; Nitric oxide (NO); Perivascular nerve; Sensory nerve; (Golden hamster) (Hill, B. (317) 275)

Nitric oxide (NO); Diabetes mellitus; Arginine (Pieper, G.M. (317) 317)

Smooth muscle, vascular; Hyperpolarization; Endothelin (Waldron, G.J. (318) 89)

Isoproterenol; β_1-Adrenoceptor; β_2-Adrenoceptor; Relaxation; Cytochrome P450; Aortic ring, rat (Satake, N. (319) 37)

K^+ channel opener; Cromakalim; Diazoxide; Mesenteric bed, rat; Nitric oxide (NO) (Feleder, E.C. (319) 229)

Hydralazine; Relaxation; cGMP (Wei, S. (321) 307)

Histamine; Histamine receptor; (*R*)-α-Methylhistamine; Histamine H_1 receptor; Histamine H_3 receptor; Nitric oxide (NO); Oviductal artery (Martínez, A.C. (326) 163)

Cyclopiazonic acid; Nitric oxide (NO); Vasodilation; N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Rahimian, R. (327) 143)

Smooth muscle; Dimalonic acid C_{60}; Nitric oxide (NO); Superoxide dismutase (Satoh, M. (327) 175)

Nitric oxide (NO); Coronary small artery; Acetylcholine; A23187; Apamin; K^+ channel (Simonsen, U. (329) 153)

Acetylcholine; Clotrimazole; EDHF (endothelium-derived hyperpolarizing factor); Nitric oxide (NO); Nitro-L-arginine (Fujimoto, S. (330) 177)

Cyclopiazonic acid; Nitric oxide (NO); K^+ channel; Contractions, rhythmic; Mesenteric artery, rat (Huang, Y. (332) 167)

EDHF (endothelium-derived hyperpolarizing factor); Anandamide; K^+ channel; Cytochrome *P*-450 inhibitor; Cannabinoid (Randall, M.D. (333) 191)

EDHF (endothelium-derived hyperpolarizing factor); Anandamide; SR141716A; Heart, rat; Cannabinoids (endocannabinoids), endogenous (Randall, M.D. (335) 205)

Aortic barodenervation; α_1-Adrenoceptor; Nitric oxide (NO) (El-Mas, M.M. (337) 235)

Cerebral vein; Histamine H_2 receptor; Venodilation; Nitric oxide (NO); Prostanoid (Monge, L. (338) 135)

Levcromakalim; Cannabinoid receptor (White, R. (339) 157)

Endothelium-dependent relaxation
Pulmonary artery, human; Halothane (Higueras, J. (326) 175)

Endotoxaemia
Hyperdynamic circulation; Nitric oxide (NO) synthase inhibition; Dopexamine (Waurick, R. (333) 181)

Endotoxemia
ABT-491; PAF (platelet-activating factor); PAF receptor antagonist; Ca^{2+} flux; Superoxide anion; Vascular permeability; Degranulation (Albert, D.H. (325) 69)

Endotoxin
Chlorpromazine; TNF (tumor necrosis factor) (Ghezzi, P. (317) 369)

Antioxidant; DNA fragmentation (Haendeler, J. (317) 407)

Nitric oxide (NO) synthase; Dexamethasone; Myocardial contractility; β-Adrenoceptor; Mercaptoethylguanidine (Sun, X. (320) 29)

Ischemia-reperfusion arrhythmia; Dexamethasone; L-Canavanine; Nitric oxide (NO) synthase, inducible (Iskit, A.B. (326) 183)

EDHF (endothelium-dependent hyperpolarizing factor); Myocardium; Nitric oxide (NO) (Kristof, A.S. (328) 69)

Neostigmine; Neurotransmission; Na^+, K^+-ATPase; N^G-nitro-L-arginine (Liu, S.-H. (333) 241)

Neuropeptide FF; Intestinal motility; Fever; PAF (platelet-activating factor) (Million, M. (334) 67)

Nitric oxide (NO); Nitric oxide (NO) synthase inhibitor; Microcirculation; Vascular permeability; Inflammation; Inducible nitric oxide (NO) synthase (László, F. (334) 99)

Gastric fundus, rat; Contractility; Nitric oxide (NO); Prostaglandin $F_{2\alpha}$ (Lefebvre, R.A. (339) 201)

Endozepine
Octadecaneuropeptide (ODN); Diazepam-binding inhibitor; Benzodiazepine receptor; Glial cell; Ca^{2+} mobilization (Gandolfo, P. (322) 275)

Energy metabolism
Succinate dehydrogenase, inhibition; Catecholamine; Toxicity; Basal ganglia (Zeevalk, G.D. (320) 111)

Enkephalin
Natural killer cell; Macrophage; Endorphin; Cytotoxicity (Kowalski, J. (326) 251)

Dynorphin; Substance P; Acetylcholine; Dopamine; Amphetamine; Nucleus accumbens; Caudoputamen; Behavior; Muscarinic receptor (Wang, J.Q. (334) 43)

[D-Pen^2,L-Pen^5]Enkephalin
[D-Ala^2]Deltorphin II; Spontaneous alternation performance; Elevated plus-maze behavior; Passive avoidance learning; δ-Opioid receptor; (Mouse) (Ukai, M. (338) 1)

Enkephalin catabolism inhibitor
Cholecystokinin; CCK-8; BC 264; CCK_B receptor antagonist; L-365,260; Devazepide; CCK_A receptor antagonist; Depression; Stress; Forced-swimming test; RB 101 (Hernando, F. (318) 221)

Enteric nervous system
Intestine; Ganglion; Myenteric plexus; Histamine; cAMP; Adenylate cyclase; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Signal transduction (Xia, Y. (320) 95)

Autonomic nerves; Nitric oxide (NO); Muscarinic receptor (Iversen, H.H. (331) 213)

Motilin; Motilin receptor; Gastric motility (Van Assche, G. (337) 267)

Entorhinal cortex
NMDA receptor; MK-801 (Lindén, A.-M. (319) R1)

Memory impairment; D-Cycloserine; Temporal cortex; Recovery of function; (Microinjection) (Myhrer, T. (328) 1)

Eosinophil
Tracheal epithelial cell, guinea pig; Neutrophil; Arachidonic acid (Prié, S. (317) 343)

Suplatast tosilate; Airway inflammation; Airway hyperresponsiveness; Lymphocyte; T cell (Taniguchi, H. (318) 447)

Suplaplast tosilate; Airway inflammation; Airway hyperresponsiveness; Lymphocyte; T cell (Taniguchi, H. (321) 397)

Salmeterol; cAMP; β_2-Adrenoceptor agonist; Eosinophil aggregation (Teixeira, M.M. (323) 255)

Asthma; Bronchodilator; Hyperreactivity; KF19514; Phosphodiesterase inhibitor (Manabe, H. (332) 97)

Cyclosporin A; Cyclosporin H; FK506; Apoptosis (Kitagaki, K. (337) 283)

Eosinophil aggregation
Salmeterol; Eosinophil; cAMP; β_2-Adrenoceptor agonist (Teixeira, M.M. (323) 255)

Eosinophil infiltration
PF-904; Airway; Airway, hyperreactivity; Microvascular leakage; Bronchus, human, isolated; Phosphodiesterase activity; Neutrophils, human; Superoxide anion generation; (Guinea pig) (Cortijo, J. (333) 69)

Epibatidine
Epiboxidine; ABT 418; Nicotinic receptor; Analgesia (Badio, B. (321) 189)

Chromaffin cell; Substance P; Noradrenaline release; Adrenaline release (Krause, W. (328) 249)

Epiboxidine
Epibatidine; ABT 418; Nicotinic receptor; Analgesia (Badio, B. (321) 189)

Epicardial mapping
Arrhythmia; Acetylsalicylic acid; Cardiac ischemia; Cardiac reperfusion; Electrophysiology; Electrocardiology (Dhein, S. (339) 129)

Epidermal growth factor
Epiregulin; Growth factor; Cell proliferation; Tyrosine phosphorylation; Epidermal growth factor receptor; Gastric cell (Sasaki, E. (338) 253)

Epidermal growth factor receptor
Epiregulin; Growth factor; Cell proliferation; Tyrosine phosphorylation; Epidermal growth factor; Gastric cell (Sasaki, E. (338) 253)

Epilepsy
(De Sarro, G. (317) 239)

Microdialysis; Hippocampus; Cerebellum; Pilocarpine; Amino acid (Smolders, I. (319) 21)

NMDA (*N*-methyl-D-aspartate); Kindling; Amygdala; Seizure (Croucher, M.J. (319) 207)

Complex partial seizure; Electrical kindling; NMDA receptor (Ebert, U. (322) 179)

Levetiracetam; GABA (γ-aminobutyric acid); Anti-epileptic drug (Sills, G.J. (325) 35)

Losigamone; Cell culture; IPSC (inhibitory postsynaptic current); EPSC (excitatory postsynaptic current) (Draguhn, A. (325) 245)

Glutamate; Genetically epilepsy-prone rat; Metabotropic glutamate receptor; L-Serine-*O*-phosphate; (*S*)-4C3HPG) ((*S*)-4-carboxy-3-hydroxyphenylglycine); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid) (Tang, E. (327) 109)

GABA (γ-aminobutyric acid) homeostasis; GABA transporter; Neuron; Glia; Microdialysis (Juhász, G. (331) 139)

Cortex; Hippocampus; Thalamus; c-Fos; $GABA_B$ receptor antagonist (Vergnes, M. (332) 245)

Seizure; Fluoxetine; 5-HT_{1A} receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) (Browning, R.A. (336) 1)

Epilepsy (rat)
$GABA_B$ receptors; CGP 56999A; brain slices (Badran, S. (333) 135)

Epileptiform activity
Hippocampus; *Aconitum* alkaloids (Ameri, A. (335) 145)

Epileptogenesis
2-Chloroadenosine; Electrical kindling; Seizure; Amygdala; Adenosine A_1 receptor, pre-synaptic (Abdul-Ghani, A.-S. (326) 7)

Epinephrine
Ethanol; Isolated hepatocyte; Piroxicam; Thiobarbituric acid-reactive substance; Triacylglyceride (Saldaña-Balmori, Y. (317) 225)

Epiregulin
Growth factor; Cell proliferation; Tyrosine phosphorylation; Epidermal growth factor; Epidermal growth factor receptor; Gastric cell (Sasaki, E. (338) 253)

Epithelial cell
Ion secretion; Histamine; Intestinal secretion (Homaidan, F.R. (331) 199)

Epithelium
Sauvagine; Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Edema; Ca^{2+}; Inositol trisphosphate; CRF receptor; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

EPSC (excitatory postsynaptic current)
Epilepsy; Losigamone; Cell culture; IPSC (inhibitory postsynaptic current) (Draguhn, A. (325) 245)

Erythrocyte
GLUT1 transporter; Glucose; Chlorambucil; Blood–brain barrier (Halmos, T. (318) 477)

Erythrocyte membrane
Diabetes mellitus, non-insulin dependent; Metformin; Insulin; Lipid fluidity (Muller, S. (337) 103)

Erythromycin
EM574; Motilin; Receptor binding; (Rabbit) (Sato, F. (322) 63)

β-Escin
Ca^{2+} sensitivity; G-protein; Protein kinase C; Pimobendan; Cardiac muscle; Smooth muscle, vascular (Tomita, F. (326) 157)

Esophagus
$5\text{-}HT_4$ receptor; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Smooth muscle; Intestinal tract (Goldhill, J. (323) 229)

Estradiol
Opioid; Uterus; Proliferation; Cell culture; (Rat) (Környei, J.L. (336) 65)

Estrogen
Urethra; Nitric oxide (NO); Nitric oxide (NO) synthase; (Rabbit) (Takahashi, W. (339) 165)

Ethanol
Stress; Ro 15-4513; Plus-maze; Sleep; $^{36}Cl^-$ uptake; [^{3}H]Ro 15-4513 (Pokk, P. (317) 15)

Epinephrine; Isolated hepatocyte; Piroxicam; Thiobarbituric acid-reactive substance; Triacylglyceride (Saldaña-Balmori, Y. (317) 225)

ANP (atrial natriuretic peptide); CNP (C-type natriuretic peptide); Hypertension (Guillaume, P. (319) 215)

Stimulus properties of drugs; Cocaine; Cocaethylene drug–drug discrimination; (Dose–response); (Rat) (Schechter, M.D. (320) 1)

$5\text{-}HT_3$ receptor; Atrium; Tachycardia; Alcohol (Nishio, H. (321) 27)

Anesthetic potency; Acetate; Adenosine (Campisi, P. (325) 165)

Spinal cord; Glutamate; GABA (γ-aminobutyric acid); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); NMDA (*N*-methyl-D-aspartate); Anesthesia (Wong, S.M.E. (329) 121)

NMDA/glycine receptor; L-701,324; MK-801; Eliprodil; Drug discrimination; (Rat) (Kotlinska, J. (332) 1)

Dopamine; Hexamethonium; Microdialysis, in vivo; Mecamylamine; Nicotinic acetylcholine receptor (Blomqvist, O. (334) 149)

Halothane; Muscarinic receptor; Protein kinase C; *Xenopus* oocyte (Minami, K. (339) 237)

Ethanol preference
Dopamine; SKF 38393; Raclopride; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); Risperidone; SCH 23390; (Rat) (Silvestre, J.S. (318) 257)

Ethanol tolerance
Ethanol withdrawal; Locus coeruleus; NMDA receptor (Poelchen, W. (332) 267)

Ethanol withdrawal
Acamprosate; Pentylenetetrazole; Hippocampus; Cerebellum; c-*fos* mRNA; Northern and dot blotting; In situ hybridization (Putzke, J. (317) 39)

Ethanol tolerance; Locus coeruleus; NMDA receptor (Poelchen, W. (332) 267)

***N*-Ethylmaleimide**
Phosphoserine phosphatase; L-Serine; D-Serine; Glycerylphosphorylcholine; Phosphorylcholine; *p*-Chloromercuriphenylsulfonic acid (Hawkinson, J.E. (337) 315)

Etorphine
Dihydroetorphine; Antinociception; Physical dependence; (Rhesus monkey); (Mouse) (Aceto, M.D. (338) 215)

μ-Opioid receptor; Regulation of mRNA; Receptor downregulation; Analgesia; Tolerance (Sehba, F. (339) 33)

ETYA (5,8,11,14-eicosatetraynoic acid)
Endothelial cell activation; Polyunsaturated fatty acid; Gene regulation; Inhibition; Adhesion molecule (Stuhlmeier, K.M. (325) 209)

Euglycaemic hyperinsulinaemic clamp
BRL 35135; β_3-adrenoceptor agonism; Zucker (*fa/fa*) rat; Insulin sensitivity; Non-esterified fatty acid (Virtanen, K.A. (332) 215)

Excitation–contraction coupling
Ca^{2+}-entry block; Ca^{2+} current; Ca^{2+}-activated K^+ channel; Natural product (Suarez-Kurtz, G. (335) 153)

Excitatory amino acid
ACPC (1-aminocyclopropanecarboxylic acid); Neuroprotection; NMDA receptor; Toxicity; Neuronal injury; Glycine (Lin, Y. (318) 491)

Anticonvulsant; Anxiolytic; Dopamine; Psychosis (Baron, B.M. (323) 181)

AMPA receptor; Glutamate; [^{3}H]D-Aspartate release; Autoreceptor (Patel, D.R. (332) 143)

GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzo-diazepine); Anticonvulsant action; Motor system; Flumazenil (Kubová, H. (333) 17)

Excitatory junctional potential
Mesenteric artery; Adrenergic nerve; Contraction; Amiloride (Shimamura, K. (320) 37)

Excitatory postsynaptic potential
Metabotropic glutamate receptor; 1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Depotentiation; CA1 area; Hippocampus; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; WAY-100635; *p*-Chlorophenylalanine; Hippocampus; Excitatory synaptic transmission; 5-HT_{1A} receptor; Ultrasonic vocalization; Anxiolytic (Xu, L. (323) 59)

Adenosine A_1 receptor; G protein; Hippocampus; Agonism, partial; Intrinsic activity (Lorenzen, A. (334) 299)

Excitatory synaptic transmission
5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; WAY-100635; *p*-Chlorophenylalanine; Hippocampus; 5-HT_{1A} receptor; Excitatory postsynaptic potential; Ultrasonic vocalization; Anxiolytic (Xu, L. (323) 59)

Excitotoxicity
Astrocyte; Glycine site; NMDA receptor; Kynurenic acid; Neurodegenerative disorder; Quinolinic acid (Wu, H.-Q. (319) 13)

NMDA receptor (Tyan, S.-H. (321) 171)

Exocytosis
RBL-2H3; Astemizole; Membrane; Protein; Tyrosine; Phosphorylation; Ca^{2+}; Flux (Fischer, M.J.E. (322) 97)

Experimental allergic encephalomyelitis
Fatty acid; α-Linolenic acid; Linolenic acid; Multiple sclerosis (Yehuda, S. (328) 23)

Exploratory behavior
Nociceptin; Locomotor activity; Dopamine transmission (Florin, S. (317) 9)

Extracellular calcium
AMPA receptor; Glutamate; Inositol phosphate; Oligodendrocyte (Liu, H.-N. (338) 277)

Extracellular matrix
Angiotensin-converting enzyme inhibitor; TGF-β1 (transforming growth factor-β1); Glomerulosclerosis; Gene expression (Hamaguchi, A. (331) 27)

Extracellular recording
5-HT_{1A} receptor; WAY 100635; Monoamine oxidase inhibitor; Dorsal raphe nucleus; Microdialysis (Sharp, T. (320) 15)

6-keto-prostaglandin $F_{1\alpha}$
Hexarelin; GH (growth hormone-)deficiency; Ischemia-reperfusion; Heart, rat; Angiotensin II (De Gennaro Colonna, V. (334) 201)

Factor VIII (F-VIII)
Vasopressin; Oxytocin; Antihemophilic factor; Blood clotting; Plasminogen activator; Neurohypophyseal hormone analog; Dose–response analysis; Time response; Non-monotonic profile (Neuenschwander, S. (323) 205)

Fatty acid
Experimental allergic encephalomyelitis; α-Linolenic acid; Linolenic acid; Multiple sclerosis (Yehuda, S. (328) 23)

Fatty acid synthase
Pravastatin sodium; HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase; Fatty acid synthesis; (Rat) (Fujioka, T. (328) 235)

Fatty acid synthesis
Pravastatin sodium; HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase; Fatty acid synthase; (Rat) (Fujioka, T. (328) 235)

Fear
Acoustic startle response; Anxiety; AP-5; Caudal pontine reticular formation; Glutamate receptor (Fendt, M. (318) 1)

Locomotion; Novelty; Anxiety (Gendreau, P.L. (337) 147)

Fedotozine
κ-Opioid receptor; μ-Opioid receptor; Visceral pain; Colonic hypersensitivity; (Colonic distension) (Langlois, A. (324) 211)

Feedback regulation
Flesinoxan; WAY 100635; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Microdialysis; (Rat) (Bosker, F.J. (333) 147)

Feeding behavior
GLP-1 (glucagon-like peptide-1); CRF (corticotropin-releasing factor); Hypothalamic-pituitary-adrenal axis; (Chicken) (Furuse, M. (339) 211)

Felbamate
Neuropathic pain; Allodynia; Antinociception; Tail-flick test; Behavior; Electroshock test, maximal; Lamotrigine; Gabapentin (Hunter, J.C. (324) 153)

Felodipine
Ventricular cell, guinea pig; Ca^{2+} channel, L-type; Voltage-dependent block; E-C (excitation-contraction) coupling (Kohmoto, O. (319) 355)

D-Fenfluramine
5-HT (5-hydroxytryptamine, serotonin); D-Norfenfluramine; Sex difference (Datla, K.P. (333) 27)

Fentanyl
μ-Opioid receptor; Downregulation; Tolerance; Clocinnamox; DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); Analgesia (Chan, K.W. (319) 225)

Heroin; Morphine; 6-Acetylmorphine; Reinforcement (Martin, T.J. (324) 141)

Agmatine; α_2-Adrenoceptor; μ-Opioid receptor; Analgesia; Spinal cord (Bradley, K.J. (331) 133)

Fever
Pentoxifylline; TNF-α (tumor necrosis factor-α); Anti-TNF strategy; Lipopolysaccharide; TNF bioassay; Radiotelemetry; (Guinea pig) (Goldbach, J.-M. (319) 273)

Melatonin; Lipopolysaccharide; Water intake; Nitric oxide (NO) (Nava, F. (331) 267)

Neuropeptide FF; Intestinal motility; Endotoxin; PAF (platelet-activating factor) (Million, M. (334) 67)

TNF-α (tumor necrosis factor-α); TNF-β; Acute-phase-response; Interleukin-6; Hypothalamic–pituitary–adrenal axis; Cortisol (Goldbach, J.-M. (334) 249)

bFGF (basic fibroblast growth factor)
Cerebral ischemia, focal (Ren, J.M. (327) 11)

Fibrinogen
MRI (magnetic resonance imaging); Ancrod; Cerebral ischemia; Hypertensive rat; Middle cerebral artery occlusion; Therapeutic window; (Delayed therapy) (Elger, B. (336) 7)

Fibrinolysis
PAI-1 (plasminogen activator inhibitor-1); Hemostasis; Thrombus; (Rat) (Ohtani, A. (330) 151)

FK409
Nitric oxide (NO); N^G-Nitro-L-arginine; Renal function; Urine formation (Urabe, K. (321) 195)

FK506
Glucocorticosteroid; Immunosuppression; Local lymph node assay; Tacrolimus; Topical drug (Homey, B. (325) 199)

Cyclosporin A; Cyclosporin H; Eosinophil; Apoptosis (Kitagaki, K. (337) 283)

FK706
Elastase inhibitor; Neutrophil elastase; Pulmonary emphysema; Hemorrhage; Edema (Shinguh, Y. (337) 63)

FK888
Cerebral blood volume; Cerebral vessel; Photoelectric method; Substance P; Tachykinin NK_1 receptor antagonist (Kobari, M. (317) 269)

FK506-binding protein
Ascomycin; Neurotransmitter release; Smooth muscle contraction; Tachykininergic nerve; Iris sphincter muscle, rabbit (Kageyama, M. (333) 223)

Flavonoid
Benzodiazepine receptor, central; Anxiolysis; Autoradiography; (Partial agonist) (Wolfman, C. (318) 23)

Flesinoxan
5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY-100635; Anxiety; Geller-Seifter, conflict; (Rat) (King, C.M.F. (325) 121)

Drug discrimination; DU125530; 5-HT_{1A} receptor; (Pigeon) (Mos, J. (325) 145)

Sexual behavior; Ejaculation; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); ATD (1,4,6-androstatriene-3,17-dione); (Wistar rat) (Haensel, S.M. (330) 1)

WAY 100635; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Feedback regulation; Microdialysis; (Rat) (Bosker, F.J. (333) 147)

Flexor reflex
Galanin; GMAP (galanin message-associated peptide), fragments; Nociception; Spinal cord (Xu, X.-J. (318) 301)

Hyperalgesia; Allodynia; Pain; Tachykinin (Ma, Q.-P. (322) 165)

Flow cytometry
Oxidative burst; ANP (atrial natriuretic peptide); Fluorescent latex bead; Dihydrorhodamine-123; Immune function (Vollmar, A.M. (319) 279)

Flumazenil
GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzo-diazepine); Excitatory amino acid; Anticonvulsant action; Motor system (Kubová, H. (333) 17)

Flunarizine
Dotarizine; Lubeluzole; Catecholamine release; Chromaffin cell; Ca^{2+} channel antagonist, 'wide-spectrum' (Lara, B. (325) 109)

Migraine; Nitric oxide (NO); Vasodilator nerve (Ayajiki, K. (329) 49)

Flunitrazepam binding
Hexachlorocyclohexane isomer; Lindane; $GABA_A$ receptor; GABA (γ-aminobutyric acid) binding; TBPS (*t*-butylbicyclophosphorothionate) binding; Cerebellar granule cell, cultured (Vale, C. (319) 343)

Fluorescent latex bead
Oxidative burst; ANP (atrial natriuretic peptide); Dihydrorhodamine-123; Immune function; Flow cytometry (Vollmar, A.M. (319) 279)

***N*-(6-[^{18}F]Fluorohexyl)-*N*-methylpropargylamine**
Fluoxetine; Norfluoxetine; Monoamine Oxidase B (Mukherjee, J. (337) 111)

(*S*)-5-Fluorowillardiine
AMPA receptor; Thiocyanate; (*S*)-AMPA ((*S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid); (*R,S*)-AMPA ((*R,S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) (Hawkinson, J.E. (329) 213)

Fluoxetine
5-HT_{2C} receptor; Antidepressant (Millan, M.J. (321) R10)

Dopamine receptor; Mesolimbic dopamine system; Antidepressant drug; Chronic treatment (Collu, M. (322) 123)

5-HT_{1A} autoreceptor; EMD 68843; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY 100635; Hypothermia; Ultrasonic vocalization; (Rat) (Bartoszyk, G.D. (322) 147)

Duloxetine; Hippocampus; Raphe nucleus, dorsal; Electrophysiology, cellular (Smith, J.E. (323) 69)

Methamphetamine; Hyperthermia; Dopamine transport; 5-HT (5-hydroxytryptamine, serotonin) (Fleckenstein, A.E. (324) 179)

Seizure; 5-HT_{1A} receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin); Epilepsy (Browning, R.A. (336) 1)

Norfluoxetine; Monoamine Oxidase B; *N*-(6-[^{18}F]fluorohexyl)-*N*-methylpropargylamine (Mukherjee, J. (337) 111)

Flupirtine
Triamnopyridine; hNT neuron; Bcl-2; Neuroprotection; Apoptosis; Glutathione (Perovic, S. (317) 157)

NMDA receptor, antagonistic; Catalepsy; Locomotion; L-DOPA (L-dihydroxyphenylalanine); Parkinson's disease (Schmidt, W.J. (327) 1)

Flux
RBL-2H3; Astemizole; Membrane; Protein; Tyrosine; Phosphorylation; Ca^{2+}; Exocytosis (Fischer, M.J.E. (322) 97)

Food intake
K^+ channel; Antisense oligodeoxyribonucleotide; K^+ channel opener; K^+ channel antagonist (Ghelardini, C. (329) 1)

Forced swim
Benzodiazepine withdrawal; Stress; GABA (γ-aminobutyric acid)-gated Cl^- flux; Carbamazepine; Two-way avoidance (Martijena, I.D. (330) 101)

Forced swimming
Antidepressant; Learned helplessness; $GABA_B$ receptor (Shimidzu, T. (338) 225)

Forced swimming test
$5\text{-}HT_{1A}$ receptor; $5\text{-}HT_{1B}$ receptor; Antidepressant (Redrobe, J.P. (318) 213)

Cholecystokinin; CCK-8; BC 264; CCK_B receptor antagonist; L-365,260; Devazepide; CCK_A receptor antagonist; Depression; Stress; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

Phencyclidine; Antidepressant; Schizophrenia, negative symptom; Depression; 5-HT (5-hydroxytryptamine, serotonin); (Mouse) (Noda, Y. (324) 135)

$5\text{-}HT_2$ receptor; $5\text{-}HT_3$ receptor; Antidepressant (Redrobe, J.P. (325) 129)

Wistar-Kyoto rat; Brown Norway rat; Sprague-Dawley rat; Imipramine; $5\text{-}HT_1$ receptor; $5\text{-}HT_2$ receptor; β-Adrenoceptor; Depression (Lahmame, A. (337) 115)

Force-frequency response
Isoproterenol; Cardiac hypertrophy; Ca^{2+}; (Rat) (Tang, L. (318) 349)

Force of contraction
Heart; Guanylyl cyclase; Phosphodiesterase; Ca^{2+} current, L-type; Fura-2 (Wegener, J.W. (326) 37)

Force transducer
Gastrointestinal motility; Migrating motor complex; Cisapride; (Ferret) (Nagakura, Y. (321) 53)

Formalin
Cyclooxygenase; Non-steroidal anti-inflammatory drugs; Release, in vitro; Spinal cord; Prostaglandin E_2; (Intrathecal) (Dirig, D.M. (331) 155)

Formalin test
c-fos; Hyperalgesia; Nociception; Antisense oligodeoxynucleotide; (Intrathecal) (Hou, W.-Y. (329) 17)

Mazindol; Lidocaine; Antinociception; Dopamine; Opioid (Bittencourt, A.L. (330) 109)

ATP; α,β-methylene-ATP; Suramin; Nociception (Sawynok, J. (330) 115)

Morphine; Clonidine; Nociception (Przesmycki, K. (337) 11)

Formoterol
Down-regulation; β_2-Adrenoceptor; Salbutamol; Salmeterol; Lung, human (Nishikawa, M. (318) 123)

Forskolin
EGF (epidermal growth factor); β-Adrenoceptor agonist; DNA synthesis; Hepatocyte proliferation (Kimura, M. (324) 267)

Nicotinic receptor; 1,9-Dideoxy-forskolin; Chromaffin cell; Ca^{2+} channel (Gandía, L. (329) 189)

α-Adrenoceptors; β-Adrenoceptors; Myocardium; K^+ channels ATP-sensitive (Kocić, I. (332) 65)

FR167344
Bradykinin; Bradykinin receptor antagonist; FR172357; Bradykinin B_2 receptor; Orally active (Inamura, N. (333) 79)

FR172357
Bradykinin; Bradykinin receptor antagonist; FR167344; Bradykinin B_2 receptor; Orally active (Inamura, N. (333) 79)

Free radical
Ca^{2+} store; Smooth muscle, vascular (Wada, S. (320) 51)

Melatonin; Cytoprotection; Ischemia-reperfusion; Gastric ulceration; Gastric blood flow (Konturek, P.Ch. (322) 73)

Methamphetamine; Dopamine transporter (Fleckenstein, A.E. (323) R7)

Glutamate; Pyrroloquinoline quinone; NMDA receptor; Redox modulatory site; Dihydroethidium (Scanlon, J.M. (326) 67)

H_2O_2; Hippocampus; CA1 region; Synaptic plasticity (Katsuki, H. (337) 213)

Frontal cortex
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; Noradrenaline; Microdialysis, in vivo; Synaptosomal uptake (Hughes, Z.A. (317) 83)

FR 139317 ((*R*)2-[(*R*)-2-[(*S*)-2-[[1-(hexahydro-1*H*-azepinyl)carbonyl] amino-4-methylpentanoil]amino-3-[3-(1-methyl-1*H*-indoyl)]propionyl]amino-3-(2-pyridyl) propionic acid)
Endothelin-1; Bosentan (4-tert-butyl-*N*-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2′-bipyrimidin-4-yl]-benzene sulfonamide); IRL 1620 (Suc-[Glu^9,$Ala^{11,15}$]endothelin-1(8–21)) (Takahashi, T. (324) 219)

Fructose
GR79236; Insulin resistance; Lipolysis; Triglyceride; Non-insulin-dependent diabetes (NIDDM) (Qu, X. (338) 269)

Fructose hypertension
Insulin resistance; Vasculature (Verma, S. (322) R1)

β-Funaltrexamine
Analgesia; Morphine; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Dynorphin; Nor-binaltorphimine; DAMGO ([D-Ala^2,*N*-Me-Phe^4,$Gly\text{-}ol^5$]enkephalin) (Reche, I. (318) 11)

Functional coupling
Semliki Forest virus system; Tachykinin NK_1 receptor; Mutagenesis, site-directed; Binding assays (Lundstrom, K. (337) 73)

Fura-2
Melanotroph; $GABA_A$ receptor; Muscimol; $GABA_A$ receptor antagonist; Bicuculline; $GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; CGP 35348; Cytosolic free Ca^{2+} (Shibuya, I. (321) 241)

α_1-Adrenoceptor, subtype; Ca^{2+} concentration, intracellular; Contraction; Smooth muscle, vascular (Tognarini, D.P. (322) 31)

Heart; Guanylyl cyclase; Phosphodiesterase; Ca^{2+} current, L-type; Force of contraction (Wegener, J.W. (326) 37)

α_2-Adrenoceptor; Ca^{2+} signaling; Receptor kinetics; Receptor binding (Kukkonen, J.P. (335) 99)

Ca^{2+}, internal; VIP (vasoactive intestinal polypeptide); Endothelial cells; Ca^{2+} imaging (Low, A.M. (339) 227)

Furaltadone
Steroid hormones; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furazolidone; Nitrofurantoin (Jager, L.P. (331) 325)

Furazolidone
Steroid hormones; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Fusion protein
β_1-Adrenoceptor; β_2-Adrenoceptor; Antibody (Jahns, R. (334) 115)

GABA (γ-aminobutyric acid)
Adenosine; Purine; (−)-Bicuculline; Paired-pulse inhibition; Inhibition; Hippocampus; Cyclopentyltheophylline (Higgins, M.J. (317) 215)

Histamine; Histamine H_1 receptor; Astrocytoma; Glia; Ca^{2+} (Soria-Jasso, L.-E. (318) 185)

Hippocampus; Network (Khalilov, I. (319) R5)

Benzodiazepine receptor, in vivo; Efficacy, intrinsic; DL-Allylglycine; Brain; (Non-human primate) (Bottlaender, M. (321) 13)

Levetiracetam; Anti-epileptic drug; Epilepsy (Sills, G.J. (325) 35)

Ethanol; Spinal cord; Glutamate; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); NMDA (*N*-methyl-D-aspartate); Anesthesia (Wong, S.M.E. (329) 121)

$GABA_C$ receptor; $GABA_B$ receptor agonist; $GABA_B$ receptor antagonist; *Xenopus* oocyte; *trans*-4-Aminocrotonic acid; *cis*-4-Aminocrotonic acid (Chebib, M. (329) 223)

Pregnanolone; Tetrahydrodeoxycorticosterone; Dehydroepiandrosterone; Pregnenolone sulfate; Neuroactive steroid; Pituitary melanotrope cell; Patch-clamp (Le Foll, F. (331) 303)

Ondansetron; Whole-cell current; Patch-clamp; Seizure (Ye, J.H. (337) 87)

Adenosine; ATP; Cholinergic; Nitric oxide (NO); Ileum; Terminal (Pencheva, N. (339) 193)

GABA (γ-aminobutyric acid) binding
Hexachlorocyclohexane isomer; Lindane; $GABA_A$ receptor; Flunitrazepam binding; TBPS (*t*-butylbicyclophosphorothionate) binding; Cerebellar granule cell, cultured (Vale, C. (319) 343)

GABA (γ-aminobutyric acid)-gated Cl^- flux
Benzodiazepine withdrawal; Stress; Forced swim; Carbamazepine; Two-way avoidance (Martijena, I.D. (330) 101)

GABA (γ-aminobutyric acid) homeostasis
GABA transporter; Neuron; Glia; Epilepsy; Microdialysis (Juhász, G. (331) 139)

GABA (γ-aminobutyric acid), innervation
Methamphetamine; Cortex, prefrontal; Synaptogenesis, reactive; (Gerbil) (Dawirs, R.R. (327) 117)

GABA (γ-aminobutyric acid) release
Kainate; Hippocampus; Domoic acid; Glutamate; Synaptosome (Cunha, R.A. (323) 167)

$GABA_A$ receptor
Acetylcholine; Blood pressure; (Rat) (Tellioğlu, T. (317) 301)

Hexachlorocyclohexane isomer; Lindane; Flunitrazepam binding; GABA (γ-aminobutyric acid) binding; TBPS (*t*-butylbicyclophosphorothionate) binding; Cerebellar granule cell, cultured (Vale, C. (319) 343)

Melanotroph; Muscimol; $GABA_A$ receptor antagonist; Bicuculline; $GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; CGP 35348; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

Anxiety; Conflict; Neurosteroid; 3α-Hydroxy-5α-pregnan-20-one; Benzodiazepine (Brot, M.D. (325) 1)

α_1 subunit; Mutation; Radioligand binding; Electrophysiology (Westh-Hansen, S.E. (329) 253)

Corymine; *Xenopus* oocytes; Glycine receptors (Leewanich, P. (332) 321)

$GABA_A$ receptor antagonist
Melanotroph; $GABA_A$ receptor; Muscimol; Bicuculline; $GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; CGP 35348; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

$GABA_B$ receptor
Microdialysis; Thalamus; Aspartate; Glutamate (Nyitrai, G. (318) 295)

GHB (γ-hydroxybutyric acid); G-protein-coupled receptor; GTP shift; Absence seizure (Mathivet, P. (321) 67)

Melanotroph; $GABA_A$ receptor; Muscimol; $GABA_A$ receptor antagonist; Bicuculline; Baclofen; $GABA_B$ receptor antagonist; CGP 35348; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

CGP 56999A; Epilepsy (rat); brain slices (Badran, S. (333) 135)

Antidepressant; Forced swimming; Learned helplessness (Shimidzu, T. (338) 225)

$GABA_B$ receptor agonist
Baclofen; Thienyl baclofen analog; 2-Hydroxysaclofen; Neocortical slice, rat (Ong, J. (329) 133)

$GABA_C$ receptor; GABA (γ-aminobutyric acid); $GABA_B$ receptor antagonist; *Xenopus* oocyte; *trans*-4-Aminocrotonic acid; *cis*-4-Aminocrotonic acid (Chebib, M. (329) 223)

$GABA_B$ receptor antagonism
Cognition; GAERS (genetic absence epilepsy rat of Strasbourg); Absence epilepsy (Getova, D. (320) 9)

$GABA_B$ receptor antagonist
Melanotroph; $GABA_A$ receptor; Muscimol; $GABA_A$ receptor antagonist; Bicuculline; $GABA_B$ receptor; Baclofen; CGP 35348; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

$GABA_C$ receptor; GABA (γ-aminobutyric acid); $GABA_B$ receptor agonist; *Xenopus* oocyte; *trans*-4-Aminocrotonic acid; *cis*-4-Aminocrotonic acid (Chebib, M. (329) 223)

Epilepsy; Cortex; Hippocampus; Thalamus; c-Fos (Vergnes, M. (332) 245)

$GABA_C$ receptor
GABA (γ-aminobutyric acid); $GABA_B$ receptor agonist; $GABA_B$ receptor antagonist; *Xenopus* oocyte; *trans*-4-Aminocrotonic acid; *cis*-4-Aminocrotonic acid (Chebib, M. (329) 223)

GABA transporter
GABA (γ-aminobutyric acid) homeostasis; Neuron; Glia; Epilepsy; Microdialysis (Juhász, G. (331) 139)

Gabapentin
Neuropathic pain; Allodynia; Antinociception; Tail-flick test; Behavior; Electroshock test, maximal; Lamotrigine; Felbamate (Hunter, J.C. (324) 153)

GAERS (genetic absence epilepsy rat of Strasbourg)
$GABA_B$ receptor antagonism; Cognition; Absence epilepsy (Getova, D. (320) 9)

Galanin
5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Hypothermia; Acetylcholine; Muscarinic receptor (Patel, S. (317) 197)

Flexor reflex; GMAP (galanin message-associated peptide), fragments; Nociception; Spinal cord (Xu, X.-J. (318) 301)

Galanin, analog
Galanin-(1–15)ol; Ileum contraction, neurally evoked, guinea-pig (Kakuyama, H. (329) 85)

Galanin-(1–15)ol
Galanin, analog; Ileum contraction, neurally evoked, guinea-pig (Kakuyama, H. (329) 85)

Gallamine
Muscarinic M_1 receptor; Muscarinic M_2 receptor; Muscarinic M_3 receptor; N^G-nitro-L-arginine methyl ester (L-NAME); N^G-nitro-L-arginine; Atropine; Pirenzepine (Koss, M.C. (335) 199)

Gallbladder
Muscarinic M_3 receptor; Muscarinic M_4 receptor; (Agonist); (Antagonist); (Guinea pig) (Eltze, M. (332) 77)

Gallbladder, guinea pig
Des-Arg^9-bradykinin; Bradykinin B_1 receptor-selective antagonist; Bradykinin B_2 receptor-selective antagonist; Prostanoid; Ca^{2+} (Cabrini, D.A. (331) 31)

Gallstone
Cholesterol; Plasma; Liver; Bile; Cholesterol 7α-hydroxylase; Acyl coenzyme A:cholesterol acyltransferase (Hajri, T. (320) 65)

Ganglion
Intestine; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenylate cyclase; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Signal transduction (Xia, Y. (320) 95)

GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
Peripheral-type benzodiazepine receptor; RT-PCR (reverse transcriptase-polymerase chain reaction); Stress; Dexamethasone (Siripurkpong, P. (331) 227)

Gap formation
2-Phenyl-4-quinolone; Endothelial cell, rat; 5-HT (5-hydroxytryptamine, serotonin); Permeability; cAMP (Lee, H.-Z. (335) 245)

Gap junction
Arrhythmia; Electrophysiology; Antiarrhythmic peptide (Müller, A. (327) 65)

Gastric acid
Adrenomedullin; Amylin; α-Calcitonin gene-related peptide; (*N*-terminal cyclic octa-peptides); (C-terminal fragments); (Chronic fistulae equipped rat); (Rat); (Human) (Rossowski, W.J. (336) 51)

Gastric acid secretion
T-330; H^+/K^+-ATPase; Omeprazole; Ranitidine (Kinoshita, M. (321) 325)

Gastric blood flow
Melatonin; Free radical; Cytoprotection; Ischemia-reperfusion; Gastric ulceration (Konturek, P.Ch. (322) 73)

Gastric cell
Epiregulin; Growth factor; Cell proliferation; Tyrosine phosphorylation; Epidermal growth factor; Epidermal growth factor receptor (Sasaki, E. (338) 253)

Gastric fundus, rat
Endotoxin; Contractility; Nitric oxide (NO); Prostaglandin $F_{2\alpha}$ (Lefebvre, R.A. (339) 201)

Gastric lesion
Pentadecapeptide BPC 157; Peptide BPC; Nitric oxide (NO); Gastrointestinal mucosal integrity; Blood pressure maintenance; Hypotension; N^G-Nitro-L-arginine methylester; L-Arginine; Stomach mucosa (Slobodnjak, Z. (332) 23)

Gastric motility
5-HT_3 receptor; *m*-Chlorophenylbiguanide; Ramosetron; (Force transducer) (Nagakura, Y. (327) 189)

Motilin; Motilin receptor; Enteric nervous system (Van Assche, G. (337) 267)

Gastric mucosa
Glutathione; Nitric oxide (NO); Oxidant; Cell damage (Wakulich, C.A. (319) 333)

Gastric mucosal blood flow
Acid secretion; Ketotifen; Mast cell; Mean arterial pressure; RX 77368; TRH (thyrotropin-releasing hormone); Vagus; Brain–gut (Király, Á. (334) 241)

Gastric ulceration
Melatonin; Free radical; Cytoprotection; Ischemia-reperfusion; Gastric blood flow (Konturek, P.Ch. (322) 73)

Gastrin-releasing peptide
Neuromedin B; Smooth muscle contraction (Ladenheim, E.E. (319) 245)

Gastroduodenal mucosa
Gastroduodenal ulceration; Cysteamine; Testosterone; Sexual dimorphism; Sexual steroid; Microcirculation; Microvascular leakage (László, F. (337) 275)

Gastroduodenal ulceration
Gastroduodenal mucosa; Cysteamine; Testosterone; Sexual dimorphism; Sexual steroid; Microcirculation; Microvascular leakage (László, F. (337) 275)

Gastrointestinal motility
Migrating motor complex; Force transducer; Cisapride; (Ferret) (Nagakura, Y. (321) 53)

Gastrointestinal mucosal integrity
Pentadecapeptide BPC 157; Peptide BPC; Nitric oxide (NO); Blood pressure maintenance; Gastric lesion; Hypotension; N^G-Nitro-L-arginine methylester; L-Arginine; Stomach mucosa (Slobodnjak, Z. (332) 23)

Gastro-intestinal tract
PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal peptide); PACAP receptor; VIP receptor; Neuropeptide Y; Motor effect; Apamin (Ekblad, E. (334) 61)

Gastrointestinal transit
Ileus; Opioid; κ-Opioid receptor; Antinociception (De Winter, B.Y. (339) 63)

GBR 12909
Single photon detection system; Dopamine transporter; 5-HT (5-hydroxytryptamine, serotonin) transporter; Paroxetine; RTI-55 (Mochizuki, T. (338) 17)

[^{3}H]GBR 12935 binding
Piperazine acceptor site; Cytochrome P-450IID6; Platelet, human (Norlén, M. (332) 227)

GDNF (glial cell line-derived neurotrophic factor)
Substantia nigra; Striatum; Dopamine; Parkinson's disease; Monoamine (Martin, D. (317) 247)

Geller-Seifter, conflict
5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Flesinoxan; WAY-100635; Anxiety; (Rat) (King, C.M.F. (325) 121)

Gene expression
Benzodiazepine tolerance; Coordinate gene regulation (Holt, R.A. (329) 129)

Neuropeptide Y Y_1 receptor; Binding; Antisense oligonucleotide; Electroporation (Hänze, J. (330) 87)

Angiotensin-converting enzyme inhibitor; TGF-β1 (transforming growth factor-β1); Extracellular matrix; Glomerulosclerosis (Hamaguchi, A. (331) 27)

Cationic amino acid transporter; TNF-α (tumor necrosis factor-α); Nitric oxide (NO); Umbilical vein endothelial cell; (Human) (Irie, K. (339) 289)

Gene regulation
ETYA (5,8,11,14-eicosatetraynoic acid); Endothelial cell activation; Polyunsaturated fatty acid; Inhibition; Adhesion molecule (Stuhlmeier, K.M. (325) 209)

Gene sequence, human
CC-1065 analog; PCR (polymerase-chain reaction) (Passadore, M. (319) 317)

Genetically epilepsy-prone rat
Epilepsy; Glutamate; Metabotropic glutamate receptor; L-Serine-*O*-phosphate; (*S*)-4C3HPG ((*S*)-4-carboxy-3-hydroxyphenylglycine); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid) (Tang, E. (327) 109)

Genistein
Myogenic response; Pressure-induced contraction; Cerebral artery, rat; Tyrosine kinase inhibitor; Herbimycin A (Masumoto, N. (330) 55)

Lipopolysaccharide; Nitric oxide (NO) synthase, inducible; Aorta, rat; Tyrphostin; Orthovanadate; Phenylarsine oxide (Duarte, J. (338) 25)

Arrhythmia, ventricular; Preconditioning; Tyrosine kinase (Fatehi-Hassanabad, Z. (338) 67)

γ-glutamylcysteinylethyl ester
Glutathione, reduced; Hepatocyte; Glycine; *Tert*-butyl hydroperoxide (Nishida, K. (333) 289)

GHB (γ-hydroxybutyric acid)
$GABA_B$ receptor; G-protein-coupled receptor; GTP shift; Absence seizure (Mathivet, P. (321) 67)

GH (growth hormone-)deficiency
Hexarelin; Ischemia-reperfusion; Heart, rat; 6-keto-prostaglandin $F_{1\alpha}$; Angiotensin II (De Gennaro Colonna, V. (334) 201)

Ginsenoside
Choline acetyltransferase; Scopolamine; Maze; Septum, medial (Yamaguchi, Y. (329) 37)

Gland cell
Cocaine; Cl^- secretion; Short-circuit current; Trachea (Chan, M.-H. (334) 281)

Glia
Histamine; Histamine H_1 receptor; Astrocytoma; GABA (γ-aminobutyric acid); Ca^{2+} (Soria-Jasso, L.-E. (318) 185)

GABA (γ-aminobutyric acid) homeostasis; GABA transporter; Neuron; Epilepsy; Microdialysis (Juhász, G. (331) 139)

Glial cell
Endozepine; Octadecaneuropeptide (ODN); Diazepam-binding inhibitor; Benzodiazepine receptor; Ca^{2+} mobilization (Gandolfo, P. (322) 275)

Endothelin; Nitric oxide synthase, inducible; TNF-α (tumor necrosis factor-α); Protein kinase C; Endothelin ET_B receptor (Oda, H. (339) 253)

Glibenclamide
Cl^- current; Niflumic acid; Noradrenaline; Caffeine; Smooth muscle (Kirkup, A.J. (317) 165)

Y-26763; K^+ channel opener; Cardioprotection; K^+ channel, ATP-sensitive (Rahman, F. (317) 293)

Vas deferens, rat; Purinergic transmission; Noradrenergic transmission; Cromakalim; Prazosin; Suramin (Grana, E. (319) 57)

Reperfusion arrhythmia; Pinacidil; Cromakalim; Anesthetized rat (Baczkó, I. (324) 77)

NS 1619; Charybdotoxin; K^+ channel, Ca^{2+}-activated; Ca^{2+} channel; Vas deferens, rat (Huang, Y. (325) 21)

Sulfonylurea; Prostanoid; Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Tolazamide; Tolbutamide; Gliclazide; Bronchiole; Artery (Delaey, C. (325) 41)

CGRP (calcitonin gene-related peptide); Electric field stimulation; K^+ channel, ATP-sensitive; Neurotransmission; Vas deferens, rat (Huang, Y. (327) 209)

Coronary artery; SIN-1 (3-morpholinosydnonimine); Nitric oxide (NO); K_{ATP} channel; Vasodilation (Deka, D.K. (330) 157)

Repaglinide; Glimepiride; Insulin secretion; (GK rat) (Ladrière, L. (335) 227)

Membrane potential; Antiepileptics; Cromakalim; Patch-clamp electrophysiology; NG 108-15 cell; hNT neuron; Cortical neuron, mouse (Rundfeldt, C. (336) 243)

Glibenclamide (glyburide)
K^+_{ATP} channel; Myocardial ischemia; Cardiac arrhythmia; Adenosine release (Bernauer, W. (326) 147)

Gliclazide
Sulfonylurea; Prostanoid; Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Tolazamide; Tolbutamide; Glibenclamide; Bronchiole; Artery (Delaey, C. (325) 41)

Glimepiride
Repaglinide; Glibenclamide; Insulin secretion; (GK rat) (Ladrière, L. (335) 227)

Glioma
Vitamin D; Apoptosis; Noradrenaline (Canova, C. (319) 365)

Gliquidone
Succinic acid monoethyl ester; Succinic acid monopropyl ester; Succinic acid monoisopropyl ester; Insulin secretion (García-Martínez, J.A. (325) 65)

Glomerular endothelial cell
Nitric oxide (NO); Nitric oxide (NO) donor; Mesangial cell; Apoptosis; Glomerular epithelial cell; Interleukin-1 (Mühl, H. (317) 137)

Glomerular epithelial cell
Nitric oxide (NO); Nitric oxide (NO) donor; Mesangial cell; Apoptosis; Glomerular endothelial cell; Interleukin-1 (Mühl, H. (317) 137)

Glomerulonephritis
Nitric oxide (NO); Prostacyclin (Ikeda, M. (324) 283)

Glomerulosclerosis
Angiotensin-converting enzyme inhibitor; TGF-β1 (transforming growth factor-β1); Extracellular matrix; Gene expression (Hamaguchi, A. (331) 27)

Glomerulus
Dopamine D_3 receptor; Kidney; Radioligand binding assay; Autoradiography; Cortical tubule (Barili, P. (338) 89)

GLP-1-(7–34)
GLP-1 (glucagon-like peptide-1); GLP-1-(7–36) amide; GLP-1-(9–36) amide; GLP-1-(7–35); Receptor binding; Receptor activation; (Metabolite) (Knudsen, L.B. (318) 429)

GLP-1-(7–35)
GLP-1 (glucagon-like peptide-1); GLP-1-(7–36) amide; GLP-1-(9–36) amide; GLP-1-(7–34); Receptor binding; Receptor activation; (Metabolite) (Knudsen, L.B. (318) 429)

GLP-1-(7–36) amide
GLP-1 (glucagon-like peptide-1); GLP-1-(9–36) amide; GLP-1-(7–35); GLP-1-(7–34); Receptor binding; Receptor activation; (Metabolite) (Knudsen, L.B. (318) 429)

GLP-1-(9–36) amide
GLP-1 (glucagon-like peptide-1); GLP-1-(7–36) amide; GLP-1-(7–35); GLP-1-(7–34); Receptor binding; Receptor activation; (Metabolite) (Knudsen, L.B. (318) 429)

GLP-1 (glucagon-like peptide-1)
GLP-1-(7–36) amide; GLP-1-(9–36) amide; GLP-1-(7–35); GLP-1-(7–34); Receptor binding; Receptor activation; (Metabolite) (Knudsen, L.B. (318) 429)

CRF (corticotropin-releasing factor); Hypothalamic-pituitary-adrenal axis; Feeding behavior; (Chicken) (Furuse, M. (339) 211)

β-D-Glucan
Alveolar macrophage; Serum component; Interferon γ; Nitric oxide (NO); β-D-Glucan receptor (Sakurai, T. (334) 255)

β-D-Glucan receptor
β-D-Glucan; Alveolar macrophage; Serum component; Interferon γ; Nitric oxide (NO) (Sakurai, T. (334) 255)

Glucocorticoid
Anthraquinone; Intestinal secretion; Nitric oxide (NO); Laxative; Natural drug (Izzo, A.A. (323) 93)

Adhesion molecule; Inflammation; PECAM-1; Interleukin-1; TNF-α (Wheller, S.K. (331) 65)

Mineralocorticoid; Hippocampal slice; Patch clamp recording (Karst, H. (339) 17)

Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; Lipocortin; J774 macrophage; Lipopolysaccharide (D'Acquisto, F. (339) 87)

Glucocorticosteroid
FK506; Immunosuppression; Local lymph node assay; Tacrolimus; Topical drug (Homey, B. (325) 199)

Glucose
GLUT1 transporter; Chlorambucil; Blood–brain barrier; Erythrocyte (Halmos, T. (318) 477)

Nitric oxide (NO); Nitrosothiol; Glutathione; *N*-Acetylcysteine; Lipopolysaccharide; Cytotoxicity; Macrophage (Zamora, R. (321) 87)

Glucose, plasma
Org 9935; Org 30029; Insulin secretion; Phosphodiesterase inhibitor; Insulin, plasma (El-Metwally, M. (324) 227)

Glucose metabolism
Amylin; CGRP (calcitonin gene-related peptide); Hepatocyte; Macrophage; Kupffer cell (Pittner, R.A. (325) 189)

D-Glucose oxidation
Endothelial cell; EDRF (endothelium-derived relaxing factor); Glutathione; Superoxide dismutase; Vitamin C; Vitamin E (Graier, W.F. (322) 113)

Glucose tolerance
Spontaneously hypertensive rat (SHR); Blood pressure; Angiotensin-converting enzyme inhibitor; Angiotensin AT_1 receptor antagonist; Valsartan (Chow, L. (319) 77)

Imidazoline; Antazoline; Insulin secretion; Somatostatin secretion; Pancreas; (Rat); (Dog) (Berdeu, D. (324) 233)

mGlu receptor
Long-term potentiation; Hippocampus; PCCG-IV ((2*S*,1'*S*,2'*S*,3'*R*)-2-(2''-carboxy-3'-phenylcyclopropyl)glycine); MTPG ((*R*,*S*)-α-methyl-4-tetrazolylphenylglycine) (Huang, L. (332) 161)

$mGlu_2$ receptor selectivity
Metabotropic glutamic acid receptor; (1*SR*,3*RS*)-ACPD ((1*SR*,3*RS*)-1-Aminocyclopentane-1,3-dicarboxylic acid); (1*RS*,2*RS*)-homo-ACPD ((1*RS*,2*RS*)-1-amino-1-carboxycyclopentane-2-acetic acid); (1,3)-homo-ACPD (1-Amino-1-carboxycyclopentane-3-acetic acid); (Partial agonist) (Bräuner-Osborne, H. (332) 327)

Glutamate
Striatum; Pregnancy; Dopamine; Progesterone; NMDA (*N*-methyl-D-aspartic acid) (Cabrera, R.J. (317) 55)

$GABA_B$ receptor; Microdialysis; Thalamus; Aspartate (Nyitrai, G. (318) 295)

Aspartate; Cocaine; Nucleus accumbens; Sensitization; (Rat) (Robinson, S.E. (319) 31)

Vitamin B; Culture; Cytotoxicity; Retina (Kaneda, K. (322) 259)

Kainate; Hippocampus; GABA (γ-aminobutyric acid) release; Domoic acid; Synaptosome (Cunha, R.A. (323) 167)

Histamine; Synaptosome; [^{3}H]Glutamate, release; Hippocampus (Rodriguez, F.J. (323) 283)

Free radical; Pyrroloquinoline quinone; NMDA receptor; Redox modulatory site; Dihydroethidium (Scanlon, J.M. (326) 67)

Oxidative stress; Glutathione depletion; Programmed cell death (Froissard, P. (326) 93)

Epilepsy; Genetically epilepsy-prone rat; Metabotropic glutamate receptor; L-Serine-*O*-phosphate; (*S*)-4C3HPG) ((*S*)-4-carboxy-3-hydroxyphenylglycine); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid) (Tang, E. (327) 109)

Ethanol; Spinal cord; GABA (γ-aminobutyric acid); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); NMDA (*N*-methyl-D-aspartate); Anesthesia (Wong, S.M.E. (329) 121)

Glycine; ACEA 1021; Psychotomimetic; Amnesia; Side effects (Kretschmer, B.D. (331) 109)

Na^+ channel blocker; Movement disorder; Paroxysmal choreoathetosis (Richter, A. (332) 133)

Excitatory amino acids; AMPA receptor; [^{3}H]D-Aspartate release; Autoreceptor (Patel, D.R. (332) 143)

Spreading depression; Nicotinic acetylcholine receptor; NMDA receptor (Sheardown, M.J. (337) 209)

Penumbra; Taurine; Lubeluzole; Neuroprotection; Swelling; Microdialysis (Scheller, D.K.A. (338) 243)

AMPA receptor; Extracellular calcium; Inositol phosphate; Oligodendrocyte (Liu, H.-N. (338) 277)

[^{3}H]Glutamate, release
Histamine; Glutamate; Synaptosome; Hippocampus (Rodriguez, F.J. (323) 283)

Glutamate receptor
Acoustic startle response; Anxiety; AP-5; Caudal pontine reticular formation; Fear (Fendt, M. (318) 1)

NMDA receptor; *Xenopus* oocyte; Ligand-gated ion channel (Buller, A.L. (320) 87)

4-Methylglutamic acid; 4-Methyleneglutamic acid (Bräuner-Osborne, H. (335) R1)

Allosteric antagonism; *Xenopus* oocyte; Ifenprodil; CP 101,606; Ro 25-6981; Haloperidol (Whittemore, E.R. (337) 197)

Novel antagonist; Neonatal rat spinal cord (Thomas, N.K. (338) 111)

Glutamate release
Synaptosome; Nitric oxide (NO); cGMP; Protein kinase G; Zaprinast (Sistiaga, A. (321) 247)

Glutamate toxicity
1-Aminocyclopropanecarboxylic acid; Neuroprotection; Neuronal injury; Glycine receptor; NMDA receptor complex (Lin, Y. (338) 289)

Glutathione
Flupirtine; Triamnopyridine; hNT neuron; Bcl-2; Neuroprotection; Apoptosis (Perovic, S. (317) 157)

Nitric oxide (NO); Oxidant; Cell damage; Gastric mucosa (Wakulich, C.A. (319) 333)

Nitric oxide (NO); Nitrosothiol; *N*-Acetylcysteine; Glucose; Lipopolysaccharide; Cytotoxicity; Macrophage (Zamora, R. (321) 87)

D-Glucose oxidation; Endothelial cell; EDRF (endothelium-derived relaxing factor); Superoxide dismutase; Vitamin C; Vitamin E (Graier, W.F. (322) 113)

MDA (3,4-Methylenedioxyamphetamine); MDMA (3,4-Methylenedioxymethamphetamine); α-Methyldopamine; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Miller, R.T. (323) 173)

Anethole dithiolethione; Hydrogen peroxide; Oxidative stress; Astrocyte; Neurodegeneration (Drukarch, B. (329) 259)

Glutathione, reduced
γ-glutamylcysteinylethyl ester; Hepatocyte; Glycine; *Tert*-butyl hydroperoxide (Nishida, K. (333) 289)

Glutathione depletion
Glutamate; Oxidative stress; Programmed cell death (Froissard, P. (326) 93)

Glutathione redox cycle
Oxygen metabolite, reactive; Superoxide dismutase; Catalase; Colonic epithelial cell (Hata, Y. (321) 113)

GLUT1 transporter
Glucose; Chlorambucil; Blood–brain barrier; Erythrocyte (Halmos, T. (318) 477)

Glybenclamide receptor
K_{ATP} channel; Skeletal muscle; Patch clamp (Tricarico, D. (321) 369)

Glycerylphosphorylcholine
Phosphoserine phosphatase; L-Serine; D-Serine; Phosphorylcholine; *p*-Chloromercuriphenylsulfonic acid; *N*-Ethylmaleimide (Hawkinson, J.E. (337) 315)

Glyceryl trinitrate
Vascular heterogeneity; Coronary artery, bovine; *S*-Nitroso-*N*-acetylpenicillamine; Sodium nitroprusside; Isoprenaline (De la Lande, I.S. (318) 65)

Glycine
ACPC (1-aminocyclopropanecarboxylic acid); Neuroprotection; NMDA receptor; Toxicity; Neuronal injury; Excitatory amino acid (Lin, Y. (318) 491)

ACEA 1021; Psychotomimetic; Amnesia; Side effects; Glutamate (Kretschmer, B.D. (331) 109)

γ-glutamylcysteinylethyl ester; Glutathione, reduced; Hepatocyte; *Tert*-butyl hydroperoxide (Nishida, K. (333) 289)

Glycine / NMDA receptor antagonist
Mesocortical dopamine neuron; Stress; Benzodiazepine/$GABA_A$ receptor agonist; Agonist, inverse (Hutson, P.H. (326) 127)

Glycine receptor
Corymine; *Xenopus* oocytes; $GABA_A$ receptors (Leewanich, P. (332) 321)

1-Aminocyclopropanecarboxylic acid; Neuroprotection; Glutamate toxicity; Neuronal injury; NMDA receptor complex (Lin, Y. (338) 289)

Glycine receptor, strychnine-insensitive
NMDA receptor; [^{3}H]Dopamine release; [^{3}H]Noradrenaline release; Synaptosome; 7-Cl-Kynurenic acid; HA 966; GV 150526A (Mennini, T. (336) 275)

Glycine receptor, strychnine-sensitive
[^{3}H]Strychnine binding; Spinal cord, rat; Autoradiography; Thiocolchicoside; Myorelaxant agent (Cimino, M. (318) 201)

Glycine site
Conditioned preference; Reward; NMDA receptor; MK-801; CGP 37849; CGP 40116; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (317) 191)

D-Cycloserine; NMDA receptor; Acetylcholine; Hippocampus; Working memory (Ohno, M. (318) 267)

Astrocyte; Excitotoxicity; NMDA receptor; Kynurenic acid; Neurodegenerative disorder; Quinolinic acid (Wu, H.-Q. (319) 13)

Glycolysis
Calmodulin antagonist; Cytoskeleton; Melanoma cell (Glass-Marmor, L. (328) 241)

Glycoprotein IIb / IIIa
Monoclonal antibody; Bleeding time; Platelet aggregation (Suzuki, K.-i. (336) 169)

GMAP (galanin message-associated peptide), fragments
Flexor reflex; Galanin; Nociception; Spinal cord (Xu, X.-J. (318) 301)

cGMP
S-nitrosothiol (stereoisomer); Nitric oxide (NO); Vascular smooth muscle (Travis, M.D. (318) 47)

Rutaecarpine; Alkaloid; Platelet, human; cAMP; Thromboxane A_2; Phosphoinositide (Sheu, J.-R. (318) 469)

Cu^{2+}; Nitric oxide (NO); Nitric oxide (NO) donor (Ohnishi, T. (319) 49)

Glutamate release; Synaptosome; Nitric oxide (NO); Protein kinase G; Zaprinast (Sistiaga, A. (321) 247)

Hydralazine; Endothelium; Relaxation (Wei, S. (321) 307)

Nitric oxide (NO); Interleukin-6; Hippocampus; Sodium nitroprusside; N^G-Nitro-L-arginine (Ma, T. (321) 343)

Phosphodiesterase; Ca^{2+}; Granule cell; Astrocyte (Agulló, L. (323) 119)

K^+ channel, Ca^{2+}-activated; Iberiotoxin; Nitric oxide (NO); Okadaic acid; Phosphatase; Smooth muscle (Johansson Rydberg, I.G.M. (329) 175)

Aorta, rat; Relaxation; Nitric oxide (NO) synthase (Takizawa, S. (330) 143)

Thoracic aorta; Vasorelaxation; Norepinephrine; cAMP; Ca^{2+} channel blocker (Cheng, Y.-W. (336) 23)

Nitric oxide (NO)-releasing compound; Nitric oxide (NO); Lymphocyte (Kosonen, O. (337) 55)

Memory; Nitric oxide (NO); Blood pressure; 7-Nitroindazole; Zaprinast; (Rat) (Prickaerts, J. (337) 125)

Lipopolysaccharide; cAMP; Phosphodiesterase III inhibitor; Monocyte; Macrophage; Interleukin-10; TNF-α (tumor necrosis factor-α); Nitric oxide (NO) (Németh, Z.H. (339) 215)

cGMP-dependent protein kinase
cAMP-dependent protein kinase; (Rp)-8-Bromo-guanosine-3′,5′-cyclic monophosphorothioate; (Rp)-Adenosine-3′,5′-cyclic monophosphorothioate; Ca^{2+} sensitivity; Smooth muscle, skinned, vascular (Kawada, T. (323) 75)

Gpp(NH)p
RX821002 (2-methoxyidazoxan); α_2-Adrenoceptor subtype; Na^+ (Callado, L.F. (332) 109)

G protein
β-Adrenoceptor; Heart, neonatal; Ca^{2+} current; Voltage clamp, whole cell (Katsube, Y. (317) 391)

Brain, mouse; Δ^9-Tetrahydrocannabinol (Burkey, T.H. (323) R3)

Metabotropic glutamate receptor; *trans*-ACPD; C6 glioma cell (Albasanz, J.L. (326) 85)

Ca^{2+} sensitivity; Protein kinase C; Pimobendan; β-Escin; Cardiac muscle; Smooth muscle, vascular (Tomita, F. (326) 157)

Adenosine A_1 receptor; Excitatory postsynaptic potential; Hippocampus; Agonism, partial; Intrinsic activity (Lorenzen, A. (334) 299)

Dopamine D_3 receptor; Receptor binding; Acidification rate; cAMP accumulation; *Fos* protein immunoreactivity (Scheideler, M.A. (339) 261)

G_i-protein
Neuropeptide Y; Dopamine release; Dopamine D_2 receptor; Striatum; Spontaneously hypertensive rat (SHR) (Tsuda, K. (321) 5)

G-protein-coupled receptor
$GABA_B$ receptor; GHB (γ-hydroxybutyric acid); GTP shift; Absence seizure (Mathivet, P. (321) 67)

5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor; Signal transduction (Gerhardt, C.C. (334) 1)

Metabotropic glutamate receptor; Alternative splicing; Constitutive activity; Phospholipase C coupling (Mary, S. (335) 65)

GR79236
Insulin resistance; Lipolysis; Fructose; Triglyceride; Non-insulin-dependent diabetes (NIDDM) (Qu, X. (338) 269)

GR 125743
5-HT (5-hydroxytryptamine, serotonin); Microdialysis; 5-$HT_{1B/1D}$ receptor; GR 127935; (Guinea pig) (Roberts, C. (326) 23)

[^{3}H]GR 125,743
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1D} receptor; [^{3}H]5-CT; (Guinea pig) (Audinot, V. (327) 247)

GR 127935
5-HT (5-hydroxytryptamine, serotonin); Microdialysis; 5-$HT_{1B/1D}$ receptor; GR 125743; (Guinea pig) (Roberts, C. (326) 23)

Granulation tissue
Allergic inflammation, recurrence of; Prostaglandin E_2; Cyclooxygenase-1; Cyclooxygenase-2; NS-398; Indomethacin; Dexamethasone (Niki, H. (320) 193)

Granule cell
cGMP; Phosphodiesterase; Ca^{2+}; Astrocyte (Agulló, L. (323) 119)

Granule neuron
Ca^{2+} channel; Cerebellum; ω-Conotoxin-GVIA; ω-Agatoxin-IVA; Eliprodil (Biton, B. (323) 277)

Grooming behavior
Dopamine 'D_1-like' receptor; Dopamine 'D_2-like' receptor; D_1/D_2 interaction; LY 270411; BW 737C; SCH 23390; Vacuous chewing; Myoclonic jerking; (Rat) (Deveney, A.M. (317) 175)

Growth
Opiate; β-Endorphin; Insulin; Development; Ornithine decarboxylase mRNA; Intracerebroventricular (Bartolome, J.V. (331) 145)

Growth factor
Epiregulin; Cell proliferation; Tyrosine phosphorylation; Epidermal growth factor; Epidermal growth factor receptor; Gastric cell (Sasaki, E. (338) 253)

GTPase
α_2-Adrenoceptor subtype; Antagonist potency; CHO cell (Virolainen, S. (338) 293)

[^{35}S]GTPγS
Dopamine D_4 receptor; L 745,870; Clozapine; Noradrenaline; Adrenaline (Newman-Tancredi, A. (319) 379)

[^{35}S]GTPγS binding
AM630; Cannabinoid receptor antagonist (Hosohata, Y. (321) R1)

Efficacy; δ-Opioid receptor, human; Radioligand binding; δ-Opioid receptor agonist (Quock, R.M. (326) 101)

[^{35}S]GTPγS binding assay
5-HT_{1A} receptor, human; Receptor reserve (Stanton, J.A. (320) 267)

GTP shift
$GABA_B$ receptor; GHB (γ-hydroxybutyric acid); G-protein-coupled receptor; Absence seizure (Mathivet, P. (321) 67)

Guanosine 3′,5′-cyclic monophosphate
Brown adipocyte; TMF-α (tumor necrosis factor-α); Nitric oxide (NO) synthase, inducible; Lipoprotein lipase (Uchida, Y. (335) 235)

Guanylate cyclase, soluble
N^{ω}-nitro-L-arginine; Nitric oxide (NO) donor; Heart muscle; Contractility; Heart rate; (Rat) (Kojda, G. (334) 181)**Guanylin**
Intestine; Ion transport; Na^+ and Cl^- unidirectional flux; STa (heat-stable enterotoxin of *Escherichia coli*); VIP (vasoactive intestinal peptide) (Volant, K. (328) 217)

Guanylyl cyclase
Smooth muscle tension; Isoliquiritigenin; YC-1; ODQ (Wegener, J.W. (323) 89)

Heart; Phosphodiesterase; Ca^{2+} current, L-type; Force of contraction; Fura-2 (Wegener, J.W. (326) 37)

Guinea pig
Cysteinyl-leukotriene receptor antagonist; Ileum; BAY u9773 (Bäck, M. (317) 107)

Talsaclidine; Arecoline; McN-A-343; Noradrenaline; Bronchospasm (Walland, A. (330) 213)

Hypothermia; 5-HT; 5-HT_{1D} receptor; 5-HT_{1B} receptor; SKF-99101H; SB-216641A; BRL-15572; SB-224289G (Hagan, J.J. (331) 169)

GV 150526A
Glycine receptor, strychnine-insensitive; NMDA receptor; [^{3}H]Dopamine release; [^{3}H]Noradrenaline release; Synaptosome; 7-Cl-Kynurenic acid; HA 966 (Mennini, T. (336) 275)

GW1229
Neuropeptide Y receptor antagonist; Neuropeptide Y Y_1 receptor; Microcirculation hamster (Bitran, M. (319) 43)

GYKI 52466
GYKI 53773; GYKI 53784; 2,3-Benzodiazepine; Analgesia; Anti-inflammatory drugs (Székely, J.I. (336) 143)

GYKI 53655
AMPA receptor; AMPA receptor antagonism; Neuroprotection; NBQX (6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione) (Kovács, A.D. (331) 93)

GYKI 53773
GYKI 52466; GYKI 53784; 2,3-Benzodiazepine; Analgesia; Anti-inflammatory drugs (Székely, J.I. (336) 143)

GYKI 53784
GYKI 52466; GYKI 53773; 2,3-Benzodiazepine; Analgesia; Anti-inflammatory drugs (Székely, J.I. (336) 143)

GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzo-diazepine)
Excitatory amino acid; Anticonvulsant action; Motor system; Flumazenil (Kubová, H. (333) 17)

HA 966
Glycine receptor, strychnine-insensitive; NMDA receptor; [^{3}H]Dopamine release; [^{3}H]Noradrenaline release; Synaptosome; 7-Cl-Kynurenic acid; GV 150526A (Mennini, T. (336) 275)

HA7 cell
5-HT_{1A} receptor; Antipsychotic; cAMP accumulation; 5-HT (extracellular concentration); Microdialysis (Assié, M.-B. (334) 141)

Haemoglobin
Nitric oxide (NO); Peroxynitrite; Sugar; Vasodilatation; L-Cysteine; Sodium nitrite; Methylene blue (Dowell, F.J. (338) 43)

Haemorrhagic shock
Mercaptoalkylguanidine; Nitric oxide (NO); 6-Keto-prostaglandin-1α; Peroxynitrite (Zingarelli, B. (338) 55)

Half-life
Endothelin-1; Endothelin receptor antagonist; Bosentan; PD155080; Clearance; Vascular effect (Hemsén, A. (318) 369)

[^{3}H]Alnespirone
5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{1A}$ receptor; Binding; Autoradiography; Physicochemical parameter (Fabre, V. (337) 297)

Haloperidol
(+)-AJ76; (+)-UH-232; (+)-PD 128907; (−)-Apomorphine; Discriminative stimulus effect; Dopamine D$_3$ receptor (Kleven, M.S. (321) 1)

Catalepsy; Theophylline; Adenosine receptor agonist; Adenosine receptor antagonist (Mandhane, S.N. (328) 135)

Neurotensin; Dopamine; Striatum; Nucleus accumbens (Huang, W. (332) 15)

Catalepsy; Muscimol; MK 801 (Kaur, S. (332) 153)

Glutamate receptor; Allosteric antagonism; *Xenopus* oocyte; Ifenprodil; CP 101,606; Ro 25-6981 (Whittemore, E.R. (337) 197)

Halothane
Pulmonary artery, human; Endothelium-dependent relaxation (Higueras, J. (326) 175)

Ethanol; Muscarinic receptor; Protein kinase C; *Xenopus* oocyte (Minami, K. (339) 237)

H9c2 heart cell line
Diuretic; Xipamide; Amiloride; Cardiocyte; Cell membrane; (Rat, newborn) (Taouil, K. (324) 289)

Headache
Dura mater encephali; Arterial blood flow; Neurogenic inflammation; 5-HT$_1$ receptor agonist; Migraine; (Rat) (Messlinger, K. (332) 173)

Head-weaving behavior
σ Receptor; Phencyclidine (PCP) receptor; Dizocilpine; (Rat) (Kitaichi, K. (318) 205)

Heart
Inflammation; Sepsis; Heart failure (Oddis, C.V. (320) 167)

Guanylyl cyclase; Phosphodiesterase; Ca^{2+} current, L-type; Force of contraction; Fura-2 (Wegener, J.W. (326) 37)

Heart damage
Ca^{2+} paradox; O_2 paradox; Caffeine; Amiloride; pH (Harding, R.J. (330) 47)

Heart failure
Ventricular pacing, rapid; Dorsal pedal artery; Saphenous vein; α_1-Adrenoceptor; 5-Methyl-urapidil (Forster, C. (318) 55)

Coronary microvessel; Acetylcholine; Nitroglycerin; L-Arginine; Nitric oxide (NO) (Larosa, G. (318) 387)

Inflammation; Heart; Sepsis (Oddis, C.V. (320) 167)

Na^+/Ca^{2+} exchange; Ca^{2+}, intracellular; cAMP (Miao, L. (321) 201)

Ventricular pacing, rapid; Blood vessel; α_1-Adrenoceptor subtype; Chloroethylclonidine (Le Tran, Y. (336) 177)

Heart muscle
Tetrandrine; $[Ca^{2+}]_i$ transient; Ca^{2+} antagonist; Ca^{2+} release; Cardiomyocyte (Wang, H.-X. (319) 115)

N^{ω}-nitro-L-arginine; Nitric oxide (NO) donor; Contractility; Guanylate cyclase, soluble; Heart rate; (Rat) (Kojda, G. (334) 181)

Heart, neonatal
β-Adrenoceptor; Ca^{2+} current; G protein; Voltage clamp, whole cell (Katsube, Y. (317) 391)

Heart, rat
Hyperbaric oxygen; Ischemia, low flow; *N*-Acetylcysteine; Defibrotide (Radice, S. (320) 43)

Hexarelin; GH (growth hormone)-deficiency; Ischemia-reperfusion; 6-keto-prostaglandin F$_{1\alpha}$; Angiotensin II (De Gennaro Colonna, V. (334) 201)

Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Anandamide; SR141716A; Cannabinoids (endocannabinoids), endogenous (Randall, M.D. (335) 205)

Heart rate
γ-MSH (γ-melanocyte-stimulating hormone) fragment; ACTH (adrenocorticotropic hormone) fragment; Blood pressure; Cerebral blood flow; Structure-activity relationship; (Rat) (Van Bergen, P. (318) 357)

Angiotensin; Arterial pressure; Spinal cord; Cardiovascular control; Losartan; PD 123319 (Park, P.D.S. (326) 139)

Nociceptin; Blood pressure; Hypotension; Vagal bradycardia (Giuliani, S. (333) 177)

N^{ω}-nitro-L-arginine; Nitric oxide (NO) donor; Heart muscle; Contractility; Guanylate cyclase, soluble; (Rat) (Kojda, G. (334) 181)

Amygdala; AV3V region; Cholinergic hypertension; Carbachol; Blood pressure (Tellioğlu, T. (336) 163)

CCK (cholecystokinin); CCK$_A$ receptor antagonist; Blood pressure; Baroreflex; (Conscious rat) (Bunting, M.W. (337) 35)

S 16257; Bradycardic agent; Stereospecificity; Transmembrane action potential; QT interval (Thollon, C. (339) 43)

HEK293 cell
Ca^{2+} channel; Na^+ channel; NNC 09-0026; CNS 1237; SB 201823-A; NS 649; Riluzole; Cerebral ischaemia (O'Neill, M.J. (332) 121)

Hematocrit
Neurotensin; Prostacyclin; Umbilical vein endothelial cell, human (Schaeffer, P. (323) 215)

Heme-L-lysinate
Vasomotor control; Chromium mesoporphyrin (Kozma, F. (323) R1)

Heme oxygenase
N^G-nitro-L-arginine; Zinc protoporphyrin IX; Nitric oxide (NO); Nitric oxide (NO) synthase; Carbon monoxide (Seki, T. (331) 87)

Hemodynamic alteration
Dantrolene; Nitric oxide (NO) synthase II; Lipopolysaccharide; Mortality (Wu, C.-C. (327) 17)

Hemodynamics
Vasopressin; Endothelin; Spontaneously hypertensive rat (SHR); Cardiac output; Radiotelemetry (Balakrishnan, S.M. (334) 55)

Hemorrhage
FK706; Elastase inhibitor; Neutrophil elastase; Pulmonary emphysema; Edema (Shinguh, Y. (337) 63)

Hemorrhagic shock
Nitric oxide (NO); Electron spin resonance; ACTH (adrenocorticotropin); Nitric oxide (NO) synthase, inducible (Guarini, S. (336) 15)

Hemostasis
PAI-1 (plasminogen activator inhibitor-1); Fibrinolysis; Thrombus; (Rat) (Ohtani, A. (330) 151)

Heparin
Caffeine contracture; Sarcoplasmic reticulum; Skinned fiber; Skeletal muscle, mammalian (Talon, S. (327) 33)

Thrombin receptor; In situ hybridization; Arterial injury (Guitteny, A.-F. (327) 157)

Tryptase; Microvascular leakage; Mast cell; Histamine; Proteinase inhibitor; Histamine receptor antagonist (He, S. (328) 89)

YM-60828; Argatroban; Dalteparin; Arterio–venous shunt; Bleeding time (Sato, K. (339) 141)

Hepatic circulation
Vasodilatation; 8-Phenyltheophylline; ATP; Adenosine; (Rat) (Browse, D.J. (320) 139)

Hepatitis
Dimaprit; Histamine H_2 receptor; TNF-α (tumor necrosis factor α); Septic shock; Inflammation (Nakamura, T. (322) 83)

Hepatocyte
Amylin; CGRP (calcitonin gene-related peptide); Glucose metabolism; Macrophage; Kupffer cell (Pittner, R.A. (325) 189)

γ-glutamylcysteinylethyl ester; Glutathione, reduced; Glycine; *Tert*-butyl hydroperoxide (Nishida, K. (333) 289)

Hepatocyte, cultured
Metabotropic glutamate receptor; Polyphosphoinositide hydrolysis (Sureda, F. (338) R1)

Hepatocyte DNA synthesis
Insulin; Hepatocyte proliferation; β-Adrenoceptor agonist; cAMP-elevating agent (Kimura, M. (327) 87)

Hepatocyte proliferation
EGF (epidermal growth factor); β-Adrenoceptor agonist; Forskolin; DNA synthesis (Kimura, M. (324) 267)

Insulin; Hepatocyte DNA synthesis; β-Adrenoceptor agonist; cAMP-elevating agent (Kimura, M. (327) 87)

Hepatorenal syndrome
CCl_4-induced liver cirrhosis; Na^+ retention; Microvascular leakage; Bradykinin B_2 receptor antagonist; HOE 140 (Icatibant) (Wirth, K.J. (337) 45)

Hepatotoxicity
Cocaine; Nitric oxide (NO); Reactive oxygen species; (Mouse) (Aoki, K. (336) 43)

Herbimycin A
Myogenic response; Pressure-induced contraction; Cerebral artery, rat; Tyrosine kinase inhibitor; Genistein (Masumoto, N. (330) 55)

Heroin
Fentanyl; Morphine; 6-Acetylmorphine; Reinforcement (Martin, T.J. (324) 141)

Balb/c mouse; Cocaine; Self-administration, intravenous; Speedball; (Mouse) (Roberts, A.J. (326) 119)

Sensitization; Deoxyglucose; Basal ganglia; c-*fos* (Pontieri, F.E. (335) 133)

Additivity; Cocaine; Dopamine; Microdialysis; Nicotine; Nucleus accumbens; Speedball; Synergism; (Interaction) (Zernig, G. (337) 1)

Heterogeneity
Levamisole; Nicotinic acetylcholine receptor; Patch clamp; (*Oesphagostomum dentatum*) (Martin, R.J. (322) 249)

Hexachlorocyclohexane isomer
Lindane; $GABA_A$ receptor; Flunitrazepam binding; GABA (γ-aminobutyric acid) binding; TBPS (*t*-butylbicyclophosphorothionate) binding; Cerebellar granule cell, cultured (Vale, C. (319) 343)

Hexamethonium
Dopamine; Ethanol; Microdialysis, in vivo; Mecamylamine; Nicotinic acetylcholine receptor (Blomqvist, O. (334) 149)

Hexarelin
GH (growth hormone)-deficiency; Ischemia-reperfusion; Heart, rat; 6-keto-prostaglandin $F_{1\alpha}$; Angiotensin II (De Gennaro Colonna, V. (334) 201)

2-Hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA)
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5′-*N*-ethylcarboxamidoadenosine (NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

HI 6
Dopamine; Microdialysis; Pharmacokinetics; Acetylcholine esterase; Soman; (Rat) (Cassel, G. (332) 43)

'High Five'
Opioid receptor; Baculovirus; Sf9; Insect cell (Obermeier, H. (318) 161)

Hind limb, isolated perfused, rat
α_{1A}-Adrenoceptor (Zhu, W. (329) 55)

Hippocampal CA1 neuron
Long-term potentiation; Depotentiation; Adenosine A_1 receptor antagonist; 8-CPT (8-cyclopentyltheophylline); Synaptic plasticity, modulation of (Fujii, S. (331) 9)

Hippocampal slice
Mineralocorticoid; Glucocorticoid; Patch clamp recording (Karst, H. (339) 17)

Hippocampus
Acamprosate; Ethanol withdrawal; Pentylenetetrazole; Cerebellum; c-*fos* mRNA; Northern and dot blotting; In situ hybridization (Putzke, J. (317) 39)

BMY-14802; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Dorsal raphe; Microdialysis (Matos, F.F. (317) 49)

Adenosine; Purine; (−)-Bicuculline; GABA (γ-aminobutyric acid); Paired-pulse inhibition; Inhibition; Cyclopentyltheophylline (Higgins, M.J. (317) 215)

D-Cycloserine; Glycine site; NMDA receptor; Acetylcholine; Working memory (Ohno, M. (318) 267)

Microdialysis; Cerebellum; Pilocarpine; Epilepsy; Amino acid (Smolders, I. (319) 21)

GABA (γ-aminobutyric acid); Network (Khalilov, I. (319) R5)

Nitric oxide (NO); cGMP; Interleukin-6; Sodium nitroprusside; N^G-Nitro-L-arginine (Ma, T. (321) 343)

Metabotropic glutamate receptor; 1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitatory postsynaptic potential; Depotentiation; CA1 area; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; WAY-100635; *p*-Chlorophenylalanine; Excitatory synaptic transmission; 5-HT_{1A} receptor; Excitatory postsynaptic potential; Ultrasonic vocalization; Anxiolytic (Xu, L. (323) 59)

Duloxetine; Fluoxetine; Raphe nucleus, dorsal; Electrophysiology, cellular (Smith, J.E. (323) 69)

Kainate; GABA (γ-aminobutyric acid) release; Domoic acid; Glutamate; Synaptosome (Cunha, R.A. (323) 167)

Histamine; Glutamate; Synaptosome; [^{3}H]Glutamate, release (Rodriguez, F.J. (323) 283)

σ_2 Receptor; Norepinephrine; BIMU-8; (+)-Pentazocine (Weatherspoon, J.K. (326) 133)

Acetylcholine; Cannabinoid (Gessa, G.L. (327) R1)

Carbamazepine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Ca^{2+}; Electroshock seizure; Tetrodotoxin; (Rat) (Dailey, J.W. (328) 153)

5-HT receptor; Adenylyl cyclase; Phosphoinositide hydrolysis; Raphe nucleus, dorsal; 5-HT_{1A} receptor (Johnson, R.G. (329) 99)

mGlu receptor; Long-term potentiation; PCCG-IV ((2*S*,1′*S*,2′*S*,3′*R*)-2-(2″-carboxy-3′-phenylcyclopropyl)glycine); MTPG ((*R*,*S*)-α-methyl-4-tetrazolylphenylglycine) (Huang, L. (332) 161)

Epilepsy; Cortex; Thalamus; c-Fos; $GABA_B$ receptor antagonist (Vergnes, M. (332) 245)

Adenosine A_1 receptor; G protein; Excitatory postsynaptic potential; Agonism, partial; Intrinsic activity (Lorenzen, A. (334) 299)

Epileptiform activity; *Aconitum* alkaloids (Ameri, A. (335) 145)

Free radical; H_2O_2; CA1 region; Synaptic plasticity (Katsuki, H. (337) 213)

Hippocampus, ventral
Nicotine; Nucleus accumbens; Striatum; Noradrenaline; Dopamine (Benwell, M.E.M. (325) 13)

Histamine
Histamine H_1 receptor; Astrocytoma; GABA (γ-aminobutyric acid); Glia; Ca^{2+} (Soria-Jasso, L.-E. (318) 185)

CRF (corticotropin-releasing factor); Inflammation; Arachidonic acid (Correa, S.G. (319) 85)

Airway, human; Prostaglandin $F_{2\alpha}$ (Knight, D.A. (319) 261)

Intestine; Ganglion; Enteric nervous system; Myenteric plexus; cAMP; Adenylate cyclase; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Signal transduction (Xia, Y. (320) 95)

ATP, extracellular; $[Ca^{2+}]_i$; HL-60 cell (Song, S.-K. (322) 265)

Glutamate; Synaptosome; [^{3}H]Glutamate, release; Hippocampus (Rodriguez, F.J. (323) 283)

Histamine receptor; (*R*)-α-Methylhistamine; Histamine H_1 receptor; Histamine H_3 receptor; Endothelium; Nitric oxide (NO); Oviductal artery (Martínez, A.C. (326) 163)

Mast cell; Interleukin-4; TNF-α (tumor necrosis factor-α) (Gibbs, B.F. (327) 73)

Tryptase; Microvascular leakage; Mast cell; Heparin; Proteinase inhibitor; Histamine receptor antagonist (He, S. (328) 89)

NO synthase inhibitors; Plasma leakage; Blood flow; Bradykinin (Perez, A.C. (330) 241)

Ion secretion; Intestinal secretion; Epithelial cell (Homaidan, F.R. (331) 199)

Adenosine; Airway; Lipooxygenase-products; NANC (non-adrenergic–non-cholinergic), inhibitory; (Guinea pig) (Nieri, P. (331) 205)

Microdialysis; Paw edema; Mast cell deficient rat (Ws/Ws rat); Compound 48/80; Degranulation (Guo, Y. (331) 237)

Adenosine A_3 receptor; Pain; 5-HT (5-hydroxytryptamine, serotonin) (Sawynok, J. (333) 1)

Histamine immunoreactivity
Vestibular nucleus; Tuberomammillary nucleus; Unilateral vestibular neurectomy; Thioperamide; Betahistine; (Cat) (Tighilet, B. (330) 65)

Histamine receptor
Ureter; Histamine H_1 receptor; Histamine H_2 receptor; 5-HT (5-hydroxytryptamine, serotonin); Prostaglandin; Noradrenaline (Dodel, R.C. (318) 395)

Plasma protein extravasation; 5-HT receptor; Tachykinin; Airways; Capsaicin; (Fisher 344 rat) (Germonpré, P.R. (324) 249)

Histamine; (*R*)-α-Methylhistamine; Histamine H_1 receptor; Histamine H_3 receptor; Endothelium; Nitric oxide (NO); Oviductal artery (Martínez, A.C. (326) 163)

Histamine H_1 receptor
Histamine; Astrocytoma; GABA (γ-aminobutyric acid); Glia; Ca^{2+} (Soria-Jasso, L.-E. (318) 185)

Ureter; Histamine receptor; Histamine H_2 receptor; 5-HT (5-hydroxytryptamine, serotonin); Prostaglandin; Noradrenaline (Dodel, R.C. (318) 395)

Histamine; Histamine receptor; (*R*)-α-Methylhistamine; Histamine H_3 receptor; Endothelium; Nitric oxide (NO); Oviductal artery (Martínez, A.C. (326) 163)

Lingual artery, dog; 2-Pyridylethylamine; Dimaprit; (Cannula insertion method) (Chiba, S. (329) 63)

Histamine H_2 receptor
Ureter; Histamine receptor; Histamine H_1 receptor; 5-HT (5-hydroxytryptamine, serotonin); Prostaglandin; Noradrenaline (Dodel, R.C. (318) 395)

Dimaprit; TNF-α (tumor necrosis factor α); Hepatitis; Septic shock; Inflammation (Nakamura, T. (322) 83)

Cerebral vein; Venodilation; Endothelium; Nitric oxide (NO); Prostanoid (Monge, L. (338) 135)

Histamine H_3 receptor
Histamine; Histamine receptor; (*R*)-α-Methylhistamine; Histamine H_1 receptor; Endothelium; Nitric oxide (NO); Oviductal artery (Martínez, A.C. (326) 163)

Prejunctional receptor; Intramural reflex; Peristalsis; Circular muscle; Ileum, guinea pig (Poli, E. (327) 49)

Histamine receptor antagonist
Tryptase; Microvascular leakage; Mast cell; Histamine; Heparin; Proteinase inhibitor (He, S. (328) 89)

L-Histidine
Hydrogen peroxide; DNA double-strand breaks; Pulsed field gel electrophoresis; Apoptosis; Necrosis (Palomba, L. (318) 167)

H^+/K^+-ATPase
T-330; Gastric acid secretion; Omeprazole; Ranitidine (Kinoshita, M. (321) 325)

[^{3}H]Ketanserin binding
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); SR 46349B; 5-HT_{2A} receptor; Anxiety; Elevated plus-maze; RHA and RLA (Roman high- and low-avoidance) rats (Chaouloff, F. (334) 25)

hKv1.5 channel
Antihistaminic agent; Terfenadine; Ebastine; Carebastine; K^+ current (Valenzuela, C. (326) 257)

HL-60 cell
Histamine; ATP, extracellular; $[Ca^{2+}]_i$ (Song, S.-K. (322) 265)

Calyculin A; Ca^{2+}, cytosolic; Mn^{2+}; Protein phosphatase; Protein phosphorylation (Leung, Y.-M. (331) 337)

HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase
Pravastatin sodium; LDL (low-density lipoprotein) receptor; Cholesterol 7α-hydroxylase; (Rat) (Fujioka, T. (323) 223)

Pravastatin sodium; Fatty acid synthesis; Fatty acid synthase; (Rat) (Fujioka, T. (328) 235)

H_2O_2
Free radical; Hippocampus; CA1 region; Synaptic plasticity (Katsuki, H. (337) 213)

HOE-140
Nitric oxide (NO); Renin-angiotensin system; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Enalapril; Blood pressure (Zappellini, A. (317) 285)

Inflammation; Arthritis; Prostaglandin E_2; Des-Arg^9-bradykinin; (Rat) (Tonussi, C.R. (326) 61)

HOE642
Na^+/H^+ exchange; Na^+/Ca^{2+} exchange; Arrhythmia ischemia; Arrhythmia reperfusion; Digitalis arrhythmia (Xue, Y.X. (317) 309)

HOE 140 (Icatibant)
CCl_4-induced liver cirrhosis; Hepatorenal syndrome; Na^+ retention; Microvascular leakage; Bradykinin B_2 receptor antagonist (Wirth, K.J. (337) 45)

Homophtalazine (2,3-benzodiazepine)
Opioid; Anxiolytics; Signal transduction; Dopamine receptor antagonist; Benzodiazepine (Fekete, M.I.K. (331) 175)

Homophthalazine
2,3-benzodiazepine; Anxiolytic drug; Antipsychotic drug; c-*fos* expression; Striatum (Palkovits, M. (331) 53)

5-HT
Hypothermia; Guinea pig; 5-HT_{1D} receptor; 5-HT_{1B} receptor; SKF-99101H; SB-216641A; BRL-15572; SB-224289G (Hagan, J.J. (331) 169)

5-HT (extracellular concentration)
5-HT_{1A} receptor; Antipsychotic; cAMP accumulation; HA7 cell; Microdialysis (Assié, M.-B. (334) 141)

5-HT (5-hydroxytryptamine, serotonin)
BMY-14802; 5-HT_{1A} receptor; Dorsal raphe; Hippocampus; Microdialysis (Matos, F.F. (317) 49)

Spinal cord; Pain; Nociception; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY100635 (Gjerstad, J. (318) 315)

Microdialysis, brain; Cocaine; Dopamine; Striatum (Norton, C.S. (318) 323)

Ureter; Histamine receptor; Histamine H_1 receptor; Histamine H_2 receptor; Prostaglandin; Noradrenaline (Dodel, R.C. (318) 395)

5-HT_3 receptor; Urinary bladder; Electrical field stimulation; (Rabbit) (Barras, M. (318) 425)

Small-cell lung carcinoma; Receptor cross-talk; 5-HT receptor subtype (Vicentini, L.M. (318) 497)

Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenylate cyclase; Adenosine; Substance P; Signal transduction (Xia, Y. (320) 95)

Diabetes; Protein kinase C; Endothelin-1; Aorta (James, G.M. (322) 55)

Behavior; Body temperature; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lower lip retraction; Tail flick; (Intracerebroventricular administration) (Bagdy, G. (323) 53)

Ipsapirone; WAY-100635; *p*-Chlorophenylalanine; Hippocampus; Excitatory synaptic transmission; 5-HT_{1A} receptor; Excitatory postsynaptic potential; Ultrasonic vocalization; Anxiolytic (Xu, L. (323) 59)

Diazepam; Withdrawal; 5-HT_{1A} receptor; Raphe nucleus, dorsal; Electrophysiological recording (Lanfumey, L. (323) 137)

MDA (3,4-Methylenedioxyamphetamine); MDMA (3,4-Methylenedioxymethamphetamine); α-Methyldopamine; Glutathione; Neurotoxicity (Miller, R.T. (323) 173)

5-HT$_4$ receptor; Substance P; Smooth muscle; Intestinal tract; Esophagus (Goldhill, J. (323) 229)

Substantia nigra reticulata; Antipsychotic; Schizophrenia; Basal ganglion; Electrophysiology; Dopamine (Bruggeman, R. (324) 49)

Phencyclidine; Antidepressant; Schizophrenia, negative symptom; Depression; Forced swimming test; (Mouse) (Noda, Y. (324) 135)

Methamphetamine; Hyperthermia; Fluoxetine; Dopamine transport (Fleckenstein, A.E. (324) 179)

5-HT$_{2C}$ receptor; Penile erection (Millan, M.J. (325) 9)

Microdialysis; 5-HT$_{1B/1D}$ receptor; GR 127935; GR 125743; (Guinea pig) (Roberts, C. (326) 23)

Intestinal fluid transport; Nitric oxide (NO); Cholera toxin; Oral rehydration solution (Beubler, E. (326) 223)

5-HT$_{1D}$ receptor; [^{3}H]GR 125,743; [^{3}H]5-CT; (Guinea pig) (Audinot, V. (327) 247)

Carbamazepine; Microdialysis; Hippocampus; Ca^{2+}; Electroshock seizure; Tetrodotoxin; (Rat) (Dailey, J.W. (328) 153)

Respiratory network, central; Neonatal mouse; Serotonergic regulation; (In vitro) (Hilaire, G. (329) 115)

5-HT receptor agonist; Renal blood flow; Kidney, autoperfused, rat; Angiotensin II (Morán, A. (330) 205)

Citric acid; Cough reflex; Ketanserin; Methysergide (Stone, R.A. (332) 201)

Hyperthermia; Methamphetamine; Serotonin (Fleckenstein, A.E. (332) 263)

Adenosine A$_3$ receptor; Pain; Histamine (Sawynok, J. (333) 1)

D-Fenfluramine; D-Norfenfluramine; Sex difference (Datla, K.P. (333) 27)

Flesinoxan; WAY 100635; 5-HT$_{1A}$ receptor; Feedback regulation; Microdialysis; (Rat) (Bosker, F.J. (333) 147)

5-HT receptor; G-protein-coupled receptor; Signal transduction (Gerhardt, C.C. (334) 1)

Spinal cord; Nociception; 5-HT$_{1B}$ receptor; CP-93,129; Cyanopindolol; WAY100635 (Gjerstad, J. (335) 127)

2-Phenyl-4-quinolone; Endothelial cell, rat; Gap formation; Permeability; cAMP (Lee, H.-Z. (335) 245)

Seizure; Fluoxetine; 5-HT$_{1A}$ receptor antagonist; Epilepsy (Browning, R.A. (336) 1)

Locomotor activity; Serotonin reuptake inhibitor, selective; (Rat) (Sills, T.L. (337) 161)

5-HT$_{1A}$ receptor; Binding; Autoradiography; Physicochemical parameter; [^{3}H]Alnespirone (Fabre, V. (337) 297)

Tachykinin; Bronchoconstriction; Substance P; Neurokinin A; Mast cell; Tachykinin NK$_1$ receptor (Joos, G.F. (338) 259)

5-HT (5-hydroxytryptamine, serotonin) re-uptake inhibition
YM992; Antidepressant; 5-HT$_{2A}$ receptor antagonistic activity; Tail suspension test; Olfactory bulbectomized rat (Takeuchi, H. (329) 27)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor
Isolation-induced aggression; 5-HT$_{1A}$ receptor; (Mouse) (Sànchez, C. (334) 127)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective
Noradrenaline; Frontal cortex; Microdialysis, in vivo; Synaptosomal uptake (Hughes, Z.A. (317) 83)

5-HT (5-hydroxytryptamine, serotonin) syndrome
Corticosterone; 5-HT$_{1A}$ receptor; 5-HT$_2$ receptor; Body temperature; Wet-dog shake (Takao, K. (333) 123)

5-HT (5-hydroxytryptamine, serotonin) transporter
Tyrosine kinase inhibitor; Tyrosine phosphorylation; Transcription; Choriocarcinoma cell, human (Prasad, P.D. (325) 85)

Single photon detection system; Dopamine transporter; GBR 12909; Paroxetine; RTI-55 (Mochizuki, T. (338) 17)

5-HT receptor
Dopamine receptor; Schizophrenia; Psychotic disorder; Antipsychotic agent (Kongsamut, S. (317) 417)

Stomach fundus, rat; Contractile response; Acetylcholine release (Amemiya, N. (318) 403)

Plasma protein extravasation; Histamine receptor; Tachykinin; Airways; Capsaicin; (Fisher 344 rat) (Germonpré, P.R. (324) 249)

Ondansetron; Ileum, guinea-pig (González, A.A. (328) 201)

Adenylyl cyclase; Phosphoinositide hydrolysis; Raphe nucleus, dorsal; Hippocampus; 5-HT$_{1A}$ receptor (Johnson, R.G. (329) 99)

5-HT (5-hydroxytryptamine, serotonin); G-protein-coupled receptor; Signal transduction (Gerhardt, C.C. (334) 1)

5-HT$_1$ receptor
Forced swimming test; Wistar-Kyoto rat; Brown Norway rat; Sprague-Dawley rat; Imipramine; 5-HT$_2$ receptor; β-Adrenoceptor; Depression (Lahmame, A. (337) 115)

5-HT$_{1A}$ autoreceptor
EMD 68843; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Fluoxetine; WAY 100635; Hypothermia; Ultrasonic vocalization; (Rat) (Bartoszyk, G.D. (322) 147)

5-HT$_{1A}$ receptor
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)-induced mydriasis; α_2-Adrenoceptor, postsynaptic; Brain, mouse (Prow, M.R. (317) 21)

BMY-14802; 5-HT (5-hydroxytryptamine, serotonin); Dorsal raphe; Hippocampus; Microdialysis (Matos, F.F. (317) 49)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Galanin; Hypothermia; Acetylcholine; Muscarinic receptor (Patel, S. (317) 197)

Forced swimming test; 5-HT$_{1B}$ receptor; Antidepressant (Redrobe, J.P. (318) 213)

Spinal cord; Pain; Nociception; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY100635 (Gjerstad, J. (318) 315)

WAY 100635; Monoamine oxidase inhibitor; Dorsal raphe nucleus; Microdialysis; Extracellular recording (Sharp, T. (320) 15)

Behavior; Body temperature; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lower lip retraction; 5-HT (5-hydroxytryptamine, serotonin); Tail flick; (Intracerebroventricular administration) (Bagdy, G. (323) 53)

5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; WAY-100635; *p*-Chlorophenylalanine; Hippocampus; Excitatory synaptic transmission; Excitatory postsynaptic potential; Ultrasonic vocalization; Anxiolytic (Xu, L. (323) 59)

5-HT (5-hydroxytryptamine, serotonin); Diazepam; Withdrawal; Raphe nucleus, dorsal; Electrophysiological recording (Lanfumey, L. (323) 137)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Flesinoxan; WAY-100635; Anxiety; Geller-Seifter, conflict; (Rat) (King, C.M.F. (325) 121)

Drug discrimination; Flesinoxan; DU125530; (Pigeon) (Mos, J. (325) 145)

5-HT receptor; Adenylyl cyclase; Phosphoinositide hydrolysis; Raphe nucleus, dorsal; Hippocampus (Johnson, R.G. (329) 99)

Efficacy; Drug discrimination; (Pigeon) (Wolff, M.C. (333) 113)

Corticosterone; 5-HT_2 receptor; Body temperature; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Wet-dog shake (Takao, K. (333) 123)

Flesinoxan; WAY 100635; 5-HT (5-hydroxytryptamine, serotonin); Feedback regulation; Microdialysis; (Rat) (Bosker, F.J. (333) 147)

Isolation-induced aggression; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; (Mouse) (Sànchez, C. (334) 127)

Antipsychotic; cAMP accumulation; HA7 cell; 5-HT (extracellular concentration); Microdialysis (Assié, M.-B. (334) 141)

5-HT (5-hydroxytryptamine, serotonin); Binding; Autoradiography; Physicochemical parameter; [^{3}H]Alnespirone (Fabre, V. (337) 297)

Clozapine; Cortical DA release (Rollema, H. (338) R3)

5-HT_{1A} receptor, human
[^{35}S]GTPγS binding assay; Receptor reserve (Stanton, J.A. (320) 267)

5-HT_{1B} receptor
Forced swimming test; 5-HT_{1A} receptor; Antidepressant (Redrobe, J.P. (318) 213)

Hypothermia; 5-HT; Guinea pig; 5-HT_{1D} receptor; SKF-99101H; SB-216641A; BRL-15572; SB-224289G (Hagan, J.J. (331) 169)

Spinal cord; Nociception; 5-HT (5-hydroxytryptamine, serotonin); CP-93,129; Cyanopindolol; WAY100635 (Gjerstad, J. (335) 127)

$5\text{-HT}_{1B/1D}$ receptor
5-HT (5-hydroxytryptamine, serotonin); Microdialysis; GR 127935; GR 125743; (Guinea pig) (Roberts, C. (326) 23)

5-HT_{1D} receptor
5-HT (5-hydroxytryptamine, serotonin); [^{3}H]GR 125,743; [^{3}H]5-CT; (Guinea pig) (Audinot, V. (327) 247)

Hypothermia; 5-HT; Guinea pig; 5-HT_{1B} receptor; SKF-99101H; SB-216641A; BRL-15572; SB-224289G (Hagan, J.J. (331) 169)

5-HT_2 receptor
Forced swimming test; 5-HT_3 receptor; Antidepressant (Redrobe, J.P. (325) 129)

Dotarizine; Ca^{2+} channels; *Xenopus* oocytes; Coronary artery (Montiel, C. (332) 183)

Corticosterone; 5-HT_{1A} receptor; Body temperature; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Wet-dog shake (Takao, K. (333) 123)

Forced swimming test; Wistar-Kyoto rat; Brown Norway rat; Sprague-Dawley rat; Imipramine; 5-HT_1 receptor; β-Adrenoceptor; Depression (Lahmame, A. (337) 115)

5-HT_{2A} receptor
Up-regulation; Dopamine D_2 receptor; Antipsychotic drug, atypical; Striatum (Ishikane, T. (321) 163)

SPECT (single photon emission computerized tomography); [^{123}I]R93274 (Abi-Dargham, A. (321) 285)

Inositol 1,4,5-triphosphate; Umbilical artery (Hu, X.-Q. (322) 107)

5-Methoxytryptamine; Hyperglycemia; 5-HT_4 receptor (Yamada, J. (323) 235)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); SR 46349B; Anxiety; Elevated plus-maze; [^{3}H]Ketanserin binding; RHA and RLA (Roman high- and low-avoidance) rats (Chaouloff, F. (334) 25)

Fluoxetine; Antidepressant (Millan, M.J. (321) R10)

5-HT (5-hydroxytryptamine, serotonin); Penile erection (Millan, M.J. (325) 9)

5-HT_3 receptor
Colon, guinea pig; Longitudinal muscle; Circular muscle; Tachykinin (Yamano, M. (317) 353)

5-HT (5-hydroxytryptamine, serotonin); Urinary bladder; Electrical field stimulation; (Rabbit) (Barras, M. (318) 425)

Colon, distal; Short-circuit current (I_{sc}); Ramosetron (YM060, (−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); (Rat) (Kiso, T. (320) 187)

Atrium; Tachycardia; Ethanol; Alcohol (Nishio, H. (321) 27)

Ligand-gated ion channel; N1E-115 mouse neuroblastoma cell; *Xenopus laevis* oocyte; (Partial agonist); (Antagonist) (Van Hooft, J.A. (322) 229)

Forced swimming test; 5-HT_2 receptor; Antidepressant (Redrobe, J.P. (325) 129)

Gastric motility; *m*-Chlorophenylbiguanide; Ramosetron; (Force transducer) (Nagakura, Y. (327) 189)

ICS-205 930; Bupivacaine; Lidocaine; Nociception inflammation (Giordano, J. (334) 39)

5-HT_4 receptor
5-HT (5-hydroxytryptamine, serotonin); Substance P; Smooth muscle; Intestinal tract; Esophagus (Goldhill, J. (323) 229)

5-Methoxytryptamine; Hyperglycemia; 5-HT_{2A} receptor (Yamada, J. (323) 235)

5-HT_1 receptor agonist
5-HT (5-hydroxytryptamine, serotonin); Renal blood flow; Kidney, autoperfused, rat; Angiotensin II (Morán, A. (330) 205)

Dura mater encephali; Arterial blood flow; Neurogenic inflammation; Migraine; Headache; (Rat) (Messlinger, K. (332) 173)

5-$HT_{1B/1D}$ receptor agonist
Rizatriptan; Trigeminal nucleus caudalis; Migraine; Electrophysiology (Cumberbatch, M.J. (328) 37)

5-HT receptor antagonist
Nicotine; Dopamine receptor agonist; Adrenoceptor antagonist; Acetylcholine receptor antagonist; Anorexia; (Rat) (Zarrindast, M.-R. (321) 157)

5-HT_{1A} receptor antagonist
Seizure; Fluoxetine; 5-HT (5-hydroxytryptamine, serotonin); Epilepsy (Browning, R.A. (336) 1)

5-HT_3 receptor antagonist
Visceral hypersensitivity; Colonic distension; (Rat) (Langlois, A. (318) 141)

N-3389; 5-HT_4 receptor antagonist; Antiemetic effect; Abdominal afferent vagus nerve activity; (Ferret) (Minami, M. (321) 333)

5-HT_4 receptor antagonist
N-3389; 5-HT_3 receptor antagonist; Antiemetic effect; Abdominal afferent vagus nerve activity; (Ferret) (Minami, M. (321) 333)

5-HT_{2A} receptor antagonistic activity
YM992; Antidepressant; 5-HT (5-hydroxytryptamine, serotonin) re-uptake inhibition; Tail suspension test; Olfactory bulbectomized rat (Takeuchi, H. (329) 27)

5-HT receptor pharmacology
Migraine models; Aminotetralin; Cerebrovascular regulation; Inflammation, neurogenic (Petty, M.A. (336) 127)

5-HT receptor subtype
5-HT (5-hydroxytryptamine, serotonin); Small-cell lung carcinoma; Receptor cross-talk (Vicentini, L.M. (318) 497)

L-5-HTP (L-5-hydroxytryptophan)
OK (Opossum kidney) cell; L-DOPA (L-3,4-dihydroxyphenylalanine); Cyanine derivative; Cellular transport (Gomes, P. (332) 219)

HU-211
NMDA receptor antagonist; Dopamine receptor antagonist; Catalepsy; Parkinson's disease (Striem, S. (338) 205)

Hybridization in situ
Dopamine D_3 receptor; c-*fos*; Neuroleptic; (Rat) (Hurley, M.J. (318) 283)

Brain; Electroconvulsive stimuli; mRNA expression; Substance P; Tachykinin receptor; (Rat) (Zachrisson, O. (319) 191)

Hydralazine
Endothelium; Relaxation; cGMP (Wei, S. (321) 307)

Quinpirole; Dopamine; Dopamine D_2 receptor; Rilmenidine; α-Methyldopa; Sympathetic nervous system; Vasopressin (Van den Buuse, M. (322) 191)

Hydrogen peroxide
L-Histidine; DNA double-strand breaks; Pulsed field gel electrophoresis; Apoptosis; Necrosis (Palomba, L. (318) 167)

Anethole dithiolethione; Glutathione; Oxidative stress; Astrocyte; Neurodegeneration (Drukarch, B. (329) 259)

Hydroxocobalamin
Nitrergic transmission; Light sensitivity (La, M. (321) R5)

3α-Hydroxy-5α-pregnan-20-one
Anxiety; Conflict; Neurosteroid; $GABA_A$ receptor; Benzodiazepine (Brot, M.D. (325) 1)

17α-Hydroxyprogesterone
Steroid hormone; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cell, in vitro, porcine; Nitrofuran; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

2-Hydroxysaclofen
Baclofen; $GABA_B$ receptor agonist; Thienyl baclofen analog; Neocortical slice, rat (Ong, J. (329) 133)

Hyperactivity
Dopamine D_1 receptor; A-86929; ABT-431; Seizure; Tolerance (Shiosaki, K. (317) 183)

Hyperalgesia
Cannabinoid; Pain (Richardson, J.D. (319) R3)

Allodynia; Pain; Tachykinin; Flexor reflex (Ma, Q.-P. (322) 165)

NMDA receptor; Non-NMDA glutamate receptor; Nociception; Allodynia; Inflammation; Pain (Lawand, N.B. (324) 169)

c-*fos*; Formalin test; Nociception; Antisense oligodeoxynucleotide; (Intrathecal) (Hou, W.-Y. (329) 17)

Hyperbaric oxygen
Heart, rat; Ischemia, low flow; *N*-Acetylcysteine; Defibrotide (Radice, S. (320) 43)

Hyperdynamic circulation
Endotoxaemia; Nitric oxide (NO) synthase inhibition; Dopexamine (Waurick, R. (333) 181)

Hyperglycemia
5-Methoxytryptamine; 5-HT_{2A} receptor; 5-HT_4 receptor (Yamada, J. (323) 235)

Hyperplasia
Smooth muscle, vascular; Cell culture; Nifedipine; Captopril; Losartan; Transgenic rat (Peiró, C. (324) 257)

Hyperplasia, intimal
Tranilast; Balloon injury; Cholesterol, high (Fukuyama, J. (318) 327)

Hyperpolarization
Endothelium; Smooth muscle, vascular; Endothelin (Waldron, G.J. (318) 89)

Hyperreactivity
Asthma; Eosinophil; Bronchodilator; KF19514; Phosphodiesterase inhibitor (Manabe, H. (332) 97)

Hypertension
Ethanol; ANP (atrial natriuretic peptide); CNP (C-type natriuretic peptide) (Guillaume, P. (319) 215)

Na^+,K^+-ATPase; Na^+,K^+-ATPase, α-subunit; Spontaneously hypertensive rat (SHR); Ca^{2+} channel blocker; Vasodilator (Liu, X. (327) 151)

Hypertensive rat
MRI (magnetic resonance imaging); Ancrod; Cerebral ischemia; Fibrinogen; Middle cerebral artery occlusion; Therapeutic window; (Delayed therapy) (Elger, B. (336) 7)

Hyperthermia
Methamphetamine; Fluoxetine; Dopamine transport; 5-HT (5-hydroxytryptamine, serotonin) (Fleckenstein, A.E. (324) 179)

Methamphetamine; 5-HT (5-hydroxytryptamine); Serotonin (Fleckenstein, A.E. (332) 263)

Hypertrophy
Cardiomyopathy; Ca^{2+}; Ischemia; Trimetazidine; Verapamil (D'hahan, N. (328) 163)

Hypotension
Pentadecapeptide BPC 157; Peptide BPC; Nitric oxide (NO); Gastrointestinal mucosal integrity; Blood pressure maintenance; Gastric lesion; N^G-Nitro-L-arginine methylester; L-Arginine; Stomach mucosa (Slobodnjak, Z. (332) 23)

Nociceptin; Blood pressure; Heart rate; Vagal bradycardia (Giuliani, S. (333) 177)

Hypothalamic–pituitary–adrenal axis
TNF-α (tumor necrosis factor-α); TNF-β; Acute-phase-response; Fever; Interleukin-6; Cortisol (Goldbach, J.-M. (334) 249)

GLP-1 (glucagon-like peptide-1); CRF (corticotropin-releasing factor); Feeding behavior; (Chicken) (Furuse, M. (339) 211)

Hypothalamus
Nimesulide; Cyclooxygenase-2; Antipyretic action; Yeast-induced hyperthermia; RT-PCR (reverse transcription and polymerase chain reaction) (Taniguchi, Y. (330) 221)

Hypothermia
5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Galanin; Acetylcholine; Muscarinic receptor (Patel, S. (317) 197)

5-HT_{1A} autoreceptor; EMD 68843; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Fluoxetine; WAY 100635; Ultrasonic vocalization; (Rat) (Bartoszyk, G.D. (322) 147)

5-HT; Guinea pig; 5-HT_{1D} receptor; 5-HT_{1B} receptor; SKF-99101H; SB-216641A; BRL-15572; SB-224289G (Hagan, J.J. (331) 169)

Hypoxia
BQ-788; Endothelin; Pulmonary hypertension (Holm, P. (323) 83)

Striatum; Xanthine; Purine; Transmitter release; Adenosine A_1 receptor (Jin, S. (329) 107)

Iberiotoxin
K^+ channel, Ca^{2+}-activated; cGMP; Nitric oxide (NO); Okadaic acid; Phosphatase; Smooth muscle (Johansson Rydberg, I.G.M. (329) 175)

Ibogaine
Catecholamine release; Nicotinic acetylcholine receptor (Schneider, A.S. (317) R1)

Noribogaine; 18-Methoxycoronaridine; Cocaine; Motor activity (Maisonneuve, I.M. (336) 123)

ICAM-1 (intercellular adhesion molecule-1)
17β-oestradiol; Myocardial ischaemia–reperfusion injury; TNF-α (tumor necrosis factor-α) (Squadrito, F. (335) 185)

Icatibant
Bradykinin; Cardiac pacing, rapid; Ischemic preconditioning; Ventricular arrhythmia (Kaszala, K. (328) 51)

ICS-205 930
5-HT_3 receptor; Bupivacaine; Lidocaine; Nociception inflammation (Giordano, J. (334) 39)

Ifenprodil
NMDA receptor; MK-801; 7-Chlorokynurenic acid; Diazepam withdrawal; (Mouse) (Tsuda, M. (324) 63)

Glutamate receptor; Allosteric antagonism; *Xenopus* oocyte; CP 101,606; Ro 25-6981; Haloperidol (Whittemore, E.R. (337) 197)

IGF-I (insulin-like growth factor-I)
Aging; (−)-Deprenyl; Tyrosine hydroxylase; (Rat) (De la Cruz, C.P. (327) 215)

Ileum
Cysteinyl-leukotriene receptor antagonist; Guinea pig; BAY u9773 (Bäck, M. (317) 107)

Arachidonic acid; Opioid; Withdrawal (Capasso, A. (330) 199)

Mn^{2+}; Smooth muscle; Ca^{2+} channel (Nasu, T. (333) 199)

Neuropeptide Y; Neuropeptide Y Y_5 receptor; (Rabbit) (Pheng, L.H. (333) R3)

Adenosine; ATP; Cholinergic; GABA (γ-aminobutyric acid); Nitric oxide (NO); Terminal (Pencheva, N. (339) 193)

Ileum, guinea pig
Tachykinin; Tachykinin NK_3 receptor; Inositol monophosphate accumulation; Nonpeptide tachykinin NK_3 receptor antagonist; Species difference (Beaujouan, J.-C. (319) 307)

Histamine H_3 receptor; Prejunctional receptor; Intramural reflex; Peristalsis; Circular muscle (Poli, E. (327) 49)

Ondansetron; 5-HT receptor (González, A.A. (328) 201)

Ileum, rat
Adenosine receptor (Nicholls, J. (338) 143)

Ileum contraction, neurally evoked, guinea-pig
Galanin, analog; Galanin-(1–15)ol (Kakuyama, H. (329) 85)

Ileus
Gastrointestinal transit; Opioid; κ-Opioid receptor; Antinociception (De Winter, B.Y. (339) 63)

IL-10 (interleukin-10)
Acyclic nucleotide analog; TNF-α (tumor necrosis factor α); NO (nitric oxide); (R)-PMPA ((R)-9-(2-phosphonomethoxypropyl)adenine) (Zídek, Z. (331) 245)

Imidapril
Enalapril; Captopril; Ozone; Angiotensin-converting enzyme; Airway hyperresponsiveness (Matsubara, S. (337) 259)

Imidazo[1,2-a]pyrazine derivative
Apoptosis; Megakaryoblastic cell, human; Phosphodiesterase; cAMP; Purinoceptor (Zurbonsen, K. (320) 215)

Imidazoline
Antazoline; Insulin secretion; Somatostatin secretion; Glucose tolerance; Pancreas; (Rat); (Dog) (Berdeu, D. (324) 233)

Pressure-natriuresis; Salt preference; Oral gavage (Cechetto, D.F. (325) 47)

Imidazoline derivative
Brown fat; Zucker rat; α_1-Adrenoceptor agonist; α_2-Adrenoceptor antagonist; Obesity, drug therapy (Savontaus, E. (328) 207)

Imidazoline receptor
Efaroxan; σ Receptor; Insulin secretion; Phencyclidine; (+)-MK-801 (dizocilpine) (Chan, S.L.F. (323) 241)

BU-224 (2-(4,5-dihydroimidazol-2yl)-quinoline hydrochloride)); Nociception; Spinal cord; (Rat) (Diaz, A. (333) 9)

BTS 67 582; Islets of Langerhans; Insulin release; Diabetes (Dickinson, K. (339) 69)

Imipramine
Forced swimming test; Wistar-Kyoto rat; Brown Norway rat; Sprague-Dawley rat; 5-HT_1 receptor; 5-HT_2 receptor; β-Adrenoceptor; Depression (Lahmame, A. (337) 115)

Dopamine D_2 autoreceptor; mRNA; Ventral tegmental area; (Rat) (Dziedzicka-Wasylewska, M. (337) 291)

Immediate-early gene
Amygdala, central; Bed nucleus of the stria terminalis; Paraventricular nucleus of the hypothalamus; Corticosterone; CRH (corticotropin-releasing hormone) (Compaan, J.C. (324) 161)

κ-Opioid receptor agonist; NMDA receptor antagonist (Panegyres, P.K. (328) 31)

Immune function
Oxidative burst; ANP (atrial natriuretic peptide); Fluorescent latex bead; Dihydrorhodamine-123; Flow cytometry (Vollmar, A.M. (319) 279)

Immune response
Anandamide; Palmitoylethanolamide; Tetrahydrocannabinol; Cannabinoid receptors; Cytokines; Mononuclear cells (Berdyshev, E.V. (330) 231)

Immunity
Opioid; Lymphocyte proliferation; Autonomic nervous system; Sympathetic division; Parasympathetic division; (Rat) (Flores, L.R. (318) 437)

Immunomodulation
δ-Opioid receptor ligands; Lymphocyte (Noviello, L. (332) R1)

Immunoregulation
Adjuvant arthritis; Cytokine (Conforti, A. (324) 241)

Immunosuppression
FK506; Glucocorticosteroid; Local lymph node assay; Tacrolimus; Topical drug (Homey, B. (325) 199)

^{111}Indium oxine
Thrombin; Thrombin receptor-activating peptide; Thrombin inhibitor; Platelet aggregation; Receptor binding; Pulmonary microcirculation (Chiu, P.J.S. (321) 129)

Indomethacin
Nitric oxide synthase, inducible (NO); Cyclooxygenase-2; Western blot; Lipopolysaccharide; cAMP; Cytotoxicity (Pang, L. (317) 151)

Allergic inflammation, recurrence of; Granulation tissue; Prostaglandin E_2; Cyclooxygenase-1; Cyclooxygenase-2; NS-398; Dexamethasone (Niki, H. (320) 193)

Inducible nitric oxide (NO) synthase
Nitric oxide (NO); Endotoxin; Nitric oxide (NO) synthase inhibitor; Microcirculation; Vascular permeability; Inflammation (László, F. (334) 99)

Inferior olivary neuron
3-Acetylpyridine; Lurcher mutant mouse; NMDA (*N*-methyl-D-aspartate), inhibition; Niacinamide (Caddy, K.W.T. (330) 139)

Inflammation
CRF (corticotropin-releasing factor); Histamine; Arachidonic acid (Correa, S.G. (319) 85)

Antidepressant; Chemotaxis; Macrophage (Sacerdote, P. (319) 287)

Heart; Sepsis; Heart failure (Oddis, C.V. (320) 167)

Dimaprit; Histamine H_2 receptor; TNF-α (tumor necrosis factor α); Hepatitis; Septic shock (Nakamura, T. (322) 83)

Neutrophil; NADPH oxidase; Phenylarsine oxide; NADPH oxidase inhibitor; Anti-inflammatory drug (Roussin, A. (322) 91)

Colitis; Interleukin-10; Nitric oxide (NO); TNF-α (tumor necrosis factor-α) (Ribbons, K.A. (323) 245)

NMDA receptor; Non-NMDA glutamate receptor; Nociception; Hyperalgesia; Allodynia; Pain (Lawand, N.B. (324) 169)

Arthritis; Prostaglandin E_2; HOE-140; Des-Arg^9-bradykinin; (Rat) (Tonussi, C.R. (326) 61)

Phospholipase A_2; Phospholipase inhibitor; Interleukin-1; Integrin (Amandi-Burgermeister, E. (326) 237)

Adhesion molecule; Glucocorticoid; PECAM-1; Interleukin-1; TNF-α (Wheller, S.K. (331) 65)

Edema; α-Trinositol; Capillary permeability; Trachea; Skin (rat); Connective tissue; Anaphylaxis (Koller, M.-E. (331) 259)

Nitric oxide (NO); Endotoxin; Nitric oxide (NO) synthase inhibitor; Microcirculation; Vascular permeability; Inducible nitric oxide (NO) synthase (László, F. (334) 99)

Airway epithelium; Airway remodelling; Neutrophil elastase; Secretory leukocyte protease inhibitor (Marchand, V. (336) 187)

NO synthase, inducible; Pristimerin; Triterpene; RAW 264.7 macrophage (Dirsch, V.M. (336) 211)

Nitric oxide (NO); N^G-nitro-L-arginine methyl ester (L-NAME); Colon; Nitric oxide (NO) synthase, constitutive; Nitric oxide (NO) synthase, inducible (Kiss, J. (336) 219)

Inflammation, chronic
Skin; 12-*O*-Tetradecanoylphorbol-13-acetate; Triterpenoids (Máñez, S. (334) 103)

Inflammation, neurogenic
5-HT receptor pharmacology; Migraine models; Aminotetralin; Cerebrovascular regulation (Petty, M.A. (336) 127)

Inflammatory hyperalgesia
Nitric oxide (NO); Microdialysis; Skin; Bradykinin; N^G-nitro-L-arginine methyl ester; Bradykinin B_2 receptor (Andoh, T. (332) 279)

Inflammatory mediator
Bradykinin; Pleurisy; Anti-inflammatory drugs; Bradykinin receptor antagonist (Saleh, T.S.F. (331) 43)

Inhibition
Adenosine; Purine; (−)-Bicuculline; GABA (γ-aminobutyric acid); Paired-pulse inhibition; Hippocampus; Cyclopentyltheophylline (Higgins, M.J. (317) 215)

ETYA (5,8,11,14-eicosatetraynoic acid); Endothelial cell activation; Polyunsaturated fatty acid; Gene regulation; Adhesion molecule (Stuhlmeier, K.M. (325) 209)

Innervation
Kidney; Dopamine; D_2-like receptor; Radioligand binding assay; Autoradiography; (Rat) (Barili, P. (334) 233)

Inositol monophosphate accumulation
Tachykinin; Tachykinin NK_3 receptor; Ileum, guinea pig; Nonpeptide tachykinin NK_3 receptor antagonist; Species difference (Beaujouan, J.-C. (319) 307)

Inositol phosphate
Thalamus; α_1-Adrenoceptor; α_{1A}-Adrenoceptor; α_{1B}-Adrenoceptor; α_{1C}-Adrenoceptor (Trejo, F. (318) 175)

Abruquinone A; Neutrophil; Phospholipase C; Ca^{2+} concentration, intracellular (Wang, J.-P. (319) 131)

Thrombin receptor; Adenosine A_1 receptor; P_{2U} purinoceptor; Arachidonic acid; CHO (Chinese hamster ovary) cell; Protein kinase C (Dickenson, J.M. (321) 77)

AMPA receptor; Extracellular calcium; Glutamate; Oligodendrocyte (Liu, H.-N. (338) 277)

Inositol 1,4,5-triphosphate
5-HT_{2A} receptor; Umbilical artery (Hu, X.-Q. (322) 107)

α_1-Adrenoceptor, subtype; Chloroethylclonidine; 5-Methylurapidil; WB 4101; BMY 7378; $^{86}Rb^+$, influx rate (Viko, H. (323) 269)

Inositol trisphosphate
Uridine nucleotide receptor; UTP (Communi, D. (317) 383)

Broussochalcone A; Neutrophil, rat; Respiratory burst; Ca^{2+} concentration, intracellular; Protein kinase C; NADPH oxidase (Wang, J.-P. (320) 201)

Sauvagine; Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Edema; Ca^{2+}; CRF receptor; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

Inotropic effect
Muscarinic M_2 receptor; Antibody; Peptide; Papillary muscle (Skomedal, T. (333) 169)

Insect cell
Opioid receptor; Baculovirus; 'High Five'; Sf9 (Obermeier, H. (318) 161)

Inside-out single channel recording
Bladder detrusor, guinea pig; Patch-clamp; BK_{Ca} channel; Whole-cell recording; Open-state probability (Hu, S. (318) 461)

In situ hybridization
Acamprosate; Ethanol withdrawal; Pentylenetetrazole; Hippocampus; Cerebellum; c-*fos* mRNA; Northern and dot blotting (Putzke, J. (317) 39)

Thrombin receptor; Heparin; Arterial injury (Guitteny, A.-F. (327) 157)

Insulin
Insulin analog; Mitogenic activity; Cardiomyocyte; Insulin-like growth factor receptor (Bähr, M. (320) 259)

Diabetic rat; Streptozotocin; Ca^{2+}; Calmodulin; Calmidazolium; Intestinal reactivity (Öztürk, Y. (321) 59)

Hepatocyte DNA synthesis; Hepatocyte proliferation; β-Adrenoceptor agonist; cAMP-elevating agent (Kimura, M. (327) 87)

Opiate; β-Endorphin; Growth; Development; Ornithine decarboxylase mRNA; Intracerebroventricular (Bartolome, J.V. (331) 145)

Diabetes mellitus, non-insulin dependent; Metformin; Erythrocyte membrane; Lipid fluidity (Muller, S. (337) 103)

Insulin, plasma
Org 9935; Org 30029; Insulin secretion; Phosphodiesterase inhibitor; Glucose, plasma (El-Metwally, M. (324) 227)

Insulin analog
Insulin; Mitogenic activity; Cardiomyocyte; Insulin-like growth factor receptor (Bähr, M. (320) 259)

Insulin-like growth factor receptor
Insulin analog; Insulin; Mitogenic activity; Cardiomyocyte (Bähr, M. (320) 259)

Insulin release
BTS 67 582; Islets of Langerhans; Imidazoline receptor; Diabetes (Dickinson, K. (339) 69)

Insulin resistance
Vasculature; Fructose hypertension (Verma, S. (322) R1)

GR79236; Lipolysis; Fructose; Triglyceride; Non-insulin-dependent diabetes (NIDDM) (Qu, X. (338) 269)

Insulin secretion
Vanadyl sulphate; Endocrine pancreas; (Rat) (Cadène, A. (318) 145)

Imidazoline receptor; Efaroxan; σ Receptor; Phencyclidine; (+)-MK-801 (dizocilpine) (Chan, S.L.F. (323) 241)

Org 9935; Org 30029; Phosphodiesterase inhibitor; Insulin, plasma; Glucose, plasma (El-Metwally, M. (324) 227)

Imidazoline; Antazoline; Somatostatin secretion; Glucose tolerance; Pancreas; (Rat); (Dog) (Berdeu, D. (324) 233)

Succinic acid monoethyl ester; Succinic acid monopropyl ester; Succinic acid monoisopropyl ester; Gliquidone (García-Martínez, J.A. (325) 65)

Pancreatic B-cell; $[Ca^{2+}]_i$; Tetracaine (Bordin, S. (327) 257)

Repaglinide; Glibenclamide; Glimepiride; (GK rat) (Ladrière, L. (335) 227)

Insulin sensitivity
BRL 35135; β_3-adrenoceptor agonism; Zucker (*fa/fa*) rat; Non-esterified fatty acid; Euglycaemic hyperinsulinaemic clamp (Virtanen, K.A. (332) 215)

Integrin
Phospholipase A_2; Inflammation; Phospholipase inhibitor; Interleukin-1 (Amandi-Burgermeister, E. (326) 237)

Interaction
Asthma; Drug combination; Smooth muscle, airway; Trachea; β_2-Adrenoceptor agonist; Methylxanthine; K^+ channel opener; Sodium nitroprusside; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

Interferon γ
β-D-glucan; Alveolar macrophage; Serum component; Nitric oxide (NO); β-D-glucan receptor (Sakurai, T. (334) 255)

Oral tolerance; Interleukin-4 (Yoshino, S. (336) 203)

Interleukin-1
Nitric oxide (NO); Nitric oxide (NO) donor; Mesangial cell; Apoptosis; Glomerular endothelial cell; Glomerular epithelial cell (Mühl, H. (317) 137)

Phospholipase A_2; Inflammation; Phospholipase inhibitor; Integrin (Amandi-Burgermeister, E. (326) 237)

TNF-α (tumor necrosis factor-α); Septic shock (Yamamoto, N. (327) 169)

Adhesion molecule; Glucocorticoid; Inflammation; PECAM-1; TNF-α (Wheller, S.K. (331) 65)

Nitrite; Atherosclerosis; Protein kinase C (Shimpo, M. (338) 97)

Interleukin-1β
Nitric oxide (NO); Prostaglandin; Central nervous system; Plasma noradrenaline (Murakami, Y. (317) 61)

Isoproterenol; β-Adrenoceptor; Nociception, mechanical; (Rat) (Yabuuchi, K. (334) 133)

Creatine kinase activity; Neutrophil adherence; Myeloperoxidase activity; Neutrophil accumulation (Hayward, R. (334) 157)

Interleukin-4
Mast cell; Histamine; TNF-α (tumor necrosis factor-α) (Gibbs, B.F. (327) 73)

Oral tolerance; Interferon-γ (Yoshino, S. (336) 203)

Interleukin-6
Nitric oxide (NO); cGMP; Hippocampus; Sodium nitroprusside; N^G-Nitro-L-arginine (Ma, T. (321) 343)

Antisense targeting; Oligodeoxynucleotides; Sickness behavior; Radiotelemetry; (Rat) (Schöbitz, B. (331) 97)

TNF-α (tumor necrosis factor-α); TNF-β; Acute-phase-response; Fever; Hypothalamic–pituitary–adrenal axis; Cortisol (Goldbach, J.-M. (334) 249)

Interleukin-10
TNF-α (tumor necrosis factor-α); cAMP-elevating agent (Siegmund, B. (321) 231)

Colitis; Inflammation; Nitric oxide (NO); TNF-α (tumor necrosis factor-α) (Ribbons, K.A. (323) 245)

TNF (tumor necrosis factor); Brain; Lipopolysaccharide (Di Santo, E. (336) 197)

Lipopolysaccharide; cAMP; cGMP; Phosphodiesterase III inhibitor; Monocyte; Macrophage; TNF-α (tumor necrosis factor-α); Nitric oxide (NO) (Németh, Z.H. (339) 215)

Internalization
σ Receptor; Cytotoxicity; Regulation; (+)-Pentazocine; Desensitization (Zambon, A.C. (324) 39)

Intestinal distension
Visceral hyperalgesia; Visceral nociception; Mast cell; Tachykinin; Tachykinin NK_2 receptor (McLean, P.G. (337) 279)

Intestinal fluid transport
Nitric oxide (NO); 5-HT (5-hydroxytryptamine, serotonin); Cholera toxin; Oral rehydration solution (Beubler, E. (326) 223)

Intestinal motility
Smooth muscle; Tachykinin receptor agonist; Tachykinin receptor antagonist (Parlani, M. (318) 419)

Neuropeptide FF; Fever; Endotoxin; PAF (platelet-activating factor) (Million, M. (334) 67)

Intestinal nerve
Peptide YY; Intestinal secretion; VIP (vasoactive intestinal peptide); α_2-Adrenoceptor; σ Receptor; (Rat) (Souli, A. (333) 87)

Intestinal reactivity
Diabetic rat; Streptozotocin; Ca^{2+}; Calmodulin; Calmidazolium; Insulin (Öztürk, Y. (321) 59)

Intestinal secretion
Anthraquinone; Nitric oxide (NO); Glucocorticoid; Laxative; Natural drug (Izzo, A.A. (323) 93)

Ion secretion; Histamine; Epithelial cell (Homaidan, F.R. (331) 199)

Peptide YY; VIP (vasoactive intestinal peptide); Intestinal nerve; α_2-Adrenoceptor; σ Receptor; (Rat) (Souli, A. (333) 87)

Intestinal tract
5-HT_4 receptor; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Smooth muscle; Esophagus (Goldhill, J. (323) 229)

Intestine
Ganglion; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenylate cyclase; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Signal transduction (Xia, Y. (320) 95)

Guanylin; Ion transport; Na^+ and Cl^- unidirectional flux; STa (heat-stable enterotoxin of *Escherichia coli*); VIP (vasoactive intestinal peptide) (Volant, K. (328) 217)

Intracerebroventricular
Opiate; β-Endorphin; Insulin; Growth; Development; Ornithine decarboxylase mRNA (Bartolome, J.V. (331) 145)

Intracerebroventricular (i.c.v.) administration
Opioid analgesia; Amphibian; Acetic acid test; (*Rana pipiens*) (Stevens, C.W. (331) 15)

Intrahippocampal injection
Metabotropic glutamate receptor; S-4C3H-PG ((*S*)-4-carbonyl-3-hydroxyphenylglycine); MSOP ((*RS*)-α-methylserine-*O*-phosphate); Drinking conflict test (Chojnacka-Wójcik, E. (319) 153)

Intramural reflex
Histamine H_3 receptor; Prejunctional receptor; Peristalsis; Circular muscle; Ileum, guinea pig (Poli, E. (327) 49)

Intraurethral pressure
NS-49; α_1-Adrenoceptor, subtype; Blood pressure (Taniguchi, N. (318) 117)

Intrinsic activity
Adenosine A_1 receptor; G protein; Excitatory postsynaptic potential; Hippocampus; Agonism, partial (Lorenzen, A. (334) 299)

Inverse agonist
SR141716A; Cannabinoid receptor, human (Landsman, R.S. (334) R1)

Signal transduction; Conformational states, multiple; Thermodynamic model; Ligand efficacy (Pardo, L. (335) 73)

In vivo
RS-79948-197; Brain; α_2-Adrenoceptor; Radioligand; PET (positron-emission tomography); (Rat) (Hume, S.P. (317) 67)

Inward current
Neuroprotection; Ischemia; Outward current; Ion channel; Patch clamp (Suma, C. (336) 283)

Ion channel
ATP; Purinoceptor P_{2X}; *Xenopus* oocyte; Site-directed mutagenesis (Nakazawa, K. (325) 101)

Neuroprotection; Ischemia; Inward current; Outward current; Patch clamp (Suma, C. (336) 283)

Ion secretion
Histamine; Intestinal secretion; Epithelial cell (Homaidan, F.R. (331) 199)

Ion-selective microelectrode
Ventricular mass; Ca^{2+} level; Diastolic (Lopez, J.R. (339) 161)

Ion transport
Guanylin; Intestine; Na^+ and Cl^- unidirectional flux; STa (heat-stable enterotoxin of *Escherichia coli*); VIP (vasoactive intestinal peptide) (Volant, K. (328) 217)

Ipsapirone
5-HT (5-hydroxytryptamine, serotonin); WAY-100635; *p*-Chlorophenylalanine; Hippocampus; Excitatory synaptic transmission; $5\text{-}HT_{1A}$ receptor; Excitatory postsynaptic potential; Ultrasonic vocalization; Anxiolytic (Xu, L. (323) 59)

IPSC (inhibitory postsynaptic current)
Epilepsy; Losigamone; Cell culture; EPSC (excitatory postsynaptic current) (Draguhn, A. (325) 245)

Iris sphincter muscle, rabbit
Ascomycin; FK506-binding protein; Neurotransmitter release; Smooth muscle contraction; Tachykininergic nerve (Kageyama, M. (333) 223)

Iris sphincter, ovine
Adenosine receptors; Adenosine receptor antagonists; Relaxation (Hourani, S.M.O. (334) 95)

IRL 1620 (Suc-[Glu^9,$Ala^{11,15}$]endothelin-1-(8–21))
Endothelin-1; Bosentan (4-tert-butyl-*N*-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2′-bipyrimidin-4-yl]-benzene sulfonamide); FR 139317 ((*R*)2-[(*R*)-2-[(*S*)-2-[[1-(hexahydro-1*H*-azepinyl)]carbonyl]amino-4-methylpentanoil]amino-3-[3-(1-methyl-1*H*-indoyl)]propionyl]-amino-3-(2-pyridyl) propionic acid) (Takahashi, T. (324) 219)

Ischaemia
Arrhythmia; K^+ channel activator; Levcromakalim; Reperfusion (Vegh, A. (333) 33)

Ischemia
Y-26763; Myocardium, stunned; Reperfusion; ATP-sensitive K^+ channel (Fukunari, A. (323) 197)

Cardiomyopathy; Ca^{2+}; Hypertrophy; Trimetazidine; Verapamil (D'hahan, N. (328) 163)

Neuroprotection; Inward current; Outward current; Ion channel; Patch clamp (Suma, C. (336) 283)

Cariporide (HOE642); Na^+–H^+ exchange; Arrhythmias; Reperfusion (Aye, N.N. (339) 121)

Ischemia, focal
Photochemical infarction, treatment; NMDA receptor antagonist; Nitric oxide (NO) (Buchkremer-Ratzmann, I. (320) 103)

Ischemia, low flow
Hyperbaric oxygen; Heart, rat; *N*-Acetylcysteine; Defibrotide (Radice, S. (320) 43)

Ischemia-reperfusion
Melatonin; Free radical; Cytoprotection; Gastric ulceration; Gastric blood flow (Konturek, P.Ch. (322) 73)

Nitric oxide (NO); Skeletal muscle; Viability; Oedema; (Mouse) (Knight, K.R. (332) 273)

Hexarelin; GH (growth hormone-)deficiency; Heart, rat; 6-keto-prostaglandin $F_{1\alpha}$; Angiotensin II (De Gennaro Colonna, V. (334) 201)

Ischemia-reperfusion arrhythmia
Endotoxin; Dexamethasone; L-Canavanine; Nitric oxide (NO) synthase, inducible (Iskit, A.B. (326) 183)

Ischemic heart disease
Mg^{2+}, extracellular; Ca^{2+}, cytosolic, free (Altura, B.M. (338) R7)

Ischemic preconditioning
Adenosine receptor; Cardiac myocyte, isolated (Wang, J. (320) 241)

Bradykinin; Icatibant; Cardiac pacing, rapid; Ventricular arrhythmia (Kaszala, K. (328) 51)

Islets of Langerhans
BTS 67 582; Insulin release; Imidazoline receptor; Diabetes (Dickinson, K. (339) 69)

Isolated hepatocyte
Epinephrine; Ethanol; Piroxicam; Thiobarbituric acid-reactive substance; Triacylglyceride (Saldaña-Balmori, Y. (317) 225)

Isolation-induced aggression
5-HT_{1A} receptor; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; (Mouse) (Sànchez, C. (334) 127)

Isoliquiritigenin
Smooth muscle tension; Guanylyl cyclase; YC-1; ODQ (Wegener, J.W. (323) 89)

Isoprenaline
Vascular heterogeneity; Coronary artery, bovine; Glyceryl trinitrate; *S*-Nitroso-*N*-acetylpenicillamine; Sodium nitroprusside (De la Lande, I.S. (318) 65)

Amylase secretion; K^+ channel; Parotid acini (Murayama, T. (322) 21)

Chelerythrine; Protein kinase C; Phosphodiesterase, cyclic nucleotide; Vasorelaxation; SK&F 94120 (Eckly-Michel, A.E. (324) 85)

Isoproterenol
Cardiac hypertrophy; Force-frequency response; Ca^{2+}; (Rat) (Tang, L. (318) 349)

β_1-Adrenoceptor; β_2-Adrenoceptor; Endothelium; Relaxation; Cytochrome P450; Aortic ring, rat (Satake, N. (319) 37)

VIP (vasoactive intestinal peptide); Peritoneal macrophage; Adenylyl cyclase; VIP receptor antagonist; VIP receptor; Propranolol; Neuroimmunobiology (Pozo, D. (321) 379)

Interleukin-1β; β-Adrenoceptor; Nociception, mechanical; (Rat) (Yabuuchi, K. (334) 133)

β-Adrenoceptor agonist; Clenbuterol; Mast cell; Allergic reaction; Vascular permeability (Inagaki, N. (336) 225)

Isradipine
ANP (atrial natriuretic polypeptide); VIP (vasoactive intestinal polypeptide); K^+ channel; Levcromakalim; Ca^{2+} channel blocker; Trachea; Smooth muscle, airway (Thirstrup, S. (319) 253)

J774 macrophage
Glucocorticoid; Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; Lipocortin; Lipopolysaccharide (D'Acquisto, F. (339) 87)

Kainate
Hippocampus; GABA (γ-aminobutyric acid) release; Domoic acid; Glutamate; Synaptosome (Cunha, R.A. (323) 167)

Dorsal lateral geniculate nucleus; Angiotensin; NMDA (*N*-methyl-D-aspartate); Bicuculline; CGP 35348; Urethane; Unit activity; (Rat) (Albrecht, D. (332) 53)

KC8851
Patch clamp, whole-cell; K^+ current; Na^+ current; Open channel blockade (McLarnon, J.G. (339) 279)

K^+ channel
ANP (atrial natriuretic polypeptide); VIP (vasoactive intestinal polypeptide); Levcromakalim; Ca^{2+} channel blocker; Isradipine; Trachea; Smooth muscle, airway (Thirstrup, S. (319) 253)

Amylase secretion; Parotid acini; Isoprenaline (Murayama, T. (322) 21)

Adrenal catecholamine; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Antisense oligodeoxyribonucleotide; Food intake; K^+ channel opener; K^+ channel antagonist (Ghelardini, C. (329) 1)

Endothelium; Nitric oxide (NO); Coronary small artery; Acetylcholine; A23187; Apamin (Simonsen, U. (329) 153)

Antisense oligonucleotide; mKv1.1; Analgesia; Antinociception; Clomipramine; Amitriptyline; Tricyclic antidepressant; (Mouse) (Galeotti, N. (330) 15)

Cyclopiazonic acid; Nitric oxide (NO); Endothelium; Contractions, rhythmic; Mesenteric artery, rat (Huang, Y. (332) 167)

Smooth muscle; Ca^{2+} stores; Charybdotoxin; Apamin; Pacemaker cells (Duridanova, D.B. (333) 105)

Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Anandamide; Cytochrome *P*-450 inhibitor; Cannabinoid (Randall, M.D. (333) 191)

Levosimendan; K^+ channel, ATP-sensitive; Patch clamp technique; Mesenteric artery, rat (Yokoshiki, H. (333) 249)

K^+ channel, ATP-sensitive
Y-26763; K^+ channel opener; Glibenclamide; Cardioprotection (Rahman, F. (317) 293)

CGRP (calcitonin gene-related peptide); Electric field stimulation; Glibenclamide; Neurotransmission; Vas deferens, rat (Huang, Y. (327) 209)

Levosimendan; K^+ channel; Patch clamp technique; Mesenteric artery, rat (Yokoshiki, H. (333) 249)

K^+ channel, Ca^{2+}-activated
Endothelin-1; Endothelin-3; Endothelin ET_A receptor; Patch-clamp (Hu, S. (324) 277)

NS 1619; Charybdotoxin; Glibenclamide; Ca^{2+} channel; Vas deferens, rat (Huang, Y. (325) 21)

cGMP; Iberiotoxin; Nitric oxide (NO); Okadaic acid; Phosphatase; Smooth muscle (Johansson Rydberg, I.G.M. (329) 175)

K_{ATP} channel
Skeletal muscle; Glybenclamide receptor; Patch clamp (Tricarico, D. (321) 369)

Coronary artery; SIN-1 (3-morpholinosydnonimine); Nitric oxide (NO); Vasodilation; Glibenclamide (Deka, D.K. (330) 157)

K^+_{ATP} channel
Glibenclamide (glyburide); Myocardial ischemia; Cardiac arrhythmia; Adenosine release (Bernauer, W. (326) 147)

K^+ channel activator
Arrhythmia; Ischaemia; Levcromakalim; Reperfusion (Vegh, A. (333) 33)

K^+ channel antagonist
Levcromakalim; Quaternary ion; Circumflex artery, right, pig; Tetraphenylphosphonium; Triphenylphosphonium compound (Piekarska, A.E. (322) 37)

K^+ channel; Antisense oligodeoxyribonucleotide; Food intake; K^+ channel opener (Ghelardini, C. (329) 1)

K^+ channel ATP-sensitive
α-Adrenoceptor; β-Adrenoceptor; Myocardium; Forskolin (Kocić, I. (332) 65)

K^+ channel opener
Y-26763; Glibenclamide; Cardioprotection; K^+ channel, ATP-sensitive (Rahman, F. (317) 293)

Cromakalim; Diazoxide; Mesenteric bed, rat; Endothelium; Nitric oxide (NO) (Feleder, E.C. (319) 229)

Asthma; Drug combination; Interaction; Smooth muscle, airway; Trachea; β_2-Adrenoceptor agonist; Methylxanthine; Sodium nitroprusside; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

K^+ channel; Antisense oligodeoxyribonucleotide; Food intake; K^+ channel antagonist (Ghelardini, C. (329) 1)

K^+ current
Antihistaminic agent; Terfenadine; Ebastine; Carebastine; hKv1.5 channel (Valenzuela, C. (326) 257)

Patch clamp, whole-cell; Na^+ current; KC8851; Open channel blockade (McLarnon, J.G. (339) 279)

K^+ current, muscarinic acetylcholine receptor-operated ($I_{K,ACh}$)
Pirmenol; Atrial fibrillation; Disopyramide (Watanabe, Y. (338) 71)

K^+-rich media
SCA40; Trachealis, bovine; Electrophysiology; $^{86}Rb^+$ efflux; Phosphodiesterase isoenzyme (Pocock, T.M. (334) 75)

Ketamine
Morphine tolerance; Morphine dependence; Dizocilpine; CGP 39551 (DL-(*E*)-2-amino-4-methyl-5-phosphonopentanoate carboxy-ethylester) (González, P. (332) 257)

Ketanserin
Citric acid; Cough reflex; 5-HT (5-hydroxytryptamine, serotonin); Methysergide (Stone, R.A. (332) 201)

6-Keto-prostaglandin-1α
Mercaptoalkylguanidine; Haemorrhagic shock; Nitric oxide (NO); Peroxynitrite (Zingarelli, B. (338) 55)

Ketotifen
1,8-cineole; Paw oedema; Mast cell; Compound 48/80; Cyproheptadine; (Rat) (Santos, F.A. (331) 253)

Acid secretion; Gastric mucosal blood flow; Mast cell; Mean arterial pressure; RX 77368; TRH (thyrotropin-releasing hormone); Vagus; Brain–gut (Király, Á. (334) 241)

KF19514
Asthma; Eosinophil; Bronchodilator; Hyperreactivity; Phosphodiesterase inhibitor (Manabe, H. (332) 97)

Kidney
Dopamine D_2-like receptor; Na^+ pump; Proximal tubule; (Rat) (Hussain, T. (321) 259)

Angiotensin II; Norepinephrine; NOC 7 (1-hydroxy-2-oxo-3-(*N*-methyl-3-aminopropyl)-3-methyl 1-triazene); Nitric oxide (NO); (Rabbit) (Adachi, Y. (324) 223)

Non-steroidal anti-inflammatory drug; Circulation; Prostanoid; Plasma renin activity; Cytochrome *P*-450 activity; Na^+ excretion (Kramp, R.A. (330) 165)

Dopamine; D_2-like receptor; Innervation; Radioligand binding assay; Autoradiography; (Rat) (Barili, P. (334) 233)

Dopamine D_3 receptor; Radioligand binding assay; Autoradiography; Cortical tubule; Glomerulus (Barili, P. (338) 89)

CNP (C-type natriuretic peptide); Angiotensin II; Norepinephrine; Vasoconstriction; (Dog) (Yoshida, K. (338) 131)

Kidney, autoperfused, rat
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists; Renal blood flow; Angiotensin II (Morán, A. (330) 205)

Kindling
NMDA (*N*-methyl-D-aspartate); Amygdala; Seizure; Epilepsy (Croucher, M.J. (319) 207)

KMD-3213
α_1-Adrenoceptor antagonist; Prostate; Benign prostatic hypertrophy; (Human) (Moriyama, N. (331) 39)

Knockout mouse
Tenascin; Apomorphine; Dopamine receptor (Fukamauchi, F. (338) 7)

K-*ras*
Lung cancer; Proliferating cell nuclear antigen; Vitamin E; Chemoprevention (Yano, T. (323) 99)

Kupffer cell
Amylin; CGRP (calcitonin gene-related peptide); Hepatocyte; Glucose metabolism; Macrophage (Pittner, R.A. (325) 189)

mKv1.1
Antisense oligonucleotide; K^+ channel; Analgesia; Antinociception; Clomipramine; Amitriptyline; Tricyclic antidepressant; (Mouse) (Galeotti, N. (330) 15)

Kynurenic acid
Astrocyte; Excitotoxicity; Glycine site; NMDA receptor; Neurodegenerative disorder; Quinolinic acid (Wu, H.-Q. (319) 13)

L-364,718
CHO (Chinese hamster ovary) cell; Cholecystokinin; CCK_A receptor; Devazepide; Ca^{2+} mobilization; Cell recruitment; Receptor modelling (Smeets, R.L.L. (325) 93)

L-365,260
Cholecystokinin; CCK-8; BC 264; CCK_B receptor antagonist; Devazepide; CCK_A receptor antagonist; Depression; Stress; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

Antinociception; Mononeuropathic rat; CCK_B receptor antagonist; Morphine; Naloxone; Vocalization threshold; Struggle latency (Idänpään-Heikkilä, J.J. (325) 155)

L-701,324
Ethanol; NMDA/glycine receptor; MK-801; Eliprodil; Drug discrimination; (Rat) (Kotlinska, J. (332) 1)

L-741,742
Anxiety; Elevated plus-maze; Clozapine; L-745,870; Dopamine D_4 receptor; Chlordiazepoxide; Mouse (Cao, B.-J. (335) 117)

L 745,870
Dopamine D_4 receptor; Clozapine; Noradrenaline; Adrenaline; [^{35}S]GTPγS (Newman-Tancredi, A. (319) 379)

Anxiety; Elevated plus-maze; Clozapine; L-741,742; Dopamine D_4 receptor; Chlordiazepoxide; Mouse (Cao, B.-J. (335) 117)

Lactate
Adenosine; Coronary artery disease; Myocardial ischaemia; Ventricular function (De Jonge, R. (337) 41)

Lamotrigine
Neuropathic pain; Allodynia; Antinociception; Tail-flick test; Behavior; Electroshock test, maximal; Felbamate; Gabapentin (Hunter, J.C. (324) 153)

Larynx
Codeine; Trachea bifurcation; Mechanical stimulation; Cough, codeine-resistant; C-fiber; A-fiber (Takahama, K. (329) 93)

Laser-Doppler flowmetry
Capsaicin-sensitive; Resiniferatoxin; Saphenous nerve; Neuropeptide Y; Vasoconstriction; Vasodilation (Pintér, E. (325) 57)

Laxative
Anthraquinone; Intestinal secretion; Nitric oxide (NO); Glucocorticoid; Natural drug (Izzo, A.A. (323) 93)

L-Cysteine
Nitric oxide (NO); Peroxynitrite; Sugar; Vasodilatation; Sodium nitrite; Methylene blue; Haemoglobin (Dowell, F.J. (338) 43)

LDL (low-density lipoprotein) receptor
Pravastatin sodium; HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase; Cholesterol 7α-hydroxylase; (Rat) (Fujioka, T. (323) 223)

Learned helplessness
CRF (Corticotropin-releasing factor); Depression; CP-154,526; (Rat) (Mansbach, R.S. (323) 21)

Antidepressant; Forced swimming; $GABA_B$ receptor (Shimidzu, T. (338) 225)

Learning
Rolipram; cAMP; Memory; 3-Panel runway; Passive avoidance (Imanishi, T. (321) 273)

σ_1 Receptor; Dizocilpine-induced amnesia; N^{ω}-Nitro-L-arginine methyl ester (L-NAME), induced amnesia; NMDA receptor (Maurice, T. (328) 9)

Dopamine; Dopamine D_2 receptor; Dopamine D_3 receptor; Memory (Sigala, S. (336) 107)

Left ventricular hypertrophy
Cocaine; Molecular biology; Collagen; Myosin; Atrial natriuretic factor; (Rat) (Besse, S. (338) 123)

Lethality
Opioid; Cocaine; Cardiovascular; Blood pressure; Seizure (Patterson, A.B. (333) 47)

Cocaine; Convulsion; NMDA receptor; Toxicity (Matsumoto, R.R. (338) 233)

Leukocyte
Albumin leakage; Lipopolysaccharide; 5-Lipoxygenase; Lung; Radioactive tracer (Bureau, M.F. (324) 89)

Leukotriene B_4
Alveolar macrophage; Nitric oxide (NO); Lipoxygenase; Cyclooxygenase (Brunn, G. (326) 53)

[Leu^{31},Pro^{34}]Peptide YY
Neuropeptide Y; Pancreatic polypeptide; Peptide YY (Gehlert, D.R. (318) 485)

Levamisole
Nicotinic acetylcholine receptor; Heterogeneity; Patch clamp; (*Oesphagostomum dentatum*) (Martin, R.J. (322) 249)

Levcromakalim
Cetiedil; Smooth muscle; Skeletal muscle (Benton, D.C.H. (317) 329)

ANP (atrial natriuretic polypeptide); VIP (vasoactive intestinal polypeptide); K^+ channel; Ca^{2+} channel blocker; Isradipine; Trachea; Smooth muscle, airway (Thirstrup, S. (319) 253)

Quaternary ion; K^+ channel antagonist; Circumflex artery, right, pig; Tetraphenylphosphonium; Triphenylphosphonium compound (Piekarska, A.E. (322) 37)

Sulphonylurea; Thromboxane A_2; U46619; Structure-activity relationship; Coronary artery, pig (McPherson, G.A. (324) 193)

Arrhythmia; Ischaemia; K^+ channel activator; Reperfusion (Vegh, A. (333) 33)

Endothelium; Cannabinoid receptor (White, R. (339) 157)

Levetiracetam
GABA (γ-aminobutyric acid); Anti-epileptic drug; Epilepsy (Sills, G.J. (325) 35)

Levosimendan
K^+ channel; K^+ channel, ATP-sensitive; Patch clamp technique; Mesenteric artery, rat (Yokoshiki, H. (333) 249)

Myocyte; $[Ca^{2+}]_i$; (Guinea pig) (Lancaster, M.K. (339) 97)

LH (luteinizing hormone)
Mifepristone; Progesterone; Oestrogen; Adrenoceptor antagonist (Salicioni, A.M. (332) 283)

Lidocaine
Formalin test; Mazindol; Antinociception; Dopamine; Opioid (Bittencourt, A.L. (330) 109)

5-HT_3 receptor; ICS-205 930; Bupivacaine; Nociception inflammation (Giordano, J. (334) 39)

Ligand binding
Melanocortin receptor subtype; MSH (melanocyte-stimulating hormone) (Schiöth, H.B. (319) 369)

Ligand binding thermodynamics
δ-Opioid receptor; Pharmacophore; Model (Maguire, P.A. (318) 505)

Ligand efficacy
Signal transduction; Conformational states, multiple; Thermodynamic model; Inverse agonist (Pardo, L. (335) 73)

Ligand-gated ion channel
NMDA receptor; Glutamate receptor; *Xenopus* oocyte (Buller, A.L. (320) 87)

5-HT_3 receptor; N1E-115 mouse neuroblastoma cell; *Xenopus laevis* oocyte; (Partial agonist); (Antagonist) (Van Hooft, J.A. (322) 229)

Light sensitivity
Hydroxocobalamin; Nitrergic transmission (La, M. (321) R5)

Lindane
Hexachlorocyclohexane isomer; $GABA_A$ receptor; Flunitrazepam binding; GABA (γ-aminobutyric acid) binding; TBPS (*t*-butylbicyclophosphorothionate) binding; Cerebellar granule cell, cultured (Vale, C. (319) 343)

Lingual artery, dog
Histamine H_1 receptor; 2-Pyridylethylamine; Dimaprit; (Cannula insertion method) (Chiba, S. (329) 63)

Linolenic acid
Experimental allergic encephalomyelitis; Fatty acid; α-Linolenic acid; Multiple sclerosis (Yehuda, S. (328) 23)

α-Linolenic acid
Experimental allergic encephalomyelitis; Fatty acid; Linolenic acid; Multiple sclerosis (Yehuda, S. (328) 23)

Lipid fluidity
Diabetes mellitus, non-insulin dependent; Metformin; Insulin; Erythrocyte membrane (Muller, S. (337) 103)

Lipid peroxidation
Piribedil; Brain; Oxygen exposure, high (Calzi, F. (338) 185)

Lipocortin
Glucocorticoid; Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; J774 macrophage; Lipopolysaccharide (D'Acquisto, F. (339) 87)

Lipolysis
GR79236; Insulin resistance; Fructose; Triglyceride; Non-insulin-dependent diabetes (NIDDM) (Qu, X. (338) 269)

Lipooxygenase-products
Adenosine; Histamine; Airway; NANC (non-adrenergic–non-cholinergic), inhibitory; (Guinea pig) (Nieri, P. (331) 205)

Lipopolysaccharide
Nitric oxide synthase, inducible (NO); Cyclooxygenase-2; Western blot; cAMP; Indomethacin; Cytotoxicity (Pang, L. (317) 151)

Pentoxifylline; TNF-α (tumor necrosis factor-α); Anti-TNF strategy; Fever; TNF bioassay; Radiotelemetry; (Guinea pig) (Goldbach, J.-M. (319) 273)

Nitric oxide (NO); Nitrosothiol; Glutathione; *N*-Acetylcysteine; Glucose; Cytotoxicity; Macrophage (Zamora, R. (321) 87)

Arachidonic acid; Phospholipase A_2; Protein kinase; UTP; RAW 264.7 macrophage (Lin, W.W. (321) 121)

Aminoguanidine; N^G-Nitro-L-arginine; PAF (platelet-activating factor); Systemic inflammatory response syndrome; Nitric oxide (NO); (Rat) (Takano, H. (323) 107)

Albumin leakage; 5-Lipoxygenase; Leukocyte; Lung; Radioactive tracer (Bureau, M.F. (324) 89)

Dantrolene; Nitric oxide (NO) synthase II; Mortality; Hemodynamic alteration (Wu, C.-C. (327) 17)

Melatonin; Water intake; Fever; Nitric oxide (NO) (Nava, F. (331) 267)

TNF (tumor necrosis factor); Interleukin 10; Brain (Di Santo, E. (336) 197)

Nitric oxide (NO) synthase, inducible; Aorta, rat; Genistein; Tyrphostin; Orthovanadate; Phenylarsine oxide (Duarte, J. (338) 25)

Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; Auranofin; Aurothioglucose; Aurothiomalate; RAW 264.7 cell (Yamashita, M. (338) 151)

Glucocorticoid; Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; Lipocortin; J774 macrophage (D'Acquisto, F. (339) 87)

cAMP; cGMP; Phosphodiesterase III inhibitor; Monocyte; Macrophage; Interleukin-10; TNF-α (tumor necrosis factor-α); Nitric oxide (NO) (Németh, Z.H. (339) 215)

Lipoprotein lipase
Brown adipocyte; TMF-α (tumor necrosis factor-α); Nitric oxide (NO) synthase, inducible; Guanosine 3′,5′-cyclic monophosphate (Uchida, Y. (335) 235)

5-Lipoxygenase
Albumin leakage; Lipopolysaccharide; Leukocyte; Lung; Radioactive tracer (Bureau, M.F. (324) 89)

Lipoxygenase
Alveolar macrophage; Nitric oxide (NO); Cyclooxygenase; Leukotriene B_4 (Brunn, G. (326) 53)

Smooth muscle cell; Proliferation; Migration (Nishio, E. (336) 267)

Liver
Cholesterol; Plasma; Bile; Gallstone; Cholesterol 7α-hydroxylase; Acyl coenzyme A:cholesterol acyltransferase (Hajri, T. (320) 65)

Endothelin; Endothelin ET_A receptor; Endothelin ET_B receptor; Pressor effect; Nitric oxide (NO); Oxygen consumption (Higuchi, H. (328) 175)

Local lymph node assay
FK506; Glucocorticosteroid; Immunosuppression; Tacrolimus; Topical drug (Homey, B. (325) 199)

Locomotion
Dopamine D_2 receptor; Adenosine A_{2A} receptor; Striatum; Catalepsy; (Rat) (Hauber, W. (323) 127)

NGF (nerve growth factor); Acetylcholine; Nicotinic receptor; Dopamine receptor antagonist (Kobayashi, S. (326) 1)

Flupirtine; NMDA receptor, antagonistic; Catalepsy; L-DOPA (L-dihydroxyphenylalanine); Parkinson's disease (Schmidt, W.J. (327) 1)

MK-801; M100907; Dopamine receptor antagonist; Schizophrenia; (Mouse) (Martin, P. (335) 107)

Novelty; Fear; Anxiety (Gendreau, P.L. (337) 147)

Locomotor activity
Nociceptin; Exploratory behavior; Dopamine transmission (Florin, S. (317) 9)

Dihydrexidine; Dopamine D_2 receptor; Sedation; Vacuous chewing; Yawning (Smith, H.P. (323) 27)

5-HT (5-hydroxytryptamine, serotonin); Serotonin reuptake inhibitor, selective; (Rat) (Sills, T.L. (337) 161)

Locomotor sensitization
Dopamine receptor agonist; D_2/D_3 receptor; Clorgyline (Culver, K.E. (339) 109)

Locus coeruleus
Ethanol tolerance; Ethanol withdrawal; NMDA receptor (Poelchen, W. (332) 267)

α_{2A}-Adrenoceptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); ARC 239 (2-[2-[4-(*o*-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethyl-1,3(2H,4H)-isoquinolinedione); Chlorpromazine (Ruiz-Ortega, J.A. (333) 159)

Longitudinal muscle
5-HT_3 receptor; Colon, guinea pig; Circular muscle; Tachykinin (Yamano, M. (317) 353)

Long-term depression
Ca^{2+}, dendritic; Metabotropic receptor (Otani, S. (318) R5)

Long-term potentiation
Depotentiation; Adenosine A_1 receptor antagonist; 8-CPT (8-cyclopentyltheophylline); Synaptic plasticity, modulation of; Hippocampal CA1 neuron (Fujii, S. (331) 9)

mGlu receptor; Hippocampus; PCCG-IV ((2*S*,1′*S*,2′*S*,3′*R*)-2-(2″-carboxy-3′-phenylcyclopropyl)glycine); MTPG ((*R*,*S*)-α-methyl-4-tetrazolylphenylglycine) (Huang, L. (332) 161)

Losartan
Angiotensin AT_1 receptor; Angiotensin II; Binding; Aorta, rabbit; UR-7280 (De Arriba, A.F. (318) 341)

Candesartan (CV-11974); [^{3}H]CV-11974; Angiotensin AT_1 receptor; Association rate constant; Dissociation rate constant (Ojima, M. (319) 137)

Hyperplasia; Smooth muscle, vascular; Cell culture; Nifedipine; Captopril; Transgenic rat (Peiró, C. (324) 257)

Angiotensin; Heart rate; Arterial pressure; Spinal cord; Cardiovascular control; PD 123319 (Park, P.D.S. (326) 139)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; PD-123319; Uterine artery; Pregnancy; (Sheep) (Burrell, J.H. (330) 257)

Angiotensin II; Angiotensin AT_1 receptor antagonist; YM358 (Shibasaki, M. (335) 167)

Losigamone
Epilepsy; Cell culture; IPSC (inhibitory postsynaptic current); EPSC (excitatory postsynaptic current) (Draguhn, A. (325) 245)

Lower lip retraction
Behavior; Body temperature; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Tail flick; (Intracerebroventricular administration) (Bagdy, G. (323) 53)

LP-BM5 murine leukemia virus
AIDS (acquired immunodeficiency syndrome); Encephalopathy; PAF (platelet-activating factor); Pentoxifylline; TNF-α (tumor necrosis factor-α) (Sei, Y. (325) 81)

LSD (lysergic acid diethylamide)
Chronic treatment; Biogenic amines; Ca^{2+} channel; Nifedipine; Brain (Antkiewicz-Michaluk, L. (332) 9)

Lubeluzole
Dotarizine; Flunarizine; Catecholamine release; Chromaffin cell; Ca^{2+} channel antagonist, 'wide-spectrum' (Lara, B. (325) 109)

Penumbra; Glutamate; Taurine; Neuroprotection; Swelling; Microdialysis (Scheller, D.K.A. (338) 243)

Lung
Albumin leakage; Lipopolysaccharide; 5-Lipoxygenase; Leukocyte; Radioactive tracer (Bureau, M.F. (324) 89)

Cannabinoid; Type II cell; Ontogeny; Development; Steroid (Rice, W. (327) 227)

Lung, human
Down-regulation; β_2-Adrenoceptor; Salbutamol; Salmeterol; Formoterol (Nishikawa, M. (318) 123)

Lung cancer
K-ras; Proliferating cell nuclear antigen; Vitamin E; Chemoprevention (Yano, T. (323) 99)

Lurcher mutant mouse
3-Acetylpyridine; Inferior olivary neuron; NMDA (*N*-methyl-D-aspartate), inhibition; Niacinamide (Caddy, K.W.T. (330) 139)

LY 270411
Dopamine 'D_1-like' receptor; Dopamine 'D_2-like' receptor; D_1/D_2 interaction; BW 737C; SCH 23390; Grooming behavior; Vacuous chewing; Myoclonic jerking; (Rat) (Deveney, A.M. (317) 175)

Lymphocyte
Suplatast tosilate; Airway inflammation; Airway hyperresponsiveness; Eosinophil; T cell (Taniguchi, H. (318) 447)

Suplaplast tosilate; Airway inflammation; Airway hyperresponsiveness; Eosinophil; T cell (Taniguchi, H. (321) 397)

δ-Opioid receptor ligands; Immunomodulation (Noviello, L. (332) R1)

Nitric oxide (NO)-releasing compound; Nitric oxide (NO); cGMP (Kosonen, O. (337) 55)

Lymphocyte proliferation
Opioid; Immunity; Autonomic nervous system; Sympathetic division; Parasympathetic division; (Rat) (Flores, L.R. (318) 437)

Lysophosphatidylcholine
Cardiomyocyte; Ca^{2+} overload; Ca^{2+} channel blocker; Creatine kinase (Chen, M. (333) 261)

M100907
MK-801; Dopamine receptor antagonist; Locomotion; Schizophrenia; (Mouse) (Martin, P. (335) 107)

Macrocirculatory blood flow
Streptozotocin-diabetic rat; ACTH-(4–9) analogue; Org 2766; Adrenergic responsiveness; Nerve blood flow (Van Buren, T. (318) 73)

Macrophage
Antidepressant; Inflammation; Chemotaxis (Sacerdote, P. (319) 287)

Nitric oxide (NO); Nitrosothiol; Glutathione; *N*-Acetylcysteine; Glucose; Lipopolysaccharide; Cytotoxicity (Zamora, R. (321) 87)

Amylin; CGRP (calcitonin gene-related peptide); Hepatocyte; Glucose metabolism; Kupffer cell (Pittner, R.A. (325) 189)

Auranofin; Prostaglandin E_2; 12-*O*-Tetradecanoylphorbol 13-acetate; Thapsigargin; A23187; Cyclooxygenase 2; Cyclooxygenase 1 (Yamashita, M. (325) 221)

Natural killer cell; Enkephalin; Endorphin; Cytotoxicity (Kowalski, J. (326) 251)

Endothelin ET_B receptor; RT-PCR (reverse transcription-polymerase chain reaction); Receptor autoradiography; (Rat) (Sakurai-Yamashita, Y. (338) 199)

Lipopolysaccharide; cAMP; cGMP; Phosphodiesterase III inhibitor; Monocyte; Interleukin-10; TNF-α (tumor necrosis factor-α); Nitric oxide (NO) (Németh, Z.H. (339) 215)

MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate)
Metabotropic glutamate receptor; 1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitatory postsynaptic potential; Depotentiation; CA1 area; Hippocampus; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid) (Hölscher, C. (322) 155)

MAP (mitogen-activated protein) kinase
ORL_1 receptor; Nociceptin; Orphanin FQ (Fawzi, A.B. (336) 233)

Mast cell
Histamine; Interleukin-4; TNF-α (tumor necrosis factor-α) (Gibbs, B.F. (327) 73)

Tryptase; Microvascular leakage; Histamine; Heparin; Proteinase inhibitor; Histamine receptor antagonist (He, S. (328) 89)

1,8-cineole; Paw oedema; Compound 48/80; Ketotifen; Cyproheptadine; (Rat) (Santos, F.A. (331) 253)

Acid secretion; Gastric mucosal blood flow; Ketotifen; Mean arterial pressure; RX 77368; TRH (thyrotropin-releasing hormone); Vagus; Brain–gut (Király, Á. (334) 241)

β-Adrenoceptor agonist; Isoproterenol; Clenbuterol; Allergic reaction; Vascular permeability (Inagaki, N. (336) 225)

Intestinal distension; Visceral hyperalgesia; Visceral nociception; Tachykinin; Tachykinin NK_2 receptor (McLean, P.G. (337) 279)

Tachykinin; Bronchoconstriction; Substance P; Neurokinin A; 5-HT (5-hydroxytryptamine, serotonin); Tachykinin NK_1 receptor (Joos, G.F. (338) 259)

Mast cell deficient rat (Ws/Ws rat)
Microdialysis; Histamine; Paw edema; Compound 48/80; Degranulation (Guo, Y. (331) 237)

Matrine
Antinociception; κ-Opioid receptor; Pentazocine; Nor-binaltorphimine; (Mouse) (Kamei, J. (337) 223)

Matrix index
Anti-Thy1 nephritis; Cytokine; OPC15161; Superoxide radical; Tubulointerstitial index (Hamada, N. (317) 123)

Maximal electroshock
APNEA (N^6-2-(4-aminophenyl)ethyl-adenosine); Adenosine receptor; Adenosine A_1 receptor; Antiepileptic drug; Seizure (Borowicz, K.K. (327) 125)

Maze
Ginsenoside; Choline acetyltransferase; Scopolamine; Septum, medial (Yamaguchi, Y. (329) 37)

Mazindol
Formalin test; Lidocaine; Antinociception; Dopamine; Opioid (Bittencourt, A.L. (330) 109)

MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine)
Metabotropic glutamate receptor; 1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitatory postsynaptic potential; Depotentiation; CA1 area; Hippocampus; MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

MCF7/6
Tamoxifen; E-cadherin; Adhesion; Ca^{2+} channel antagonist (Charlier, C. (317) 413)

McN-A-343
Talsaclidine; Arecoline; Noradrenaline; Bronchospasm; Guinea pig (Walland, A. (330) 213)

Muscarinic receptor; Operational model; Allosteric interaction (Christopoulos, A. (339) 153)

MDA (3,4-Methylenedioxyamphetamine)
MDMA (3,4-Methylenedioxymethamphetamine); α-Methyldopamine; Glutathione; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Miller, R.T. (323) 173)

MDMA (3,4-Methylenedioxymethamphetamine)
MDA (3,4-Methylenedioxyamphetamine); α-Methyldopamine; Glutathione; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Miller, R.T. (323) 173)

Drug discrimination; Cocaine; Dose response; Cumulative dosing; (Rat) (Schechter, M.D. (326) 113)

Dopamine; Cocaine (Morgan, A.E. (331) R1)

Mean arterial pressure
Acid secretion; Gastric mucosal blood flow; Ketotifen; Mast cell; RX 77368; TRH (thyrotropin-releasing hormone); Vagus; Brain–gut (Király, Á. (334) 241)

Mecamylamine
Dopamine; Ethanol; Hexamethonium; Microdialysis, in vivo; Nicotinic acetylcholine receptor (Blomqvist, O. (334) 149)

Mechanical activity
Neurotensin; Colon; Ca^{2+} channel, L-type (Mulè, F. (319) 269)

Mechanical stimulation
Codeine; Larynx; Trachea bifurcation; Cough, codeine-resistant; C-fiber; A-fiber (Takahama, K. (329) 93)

Medetomidine
α_2-Adrenoceptor; Pineal gland; Melatonin; Circadian rhythm; Atipamezole (Mustanoja, S.M. (326) 229)

Atipamezole; Dopamine overflow; Dopamine metabolisms; Voltammetry, in vivo; Mouse (Yavich, L. (339) 113)

Medial prefrontal cortex
Dopamine D_1 receptor; Substantia nigra; Ventral tegmental area (Dewar, K.M. (336) 155)

Medial septal-lesion
Metrifonate; Spatial navigation; Cholinesterase inhibition; Alzheimer's disease (Riekkinen, M. (338) 105)

Medial septum-lesioned rat
Nimodipine, chronic; Metrifonate, acute; Water maze; Passive avoidance; Motor test; Washout; Aged rat (Riekkinen, M. (322) 1)

Median eminence
Dopamine receptor agonist; PNU-95.666; PD128907; DOPAC (3,4-dihydroxyphenylal acetic acid) (Durham, R.A. (335) 37)

Megakaryoblastic cell, human
Apoptosis; Imidazo[1,2-*a*]pyrazine derivative; Phosphodiesterase; cAMP; Purinoceptor (Zurbonsen, K. (320) 215)

Megakaryocyte, rat
Thrombin receptor; Ca^{2+}-activated K^+ current; Patch clamp, perforated (Uneyama, C. (319) 299)

Melanocortin receptor subtype
MSH (melanocyte-stimulating hormone); Ligand binding (Schiöth, H.B. (319) 369)

Melanoma cell
Calmodulin antagonist; Glycolysis; Cytoskeleton (Glass-Marmor, L. (328) 241)

Melanotroph
$GABA_A$ receptor; Muscimol; $GABA_A$ receptor antagonist; Bicuculline; $GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; CGP 35348; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

Melatonin
Free radical; Cytoprotection; Ischemia-reperfusion; Gastric ulceration; Gastric blood flow (Konturek, P.Ch. (322) 73)

α_2-Adrenoceptor; Pineal gland; Circadian rhythm; Medetomidine; Atipamezole (Mustanoja, S.M. (326) 229)

Lipopolysaccharide; Water intake; Fever; Nitric oxide (NO) (Nava, F. (331) 267)

Pineal; Adenosine; Adenosine receptor; (Sheep) (Falcón, J. (337) 325)

Brown adipocyte; Melatonin receptor; (Siberian hamster) (Le Gouic, S. (339) 271)

Melatonin receptor
Melatonin; Brown adipocyte; (Siberian hamster) (Le Gouic, S. (339) 271)

Membrane
RBL-2H3; Astemizole; Protein; Tyrosine; Phosphorylation; Ca^{2+}; Flux; Exocytosis (Fischer, M.J.E. (322) 97)

Membrane current
Sematilide; Atrium, rabbit; Antiarrhythmic agent (Ishii, Y. (331) 295)

Membrane potential
Antiepileptics; Cromakalim; Glibenclamide; Patch-clamp electrophysiology; NG 108-15 cell; hNT neuron; Cortical neuron, mouse (Rundfeldt, C. (336) 243)

Memory
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Noradrenaline; EEG (electroencephalogram); Basal forebrain lesion; Tetrahydroaminoacridine (Abe, K. (321) 149)

Rolipram; cAMP; Learning; 3-Panel runway; Passive avoidance (Imanishi, T. (321) 273)

R-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-*N*,*N*-(di-*n*-propyl-2-amino)tetralin); Dopamine D_3 receptor; Passive avoidance learning; Spontaneous locomotor activity; (Mouse) (Ukai, M. (324) 147)

Adenosine A_1 receptor antagonist; BIIP 20; Passive avoidance (Pitsikas, N. (328) 19)

Defibrotide; Cerebral ischemia; EEG (electroencephalographic) spectral power; Neuronal damage (Sala, M. (328) 143)

Dopamine; Dopamine D_2 receptor; Dopamine D_3 receptor; Learning (Sigala, S. (336) 107)

Nitric oxide (NO); cGMP; Blood pressure; 7-Nitroindazole; Zaprinast; (Rat) (Prickaerts, J. (337) 125)

Memory impairment
D-Cycloserine; Temporal cortex; Entorhinal cortex; Recovery of function; (Microinjection) (Myhrer, T. (328) 1)

Meningeal artery, middle
Rizatriptan; Microscopy, intravital; CGRP (calcitonin gene-related peptide); Migraine (Williamson, D.J. (328) 61)

Mercaptoalkylguanidine
Haemorrhagic shock; Nitric oxide (NO); 6-Keto-prostaglandin-1α; Peroxynitrite (Zingarelli, B. (338) 55)

Mercaptoethylguanidine
Endotoxin; Nitric oxide (NO) synthase; Dexamethasone; Myocardial contractility; β-Adrenoceptor (Sun, X. (320) 29)

Mesangial cell
Nitric oxide (NO); Nitric oxide (NO) donor; Apoptosis; Glomerular endothelial cell; Glomerular epithelial cell; Interleukin-1 (Mühl, H. (317) 137)

Proliferation; Captopril; Angiotensin II-converting enzyme inhibitor; Tyrosine phosphorylation; $pp60^{c\text{-}src}$ (Ruiz-Ginés, J.A. (336) 251)

Beraprost sodium; Mitogen-activated protein kinase phosphatase 1 (MKP-1); cAMP (Togawa, M. (336) 291)

Mesenteric arterial bed
Endothelium; Nitric oxide (NO); Perivascular nerve; Sensory nerve; (Golden hamster) (Hill, B. (317) 275)

Mesenteric artery
Adrenergic nerve; Contraction; Excitatory junctional potential; Amiloride (Shimamura, K. (320) 37)

Angiotensin II; EDRF (endothelium-derived relaxing factor); Prostanoid; Mesenteric vein; Aging; Development (Konishi, C. (320) 175)

α_1-Adrenoceptor; Prostate; Trigone; Urethra; (Rabbit) (Van der Graaf, P.H. (327) 25)

Mesenteric artery, human, inferior
BIBP 3226; Neuropeptide Y receptor; Neuropeptide Y Y_1 receptor; Sympathetic stimulation; Mesenteric vein, human, inferior (Racchi, H. (329) 79)

Mesenteric artery, rat
Cyclopiazonic acid; Nitric oxide (NO); Endothelium; K^+ channel; Contractions, rhythmic (Huang, Y. (332) 167)

Levosimendan; K^+ channel; K^+ channel, ATP-sensitive; Patch clamp technique (Yokoshiki, H. (333) 249)

Mesenteric bed
Vasodilation; Vasoconstriction; Bradykinin; Bradykinin receptor; B_2 knockout mice (Berthiaume, N. (333) 55)

Mesenteric bed, rat
K^+ channel opener; Cromakalim; Diazoxide; Endothelium; Nitric oxide (NO) (Feleder, E.C. (319) 229)

Mesenteric blood vessel
α_1-Adrenoceptor; Chloride ion; Niflumic acid; Two-kidney one-clip hypertensive rat (He, Y. (328) 191)

Mesenteric vein
Angiotensin II; EDRF (endothelium-derived relaxing factor); Prostanoid; Mesenteric artery; Aging; Development (Konishi, C. (320) 175)

Mesenteric vein, human, inferior
BIBP 3226; Neuropeptide Y receptor; Neuropeptide Y Y_1 receptor; Sympathetic stimulation; Mesenteric artery, human, inferior (Racchi, H. (329) 79)

Mesocortical dopamine neuron
Stress; Benzodiazepine/$GABA_A$ receptor agonist; Agonist, inverse; Glycine/NMDA receptor antagonist (Hutson, P.H. (326) 127)

Mesolimbic dopamine system
Diabetes; Methamphetamine; Place preference; Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Kamei, J. (318) 251)

Dopamine receptor; Antidepressant drug; Fluoxetine; Chronic treatment (Collu, M. (322) 123)

Metabotropic glutamate (mGlu) receptor
Contextual conditioning; AIDA (1-aminoindan-1,5-dicarboxylic acid) (Nielsen, K.S. (326) 105)

Metabotropic glutamate receptor
S-4C3H-PG ((*S*)-4-carbonyl-3-hydroxyphenylglycine); MSOP ((*RS*)-α-methylserine-*O*-phosphate); Drinking conflict test; Intrahippocampal injection (Chojnacka-Wójcik, E. (319) 153)

1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitatory postsynaptic potential; Depotentiation; CA1 area; Hippocampus; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

DCG-IV; NMDA receptor; AP5 (D-2-amino-5-phosphonopentanoic acid) (Breakwell, N.A. (322) 173)

trans-ACPD; C6 glioma cell; G-protein (Albasanz, J.L. (326) 85)

Epilepsy; Glutamate; Genetically epilepsy-prone rat; L-Serine-*O*-phosphate; (*S*)-4C3HPG ((*S*)-4-carboxy-3-hydroxyphenylglycine); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid) (Tang, E. (327) 109)

Alternative splicing; Constitutive activity; G-protein coupled receptor; Phospholipase C coupling (Mary, S. (335) 65)

Hepatocyte, cultured; Polyphosphoinositide hydrolysis (Sureda, F. (338) R1)

Metabotropic glutamic acid receptor
$mGlu_2$ receptor selectivity; (1*SR*,3*RS*)-ACPD ((1*SR*,3*RS*)-1-Aminocyclopentane-1,3-dicarboxylic acid); (1*RS*,2*RS*)-homo-ACPD ((1*RS*,2*RS*)-1-amino-1-carboxycyclopentane-2-acetic acid); (1,3)-homo-ACPD (1-Amino-1-carboxycyclopentane-3-acetic acid); (Partial agonist) (Bräuner-Osborne, H. (332) 327)

Metabotropic receptor
Long-term depression; Ca^{2+}, dendritic (Otani, S. (318) R5)

Metformin
Diabetes mellitus, non-insulin dependent; Insulin; Erythrocyte membrane; Lipid fluidity (Muller, S. (337) 103)

Methamphetamine
Diabetes; Place preference; Dopamine D_3 receptor; Mesolimbic dopamine system; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Kamei, J. (318) 251)

Dopamine transporter; Free radical (Fleckenstein, A.E. (323) R7)

Hyperthermia; Fluoxetine; Dopamine transport; 5-HT (5-hydroxytryptamine, serotonin) (Fleckenstein, A.E. (324) 179)

Cortex, prefrontal; Synaptogenesis, reactive; GABA (γ-aminobutyric acid), innervation; (Gerbil) (Dawirs, R.R. (327) 117)

δ-Opioid receptor; Drug discrimination; TAN-67 (Suzuki, T. (331) 1)

Hyperthermia; 5-HT (5-hydroxytryptamine); Serotonin (Fleckenstein, A.E. (332) 263)

Oxygen radical; Dopamine transporter (Fleckenstein, A.E. (334) 111)

Vesicular monoamine transporter type-2 (VMAT2); Dopamine transporter, neuronal membrane; Amphetamine; Dihydrotetrabenazine; WIN 35,428; Dopamine (Frey, K. (334) 273)

Methoctramine
Muscarinic M_1 receptor; Muscarinic M_2 receptor; Scopolamine; Pirenzepine; Alzheimer's disease; (Delay-dependent and -independent); (% correct choice) (Aura, J. (333) 129)

18-Methoxycoronaridine
Ibogaine; Noribogaine; Cocaine; Motor activity (Maisonneuve, I.M. (336) 123)

5-Methoxytryptamine
Hyperglycemia; 5-HT_{2A} receptor; 5-HT_4 receptor (Yamada, J. (323) 235)

3-Methoxytyramine
Monoamine oxidase; Wernicke-Korsakoff syndrome (Mousseau, D.D. (317) 263)

α-Methyl-digitoxigenin-glucoside
ATPase (Na^+, K^+); Cardiac glycoside; Ouabain; Therapeutic index (Gleitz, J. (335) 89)

α-Methyldopa
Quinpirole; Dopamine; Dopamine D_2 receptor; Rilmenidine; Hydralazine; Sympathetic nervous system; Vasopressin (Van den Buuse, M. (322) 191)

α-Methyldopamine
MDA (3,4-Methylenedioxyamphetamine); MDMA (3,4-Methylenedioxymethamphetamine); Glutathione; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Miller, R.T. (323) 173)

α,β-Methylene-ATP
P_{2X} purinoceptor; Chorionic surface artery; Placenta, human, term; UTP receptor; Smooth muscle, vascular (Dobronyi, I. (320) 61)

Methylene blue
Nitric oxide (NO); Peroxynitrite; Sugar; Vasodilatation; L-Cysteine; Sodium nitrite; Haemoglobin (Dowell, F.J. (338) 43)

4-Methyleneglutamic acid
Glutamate receptors; 4-Methylglutamic acid (Bräuner-Osborne, H. (335) R1)

4-Methylglutamic acid
Glutamate receptors; 4-Methyleneglutamic acid (Bräuner-Osborne, H. (335) R1)

(*R*)-α-Methylhistamine
Histamine; Histamine receptor; Histamine H_1 receptor; Histamine H_3 receptor; Endothelium; Nitric oxide (NO); Oviductal artery (Martínez, A.C. (326) 163)

***S*-Methyl-L-thiocitrulline**
Morphine withdrawal; Blood pressure; Nitric oxide (NO) synthase inhibitor; 3-Bromo-7-nitro indazole; Aminoguanidine; 7-Nitro indazole; Nitric oxide (NO) (Vaupel, D.B. (324) 11)

Methylprednisolone
Allergic late phase; (Guinea pig) (Heuer, H.O. (317) 361)

5-Methyl-urapidil
Ventricular pacing, rapid; Heart failure; Dorsal pedal artery; Saphenous vein; α_1-Adrenoceptor (Forster, C. (318) 55)

α_{1D}-Adrenoceptor; Renal artery; Contraction; BMY 7378; Chloroethylclonidine (Villalobos-Molina, R. (322) 225)

α_1-Adrenoceptor, subtype; Chloroethylclonidine; WB 4101; BMY 7378; $^{86}Rb^+$, influx rate; Inositol 1,4,5-trisphosphate (Viko, H. (323) 269)

Methylxanthine
Asthma; Drug combination; Interaction; Smooth muscle, airway; Trachea; β_2-Adrenoceptor agonist; K^+ channel opener; Sodium nitroprusside; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

Methysergide
Citric acid; Cough reflex; 5-HT (5-hydroxytryptamine, serotonin); Ketanserin (Stone, R.A. (332) 201)

Metoprolol
Propranolol; Butoxamine; Neutrophil; Myeloperoxidase; Prostaglandin E_2 (Kaan, S.K. (317) 115)

Cardiomyopathy; β-Adrenoceptor subtype; Coupling efficacy; Adenylyl cyclase; Propranolol; (Hamster) (Witte, K. (334) 209)

Metrifonate
Nimodipine; Cognitive function; EEG (electroencephalograph), cortical; (Rat) (Jäkälä, P. (318) 239)

Septum lesion, medial; Spatial navigation; Spatial bias; Reversal learning (Riekkinen Jr., P. (323) 11)

Aging; Object recognition; Acetylcholine, release; Cholinesterase inhibitor (Scali, C. (325) 173)

Spatial navigation; Cholinesterase inhibition; Alzheimer's disease; Medial septal-lesion (Riekkinen, M. (338) 105)

Metrifonate, acute
Nimodipine, chronic; Water maze; Passive avoidance; Motor test; Washout; Aged rat; Medial septum-lesioned rat (Riekkinen, M. (322) 1)

Mg^{2+}, extracellular
Smooth muscle cell, vascular; Ca^{2+}-permeable non-selective cation channel; Vasopressin; Endothelin-1 (Nakajima, T. (320) 81)

Ca^{2+}, cytosolic, free; Ischemic heart disease (Altura, B.M. (338) R7)

Miconazole
Ca^{2+}; Contraction; Trachea; Econazole; SK&F 96365; Nifedipine (Li, L. (331) 221)

Microcirculation
Nitric oxide (NO); Endotoxin; Nitric oxide (NO) synthase inhibitor; Vascular permeability; Inflammation; Inducible nitric oxide (NO) synthase (László, F. (334) 99)

Gastroduodenal ulceration; Gastroduodenal mucosa; Cysteamine; Testosterone; Sexual dimorphism; Sexual steroid; Microvascular leakage (László, F. (337) 275)

Microcirculation hamster
Neuropeptide Y receptor antagonist; GW1229; Neuropeptide Y Y_1 receptor (Bitran, M. (319) 43)

Microdialysis
BMY-14802; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Dorsal raphe; Hippocampus (Matos, F.F. (317) 49)

Chloral hydrate; (Rat) (Pan, W.H.T. (317) 205)

Chronic transversal; Amphetamine, repeated; Ventral striatum; Dopamine release; Dopamine synthesis; Behavioral sensitization (Imperato, A. (317) 231)

Acetylcholine; Dopamine; Dopamine D_1 receptor; Dopamine D_2 receptor; Neostigmine; Striatum (DeBoer, P. (317) 257)

$GABA_B$ receptor; Thalamus; Aspartate; Glutamate (Nyitrai, G. (318) 295)

Hippocampus; Cerebellum; Pilocarpine; Epilepsy; Amino acid (Smolders, I. (319) 21)

2-Deoxyglucose autoradiography; Dopamine; Autoreceptor antagonist; Cocaine; Drug addiction (Koch, S. (319) 173)

5-HT_{1A} receptor; WAY 100635; Monoamine oxidase inhibitor; Dorsal raphe nucleus; Extracellular recording (Sharp, T. (320) 15)

Adenosine; Caffeine; Carbamazepine; Dopamine (Okada, M. (321) 181)

5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1B/1D}$ receptor; GR 127935; GR 125743; (Guinea pig) (Roberts, C. (326) 23)

Carbamazepine; 5-HT (5-hydroxytryptamine, serotonin); Hippocampus; Ca^{2+}; Electroshock seizure; Tetrodotoxin; (Rat) (Dailey, J.W. (328) 153)

GABA (γ-aminobutyric acid) homeostasis; GABA transporter; Neuron; Glia; Epilepsy (Juhász, G. (331) 139)

Histamine; Paw edema; Mast cell deficient rat (Ws/Ws rat); Compound 48/80; Degranulation (Guo, Y. (331) 237)

Dopamine; HI 6; Pharmacokinetics; Acetylcholine esterase; Soman; (Rat) (Cassel, G. (332) 43)

Nitric oxide (NO); Skin; Bradykinin; Inflammatory hyperalgesia; N^G-nitro-L-arginine methyl ester; Bradykinin B_2 receptor (Andoh, T. (332) 279)

Flesinoxan; WAY 100635; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Feedback regulation; (Rat) (Bosker, F.J. (333) 147)

5-HT_{1A} receptor; Antipsychotic; cAMP accumulation; HA7 cell; 5-HT (extracellular concentration) (Assié, M.-B. (334) 141)

Additivity; Cocaine; Dopamine; Heroin; Nicotine; Nucleus accumbens; Speedball; Synergism; (Interaction) (Zernig, G. (337) 1)

Dopamine; Stratium, ventral; Amphetamine; Stress; (Relapse) (Weiss, F. (337) 219)

Penumbra; Glutamate; Taurine; Lubeluzole; Neuroprotection; Swelling (Scheller, D.K.A. (338) 243)

Microdialysis, brain
Cocaine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Striatum (Norton, C.S. (318) 323)

Microdialysis, in vivo
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; Noradrenaline; Frontal cortex; Synaptosomal uptake (Hughes, Z.A. (317) 83)

Dopamine; Ethanol; Hexamethonium; Mecamylamine; Nicotinic acetylcholine receptor (Blomqvist, O. (334) 149)

Microscopy, intravital
Rizatriptan; Meningeal artery, middle; CGRP (calcitonin gene-related peptide); Migraine (Williamson, D.J. (328) 61)

Microtubule assembly
Antidepressant; Desipramine; Microtubule-associated protein 2; Phosphorylation (Miyamoto, S. (333) 279)

Microtubule-associated protein 2
Antidepressant; Desipramine; Microtubule assembly; Phosphorylation (Miyamoto, S. (333) 279)

Microvascular leakage
Tryptase; Mast cell; Histamine; Heparin; Proteinase inhibitor; Histamine receptor antagonist (He, S. (328) 89)

PF-904; Airway; Airway, hyperreactivity; Eosinophil infiltration; Bronchus, human, isolated; Phosphodiesterase activity; Neutrophils, human; Superoxide anion generation; (Guinea pig) (Cortijo, J. (333) 69)

CCl_4-induced liver cirrhosis; Hepatorenal syndrome; Na^+ retention; Bradykinin B_2 receptor antagonist; HOE 140 (Icatibant) (Wirth, K.J. (337) 45)

Gastroduodenal ulceration; Gastroduodenal mucosa; Cysteamine; Testosterone; Sexual dimorphism; Sexual steroid; Microcirculation (László, F. (337) 275)

Microwave
Brain; Adenosine; Diadenosine polyphosphate; Adenine nucleotide; (Rat) (Delaney, S.M. (332) 35)

Micturition contraction
Bladder; Pelvic nerve; Periurethral muscle; Pudendal nerve; (Rat) (Kagitani, F. (332) 89)

Midazolam
Appetitive discrimination; Occasion setting; Amphetamine; Unconditioned drug effect; Conditioned drug effect (Maes, J.H.R. (319) 5)

Midbrain
Tyrosine hydroxylase; Aromatic L-amino acid decarboxylase; Dopamine receptor; Striatum (Cho, S. (323) 149)

Middle cerebral artery occlusion
MRI (magnetic resonance imaging); Ancrod; Cerebral ischemia; Hypertensive rat; Fibrinogen; Therapeutic window; (Delayed therapy) (Elger, B. (336) 7)

Mifepristone
Progesterone; Oestrogen; LH (luteinizing hormone); Adrenoceptor antagonist (Salicioni, A.M. (332) 283)

Migraine
Substance P; Tachykinin NK_1 receptor; Plasma extravasation; Pain (Seabrook, G.R. (317) 129)

5-$HT_{1B/1D}$ receptor agonist; Rizatriptan; Trigeminal nucleus caudalis; Electrophysiology (Cumberbatch, M.J. (328) 37)

Rizatriptan; Microscopy, intravital; Meningeal artery, middle; CGRP (calcitonin gene-related peptide) (Williamson, D.J. (328) 61)

Flunarizine; Nitric oxide (NO); Vasodilator nerve (Ayajiki, K. (329) 49)

Dura mater encephali; Arterial blood flow; Neurogenic inflammation; 5-HT_1 receptor agonist; Headache; (Rat) (Messlinger, K. (332) 173)

Migraine models
5-HT receptor pharmacology; Aminotetralin; Cerebrovascular regulation; Inflammation, neurogenic (Petty, M.A. (336) 127)

Migrating motor complex
Gastrointestinal motility; Force transducer; Cisapride; (Ferret) (Nagakura, Y. (321) 53)

Migration
Smooth muscle cell; Lipoxygenase; Proliferation (Nishio, E. (336) 267)

Mineralocorticoid
Glucocorticoid; Hippocampal slice; Patch clamp recording (Karst, H. (339) 17)

Mitogen-activated protein kinase
Zooxanthellatoxin-A; Tyrphostin 23; Platelet aggregation (Rho, M.-C. (319) 375)

α_1-Adrenoreceptor subtype; Cardiac myocyte, rat, neonatal; Phosphatidylinositol hydrolysis (Wenham, D. (339) 77)

Mitogen-activated protein kinase phosphatase 1 (MKP-1)
Beraprost sodium; Mesangial cell; cAMP (Togawa, M. (336) 291)

Mitogenesis
Coronary artery smooth muscle cell; Thromboxane A_2; PDGF (platelet-derived growth factor) (Grosser, T. (319) 327)

Mitogenic activity
Insulin analog; Insulin; Cardiomyocyte; Insulin-like growth factor receptor (Bähr, M. (320) 259)

Mitragynine
Antinociception; Noradrenergic system; α_2-Adrenoceptor; Serotonergic system; (Mouse) (Matsumoto, K. (317) 75)

MK-801
Conditioned preference; Reward; NMDA receptor; Glycine site; CGP 37849; CGP 40116; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (317) 191)

NMDA receptor; Calcium; Neuron; Uncompetitive; Neuroprotection (Black, M. (317) 377)

Polyamine; Putrescine; Spermidine; Spermine; NMDA (*N*-methyl-D-aspartate); Motor activity; Amphetamine; Theophylline; (Mouse) (Giménez-Llort, L. (318) 231)

NMDA receptor; Entorhinal cortex (Lindén, A.-M. (319) R1)

NMDA receptor; 7-Chlorokynurenic acid; Ifenprodil; Diazepam withdrawal; (Mouse) (Tsuda, M. (324) 63)

Zn^{2+} inhibition; NMDA receptor, binding; σ Receptor; Spinal cord; (Mouse) (Kovács, K.J. (324) 117)

Ethanol; NMDA/glycine receptor; L-701,324; Eliprodil; Drug discrimination; (Rat) (Kotlinska, J. (332) 1)

Catalepsy; Haloperidol; Muscimol (Kaur, S. (332) 153)

M100907; Dopamine receptor antagonist; Locomotion; Schizophrenia; (Mouse) (Martin, P. (335) 107)

MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo-(a,d)cyclohepten-5,10-imine maleate)
Adenosine receptor; Electroencephalogram; (Rat) (Popoli, P. (333) 143)

MK-801, LY 235959
DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]Deltorphin II; δ_1-/δ_2-opioid receptor agonist; NMDA receptor antagonist (Cao, Y.-J. (335) 161)

Mn^{2+}
Ca^{2+} channel, receptor-operated; Uterus, rat (Magraner, J. (326) 211)

Calyculin A; Ca^{2+}, cytosolic; Protein phosphatase; Protein phosphorylation; HL-60 cells (Leung, Y.-M. (331) 337)

Ileum; Smooth muscle; Ca^{2+} channel (Nasu, T. (333) 199)

Model
δ-Opioid receptor; Ligand binding thermodynamics; Pharmacophore (Maguire, P.A. (318) 505)

Molecular biology
Cocaine; Collagen; Myosin; Atrial natriuretic factor; Left ventricular hypertrophy; (Rat) (Besse, S. (338) 123)

Monoamine
GDNF (glial cell line-derived neurotrophic factor); Substantia nigra; Striatum; Dopamine; Parkinson's disease (Martin, D. (317) 247)

Monoamine transporter, vesicular; Dihydrotetrabenazine (Kilbourn, M. (331) 161)

Monoamine oxidase
3-Methoxytyramine; Wernicke-Korsakoff syndrome (Mousseau, D.D. (317) 263)

Monoamine oxidase B
Fluoxetine; Norfluoxetine; *N*-(6-[^{18}F]fluorohexyl)-*N*-methylpropargylamine (Mukherjee, J. (337) 111)

Monoamine oxidase inhibition
PET (positron emission tomography); 6-[^{18}F]L-DOPA (6-[^{18}F]L-3-4-dihydroxyphenylalanine); Catechol-*O*-methyltransferase inhibition; Dopamine turnover (Doudet, D.J. (334) 31)

Monoamine oxidase inhibitor
5-HT_{1A} receptor; WAY 100635; Dorsal raphe nucleus; Microdialysis; Extracellular recording (Sharp, T. (320) 15)

Monoamine transporter, vesicular
Dihydrotetrabenazine; Monoamine (Kilbourn, M. (331) 161)

Monoclonal antibody
Glycoprotein IIb/IIIa; Bleeding time; Platelet aggregation (Suzuki, K.-i. (336) 169)

Monocyte
Aceclofenac; Cyclooxygenase; Prostaglandin E_2; Polymorphonuclear leukocyte; Synovial cell (Yamazaki, R. (329) 181)

Lipopolysaccharide; cAMP; cGMP; Phosphodiesterase III inhibitor; Macrophage; Interleukin-10; TNF-α (tumor necrosis factor-α); Nitric oxide (NO) (Németh, Z.H. (339) 215)

Mononeuropathic rat
Neuropathic pain; Morphine; Tolerance; Opioid receptor agonist (Catheline, G. (318) 273)

Antinociception; CCK_B receptor antagonist; L-365,260; Morphine; Naloxone; Vocalization threshold; Struggle latency (Idänpään-Heikkilä, J.J. (325) 155)

Mononuclear blood cell
Steroid resistance; Corticosteroid; Cytokine; Asthma (Larsson, S. (334) 265)

Mononuclear cell
Anandamide; Palmitoylethanolamide; Tetrahydrocannabinol; Cannabinoid receptor; Cytokine; Immune response (Berdyshev, E.V. (330) 231)

Morphine
U-50,488; Reward; Ontogeny; (Rat) (Bolanos, C.A. (317) 1)

Analgesia; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Dynorphin; Nor-binaltorphimine; β-Funaltrexamine; DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly-ol^5]enkephalin) (Reche, I. (318) 11)

Neuropathic pain; Mononeuropathic rat; Tolerance; Opioid receptor agonist (Catheline, G. (318) 273)

Drug self-administration; Cocaine; κ-Opioid receptor; U50,488H; (Rat); (Mouse) (Kuzmin, A.V. (321) 265)

Fentanyl; Heroin; 6-Acetylmorphine; Reinforcement (Martin, T.J. (324) 141)

Antinociception; Mononeuropathic rat; CCK_B receptor antagonist; L-365,260; Naloxone; Vocalization threshold; Struggle latency (Idänpään-Heikkilä, J.J. (325) 155)

Clonidine; Nociception; Formalin test (Przesmycki, K. (337) 11)

Neurosteroid; Pregnenolone sulfate; Allopregnanolone; Progesterone; 4'-Chlordiazepam; Opiate tolerance; Opiate dependence (Reddy, D.S. (337) 19)

Analgesia; Clocinnamox; [^{3}H]DAMGO ([^{3}H][D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]-enkephalin); Opioid receptor binding; (Rat) (Paronis, C.A. (337) 27)

Conditioned place preference; Diabetes; Opioid receptor; Naloxonazine; Reinforcement (Kamei, J. (337) 137)

Adenosine receptor agonist; Adenosine receptor antagonist; Naloxone; Catalepsy; (Mouse) (Zarrindast, M.-R. (338) 11)

Morphine-analgesia
Neuropeptide FF; Receptors; Rat; Dorsal raphe nucleus; Parafascicular nucleus; Serotonin (Dupouy, V. (330) 129)

Morphine dependence
Morphine tolerance; Dizocilpine; Ketamine; CGP 39551 (DL-(*E*)-2-amino-4-methyl-5-phosphonopentanoate carboxy-ethylester) (González, P. (332) 257)

Morphine derivative
Cinnamoylamino group; β-Endorphin receptor; Analgesia; (Irreversible antagonist); (Mouse) (McLaughlin, J.P. (320) 121)

Morphine tolerance
Morphine dependence; Dizocilpine; Ketamine; CGP 39551 (DL-(*E*)-2-amino-4-methyl-5-phosphonopentanoate carboxy-ethylester) (González, P. (332) 257)

Morphine withdrawal
Blood pressure; Nitric oxide (NO) synthase inhibitor; 3-Bromo-7-nitro indazole; Aminoguanidine; *S*-Methyl-L-thiocitrulline; 7-Nitro indazole; Nitric oxide (NO) (Vaupel, D.B. (324) 11)

Mortality
Dantrolene; Nitric oxide (NO) synthase II; Lipopolysaccharide; Hemodynamic alteration (Wu, C.-C. (327) 17)

Motilin
Erythromycin; EM574; Receptor binding; (Rabbit) (Sato, F. (322) 63)

Motilin receptor; Gastric motility; Enteric nervous system (Van Assche, G. (337) 267)

Motilin receptor
Motilin; Gastric motility; Enteric nervous system (Van Assche, G. (337) 267)

Motor activity
Polyamine; Putrescine; Spermidine; Spermine; NMDA (*N*-methyl-D-aspartate); MK-801; Amphetamine; Theophylline; (Mouse) (Giménez-Llort, L. (318) 231)

Ibogaine; Noribogaine; 18-Methoxycoronaridine; Cocaine (Maisonneuve, I.M. (336) 123)

Motor coordination
Adenosine receptor; Antisense oligodeoxynucleotide (Phan, T.A. (323) R5)

Motor effect
PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal peptide); PACAP receptor; VIP receptor; Neuropeptide Y; Gastro-intestinal tract; Apamin (Ekblad, E. (334) 61)

Ca^{2+} channels; Dihydropyridine; Drug discrimination (Cohen, C. (336) 113)

Motor suppression
Conditioned fear stress; σ Receptor; Dopaminergic system; Nucleus accumbens; (Rat) (Kamei, H. (319) 165)

Motor system
GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzo-diazepine); Excitatory amino acid; Anticonvulsant action; Flumazenil (Kubová, H. (333) 17)

Motor test
Nimodipine, chronic; Metrifonate, acute; Water maze; Passive avoidance; Washout; Aged rat; Medial septum-lesioned rat (Riekkinen, M. (322) 1)

Mouse
Anxiety; Elevated plus-maze; Clozapine; L-745,870; L-741,742; Dopamine D_4 receptor; Chlordiazepoxide (Cao, B.-J. (335) 117)

Atipamezole; Medetomidine; Dopamine overflow; Dopamine metabolisms; Voltammetry, in vivo (Yavich, L. (339) 113)

Movement disorder
Glutamate; Na^+ channel blocker; Paroxysmal choreoathetosis (Richter, A. (332) 133)

MPTP-induced hemiparkinsonism
Talipexole; Pramipexole; Chloro-APB; SKF 82958; Dopamine D_1-like receptor agonist; Dopamine D_2-like receptor agonist; (Monkey) (Domino, E.F. (325) 137)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Apoptosis; DNA fragmentation; Nicotinamide (Mukherjee, S.K. (330) 27)

MRI (magnetic resonance imaging)
Ancrod; Cerebral ischemia; Hypertensive rat; Fibrinogen; Middle cerebral artery occlusion; Therapeutic window; (Delayed therapy) (Elger, B. (336) 7)

γ-MSH (γ-melanocyte-stimulating hormone) fragment
ACTH (adrenocorticotropic hormone) fragment; Blood pressure; Heart rate; Cerebral blood flow; Structure-activity relationship; (Rat) (Van Bergen, P. (318) 357)

MSH (melanocyte-stimulating hormone)
Melanocortin receptor subtype; Ligand binding (Schiöth, H.B. (319) 369)

MSOP ((*RS*)-α-methylserine-*O*-phosphate)
Metabotropic glutamate receptor; S-4C3H-PG ((*S*)-4-carbonyl-3-hydroxyphenylglycine); Drinking conflict test; Intrahippocampal injection (Chojnacka-Wójcik, E. (319) 153)

MTPG ((*RS*)-α-methyl-4-tetrazolylphenylglycine)
Metabotropic glutamate receptor; 1*S*,3*S*-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid); Excitatory postsynaptic potential; Depotentiation; CA1 area; Hippocampus; MCCG (α-methyl-(2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); AIDA ((*RS*)-1-aminoindan-1,5-dicarboxylic acid); MAP4 (α-methyl-L-2-amino-4-phosphonobutyrate) (Hölscher, C. (322) 155)

MTPG ((*R*,*S*)-α-methyl-4-tetrazolylphenylglycine)
mGlu receptor; Long-term potentiation; Hippocampus; PCCG-IV ((2*S*,1′*S*,2′*S*,3′*R*)-2-(2″-carboxy-3′-phenylcyclopropyl)glycine) (Huang, L. (332) 161)

Multidrug resistance
Renal clearance; Active secretion; Drug interaction; P-glycoprotein; Organic cation carrier (Masereeuw, R. (321) 315)

Multiple sclerosis
Experimental allergic encephalomyelitis; Fatty acid; α-Linolenic acid; Linolenic acid (Yehuda, S. (328) 23)

Muscarine
Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium) (Nagayama, T. (327) 135)

Muscarinic acetylcholine receptor agonist
Bisquaternary allosteric antagonist (Lanzafame, A. (321) 399)

Muscarinic acetylcholine receptor-operated K^+ current
ATP, extracellular; Atrial cell; Purinoceptor; Action potential duration (Hara, Y. (324) 295)

Muscarinic acetylcholine receptor
Nitric oxide (NO) synthase; Nitric oxide (NO); Neuronal; Potentiation; (Intact cell) (Cuadra, A.E. (334) 107)

Muscarinic receptor
5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Galanin; Hypothermia; Acetylcholine (Patel, S. (317) 197)

$[Ca^{2+}]_i$ transient; Electrical stimulation; Na^+-Ca^{2+} exchange; Carbachol (Wang, H.-X. (319) 91)

Muscarinic receptor subtype; Placenta; (Human) (Pavía, J. (320) 209)

Ciliary muscle, bovine; Desensitization; Protein kinase C (Daniele, E. (330) 247)

Autonomic nerve; Nitric oxide (NO); Enteric nervous system (Iversen, H.H. (331) 213)

Muscarinic receptor, m2 subtype; Sf9 cells; Covalent labelling; Aryldiazonium salt (Weill, C. (333) 269)

Xanomeline; Alzheimer's disease (Christopoulos, A. (334) R3)

Dynorphin; Substance P; Enkephalin; Acetylcholine; Dopamine; Amphetamine; Nucleus accumbens; Caudoputamen; Behavior (Wang, J.Q. (334) 43)

McN-A-343; Operational model; Allosteric interaction (Christopoulos, A. (339) 153)

Halothane; Ethanol; Protein kinase C; *Xenopus* oocyte (Minami, K. (339) 237)

Muscarinic M_1 receptor
Carbachol; Blood pressure; Amygdala, central nucleus of; (Rat) (Aslan, N. (333) 63)

Muscarinic M_2 receptor; Scopolamine; Pirenzepine; Methoctramine; Alzheimer's disease; (Delay-dependent and -independent); (% correct choice) (Aura, J. (333) 129)

Muscarinic M_2 receptor; Muscarinic M_3 receptor; N^G-nitro-L-arginine methyl ester (L-NAME); N^G-nitro-L-arginine; Atropine; Gallamine; Pirenzepine (Koss, M.C. (335) 199)

Muscarinic M_2 receptor
Muscarinic M_1 receptor; Scopolamine; Pirenzepine; Methoctramine; Alzheimer's disease; (Delay-dependent and -independent); (% correct choice) (Aura, J. (333) 129)

Antibody; Peptide; Inotropic effect; Papillary muscle (Skomedal, T. (333) 169)

Muscarinic M_1 receptor; Muscarinic M_3 receptor; N^G-nitro-L-arginine methyl ester (L-NAME); N^G-nitro-L-arginine; Atropine; Gallamine; Pirenzepine (Koss, M.C. (335) 199)

Muscarinic M_3 receptor
Muscarinic M_4 receptor; Gallbladder; (Agonist); (Antagonist); (Guinea pig) (Eltze, M. (332) 77)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; N^G-nitro-L-arginine methyl ester (L-NAME); N^G-nitro-L-arginine; Atropine; Gallamine; Pirenzepine (Koss, M.C. (335) 199)

Muscarinic M4 receptor
Clozapine; Neuroleptic, atypical; Neuroleptics, typical; cAMP; Chinese hamster ovary cell; Striatum, rat (Zeng, X.P. (321) 349)

Muscarinic M_3 receptor; Gallbladder; (Agonist); (Antagonist); (Guinea pig) (Eltze, M. (332) 77)

Muscarinic M_2 receptor, prejunctional
Vagus nerve stimulation; Receptor dysfunction; Muscarinic receptor antagonist; Allergic reaction, early, late; Bronchial hyperresponsiveness; (Conscious, unrestrained guinea pig) (Ten Berge, R.E.J. (318) 131)

Muscarinic receptor agonist
Salivary gland; Sjögren's syndrome; AF-102B (Masunaga, H. (339) 1)

Muscarinic receptor antagonist
Vagus nerve stimulation; Muscarinic M_2 receptor, prejunctional; Receptor dysfunction; Allergic reaction, early, late; Bronchial hyperresponsiveness; (Conscious, unrestrained guinea pig) (Ten Berge, R.E.J. (318) 131)

Urinary bladder contraction; Salivation; Muscarinic receptor subtype; (Guinea pig); (Cat); (Human) (Nilvebrant, L. (327) 195)

Muscarinic receptor, m2 subtype
Muscarinic receptor; Sf9 cells; Covalent labelling; Aryldiazonium salt (Weill, C. (333) 269)

Muscarinic receptor subtype
Muscarinic receptor; Placenta; (Human) (Pavía, J. (320) 209)

Urinary bladder contraction; Salivation; Muscarinic receptor antagonist; (Guinea pig); (Cat); (Human) (Nilvebrant, L. (327) 195)

Muscimol
Melanotroph; $GABA_A$ receptor; $GABA_A$ receptor antagonist; Bicuculline; $GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; CGP 35348; Cytosolic free Ca^{2+}; Fura-2 (Shibuya, I. (321) 241)

Catalepsy; Haloperidol; MK 801 (Kaur, S. (332) 153)

Muscle contraction
Tranilast; Restenosis; Angioplasty (Ihara, T. (329) 43)

Muscle relaxant
NK433; Spinal reflex; Active metabolite (Sakitama, K. (337) 175)

Muscle relaxation
β-Adrenoceptor; β_3-Adrenoceptor; BRL37344A, BRL35135A; Taenia caecum, guinea pig (Koike, K. (334) 217)

Mustard oil
Neurogenic inflammation; Plasma extravasation; Ear oedema; Capsaicin; SR 140333 (Inoue, H. (333) 231)

Mutagenesis, site-directed
Semliki Forest virus system; Tachykinin NK_1 receptor; Binding assays; Functional coupling (Lundstrom, K. (337) 73)

Mutation
$GABA_A$ receptor; α_1 subunit; Radioligand binding; Electrophysiology (Westh-Hansen, S.E. (329) 253)

Myeloperoxidase
Propranolol; Butoxamine; Metoprolol; Neutrophil; Prostaglandin E_2 (Kaan, S.K. (317) 115)

Myeloperoxidase activity
Creatine kinase activity; Neutrophil adherence; Interleukin-1β; Neutrophil accumulation (Hayward, R. (334) 157)

Myenteric plexus
Intestine; Ganglion; Enteric nervous system; Histamine; cAMP; Adenylate cyclase; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Signal transduction (Xia, Y. (320) 95)

Myenteric plexus-longitudinal muscle preparation, guinea-pig small intestine
Cannabinoids; Cannabinoid CB_1 receptors; Cannabinoid CB_2 receptors; SR141716A; Vas deferens, mouse (Griffin, G. (339) 53)

Myocardial cell, single
Doxorubicin; Cardiotoxicity; Cell contraction; Ca^{2+} concentration, intracellular (Temma, K. (322) 235)

Myocardial contractility
Endotoxin; Nitric oxide (NO) synthase; Dexamethasone; β-Adrenoceptor; Mercaptoethylguanidine (Sun, X. (320) 29)

Myocardial ischaemia
Adenosine; Coronary artery disease; Lactate; Ventricular function (De Jonge, R. (337) 41)

Myocardial ischaemia–reperfusion injury
17β-oestradiol; ICAM-1 (intercellular adhesion molecule-1); TNF-α (tumor necrosis factor-α) (Squadrito, F. (335) 185)

Myocardial ischemia
Nicotine; N^G-Nitro-L-arginine (LNNA); L-Arginine (L-Arg) (Koley, J. (325) 181)

Glibenclamide (glyburide); K^+_{ATP} channel; Cardiac arrhythmia; Adenosine release (Bernauer, W. (326) 147)

Myocardial ischemia, myocardial stunning
Adenosine; Myocardial ischemia, reperfusion injury; Coronary vessel (Kurz, M.A. (322) 211)

Myocardial ischemia, reperfusion injury
Adenosine; Myocardial ischemia, myocardial stunning; Coronary vessel (Kurz, M.A. (322) 211)

Myocardium
Endotoxin; EDHF (endothelium-dependent hyperpolarizing factor); Nitric oxide (NO) (Kristof, A.S. (328) 69)

α-Adrenoceptors; β-Adrenoceptors; K^+ channels ATP-sensitive; Forskolin (Kocić, I. (332) 65)

Myocardium, rabbit
α_1-Adrenoceptor, subtype; Endogenous noradrenaline; WB4101; Chlorethylclonidine; Positive inotropic action (Hattori, Y. (329) 165)

Myocardium, stunned
Y-26763; Ischemia; Reperfusion; ATP-sensitive K^+ channel (Fukunari, A. (323) 197)

Myoclonic jerking
Dopamine 'D_1-like' receptor; Dopamine 'D_2-like' receptor; D_1/D_2 interaction; LY 270411; BW 737C; SCH 23390; Grooming behavior; Vacuous chewing; (Rat) (Deveney, A.M. (317) 175)

Myocyte
l-cis-Diltiazem; *d-cis*-Diltiazem; Veratridine; Ca^{2+} overload; Na^+ overload; (Rat) (Itogawa, E. (317) 401)

Levosimendan; $[Ca^{2+}]_i$; (Guinea pig) (Lancaster, M.K. (339) 97)

Myogenic response
Pressure-induced contraction; Cerebral artery, rat; Tyrosine kinase inhibitor; Herbimycin A; Genistein (Masumoto, N. (330) 55)

Myorelaxant agent
Glycine receptor, strychnine-sensitive; [^{3}H]Strychnine binding; Spinal cord, rat; Autoradiography; Thiocolchicoside (Cimino, M. (318) 201)

Myosin
Cocaine; Molecular biology; Collagen; Atrial natriuretic factor; Left ventricular hypertrophy; (Rat) (Besse, S. (338) 123)

Myosin heavy chain
Cardiac remodeling; Nitric oxide (NO); Collagen (Takaori, K. (322) 59)

N-3389
5-HT_3 receptor antagonist; 5-HT_4 receptor antagonist; Antiemetic effect; Abdominal afferent vagus nerve activity; (Ferret) (Minami, M. (321) 333)

Na^+
RX821002 (2-methoxyidazoxan); α_2-Adrenoceptor subtype; Gpp(NH)p (Callado, L.F. (332) 109)

Na^+ and Cl^- unidirectional flux
Guanylin; Intestine; Ion transport; STa (heat-stable enterotoxin of *Escherichia coli*); VIP (vasoactive intestinal peptide) (Volant, K. (328) 217)

Na^+/Ca^{2+} exchange
HOE642; Na^+/H^+ exchange; Arrhythmia ischemia; Arrhythmia reperfusion; Digitalis arrhythmia (Xue, Y.X. (317) 309)

Ca^{2+}, intracellular; Heart failure; cAMP (Miao, L. (321) 201)

Na^+ channel
HEK293 cell; Ca^{2+} channel; NNC 09-0026; CNS 1237; SB 201823-A; NS 649; Riluzole; Cerebral ischaemia (O'Neill, M.J. (332) 121)

Aconitum alkaloid; Toxicity; Antinociception (Friese, J. (337) 165)

Na^+-Ca^{2+} exchange
Muscarinic receptor; $[Ca^{2+}]_i$ transient; Electrical stimulation; Carbachol (Wang, H.-X. (319) 91)

Na^+ channel blocker
Glutamate; Movement disorder; Paroxysmal choreoathetosis (Richter, A. (332) 133)

Na^+ current
Patch clamp, whole-cell; K^+ current; KC8851; Open channel blockade (McLarnon, J.G. (339) 279)

Na^+ depletion
Renovascular hypertension; Renal failure, acute; Angiotensin converting enzyme inhibition; Angiotensin AT_1 receptor antagonists, non-peptide (Abdi, A. (331) 185)

Na^+ excretion
Non-steroidal anti-inflammatory drug; Kidney; Circulation; Prostanoid; Plasma renin activity; Cytochrome *P*-450 activity (Kramp, R.A. (330) 165)

Na^+, external
Ca^{2+} release; P_2 purinoceptor; Parotid acinar cell (Fukushi, Y. (336) 89)

Na^+/H^+ exchange
HOE642; Na^+/Ca^{2+} exchange; Arrhythmia ischemia; Arrhythmia reperfusion; Digitalis arrhythmia (Xue, Y.X. (317) 309)

Na^+–H^+ exchange
Cariporide (HOE642); Arrhythmias; Ischemia; Reperfusion (Aye, N.N. (339) 121)

Na^+,K^+-ATPase
Na^+,K^+-ATPase, α-subunit; Hypertension; Spontaneously hypertensive rat (SHR); Ca^{2+} channel blocker; Vasodilator (Liu, X. (327) 151)

Endotoxin; Neostigmine; Neurotransmission; N^G-nitro-L-arginine (Liu, S.-H. (333) 241)

Na^+,K^+-ATPase, α-subunit
Na^+,K^+-ATPase; Hypertension; Spontaneously hypertensive rat (SHR); Ca^{2+} channel blocker; Vasodilator (Liu, X. (327) 151)

Na^+/K^+ ATPase isoform
Bufadienolide; Na^+/K^+ pump; Dorsal root ganglion cell; Cardiac cell (Van der Walt, J.J. (329) 201)

Na^+/K^+ pump
Bufadienolide; Dorsal root ganglion cell; Cardiac cell; Na^+/K^+ ATPase isoform (Van der Walt, J.J. (329) 201)

Na^+ overload
l-cis-Diltiazem; *d-cis*-Diltiazem; Veratridine; Ca^{2+} overload; Myocyte; (Rat) (Itogawa, E. (317) 401)

Na^+ pump
Dopamine D_2-like receptor; Proximal tubule; Kidney; (Rat) (Hussain, T. (321) 259)

Na^+ retention
CCl_4-induced liver cirrhosis; Hepatorenal syndrome; Microvascular leakage; Bradykinin B_2 receptor antagonist; HOE 140 (Icatibant) (Wirth, K.J. (337) 45)

NADPH oxidase
Broussochalcone A; Neutrophil, rat; Respiratory burst; Inositol trisphosphate; Ca^{2+} concentration, intracellular; Protein kinase C (Wang, J.-P. (320) 201)

Neutrophil; Phenylarsine oxide; Inflammation; NADPH oxidase inhibitor; Anti-inflammatory drug (Roussin, A. (322) 91)

NADPH oxidase inhibitor
Neutrophil; NADPH oxidase; Phenylarsine oxide; Inflammation; Anti-inflammatory drug (Roussin, A. (322) 91)

Naloxonazine
Conditioned place preference; Diabetes; Opioid receptor; Morphine; Reinforcement (Kamei, J. (337) 137)

Naloxone
Antinociception; Mononeuropathic rat; CCK_B receptor antagonist; L-365,260; Morphine; Vocalization threshold; Struggle latency (Idänpään-Heikkilä, J.J. (325) 155)

Morphine; Adenosine receptor agonist; Adenosine receptor antagonist; Catalepsy; (Mouse) (Zarrindast, M.-R. (338) 11)

Naltriben
δ-Opioid receptor; NG108-15 cell; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin); BNTX (7-benzylidenenaltrexone) (Ho, B.Y. (319) 109)

Nociception, formalin-induced; δ_1-Opioid receptor; 7-Benzylidenenaltrexone; Diabetes; (Mouse) (Kamei, J. (326) 31)

Naltriben, diabetes
(−)-TAN-67; (+)-TAN-67; Antinociception; δ-Opioid receptor; 7-Benzylidenenaltrexone (Kamei, J. (322) 27)

L-nitro-arginine methyl ester (L-NAME)
Angiotensin II; Enalapril; Nitric oxide (NO); Stroke (Ahmad, S. (333) 39)

***N*-nitro-L-arginine methyl ester (L-NAME)**
Vas deferens, rat; Nitric oxide (NO); L-Arginine; Sodium nitroprusside; (Neurotransmission) (Ventura, S. (334) 87)

N^G-nitro-L-arginine methyl ester (L-NAME)
Muscarinic M_1 receptor; Muscarinic M_2 receptor; Muscarinic M_3 receptor; N^G-nitro-L-arginine; Atropine; Gallamine; Pirenzepine (Koss, M.C. (335) 199)

Nitric oxide (NO); Colon; Inflammation; Nitric oxide (NO) synthase, constitutive; Nitric oxide (NO) synthase, inducible (Kiss, J. (336) 219)

NANC (non-adrenergic non-cholinergic), inhibitory
Adenosine; Histamine; Airway; Lipooxygenase-product; (Guinea pig) (Nieri, P. (331) 205)

NANC (non-adrenergic non-cholinergic) innervation
Noradrenergic innervation; Nitrergic innervation; Prostate gland; (Rat); (Guinea pig); (Pig); (Rabbit) (Najbar-Kaszkiel, A.T. (337) 251)

NANC (non-adrenergic non-cholinergic) transmission
Drenergic transmission; Anococcygeus muscle; Neuropeptide Y (Iravani, M.M. (338) 75)

α-Naphthylthiourea
Nitric oxide (NO); L-Arginine; D-Arginine; N^G-Nitro-L-arginine methyl ester; Pulmonary oedema (Sipahi (Yılmaz), E. (321) 45)

Natural drug
Anthraquinone; Intestinal secretion; Nitric oxide (NO); Glucocorticoid; Laxative (Izzo, A.A. (323) 93)

Natural killer cell
Macrophage; Enkephalin; Endorphin; Cytotoxicity (Kowalski, J. (326) 251)

Natural product
Ca^{2+}-entry block; Ca^{2+} current; Ca^{2+}-activated K^+ channel; Excitation–contraction coupling (Suarez-Kurtz, G. (335) 153)

Nausea
Radioligand binding; Oral bioavailability; $t_{1/2}$; Brain penetration; Vomiting; Retching; Ondansetron (Singh, L. (321) 209)

NBQX (6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione)
AMPA receptor; AMPA receptor antagonism; Neuroprotection; GYKI 53655 (Kovács, A.D. (331) 93)

5′-*N*-ethylcarboxamidoadenosine (NECA)
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 2-hexynyl-5′-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

Necrosis
Hydrogen peroxide; L-Histidine; DNA double-strand breaks; Pulsed field gel electrophoresis; Apoptosis (Palomba, L. (318) 167)

N1E-115 mouse neuroblastoma cell
5-HT_3 receptor; Ligand-gated ion channel; *Xenopus laevis* oocyte; (Partial agonist); (Antagonist) (Van Hooft, J.A. (322) 229)

Neocortical slice, rat
Baclofen; $GABA_B$ receptor agonist; Thienyl baclofen analog; 2-Hydroxysaclofen (Ong, J. (329) 133)

Neonatal mouse
Respiratory network, central; Serotonergic regulation; 5-HT (5-hydroxytryptamine, serotonin); (In vitro) (Hilaire, G. (329) 115)

Neonatal rat
Behavioral sensitization; Cocaine; Development, ontogeny; Preweanling rat (Tirelli, E. (328) 103)

Neonatal rat spinal cord
Glutamate receptor; Novel antagonist (Thomas, N.K. (338) 111)

Neostigmine
Acetylcholine; Dopamine; Dopamine D_1 receptor; Dopamine D_2 receptor; Microdialysis; Striatum (DeBoer, P. (317) 257)

CGRP (calcitonin gene-related peptide) release; Acetylcholine release; Phrenic nerve-diaphragm muscle preparation (Kimura, I. (330) 123)

Amylin; Ulcer; CGRP (calcitonin gene-related peptide), human; Capsaicin; Domperidone (Clementi, G. (332) 209)

Endotoxin; Neurotransmission; Na^+, K^+-ATPase; N^G-nitro-L-arginine (Liu, S.-H. (333) 241)

Arterial blood pressure; c-Fos; Cholinergic system, central (Li, J. (337) 227)

Nerve blood flow
Streptozotocin-diabetic rat; ACTH-(4–9) analogue; Org 2766; Adrenergic responsiveness; Macrocirculatory blood flow (Van Buren, T. (318) 73)

Adrenergic nerve; Diabetes mellitus; Noradrenaline; Sciatic nerve, rat (Vo, P.A. (329) 147)

Nerve conduction
Blood flow; L-Carnitine; Nitric oxide (NO); Diabetic rat (Cameron, N.E. (319) 239)

Network
Hippocampus; GABA (γ-aminobutyric acid) (Khalilov, I. (319) R5)

Neuroactive steroid
Pregnanolone; Neurosteroid; Drug discrimination; Behavior (Vanover, K.E. (327) 97)

GABA (γ-aminobutyric acid); Pregnanolone; Tetrahydrodeoxycorticosterone; Dehydroepiandrosterone; Pregnenolone sulfate; Pituitary melanotrope cell; Patch-clamp (Le Foll, F. (331) 303)

Neuroamine
$P2X_2$ purinoceptor; pH dependence; Adenosine; Zn^{2+}; Cd^{2+} (Nakazawa, K. (337) 309)

Neuroblastoma
Opiate receptor; δ-Opioid receptor, subtype; SH-SY5Y (Toll, L. (323) 261)

Neurodegeneration
Anethole dithiolethione; Glutathione; Hydrogen peroxide; Oxidative stress; Astrocyte (Drukarch, B. (329) 259)

Neurodegenerative disease
NMDA receptor antagonist; Neurotoxicity (Menniti, F. (331) 117)

Neurodegenerative disorder
Astrocyte; Excitotoxicity; Glycine site; NMDA receptor; Kynurenic acid; Quinolinic acid (Wu, H.-Q. (319) 13)

Neurogenic inflammation
Dura mater encephali; Arterial blood flow; 5-HT_1 receptor agonist; Migraine; Headache; (Rat) (Messlinger, K. (332) 173)

Mustard oil; Plasma extravasation; Ear oedema; Capsaicin; SR 140333 (Inoue, H. (333) 231)

Neurogenic oedema
Sensory nerves; Capsaicin; *Phoneutria nigriventer* venom; Tachykinin NK_1 receptor agonist (Costa, S.K.P. (339) 223)

Neurohypophyseal hormone analog
Vasopressin; Oxytocin; Factor VIII (F-VIII); Antihemophilic factor; Blood clotting; Plasminogen activator; Dose–response analysis; Time response; Non-monotonic profile (Neuenschwander, S. (323) 205)

Neuroimmunobiology
VIP (vasoactive intestinal peptide); Peritoneal macrophage; Adenylyl cyclase; VIP receptor antagonist; VIP receptor; Propranolol; Isoproterenol (Pozo, D. (321) 379)

Neurokinin A
Tachykinin; Bronchoconstriction; Substance P; Mast cell; 5-HT (5-hydroxytryptamine, serotonin); Tachykinin NK_1 receptor (Joos, G.F. (338) 259)

Neuroleptic
Dopamine D_3 receptor; c-*fos*; Hybridization in situ; (Rat) (Hurley, M.J. (318) 283)

Neuroleptic, atypical
Clozapine; Muscarinic m4 receptor; Neuroleptic, typical; cAMP; Chinese hamster ovary cell; Striatum, rat (Zeng, X.P. (321) 349)

Neuroleptic, typical
Clozapine; Muscarinic m4 receptor; Neuroleptic, atypical; cAMP; Chinese hamster ovary cell; Striatum, rat (Zeng, X.P. (321) 349)

Neuromedin B
Gastrin-releasing peptide; Smooth muscle contraction (Ladenheim, E.E. (319) 245)

Neuromuscular junction
Nicotinic receptor antagonist; Adenosine; Acetylcholine release (Prior, C. (327) 103)

Neuron
NMDA receptor; Calcium; Uncompetitive; Neuroprotection; MK-801 (Black, M. (317) 377)

GABA (γ-aminobutyric acid) homeostasis; GABA transporter; Glia; Epilepsy; Microdialysis (Juhász, G. (331) 139)

Neuronal
Nitric oxide (NO) synthase; Nitric oxide (NO); Potentiation; Muscarinic acetylcholine receptor; (Intact cell) (Cuadra, A.E. (334) 107)

Neuronal damage
Cerebral ischemia; Adenosine kinase inhibitor (Jiang, N. (320) 131)

Defibrotide; Cerebral ischemia; EEG (electroencephalographic) spectral power; Memory (Sala, M. (328) 143)

Neuronal injury
ACPC (1-aminocyclopropanecarboxylic acid); Neuroprotection; NMDA receptor; Toxicity; Glycine; Excitatory amino acid (Lin, Y. (318) 491)

1-Aminocyclopropanecarboxylic acid; Neuroprotection; Glutamate toxicity; Glycine receptor; NMDA receptor complex (Lin, Y. (338) 289)

Neuronal nicotinic receptor
ω-Toxin; Ca^{2+} channel; Ca^{2+} channel antagonist; Chromaffin cell (Villarroya, M. (320) 249)

Neuropathic pain
Mononeuropathic rat; Morphine; Tolerance; Opioid receptor agonist (Catheline, G. (318) 273)

Allodynia; Antinociception; Tail-flick test; Behavior; Electroshock test, maximal; Lamotrigine; Felbamate; Gabapentin (Hunter, J.C. (324) 153)

Neuropeptide FF
Receptors; Morphine-analgesia; Rat; Dorsal raphe nucleus; Parafascicular nucleus; Serotonin (Dupouy, V. (330) 129)

Intestinal motility; Fever; Endotoxin; PAF (platelet-activating factor) (Million, M. (334) 67)

Neuropeptide Y-(2–36)
Neuropeptide Y; SK-N-MC cell; SK-N-BE(2) cell; Autoradiography (Schober, D.A. (318) 307)

Neuropeptide Y
Neuropeptide Y-(2–36); SK-N-MC cell; SK-N-BE(2) cell; Autoradiography (Schober, D.A. (318) 307)

Pancreatic polypeptide; Peptide YY; [Leu^{31},Pro^{34}]Peptide YY (Gehlert, D.R. (318) 485)

Pancreatic polypeptide; Neuropeptide Y receptor, Y_4 and Y_5 subtype (Trinh, T. (318) R1)

Dopamine release; Dopamine D_2 receptor; G_i-protein; Striatum; Spontaneously hypertensive rat (SHR) (Tsuda, K. (321) 5)

Capsaicin-sensitive; Resiniferatoxin; Saphenous nerve; Vasoconstriction; Vasodilation; Laser-Doppler flowmetry (Pintér, E. (325) 57)

Bioassay; Saphenous vein, dog; Neuropeptide Y Y_2 receptor (Pheng, L.H. (327) 163)

Nitric oxide (NO) pharmacology; PC12 cells (Dötsch, J. (331) 313)

Radioligand binding; Neuropeptide Y_1 receptor; Neuropeptide Y_2 receptor; (Human) (Statnick, M.A. (332) 299)

Ileum; Neuropeptide Y Y_5 receptor; (Rabbit) (Pheng, L.H. (333) R3)

PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal peptide); PACAP receptor; VIP receptor; Motor effect; Gastrointestinal tract; Apamin (Ekblad, E. (334) 61)

Receptor subtype; Contraction; Cardiomyocyte, ventricular (McDermott, B.J. (336) 257)

Drenergic transmission; Anococcygeus muscle; NANC (non-adrenergic non-cholinergic) transmission (Iravani, M.M. (338) 75)

Neuropeptide Y, Neuropeptide Y Y_1 receptor
Rat brain; BIBP3226; Radioligand binding (Vanderheyden, P.M.L. (331) 275)

Neuropeptide Y receptor
BIBP 3226; Neuropeptide Y Y_1 receptor; Sympathetic stimulation; Mesenteric artery, human, inferior; Mesenteric vein, human, inferior (Racchi, H. (329) 79)

Neuropeptide Y_1 receptor
Radioligand binding; Neuropeptide Y; Neuropeptide Y_2 receptor; (Human) (Statnick, M.A. (332) 299)

Neuropeptide Y_2 receptor
Radioligand binding; Neuropeptide Y; Neuropeptide Y_1 receptor; (Human) (Statnick, M.A. (332) 299)

Neuropeptide Y receptor antagonist
GW1229; Neuropeptide Y Y_1 receptor; Microcirculation hamster (Bitran, M. (319) 43)

Neuropeptide Y receptor, Y_4 and Y_5 subtype
Neuropeptide Y; Pancreatic polypeptide (Trinh, T. (318) R1)

Neuropeptide Y receptor, Y_1 subtype
Neuropeptide Y receptor, Y_2 subtype; Cation regulation (Parker, M.S. (318) 193)

Neuropeptide Y receptor, Y_2 subtype
Neuropeptide Y receptor, Y_1 subtype; Cation regulation (Parker, M.S. (318) 193)

Neuropeptide Y Y_1 receptor
BIBP3226; Elevated plus-maze (Kask, A. (317) R3)

Neuropeptide Y receptor antagonist; GW1229; Microcirculation hamster (Bitran, M. (319) 43)

BIBP 3226; Neuropeptide Y receptor; Sympathetic stimulation; Mesenteric artery, human, inferior; Mesenteric vein, human, inferior (Racchi, H. (329) 79)

Binding; Gene expression; Antisense oligonucleotide; Electroporation (Hänze, J. (330) 87)

Neuropeptide Y Y_2 receptor
Neuropeptide Y; Bioassay; Saphenous vein, dog (Pheng, L.H. (327) 163)

Neuropeptide Y Y_5 receptor
Ileum; Neuropeptide Y; (Rabbit) (Pheng, L.H. (333) R3)

Neuroprotection
Flupirtine; Triamnopyridine; hNT neuron; Bcl-2; Apoptosis; Glutathione (Perovic, S. (317) 157)

NMDA receptor; Calcium; Neuron; Uncompetitive; MK-801 (Black, M. (317) 377)

ACPC (1-aminocyclopropanecarboxylic acid); NMDA receptor; Toxicity; Neuronal injury; Glycine; Excitatory amino acid (Lin, Y. (318) 491)

AMPA receptor; AMPA receptor antagonism; GYKI 53655; NBQX (6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione) (Kovács, A.D. (331) 93)

DY-9760e; W-7; Calmodulin antagonist; Cytotoxicity (Sugimura, M. (336) 99)

Ischemia; Inward current; Outward current; Ion channel; Patch clamp (Suma, C. (336) 283)

Penumbra; Glutamate; Taurine; Lubeluzole; Swelling; Microdialysis (Scheller, D.K.A. (338) 243)

1-Aminocyclopropanecarboxylic acid; Glutamate toxicity; Neuronal injury; Glycine receptor; NMDA receptor complex (Lin, Y. (338) 289)

Neuroprotective
Ca^{2+} channel, cloned; Ca^{2+} channel antagonist; T-477 ((*R*)-(+)-2-(4-chlorophenyl)-2,3-dihydro-4-diethylaminoacetyl-4H-1,4-benzothiazine); Oocyte; (*Xenopus*) (Kobayashi, T. (332) 313)

Neurosteroid
Anxiety; Conflict; 3α-Hydroxy-5α-pregnan-20-one; $GABA_A$ receptor; Benzodiazepine (Brot, M.D. (325) 1)

Pregnanolone; Neuroactive steroid; Drug discrimination; Behavior (Vanover, K.E. (327) 97)

Morphine; Pregnenolone sulfate; Allopregnanolone; Progesterone; 4'-Chlordiazepam; Opiate tolerance; Opiate dependence (Reddy, D.S. (337) 19)

Neurotensin
Colon; Ca^{2+} channel, L-type; Mechanical activity (Mulè, F. (319) 269)

Prostacyclin; Umbilical vein endothelial cell, human; Hematocrit (Schaeffer, P. (323) 215)

Amphetamine; [D-Tyr^{11}]Neurotensin; Sensitization (Rompré, P.-P. (328) 131)

Haloperidol; Dopamine; Striatum; Nucleus accumbens (Huang, W. (332) 15)

Endopeptidase 3.4.24.15; Phosphinic inhibitor; Analgesia; (Mouse) (Vincent, B. (334) 49)

[D-Tyr^{11}]Neurotensin
Amphetamine; Neurotensin; Sensitization (Rompré, P.-P. (328) 131)

Neurotoxicity
MDA (3,4-Methylenedioxyamphetamine); MDMA (3,4-Methylenedioxymethamphetamine); α-Methyldopamine; Glutathione; 5-HT (5-hydroxytryptamine, serotonin) (Miller, R.T. (323) 173)

Nitric oxide (NO); NMDA (*N*-methyl-D-aspartate); N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Retina (Morizane, C. (328) 45)

NMDA receptor antagonist; Neurodegenerative disease (Menniti, F. (331) 117)

Neurotransmission
CGRP (calcitonin gene-related peptide); Electric field stimulation; Glibenclamide; K^+ channel, ATP-sensitive; Vas deferens, rat (Huang, Y. (327) 209)

ATP; Dopamine D_1 receptor; α_2-Adrenoceptor; Vas deferens, guinea-pig (Furukawa, T. (328) 229)

Endotoxin; Neostigmine; Na^+, K^+-ATPase; N^G-nitro-L-arginine (Liu, S.-H. (333) 241)

Ca^{2+} channel, voltage-dependent; ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Conotoxin SVIB; ω-Agatoxin IVA (Tran, S. (335) 31)

Neurotransmitter release
Ascomycin; FK506-binding protein; Smooth muscle contraction; Tachykininergic nerve; Iris sphincter muscle, rabbit (Kageyama, M. (333) 223)

Neutrophil
Propranolol; Butoxamine; Metoprolol; Myeloperoxidase; Prostaglandin E_2 (Kaan, S.K. (317) 115)

Tracheal epithelial cell, guinea pig; Eosinophil; Arachidonic acid (Prié, S. (317) 343)

Abruquinone A; Inositol phosphate; Phospholipase C; Ca^{2+} concentration, intracellular (Wang, J.-P. (319) 131)

Substance P; CGRP (calcitonin gene-related peptide); Superoxide (Tanabe, T. (321) 137)

NADPH oxidase; Phenylarsine oxide; Inflammation; NADPH oxidase inhibitor; Anti-inflammatory drug (Roussin, A. (322) 91)

Cell locomotion; Wortmannin; Phosphatidylinositol 3-kinase; Actin, α-Actinin (Niggli, V. (335) 43)

Neutrophil, rat
Broussochalcone A; Respiratory burst; Inositol trisphosphate; Ca^{2+} concentration, intracellular; Protein kinase C; NADPH oxidase (Wang, J.-P. (320) 201)

Norathyriol; Respiratory burst; Aggregation; Protein kinase C; Phorbol 12-myristate 13-acetate; Translocation (Wang, J.-P. (336) 81)

Neutrophil, human
PF-904; Airway; Airway, hyperreactivity; Eosinophil infiltration; Microvascular leakage; Bronchus, human, isolated; Phosphodiesterase activity; Superoxide anion generation; (Guinea pig) (Cortijo, J. (333) 69)

Neutrophil accumulation
Creatine kinase activity; Neutrophil adherence; Myeloperoxidase activity; Interleukin-1β (Hayward, R. (334) 157)

Neutrophil adherence
Creatine kinase activity; Myeloperoxidase activity; Interleukin-1β; Neutrophil accumulation (Hayward, R. (334) 157)

Neutrophil elastase
Airway epithelium; Inflammation; Airway remodelling; Secretory leukocyte protease inhibitor (Marchand, V. (336) 187)

FK706; Elastase inhibitor; Pulmonary emphysema; Hemorrhage; Edema (Shinguh, Y. (337) 63)

NG108-15 cell
δ-Opioid receptor; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin); BNTX (7-benzylidenenaltrexone); Naltriben (Ho, B.Y. (319) 109)

Membrane potential; Antiepileptics; Cromakalim; Glibenclamide; Patch-clamp electrophysiology; hNT neuron; Cortical neuron, mouse (Rundfeldt, C. (336) 243)

NGF (nerve growth factor)
Locomotion; Acetylcholine; Nicotinic receptor; Dopamine receptor antagonist (Kobayashi, S. (326) 1)

***N*$^{\omega}$-nitro-L-arginine**
Nitric oxide (NO) donor; Heart muscle; Contractility; Guanylate cyclase, soluble; Heart rate; (Rat) (Kojda, G. (334) 181)

***N*$^{\omega}$-Nitro-L-arginine methyl ester (L-NAME)**
Nitric oxide (NO); Renin-angiotensin system; Hoe 140; Enalapril; Blood pressure (Zappellini, A. (317) 285)

Pulmonary hypertension; Nitric oxide (NO); TP receptor; U-46619; SQ 29,548 (Valentin, J.-P. (317) 335)

Nitric oxide (NO); Anxiety; Plus maze, elevated; Arterial blood pressure; Nitric oxide (NO) synthase; Brain (Faria, M.S. (323) 37)

Cyclopiazonic acid; Nitric oxide (NO); Endothelium; Vasodilation (Rahimian, R. (327) 143)

Neurotoxicity; Nitric oxide (NO); NMDA (*N*-methyl-D-aspartate); Retina (Morizane, C. (328) 45)

L-Arginine; Superior colliculus; Blood pressure (D'Amico, M. (328) 65)

***N*$^{\omega}$-Nitro-L-arginine methyl ester (L-NAME), induced amnesia**
σ_1 Receptor; Dizocilpine-induced amnesia; NMDA receptor; Learning (Maurice, T. (328) 9)

Niacinamide
3-Acetylpyridine; Inferior olivary neuron; Lurcher mutant mouse; NMDA (*N*-methyl-D-aspartate), inhibition (Caddy, K.W.T. (330) 139)

Nicotinamide
Apoptosis; DNA fragmentation; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Mukherjee, S.K. (330) 27)

Nicotine
Tolerance; Dopamine metabolism; Striatum, mouse; Dopamine receptor (Pietilä, K. (318) 17)

Dopamine receptor agonist; Adrenoceptor antagonist; Acetylcholine receptor antagonist; 5-HT receptor antagonist; Anorexia; (Rat) (Zarrindast, M.-R. (321) 157)

Antinociception; Ca^{2+}; Ca^{2+} channel; Tolerance; Thapsigargin; (Intrathecal) (Damaj, M.I. (322) 129)

Hippocampus, ventral; Nucleus accumbens; Striatum; Noradrenaline; Dopamine (Benwell, M.E.M. (325) 13)

Myocardial ischemia; N^{G}-Nitro-L-arginine (LNNA); L-Arginine (L-Arg) (Koley, J. (325) 181)

Tail-tremor; Chronic administration; Nitric oxide (NO); NMDA receptor (Suemaru, K. (335) 139)

Additivity; Cocaine; Dopamine; Heroin; Microdialysis; Nucleus accumbens; Speedball; Synergism; (Interaction) (Zernig, G. (337) 1)

Nicotine-induced inward current
Acetylcholine; Acetylcholinesterase activity; Adrenal homogenate; Physostigmine; Patch clamp (Sugawara, T. (319) 123)

Nicotinic acetylcholine receptor
Ibogaine; Catecholamine release (Schneider, A.S. (317) R1)

Levamisole; Heterogeneity; Patch clamp; (*Oesphagostomum dentatum*) (Martin, R.J. (322) 249)

Dopamine; Ethanol; Hexamethonium; Microdialysis, in vivo; Mecamylamine (Blomqvist, O. (334) 149)

Spreading depression; NMDA receptor; Glutamate (Sheardown, M.J. (337) 209)

Nicotinic receptor
Epibatidine; Epiboxidine; ABT 418; Analgesia (Badio, B. (321) 189)

NGF (nerve growth factor); Locomotion; Acetylcholine; Dopamine receptor antagonist (Kobayashi, S. (326) 1)

Forskolin; 1,9-Dideoxy-forskolin; Chromaffin cell; Ca^{2+} channel (Gandía, L. (329) 189)

Nicotinic receptor antagonist
Adenosine; Neuromuscular junction; Acetylcholine release (Prior, C. (327) 103)

Nifedipine
Semotiadil; Diltiazem; Amlodipine; Ca^{2+} current; Ventricular myocyte (Koidl, B. (322) 243)

Hyperplasia; Smooth muscle, vascular; Cell culture; Captopril; Losartan; Transgenic rat (Peiró, C. (324) 257)

Ca^{2+}; Contraction; Trachea; Econazole; Miconazole; SK&F 96365 (Li, L. (331) 221)

LSD (lysergic acid diethylamide); Chronic treatment; Biogenic amines; Ca^{2+} channel; Brain (Antkiewicz-Michaluk, L. (332) 9)

Detrusor muscle, rat; Purinergic transmission; Cholinergic transmission; Cromakalim; Atropine; Suramin (Boselli, C. (335) 23)

Niflumic acid
Cl^- current; Noradrenaline; Caffeine; Glibenclamide; Smooth muscle (Kirkup, A.J. (317) 165)

α_1-Adrenoceptor; Chloride ion; Two-kidney one-clip hypertensive rat; Mesenteric blood vessel (He, Y. (328) 191)

Nimesulide
Cyclooxygenase-2; Antipyretic action; Hypothalamus; Yeast-induced hyperthermia; RT-PCR (reverse transcription and polymerase chain reaction) (Taniguchi, Y. (330) 221)

Nimodipine
Metrifonate; Cognitive function; EEG (electroencephalograph), cortical; (Rat) (Jäkälä, P. (318) 239)

Nimodipine, chronic
Metrifonate, acute; Water maze; Passive avoidance; Motor test; Washout; Aged rat; Medial septum-lesioned rat (Riekkinen, M. (322) 1)

Nitrergic innervation
NANC (non-adrenergic non-cholinergic) innervation; Noradrenergic innervation; Prostate gland; (Rat); (Guinea pig); (Pig); (Rabbit) (Najbar-Kaszkiel, A.T. (337) 251)

Nitrergic neurotransmission
Aldose reductase; Anococcygeus muscle, rat; Diabetes; Nitric oxide (NO); Sorbinil (Way, K.J. (318) 101)

Nitrergic transmission
Hydroxocobalamin; Light sensitivity (La, M. (321) R5)

Nitric oxide
Apoptosis; Smooth muscle cell; Protein kinase C; Protein kinase A (Nishio, E. (339) 245)

Nitric oxide (NO)
Interleukin-1β; Prostaglandin; Central nervous system; Plasma noradrenaline (Murakami, Y. (317) 61)

Nitric oxide (NO) donor; Mesangial cell; Apoptosis; Glomerular endothelial cell; Glomerular epithelial cell; Interleukin-1 (Mühl, H. (317) 137)

Endothelium; Mesenteric arterial bed; Perivascular nerve; Sensory nerve; (Golden hamster) (Hill, B. (317) 275)

Renin-angiotensin system; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Hoe 140; Enalapril; Blood pressure (Zappellini, A. (317) 285)

Endothelium; Diabetes mellitus; Arginine (Pieper, G.M. (317) 317)

Pulmonary hypertension; TP receptor; U-46619; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); SQ 29,548 (Valentin, J.-P. (317) 335)

S-nitrosothiol (stereoisomer); cGMP; Vascular smooth muscle (Travis, M.D. (318) 47)

Aldose reductase; Anococcygeus muscle, rat; Diabetes; Nitrergic neurotransmission; Sorbinil (Way, K.J. (318) 101)

Coronary microvessel; Acetylcholine; Nitroglycerin; Heart failure; L-Arginine (Larosa, G. (318) 387)

Cu^{2+}; cGMP; Nitric oxide (NO) donor (Ohnishi, T. (319) 49)

K^+ channel opener; Cromakalim; Diazoxide; Mesenteric bed, rat; Endothelium (Feleder, E.C. (319) 229)

Nerve conduction; Blood flow; L-Carnitine; Diabetic rat (Cameron, N.E. (319) 239)

Glutathione; Oxidant; Cell damage; Gastric mucosa (Wakulich, C.A. (319) 333)

Ischemia, focal; Photochemical infarction, treatment; NMDA receptor antagonist (Buchkremer-Ratzmann, I. (320) 103)

CGRP (calcitonin gene-related peptide); Nitric oxide (NO) synthase containing nerve; Vasodilation (Uchiyama, M. (321) 19)

α-Naphthylthiourea; L-Arginine; D-Arginine; N^G-Nitro-L-arginine methyl ester; Pulmonary oedema (Sipahi (Yılmaz), E. (321) 45)

Nitrosothiol; Glutathione; *N*-Acetylcysteine; Glucose; Lipopolysaccharide; Cytotoxicity; Macrophage (Zamora, R. (321) 87)

FK409; N^G-Nitro-L-arginine; Renal function; Urine formation (Urabe, K. (321) 195)

Glutamate release; Synaptosome; cGMP; Protein kinase G; Zaprinast (Sistiaga, A. (321) 247)

cGMP; Interleukin-6; Hippocampus; Sodium nitroprusside; N^G-Nitro-L-arginine (Ma, T. (321) 343)

Cardiac remodeling; Collagen; Myosin heavy chain (Takaori, K. (322) 59)

Anxiety; Plus maze, elevated; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Arterial blood pressure; Nitric oxide (NO) synthase; Brain (Faria, M.S. (323) 37)

Anthraquinone; Intestinal secretion; Glucocorticoid; Laxative; Natural drug (Izzo, A.A. (323) 93)

Aminoguanidine; N^G-Nitro-L-arginine; PAF (platelet-activating factor); Lipopolysaccharide; Systemic inflammatory response syndrome; (Rat) (Takano, H. (323) 107)

Colitis; Interleukin-10; Inflammation; TNF-α (tumor necrosis factor-α) (Ribbons, K.A. (323) 245)

Morphine withdrawal; Blood pressure; Nitric oxide (NO) synthase inhibitor; 3-Bromo-7-nitro indazole; Aminoguanidine; *S*-Methyl-L-thiocitrulline; 7-Nitro indazole (Vaupel, D.B. (324) 11)

Angiotensin II; Norepinephrine; NOC 7 (1-hydroxy-2-oxo-3-(*N*-methyl-3-aminopropyl)-3-methyl 1-triazene); Kidney; (Rabbit) (Adachi, Y. (324) 223)

Prostacyclin; Glomerulonephritis (Ikeda, M. (324) 283)

Alveolar macrophage; Lipoxygenase; Cyclooxygenase; Leukotriene B_4 (Brunn, G. (326) 53)

Histamine; Histamine receptor; (*R*)-α-Methylhistamine; Histamine H_1 receptor; Histamine H_3 receptor; Endothelium; Oviductal artery (Martínez, A.C. (326) 163)

Intestinal fluid transport; 5-HT (5-hydroxytryptamine, serotonin); Cholera toxin; Oral rehydration solution (Beubler, E. (326) 223)

Cyclopiazonic acid; Endothelium; Vasodilation; N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Rahimian, R. (327) 143)

Smooth muscle; Endothelium; Dimalonic acid C_{60}; Superoxide dismutase (Satoh, M. (327) 175)

Neurotoxicity; NMDA (*N*-methyl-D-aspartate); N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Retina (Morizane, C. (328) 45)

Endotoxin; EDHF (endothelium-dependent hyperpolarizing factor); Myocardium (Kristof, A.S. (328) 69)

Nodose ganglion; Adenosine; Adenosine receptor; Electrophysiology (Lawrence, A.J. (328) 83)

NMDA (*N*-methyl-D-aspartate); Dopamine; Oxytocin; Penile erection; Yawning; Paraventricular nucleus of the hypothalamus; (Rat) (Melis, M.R. (328) 115)

Startle; Prepulse inhibition; Startle reaction; Schizophrenia (Wiley, J.L. (328) 125)

Endothelin; Endothelin ET_A receptor; Endothelin ET_B receptor; Pressor effect; Oxygen consumption; Liver (Higuchi, H. (328) 175)

β-Adrenoceptor; Tachyphylaxis (Travis, M.D. (328) R1)

Migraine; Flunarizine; Vasodilator nerve (Ayajiki, K. (329) 49)

Nitric oxide (NO) synthase; Aminoguanidine; Portal vein ligation, rat; Portal hypertension (Michielsen, P.P. (329) 137)

Endothelium; Coronary small artery; Acetylcholine; A23187; Apamin; K^+ channel (Simonsen, U. (329) 153)

K^+ channel, Ca^{2+}-activated; cGMP; Iberiotoxin; Okadaic acid; Phosphatase; Smooth muscle (Johansson Rydberg, I.G.M. (329) 175)

Coronary artery; SIN-1 (3-morpholinosydnonimine); K_{ATP} channel; Vasodilation; Glibenclamide (Deka, D.K. (330) 157)

Acetylcholine; Clotrimazole; Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Nitro-L-arginine (Fujimoto, S. (330) 177)

N^G-nitro-L-arginine; Zinc protoporphyrin IX; Nitric oxide (NO) synthase; Carbon monoxide; Heme oxygenase (Seki, T. (331) 87)

7-Nitroindazole; Antiepileptic drug; Seizure (Borowicz, K.K. (331) 127)

Autonomic nerves; Enteric nervous system; Muscarinic receptor (Iversen, H.H. (331) 213)

Acyclic nucleotide analog; TNF-α (tumor necrosis factor α); IL-10 (interleukin-10); (R)-PMPA ((R)-9-(2-phosphonomethoxypropyl)adenine) (Zídek, Z. (331) 245)

Melatonin; Lipopolysaccharide; Water intake; Fever (Nava, F. (331) 267)

Pentadecapeptide BPC 157; Peptide BPC; Gastrointestinal mucosal integrity; Blood pressure maintenance; Gastric lesion; Hypotension; N^G-Nitro-L-arginine methylester; L-Arginine; Stomach mucosa (Slobodnjak, Z. (332) 23)

Cyclopiazonic acid; Endothelium; K^+ channel; Contractions, rhythmic; Mesenteric artery, rat (Huang, Y. (332) 167)

Endothelin-1; cAMP (Zhu, Y. (332) 195)

Ischaemia-reperfusion; Skeletal muscle; Viability; Oedema; (Mouse) (Knight, K.R. (332) 273)

Microdialysis; Skin; Bradykinin; Inflammatory hyperalgesia; N^G-nitro-L-arginine methyl ester; Bradykinin B_2 receptor (Andoh, T. (332) 279)

Angiotensin II; Enalapril; L-nitro-arginine methyl ester (L-NAME); Stroke (Ahmad, S. (333) 39)

Vas deferens, rat; L-Arginine; Sodium nitroprusside; *N*-nitro-L-arginine methyl ester (L-NAME); (Neurotransmission) (Ventura, S. (334) 87)

Endotoxin; Nitric oxide (NO) synthase inhibitor; Microcirculation; Vascular permeability; Inflammation; Inducible nitric oxide (NO) synthase (László, F. (334) 99)

Nitric oxide (NO) synthase; Neuronal; Potentiation; Muscarinic acetylcholine receptor; (Intact cell) (Cuadra, A.E. (334) 107)

Apamin; Colon; DMPP (1,1-dimethyl-4-phenylpiperazinium iodide); P_{2y} purinoceptor; Reactive blue 2; (Rat) (Börjesson, L. (334) 223)

β-D-glucan; Alveolar macrophage; Serum component; Interferon γ; β-D-glucan receptor (Sakurai, T. (334) 255)

Nicotine; Tail-tremor; Chronic administration; NMDA receptor (Suemaru, K. (335) 139)

Capsaicin; Urethra, dog; Smooth muscle relaxation (Nishizawa, S. (335) 211)

Hemorrhagic shock; Electron spin resonance; ACTH (adrenocorticotropin); Nitric oxide (NO) synthase, inducible (Guarini, S. (336) 15)

Cocaine; Hepatotoxicity; Reactive oxygen species; (Mouse) (Aoki, K. (336) 43)

$α_2$-Adrenoceptor; Antinociception; Opiate receptor; Periaqueductal gray (Fang, F. (336) 137)

N^G-nitro-L-arginine methyl ester (L-NAME); Colon; Inflammation; Nitric oxide (NO) synthase, constitutive; Nitric oxide (NO) synthase, inducible (Kiss, J. (336) 219)

Nitric oxide (NO)-releasing compound; cGMP; Lymphocyte (Kosonen, O. (337) 55)

Memory; cGMP; Blood pressure; 7-Nitroindazole; Zaprinast; (Rat) (Prickaerts, J. (337) 125)

Aortic barodenervation; α_1-Adrenoceptor; Endothelium (El-Mas, M.M. (337) 235)

Peroxynitrite; Sugar; Vasodilatation; L-Cysteine; Sodium nitrite; Methylene blue; Haemoglobin (Dowell, F.J. (338) 43)

Mercaptoalkylguanidine; Haemorrhagic shock; 6-Keto-prostaglandin-1α; Peroxynitrite (Zingarelli, B. (338) 55)

Cerebral vein; Histamine H_2 receptor; Venodilation; Endothelium; Prostanoid (Monge, L. (338) 135)

Nitric oxide (NO) synthase, inducible; Lipopolysaccharide; Auranofin; Aurothioglucose; Aurothiomalate; RAW 264.7 cell (Yamashita, M. (338) 151)

Glucocorticoid; Nitric oxide (NO) synthase, inducible; Lipocortin; J774 macrophage; Lipopolysaccharide (D'Acquisto, F. (339) 87)

Estrogen; Urethra; Nitric oxide (NO) synthase; (Rabbit) (Takahashi, W. (339) 165)

Adenosine; ATP; Cholinergic; GABA (γ-aminobutyric acid); Ileum; Terminal (Pencheva, N. (339) 193)

Gastric fundus, rat; Endotoxin; Contractility; Prostaglandin $F_{2\alpha}$ (Lefebvre, R.A. (339) 201)

Lipopolysaccharide; cAMP; cGMP; Phosphodiesterase III inhibitor; Monocyte; Macrophage; Interleukin-10; TNF-α (tumor necrosis factor-α) (Németh, Z.H. (339) 215)

Cationic amino acid transporter; Gene expression; TNF-α (tumor necrosis factor-α); Umbilical vein endothelial cell; (Human) (Irie, K. (339) 289)

Nitric oxide (NO) donor
Nitric oxide (NO); Mesangial cell; Apoptosis; Glomerular endothelial cell; Glomerular epithelial cell; Interleukin-1 (Mühl, H. (317) 137)

Cu^{2+}; Nitric oxide (NO); cGMP (Ohnishi, T. (319) 49)

N^{ω}-nitro-L-arginine; Heart muscle; Contractility; Guanylate cyclase, soluble; Heart rate; (Rat) (Kojda, G. (334) 181)

Nitric oxide (NO) pharmacology
Neuropeptide Y; PC12 cells (Dötsch, J. (331) 313)

Nitric oxide (NO)-releasing compound
Nitric oxide (NO); cGMP; Lymphocyte (Kosonen, O. (337) 55)

Nitric oxide (NO) synthase
Endotoxin; Dexamethasone; Myocardial contractility; β-Adrenoceptor; Mercaptoethylguanidine (Sun, X. (320) 29)

Alcohol; Brain, rat (Chen, Q.-m. (321) 355)

Nitric oxide (NO); Anxiety; Plus maze, elevated; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Arterial blood pressure; Brain (Faria, M.S. (323) 37)

Nitric oxide (NO); Aminoguanidine; Portal vein ligation, rat; Portal hypertension (Michielsen, P.P. (329) 137)

Aorta, rat; cGMP; Relaxation (Takizawa, S. (330) 143)

N^{G}-nitro-L-arginine; Zinc protoporphyrin IX; Nitric oxide (NO); Carbon monoxide; Heme oxygenase (Seki, T. (331) 87)

Nitric oxide (NO); Neuronal; Potentiation; Muscarinic acetylcholine receptor; (Intact cell) (Cuadra, A.E. (334) 107)

Arginase; L-Arginine; L-Citrulline; Prostate; (Pig); (Rabbit); (Rat) (Di Iulio, J.L. (337) 245)

Estrogen; Urethra; Nitric oxide (NO); (Rabbit) (Takahashi, W. (339) 165)

Nitric oxide (NO) synthase, constitutive
Nitric oxide (NO); N^{G}-nitro-L-arginine methyl ester (L-NAME); Colon; Inflammation; Nitric oxide (NO) synthase, inducible (Kiss, J. (336) 219)

Nitric oxide (NO) synthase containing nerve
Nitric oxide (NO); CGRP (calcitonin gene-related peptide); Vasodilation (Uchiyama, M. (321) 19)

Nitric oxide (NO) synthase II
Dantrolene; Lipopolysaccharide; Mortality; Hemodynamic alteration (Wu, C.-C. (327) 17)

Nitric oxide (NO) synthase, inducible
Cyclooxygenase-2; Western blot; Lipopolysaccharide; cAMP; Indomethacin; Cytotoxicity (Pang, L. (317) 151)

Ischemia-reperfusion arrhythmia; Endotoxin; Dexamethasone; L-Canavanine (Iskit, A.B. (326) 183)

Brown adipocyte; TMF-α (tumor necrosis factor-α); Lipoprotein lipase; Guanosine 3′,5′-cyclic monophosphate (Uchida, Y. (335) 235)

Hemorrhagic shock; Nitric oxide (NO); Electron spin resonance; ACTH (adrenocorticotropin) (Guarini, S. (336) 15)

Nitric oxide (NO); N^{G}-nitro-L-arginine methyl ester (L-NAME); Colon; Inflammation; Nitric oxide (NO) synthase, constitutive (Kiss, J. (336) 219)

Lipopolysaccharide; Aorta, rat; Genistein; Tyrphostin; Orthovanadate; Phenylarsine oxide (Duarte, J. (338) 25)

Nitric oxide (NO); Lipopolysaccharide; Auranofin; Aurothioglucose; Aurothiomalate; RAW 264.7 cell (Yamashita, M. (338) 151)

Glucocorticoid; Nitric oxide (NO); Lipocortin; J774 macrophage; Lipopolysaccharide (D'Acquisto, F. (339) 87)

Endothelin; Glial cell; TNF-α (tumor necrosis factor-α); Protein kinase C; Endothelin ET_B receptor (Oda, H. (339) 253)

Nitric oxide (NO) synthase inhibition
Endotoxaemia; Hyperdynamic circulation; Dopexamine (Waurick, R. (333) 181)

Nitric oxide (NO) synthase inhibitor
Morphine withdrawal; Blood pressure; 3-Bromo-7-nitro indazole; Aminoguanidine; *S*-Methyl-L-thiocitrulline; 7-Nitro indazole; Nitric oxide (NO) (Vaupel, D.B. (324) 11)

Nitric oxide (NO); Endotoxin; Microcirculation; Vascular permeability; Inflammation; Inducible nitric oxide (NO) synthase (László, F. (334) 99)

Nitrite
Interleukin-1; Atherosclerosis; Protein kinase C (Shimpo, M. (338) 97)

Nitrobenzylthioinosine
Adenosine; Nucleoside transport; L-Adenosine (Foga, I.O. (318) 455)

Nitrofuran
Steroid hormone; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cell, in vitro, porcine; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Nitrofurantoin
Steroid hormones; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furazolidone; Furaltadone (Jager, L.P. (331) 325)

Nitroglycerin
Coronary microvessel; Acetylcholine; Heart failure; L-Arginine; Nitric oxide (NO) (Larosa, G. (318) 387)

7-Nitro indazole
Morphine withdrawal; Blood pressure; Nitric oxide (NO) synthase inhibitor; 3-Bromo-7-nitro indazole; Aminoguanidine; *S*-Methyl-L-thiocitrulline; Nitric oxide (NO) (Vaupel, D.B. (324) 11)

Nitric oxide (NO); Antiepileptic drug; Seizure (Borowicz, K.K. (331) 127)

Memory; Nitric oxide (NO); cGMP; Blood pressure; Zaprinast; (Rat) (Prickaerts, J. (337) 125)

Nitro-L-arginine
Acetylcholine; Clotrimazole; Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Nitric oxide (NO) (Fujimoto, S. (330) 177)

Myocardial ischemia; Nicotine; L-Arginine (L-Arg) (Koley, J. (325) 181)

N^G-Nitro-L-arginine
Zinc protoporphyrin IX; Nitric oxide (NO); Nitric oxide (NO) synthase; Carbon monoxide; Heme oxygenase (Seki, T. (331) 87)

Endotoxin; Neostigmine; Neurotransmission; Na^+, K^+-ATPase (Liu, S.-H. (333) 241)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; Muscarinic M_3 receptor; N^G-nitro-L-arginine methyl ester (L-NAME); Atropine; Gallamine; Pirenzepine (Koss, M.C. (335) 199)

N^G-Nitro-L-arginine (LNNA)
FK409; Nitric oxide (NO); Renal function; Urine formation (Urabe, K. (321) 195)

Nitric oxide (NO); cGMP; Interleukin-6; Hippocampus; Sodium nitroprusside (Ma, T. (321) 343)

Aminoguanidine; PAF (platelet-activating factor); Lipopolysaccharide; Systemic inflammatory response syndrome; Nitric oxide (NO); (Rat) (Takano, H. (323) 107)

N^G-Nitro-L-arginine methyl ester
α-Naphthylthiourea; Nitric oxide (NO); L-Arginine; D-Arginine; Pulmonary oedema (Sipahi (Yılmaz), E. (321) 45)

Pentadecapeptide BPC 157; Peptide BPC; Nitric oxide (NO); Gastrointestinal mucosal integrity; Blood pressure maintenance; Gastric lesion; Hypotension; L-Arginine; Stomach mucosa (Slobodnjak, Z. (332) 23)

Nitric oxide (NO); Microdialysis; Skin; Bradykinin; Inflammatory hyperalgesia; Bradykinin B_2 receptor (Andoh, T. (332) 279)

***N*-Nitro-L-arginine methyl ester (L-NAME)**
Smooth muscle, vascular; Ouabain; Adenosine receptor; Coronary circulation; EDHF (endothelium-derived hyperpolarizing factor) (Olanrewaju, H.A. (322) 185)

N^G-Nitro-L-arginine methyl ester (L-NAME)
Cerebral blood flow; Cerebrovascular resistance; Cerebral vasodilatation; Acetylcholine (Diéguez, G. (330) 185)

***S*-Nitroso-*N*-acetylpenicillamine**
Vascular heterogeneity; Coronary artery, bovine; Glyceryl trinitrate; Sodium nitroprusside; Isoprenaline (De la Lande, I.S. (318) 65)

Nitrosothiol
Nitric oxide (NO); Glutathione; *N*-Acetylcysteine; Glucose; Lipopolysaccharide; Cytotoxicity; Macrophage (Zamora, R. (321) 87)

***S*-Nitrosothiol (stereoisomer)**
Nitric oxide (NO); cGMP; Vascular smooth muscle (Travis, M.D. (318) 47)

NK433
Muscle relaxant; Spinal reflex; Active metabolite (Sakitama, K. (337) 175)

NMDA / glycine receptor
Ethanol; L-701,324; MK-801; Eliprodil; Drug discrimination; (Rat) (Kotlinska, J. (332) 1)

NMDA (*N*-methyl-D-aspartate)
Polyamine; Putrescine; Spermidine; Spermine; Motor activity; MK-801; Amphetamine; Theophylline; (Mouse) (Giménez-Llort, L. (318) 231)

Kindling; Amygdala; Seizure; Epilepsy (Croucher, M.J. (319) 207)

Neurotoxicity; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Retina (Morizane, C. (328) 45)

Nitric oxide (NO); Dopamine; Oxytocin; Penile erection; Yawning; Paraventricular nucleus of the hypothalamus; (Rat) (Melis, M.R. (328) 115)

Ethanol; Spinal cord; Glutamate; GABA (γ-aminobutyric acid); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Anesthesia (Wong, S.M.E. (329) 121)

Dorsal lateral geniculate nucleus; Angiotensin; Kainate; Bicuculline; CGP 35348; Urethane; Unit activity; (Rat) (Albrecht, D. (332) 53)

Pain; Analgesia; Calmodulin inhibitor; Spinal cord; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Septide (Menéndez, L. (335) 9)

NMDA (*N*-methyl-D-aspartate), inhibition
3-Acetylpyridine; Inferior olivary neuron; Lurcher mutant mouse; Niacinamide (Caddy, K.W.T. (330) 139)

NMDA (*N*-methyl-D-aspartic acid)
Striatum; Pregnancy; Dopamine; Progesterone; Glutamate (Cabrera, R.J. (317) 55)

NMDA receptor
Conditioned preference; Reward; Glycine site; MK-801; CGP 37849; CGP 40116; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (317) 191)

Calcium; Neuron; Uncompetitive; Neuroprotection; MK-801 (Black, M. (317) 377)

D-Cycloserine; Glycine site; Acetylcholine; Hippocampus; Working memory (Ohno, M. (318) 267)

ACPC (1-aminocyclopropanecarboxylic acid); Neuroprotection; Toxicity; Neuronal injury; Glycine; Excitatory amino acid (Lin, Y. (318) 491)

Astrocyte; Excitotoxicity; Glycine site; Kynurenic acid; Neurodegenerative disorder; Quinolinic acid (Wu, H.-Q. (319) 13)

MK-801; Entorhinal cortex (Lindén, A.-M. (319) R1)

Glutamate receptor; *Xenopus* oocyte; Ligand-gated ion channel (Buller, A.L. (320) 87)

Excitotoxicity (Tyan, S.-H. (321) 171)

DCG-IV; Metabotropic glutamate receptor; AP5 (D-2-amino-5-phosphonopentanoic acid) (Breakwell, N.A. (322) 173)

Complex partial seizure; Electrical kindling; Epilepsy (Ebert, U. (322) 179)

MK-801; 7-Chlorokynurenic acid; Ifenprodil; Diazepam withdrawal; (Mouse) (Tsuda, M. (324) 63)

Non-NMDA glutamate receptor; Nociception; Hyperalgesia; Allodynia; Inflammation; Pain (Lawand, N.B. (324) 169)

Free radical; Glutamate; Pyrroloquinoline quinone; Redox modulatory site; Dihydroethidium (Scanlon, J.M. (326) 67)

σ_1 Receptor; Dizocilpine-induced amnesia; N^{ω}-Nitro-L-arginine methyl ester (L-NAME), induced amnesia; Learning (Maurice, T. (328) 9)

Dizocilpine; Dopamine receptor; Electroconvulsive shock; Supersensitivity (D'Aquila, P.S. (330) 11)

Ethanol tolerance; Ethanol withdrawal; Locus coeruleus (Poelchen, W. (332) 267)

Nicotine; Tail-tremor; Chronic administration; Nitric oxide (NO) (Suemaru, K. (335) 139)

Glycine receptor, strychnine-insensitive; [^{3}H]Dopamine release; [^{3}H]Noradrenaline release; Synaptosome; 7-Cl-Kynurenic acid; HA 966; GV 150526A (Mennini, T. (336) 275)

Non-NMDA receptor; Antiepileptic; Cortical wedge (Phillips, I. (337) 189)

Spreading depression; Nicotinic acetylcholine receptor; Glutamate (Sheardown, M.J. (337) 209)

Cocaine; Convulsion; Lethality; Toxicity (Matsumoto, R.R. (338) 233)

NMDA receptor, antagonistic
Flupirtine; Catalepsy; Locomotion; L-DOPA (L-dihydroxyphenylalanine); Parkinson's disease (Schmidt, W.J. (327) 1)

NMDA receptor, binding
Zn^{2+} inhibition; MK-801; σ Receptor; Spinal cord; (Mouse) (Kovács, K.J. (324) 117)

NMDA receptor antagonist
Ischemia, focal; Photochemical infarction, treatment; Nitric oxide (NO) (Buchkremer-Ratzmann, I. (320) 103)

Cocaine; Dextromethorphan; Self-administration (Pulvirenti, L. (321) 279)

Electrical brain stimulation; Conditioning; Reward; (Rat) (Bespalov, A. (326) 109)

κ-Opioid receptor agonist; Immediate early gene (Panegyres, P.K. (328) 31)

Neurotoxicity; Neurodegenerative disease (Menniti, F. (331) 117)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]Deltorphin II; δ_1-/δ_2-opioid receptor agonist; MK-801, LY 235959 (Cao, Y.-J. (335) 161)

HU-211; Dopamine receptor antagonist; Catalepsy; Parkinson's disease (Striem, S. (338) 205)

NMDA receptor antagonist, non-competitive
Electrophysiology; Cortex, rat; Spinal cord, rat; Enantiomer (Ebert, B. (333) 99)

NMDA receptor complex
1-Aminocyclopropanecarboxylic acid; Neuroprotection; Glutamate toxicity; Neuronal injury; Glycine receptor (Lin, Y. (338) 289)

NNC 09-0026
HEK293 cell; Ca^{2+} channel; Na^+ channel; CNS 1237; SB 201823-A; NS 649; Riluzole; Cerebral ischaemia (O'Neill, M.J. (332) 121)

NOC 7 (1-hydroxy-2-oxo-3-(*N*-methyl-3-aminopropyl)-3-methyl 1-triazene)
Angiotensin II; Norepinephrine; Nitric oxide (NO); Kidney; (Rabbit) (Adachi, Y. (324) 223)

Nociceptin
Locomotor activity; Exploratory behavior; Dopamine transmission (Florin, S. (317) 9)

Pain threshold; Opioid receptor; Endorphin (Gintzler, A.R. (325) 29)

Capsaicin; Sensory nerve; Efferent function; Atrium; (Guinea pig) (Giuliani, S. (332) 231)

Blood pressure; Hypotension; Heart rate; Vagal bradycardia (Giuliani, S. (333) 177)

ORL_1 receptor; Orphanin FQ; MAP (mitogen-activated protein) kinase (Fawzi, A.B. (336) 233)

Orphanin FQ; Retina; Striatum; Dynorphin A; Opioid (Makman, M.H. (338) 171)

[^{3}H]Nociceptin
Nociceptin receptor; Radioreceptor assay; Adenylylcyclase, inhibition; Drug screening (Butour, J.-L. (321) 97)

Nociceptin receptor
[^{3}H]Nociceptin; Radioreceptor assay; Adenylylcyclase, inhibition; Drug screening (Butour, J.-L. (321) 97)

Nociception
Descending inhibition; Non-steroidal anti-inflammatory drug; Raphe magnus (Jones, S.L. (318) 37)

Flexor reflex; Galanin; GMAP (galanin message-associated peptide), fragments; Spinal cord (Xu, X.-J. (318) 301)

Spinal cord; Pain; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY100635 (Gjerstad, J. (318) 315)

Bradykinin; Carrageenan inflammation; c-Fos; Spinal cord (Buritova, J. (320) 73)

Opioid; Nor-binaltorphimine; κ-Opioid receptor; Antinociception; Dorsal horn; Tachykinin; Pain (Zachariou, V. (323) 159)

NMDA receptor; Non-NMDA glutamate receptor; Hyperalgesia; Allodynia; Inflammation; Pain (Lawand, N.B. (324) 169)

c-*fos*; Formalin test; Hyperalgesia; Antisense oligodeoxynucleotide; (Intrathecal) (Hou, W.-Y. (329) 17)

ATP; α,β-methylene-ATP; Suramin; Formalin test (Sawynok, J. (330) 115)

Imidazoline receptor; BU-224 (2-(4,5-dihydroimidazol-2yl)-quinoline hydrochloride)); Spinal cord; (Rat) (Diaz, A. (333) 9)

Spinal cord; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; CP-93,129; Cyanopindolol; WAY100635 (Gjerstad, J. (335) 127)

Morphine; Clonidine; Formalin test (Przesmycki, K. (337) 11)

Nociception, formalin-induced
δ_1-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben; Diabetes; (Mouse) (Kamei, J. (326) 31)

Nociception, mechanical
Isoproterenol; Interleukin-1β; β-Adrenoceptor; (Rat) (Yabuuchi, K. (334) 133)

Nociception inflammation
5-HT_3 receptor; ICS-205 930; Bupivacaine; Lidocaine (Giordano, J. (334) 39)

Nodose ganglion
Nitric oxide (NO); Adenosine; Adenosine receptor; Electrophysiology (Lawrence, A.J. (328) 83)

Non-esterified fatty acid
BRL 35135; β_3-adrenoceptor agonism; Zucker (*fa/fa*) rat; Insulin sensitivity; Euglycaemic hyperinsulinaemic clamp (Virtanen, K.A. (332) 215)

Non-insulin-dependent diabetes (NIDDM)
GR79236; Insulin resistance; Lipolysis; Fructose; Triglyceride (Qu, X. (338) 269)

Non-monotonic profile
Vasopressin; Oxytocin; Factor VIII (F-VIII); Antihemophilic factor; Blood clotting; Plasminogen activator; Neurohypophyseal hormone analog; Dose–response analysis; Time response (Neuenschwander, S. (323) 205)

Non-NMDA glutamate receptor
NMDA receptor; Nociception; Hyperalgesia; Allodynia; Inflammation; Pain (Lawand, N.B. (324) 169)

Non-NMDA receptor
NMDA receptor; Antiepileptic; Cortical wedge (Phillips, I. (337) 189)

Non-peptide antagonist
YM087; Vasopressin; Vasopressin V_{1A} receptor; Vasopressin V_2 receptor (Yatsu, T. (321) 225)

Nonpeptide tachykinin NK_3 receptor antagonist
Tachykinin; Tachykinin NK_3 receptor; Inositol monophosphate accumulation; Ileum, guinea pig; Species difference (Beaujouan, J.-C. (319) 307)

Non-steroidal anti-inflammatory drug (NSAID)
Descending inhibition; Nociception; Raphe magnus (Jones, S.L. (318) 37)

Adenosine transport, Na^+-dependent; Brush-border membrane vesicle; Cyclooxygenase; Prostanoid (González-Castillo, C. (329) 245)

Kidney; Circulation; Prostanoid; Plasma renin activity; Cytochrome *P*-450 activity; Na^+ excretion (Kramp, R.A. (330) 165)

Prostaglandin H synthase-2; WISH cell (Hulkower, K.I. (331) 79)

Cyclooxygenase; Formalin; Release, in vitro; Spinal cord; Prostaglandin E_2; (Intrathecal) (Dirig, D.M. (331) 155)

Noradrenaline
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; Frontal cortex; Microdialysis, in vivo; Synaptosomal uptake (Hughes, Z.A. (317) 83)

Cl^- current; Niflumic acid; Caffeine; Glibenclamide; Smooth muscle (Kirkup, A.J. (317) 165)

Ureter; Histamine receptor; Histamine H_1 receptor; Histamine H_2 receptor; 5-HT (5-hydroxytryptamine, serotonin); Prostaglandin (Dodel, R.C. (318) 395)

Vitamin D; Glioma; Apoptosis (Canova, C. (319) 365)

Dopamine D_4 receptor; L 745,870; Clozapine; Adrenaline; [^{35}S]GTPγS (Newman-Tancredi, A. (319) 379)

DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); EEG (electroencephalogram); Memory; Basal forebrain lesion; Tetrahydroaminoacridine (Abe, K. (321) 149)

Nicotine; Hippocampus, ventral; Nucleus accumbens; Striatum; Dopamine (Benwell, M.E.M. (325) 13)

Pain; Vein; Phentolamine; (Human) (Kindgen-Milles, D. (328) 41)

Adrenergic nerve; Diabetes mellitus; Nerve blood flow; Sciatic nerve, rat (Vo, P.A. (329) 147)

Talsaclidine; Arecoline; McN-A-343; Bronchospasm; Guinea pig (Walland, A. (330) 213)

Noradrenaline, endogenous
α_1-Adrenoceptor, subtype; WB4101; Chlorethylclonidine; Positive inotropic action; Myocardium, rabbit (Hattori, Y. (329) 165)

Noradrenaline release
Chromaffin cell; Epibatidine; Substance P; Adrenaline release (Krause, W. (328) 249)

[^{3}H]Noradrenaline release
Glycine receptor, strychnine-insensitive; NMDA receptor; [^{3}H]Dopamine release; Synaptosome; 7-Cl-Kynurenic acid; HA 966; GV 150526A (Mennini, T. (336) 275)

Noradrenaline uptake inhibitor
Protriptyline; Amitriptyline; Xylamine; Electric field stimulation; Contraction; Vas deferens, rat (Huang, Y. (327) 41)

Noradrenergic innervation
NANC (non-adrenergic non-cholinergic) innervation; Nitrergic innervation; Prostate gland; (Rat); (Guinea pig); (Pig); (Rabbit) (Najbar-Kaszkiel, A.T. (337) 251)

Noradrenergic system
Mitragynine; Antinociception; α_2-Adrenoceptor; Serotonergic system; (Mouse) (Matsumoto, K. (317) 75)

Noradrenergic transmission
Vas deferens, rat; Purinergic transmission; Cromakalim; Prazosin; Suramin; Glibenclamide (Grana, E. (319) 57)

Norathyriol
Neutrophil, rat; Respiratory burst; Aggregation; Protein kinase C; Phorbol 12-myristate 13-acetate; Translocation (Wang, J.-P. (336) 81)

Nor-binaltorphimine
Analgesia; Morphine; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Dynorphin; β-Funaltrexamine; DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly-ol^5]enkephalin) (Reche, I. (318) 11)

Opioid; κ-Opioid receptor; Antinociception; Dorsal horn; Tachykinin; Nociception; Pain (Zachariou, V. (323) 159)

Matrine; Antinociception; κ-Opioid receptor; Pentazocine; (Mouse) (Kamei, J. (337) 223)

Norepinephrine
Angiotensin II; NOC 7 (1-hydroxy-2-oxo-3-(*N*-methyl-3-aminopropyl)-3-methyl 1-triazene); Nitric oxide (NO); Kidney; (Rabbit) (Adachi, Y. (324) 223)

σ_2 Receptor; Hippocampus; BIMU-8; (+)-Pentazocine (Weatherspoon, J.K. (326) 133)

Thoracic aorta; Vasorelaxation; cAMP; cGMP; Ca^{2+} channel blocker (Cheng, Y.-W. (336) 23)

Kidney; CNP (C-type natriuretic peptide); Angiotensin II; Vasoconstriction; (Dog) (Yoshida, K. (338) 131)

Norepinephrine uptake
Cyclosporine chronopharmacology; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Ornithine decarboxylase; Acetylcholine synthesis; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (319) 181)

D-Norfenfluramine
D-Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); Sex difference (Datla, K.P. (333) 27)

Norfluoxetine
Fluoxetine; Monoamine Oxidase B; *N*-(6-[^{18}F]fluorohexyl)-*N*-methylpropargylamine (Mukherjee, J. (337) 111)

Noribogaine
Ibogaine; 18-Methoxycoronaridine; Cocaine; Motor activity (Maisonneuve, I.M. (336) 123)

Northern and dot blotting
Acamprosate; Ethanol withdrawal; Pentylenetetrazole; Hippocampus; Cerebellum; c-*fos* mRNA; In situ hybridization (Putzke, J. (317) 39)

NO synthase, inducible
Inflammation; Pristimerin; Triterpene; RAW 264.7 macrophage (Dirsch, V.M. (336) 211)

NO synthase inhibitor
Plasma leakage; Blood flow; Bradykinin; Histamine (Perez, A.C. (330) 241)

Novel antagonist
Glutamate receptor; Neonatal rat spinal cord (Thomas, N.K. (338) 111)

Novelty
Locomotion; Fear; Anxiety (Gendreau, P.L. (337) 147)

NS-49
α_1-Adrenoceptor, subtype; Intraurethral pressure; Blood pressure (Taniguchi, N. (318) 117)

NS-398
Allergic inflammation, recurrence of; Granulation tissue; Prostaglandin E_2; Cyclooxygenase-1; Cyclooxygenase-2; Indomethacin; Dexamethasone (Niki, H. (320) 193)

NS 649
HEK293 cell; Ca^{2+} channel; Na^+ channel; NNC 09-0026; CNS 1237; SB 201823-A; Riluzole; Cerebral ischaemia (O'Neill, M.J. (332) 121)

NS 1619
Charybdotoxin; Glibenclamide; K^+ channel, Ca^{2+}-activated; Ca^{2+} channel; Vas deferens, rat (Huang, Y. (325) 21)

hNT neuron
Flupirtine; Triamnopyridine; Bcl-2; Neuroprotection; Apoptosis; Glutathione (Perovic, S. (317) 157)

Membrane potential; Antiepileptics; Cromakalim; Glibenclamide; Patch-clamp electrophysiology; NG 108-15 cell; Cortical neuron, mouse (Rundfeldt, C. (336) 243)

Nucleoside transport
Nitrobenzylthioinosine; Adenosine; L-Adenosine (Foga, I.O. (318) 455)

Nucleotide
UDP; $P2Y_6$ receptor (Robaye, B. (329) 231)

Nucleus accumbens
Adenylyl cyclase; Caudate putamen; SKF 82958; cAMP (Unterwald, E.M. (318) 31)

Aspartate; Cocaine; Glutamate; Sensitization; (Rat) (Robinson, S.E. (319) 31)

Conditioned fear stress; σ Receptor; Dopaminergic system; Motor suppression; (Rat) (Kamei, H. (319) 165)

Nicotine; Hippocampus, ventral; Striatum; Noradrenaline; Dopamine (Benwell, M.E.M. (325) 13)

Neurotensin; Haloperidol; Dopamine; Striatum (Huang, W. (332) 15)

Dynorphin; Substance P; Enkephalin; Acetylcholine; Dopamine; Amphetamine; Caudoputamen; Behavior; Muscarinic receptor (Wang, J.Q. (334) 43)

Additivity; Cocaine; Dopamine; Heroin; Microdialysis; Nicotine; Speedball; Synergism; (Interaction) (Zernig, G. (337) 1)

Obesity, drug therapy
Brown fat; Zucker rat; α_1-Adrenoceptor agonist; α_2-Adrenoceptor antagonist; Imidazoline derivative (Savontaus, E. (328) 207)

Object recognition
Aging; Metrifonate; Acetylcholine, release; Cholinesterase inhibitor (Scali, C. (325) 173)

Occasion setting
Appetitive discrimination; Midazolam; Amphetamine; Unconditioned drug effect; Conditioned drug effect (Maes, J.H.R. (319) 5)

Octadecaneuropeptide (ODN)
Endozepine; Diazepam-binding inhibitor; Benzodiazepine receptor; Glial cell; Ca^{2+} mobilization (Gandolfo, P. (322) 275)

ODQ
Smooth muscle tension; Guanylyl cyclase; Isoliquiritigenin; YC-1 (Wegener, J.W. (323) 89)

Oedema
Ischaemia-reperfusion; Nitric oxide (NO); Skeletal muscle; Viability; (Mouse) (Knight, K.R. (332) 273)

17β-Oestradiol
Myocardial ischaemia–reperfusion injury; ICAM-1 (intercellular adhesion molecule-1); TNF-α (tumor necrosis factor-α) (Squadrito, F. (335) 185)

Oestrogen
Mifepristone; Progesterone; LH (luteinizing hormone); Adrenoceptor antagonist (Salicioni, A.M. (332) 283)

Tachykinin receptor; Peptidase inhibitor; Uterus; SR 142801 (Fisher, L. (335) 221)

7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin)
Diabetes; Methamphetamine; Place preference; Dopamine D_3 receptor; Mesolimbic dopamine system (Kamei, J. (318) 251)

Ethanol preference; Dopamine; SKF 38393; Raclopride; Risperidone; SCH 23390; (Rat) (Silvestre, J.S. (318) 257)

Dopamine D_3 receptor; Drug discrimination; D-Amphetamine; (Rat) (Varty, G.B. (339) 101)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)
$5\text{-}HT_{1A}$ receptor; Galanin; Hypothermia; Acetylcholine; Muscarinic receptor (Patel, S. (317) 197)

Spinal cord; Pain; Nociception; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1A}$ receptor; WAY100635 (Gjerstad, J. (318) 315)

$5\text{-}HT_{1A}$ autoreceptor; EMD 68843; Fluoxetine; WAY 100635; Hypothermia; Ultrasonic vocalization; (Rat) (Bartoszyk, G.D. (322) 147)

Behavior; Body temperature; $5\text{-}HT_{1A}$ receptor; Lower lip retraction; 5-HT (5-hydroxytryptamine, serotonin); Tail flick; (Intracerebroventricular administration) (Bagdy, G. (323) 53)

$5\text{-}HT_{1A}$ receptor; Flesinoxan; WAY-100635; Anxiety; Geller-Seifter, conflict; (Rat) (King, C.M.F. (325) 121)

Sexual behavior; Ejaculation; Flesinoxan; ATD (1,4,6-androstatriene-3,17-dione); (Wistar rat) (Haensel, S.M. (330) 1)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin)
Locus coeruleus; α_{2A}-Adrenoceptor; ARC 239 (2-[2-[4-(*o*-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethyl-1,3(2H,4H)-isoquinolinedione); Chlorpromazine (Ruiz-Ortega, J.A. (333) 159)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)-induced mydriasis
α_2-Adrenoceptor, postsynaptic; $5\text{-}HT_{1A}$ receptor; Brain, mouse (Prow, M.R. (317) 21)

***R*-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-*N*,*N*-(di-*n*-propyl-2-amino)tetralin)**
Dopamine D_3 receptor; Passive avoidance learning; Spontaneous locomotor activity; Memory; (Mouse) (Ukai, M. (324) 147)

OK (Opossum kidney) cell
L-DOPA (L-3,4-dihydroxyphenylalanine); L-5-HTP (L-5-hydroxytryptophan); Cyanine derivative; Cellular transport (Gomes, P. (332) 219)

Okadaic acid
Calyculin A; Phosphatase; Tumor cell locomotion; Walker 256 carcinosarcoma cell; Vimentin (Niggli, V. (324) 99)

K^+ channel, Ca^{2+}-activated; cGMP; Iberiotoxin; Nitric oxide (NO); Phosphatase; Smooth muscle (Johansson Rydberg, I.G.M. (329) 175)

Olfactory bulbectomized rat
YM992; Antidepressant; 5-HT (5-hydroxytryptamine, serotonin) re-uptake inhibition; $5\text{-}HT_{2A}$ receptor antagonistic activity; Tail suspension test (Takeuchi, H. (329) 27)

Oligodendrocyte
AMPA receptor; Extracellular calcium; Glutamate; Inositol phosphate (Liu, H.-N. (338) 277)

Oligodeoxynucleotides
Antisense targeting; Sickness behavior; Interleukin 6; Radiotelemetry; (Rat) (Schöbitz, B. (331) 97)

Omeprazole
T-330; H^+/K^+-ATPase; Gastric acid secretion; Ranitidine (Kinoshita, M. (321) 325)

Ondansetron
Radioligand binding; Oral bioavailability; $t_{1/2}$; Brain penetration; Vomiting; Retching; Nausea (Singh, L. (321) 209)

Cisplatin; Anti-emetic; Dexamethasone; (Acute and delayed) (Rudd, J.A. (322) 79)

Ileum, guinea-pig; 5-HT receptor (González, A.A. (328) 201)

GABA (γ-aminobutyric acid); Whole-cell current; Patch-clamp; Seizure (Ye, J.H. (337) 87)

Stomach fundus; Contractile response; Acetylcholine release; (Rat) (Amemiya, N. (339) 173)

Ontogeny
U-50,488; Morphine; Reward; (Rat) (Bolanos, C.A. (317) 1)

Duodenum longitudinal muscle, rat; Duodenum muscularis mucosae, rat; P_1 purinoceptor; Development; Adenosine receptor (Brownhill, V.R. (317) 321)

Cannabinoid; Lung; Type II cell; Development; Steroid (Rice, W. (327) 227)

Oocyte
Ca^{2+} channel, cloned; Ca^{2+} channel antagonist; Neuroprotective; T-477 ((*R*)-(+)-2-(4-chlorophenyl)-2,3-dihydro-4-diethylaminoacetyl-4H-1,4-benzothiazine); (*Xenopus*) (Kobayashi, T. (332) 313)

O_2 paradox
Ca^{2+} paradox; Caffeine; Amiloride; pH; Heart damage (Harding, R.J. (330) 47)

OPC15161
Anti-Thy1 nephritis; Cytokine; Matrix index; Superoxide radical; Tubulointerstitial index (Hamada, N. (317) 123)

Open channel blockade
Patch clamp, whole-cell; K^+ current; Na^+ current; KC8851 (McLarnon, J.G. (339) 279)

Open-state probability
Bladder detrusor, guinea pig; Patch-clamp; BK_{Ca} channel; Whole-cell recording; Inside-out single channel recording (Hu, S. (318) 461)

Operational model
McN-A-343; Muscarinic receptors; Allosteric interaction (Christopoulos, A. (339) 153)

Opiate
β-Endorphin; Insulin; Growth; Development; Ornithine decarboxylase mRNA; Intracerebroventricular (Bartolome, J.V. (331) 145)

Opiate dependence
Neurosteroids; Morphine; Pregnenolone sulfate; Allopregnanolone; Progesterone; 4′-Chlordiazepam; Opiate tolerance (Reddy, D.S. (337) 19)

Opiate receptor
Neuroblastoma; δ-Opioid receptor, subtype; SH-SY5Y (Toll, L. (323) 261)

α_2-Adrenoceptor; Antinociception; Nitric oxide (NO); Periaqueductal gray (Fang, F. (336) 137)

Opiate tolerance
Neurosteroids; Morphine; Pregnenolone sulfate; Allopregnanolone; Progesterone; 4′-Chlordiazepam; Opiate dependence (Reddy, D.S. (337) 19)

Opioid
Analgesia; Morphine; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Dynorphin; Nor-binaltorphimine; β-Funaltrexamine; DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly-ol^5]enkephalin) (Reche, I. (318) 11)

Immunity; Lymphocyte proliferation; Autonomic nervous system; Sympathetic division; Parasympathetic division; (Rat) (Flores, L.R. (318) 437)

Pain; Analgesia; Opioid receptor, peripheral; Stress (Schäfer, M. (323) 1)

Benzodiazepine; Buspirone; Elevated plus-maze test; (Mouse) (Belzung, C. (323) 133)

Nor-binaltorphimine; κ-Opioid receptor; Antinociception; Dorsal horn; Tachykinin; Nociception; Pain (Zachariou, V. (323) 159)

Δ^9-Tetrahydrocannabinol; Proopiomelanocortin; mRNA; Arcuate nucleus (Corchero, J. (323) 193)

Cocaine; Drug discrimination; Drug interaction (Suzuki, T. (324) 21)

Steroid; Cyproterone acetate; Binding (Gutiérrez, M. (328) 99)

Formalin test; Mazindol; Lidocaine; Antinociception; Dopamine (Bittencourt, A.L. (330) 109)

Arachidonic acid; Withdrawal; Ileum (Capasso, A. (330) 199)

Anxiolytics; Signal transduction; Dopamine receptor antagonist; Benzodiazepine; Homophtalazine (2,3-benzodiazepine) (Fekete, M.I.K. (331) 175)

Analgesia; σ Receptor (King, M. (331) R5)

Cocaine; Lethality; Cardiovascular; Blood pressure; Seizure (Patterson, A.B. (333) 47)

Estradiol; Uterus; Proliferation; Cell culture; (Rat) (Környei, J.L. (336) 65)

Nociceptin; Orphanin FQ; Retina; Striatum; Dynorphin A (Makman, M.H. (338) 171)

Partial agonism; Dynorphin (Soderstrom, K. (338) 191)

Ileus; Gastrointestinal transit; κ-Opioid receptor; Antinociception (De Winter, B.Y. (339) 63)

Opioid analgesia
Amphibian; Acetic acid test; Intracerebroventricular (i.c.v.) administration; (*Rana pipiens*) (Stevens, C.W. (331) 15)

Opioid receptor
Baculovirus; 'High Five'; Sf9; Insect cell (Obermeier, H. (318) 161)

Nociceptin; Pain threshold; Endorphin (Gintzler, A.R. (325) 29)

Conditioned place preference; Diabetes; Morphine; Naloxonazine; Reinforcement (Kamei, J. (337) 137)

Opioid receptor, peripheral
Pain; Analgesia; Opioid; Stress (Schäfer, M. (323) 1)

δ-Opioid receptor
Ligand binding thermodynamics; Pharmacophore; Model (Maguire, P.A. (318) 505)

NG108-15 cell; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); DSLET ([D-Ser^2,Leu^5,Thr^6]enkephalin); BNTX (7-benzylidenenaltrexone); Naltriben (Ho, B.Y. (319) 109)

(−)-TAN-67; (+)-TAN-67; Antinociception; 7-Benzylidenenaltrexone; Naltriben, diabetes (Kamei, J. (322) 27)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin); μ-Opioid receptor knockout mouse (Sora, I. (324) R1)

Methamphetamine; Drug discrimination; TAN-67 (Suzuki, T. (331) 1)

[D-Pen^2,L-Pen^5]Enkephalin; [D-Ala^2]Deltorphin II; Spontaneous alternation performance; Elevated plus-maze behavior; Passive avoidance learning; (Mouse) (Ukai, M. (338) 1)

δ_1-Opioid receptor
Nociception, formalin-induced; 7-Benzylidenenaltrexone; Naltriben; Diabetes; (Mouse) (Kamei, J. (326) 31)

δ-Opioid receptor, human
Efficacy; Radioligand binding; δ-Opioid receptor agonist; [^{35}S]GTPγS binding (Quock, R.M. (326) 101)

***δ*-Opioid receptor, *μ*-Opioid receptor, *κ*-Opioid receptor**
Prostate cancer; Cell line, LNCaP, DU145, PC3; Cell proliferation; Receptor subtype; Casein, bovine, human; Casomorphin (Kampa, M. (335) 255)

δ-Opioid receptor, subtype
Opiate receptor; Neuroblastoma; SH-SY5Y (Toll, L. (323) 261)

δ-Opioid receptor agonist
Efficacy; δ-Opioid receptor, human; Radioligand binding; [^{35}S]GTPγS binding (Quock, R.M. (326) 101)

δ_1-/ δ_2-Opioid receptor agonist
DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]Deltorphin II; NMDA receptor antagonist; MK-801, LY 235959 (Cao, Y.-J. (335) 161)

δ-Opioid receptor ligand
Immunomodulation; Lymphocyte (Noviello, L. (332) R1)

κ-Opioid receptor
Drug self-administration; Cocaine; Morphine; U50,488H; (Rat); (Mouse) (Kuzmin, A.V. (321) 265)

Opioid; Nor-binaltorphimine; Antinociception; Dorsal horn; Tachykinin; Nociception; Pain (Zachariou, V. (323) 159)

Fedotozine; μ-Opioid receptor; Visceral pain; Colonic hypersensitivity; (Colonic distension) (Langlois, A. (324) 211)

Matrine; Antinociception; Pentazocine; Nor-binaltorphimine; (Mouse) (Kamei, J. (337) 223)

Ileus; Gastrointestinal transit; Opioid; Antinociception (De Winter, B.Y. (339) 63)

κ-Opioid receptor agonist
NMDA receptor antagonist; Immediate early gene (Panegyres, P.K. (328) 31)

μ-Opioid receptor
Downregulation; Tolerance; Fentanyl; Clocinnamox; DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); Analgesia (Chan, K.W. (319) 225)

Fedotozine; κ-Opioid receptor; Visceral pain; Colonic hypersensitivity; (Colonic distension) (Langlois, A. (324) 211)

Agmatine; α_2-Adrenoceptor; Analgesia; Fentanyl; Spinal cord (Bradley, K.J. (331) 133)

Regulation of mRNA; Etorphine; Receptor downregulation; Analgesia; Tolerance (Sehba, F. (339) 33)

μ-Opioid receptor knockout mouse
DPDPE ([D-Pen^2,D-Pen^5]enkephalin); δ-Opioid receptor (Sora, I. (324) R1)

Opioid receptor agonist
Neuropathic pain; Mononeuropathic rat; Morphine; Tolerance (Catheline, G. (318) 273)

Opioid receptor binding
Analgesia; Morphine; Clocinnamox; [^{3}H]DAMGO ([^{3}H][D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]-enkephalin); (Rat) (Paronis, C.A. (337) 27)

Oral bioavailability
Radioligand binding; $t_{1/2}$; Brain penetration; Vomiting; Retching; Nausea; Ondansetron (Singh, L. (321) 209)

Oral dyskinesia
Reserpine; Tongue protrusion; Dopamine; Tardive dyskinesia (Sussman, A.N. (337) 157)

Oral gavage
Pressure-natriuresis; Imidazoline; Salt preference (Cechetto, D.F. (325) 47)

Orally active
Bradykinin; Bradykinin receptor antagonist; FR167344; FR172357; Bradykinin B_2 receptor (Inamura, N. (333) 79)

Oral rehydration solution
Intestinal fluid transport; Nitric oxide (NO); 5-HT (5-hydroxytryptamine, serotonin); Cholera toxin (Beubler, E. (326) 223)

Oral tolerance
Interleukin-4; Interferon-γ (Yoshino, S. (336) 203)

Org 2766
Streptozotocin-diabetic rat; ACTH-(4–9) analogue; Adrenergic responsiveness; Nerve blood flow; Macrocirculatory blood flow (Van Buren, T. (318) 73)

Org 9935
Org 30029; Insulin secretion; Phosphodiesterase inhibitor; Insulin, plasma; Glucose, plasma (El-Metwally, M. (324) 227)

Org 30029
Org 9935; Insulin secretion; Phosphodiesterase inhibitor; Insulin, plasma; Glucose, plasma (El-Metwally, M. (324) 227)

Organ culture
Endothelin ET_A receptor; Endothelin ET_B receptor; Reverse transcription-polymerase chain reaction; Up-regulation (Möller, S. (329) 69)

Organic cation carrier
Renal clearance; Active secretion; Drug interaction; P-glycoprotein; Multidrug resistance (Masereeuw, R. (321) 315)

ORL_1 receptor
Nociceptin; Orphanin FQ; MAP (mitogen-activated protein) kinase (Fawzi, A.B. (336) 233)

Ornithine decarboxylase
Cyclosporine chronopharmacology; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Norepinephrine uptake; Acetylcholine synthesis; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (319) 181)

Ornithine decarboxylase mRNA
Opiate; β-Endorphin; Insulin; Growth; Development; Intracerebroventricular (Bartolome, J.V. (331) 145)

Orphanin FQ
ORL_1 receptor; Nociceptin; MAP (mitogen-activated protein) kinase (Fawzi, A.B. (336) 233)

Nociceptin; Retina; Striatum; Dynorphin A; Opioid (Makman, M.H. (338) 171)

Orthovanadate
Lipopolysaccharide; Nitric oxide (NO) synthase, inducible; Aorta, rat; Genistein; Tyrphostin; Phenylarsine oxide (Duarte, J. (338) 25)

Ouabain
Smooth muscle, vascular; *N*-Nitro-L-arginine methyl ester (L-NAME); Adenosine receptor; Coronary circulation; EDHF (endothelium-derived hyperpolarizing factor) (Olanrewaju, H.A. (322) 185)

ATPase (Na^+, K^+); Cardiac glycoside; α-Methyl-digitoxigenin-glucoside; Therapeutic index (Gleitz, J. (335) 89)

Outward current
Neuroprotection; Ischemia; Inward current; Ion channel; Patch clamp (Suma, C. (336) 283)

Oviductal artery
Histamine; Histamine receptor; (*R*)-α-Methylhistamine; Histamine H_1 receptor; Histamine H_3 receptor; Endothelium; Nitric oxide (NO) (Martínez, A.C. (326) 163)

Oxidant
Glutathione; Nitric oxide (NO); Cell damage; Gastric mucosa (Wakulich, C.A. (319) 333)

Oxidative burst
ANP (atrial natriuretic peptide); Fluorescent latex bead; Dihydrorhodamine-123; Immune function; Flow cytometry (Vollmar, A.M. (319) 279)

Oxidative stress
Glutamate; Glutathione depletion; Programmed cell death (Froissard, P. (326) 93)

Anethole dithiolethione; Glutathione; Hydrogen peroxide; Astrocyte; Neurodegeneration (Drukarch, B. (329) 259)

Oxygen consumption
Endothelin; Endothelin ET_A receptor; Endothelin ET_B receptor; Pressor effect; Nitric oxide (NO); Liver (Higuchi, H. (328) 175)

Oxygen exposure, high
Piribedil; Lipid peroxidation; Brain (Calzi, F. (338) 185)

Oxygen metabolite, reactive
Superoxide dismutase, Glutathione redox cycle; Catalase; Colonic epithelial cell (Hata, Y. (321) 113)

Oxygen radical
Dopamine transporter; Methamphetamine (Fleckenstein, A.E. (334) 111)

Oxytocin
Vasopressin; Factor VIII (F-VIII); Antihemophilic factor; Blood clotting; Plasminogen activator; Neurohypophyseal hormone analog; Dose–response analysis; Time response; Non-monotonic profile (Neuenschwander, S. (323) 205)

NMDA (*N*-methyl-D-aspartate); Nitric oxide (NO); Dopamine; Penile erection; Yawning; Paraventricular nucleus of the hypothalamus; (Rat) (Melis, M.R. (328) 115)

Ozone
Imidapril; Enalapril; Captopril; Angiotensin-converting enzyme; Airway hyperresponsiveness (Matsubara, S. (337) 259)

PACAP (pituitary adenylate cyclase-activating peptide)
VIP (vasoactive intestinal peptide); PACAP receptor; VIP receptor; Neuropeptide Y; Motor effect; Gastro-intestinal tract; Apamin (Ekblad, E. (334) 61)

PACAP (pituitary adenylate cyclase-activating polypeptide)
Atrioventricular conduction; Parasympathetic nerve; VIP (vasoactive intestinal peptide) (Hirose, M. (338) 35)

PACAP receptor
PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal peptide); VIP receptor; Neuropeptide Y; Motor effect; Gastro-intestinal tract; Apamin (Ekblad, E. (334) 61)

Pacemaker cells
Smooth muscle; K^+ channels; Ca^{2+} stores; Charybdotoxin; Apamin (Duridanova, D.B. (333) 105)

PAF (platelet-activating factor)
YM435; Dopamine D_1 receptor agonist; Renal vasodilator; Angiotensin II; Renal nerve stimulation (Yatsu, T. (322) 45)

Aminoguanidine; N^G-Nitro-L-arginine; Lipopolysaccharide; Systemic inflammatory response syndrome; Nitric oxide (NO); (Rat) (Takano, H. (323) 107)

ABT-491; PAF receptor antagonist; Ca^{2+} flux; Superoxide anion; Vascular permeability; Degranulation; Endotoxemia (Albert, D.H. (325) 69)

AIDS (acquired immunodeficiency syndrome); LP-BM5 murine leukemia virus; Encephalopathy; Pentoxifylline; TNF-α (tumor necrosis factor-α) (Sei, Y. (325) 81)

Neuropeptide FF; Intestinal motility; Fever; Endotoxin (Million, M. (334) 67)

PAF receptor antagonist
ABT-491; PAF (platelet-activating factor); Ca^{2+} flux; Superoxide anion; Vascular permeability; Degranulation; Endotoxemia (Albert, D.H. (325) 69)

Pain
Substance P; Tachykinin NK_1 receptor; Plasma extravasation; Migraine (Seabrook, G.R. (317) 129)

Spinal cord; Nociception; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1A}$ receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY100635 (Gjerstad, J. (318) 315)

Cannabinoid; Hyperalgesia (Richardson, J.D. (319) R3)

Hyperalgesia; Allodynia; Tachykinin; Flexor reflex (Ma, Q.-P. (322) 165)

Analgesia; Opioid; Opioid receptor, peripheral; Stress (Schäfer, M. (323) 1)

Opioid; Nor-binaltorphimine; κ-Opioid receptor; Antinociception; Dorsal horn; Tachykinin; Nociception (Zachariou, V. (323) 159)

NMDA receptor; Non-NMDA glutamate receptor; Nociception; Hyperalgesia; Allodynia; Inflammation (Lawand, N.B. (324) 169)

Vein; Noradrenaline; Phentolamine; (Human) (Kindgen-Milles, D. (328) 41)

Adenosine A_3 receptor; Histamine; 5-HT (5-hydroxytryptamine, serotonin) (Sawynok, J. (333) 1)

Analgesia; C-fiber reflex; Clomipramine; Desipramine; Tricyclic antidepressant (Mestre, C. (335) 1)

Analgesia; Calmodulin inhibitor; Spinal cord; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Septide (Menéndez, L. (335) 9)

Pain threshold
Nociceptin; Opioid receptor; Endorphin (Gintzler, A.R. (325) 29)

PAI-1 (plasminogen activator inhibitor-1)
Fibrinolysis; Hemostasis; Thrombus; (Rat) (Ohtani, A. (330) 151)

Paired-pulse inhibition
Adenosine; Purine; (−)-Bicuculline; GABA (γ-aminobutyric acid); Inhibition; Hippocampus; Cyclopentyltheophylline (Higgins, M.J. (317) 215)

Palmitoylation
Dopamine; Dopamine D_1 receptor; Adenylyl cyclase; Desensitization (Jin, H. (324) 109)

Palmitoylethanolamide
Anandamide; Tetrahydrocannabinol; Cannabinoid receptors; Cytokines; Mononuclear cells; Immune response (Berdyshev, E.V. (330) 231)

Pancreas
Imidazoline; Antazoline; Insulin secretion; Somatostatin secretion; Glucose tolerance; (Rat); (Dog) (Berdeu, D. (324) 233)

Pancreatic B-cell
Insulin secretion; $[Ca^{2+}]_i$; Tetracaine (Bordin, S. (327) 257)

Pancreatic polypeptide
Neuropeptide Y; Peptide YY; [Leu^{31},Pro^{34}]Peptide YY (Gehlert, D.R. (318) 485)

Neuropeptide Y; Neuropeptide Y receptor, Y_4 and Y_5 subtype (Trinh, T. (318) R1)

3-Panel runway
Rolipram; cAMP; Learning; Memory; Passive avoidance (Imanishi, T. (321) 273)

Papillary muscle
α-Adrenoceptor, subtype; Atrial muscle; BMY 7378; Contractility; (Rat) (Wang, S.-N. (321) 39)

Muscarinic M_2 receptor; Antibody; Peptide; Inotropic effect (Skomedal, T. (333) 169)

Parafascicular nucleus
Neuropeptide FF; Receptors; Morphine-analgesia; Rat; Dorsal raphe nucleus; Serotonin (Dupouy, V. (330) 129)

Parasympathetic division
Opioid; Immunity; Lymphocyte proliferation; Autonomic nervous system; Sympathetic division; (Rat) (Flores, L.R. (318) 437)

Parasympathetic nerve
PACAP (pituitary adenylate cyclase-activating polypeptide); Atrioventricular conduction; VIP (vasoactive intestinal peptide) (Hirose, M. (338) 35)

Parasympathetic nervous system
Cyclosporine chronopharmacology; Sympathetic nervous system; Submaxillary lymph node; Ornithine decarboxylase; Norepinephrine uptake; Acetylcholine synthesis; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (319) 181)

Paraventricular nucleus of the hypothalamus
Immediate-early gene; Amygdala, central; Bed nucleus of the stria terminalis; Corticosterone; CRH (corticotropin-releasing hormone) (Compaan, J.C. (324) 161)

NMDA (*N*-methyl-D-aspartate); Nitric oxide (NO); Dopamine; Oxytocin; Penile erection; Yawning; (Rat) (Melis, M.R. (328) 115)

Parkinson's disease
GDNF (glial cell line-derived neurotrophic factor); Substantia nigra; Striatum; Dopamine; Monoamine (Martin, D. (317) 247)

Talipexole; Bromocriptine; Dopamine D_2 receptor agonist; Anti-tremor effect; Ventromedial tegmentum lesion; (Cynomolgus monkey) (Kohno, Y. (319) 197)

L-DOPA (3,4-dihydroxyphenyl-L-alanine); Striatum; Early gene; Dopamine D_1 receptor; Dopamine D_2 receptor (Fenu, S. (321) 143)

Tacrine; Cognex; Acetylcholine; Vacuous chew; Purposeless; Tremor; Alzheimer's disease (Cousins, M.S. (322) 137)

Dopamine transporter; WIN 35,428 binding; Arachidonic acid; Protein kinase C; Drug abuse (Reith, M.E.A. (324) 1)

Flupirtine; NMDA receptor, antagonistic; Catalepsy; Locomotion; L-DOPA (L-dihydroxyphenylalanine) (Schmidt, W.J. (327) 1)

cAMP; Dopamine D_1 receptor; Dopamine D_2 receptor; Striatum (Pinna, A. (331) 23)

HU-211; NMDA receptor antagonist; Dopamine receptor antagonist; Catalepsy (Striem, S. (338) 205)

Parotid acinar cell
Ca^{2+} release; Na^+, external; P_2 purinoceptor (Fukushi, Y. (336) 89)

Parotid acini
Amylase secretion; K^+ channel; Isoprenaline (Murayama, T. (322) 21)

Paroxetine
Single photon detection system; Dopamine transporter; 5-HT (5-hydroxytryptamine, serotonin) transporter; GBR 12909; RTI-55 (Mochizuki, T. (338) 17)

Paroxysmal choreoathetosis
Glutamate; Na^+ channel blocker; Movement disorder (Richter, A. (332) 133)

Partial agonism
Opioid; Dynorphin (Soderstrom, K. (338) 191)

Partial agonist
[^{3}H]CGP-39653; Binding; Allosteric modulation (Robichon, R. (328) 255)

Passive avoidance
Rolipram; cAMP; Learning; Memory; 3-Panel runway (Imanishi, T. (321) 273)

Nimodipine, chronic; Metrifonate, acute; Water maze; Motor test; Washout; Aged rat; Medial septum-lesioned rat (Riekkinen, M. (322) 1)

Adenosine A_1 receptor antagonist; BIIP 20; Memory (Pitsikas, N. (328) 19)

Passive avoidance learning
R-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-*N*,*N*-(di-*n*-propyl-2-amino)tetralin); Dopamine D_3 receptor; Spontaneous locomotor activity; Memory; (Mouse) (Ukai, M. (324) 147)

[D-Pen^2,L-Pen^5]Enkephalin; [D-Ala^2]Deltorphin II; Spontaneous alternation performance; Elevated plus-maze behavior; δ-Opioid receptor; (Mouse) (Ukai, M. (338) 1)

Patch-clamp
Bladder detrusor, guinea pig; BK_{Ca} channel; Whole-cell recording; Inside-out single channel recording; Open-state probability (Hu, S. (318) 461)

Acetylcholine; Acetylcholinesterase activity; Adrenal homogenate; Nicotine-induced inward current; Physostigmine (Sugawara, T. (319) 123)

K_{ATP} channel; Skeletal muscle; Glybenclamide receptor (Tricarico, D. (321) 369)

Levamisole; Nicotinic acetylcholine receptor; Heterogeneity; (*Oesphagostomum dentatum*) (Martin, R.J. (322) 249)

K^+ channel, Ca^{2+}-activated; Endothelin-1; Endothelin-3; Endothelin ET_A receptor (Hu, S. (324) 277)

GABA (γ-aminobutyric acid); Pregnanolone; Tetrahydrodeoxycorticosterone; Dehydroepiandrosterone; Pregnenolone sulfate; Neuroactive steroid; Pituitary melanotrope cell (Le Foll, F. (331) 303)

Neuroprotection; Ischemia; Inward current; Outward current; Ion channel (Suma, C. (336) 283)

Ondansetron; GABA (γ-aminobutyric acid); Whole-cell current; Seizure (Ye, J.H. (337) 87)

Patch clamp, perforated
Thrombin receptor; Megakaryocyte, rat; Ca^{2+}-activated K^+ current (Uneyama, C. (319) 299)

Patch clamp, whole-cell
K^+ current; Na^+ current; KC8851; Open channel blockade (McLarnon, J.G. (339) 279)

Patch-clamp electrophysiology
Membrane potential; Antiepileptics; Cromakalim; Glibenclamide; NG 108-15 cell; hNT neuron; Cortical neuron, mouse (Rundfeldt, C. (336) 243)

Patch clamp recording
Mineralocorticoid; Glucocorticoid; Hippocampal slice (Karst, H. (339) 17)

Patch clamp technique
Levosimendan; K^+ channel; K^+ channel, ATP-sensitive; Mesenteric artery, rat (Yokoshiki, H. (333) 249)

Pathogenesis
Brain damage; Cerebral cortex; Receptor isoform; Receptor subtype; (Human) (Lewohl, J.M. (326) 265)

Paw edema
Microdialysis; Histamine; Mast cell deficient rat (Ws/Ws rat); Compound 48/80; Degranulation (Guo, Y. (331) 237)

Paw oedema
1,8-cineole; Mast cell; Compound 48/80; Ketotifen; Cyproheptadine; (Rat) (Santos, F.A. (331) 253)

PC12 cell
ATP; Purinoceptor P_{2X}; Trivalent cation; *Xenopus* oocyte (Nakazawa, K. (325) 237)

Nitric oxide (NO) pharmacology; Neuropeptide Y (Dötsch, J. (331) 313)

PCCG-IV ((2*S*,1′*S*,2′*S*,3′*R*)-2-(2″-carboxy-3′-phenylcyclopropyl)-glycine)
mGlu receptor; Long-term potentiation; Hippocampus; MTPG ((*R,S*)-α-methyl-4-tetrazolylphenylglycine) (Huang, L. (332) 161)

PCR (polymerase-chain reaction)
CC-1065 analog; Gene sequence, human (Passadore, M. (319) 317)

(+)-PD 128907
Haloperidol; (+)-AJ76; (+)-UH-232; (−)-Apomorphine; Discriminative stimulus effect; Dopamine D_3 receptor (Kleven, M.S. (321) 1)

PD 123319
Angiotensin; Heart rate; Arterial pressure; Spinal cord; Cardiovascular control; Losartan (Park, P.D.S. (326) 139)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Losartan; Uterine artery; Pregnancy; (Sheep) (Burrell, J.H. (330) 257)

PD128907
Dopamine receptor agonist; PNU-95,666; DOPAC (3,4-dihydroxyphenylal acetic acid); Median eminence (Durham, R.A. (335) 37)

PD155080
Endothelin-1; Endothelin receptor antagonist; Bosentan; Clearance; Half-life; Vascular effect (Hemsén, A. (318) 369)

PDGF (platelet-derived growth factor)
Coronary artery smooth muscle cell; Mitogenesis; Thromboxane A_2 (Grosser, T. (319) 327)

PECAM-1
Adhesion molecule; Glucocorticoid; Inflammation; Interleukin-1; TNF-α (Wheller, S.K. (331) 65)

Pelvic nerve
Bladder; Micturition contraction; Periurethral muscle; Pudendal nerve; (Rat) (Kagitani, F. (332) 89)

Penile erection
Adrenomedullin; Cavernosal pressure; (Cat) (Champion, H.C. (319) 71)

5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{2C}$ receptor (Millan, M.J. (325) 9)

NMDA (*N*-methyl-D-aspartate); Nitric oxide (NO); Dopamine; Oxytocin; Yawning; Paraventricular nucleus of the hypothalamus; (Rat) (Melis, M.R. (328) 115)

Pentadecapeptide BPC 157
Peptide BPC; Nitric oxide (NO); Gastrointestinal mucosal integrity; Blood pressure maintenance; Gastric lesion; Hypotension; N^G-Nitro-L-arginine methylester; L-Arginine; Stomach mucosa (Slobodnjak, Z. (332) 23)

(+)-Pentazocine
σ Receptor; Cytotoxicity; Regulation; Internalization; Desensitization (Zambon, A.C. (324) 39)

σ_2 Receptor; Norepinephrine; Hippocampus; BIMU-8 (Weatherspoon, J.K. (326) 133)

[^{3}H](+)-Pentazocine
σ Receptor; 2(3*H*)-Benzoxazolone; 2(3*H*)-Benzothiazolone; Anticonvulsant (Ucar, H. (335) 267)

Pentazocine
Matrine; Antinociception; κ-Opioid receptor; Nor-binaltorphimine; (Mouse) (Kamei, J. (337) 223)

Pentoxifylline
TNF-α (tumor necrosis factor-α); Anti-TNF strategy; Lipopolysaccharide; Fever; TNF bioassay; Radiotelemetry; (Guinea pig) (Goldbach, J.-M. (319) 273)

AIDS (acquired immunodeficiency syndrome); LP-BM5 murine leukemia virus; Encephalopathy; PAF (platelet-activating factor); TNF-α (tumor necrosis factor-α) (Sei, Y. (325) 81)

Pentylenetetrazole
Acamprosate; Ethanol withdrawal; Hippocampus; Cerebellum; c-*fos* mRNA; Northern and dot blotting; In situ hybridization (Putzke, J. (317) 39)

Penumbra
Glutamate; Taurine; Lubeluzole; Neuroprotection; Swelling; Microdialysis (Scheller, D.K.A. (338) 243)

Peptidase inhibitor
Tachykinin receptor; Oestrogen; Uterus; SR 142801 (Fisher, L. (335) 221)

Peptide
Muscarinic M_2 receptor; Antibody; Inotropic effect; Papillary muscle (Skomedal, T. (333) 169)

Peptide BPC
Pentadecapeptide BPC 157; Nitric oxide (NO); Gastrointestinal mucosal integrity; Blood pressure maintenance; Gastric lesion; Hypotension; N^G-Nitro-L-arginine methylester; L-Arginine; Stomach mucosa (Slobodnjak, Z. (332) 23)

Peptide YY
Neuropeptide Y; Pancreatic polypeptide; [Leu^{31},Pro^{34}]Peptide YY (Gehlert, D.R. (318) 485)

Intestinal secretion; VIP (vasoactive intestinal peptide); Intestinal nerve; α_2-Adrenoceptor; σ Receptor; (Rat) (Souli, A. (333) 87)

Periaqueductal gray
α_2-Adrenoceptor; Antinociception; Nitric oxide (NO); Opiate receptor (Fang, F. (336) 137)

Peripheral tissue, rat
[^{125}I]*R*(+)-Zacopride; Autoradiography; Radioligand binding; *R*(+)-site; Brain, rat (Ge, J. (332) 307)

Peripheral-type benzodiazepine receptor
RT-PCR (reverse transcriptase-polymerase chain reaction); GAPDH (glyceraldehyde-3-phosphate dehydrogenase); Stress; Dexamethasone (Siripurkpong, P. (331) 227)

Peristalsis
Histamine H_3 receptor; Prejunctional receptor; Intramural reflex; Circular muscle; Ileum, guinea pig (Poli, E. (327) 49)

Peritoneal macrophage
VIP (vasoactive intestinal peptide); Adenylyl cyclase; VIP receptor antagonist; VIP receptor; Propranolol; Isoproterenol; Neuroimmunobiology (Pozo, D. (321) 379)

Periurethral muscle
Bladder; Pelvic nerve; Micturition contraction; Pudendal nerve; (Rat) (Kagitani, F. (332) 89)

Perivascular nerve
Endothelium; Mesenteric arterial bed; Nitric oxide (NO); Sensory nerve; (Golden hamster) (Hill, B. (317) 275)

Permeability
2-Phenyl-4-quinolone; Endothelial cell, rat; 5-HT (5-hydroxytryptamine, serotonin); Gap formation; cAMP (Lee, H.-Z. (335) 245)

Peroxynitrite
Nitric oxide (NO); Sugar; Vasodilatation; L-Cysteine; Sodium nitrite; Methylene blue; Haemoglobin (Dowell, F.J. (338) 43)

Mercaptoalkylguanidine; Haemorrhagic shock; Nitric oxide (NO); 6-Keto-prostaglandin-1α (Zingarelli, B. (338) 55)

PET (positron-emission tomography)
RS-79948-197; Brain; α_2-Adrenoceptor; Radioligand; In vivo; (Rat) (Hume, S.P. (317) 67)

6-[^{18}F]L-DOPA (6-[^{18}F]L-3-4-dihydroxyphenylalanine); Catechol-*O*-methyltransferase inhibition; Monoamine oxidase inhibition; Dopamine turnover (Doudet, D.J. (334) 31)

PF-904
Airway; Airway, hyperreactivity; Eosinophil infiltration; Microvascular leakage; Bronchus, human, isolated; Phosphodiesterase activity; Neutrophils, human; Superoxide anion generation; (Guinea pig) (Cortijo, J. (333) 69)

P-glycoprotein
Renal clearance; Active secretion; Drug interaction; Multidrug resistance; Organic cation carrier (Masereeuw, R. (321) 315)

Chemotherapeutic; Ca^{2+} current; Verapamil (Nanaumi, K. (327) 239)

pH
Ca^{2+} paradox; O_2 paradox; Caffeine; Amiloride; Heart damage (Harding, R.J. (330) 47)

pH dependence
$P2X_2$ purinoceptor; Neuroamine; Adenosine; Zn^{2+}; Cd^{2+} (Nakazawa, K. (337) 309)

Phagocytosis
Antibiotics; Polymorphonuclear leukocyte; Respiratory burst (Hoeben, D. (332) 289)

Pharmacokinetics
Dopamine; HI 6; Microdialysis; Acetylcholine esterase; Soman; (Rat) (Cassel, G. (332) 43)

Pharmacological method, new
Efficacy estimation; Agonist affinity; Carbachol; Salbutamol (Venter, D.P. (320) 233)

Pharmacophore
δ-Opioid receptor; Ligand binding thermodynamics; Model (Maguire, P.A. (318) 505)

Phencyclidine
Place conditioning paradigm; Place aversion; Place preference; (Rat) (Kitaichi, K. (318) 7)

Choice reaction time; Attention; σ Receptor (Jin, J. (319) 147)

Imidazoline receptor; Efaroxan; σ Receptor; Insulin secretion; (+)-MK-801 (dizocilpine) (Chan, S.L.F. (323) 241)

Antidepressant; Schizophrenia, negative symptom; Depression; 5-HT (5-hydroxytryptamine, serotonin); Forced swimming test; (Mouse) (Noda, Y. (324) 135)

Phencyclidine (PCP) receptor
σ Receptor; Dizocilpine; Head-weaving behavior; (Rat) (Kitaichi, K. (318) 205)

Phentolamine
Pain; Vein; Noradrenaline; (Human) (Kindgen-Milles, D. (328) 41)

Phenylarsine oxide
Neutrophil; NADPH oxidase; Inflammation; NADPH oxidase inhibitor; Anti-inflammatory drug (Roussin, A. (322) 91)

Lipopolysaccharide; Nitric oxide (NO) synthase, inducible; Aorta, rat; Genistein; Tyrphostin; Orthovanadate (Duarte, J. (338) 25)

Phenylglycine
Ca^{2+} imaging; Cross talk; cAMP (Schaffhauser, H. (334) 289)

2-Phenyl-4-quinolone
Endothelial cell, rat; 5-HT (5-hydroxytryptamine, serotonin); Gap formation; Permeability; cAMP (Lee, H.-Z. (335) 245)

8-Phenyltheophylline
Hepatic circulation; Vasodilatation; ATP; Adenosine; (Rat) (Browse, D.J. (320) 139)

Phenytoin
BW1003C87; Carbamazopine; Anticonvulsant effects; Amygdala-kindling; Seizure threshold (Morimoto, K. (339) 11)

***Phoneutria nigriventer* venom**
Sensory nerves; Capsaicin; Neurogenic oedema; Tachykinin NK_1 receptor agonist (Costa, S.K.P. (339) 223)

Phorbol ester
Adenosine receptor; Protein kinase C; SH-SY5Y neuroblastoma cell; cAMP (Peterfreund, R.A. (336) 71)

Phorbol 12-myristate 13-acetate
Norathyriol; Neutrophil, rat; Respiratory burst; Aggregation; Protein kinase C; Translocation (Wang, J.-P. (336) 81)

Phosphatase
Okadaic acid; Calyculin A; Tumor cell locomotion; Walker 256 carcinosarcoma cell; Vimentin (Niggli, V. (324) 99)

K^+ channel, Ca^{2+}-activated; cGMP; Iberiotoxin; Nitric oxide (NO); Okadaic acid; Smooth muscle (Johansson Rydberg, I.G.M. (329) 175)

Phosphatidylinositol hydrolysis
α_1-Adrenoreceptor subtype; Cardiac myocyte, rat, neonatal; Mitogen activated protein kinase (Wenham, D. (339) 77)

Phosphatidylinositol 3-kinase
Neutrophils; Cell locomotion; Wortmannin; Actin, α-Actinin (Niggli, V. (335) 43)

Phosphatidylinositol 3-kinase inhibitor
Wortmannin; Anti-angiogenic activity; Angiogenesis, embryonic; Chorioallantoic membrane (Oikawa, T. (318) 93)

Phosphinic inhibitor
Endopeptidase 3.4.24.15; Neurotensin; Analgesia; (Mouse) (Vincent, B. (334) 49)

Phosphodiesterase
Apoptosis; Imidazo[1,2-*a*]pyrazine derivative; Megakaryoblastic cell, human; cAMP; Purinoceptor (Zurbonsen, K. (320) 215)

cGMP; Ca^{2+}; Granule cell; Astrocyte (Agulló, L. (323) 119)

Heart; Guanylyl cyclase; Ca^{2+} current, L-type; Force of contraction; Fura-2 (Wegener, J.W. (326) 37)

Rolipram; Cortical neuron; cAMP (Yamashita, N. (337) 95)

Phosphodiesterase, cyclic nucleotide
Chelerythrine; Protein kinase C; Vasorelaxation; SK&F 94120; Isoprenaline (Eckly-Michel, A.E. (324) 85)

Phosphodiesterase activity
PF-904; Airway; Airway, hyperreactivity; Eosinophil infiltration; Microvascular leakage; Bronchus, human, isolated; Neutrophils, human; Superoxide anion generation; (Guinea pig) (Cortijo, J. (333) 69)

Phosphodiesterase I / IV inhibitor
Phosphodiesterase III inhibitor; Anti-allergic effect; Bronchodilator effect; (Guinea pig) (Fujimura, M. (327) 57)

Phosphodiesterase III inhibitor
Phosphodiesterase I/IV inhibitor; Anti-allergic effect; Bronchodilator effect; (Guinea pig) (Fujimura, M. (327) 57)

Lipopolysaccharide; cAMP; cGMP; Monocyte; Macrophage; Interleukin-10; TNF-α (tumor necrosis factor-α); Nitric oxide (NO) (Németh, Z.H. (339) 215)

Phosphodiesterase inhibitor
Org 9935; Org 30029; Insulin secretion; Insulin, plasma; Glucose, plasma (El-Metwally, M. (324) 227)

Asthma; Eosinophil; Bronchodilator; Hyperreactivity; KF19514 (Manabe, H. (332) 97)

Smooth muscle, airway; Airway tone, spontaneous; Prostaglandin; (Guinea pig) (Thirstrup, S. (333) 215)

Phosphodiesterase isoenzyme
SCA40; Trachealis, bovine; K^+-rich media; Electrophysiology; $^{86}Rb^+$ efflux (Pocock, T.M. (334) 75)

Phosphoinositide
Rutaecarpine; Alkaloid; Platelet, human; cAMP; cGMP; Thromboxane A_2 (Sheu, J.-R. (318) 469)

Phosphoinositide hydrolysis
5-HT receptor; Adenylyl cyclase; Raphe nucleus, dorsal; Hippocampus; $5\text{-}HT_{1A}$ receptor (Johnson, R.G. (329) 99)

Phospholipase A_2
Lipopolysaccharide; Arachidonic acid; Protein kinase; UTP; RAW 264.7 macrophage (Lin, W.W. (321) 121)

Endothelin-1; Endothelin-converting enzyme; Phospholipase C; Phosphoramidon (N'Diaye, N. (321) 387)

Inflammation; Phospholipase inhibitor; Interleukin-1; Integrin (Amandi-Burgermeister, E. (326) 237)

Phospholipase C
Abruquinone A; Neutrophil; Inositol phosphate; Ca^{2+} concentration, intracellular (Wang, J.-P. (319) 131)

Endothelin-1; Endothelin-converting enzyme; Phospholipase A_2; Phosphoramidon (N'Diaye, N. (321) 387)

Phospholipase C coupling
Metabotropic glutamate receptor; Alternative splicing; Constitutive activity; G-protein coupled receptor (Mary, S. (335) 65)

Phospholipase inhibitor
Phospholipase A_2; Inflammation; Interleukin-1; Integrin (Amandi-Burgermeister, E. (326) 237)

Phosphoramidon
Endothelin-1; Endothelin-converting enzyme; Phospholipase C; Phospholipase A_2 (N'Diaye, N. (321) 387)

Phosphorylation
RBL-2H3; Astemizole; Membrane; Protein; Tyrosine; Ca^{2+}; Flux; Exocytosis (Fischer, M.J.E. (322) 97)

Sauvagine; Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Edema; Ca^{2+}; Inositol trisphosphate; CRF receptor; Skin; Tyrosine (Kiang, J.G. (329) 237)

Antidepressant; Desipramine; Microtubule-associated protein 2; Microtubule assembly (Miyamoto, S. (333) 279)

Phosphorylcholine
Phosphoserine phosphatase; L-Serine; D-Serine; Glycerylphosphorylcholine; *p*-Chloromercuriphenylsulfonic acid; *N*-Ethylmaleimide (Hawkinson, J.E. (337) 315)

Phosphoserine phosphatase
L-Serine; D-Serine; Glycerylphosphorylcholine; Phosphorylcholine; *p*-Chloromercuriphenylsulfonic acid; *N*-Ethylmaleimide (Hawkinson, J.E. (337) 315)

Photochemical infarction, treatment
Ischemia, focal; NMDA receptor antagonist; Nitric oxide (NO) (Buchkremer-Ratzmann, I. (320) 103)

Photoelectric method
Cerebral blood volume; Cerebral vessel; FK888; Substance P; Tachykinin NK_1 receptor antagonist (Kobari, M. (317) 269)

Phrenic nerve-diaphragm muscle preparation
CGRP (calcitonin gene-related peptide) release; Acetylcholine release; Neostigmine (Kimura, I. (330) 123)

Physical dependence
Dihydroetorphine; Etorphine; Antinociception; (Rhesus monkey); (Mouse) (Aceto, M.D. (338) 215)

Physicochemical parameter
5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1A}$ receptor; Binding; Autoradiography; [^{3}H]Alnespirone (Fabre, V. (337) 297)

Physostigmine
Acetylcholine; Acetylcholinesterase activity; Adrenal homogenate; Nicotine-induced inward current; Patch clamp (Sugawara, T. (319) 123)

Pial vein
Dopamine D_1 receptor; Dopamine D_2 receptor; α_2-Adrenoceptor; (Constriction); (Porcine) (Sun, M.-H. (334) 165)

Pilocarpine
Microdialysis; Hippocampus; Cerebellum; Epilepsy; Amino acid (Smolders, I. (319) 21)

Pimobendan
Ca^{2+} sensitivity; G-protein; Protein kinase C; β-Escin; Cardiac muscle; Smooth muscle, vascular (Tomita, F. (326) 157)

Pinacidil
Reperfusion arrhythmia; Cromakalim; Glibenclamide; Anesthetized rat (Baczkó, I. (324) 77)

Pineal
Adenosine; Adenosine receptor; Melatonin; (Sheep) (Falcón, J. (337) 325)

Pineal gland
α_2-Adrenoceptor; Melatonin; Circadian rhythm; Medetomidine; Atipamezole (Mustanoja, S.M. (326) 229)

Piperazine acceptor site
[^{3}H]GBR 12935 binding; Cytochrome P-450IID6; Platelet, human (Norlén, M. (332) 227)

Pirenzepine
Muscarinic M_1 receptor; Muscarinic M_2 receptor; Scopolamine; Methoctramine; Alzheimer's disease; (Delay-dependent and -independent); (% correct choice) (Aura, J. (333) 129)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; Muscarinic M_3 receptor; N^G-nitro-L-arginine methyl ester (L-NAME); N^G-nitro-L-arginine; Atropine; Gallamine (Koss, M.C. (335) 199)

Piribedil
Lipid peroxidation; Brain; Oxygen exposure, high (Calzi, F. (338) 185)

Pirmenol
K^+ current, muscarinic acetylcholine receptor-operated ($I_{K,ACh}$); Atrial fibrillation; Disopyramide (Watanabe, Y. (338) 71)

Piroxicam
Epinephrine; Ethanol; Isolated hepatocyte; Thiobarbituric acid-reactive substance; Triacylglyceride (Saldaña-Balmori, Y. (317) 225)

Pithed rat
α_1-Adrenoceptor, subtype; Aging; Blood pressure; BMY 7378 (Ibarra, M. (322) 221)

Pituitary melanotrope cell
GABA (γ-aminobutyric acid); Pregnanolone; Tetrahydrodeoxycorticosterone; Dehydroepiandrosterone; Pregnenolone sulfate; Neuroactive steroid; Patch-clamp (Le Foll, F. (331) 303)

Place aversion
Phencyclidine; Place conditioning paradigm; Place preference; (Rat) (Kitaichi, K. (318) 7)

Place conditioning paradigm
Phencyclidine; Place aversion; Place preference; (Rat) (Kitaichi, K. (318) 7)

Placenta
Muscarinic receptor; Muscarinic receptor subtype; (Human) (Pavía, J. (320) 209)

Placenta, human, term
P_{2X} purinoceptor; Chorionic surface artery; α,β-Methylene-ATP; UTP receptor; Smooth muscle, vascular (Dobronyi, I. (320) 61)

Place preference
Phencyclidine; Place conditioning paradigm; Place aversion; (Rat) (Kitaichi, K. (318) 7)

Diabetes; Methamphetamine; Dopamine D_3 receptor; Mesolimbic dopamine system; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Kamei, J. (318) 251)

Plasma
Cholesterol; Liver; Bile; Gallstone; Cholesterol 7α-hydroxylase; Acyl coenzyme A:cholesterol acyltransferase (Hajri, T. (320) 65)

Plasma extravasation
Substance P; Tachykinin NK_1 receptor; Migraine; Pain (Seabrook, G.R. (317) 129)

Mustard oil; Neurogenic inflammation; Ear oedema; Capsaicin; SR 140333 (Inoue, H. (333) 231)

Plasma leakage
NO synthase inhibitors; Blood flow; Bradykinin; Histamine (Perez, A.C. (330) 241)

β_2-Adrenoceptor agonist; Substance P; Trachea; Vascular permeability (Bowden, J.J. (338) 83)

Plasma noradrenaline
Nitric oxide (NO); Interleukin-1β; Prostaglandin; Central nervous system (Murakami, Y. (317) 61)

Plasma protein extravasation
5-HT receptor; Histamine receptor; Tachykinin; Airways; Capsaicin; (Fisher 344 rat) (Germonpré, P.R. (324) 249)

Plasma renin activity
Non-steroidal anti-inflammatory drug; Kidney; Circulation; Prostanoid; Cytochrome *P*-450 activity; Na^+ excretion (Kramp, R.A. (330) 165)

Plasminogen activator
Vasopressin; Oxytocin; Factor VIII (F-VIII); Antihemophilic factor; Blood clotting; Neurohypophyseal hormone analog; Dose–response analysis; Time response; Non-monotonic profile (Neuenschwander, S. (323) 205)

Platelet, human
Rutaecarpine; Alkaloid; cAMP; cGMP; Thromboxane A_2; Phosphoinositide (Sheu, J.-R. (318) 469)

[^{3}H]GBR 12935 binding; Piperazine acceptor site; Cytochrome P-450IID6 (Norlén, M. (332) 227)

Platelet aggregation
Zooxanthellatoxin-A; Tyrphostin 23; Mitogen-activated protein kinase (Rho, M.-C. (319) 375)

YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole); Tail bleeding time; Antithrombotic effect; Profibrinolytic effect (Teng, C.-M. (320) 161)

Thrombin; Thrombin receptor-activating peptide; Thrombin inhibitor; ^{111}Indium oxine; Receptor binding; Pulmonary microcirculation (Chiu, P.J.S. (321) 129)

Cerebral ischemia; Thrombosis; (Rat) (Kaku, S. (321) 301)

Aldose reductase inhibitor; Electroretinogram; Sorbitol; 2,3-Diphosphoglycerate; Diabetic retinopathy (Hotta, N. (326) 45)

Arterial thrombosis; Cyclooxygenase; Thromboxane A_2 (Shimazawa, M. (328) 183)

Glycoprotein IIb/IIIa; Monoclonal antibody; Bleeding time (Suzuki, K.-i. (336) 169)

Pleurisy
Bradykinin; Anti-inflammatory drugs; Bradykinin receptor antagonist; Inflammatory mediator (Saleh, T.S.F. (331) 43)

Plus-maze
Stress; Ethanol; Ro 15-4513; Sleep; $^{36}Cl^-$ uptake; [^{3}H]Ro 15-4513 (Pokk, P. (317) 15)

Plus maze, elevated
Nitric oxide (NO); Anxiety; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Arterial blood pressure; Nitric oxide (NO) synthase; Brain (Faria, M.S. (323) 37)

P-4 (1-methyl-4-piperidyl diphenylpropoxyacetate hydrochloride)
Anti-pollakiuric agent; Urinary bladder; Smooth muscle; Actomyosin ATPase activity; Calmodulin (Matsushima, S. (333) 93)

PNU-95,666
Dopamine receptor agonist; PD128907; DOPAC (3,4-dihydroxyphenylal acetic acid); Median eminence (Durham, R.A. (335) 37)

Polyamine
Putrescine; Spermidine; Spermine; NMDA (*N*-methyl-D-aspartate); Motor activity; MK-801; Amphetamine; Theophylline; (Mouse) (Giménez-Llort, L. (318) 231)

Polymerase chain reaction
Tachykinin NK_3 receptor, expression; Uterus, rat (Pinto, F.M. (324) 125)

Polymorphonuclear leukocyte
Aceclofenac; Cyclooxygenase; Prostaglandin E_2; Monocyte; Synovial cell (Yamazaki, R. (329) 181)

Antibiotics; Respiratory burst; Phagocytosis (Hoeben, D. (332) 289)

Polyphosphoinositide hydrolysis
Metabotropic glutamate receptor; Hepatocyte, cultured (Sureda, F. (338) R1)

Polyunsaturated fatty acid
ETYA (5,8,11,14-eicosatetraynoic acid); Endothelial cell activation; Gene regulation; Inhibition; Adhesion molecule (Stuhlmeier, K.M. (325) 209)

Portal hypertension
Nitric oxide (NO); Nitric oxide (NO) synthase; Aminoguanidine; Portal vein ligation, rat (Michielsen, P.P. (329) 137)

Portal vein ligation, rat
Nitric oxide (NO); Nitric oxide (NO) synthase; Aminoguanidine; Portal hypertension (Michielsen, P.P. (329) 137)

Positive inotropic action
α_1-Adrenoceptor, subtype; Endogenous noradrenaline; WB4101; Chlorethylclonidine; Myocardium, rabbit (Hattori, Y. (329) 165)

Postsynaptic dopamine receptor
Dopamine D_2 receptor; Dopamine agonist; Dopamine autoreceptor (Piercey, M.F. (317) 29)

Potentiation
Nitric oxide (NO) synthase; Nitric oxide (NO); Neuronal; Muscarinic acetylcholine receptor; (Intact cell) (Cuadra, A.E. (334) 107)

$pp60^{c\text{-}src}$
Mesangial cell; Proliferation; Captopril; Angiotensin II-converting enzyme inhibitor; Tyrosine phosphorylation (Ruiz-Ginés, J.A. (336) 251)

P_1 purinoceptor
Duodenum longitudinal muscle, rat; Duodenum muscularis mucosae, rat; Development; Ontogeny; Adenosine receptor (Brownhill, V.R. (317) 321)

P_2 purinoceptor
Coronary artery, canine; Vasoconstriction; Vasodilation; ATP; UTP; Suramin; Reactive blue 2 (Matsumoto, T. (334) 173)

Ca^{2+} release; Na^+, external; Parotid acinar cell (Fukushi, Y. (336) 89)

P_{2U} purinoceptor
Thrombin receptor; Adenosine A_1 receptor; Inositol phosphate; Arachidonic acid; CHO (Chinese hamster ovary) cell; Protein kinase C (Dickenson, J.M. (321) 77)

P_{2X} purinoceptor
Chorionic surface artery; Placenta, human, term; α,β-Methylene-ATP; UTP receptor; Smooth muscle, vascular (Dobronyi, I. (320) 61)

Auricular artery; Sympathetic nerve stimulation; Purinergic transmission (Haniuda, K. (333) 163)

P_{2Y} purinoceptor
Apamin; Colon; DMPP (1,1-dimethyl-4-phenylpiperazinium iodide); Nitric oxide (NO); Reactive blue 2; (Rat) (Börjesson, L. (334) 223)

Pramipexole
Dopamine receptor agonist; Antipsychotic potential activity; Antiparkinsonian potential activity (Maj, J. (324) 31)

Talipexole; Chloro-APB; MPTP-induced hemiparkinsonism; SKF 82958; Dopamine D_1-like receptor agonist; Dopamine D_2-like receptor agonist; (Monkey) (Domino, E.F. (325) 137)

Pranidipine (OPC-13340)
Ca^{2+} channel antagonist; Circulatory filling pressure, mean; Venodilator effect; (Rat) (Hirano, T. (324) 201)

Pravastatin sodium
HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase; LDL (low-density lipoprotein) receptor; Cholesterol 7α-hydroxylase; (Rat) (Fujioka, T. (323) 223)

HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase; Fatty acid synthesis; Fatty acid synthase; (Rat) (Fujioka, T. (328) 235)

Prazosin
Vas deferens, rat; Purinergic transmission; Noradrenergic transmission; Cromakalim; Suramin; Glibenclamide (Grana, E. (319) 57)

α_1-Adrenoceptor; Terazosin; Radioligand assay (Ireland, L.M. (327) 79)

Chloroethylclonidine; Aorta; Spleen; Submandibular gland; α_1-Adrenoceptor; α_2-Adrenoceptor; (Rat) (O'Rourke, M. (336) 37)

Preconditioning
Genistein; Arrhythmia, ventricular; Tyrosine kinase (Fatehi-Hassanabad, Z. (338) 67)

Pregnancy
Striatum; Dopamine; Progesterone; NMDA (*N*-methyl-D-aspartic acid); Glutamate (Cabrera, R.J. (317) 55)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Losartan; PD-123319; Uterine artery; (Sheep) (Burrell, J.H. (330) 257)

Pregnanolone
Neurosteroid; Neuroactive steroid; Drug discrimination; Behavior (Vanover, K.E. (327) 97)

GABA (γ-aminobutyric acid); Tetrahydrodeoxycorticosterone; Dehydroepiandrosterone; Pregnenolone sulfate; Neuroactive steroid; Pituitary melanotrope cell; Patch-clamp (Le Foll, F. (331) 303)

Pregnenolone
Steroid hormones; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Pregnenolone sulfate
GABA (γ-aminobutyric acid); Pregnanolone; Tetrahydrodeoxycorticosterone; Dehydroepiandrosterone; Neuroactive steroid; Pituitary melanotrope cell; Patch-clamp (Le Foll, F. (331) 303)

Neurosteroids; Morphine; Allopregnanolone; Progesterone; 4′-Chlordiazepam; Opiate tolerance; Opiate dependence (Reddy, D.S. (337) 19)

Prejunctional receptor
Histamine H_3 receptor; Intramural reflex; Peristalsis; Circular muscle; Ileum, guinea pig (Poli, E. (327) 49)

Prepulse inhibition
Nitric oxide (NO); Startle; Startle reaction; Schizophrenia (Wiley, J.L. (328) 125)

Pressor effect
Endothelin; Endothelin ET_A receptor; Endothelin ET_B receptor; Nitric oxide (NO); Oxygen consumption; Liver (Higuchi, H. (328) 175)

Pressure-induced contraction
Myogenic response; Cerebral artery, rat; Tyrosine kinase inhibitor; Herbimycin A; Genistein (Masumoto, N. (330) 55)

Pressure-natriuresis
Imidazoline; Salt preference; Oral gavage (Cechetto, D.F. (325) 47)

Preweanling rat
Behavioral sensitization; Cocaine; Development, ontogeny; Neonatal rat (Tirelli, E. (328) 103)

Pristimerin
Inflammation; NO synthase, inducible; Triterpene; RAW 264.7 macrophage (Dirsch, V.M. (336) 211)

Profibrinolytic effect
YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole); Tail bleeding time; Antithrombotic effect; Platelet aggregation (Teng, C.-M. (320) 161)

Progesterone
Striatum; Pregnancy; Dopamine; NMDA (*N*-methyl-D-aspartic acid); Glutamate (Cabrera, R.J. (317) 55)

Steroid hormones; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Mifepristone; Oestrogen; LH (luteinizing hormone); Adrenoceptor antagonist (Salicioni, A.M. (332) 283)

Neurosteroids; Morphine; Pregnenolone sulfate; Allopregnanolone; 4'-Chlordiazepam; Opiate tolerance; Opiate dependence (Reddy, D.S. (337) 19)

Programmed cell death
Glutamate; Oxidative stress; Glutathione depletion (Froissard, P. (326) 93)

Proliferating cell nuclear antigen
Lung cancer; K-*ras*; Vitamin E; Chemoprevention (Yano, T. (323) 99)

Proliferation
Opioid; Estradiol; Uterus; Cell culture; (Rat) (Környei, J.L. (336) 65)

Mesangial cell; Captopril; Angiotensin II-converting enzyme inhibitor; Tyrosine phosphorylation; $pp60^{c\text{-}src}$ (Ruiz-Ginés, J.A. (336) 251)

Smooth muscle cell; Lipoxygenase; Migration (Nishio, E. (336) 267)

Proopiomelanocortin
Δ^9-Tetrahydrocannabinol; Opioid; mRNA; Arcuate nucleus (Corchero, J. (323) 193)

Propranolol
Butoxamine; Metoprolol; Neutrophil; Myeloperoxidase; Prostaglandin E_2 (Kaan, S.K. (317) 115)

VIP (vasoactive intestinal peptide); Peritoneal macrophage; Adenylyl cyclase; VIP receptor antagonist; VIP receptor; Isoproterenol; Neuroimmunobiology (Pozo, D. (321) 379)

DTG (1,3-di-*o*-tolylguanidine); σ Binding site; Desipramine; Alprenolol; Cerebral cortex, rat (Shirayama, Y. (331) 319)

Cardiomyopathy; β-Adrenoceptor subtype; Coupling efficacy; Adenylyl cyclase; Metoprolol; (Hamster) (Witte, K. (334) 209)

Prostacyclin
Neurotensin; Umbilical vein endothelial cell, human; Hematocrit (Schaeffer, P. (323) 215)

Nitric oxide (NO); Glomerulonephritis (Ikeda, M. (324) 283)

Prostaglandin
Nitric oxide (NO); Interleukin-1β; Central nervous system; Plasma noradrenaline (Murakami, Y. (317) 61)

Ureter; Histamine receptor; Histamine H_1 receptor; Histamine H_2 receptor; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Dodel, R.C. (318) 395)

Smooth muscle, airway; Airway tone, spontaneous; Phosphodiesterase inhibitor; (Guinea pig) (Thirstrup, S. (333) 215)

Prostaglandin E_2
Propranolol; Butoxamine; Metoprolol; Neutrophil; Myeloperoxidase (Kaan, S.K. (317) 115)

Allergic inflammation, recurrence of; Granulation tissue; Cyclooxygenase-1; Cyclooxygenase-2; NS-398; Indomethacin; Dexamethasone (Niki, H. (320) 193)

Auranofin; 12-*O*-Tetradecanoylphorbol 13-acetate; Thapsigargin; A23187; Cyclooxygenase 2; Cyclooxygenase 1; Macrophage (Yamashita, M. (325) 221)

Inflammation; Arthritis; HOE-140; Des-Arg^9-bradykinin; (Rat) (Tonussi, C.R. (326) 61)

Aceclofenac; Cyclooxygenase; Polymorphonuclear leukocyte; Monocyte; Synovial cell (Yamazaki, R. (329) 181)

Cyclooxygenase; Non-steroidal anti-inflammatory drugs; Formalin; Release, in vitro; Spinal cord; (Intrathecal) (Dirig, D.M. (331) 155)

Prostaglandin $F_{2\alpha}$
Airway, human; Histamine (Knight, D.A. (319) 261)

Sulfonylurea; Prostanoid; Thromboxane A_2; Tolazamide; Tolbutamide; Gliclazide; Glibenclamide; Bronchiole; Artery (Delaey, C. (325) 41)

Gastric fundus, rat; Endotoxin; Contractility; Nitric oxide (NO) (Lefebvre, R.A. (339) 201)

8-epi-Prostaglandin $F_{2\alpha}$
Thromboxane; Smooth muscle, vascular; U-46619; BMS-180291; SQ 29,548; Daltroban; BM-13505; SQ 30,741; AA-2414 (Zhang, R. (317) 91)

Prostaglandin H synthase-2
Non-steroidal anti-inflammatory drug; WISH cell (Hulkower, K.I. (331) 79)

Prostanoid
Angiotensin II; EDRF (endothelium-derived relaxing factor); Mesenteric artery; Mesenteric vein; Aging; Development (Konishi, C. (320) 175)

Sulfonylurea; Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Tolazamide; Tolbutamide; Gliclazide; Glibenclamide; Bronchiole; Artery (Delaey, C. (325) 41)

Adenosine transport, Na^+-dependent; Brush-border membrane vesicle; Cyclooxygenase; Non-steroidal anti-inflammatory drug (NSAID) (González-Castillo, C. (329) 245)

Non-steroidal anti-inflammatory drug; Kidney; Circulation; Plasma renin activity; Cytochrome *P*-450 activity; Na^+ excretion (Kramp, R.A. (330) 165)

Des-Arg^9-bradykinin; Gallbladder, guinea pig; Bradykinin B_1 receptor-selective antagonist; Bradykinin B_2 receptor-selective antagonist; Ca^{2+} (Cabrini, D.A. (331) 31)

Cerebral vein; Histamine H_2 receptor; Venodilation; Endothelium; Nitric oxide (NO) (Monge, L. (338) 135)

Prostate
α_1-Adrenoceptor; Mesenteric artery; Trigone; Urethra; (Rabbit) (Van der Graaf, P.H. (327) 25)

α_1-Adrenoceptor antagonist; KMD-3213; Benign prostatic hypertrophy; (Human) (Moriyama, N. (331) 39)

Arginase; L-Arginine; L-Citrulline; Nitric oxide (NO) synthase; (Pig); (Rabbit); (Rat) (Di Iulio, J.L. (337) 245)

Prostate cancer
Cell line, LNCaP, DU145, PC3; Cell proliferation; δ-Opioid receptor, μ-Opioid receptor, κ-Opioid receptor; Receptor subtype; Casein, bovine, human; Casomorphin (Kampa, M. (335) 255)

Prostate gland
NANC (non-adrenergic non-cholinergic) innervation; Noradrenergic innervation; Nitrergic innervation; (Rat); (Guinea pig); (Pig); (Rabbit) (Najbar-Kaszkiel, A.T. (337) 251)

Protease-activated receptor
Thrombin; Astrocyte culture (Debeir, T. (323) 111)

Protein
RBL-2H3; Astemizole; Membrane; Tyrosine; Phosphorylation; Ca^{2+}; Flux; Exocytosis (Fischer, M.J.E. (322) 97)

Proteinase inhibitor
Tryptase; Microvascular leakage; Mast cell; Histamine; Heparin; Histamine receptor antagonist (He, S. (328) 89)

Protein kinase
Lipopolysaccharide; Arachidonic acid; Phospholipase A_2; UTP; RAW 264.7 macrophage (Lin, W.W. (321) 121)

Protein kinase, cAMP dependent
Desensitization; β-Adrenoceptor; Adenylyl cyclase; Receptor density (Rousseau, G. (326) 75)

Protein kinase A
Nitric oxide; Apoptosis; Smooth muscle cell; Protein kinase C (Nishio, E. (339) 245)

Protein kinase C
Broussochalcone A; Neutrophil, rat; Respiratory burst; Inositol trisphosphate; Ca^{2+} concentration, intracellular; NADPH oxidase (Wang, J.-P. (320) 201)

Thrombin receptor; Adenosine A_1 receptor; P_{2U} purinoceptor; Inositol phosphate; Arachidonic acid; CHO (Chinese hamster ovary) cell (Dickenson, J.M. (321) 77)

Diabetes; 5-HT (5-hydroxytryptamine); Endothelin-1; Aorta (James, G.M. (322) 55)

Dopamine transporter; WIN 35,428 binding; Arachidonic acid; Parkinson's disease; Drug abuse (Reith, M.E.A. (324) 1)

Chelerythrine; Phosphodiesterase, cyclic nucleotide; Vasorelaxation; SK&F 94120; Isoprenaline (Eckly-Michel, A.E. (324) 85)

Ca^{2+} channel antagonist; Calmodulin; Tyrosine kinase; Smooth muscle contraction (Sim, S.-S. (324) 205)

Ca^{2+} sensitivity; G-protein; Pimobendan; β-Escin; Cardiac muscle; Smooth muscle, vascular (Tomita, F. (326) 157)

Ciliary muscle, bovine; Muscarinic receptor; Desensitization (Daniele, E. (330) 247)

Adenosine receptor; Phorbol ester; SH-SY5Y neuroblastoma cell; cAMP (Peterfreund, R.A. (336) 71)

Norathyriol; Neutrophil, rat; Respiratory burst; Aggregation; Phorbol 12-myristate 13-acetate; Translocation (Wang, J.-P. (336) 81)

Nitrite; Interleukin-1; Atherosclerosis (Shimpo, M. (338) 97)

Antinociception; DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); Diabetes; Calphostin C; (Mouse) (Ohsawa, M. (339) 27)

Halothane; Ethanol; Muscarinic receptor; *Xenopus* oocyte (Minami, K. (339) 237)

Nitric oxide; Apoptosis; Smooth muscle cell; Protein kinase A (Nishio, E. (339) 245)

Endothelin; Glial cell; Nitric oxide synthase, inducible; TNF-α (tumor necrosis factor-α); Endothelin ET_B receptor (Oda, H. (339) 253)

Protein kinase G
Glutamate release; Synaptosome; Nitric oxide (NO); cGMP; Zaprinast (Sistiaga, A. (321) 247)

Protein phosphatase
Calyculin A; Ca^{2+}, cytosolic; Mn^{2+}; Protein phosphorylation; HL-60 cells (Leung, Y.-M. (331) 337)

Protein phosphorylation
Calyculin A; Ca^{2+}, cytosolic; Mn^{2+}; Protein phosphatase; HL-60 cells (Leung, Y.-M. (331) 337)

Protriptyline
Noradrenaline uptake inhibitor; Amitriptyline; Xylamine; Electric field stimulation; Contraction; Vas deferens, rat (Huang, Y. (327) 41)

Proximal tubule
Dopamine D_2-like receptor; Na^+ pump; Kidney; (Rat) (Hussain, T. (321) 259)

Psychosis
Excitatory amino acid; Anticonvulsant; Anxiolytic; Dopamine (Baron, B.M. (323) 181)

Psychotic disorder
Dopamine receptor; 5-HT receptor; Schizophrenia; Antipsychotic agent (Kongsamut, S. (317) 417)

Psychotomimetic
Glycine; ACEA 1021; Amnesia; Side effects; Glutamate (Kretschmer, B.D. (331) 109)

Pudendal nerve
Bladder; Pelvic nerve; Micturition contraction; Periurethral muscle; (Rat) (Kagitani, F. (332) 89)

Pulmonary artery, human
Halothane; Endothelium-dependent relaxation (Higueras, J. (326) 175)

Pulmonary emphysema
FK706; Elastase inhibitor; Neutrophil elastase; Hemorrhage; Edema (Shinguh, Y. (337) 63)

Pulmonary hypertension
Nitric oxide (NO); TP receptor; U-46619; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); SQ 29,548 (Valentin, J.-P. (317) 335)

BQ-788; Endothelin; Hypoxia (Holm, P. (323) 83)

Pulmonary microcirculation
Thrombin; Thrombin receptor-activating peptide; Thrombin inhibitor; Platelet aggregation; ^{111}Indium oxine; Receptor binding (Chiu, P.J.S. (321) 129)

Pulmonary oedema
α-Naphthylthiourea; Nitric oxide (NO); L-Arginine; D-Arginine; N^G-Nitro-L-arginine methyl ester (Sipahi (Yılmaz), E. (321) 45)

Pulsed field gel electrophoresis
Hydrogen peroxide; L-Histidine; DNA double-strand breaks; Apoptosis; Necrosis (Palomba, L. (318) 167)

Purine
Adenosine; (−)-Bicuculline; GABA (γ-aminobutyric acid); Paired-pulse inhibition; Inhibition; Hippocampus; Cyclopentyltheophylline (Higgins, M.J. (317) 215)

Striatum; Hypoxia; Xanthine; Transmitter release; Adenosine A_1 receptor (Jin, S. (329) 107)

Purinergic
ATP; Ecto-ATPase; ARL 67156; Urinary bladder (Westfall, T.D. (329) 169)

Purinergic neurotransmission
Ca^{2+} channel; ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Agatoxin IVA; Vas deferens (Hirata, H. (321) 217)

Purinergic transmission
Adrenergic transmission; Contractile response; Circular muscle; Development; Vas deferens; (Guinea pig) (Ren, L.-M. (318) 411)

Vas deferens, rat; Noradrenergic transmission; Cromakalim; Prazosin; Suramin; Glibenclamide (Grana, E. (319) 57)

Auricular artery; Sympathetic nerve stimulation; P_{2x} purinoceptor (Haniuda, K. (333) 163)

Detrusor muscle, rat; Cholinergic transmission; Cromakalim; Atropine; Suramin; Nifedipine (Boselli, C. (335) 23)

Purinoceptor
UTP; ATP; Pyrimidinoceptor; Stomach, rat; Suramin (Otsuguro, K.-i. (317) 97)

Apoptosis; Imidazo[1,2-*a*]pyrazine derivative; Megakaryoblastic cell, human; Phosphodiesterase; cAMP (Zurbonsen, K. (320) 215)

Adenosine; Taenia caecum; Adenosine A_{2B} receptor; Adenosine A_3 receptor (Prentice, D.J. (323) 103)

ATP, extracellular; Muscarinic acetylcholine receptor-operated K^+ current; Atrial cell; Action potential duration (Hara, Y. (324) 295)

Purinoceptor P_{2X}
ATP; Ion channel; *Xenopus* oocyte; Site-directed mutagenesis (Nakazawa, K. (325) 101)

ATP; Trivalent cation; PC12 cell; *Xenopus* oocyte (Nakazawa, K. (325) 237)

Purposeless
Tacrine; Cognex; Acetylcholine; Vacuous chew; Tremor; Parkinson's disease; Alzheimer's disease (Cousins, M.S. (322) 137)

Putrescine
Polyamine; Spermidine; Spermine; NMDA (*N*-methyl-D-aspartate); Motor activity; MK-801; Amphetamine; Theophylline; (Mouse) (Giménez-Llort, L. (318) 231)

$P2X_2$ purinoceptor
pH dependence; Neuroamine; Adenosine; Zn^{2+}; Cd^{2+} (Nakazawa, K. (337) 309)

$P2Y_6$ receptor
Nucleotide; UDP (Robaye, B. (329) 231)

Pyresis
Cyclooxygenase 2; Cyclooxygenase 2 inhibitor; Telemetry; (Squirrel monkey) (Chan, C.-C. (327) 221)

2-Pyridylethylamine
Lingual artery, dog; Histamine H_1 receptor; Dimaprit; (Cannula insertion method) (Chiba, S. (329) 63)

Pyrimidinoceptor
UTP; ATP; Purinoceptor; Stomach, rat; Suramin (Otsuguro, K.-i. (317) 97)

Pyrroloquinoline quinone
Free radical; Glutamate; NMDA receptor; Redox modulatory site; Dihydroethidium (Scanlon, J.M. (326) 67)

QT interval
S 16257; Bradycardic agent; Stereospecificity; Transmembrane action potential; Heart rate (Thollon, C. (339) 43)

Quaternary ion
Levcromakalim; K^+ channel antagonist; Circumflex artery, right, pig; Tetraphenylphosphonium; Triphenylphosphonium compound (Piekarska, A.E. (322) 37)

Quinolinic acid
Astrocyte; Excitotoxicity; Glycine site; NMDA receptor; Kynurenic acid; Neurodegenerative disorder (Wu, H.-Q. (319) 13)

Quinpirole
Dopamine; Dopamine D_2 receptor; Rilmenidine; α-Methyldopa; Hydralazine; Sympathetic nervous system; Vasopressin (Van den Buuse, M. (322) 191)

Amphetamine administration, chronic; Deoxyglucose; Sensitization; SKF 38393 (Huang, Y.-H. (338) 117)

[^{123}I]R93274
5-HT_{2A} receptor; SPECT (single photon emission computerized tomography) (Abi-Dargham, A. (321) 285)

Raclopride
Ethanol preference; Dopamine; SKF 38393; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); Risperidone; SCH 23390; (Rat) (Silvestre, J.S. (318) 257)

Radioactive tracer
Albumin leakage; Lipopolysaccharide; 5-Lipoxygenase; Leukocyte; Lung (Bureau, M.F. (324) 89)

Radioligand
RS-79948-197; Brain; α_2-Adrenoceptor; In vivo; PET (positron-emission tomography); (Rat) (Hume, S.P. (317) 67)

Radioligand assay
α_1-Adrenoceptor; Terazosin; Prazosin (Ireland, L.M. (327) 79)

Radioligand binding
Oral bioavailability; $t_{1/2}$; Brain penetration; Vomiting; Retching; Nausea; Ondansetron (Singh, L. (321) 209)

Efficacy; δ-Opioid receptor, human; δ-Opioid receptor agonist; [^{35}S]GTPγS binding (Quock, R.M. (326) 101)

$GABA_A$ receptor; α_1 subunit; Mutation; Electrophysiology (Westh-Hansen, S.E. (329) 253)

Neuropeptide Y, Neuropeptide Y Y_1 receptors; Rat brain; BIBP3226 (Vanderheyden, P.M.L. (331) 275)

Neuropeptide Y; Neuropeptide Y_1 receptor; Neuropeptide Y_2 receptor; (Human) (Statnick, M.A. (332) 299)

[^{125}I]*R*(+)-Zacopride; Autoradiography; *R*(+)-site; Brain, rat; Peripheral tissue, rat (Ge, J. (332) 307)

Radioligand binding assay
Kidney; Dopamine; D_2-like receptor; Innervation; Autoradiography; (Rat) (Barili, P. (334) 233)

Dopamine D_3 receptor; Kidney; Autoradiography; Cortical tubule; Glomerulus (Barili, P. (338) 89)

Radioreceptor assay
[^{3}H]Nociceptin; Nociceptin receptor; Adenylylcyclase, inhibition; Drug screening (Butour, J.-L. (321) 97)

Radiotelemetry
Pentoxifylline; TNF-α (tumor necrosis factor-α); Anti-TNF strategy; Lipopolysaccharide; Fever; TNF bioassay; (Guinea pig) (Goldbach, J.-M. (319) 273)

Antisense targeting; Oligodeoxynucleotides; Sickness behavior; Interleukin 6; (Rat) (Schöbitz, B. (331) 97)

Vasopressin; Endothelin; Spontaneously hypertensive rat (SHR); Hemodynamics; Cardiac output (Balakrishnan, S.M. (334) 55)

Ramosetron
5-HT_3 receptor; Gastric motility; *m*-Chlorophenylbiguanide; (Force transducer) (Nagakura, Y. (327) 189)

Ramosetron (YM060, (−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride)
5-HT_3 receptor; Colon, distal; Short-circuit current (I_{sc}); (Rat) (Kiso, T. (320) 187)

Ranitidine
T-330; H^+/K^+-ATPase; Gastric acid secretion; Omeprazole (Kinoshita, M. (321) 325)

Raphe magnus
Descending inhibition; Nociception; Non-steroidal anti-inflammatory drug (Jones, S.L. (318) 37)

Raphe nucleus, dorsal
Duloxetine; Fluoxetine; Hippocampus; Electrophysiology, cellular (Smith, J.E. (323) 69)

5-HT (5-hydroxytryptamine, serotonin); Diazepam; Withdrawal; 5-HT_{1A} receptor; Electrophysiological recording (Lanfumey, L. (323) 137)

5-HT receptor; Adenylyl cyclase; Phosphoinositide hydrolysis; Hippocampus; 5-HT_{1A} receptor (Johnson, R.G. (329) 99)

Rat
Neuropeptide FF; Receptors; Morphine-analgesia; Dorsal raphe nucleus; Parafascicular nucleus; Serotonin (Dupouy, V. (330) 129)

Rat brain
Neuropeptide Y, Neuropeptide Y Y_1 receptors; BIBP3226; Radioligand binding (Vanderheyden, P.M.L. (331) 275)

RAW 264.7 cell
Nitric oxide (NO); Nitric oxide (NO) synthase, inducible; Lipopolysaccharide; Auranofin; Aurothioglucose; Aurothiomalate (Yamashita, M. (338) 151)

RAW 264.7 macrophage
Lipopolysaccharide; Arachidonic acid; Phospholipase A_2; Protein kinase; UTP (Lin, W.W. (321) 121)

Inflammation; NO synthase, inducible; Pristimerin; Triterpene (Dirsch, V.M. (336) 211)

$^{86}Rb^+$, influx rate
α_1-Adrenoceptor, subtype; Chloroethylclonidine; 5-Methylurapidil; WB 4101; BMY 7378; Inositol 1,4,5-trisphosphate (Viko, H. (323) 269)

$^{86}Rb^+$ efflux
SCA40; Trachealis, bovine; K^+-rich media; Electrophysiology; Phosphodiesterase isoenzyme (Pocock, T.M. (334) 75)

RB 101
Cholecystokinin; CCK-8; BC 264; CCK_B receptor antagonist; L-365,260; Devazepide; CCK_A receptor antagonist; Depression; Stress; Forced-swimming test; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

RBI-257
Dopamine; Dopamine D_4-receptors; U-101,958 (Kula, N.S. (331) 333)

RBL-2H3
Astemizole; Membrane; Protein; Tyrosine; Phosphorylation; Ca^{2+}; Flux; Exocytosis (Fischer, M.J.E. (322) 97)

T-477 ((*R*)-(+)-2-(4-chlorophenyl)-2,3-dihydro-4-diethylaminoacetyl-4H-1,4-benzothiazine)
Ca^{2+} channel, cloned; Ca^{2+} channel antagonist; Neuroprotective; Oocyte; (*Xenopus*) (Kobayashi, T. (332) 313)

Reactive blue 2
Coronary artery, canine; Vasoconstriction; Vasodilation; P2 purinoceptor; ATP; UTP; Suramin (Matsumoto, T. (334) 173)

Apamin; Colon; DMPP (1,1-dimethyl-4-phenylpiperazinium iodide); Nitric oxide (NO); P_{2y} purinoceptor; (Rat) (Börjesson, L. (334) 223)

Reactive oxygen species
Cocaine; Hepatotoxicity; Nitric oxide (NO); (Mouse) (Aoki, K. (336) 43)

Receptor
Neuropeptide FF; Morphine-analgesia; Rat; Dorsal raphe nucleus; Parafascicular nucleus; Serotonin (Dupouy, V. (330) 129)

σ Receptor
Phencyclidine (PCP) receptor; Dizocilpine; Head-weaving behavior; (Rat) (Kitaichi, K. (318) 205)

Choice reaction time; Attention; Phencyclidine (Jin, J. (319) 147)

Conditioned fear stress; Dopaminergic system; Nucleus accumbens; Motor suppression; (Rat) (Kamei, H. (319) 165)

Benzomorphan; Affinity label (Chien, C.-C. (321) 361)

Imidazoline receptor; Efaroxan; Insulin secretion; Phencyclidine; (+)-MK-801 (dizocilpine) (Chan, S.L.F. (323) 241)

Cytotoxicity; Regulation; Internalization; (+)-Pentazocine; Desensitization (Zambon, A.C. (324) 39)

Zn^{2+} inhibition; NMDA receptor, binding; MK-801; Spinal cord; (Mouse) (Kovács, K.J. (324) 117)

Opioid; Analgesia (King, M. (331) R5)

Peptide YY; Intestinal secretion; VIP (vasoactive intestinal peptide); Intestinal nerve; α_2-Adrenoceptor; (Rat) (Souli, A. (333) 87)

2(*3H*)-Benzoxazolone; 2(*3H*)-Benzothiazolone; Anticonvulsant; [^{3}H](+)-Pentazocine (Ucar, H. (335) 267)

σ_1 Receptor
Dizocilpine-induced amnesia; N^{ω}-Nitro-L-arginine methyl ester (L-NAME), induced amnesia; NMDA receptor; Learning (Maurice, T. (328) 9)

σ_2 Receptor
Norepinephrine; Hippocampus; BIMU-8; (+)-Pentazocine (Weatherspoon, J.K. (326) 133)

Receptor activation
GLP-1 (glucagon-like peptide-1); GLP-1-(7–36) amide; GLP-1-(9–36) amide; GLP-1-(7–35); GLP-1-(7–34); Receptor binding; (Metabolite) (Knudsen, L.B. (318) 429)

Receptor autoradiography
Endothelin ET_B receptor; Macrophage; RT-PCR (reverse transcription-polymerase chain reaction); (Rat) (Sakurai-Yamashita, Y. (338) 199)

Receptor binding
GLP-1 (glucagon-like peptide-1); GLP-1-(7–36) amide; GLP-1-(9–36) amide; GLP-1-(7–35); GLP-1-(7–34); Receptor activation; (Metabolite) (Knudsen, L.B. (318) 429)

Thrombin; Thrombin receptor-activating peptide; Thrombin inhibitor; Platelet aggregation; ^{111}Indium oxine; Pulmonary microcirculation (Chiu, P.J.S. (321) 129)

Erythromycin; EM574; Motilin; (Rabbit) (Sato, F. (322) 63)

Dopamine D_4 receptor, human; Aminopiperidine (Schlachter, S.K. (322) 283)

α_2-Adrenoceptor; Ca^{2+} signaling; Fura-2; Receptor kinetics (Kukkonen, J.P. (335) 99)

Dopamine D_3 receptor; G protein; Acidification rate; cAMP accumulation; *Fos* protein immunoreactivity (Scheideler, M.A. (339) 261)

σ Receptor binding site
Vesamicol; AH5183; Alzheimer's disease; Acetylcholine transporter; SPECT (Single-photon emission computed tomography) (Custers, F.G.J. (338) 177)

Receptor cross-talk
5-HT (5-hydroxytryptamine, serotonin); Small-cell lung carcinoma; 5-HT receptor subtype (Vicentini, L.M. (318) 497)

Receptor density
Desensitization; β-Adrenoceptor; Adenylyl cyclase; Protein kinase, cAMP dependent (Rousseau, G. (326) 75)

Receptor desensitization
Aortic barodenervation; α_1-Adrenoceptor; Aorta; Sympathetic activity (El-Mas, M.M. (322) 201)

Receptor down-regulation
β_2-Adrenoceptor; mRNA half-life (Danner, S. (331) 73)

μ-Opioid receptor; Regulation of mRNA; Etorphine; Analgesia; Tolerance (Sehba, F. (339) 33)

Receptor dysfunction
Vagus nerve stimulation; Muscarinic M_2 receptor, prejunctional; Muscarinic receptor antagonist; Allergic reaction, early, late; Bronchial hyperresponsiveness; (Conscious, unrestrained guinea pig) (Ten Berge, R.E.J. (318) 131)

Receptor isoform
Brain damage; Pathogenesis; Cerebral cortex; Receptor subtype; (Human) (Lewohl, J.M. (326) 265)

Receptor kinetics
α_2-Adrenoceptor; Ca^{2+} signaling; Fura-2; Receptor binding (Kukkonen, J.P. (335) 99)

Receptor modelling
CHO (Chinese hamster ovary) cell; Cholecystokinin; CCK_A receptor; Devazepide; L-364,718; Ca^{2+} mobilization; Cell recruitment (Smeets, R.L.L. (325) 93)

Receptor reserve
[^{35}S]GTPγS binding assay; $5\text{-}HT_{1A}$ receptor, human (Stanton, J.A. (320) 267)

Receptor subtype
Brain damage; Pathogenesis; Cerebral cortex; Receptor isoform; (Human) (Lewohl, J.M. (326) 265)

Prostate cancer; Cell line, LNCaP, DU145, PC3; Cell proliferation; δ-Opioid receptor, μ-Opioid receptor, κ-Opioid receptor; Casein, bovine, human; Casomorphin (Kampa, M. (335) 255)

Neuropeptide Y; Contraction; Cardiomyocyte, ventricular (McDermott, B.J. (336) 257)

Recovery of function
Memory impairment; D-Cycloserine; Temporal cortex; Entorhinal cortex; (Microinjection) (Myhrer, T. (328) 1)

Redox modulatory site
Free radical; Glutamate; Pyrroloquinoline quinone; NMDA receptor; Dihydroethidium (Scanlon, J.M. (326) 67)

Regulation
σ Receptor; Cytotoxicity; Internalization; (+)-Pentazocine; Desensitization (Zambon, A.C. (324) 39)

Regulation of mRNA
μ-Opioid receptor; Etorphine; Receptor downregulation; Analgesia; Tolerance (Sehba, F. (339) 33)

Reinforcement
Fentanyl; Heroin; Morphine; 6-Acetylmorphine (Martin, T.J. (324) 141)

Conditioned place preference; Diabetes; Opioid receptor; Morphine; Naloxonazine (Kamei, J. (337) 137)

Relaxation
Isoproterenol; β_1-Adrenoceptor; β_2-Adrenoceptor; Endothelium; Cytochrome P450; Aortic ring, rat (Satake, N. (319) 37)

Hydralazine; Endothelium; cGMP (Wei, S. (321) 307)

Aorta, rat; cGMP; Nitric oxide (NO) synthase (Takizawa, S. (330) 143)

Adenosine receptors; Iris sphincter, ovine; Adenosine receptor antagonists (Hourani, S.M.O. (334) 95)

Release, in vitro
Cyclooxygenase; Non-steroidal anti-inflammatory drugs; Formalin; Spinal cord; Prostaglandin E_2; (Intrathecal) (Dirig, D.M. (331) 155)

Renal artery
α_{1D}-Adrenoceptor; Contraction; BMY 7378; Chloroethylclonidine; 5-Methylurapidil (Villalobos-Molina, R. (322) 225)

Renal blood flow
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists; Kidney, autoperfused, rat; Angiotensin II (Morán, A. (330) 205)

Renal clearance
Active secretion; Drug interaction; P-glycoprotein; Multidrug resistance; Organic cation carrier (Masereeuw, R. (321) 315)

Renal failure, acute
Renovascular hypertension; Angiotensin converting enzyme inhibition; Na^+ depletion; Angiotensin AT_1 receptor antagonists, non-peptide (Abdi, A. (331) 185)

Renal function
Endothelin-1; Endothelin ET_A receptor; DOCA (deoxycorticosterone acetate)-salt hypertension; Urine formation (Matsumura, Y. (319) 65)

FK409; Nitric oxide (NO); N^G-Nitro-L-arginine; Urine formation (Urabe, K. (321) 195)

Renal lesion
CD-832; Ca^{2+} channel antagonist; Stroke-prone spontaneously hypertensive rats (SHRSPs) (Takahashi, T. (331) 193)

Renal nerve stimulation
YM435; Dopamine D_1 receptor agonist; Renal vasodilator; Angiotensin II; PAF (platelet-activating factor) (Yatsu, T. (322) 45)

Renal vasodilator
YM435; Dopamine D_1 receptor agonist; Angiotensin II; Renal nerve stimulation; PAF (platelet-activating factor) (Yatsu, T. (322) 45)

Renin
Adrenomedullin; Blood pressure; Renovascular hypertension; Aldosterone; (Rat) (Khan, A.I. (333) 187)

Renin-angiotensin system
Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester (L-NAME); Hoe 140; Enalapril; Blood pressure (Zappellini, A. (317) 285)

Renovascular hypertension
Renal failure, acute; Angiotensin converting enzyme inhibition; Na^+ depletion; Angiotensin AT_1 receptor antagonists, non-peptide (Abdi, A. (331) 185)

Adrenomedullin; Blood pressure; Renin; Aldosterone; (Rat) (Khan, A.I. (333) 187)

Repaglinide
Glibenclamide; Glimepiride; Insulin secretion; (GK rat) (Ladrière, L. (335) 227)

Reperfusion
Y-26763; Myocardium, stunned; Ischemia; ATP-sensitive K^+ channel (Fukunari, A. (323) 197)

Arrhythmia; Ischaemia; K^+ channel activator; Levcromakalim (Vegh, A. (333) 33)

Cariporide (HOE642); Na^+–H^+ exchange; Arrhythmias; Ischemia (Aye, N.N. (339) 121)

Reperfusion arrhythmia
Pinacidil; Cromakalim; Glibenclamide; Anesthetized rat (Baczkó, I. (324) 77)

Reserpine
Oral dyskinesia; Tongue protrusion; Dopamine; Tardive dyskinesia (Sussman, A.N. (337) 157)

Resiniferatoxin
Capsaicin-sensitive; Saphenous nerve; Neuropeptide Y; Vasoconstriction; Vasodilation; Laser-Doppler flowmetry (Pintér, E. (325) 57)

Vomiting; Capsaicin; Solitary nucleus; Vagus nerve; (Dog) (Shiroshita, Y. (339) 183)

Respiratory burst
Broussochalcone A; Neutrophil, rat; Inositol trisphosphate; Ca^{2+} concentration, intracellular; Protein kinase C; NADPH oxidase (Wang, J.-P. (320) 201)

Antibiotics; Polymorphonuclear leukocyte; Phagocytosis (Hoeben, D. (332) 289)

Norathyriol; Neutrophil, rat; Aggregation; Protein kinase C; Phorbol 12-myristate 13-acetate; Translocation (Wang, J.-P. (336) 81)

Respiratory network, central
Neonatal mouse; Serotonergic regulation; 5-HT (5-hydroxytryptamine, serotonin); (In vitro) (Hilaire, G. (329) 115)

Respiratory resistance
Zatebradine; Tachycardia; cAMP (Yamazaki, K. (320) 21)

Restenosis
Tranilast; Muscle contraction; Angioplasty (Ihara, T. (329) 43)

Retching
Radioligand binding; Oral bioavailability; $t_{1/2}$; Brain penetration; Vomiting; Nausea; Ondansetron (Singh, L. (321) 209)

Retina
Vitamin B; Culture; Cytotoxicity; Glutamate (Kaneda, K. (322) 259)

Neurotoxicity; Nitric oxide (NO); NMDA (*N*-methyl-D-aspartate); N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Morizane, C. (328) 45)

Nociceptin; Orphanin FQ; Striatum; Dynorphin A; Opioid (Makman, M.H. (338) 171)

Reversal learning
Septum lesion, medial; Metrifonate; Spatial navigation; Spatial bias (Riekkinen Jr., P. (323) 11)

Reverse transcription-polymerase chain reaction
Endothelin ET_A receptor; Endothelin ET_B receptor; Organ culture; Upregulation (Möller, S. (329) 69)

Reward
U-50,488; Morphine; Ontogeny; (Rat) (Bolanos, C.A. (317) 1)

Conditioned preference; NMDA receptor; Glycine site; MK-801; CGP 37849; CGP 40116; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (317) 191)

NMDA receptor antagonist; Electrical brain stimulation; Conditioning; (Rat) (Bespalov, A. (326) 109)

RHA and RLA (Roman high- and low-avoidance) rats
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); SR 46349B; 5-HT_{2A} receptor; Anxiety; Elevated plus-maze; [^{3}H]Ketanserin binding (Chaouloff, F. (334) 25)

Ribonuclease protection assay
Aripiprazole; Antipsychotic drug; Dopamine receptor; Striatum, rat (Inoue, A. (321) 105)

Rilmenidine
Quinpirole; Dopamine; Dopamine D_2 receptor; α-Methyldopa; Hydralazine; Sympathetic nervous system; Vasopressin (Van den Buuse, M. (322) 191)

Riluzole
HEK293 cell; Ca^{2+} channel; Na^+ channel; NNC 09-0026; CNS 1237; SB 201823-A; NS 649; Cerebral ischaemia (O'Neill, M.J. (332) 121)

Risperidone
Ethanol preference; Dopamine; SKF 38393; Raclopride; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); SCH 23390; (Rat) (Silvestre, J.S. (318) 257)

Rizatriptan
5-$HT_{1B/1D}$ receptor agonist; Trigeminal nucleus caudalis; Migraine; Electrophysiology (Cumberbatch, M.J. (328) 37)

Microscopy, intravital; Meningeal artery, middle; CGRP (calcitonin gene-related peptide); Migraine (Williamson, D.J. (328) 61)

mRNA
Δ^9-Tetrahydrocannabinol; Opioid; Proopiomelanocortin; Arcuate nucleus (Corchero, J. (323) 193)

Imipramine; Dopamine D_2 autoreceptor; Ventral tegmental area; (Rat) (Dziedzicka-Wasylewska, M. (337) 291)

mRNA expression
Brain; Electroconvulsive stimuli; Hybridization, in situ; Substance P; Tachykinin receptor; (Rat) (Zachrisson, O. (319) 191)

mRNA half-life
β_2-Adrenoceptor; Receptor down-regulation (Danner, S. (331) 73)

Ro 15-4513
Stress; Ethanol; Plus-maze; Sleep; $^{36}Cl^-$ uptake; [^{3}H]Ro 15-4513 (Pokk, P. (317) 15)

[^{3}H]Ro 15-4513
Stress; Ethanol; Ro 15-4513; Plus-maze; Sleep; $^{36}Cl^-$ uptake (Pokk, P. (317) 15)

Ro 25-6981
Glutamate receptor; Allosteric antagonism; *Xenopus* oocyte; Ifenprodil; CP 101,606; Haloperidol (Whittemore, E.R. (337) 197)

Rolipram
cAMP; Learning; Memory; 3-Panel runway; Passive avoidance (Imanishi, T. (321) 273)

Phosphodiesterase; Cortical neuron; cAMP (Yamashita, N. (337) 95)

RS-79948-197
Brain; α_2-Adrenoceptor; Radioligand; In vivo; PET (positron-emission tomography); (Rat) (Hume, S.P. (317) 67)

***R*(+)-site**
[^{125}I]*R*(+)-Zacopride; Autoradiography; Radioligand binding; Brain, rat; Peripheral tissue, rat (Ge, J. (332) 307)

RTI-55
Single photon detection system; Dopamine transporter; 5-HT (5-hydroxytryptamine, serotonin) transporter; GBR 12909; Paroxetine (Mochizuki, T. (338) 17)

RT-PCR (reverse transcriptase-polymerase chain reaction)
Nimesulide; Cyclooxygenase-2; Antipyretic action; Hypothalamus; Yeast-induced hyperthermia (Taniguchi, Y. (330) 221)

Peripheral-type benzodiazepine receptor; GAPDH (glyceraldehyde-3-phosphate dehydrogenase); Stress; Dexamethasone (Siripurkpong, P. (331) 227)

Endothelin ET_B receptor; Macrophage; Receptor autoradiography; (Rat) (Sakurai-Yamashita, Y. (338) 199)

Rutaecarpine
Alkaloid; Platelet, human; cAMP; cGMP; Thromboxane A_2; Phosphoinositide (Sheu, J.-R. (318) 469)

RX 77368
Acid secretion; Gastric mucosal blood flow; Ketotifen; Mast cell; Mean arterial pressure; TRH (thyrotropin-releasing hormone); Vagus; Brain–gut (Király, Á. (334) 241)

RX821002 (2-methoxyidazoxan)
α_2-Adrenoceptor subtype; Gpp(NH)p; Na^+ (Callado, L.F. (332) 109)

[^{3}H]RX821002 binding
α_2-Adrenoceptor subtype; CHO cell; Adenylyl cyclase; cAMP (Pohjanoksa, K. (335) 53)

[^{125}I]*R*(+)-Zacopride
Autoradiography; Radioligand binding; *R*(+)-site; Brain, rat; Peripheral tissue, rat (Ge, J. (332) 307)

S 16257
Bradycardic agent; Stereospecificity; Transmembrane action potential; Heart rate; QT interval (Thollon, C. (339) 43)

Salbutamol
Down-regulation; β_2-Adrenoceptor; Salmeterol; Formoterol; Lung, human (Nishikawa, M. (318) 123)

Pharmacological method, new; Efficacy estimation; Agonist affinity; Carbachol (Venter, D.P. (320) 233)

Salivary gland
Muscarinic receptor agonists; Sjögren's syndrome; AF-102B (Masunaga, H. (339) 1)

Salivation
Tachykinin receptor antagonist; Substance P; Tachykinin NK_1 receptor; Blood pressure (Cellier, E. (318) 377)

Urinary bladder contraction; Muscarinic receptor subtype; Muscarinic receptor antagonist; (Guinea pig); (Cat); (Human) (Nilvebrant, L. (327) 195)

Salmeterol
Down-regulation; β_2-Adrenoceptor; Salbutamol; Formoterol; Lung, human (Nishikawa, M. (318) 123)

Eosinophil; cAMP; β_2-Adrenoceptor agonist; Eosinophil aggregation (Teixeira, M.M. (323) 255)

Salt preference
Pressure-natriuresis; Imidazoline; Oral gavage (Cechetto, D.F. (325) 47)

SAO (Splanchnic artery occlusion shock)
VLA-4 (very late antigen-4) integrin; VCAM-1 (vascular cell adhesion molecule-1); (Rat) (Squadrito, F. (318) 153)

Saphenous nerve
Capsaicin-sensitive; Resiniferatoxin; Neuropeptide Y; Vasoconstriction; Vasodilation; Laser-Doppler flowmetry (Pintér, E. (325) 57)

Saphenous vein
Ventricular pacing, rapid; Heart failure; Dorsal pedal artery; α_1-Adrenoceptor; 5-Methyl-urapidil (Forster, C. (318) 55)

Saphenous vein, dog
Neuropeptide Y; Bioassay; Neuropeptide Y Y_2 receptor (Pheng, L.H. (327) 163)

Sarcoplasmic reticulum
Cyclopiazonic acid; Ca^{2+}-ATPase; Smooth muscle; Stomach; Contraction (Petkov, G.V. (318) 109)

Heparin; Caffeine contracture; Skinned fiber; Skeletal muscle, mammalian (Talon, S. (327) 33)

Sauvagine
Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Edema; Ca^{2+}; Inositol trisphosphate; CRF receptor; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

SB 201823-A
HEK293 cell; Ca^{2+} channel; Na^+ channel; NNC 09-0026; CNS 1237; NS 649; Riluzole; Cerebral ischaemia (O'Neill, M.J. (332) 121)

SB-216641A
Hypothermia; 5-HT; Guinea pig; 5-HT_{1D} receptor; 5-HT_{1B} receptor; SKF-99101H; BRL-15572; SB-224289G (Hagan, J.J. (331) 169)

SB-224289G
Hypothermia; 5-HT; Guinea pig; 5-HT_{1D} receptor; 5-HT_{1B} receptor; SKF-99101H; SB-216641A; BRL-15572 (Hagan, J.J. (331) 169)

SCA40
Trachealis, bovine; K^+-rich media; Electrophysiology; $^{86}Rb^+$ efflux; Phosphodiesterase isoenzyme (Pocock, T.M. (334) 75)

SCH 23390
Dopamine 'D_1-like' receptor; Dopamine 'D_2-like' receptor; D_1/D_2 interaction; LY 270411; BW 737C; Grooming behavior; Vacuous chewing; Myoclonic jerking; (Rat) (Deveney, A.M. (317) 175)

Ethanol preference; Dopamine; SKF 38393; Raclopride; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); Risperidone; (Rat) (Silvestre, J.S. (318) 257)

SCH 58261
Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); 5'-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5'-*N*-ethylcarboxamidoadenosine (2HE-NECA); Seizure; (DBA/2 mouse) (De Sarro, G. (317) 239)

Schizophrenia
Dopamine receptor; 5-HT receptor; Psychotic disorder; Antipsychotic agent (Kongsamut, S. (317) 417)

Substantia nigra reticulata; Antipsychotic; Basal ganglion; Electrophysiology; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Bruggeman, R. (324) 49)

Nitric oxide (NO); Startle; Prepulse inhibition; Startle reaction (Wiley, J.L. (328) 125)

AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid); Antipsychotic; Behavior; Dopamine; (Mouse) (Vanover, K.E. (332) 115)

MK-801; M100907; Dopamine receptor antagonist; Locomotion; (Mouse) (Martin, P. (335) 107)

Schizophrenia, negative symptom
Phencyclidine; Antidepressant; Depression; 5-HT (5-hydroxytryptamine, serotonin); Forced swimming test; (Mouse) (Noda, Y. (324) 135)

Sciatic nerve, rat
Adrenergic nerve; Diabetes mellitus; Nerve blood flow; Noradrenaline (Vo, P.A. (329) 147)

Scopolamine
Alzheimer's disease; Acetylcholine; Basal forebrain lesion; Cholinesterase inhibitor; (Rat) (Itoh, A. (322) 11)

Ginsenoside; Choline acetyltransferase; Maze; Septum, medial (Yamaguchi, Y. (329) 37)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; Pirenzepine; Methoctramine; Alzheimer's disease; (Delay-dependent and -independent); (% correct choice) (Aura, J. (333) 129)

Secretory leukocyte protease inhibitor
Airway epithelium; Inflammation; Airway remodelling; Neutrophil elastase (Marchand, V. (336) 187)

Sedation
Dihydrexidine; Dopamine D_2 receptor; Locomotor activity; Vacuous chewing; Yawning (Smith, H.P. (323) 27)

Seizure
Dopamine D_1 receptor; A-86929; ABT-431; Hyperactivity; Tolerance (Shiosaki, K. (317) 183)

Adenosine analog; Audiogenic seizure; 3-(2-carboxypiperazine-4y)propenyl-1-phosphonic acid (CPPene); Adenosine A_1 receptor agonist; Adenosine A_1 receptor antagonist; Adenosine A_2 receptor agonist; Adenosine A_2 receptor antagonist; 2-chloro-N^6-cyclopentyladenosine (CCPA); 8-cyclopentyl-1,3 dipropylxanthine (DPCPX); SCH 58261; 5'-*N*-ethylcarboxamidoadenosine (NECA); 2-hexynyl-5'-*N*-ethylcarboxamidoadenosine (2HE-NECA); (DBA/2 mouse) (De Sarro, G. (317) 239)

NMDA (*N*-methyl-D-aspartate); Kindling; Amygdala; Epilepsy (Croucher, M.J. (319) 207)

Dihydropyridine; Dantrolene; Anti-epileptic; Electroshock, maximal (Borowicz, K.K. (323) 45)

2-Chloroadenosine; Electrical kindling; Epileptogenesis; Amygdala; Adenosine A_1 receptor, pre-synaptic (Abdul-Ghani, A.-S. (326) 7)

APNEA (N^6-2-(4-aminophenyl)ethyl-adenosine); Adenosine receptor; Adenosine A_3 receptor; Maximal electroshock; Antiepileptic drug (Borowicz, K.K. (327) 125)

Nitric oxide (NO); 7-Nitroindazole; Antiepileptic drug (Borowicz, K.K. (331) 127)

Opioid; Cocaine; Lethality; Cardiovascular; Blood pressure (Patterson, A.B. (333) 47)

Fluoxetine; 5-HT_{1A} receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin); Epilepsy (Browning, R.A. (336) 1)

Ondansetron; GABA (γ-aminobutyric acid); Whole-cell current; Patch-clamp (Ye, J.H. (337) 87)

Seizure threshold
BW1003C87; Phenytoin; Carbamazopine; Anticonvulsant effects; Amygdala-kindling (Morimoto, K. (339) 11)

Self-administration
Cocaine; Dextromethorphan; NMDA receptor antagonist (Pulvirenti, L. (321) 279)

Self-administration, intravenous
Balb/c mouse; Cocaine; Heroin; Speedball; (Mouse) (Roberts, A.J. (326) 119)

Sematilide
Atrium, rabbit; Membrane current; Antiarrhythmic agent (Ishii, Y. (331) 295)

Semliki Forest virus system
Tachykinin NK_1 receptor; Mutagenesis, site-directed; Binding assays; Functional coupling (Lundstrom, K. (337) 73)

Semotiadil
Diltiazem; Amlodipine; Nifedipine; Ca^{2+} current; Ventricular myocyte (Koidl, B. (322) 243)

Sensitization
Aspartate; Cocaine; Glutamate; Nucleus accumbens; (Rat) (Robinson, S.E. (319) 31)

Des-Arg^9-bradykinin; Des-Arg^9-[Leu^8]bradykinin; Umbilical vein, human; Bradykinin B_1 receptor (Sardi, S.P. (321) 33)

Amphetamine; [D-Tyr^{11}]Neurotensin; Neurotensin (Rompré, P.-P. (328) 131)

Heroin; Deoxyglucose; Basal ganglia; c-*fos* (Pontieri, F.E. (335) 133)

Amphetamine administration, chronic; Deoxyglucose; SKF 38393; Quinpirole (Huang, Y.-H. (338) 117)

Sensory nerve
Endothelium; Mesenteric arterial bed; Nitric oxide (NO); Perivascular nerve; (Golden hamster) (Hill, B. (317) 275)

Nociceptin; Capsaicin; Efferent function; Atrium; (Guinea pig) (Giuliani, S. (332) 231)

Capsaicin; *Phoneutria nigriventer* venom; Neurogenic oedema; Tachykinin NK_1 receptor agonist (Costa, S.K.P. (339) 223)

Sensory processing
(Baron, B.M. (323) 181)

Sepsis
Inflammation; Heart; Heart failure (Oddis, C.V. (320) 167)

Septic shock
Dimaprit; Histamine H_2 receptor; TNF-α (tumor necrosis factor α); Hepatitis; Inflammation (Nakamura, T. (322) 83)

Interleukin-1; TNF-α (tumor necrosis factor-α) (Yamamoto, N. (327) 169)

Septide
Pain; Analgesia; Calmodulin inhibitor; Spinal cord; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) (Menéndez, L. (335) 9)

Septum, medial
Ginsenoside; Choline acetyltransferase; Scopolamine; Maze (Yamaguchi, Y. (329) 37)

Septum lesion, medial
Metrifonate; Spatial navigation; Spatial bias; Reversal learning (Riekkinen Jr., P. (323) 11)

D-Serine
Phosphoserine phosphatase; L-Serine; Glycerylphosphorylcholine; Phosphorylcholine; *p*-Chloromercuriphenylsulfonic acid; *N*-Ethylmaleimide (Hawkinson, J.E. (337) 315)

L-Serine
Phosphoserine phosphatase; D-Serine; Glycerylphosphorylcholine; Phosphorylcholine; *p*-Chloromercuriphenylsulfonic acid; *N*-Ethylmaleimide (Hawkinson, J.E. (337) 315)

L-Serine-*O*-phosphate
Epilepsy; Glutamate; Genetically epilepsy-prone rat; Metabotropic glutamate receptor; (*S*)-4C3HPG ((*S*)-4-carboxy-3-hydroxyphenylglycine); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylic acid) (Tang, E. (327) 109)

Serotonergic regulation
Respiratory network, central; Neonatal mouse; 5-HT (5-hydroxytryptamine, serotonin); (In vitro) (Hilaire, G. (329) 115)

Serotonergic system
Mitragynine; Antinociception; Noradrenergic system; α_2-Adrenoceptor; (Mouse) (Matsumoto, K. (317) 75)

Serotonin
Neuropeptide FF; Receptors; Morphine-analgesia; Rat; Dorsal raphe nucleus; Parafascicular nucleus (Dupouy, V. (330) 129)

Hyperthermia; Methamphetamine; 5-HT (5-hydroxytryptamine) (Fleckenstein, A.E. (332) 263)

Serotonin reuptake inhibitor, selective
5-HT (5-hydroxytryptamine, serotonin); Locomotor activity; (Rat) (Sills, T.L. (337) 161)

Serum component
β-D-glucan; Alveolar macrophage; Interferon γ; Nitric oxide (NO); β-D-glucan receptor (Sakurai, T. (334) 255)

Sex difference
D-Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); D-Norfenfluramine (Datla, K.P. (333) 27)

Sexual behavior
Ejaculation; Flesinoxan; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); ATD (1,4,6-androstatriene-3,17-dione); (Wistar rat) (Haensel, S.M. (330) 1)

Sexual dimorphism
Gastroduodenal ulceration; Gastroduodenal mucosa; Cysteamine; Testosterone; Sexual steroid; Microcirculation; Microvascular leakage (László, F. (337) 275)

Sexual steroid
Gastroduodenal ulceration; Gastroduodenal mucosa; Cysteamine; Testosterone; Sexual dimorphism; Microcirculation; Microvascular leakage (László, F. (337) 275)

Sf9
Opioid receptor; Baculovirus; 'High Five'; Insect cell (Obermeier, H. (318) 161)

Sf9 cell
Muscarinic receptor; Muscarinic receptor, m2 subtype; Covalent labelling; Aryldiazonium salt (Weill, C. (333) 269)

Short-circuit current (I_{sc})
5-HT_3 receptor; Colon, distal; Ramosetron (YM060, (−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); (Rat) (Kiso, T. (320) 187)

Cocaine; Cl^- secretion; Trachea; Gland cell (Chan, M.-H. (334) 281)

SH-SY5Y
Opiate receptor; Neuroblastoma; δ-Opioid receptor, subtype (Toll, L. (323) 261)

SH-SY5Y neuroblastoma cell
Adenosine receptor; Phorbol ester; Protein kinase C; cAMP (Peterfreund, R.A. (336) 71)

Sickness behavior
Antisense targeting; Oligodeoxynucleotides; Interleukin 6; Radiotelemetry; (Rat) (Schöbitz, B. (331) 97)

Side effects
Glycine; ACEA 1021; Psychotomimetic; Amnesia; Glutamate (Kretschmer, B.D. (331) 109)

Signal transduction
Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenylate cyclase; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Substance P (Xia, Y. (320) 95)

Opioid; Anxiolytics; Dopamine receptor antagonist; Benzodiazepine; Homophtalazine (2,3-benzodiazepine) (Fekete, M.I.K. (331) 175)

5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor; G-protein-coupled receptor (Gerhardt, C.C. (334) 1)

Conformational states, multiple; Thermodynamic model; Ligand efficacy; Inverse agonist (Pardo, L. (335) 73)

Single photon detection system
Dopamine transporter; 5-HT (5-hydroxytryptamine, serotonin) transporter; GBR 12909; Paroxetine; RTI-55 (Mochizuki, T. (338) 17)

SIN-1 (3-morpholinosydnonimine)
Coronary artery; Nitric oxide (NO); K_{ATP} channel; Vasodilation; Glibenclamide (Deka, D.K. (330) 157)

Sinus node
Efonidipine; Chronotropism; Action potential; Ca^{2+} channel antagonist; Ca^{2+} channel, T-type (Masumiya, H. (335) 15)

Sinus rate
Autonomic nervous system; Sympathetic-parasympathetic interaction; Atrioventricular conduction; Aminophylline (Furukawa, Y. (334) 191)

Site-directed mutagenesis
ATP; Purinoceptor P_{2X}; Ion channel; *Xenopus* oocyte (Nakazawa, K. (325) 101)

Sjögren's syndrome
Muscarinic receptor agonists; Salivary gland; AF-102B (Masunaga, H. (339) 1)

SK_{Ca} channel
Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; BK_{Ca} channel; Apamin; Charybdotoxin; Splanchnic nerve stimulation; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Skeletal muscle
Levcromakalim; Cetiedil; Smooth muscle (Benton, D.C.H. (317) 329)

K_{ATP} channel; Glybenclamide receptor; Patch clamp (Tricarico, D. (321) 369)

Ischaemia-reperfusion; Nitric oxide (NO); Viability; Oedema; (Mouse) (Knight, K.R. (332) 273)

Skeletal muscle, mammalian
Heparin; Caffeine contracture; Sarcoplasmic reticulum; Skinned fiber (Talon, S. (327) 33)

SKF 38393
Ethanol preference; Dopamine; Raclopride; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); Risperidone; SCH 23390; (Rat) (Silvestre, J.S. (318) 257)

Amphetamine administration, chronic; Deoxyglucose; Sensitization; Quinpirole (Huang, Y.-H. (338) 117)

SKF 82958
Adenylyl cyclase; Nucleus accumbens; Caudate putamen; cAMP (Unterwald, E.M. (318) 31)

Talipexole; Pramipexole; Chloro-APB; MPTP-induced hemiparkinsonism; Dopamine D_1-like receptor agonist; Dopamine D_2-like receptor agonist; (Monkey) (Domino, E.F. (325) 137)

SK & F 94120
Chelerythrine; Protein kinase C; Phosphodiesterase, cyclic nucleotide; Vasorelaxation; Isoprenaline (Eckly-Michel, A.E. (324) 85)

SK & F 96365
Ca^{2+}; Contraction; Trachea; Econazole; Miconazole; Nifedipine (Li, L. (331) 221)

SKF-99101H
Hypothermia; 5-HT; Guinea pig; 5-HT_{1D} receptor; 5-HT_{1B} receptor; SB-216641A; BRL-15572; SB-224289G (Hagan, J.J. (331) 169)

Skin
Sauvagine; Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Edema; Ca^{2+}; Inositol trisphosphate; CRF receptor; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

Nitric oxide (NO); Microdialysis; Bradykinin; Inflammatory hyperalgesia; N^G-nitro-L-arginine methyl ester; Bradykinin B_2 receptor (Andoh, T. (332) 279)

Inflammation, chronic; 12-*O*-Tetradecanoylphorbol-13-acetate; Triterpenoids (Máñez, S. (334) 103)

Skinned fiber
Heparin; Caffeine contracture; Sarcoplasmic reticulum; Skeletal muscle, mammalian (Talon, S. (327) 33)

Skin (rat)
Edema; α-Trinositol; Capillary permeability; Trachea; Connective tissue; Inflammation; Anaphylaxis (Koller, M.-E. (331) 259)

SK-N-BE(2) cell
Neuropeptide Y; Neuropeptide Y-(2–36); SK-N-MC cell; Autoradiography (Schober, D.A. (318) 307)

SK-N-MC cell
Neuropeptide Y; Neuropeptide Y-(2–36); SK-N-BE(2) cell; Autoradiography (Schober, D.A. (318) 307)

Sleep
Stress; Ethanol; Ro 15-4513; Plus-maze; $^{36}Cl^-$ uptake; [^{3}H]Ro 15-4513 (Pokk, P. (317) 15)

Small artery
Adrenoceptor subtype; Antipsychotic (Ipsen, M. (336) 29)

Small-cell lung carcinoma
5-HT (5-hydroxytryptamine, serotonin); Receptor cross-talk; 5-HT receptor subtype (Vicentini, L.M. (318) 497)

Smooth muscle
Cl^- current; Niflumic acid; Noradrenaline; Caffeine; Glibenclamide (Kirkup, A.J. (317) 165)

Levcromakalim; Cetiedil; Skeletal muscle (Benton, D.C.H. (317) 329)

Ca^{2+} efflux; Ca^{2+}, intracellular; α_1-Adrenoceptor (Lum Min, S.A. (318) 97)

Cyclopiazonic acid; Ca^{2+}-ATPase; Sarcoplasmic reticulum; Stomach; Contraction (Petkov, G.V. (318) 109)

Intestinal motility; Tachykinin receptor agonist; Tachykinin receptor antagonist (Parlani, M. (318) 419)

5-HT_4 receptor; 5-HT (5-hydroxytryptamine, serotonin); Substance P; Intestinal tract; Esophagus (Goldhill, J. (323) 229)

Endothelium; Dimalonic acid C_{60}; Nitric oxide (NO); Superoxide dismutase (Satoh, M. (327) 175)

K^+ channel, Ca^{2+}-activated; cGMP; Iberiotoxin; Nitric oxide (NO); Okadaic acid; Phosphatase (Johansson Rydberg, I.G.M. (329) 175)

P-4 (1-methyl-4-piperidyl diphenylpropoxyacetate hydrochloride); Antipollakiuric agent; Urinary bladder; Actomyosin ATPase activity; Calmodulin (Matsushima, S. (333) 93)

K^+ channels; Ca^{2+} stores; Charybdotoxin; Apamin; Pacemaker cells (Duridanova, D.B. (333) 105)

Mn^{2+}; Ileum; Ca^{2+} channel (Nasu, T. (333) 199)

Smooth muscle, airway
ANP (atrial natriuretic polypeptide); VIP (vasoactive intestinal polypeptide); K^+ channel; Levcromakalim; Ca^{2+} channel blocker; Isradipine; Trachea (Thirstrup, S. (319) 253)

Asthma; Drug combination; Interaction; Trachea; β_2-Adrenoceptor agonist; Methylxanthine; K^+ channel opener; Sodium nitroprusside; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

Airway tone, spontaneous; Phosphodiesterase inhibitor; Prostaglandin; (Guinea pig) (Thirstrup, S. (333) 215)

Smooth muscle, skinned, vascular
cGMP-dependent protein kinase; cAMP-dependent protein kinase; (Rp)-8-Bromo-guanosine-3′,5′-cyclic monophosphorothioate; (Rp)-Adenosine-3′,5′-cyclic monophosphorothioate; Ca^{2+} sensitivity (Kawada, T. (323) 75)

Smooth muscle, vascular
Thromboxane; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; SQ 29,548; Daltroban; BM-13505; SQ 30,741; AA-2414 (Zhang, R. (317) 91)

Endothelium; Hyperpolarization; Endothelin (Waldron, G.J. (318) 89)

Free radical; Ca^{2+} store (Wada, S. (320) 51)

P_{2X} purinoceptor; Chorionic surface artery; Placenta, human, term; α,β-Methylene-ATP; UTP receptor (Dobronyi, I. (320) 61)

Bradykinin; Arachidonic acid; Thromboxane; Arterial ring, mesenteric (Weinberg, M.L.D. (320) 145)

α_1-Adrenoceptor, subtype; Ca^{2+} concentration, intracellular; Contraction; Fura-2 (Tognarini, D.P. (322) 31)

N-Nitro-L-arginine methyl ester (L-NAME); Ouabain; Adenosine receptor; Coronary circulation; EDHF (endothelium-derived hyperpolarizing factor) (Olanrewaju, H.A. (322) 185)

Hyperplasia; Cell culture; Nifedipine; Captopril; Losartan; Transgenic rat (Peiró, C. (324) 257)

Ca^{2+} sensitivity; G-protein; Protein kinase C; Pimobendan; β-Escin; Cardiac muscle (Tomita, F. (326) 157)

Ca^{2+} channel; CP-060*S*; Electrophysiology; Voltage clamp; Ca^{2+} channel antagonist (Ohya, Y. (330) 93)

Brefeldin A; Contraction; Ca^{2+} entry (Filipeanu, C.M. (332) 71)

Smooth muscle cell
Lipoxygenase; Proliferation; Migration (Nishio, E. (336) 267)

Nitric oxide; Apoptosis; Protein kinase C; Protein kinase A (Nishio, E. (339) 245)

Smooth muscle cell, vascular
Ca^{2+}-permeable non-selective cation channel; Vasopressin; Endothelin-1; Mg^{2+}, extracellular (Nakajima, T. (320) 81)

Tetrandrine; Ca^{2+} current (Wu, S.-N. (327) 233)

Smooth muscle contraction
Gastrin-releasing peptide; Neuromedin B (Ladenheim, E.E. (319) 245)

Ca^{2+} channel antagonist; Protein kinase C; Calmodulin; Tyrosine kinase (Sim, S.-S. (324) 205)

Ascomycin; FK506-binding protein; Neurotransmitter release; Tachykininergic nerve; Iris sphincter muscle, rabbit (Kageyama, M. (333) 223)

Smooth muscle relaxation
Capsaicin; Urethra, dog; Nitric oxide (NO) (Nishizawa, S. (335) 211)

Smooth muscle tension
Guanylyl cyclase; Isoliquiritigenin; YC-1; ODQ (Wegener, J.W. (323) 89)

Sodium nitrite
Nitric oxide (NO); Peroxynitrite; Sugar; Vasodilatation; L-Cysteine; Methylene blue; Haemoglobin (Dowell, F.J. (338) 43)

Sodium nitroprusside
Vascular heterogeneity; Coronary artery, bovine; Glyceryl trinitrate; *S*-Nitroso-*N*-acetylpenicillamine; Isoprenaline (De la Lande, I.S. (318) 65)

Nitric oxide (NO); cGMP; Interleukin-6; Hippocampus; N^G-Nitro-L-arginine (Ma, T. (321) 343)

Asthma; Drug combination; Interaction; Smooth muscle, airway; Trachea; β_2-Adrenoceptor agonist; Methylxanthine; K^+ channel opener; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

Vas deferens, rat; Nitric oxide (NO); L-Arginine; *N*-nitro-L-arginine methyl ester (L-NAME); (Neurotransmission) (Ventura, S. (334) 87)

Sodium tauroursodeoxycholate (UR-906)
Bile duct ligation; Dehydrocholic acid; Blood coagulation factor; Cholestasis; (Rat) (Ishizaki, K. (333) 207)

Solitary nucleus
Vomiting; Capsaicin; Resiniferatoxin; Vagus nerve; (Dog) (Shiroshita, Y. (339) 183)

Soman
Dopamine; HI 6; Microdialysis; Pharmacokinetics; Acetylcholine esterase; (Rat) (Cassel, G. (332) 43)

Somatostatin binding site
CH-275; CH-288; Cerebellar nucleus (Leroux, P. (337) 333)

Somatostatin secretion
Imidazoline; Antazoline; Insulin secretion; Glucose tolerance; Pancreas; (Rat); (Dog) (Berdeu, D. (324) 233)

Sorbinil
Aldose reductase; Anococcygeus muscle, rat; Diabetes; Nitrergic neurotransmission; Nitric oxide (NO) (Way, K.J. (318) 101)

Sorbitol
Aldose reductase inhibitor; Electroretinogram; Platelet aggregation; 2,3-Diphosphoglycerate; Diabetic retinopathy (Hotta, N. (326) 45)

Spare receptor
Efficacy, agonist; Efficacy, relative; Agonist-antagonist combination; (New parameter) (Venter, D.P. (320) 223)

Spatial bias
Septum lesion, medial; Metrifonate; Spatial navigation; Reversal learning (Riekkinen Jr., P. (323) 11)

Spatial navigation
Septum lesion, medial; Metrifonate; Spatial bias; Reversal learning (Riekkinen Jr., P. (323) 11)

Metrifonate; Cholinesterase inhibition; Alzheimer's disease; Medial septal-lesion (Riekkinen, M. (338) 105)

Species difference
Tachykinin; Tachykinin NK_3 receptor; Inositol monophosphate accumulation; Ileum, guinea pig; Nonpeptide tachykinin NK_3 receptor antagonist (Beaujouan, J.-C. (319) 307)

SPECT (single photon emission computerized tomography)
5-HT_{2A} receptor; [^{123}I]R93274 (Abi-Dargham, A. (321) 285)

SPECT (Single-photon emission computed tomography)
Vesamicol; AH5183; Alzheimer's disease; Acetylcholine transporter; σ binding site (Custers, F.G.J. (338) 177)

Speedball
Balb/c mouse; Cocaine; Heroin; Self-administration, intravenous; (Mouse) (Roberts, A.J. (326) 119)

Additivity; Cocaine; Dopamine; Heroin; Microdialysis; Nicotine; Nucleus accumbens; Synergism; (Interaction) (Zernig, G. (337) 1)

Spermidine
Polyamine; Putrescine; Spermine; NMDA (*N*-methyl-D-aspartate); Motor activity; MK-801; Amphetamine; Theophylline; (Mouse) (Giménez-Llort, L. (318) 231)

Spermine
Polyamine; Putrescine; Spermidine; NMDA (*N*-methyl-D-aspartate); Motor activity; MK-801; Amphetamine; Theophylline; (Mouse) (Giménez-Llort, L. (318) 231)

Spinal cord
Flexor reflex; Galanin; GMAP (galanin message-associated peptide), fragments; Nociception (Xu, X.-J. (318) 301)

Pain; Nociception; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY 100635 (Gjerstad, J. (318) 315)

Bradykinin; Carrageenan inflammation; c-Fos; Nociception (Buritova, J. (320) 73)

Zn^{2+} inhibition; NMDA receptor, binding; MK-801; σ Receptor; (Mouse) (Kovács, K.J. (324) 117)

Angiotensin; Heart rate; Arterial pressure; Cardiovascular control; Losartan; PD 123319 (Park, P.D.S. (326) 139)

Ethanol; Glutamate; GABA (γ-aminobutyric acid); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); NMDA (*N*-methyl-D-aspartate); Anesthesia (Wong, S.M.E. (329) 121)

Agmatine; α_2-Adrenoceptor; μ-Opioid receptor; Analgesia; Fentanyl (Bradley, K.J. (331) 133)

Cyclooxygenase; Non-steroidal anti-inflammatory drugs; Formalin; Release, in vitro; Prostaglandin E_2; (Intrathecal) (Dirig, D.M. (331) 155)

Imidazoline receptor; BU-224 (2-(4,5-dihydroimidazol-2yl)-quinoline hydrochloride)); Nociception; (Rat) (Diaz, A. (333) 9)

Pain; Analgesia; Calmodulin inhibitor; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Septide (Menéndez, L. (335) 9)

Nociception; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; CP-93,129; Cyanopindolol; WAY100635 (Gjerstad, J. (335) 127)

Spinal cord, rat
Glycine receptor, strychnine-sensitive; [^{3}H]Strychnine binding; Autoradiography; Thiocolchicoside; Myorelaxant agent (Cimino, M. (318) 201)

NMDA receptor antagonist, non-competitive; Electrophysiology; Cortex, rat; Enantiomer (Ebert, B. (333) 99)

Spinal reflex
NK433; Muscle relaxant; Active metabolite (Sakitama, K. (337) 175)

Splanchnic nerve stimulation
Adrenal catecholamine; K^+ channel; Ca^{2+}-activated; SK_{Ca} channel; BK_{Ca} channel; Apamin; Charybdotoxin; Acetylcholine; DMPP (1,1-dimethyl-4-phenyl-piperazinium); Muscarine (Nagayama, T. (327) 135)

Spleen
Chloroethylclonidine; Prazosin; Aorta; Submandibular gland; α_1-Adrenoceptor; α_2-Adrenoceptor; (Rat) (O'Rourke, M. (336) 37)

Spontaneous alternation performance
[D-Pen^2,L-Pen^5]Enkephalin; [D-Ala^2]Deltorphin II; Elevated plus-maze behavior; Passive avoidance learning; δ-Opioid receptor; (Mouse) (Ukai, M. (338) 1)

Spontaneous locomotor activity
R-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-*N*,*N*-(di-*n*-propyl-2-amino)tetralin); Dopamine D_3 receptor; Passive avoidance learning; Memory; (Mouse) (Ukai, M. (324) 147)

Spontaneously hypertensive rat (SHR)
Glucose tolerance; Blood pressure; Angiotensin-converting enzyme inhibitor; Angiotensin AT_1 receptor antagonist; Valsartan (Chow, L. (319) 77)

Neuropeptide Y; Dopamine release; Dopamine D_2 receptor; G_i-protein; Striatum (Tsuda, K. (321) 5)

Na^+,K^+-ATPase; Na^+,K^+-ATPase, α-subunit; Hypertension; Ca^{2+} channel blocker; Vasodilator (Liu, X. (327) 151)

Vasopressin; Endothelin; Hemodynamics; Cardiac output; Radiotelemetry (Balakrishnan, S.M. (334) 55)

Sprague-Dawley rat
Forced swimming test; Wistar-Kyoto rat; Brown Norway rat; Imipramine; 5-HT_1 receptor; 5-HT_2 receptor; β-Adrenoceptor; Depression (Lahmame, A. (337) 115)

Spreading depression
Nicotinic acetylcholine receptor; NMDA receptor; Glutamate (Sheardown, M.J. (337) 209)

SQ 29,548
Thromboxane; Smooth muscle, vascular; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; Daltroban; BM-13505; SQ 30,741; AA-2414 (Zhang, R. (317) 91)

Pulmonary hypertension; Nitric oxide (NO); TP receptor; U-46619; N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Valentin, J.-P. (317) 335)

SQ 30,741
Thromboxane; Smooth muscle, vascular; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; SQ 29,548; Daltroban; BM-13505; AA-2414 (Zhang, R. (317) 91)

SR 140333
Mustard oil; Neurogenic inflammation; Plasma extravasation; Ear oedema; Capsaicin (Inoue, H. (333) 231)

SR 142801
Tachykinin receptor; Peptidase inhibitor; Oestrogen; Uterus (Fisher, L. (335) 221)

SR-141,716 A
Analgesia; Morphine; Opioid; Δ^9-Tetrahydrocannabinol; Dynorphin; Nor-binaltorphimine; β-Funaltrexamine; DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly-ol^5]enkephalin) (Reche, I. (318) 11)

SR 141716A
Cannabinoid receptor; CP 55,940; Brain slice; Acetylcholine (Gifford, A.N. (324) 187)

Inverse agonist; Cannabinoid receptor, human (Landsman, R.S. (334) R1)

Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Anandamide; Heart, rat; Cannabinoids (endocannabinoids), endogenous (Randall, M.D. (335) 205)

Cannabinoids; Cannabinoid CB_1 receptors; Cannabinoid CB_2 receptors; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation, guinea-pig small intestine (Griffin, G. (339) 53)

SR 46349B
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_{2A} receptor; Anxiety; Elevated plus-maze; [^{3}H]Ketanserin binding; RHA and RLA (Roman high- and low-avoidance) rats (Chaouloff, F. (334) 25)

STa (heat-stable enterotoxin of *Escherichia coli*)
Guanylin; Intestine; Ion transport; Na^+ and Cl^- unidirectional flux; VIP (vasoactive intestinal peptide) (Volant, K. (328) 217)

Startle
Nitric oxide (NO); Prepulse inhibition; Startle reaction; Schizophrenia (Wiley, J.L. (328) 125)

Startle reaction
Nitric oxide (NO); Startle; Prepulse inhibition; Schizophrenia (Wiley, J.L. (328) 125)

Stereospecificity
S 16257; Bradycardic agent; Transmembrane action potential; Heart rate; QT interval (Thollon, C. (339) 43)

Steroid
Cannabinoid; Lung; Type II cell; Ontogeny; Development (Rice, W. (327) 227)

Opioid; Cyproterone acetate; Binding (Gutiérrez, M. (328) 99)

Steroid biogenesis
Steroid hormones; Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Pregnenolone; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Steroid hormone
Aldosterone; Corticosterone; Cortisol; Deoxycortisol; Progesterone; 17α-hydroxyprogesterone; Androstenedione; Steroid biogenesis; Pregnenolone; Adrenocortical cells, in vitro, porcine; Nitrofurans; Furazolidone; Furaltadone; Nitrofurantoin (Jager, L.P. (331) 325)

Steroid resistance
Corticosteroid; Cytokine; Asthma; Mononuclear blood cell (Larsson, S. (334) 265)

Stimulus properties of drugs
Cocaine; Ethanol; Cocaethylene drug–drug discrimination; (Dose–response); (Rat) (Schechter, M.D. (320) 1)

Stomach
Cyclopiazonic acid; Ca^{2+}-ATPase; Sarcoplasmic reticulum; Smooth muscle; Contraction (Petkov, G.V. (318) 109)

Stomach, rat
UTP; ATP; Purinoceptor; Pyrimidinoceptor; Suramin (Otsuguro, K.-i. (317) 97)

Stomach fundus
Ondansetron; Contractile response; Acetylcholine release; (Rat) (Amemiya, N. (339) 173)

Stomach fundus, rat
5-HT receptor; Contractile response; Acetylcholine release (Amemiya, N. (318) 403)

Stomach mucosa
Pentadecapeptide BPC 157; Peptide BPC; Nitric oxide (NO); Gastrointestinal mucosal integrity; Blood pressure maintenance; Gastric lesion; Hypotension; N^G-Nitro-L-arginine methylester; L-Arginine (Slobodnjak, Z. (332) 23)

Stratium, ventral
Dopamine; Amphetamine; Stress; Microdialysis; (Relapse) (Weiss, F. (337) 219)

Streptozotocin
Diabetic rat; Ca^{2+}; Calmodulin; Calmidazolium; Insulin; Intestinal reactivity (Öztürk, Y. (321) 59)

Streptozotocin-diabetic rat
ACTH-(4–9) analogue; Org 2766; Adrenergic responsiveness; Nerve blood flow; Macrocirculatory blood flow (Van Buren, T. (318) 73)

Stress
Ethanol; Ro 15-4513; Plus-maze; Sleep; $^{36}Cl^-$ uptake; [^{3}H]Ro 15-4513 (Pokk, P. (317) 15)

Cholecystokinin; CCK-8; BC 264; CCK_B receptor antagonist; L-365,260; Devazepide; CCK_A receptor antagonist; Depression; Forced-swimming test; RB 101; Enkephalin catabolism inhibitor (Hernando, F. (318) 221)

Pain; Analgesia; Opioid; Opioid receptor, peripheral (Schäfer, M. (323) 1)

Mesocortical dopamine neuron; Benzodiazepine/$GABA_A$ receptor agonist; Agonist, inverse; Glycine/NMDA receptor antagonist (Hutson, P.H. (326) 127)

Benzodiazepine withdrawal; GABA (γ-aminobutyric acid)-gated Cl^- flux; Forced swim; Carbamazepine; Two-way avoidance (Martijena, I.D. (330) 101)

Peripheral-type benzodiazepine receptor; RT-PCR (reverse transcriptase-polymerase chain reaction); GAPDH (glyceraldehyde-3-phosphate dehydrogenase); Dexamethasone (Siripurkpong, P. (331) 227)

Dopamine; Stratium, ventral; Amphetamine; Microdialysis; (Relapse) (Weiss, F. (337) 219)

Striatum
Pregnancy; Dopamine; Progesterone; NMDA (*N*-methyl-D-aspartic acid); Glutamate (Cabrera, R.J. (317) 55)

GDNF (glial cell line-derived neurotrophic factor); Substantia nigra; Dopamine; Parkinson's disease; Monoamine (Martin, D. (317) 247)

Acetylcholine; Dopamine; Dopamine D_1 receptor; Dopamine D_2 receptor; Microdialysis; Neostigmine (DeBoer, P. (317) 257)

Microdialysis, brain; Cocaine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Norton, C.S. (318) 323)

Neuropeptide Y; Dopamine release; Dopamine D_2 receptor; G_i-protein; Spontaneously hypertensive rat (SHR) (Tsuda, K. (321) 5)

L-DOPA (3,4-dihydroxyphenyl-L-alanine); Early gene; Parkinson's disease; Dopamine D_1 receptor; Dopamine D_2 receptor (Fenu, S. (321) 143)

Up-regulation; Dopamine D_2 receptor; Antipsychotic drug, atypical; 5-HT_{2A} receptor (Ishikane, T. (321) 163)

Dopamine D_2 receptor; Adenosine A_{2A} receptor; Locomotion; Catalepsy; (Rat) (Hauber, W. (323) 127)

Tyrosine hydroxylase; Aromatic L-amino acid decarboxylase; Dopamine receptor; Midbrain (Cho, S. (323) 149)

Nicotine; Hippocampus, ventral; Nucleus accumbens; Noradrenaline; Dopamine (Benwell, M.E.M. (325) 13)

Voltammetry, in vivo; Dopamine; Dopamine D_2 receptor antagonist; Behavior; (Rat) (Horikawa, H.P.M. (326) 15)

Hypoxia; Xanthine; Purine; Transmitter release; Adenosine A_1 receptor (Jin, S. (329) 107)

cAMP; Dopamine D_1 receptor; Dopamine D_2 receptor; Parkinson's disease (Pinna, A. (331) 23)

Homophthalazine; 2,3-benzodiazepine; Anxiolytic drug; Antipsychotic drug; c-*fos* expression (Palkovits, M. (331) 53)

Neurotensin; Haloperidol; Dopamine; Nucleus accumbens (Huang, W. (332) 15)

Nociceptin; Orphanin FQ; Retina; Dynorphin A; Opioid (Makman, M.H. (338) 171)

Striatum, mouse
Nicotine; Tolerance; Dopamine metabolism; Dopamine receptor (Pietilä, K. (318) 17)

Striatum, rat
Cassia siamea; Barakol; Dopamine release; Dopamine uptake, in vitro (Thongsaard, W. (319) 157)

Aripiprazole; Antipsychotic drug; Dopamine receptor; Ribonuclease protection assay (Inoue, A. (321) 105)

Clozapine; Muscarinic m4 receptor; Neuroleptic, atypical; Neuroleptics, typical; cAMP; Chinese hamster ovary cell (Zeng, X.P. (321) 349)

Stroke
Angiotensin II; Enalapril; L-nitro-arginine methyl ester (L-NAME); Nitric oxide (NO) (Ahmad, S. (333) 39)

Stroke-prone spontaneously hypertensive rats (SHRSPs)
CD-832; Ca^{2+} channel antagonist; Renal lesion (Takahashi, T. (331) 193)

Structure-activity relationship
γ-MSH (γ-melanocyte-stimulating hormone) fragment; ACTH (adrenocorticotropic hormone) fragment; Blood pressure; Heart rate; Cerebral blood flow; (Rat) (Van Bergen, P. (318) 357)

Sulphonylurea; Levcromakalim; Thromboxane A_2; U46619; Coronary artery, pig (McPherson, G.A. (324) 193)

Struggle latency
Antinociception; Mononeuropathic rat; CCK_B receptor antagonist; L-365,260; Morphine; Naloxone; Vocalization threshold (Idänpään-Heikkilä, J.J. (325) 155)

[^{3}H]Strychnine binding
Glycine receptor, strychnine-sensitive; Spinal cord, rat; Autoradiography; Thiocolchicoside; Myorelaxant agent (Cimino, M. (318) 201)

Submandibular gland
Chloroethylclonidine; Prazosin; Aorta; Spleen; α_1-Adrenoceptor; α_2-Adrenoceptor; (Rat) (O'Rourke, M. (336) 37)

Submaxillary lymph node
Cyclosporine chronopharmacology; Sympathetic nervous system; Parasympathetic nervous system; Ornithine decarboxylase; Norepinephrine uptake; Acetylcholine synthesis; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (319) 181)

Substance P
Tachykinin NK_1 receptor; Plasma extravasation; Migraine; Pain (Seabrook, G.R. (317) 129)

Cerebral blood volume; Cerebral vessel; FK888; Photoelectric method; Tachykinin NK_1 receptor antagonist (Kobari, M. (317) 269)

Tachykinin receptor antagonist; Tachykinin NK_1 receptor; Salivation; Blood pressure (Cellier, E. (318) 377)

Brain; Electroconvulsive stimuli; Hybridization, in situ; mRNA expression; Tachykinin receptor; (Rat) (Zachrisson, O. (319) 191)

Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenylate cyclase; Adenosine; 5-HT (5-hydroxytryptamine, serotonin); Signal transduction (Xia, Y. (320) 95)

CGRP (calcitonin gene-related peptide); Superoxide; Neutrophil (Tanabe, T. (321) 137)

5-HT_4 receptor; 5-HT (5-hydroxytryptamine, serotonin); Smooth muscle; Intestinal tract; Esophagus (Goldhill, J. (323) 229)

Diclofenac; Analgesia (Papworth, J. (325) R1)

Chromaffin cell; Epibatidine; Noradrenaline release; Adrenaline release (Krause, W. (328) 249)

Dynorphin; Enkephalin; Acetylcholine; Dopamine; Amphetamine; Nucleus accumbens; Caudoputamen; Behavior; Muscarinic receptor (Wang, J.Q. (334) 43)

β_2-Adrenoceptor agonist; Plasma leakage; Trachea; Vascular permeability (Bowden, J.J. (338) 83)

Tachykinin; Bronchoconstriction; Neurokinin A; Mast cell; 5-HT (5-hydroxytryptamine, serotonin); Tachykinin NK_1 receptor (Joos, G.F. (338) 259)

Substantia nigra
GDNF (glial cell line-derived neurotrophic factor); Striatum; Dopamine; Parkinson's disease; Monoamine (Martin, D. (317) 247)

Dopamine D_1 receptor; Medial prefrontal cortex; Ventral tegmental area (Dewar, K.M. (336) 155)

Substantia nigra reticulata
Antipsychotic; Schizophrenia; Basal ganglion; Electrophysiology; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Bruggeman, R. (324) 49)

α_1 Subunit
$GABA_A$ receptor; Mutation; Radioligand binding; Electrophysiology (Westh-Hansen, S.E. (329) 253)

Succinate dehydrogenase, inhibition
Catecholamine; Toxicity; Energy metabolism; Basal ganglia (Zeevalk, G.D. (320) 111)

Succinic acid monoethyl ester
Succinic acid monopropyl ester; Succinic acid monoisopropyl ester; Gliquidone; Insulin secretion (García-Martínez, J.A. (325) 65)

Succinic acid monoisopropyl ester
Succinic acid monoethyl ester; Succinic acid monopropyl ester; Gliquidone; Insulin secretion (García-Martínez, J.A. (325) 65)

Succinic acid monopropyl ester
Succinic acid monoethyl ester; Succinic acid monoisopropyl ester; Gliquidone; Insulin secretion (García-Martínez, J.A. (325) 65)

Sugar
Nitric oxide (NO); Peroxynitrite; Vasodilatation; L-Cysteine; Sodium nitrite; Methylene blue; Haemoglobin (Dowell, F.J. (338) 43)

Sulfonylurea
Prostanoid; Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Tolazamide; Tolbutamide; Gliclazide; Glibenclamide; Bronchiole; Artery (Delaey, C. (325) 41)

Sulphonylurea
Levcromakalim; Thromboxane A_2; U46619; Structure-activity relationship; Coronary artery, pig (McPherson, G.A. (324) 193)

Superior cervical ganglion
Cyclosporine chronopharmacology; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Ornithine decarboxylase; Norepinephrine uptake; Acetylcholine synthesis; Chorda tympani (Esquifino, A.I. (319) 181)

Superior colliculus
N^{ω}-Nitro-L-arginine methyl ester (L-NAME); L-Arginine; Blood pressure (D'Amico, M. (328) 65)

Superoxide
Substance P; CGRP (calcitonin gene-related peptide); Neutrophil (Tanabe, T. (321) 137)

Superoxide anion
ABT-491; PAF (platelet-activating factor); PAF receptor antagonist; Ca^{2+} flux; Vascular permeability; Degranulation; Endotoxemia (Albert, D.H. (325) 69)

Superoxide anion generation
PF-904; Airway; Airway, hyperreactivity; Eosinophil infiltration; Microvascular leakage; Bronchus, human, isolated; Phosphodiesterase activity; Neutrophils, human; (Guinea pig) (Cortijo, J. (333) 69)

Superoxide dismutase
Oxygen metabolite, reactive; Glutathione redox cycle; Catalase; Colonic epithelial cell (Hata, Y. (321) 113)

D-Glucose oxidation; Endothelial cell; EDRF (endothelium-derived relaxing factor); Glutathione; Vitamin C; Vitamin E (Graier, W.F. (322) 113)

Smooth muscle; Endothelium; Dimalonic acid C_{60}; Nitric oxide (NO) (Satoh, M. (327) 175)

Superoxide radical
Anti-Thy1 nephritis; Cytokine; OPC15161; Matrix index; Tubulointerstitial index (Hamada, N. (317) 123)

Supersensitivity
Dizocilpine; Dopamine receptor; Electroconvulsive shock; NMDA receptor (D'Aquila, P.S. (330) 11)

Suplaplast tosilate
Airway inflammation; Airway hyperresponsiveness; Eosinophil; Lymphocyte; T cell (Taniguchi, H. (321) 397)

Suplatast tosilate
Airway inflammation; Airway hyperresponsiveness; Eosinophil; Lymphocyte; T cell (Taniguchi, H. (318) 447)

Suramin
UTP; ATP; Purinoceptor; Pyrimidinoceptor; Stomach, rat (Otsuguro, K.-i. (317) 97)

Vas deferens, rat; Purinergic transmission; Noradrenergic transmission; Cromakalim; Prazosin; Glibenclamide (Grana, E. (319) 57)

ATP; α,β-methylene-ATP; Nociception; Formalin test (Sawynok, J. (330) 115)

Coronary artery, canine; Vasoconstriction; Vasodilation; P2 purinoceptor; ATP; UTP; Reactive blue 2 (Matsumoto, T. (334) 173)

Detrusor muscle, rat; Purinergic transmission; Cholinergic transmission; Cromakalim; Atropine; Nifedipine (Boselli, C. (335) 23)

Swelling
Penumbra; Glutamate; Taurine; Lubeluzole; Neuroprotection; Microdialysis (Scheller, D.K.A. (338) 243)

Sympathetic activity
Aortic barodenervation; α_1-Adrenoceptor; Aorta; Receptor desensitization (El-Mas, M.M. (322) 201)

Sympathetic division
Opioid; Immunity; Lymphocyte proliferation; Autonomic nervous system; Parasympathetic division; (Rat) (Flores, L.R. (318) 437)

Sympathetic nerve activity
α_2-Adrenoceptor; Blood pressure; Ventrolateral medulla, rostral (Vayssettes-Courchay, C. (320) 151)

Sympathetic nerve stimulation
Auricular artery; Purinergic transmission; P_{2_1} purinoceptor (Haniuda, K. (333) 163)

Sympathetic nervous system
Cyclosporine chronopharmacology; Parasympathetic nervous system; Submaxillary lymph node; Ornithine decarboxylase; Norepinephrine uptake; Acetylcholine synthesis; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (319) 181)

Quinpirole; Dopamine; Dopamine D_2 receptor; Rilmenidine; α-Methyldopa; Hydralazine; Vasopressin (Van den Buuse, M. (322) 191)

Sympathetic-parasympathetic interaction
Autonomic nervous system; Sinus rate; Atrioventricular conduction; Aminophylline (Furukawa, Y. (334) 191)

Sympathetic stimulation
BIBP 3226; Neuropeptide Y receptor; Neuropeptide Y Y_1 receptor; Mesenteric artery, human, inferior; Mesenteric vein, human, inferior (Racchi, H. (329) 79)

Synaptic plasticity
Free radical; H_2O_2; Hippocampus; CA1 region (Katsuki, H. (337) 213)

Synaptic plasticity, modulation of
Long-term potentiation; Depotentiation; Adenosine A_1 receptor antagonist; 8-CPT (8-cyclopentyltheophylline); Hippocampal CA1 neuron (Fujii, S. (331) 9)

Synaptic vesicle
Vesamicol receptor; Acetylcholine; Acetylcholine transporter, vesicular (Staley, J.K. (338) 159)

Synaptogenesis, reactive
Methamphetamine; Cortex, prefrontal; GABA (γ-aminobutyric acid), innervation; (Gerbil) (Dawirs, R.R. (327) 117)

Synaptosomal uptake
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; Noradrenaline; Frontal cortex; Microdialysis, in vivo (Hughes, Z.A. (317) 83)

Synaptosome
Glutamate release; Nitric oxide (NO); cGMP; Protein kinase G; Zaprinast (Sistiaga, A. (321) 247)

Kainate; Hippocampus; GABA (γ-aminobutyric acid) release; Domoic acid; Glutamate (Cunha, R.A. (323) 167)

Histamine; Glutamate; [^{3}H]Glutamate, release; Hippocampus (Rodriguez, F.J. (323) 283)

Glycine receptor, strychnine-insensitive; NMDA receptor; [^{3}H]Dopamine release; [^{3}H]Noradrenaline release; 7-Cl-Kynurenic acid; HA 966; GV 150526A (Mennini, T. (336) 275)

Synergism
Additivity; Cocaine; Dopamine; Heroin; Microdialysis; Nicotine; Nucleus accumbens; Speedball; (Interaction) (Zernig, G. (337) 1)

Synovial cell
Aceclofenac; Cyclooxygenase; Prostaglandin E_2; Polymorphonuclear leukocyte; Monocyte (Yamazaki, R. (329) 181)

Systemic inflammatory response syndrome
Aminoguanidine; N^G-Nitro-L-arginine; PAF (platelet-activating factor); Lipopolysaccharide; Nitric oxide (NO); (Rat) (Takano, H. (323) 107)

$t_{1/2}$
Radioligand binding; Oral bioavailability; Brain penetration; Vomiting; Retching; Nausea; Ondansetron (Singh, L. (321) 209)

T-330
H^+/K^+-ATPase; Gastric acid secretion; Omeprazole; Ranitidine (Kinoshita, M. (321) 325)

Tachycardia
Zatebradine; Respiratory resistance; cAMP (Yamazaki, K. (320) 21)

5-HT_3 receptor; Atrium; Ethanol; Alcohol (Nishio, H. (321) 27)

Tachycardia, reflex
Elgodipine; Blood pressure; Dihydropyridin (Valdivielso, J.M. (335) 193)

Tachykinin
5-HT_3 receptor; Colon, guinea pig; Longitudinal muscle; Circular muscle (Yamano, M. (317) 353)

Tachykinin NK_3 receptor; Inositol monophosphate accumulation; Ileum, guinea pig; Nonpeptide tachykinin NK_3 receptor antagonist; Species difference (Beaujouan, J.-C. (319) 307)

Hyperalgesia; Allodynia; Pain; Flexor reflex (Ma, Q.-P. (322) 165)

Opioid; Nor-binaltorphimine; κ-Opioid receptor; Antinociception; Dorsal horn; Nociception; Pain (Zachariou, V. (323) 159)

Plasma protein extravasation; 5-HT receptor; Histamine receptor; Airways; Capsaicin; (Fisher 344 rat) (Germonpré, P.R. (324) 249)

Intestinal distension; Visceral hyperalgesia; Visceral nociception; Mast cell; Tachykinin NK_2 receptor (McLean, P.G. (337) 279)

Bronchoconstriction; Substance P; Neurokinin A; Mast cell; 5-HT (5-hydroxytryptamine, serotonin); Tachykinin NK_1 receptor (Joos, G.F. (338) 259)

Tachykininergic nerve
Ascomycin; FK506-binding protein; Neurotransmitter release; Smooth muscle contraction; Iris sphincter muscle, rabbit (Kageyama, M. (333) 223)

Tachykinin receptor
Brain; Electroconvulsive stimuli; Hybridization, in situ; mRNA expression; Substance P; (Rat) (Zachrisson, O. (319) 191)

Peptidase inhibitor; Oestrogen; Uterus; SR 142801 (Fisher, L. (335) 221)

Tachykinin receptor agonist
Smooth muscle; Intestinal motility; Tachykinin receptor antagonist (Parlani, M. (318) 419)

Tachykinin receptor antagonist
Substance P; Tachykinin NK_1 receptor; Salivation; Blood pressure (Cellier, E. (318) 377)

Smooth muscle; Intestinal motility; Tachykinin receptor agonist (Parlani, M. (318) 419)

Tachykinin NK_1 receptor
Substance P; Plasma extravasation; Migraine; Pain (Seabrook, G.R. (317) 129)

Tachykinin receptor antagonist; Substance P; Salivation; Blood pressure (Cellier, E. (318) 377)

Anti-emetic; Brain penetration (Rupniak, N.M.J. (326) 201)

Semliki Forest virus system; Mutagenesis, site-directed; Binding assays; Functional coupling (Lundstrom, K. (337) 73)

Tachykinin; Bronchoconstriction; Substance P; Neurokinin A; Mast cell; 5-HT (5-hydroxytryptamine, serotonin) (Joos, G.F. (338) 259)

Tachykinin NK_2 receptor
Intestinal distension; Visceral hyperalgesia; Visceral nociception; Mast cell; Tachykinin (McLean, P.G. (337) 279)

Tachykinin NK_3 receptor
Tachykinin; Inositol monophosphate accumulation; Ileum, guinea pig; Nonpeptide tachykinin NK_3 receptor antagonist; Species difference (Beaujouan, J.-C. (319) 307)

Tachykinin NK_1 receptor agonist
Sensory nerves; Capsaicin; *Phoneutria nigriventer* venom; Neurogenic oedema (Costa, S.K.P. (339) 223)

Tachykinin NK_1 receptor antagonist
Cerebral blood volume; Cerebral vessel; FK888; Photoelectric method; Substance P (Kohari, M. (317) 269)

Antagonism, pseudo-irreversible (Cascieri, M.A. (325) 253)

Tachykinin NK_3 receptor, expression
Polymerase chain reaction; Uterus, rat (Pinto, F.M. (324) 125)

Tachyphylaxis
β-Adrenoceptor; Nitric oxide (NO) (Travis, M.D. (328) R1)

Tacrine
Cognex; Acetylcholine; Vacuous chew; Purposeless; Tremor; Parkinson's disease; Alzheimer's disease (Cousins, M.S. (322) 137)

Tacrolimus
FK506; Glucocorticosteroid; Immunosuppression; Local lymph node assay; Topical drug (Homey, B. (325) 199)

Taenia caecum
Adenosine; Purinoceptor; Adenosine A_{2B} receptor; Adenosine A_3 receptor (Prentice, D.J. (323) 103)

Taenia caecum, guinea pig
β-Adrenoceptor; β_3-Adrenoceptor; BRL37344A, BRL35135A; Muscle relaxation (Koike, K. (334) 217)

Tail artery
α-Adrenoceptors; Dissociation constant; Caudal artery; (Bovine) (Hill, B.J.F. (339) 147)

Tail bleeding time
YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole); Antithrombotic effect; Platelet aggregation; Profibrinolytic effect (Teng, C.-M. (320) 161)

Tail flick
Behavior; Body temperature; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lower lip retraction; 5-HT (5-hydroxytryptamine, serotonin); (Intracerebroventricular administration) (Bagdy, G. (323) 53)

Tail-flick test
Neuropathic pain; Allodynia; Antinociception; Behavior; Electroshock test, maximal; Lamotrigine; Felbamate; Gabapentin (Hunter, J.C. (324) 153)

Tail suspension test
YM992; Antidepressant; 5-HT (5-hydroxytryptamine, serotonin) re-uptake inhibition; 5-HT_{2A} receptor antagonistic activity; Olfactory bulbectomized rat (Takeuchi, H. (329) 27)

Tail-tremor
Nicotine; Chronic administration; Nitric oxide (NO); NMDA receptor (Suemaru, K. (335) 139)

Talipexole
Bromocriptine; Dopamine D_2 receptor agonist; Anti-tremor effect; Ventromedial tegmentum lesion; Parkinson's disease; (Cynomolgus monkey) (Kohno, Y. (319) 197)

Pramipexole; Chloro-APB; MPTP-induced hemiparkinsonism; SKF 82958; Dopamine D_1-like receptor agonist; Dopamine D_2-like receptor agonist; (Monkey) (Domino, E.F. (325) 137)

Talsaclidine
Arecoline; McN-A-343; Noradrenaline; Bronchospasm; Guinea pig (Walland, A. (330) 213)

Tamoxifen
MCF7/6; E-cadherin; Adhesion; Ca^{2+} channel antagonist (Charlier, C. (317) 413)

TAN-67
Methamphetamine; δ-Opioid receptor; Drug discrimination (Suzuki, T. (331) 1)

(+)-TAN-67
(−)-TAN-67; Antinociception; δ-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben, diabetes (Kamei, J. (322) 27)

(−)-TAN-67
(+)-TAN-67; Antinociception; δ-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben, diabetes (Kamei, J. (322) 27)

Tardive dyskinesia
Reserpine; Oral dyskinesia; Tongue protrusion; Dopamine (Sussman, A.N. (337) 157)

Taurine
Penumbra; Glutamate; Lubeluzole; Neuroprotection; Swelling; Microdialysis (Scheller, D.K.A. (338) 243)

TBPS (*t*-butylbicyclophosphorothionate) binding
Hexachlorocyclohexane isomer; Lindane; $GABA_A$ receptor; Flunitrazepam binding; GABA (γ-aminobutyric acid) binding; Cerebellar granule cell, cultured (Vale, C. (319) 343)

T cell
Suplatast tosilate; Airway inflammation; Airway hyperresponsiveness; Eosinophil; Lymphocyte (Taniguchi, H. (318) 447)

Suplaplast tosilate; Airway inflammation; Airway hyperresponsiveness; Eosinophil; Lymphocyte (Taniguchi, H. (321) 397)

Telemetry
Cyclooxygenase 2; Cyclooxygenase 2 inhibitor; Pyresis; (Squirrel monkey) (Chan, C.-C. (327) 221)

Temporal cortex
Memory impairment; D-Cycloserine; Entorhinal cortex; Recovery of function; (Microinjection) (Myhrer, T. (328) 1)

Tenascin
Knockout mouse; Apomorphine; Dopamine receptor (Fukamauchi, F. (338) 7)

Terazosin
α_1-Adrenoceptor; Prazosin; Radioligand assay (Ireland, L.M. (327) 79)

Terfenadine
Antihistaminic agent; Ebastine; Carebastine; K^+ current; hKv1.5 channel (Valenzuela, C. (326) 257)

Terminal
Adenosine; ATP; Cholinergic; GABA (γ-aminobutyric acid); Nitric oxide (NO); Ileum (Pencheva, N. (339) 193)

***Tert*-butyl hydroperoxide**
γ-glutamylcysteinylethyl ester; Glutathione, reduced; Hepatocyte; Glycine (Nishida, K. (333) 289)

Testosterone
Gastroduodenal ulceration; Gastroduodenal mucosa; Cysteamine; Sexual dimorphism; Sexual steroid; Microcirculation; Microvascular leakage (László, F. (337) 275)

Tetracaine
Pancreatic B-cell; Insulin secretion; $[Ca^{2+}]_i$ (Bordin, S. (327) 257)

12-*O*-Tetradecanoylphorbol 13-acetate
Auranofin; Prostaglandin E_2; Thapsigargin; A23187; Cyclooxygenase 2; Cyclooxygenase 1; Macrophage (Yamashita, M. (325) 221)

Inflammation, chronic; Skin; Triterpenoids (Máñez, S. (334) 103)

Tetrahydroaminoacridine
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Noradrenaline; EEG (electroencephalogram); Memory; Basal forebrain lesion (Abe, K. (321) 149)

Tetrahydrocannabinol
Anandamide; Palmitoylethanolamide; Cannabinoid receptors; Cytokines; Mononuclear cells; Immune response (Berdyshev, E.V. (330) 231)

Cannabinoid; Cannabinoid receptor; Drug efficacy; Brain, mouse; (Partial agonist) (Burkey, T.H. (336) 295)

Δ^9-Tetrahydrocannabinol
Analgesia; Morphine; Opioid; SR-141,716 A; Dynorphin; Nor-binaltorphimine; β-Funaltrexamine; DAMGO ([D-Ala^2,*N*-Me-Phe^4,$Gly\text{-}ol^5$]enkephalin) (Reche, I. (318) 11)

Opioid; Proopiomelanocortin; mRNA; Arcuate nucleus (Corchero, J. (323) 193)

Brain, mouse; G-protein (Burkey, T.H. (323) R3)

$[Ca^{2+}]_i$; DDT$_1$MF-2 cell (Filipeanu, C.M. (336) R1)

Tetrahydrodeoxycorticosterone
GABA (γ-aminobutyric acid); Pregnanolone; Dehydroepiandrosterone; Pregnenolone sulfate; Neuroactive steroid; Pituitary melanotrope cell; Patch-clamp (Le Foll, F. (331) 303)

Tetrandrine
$[Ca^{2+}]_i$ transient; Heart muscle; Ca^{2+} antagonist; Ca^{2+} release; Cardiomyocyte (Wang, H.-X. (319) 115)

Smooth muscle cell, vascular; Ca^{2+} current (Wu, S.-N. (327) 233)

Tetraphenylphosphonium
Levcromakalim; Quaternary ion; K^+ channel antagonist; Circumflex artery, right, pig; Triphenylphosphonium compound (Piekarska, A.E. (322) 37)

Tetrodotoxin
Carbamazepine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Hippocampus; Ca^{2+}; Electroshock seizure; (Rat) (Dailey, J.W. (328) 153)

TGF-β1 (transforming growth factor-β1)
Angiotensin-converting enzyme inhibitor; Extracellular matrix; Glomerulosclerosis; Gene expression (Hamaguchi, A. (331) 27)

Thalamus
α_1-Adrenoceptor; α_{1A}-Adrenoceptor; α_{1B}-Adrenoceptor; α_{1C}-Adrenoceptor; Inositol phosphate (Trejo, F. (318) 175)

$GABA_B$ receptor; Microdialysis; Aspartate; Glutamate (Nyitrai, G. (318) 295)

Epilepsy; Cortex; Hippocampus; c-Fos; $GABA_B$ receptor antagonist (Vergnes, M. (332) 245)

Thapsigargin
Ca^{2+} release; Ca^{2+} entry; Endothelial cell; ATP (Oike, M. (319) 291)

Nicotine; Antinociception; Ca^{2+}; Ca^{2+} channel; Tolerance; (Inthrathecal) (Damaj, M.I. (322) 129)

Auranofin; Prostaglandin E_2; 12-*O*-Tetradecanoylphorbol 13-acetate; A23187; Cyclooxygenase 2; Cyclooxygenase 1; Macrophage (Yamashita, M. (325) 221)

Theophylline
Polyamine; Putrescine; Spermidine; Spermine; NMDA (*N*-methyl-D-aspartate); Motor activity; MK-801; Amphetamine; (Mouse) (Giménez-Llort, L. (318) 231)

Haloperidol; Catalepsy; Adenosine receptor agonist; Adenosine receptor antagonist (Mandhane, S.N. (328) 135)

Therapeutic index
ATPase (Na^+, K^+); Cardiac glycoside; α-Methyl-digitoxigenin-glucoside; Ouabain (Gleitz, J. (335) 89)

Therapeutic window
MRI (magnetic resonance imaging); Ancrod; Cerebral ischemia; Hypertensive rat; Fibrinogen; Middle cerebral artery occlusion; (Delayed therapy) (Elger, B. (336) 7)

Thermodynamic model
Signal transduction; Conformational states, multiple; Ligand efficacy; Inverse agonist (Pardo, L. (335) 73)

Thienyl baclofen analog
Baclofen; $GABA_B$ receptor agonist; 2-Hydroxysaclofen; Neocortical slice, rat (Ong, J. (329) 133)

Thiobarbituric acid-reactive substance
Epinephrine; Ethanol; Isolated hepatocyte; Piroxicam; Triacylglyceride (Saldaña-Balmori, Y. (317) 225)

Thiocolchicoside
Glycine receptor, strychnine-sensitive; [^{3}H]Strychnine binding; Spinal cord, rat; Autoradiography; Myorelaxant agent (Cimino, M. (318) 201)

Thiocyanate
AMPA receptor; (*S*)-5-Fluorowillardiine; (*S*)-AMPA ((*S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid); (*R,S*)-AMPA ((*R,S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) (Hawkinson, J.E. (329) 213)

Thioperamide
Histamine immunoreactivity; Vestibular nucleus; Tuberomammillary nucleus; Unilateral vestibular neurectomy; Betahistine; (Cat) (Tighilet, B. (330) 65)

Thoracic aorta
Vasorelaxation; Norepinephrine; cAMP; cGMP; Ca^{2+} channel blocker (Cheng, Y.-W. (336) 23)

Thrombin
Thrombin receptor-activating peptide; Thrombin inhibitor; Platelet aggregation; ^{111}Indium oxine; Receptor binding; Pulmonary microcirculation (Chiu, P.J.S. (321) 129)

Protease-activated receptor; Astrocyte culture (Debeir, T. (323) 111)

Thrombin inhibitor
Thrombin; Thrombin receptor-activating peptide; Platelet aggregation; ^{111}Indium oxine; Receptor binding; Pulmonary microcirculation (Chiu, P.J.S. (321) 129)

Thrombin receptor
Megakaryocyte, rat; Ca^{2+}-activated K^+ current; Patch clamp, perforated (Uneyama, C. (319) 299)

Adenosine A_1 receptor; P_{2U} purinoceptor; Inositol phosphate; Arachidonic acid; CHO (Chinese hamster ovary) cell; Protein kinase C (Dickenson, J.M. (321) 77)

In situ hybridization; Heparin; Arterial injury (Guitteny, A.-F. (327) 157)

Thrombin receptor-activating peptide
Thrombin; Thrombin inhibitor; Platelet aggregation; ^{111}Indium oxine; Receptor binding; Pulmonary microcirculation (Chiu, P.J.S. (321) 129)

Thrombosis
Platelet aggregation; Cerebral ischemia; (Rat) (Kaku, S. (321) 301)

Thromboxane
Smooth muscle, vascular; U-46619; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; SQ 29,548; Daltroban; BM-13505; SQ 30,741; AA-2414 (Zhang, R. (317) 91)

Bradykinin; Arachidonic acid; Arterial ring, mesenteric; Smooth muscle, vascular (Weinberg, M.L.D. (320) 145)

Thromboxane A_2
Rutaecarpine; Alkaloid; Platelet, human; cAMP; cGMP; Phosphoinositide (Sheu, J.-R. (318) 469)

Coronary artery smooth muscle cell; Mitogenesis; PDGF (platelet-derived growth factor) (Grosser, T. (319) 327)

Sulphonylurea; Levcromakalim; U46619; Structure-activity relationship; Coronary artery, pig (McPherson, G.A. (324) 193)

Sulfonylurea; Prostanoid; Prostaglandin $F_{2\alpha}$; Tolazamide; Tolbutamide; Gliclazide; Glibenclamide; Bronchiole; Artery (Delaey, C. (325) 41)

Arterial thrombosis; Cyclooxygenase; Platelet aggregation (Shimazawa, M. (328) 183)

Thrombus
PAI-1 (plasminogen activator inhibitor-1); Fibrinolysis; Hemostasis; (Rat) (Ohtani, A. (330) 151)

Time response
Vasopressin; Oxytocin; Factor VIII (F-VIII); Antihemophilic factor; Blood clotting; Plasminogen activator; Neurohypophyseal hormone analog; Dose–response analysis; Non-monotonic profile (Neuenschwander, S. (323) 205)

TJN-505
Aconitine; Antiarrhythmic drug; Arrhythmia model, canine (Arita, J. (318) 333)

TNF (tumor necrosis factor)
Chlorpromazine; Endotoxin (Ghezzi, P. (317) 369)

Interleukin 10; Brain; Lipopolysaccharide (Di Santo, E. (336) 197)

TNF bioassay
Pentoxifylline; TNF-α (tumor necrosis factor-α); Anti-TNF strategy; Lipopolysaccharide; Fever; Radiotelemetry; (Guinea pig) (Goldbach, J.-M. (319) 273)

TNF-α (tumor necrosis factor-α)
Pentoxifylline; Anti-TNF strategy; Lipopolysaccharide; Fever; TNF bioassay; Radiotelemetry; (Guinea pig) (Goldbach, J.-M. (319) 273)

Interleukin-10; cAMP-elevating agent (Siegmund, B. (321) 231)

Dimaprit; Histamine H_2 receptor; Hepatitis; Septic shock; Inflammation (Nakamura, T. (322) 83)

Colitis; Interleukin-10; Inflammation; Nitric oxide (NO) (Ribbons, K.A. (323) 245)

AIDS (acquired immunodeficiency syndrome); LP-BM5 murine leukemia virus; Encephalopathy; PAF (platelet-activating factor); Pentoxifylline (Sei, Y. (325) 81)

Mast cell; Histamine; Interleukin-4 (Gibbs, B.F. (327) 73)

Interleukin-1; Septic shock (Yamamoto, N. (327) 169)

Adhesion molecule; Glucocorticoid; Inflammation; PECAM-1; Interleukin-1 (Wheller, S.K. (331) 65)

Acyclic nucleotide analog; IL-10 (interleukin-10); NO (nitric oxide); (R)-PMPA ((R)-9-(2-phosphonomethoxypropyl)adenine) (Zídek, Z. (331) 245)

TNF-β; Acute-phase-response; Fever; Interleukin-6; Hypothalamic–pituitary–adrenal axis; Cortisol (Goldbach, J.-M. (334) 249)

17β-oestradiol; Myocardial ischaemia–reperfusion injury; ICAM-1 (intercellular adhesion molecule-1) (Squadrito, F. (335) 185)

Brown adipocyte; Nitric oxide (NO) synthase, inducible; Lipoprotein lipase; Guanosine 3′,5′-cyclic monophosphate (Uchida, Y. (335) 235)

Lipopolysaccharide; cAMP; cGMP; Phosphodiesterase III inhibitor; Monocyte; Macrophage; Interleukin-10; Nitric oxide (NO) (Németh, Z.H. (339) 215)

Endothelin; Glial cell; Nitric oxide synthase, inducible; Protein kinase C; Endothelin ET_B receptor (Oda, H. (339) 253)

Cationic amino acid transporter; Gene expression; Nitric oxide (NO); Umbilical vein endothelial cell; (Human) (Irie, K. (339) 289)

TNF-β
TNF-α (tumor necrosis factor-α); Acute-phase-response; Fever; Interleukin-6; Hypothalamic–pituitary–adrenal axis; Cortisol (Goldbach, J.-M. (334) 249)

Tolazamide
Sulfonylurea; Prostanoid; Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Tolbutamide; Gliclazide; Glibenclamide; Bronchiole; Artery (Delaey, C. (325) 41)

Tolbutamide
Sulfonylurea; Prostanoid; Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Tolazamide; Gliclazide; Glibenclamide; Bronchiole; Artery (Delaey, C. (325) 41)

Tolerance
Dopamine D_1 receptor; A-86929; ABT-431; Hyperactivity; Seizure (Shiosaki, K. (317) 183)

Nicotine; Dopamine metabolism; Striatum, mouse; Dopamine receptor (Pietilä, K. (318) 17)

Neuropathic pain; Mononeuropathic rat; Morphine; Opioid receptor agonist (Catheline, G. (318) 273)

μ-Opioid receptor; Downregulation; Fentanyl; Clocinnamox; DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); Analgesia (Chan, K.W. (319) 225)

Nicotine; Antinociception; Ca^{2+}; Ca^{2+} channel; Thapsigargin; (Intrathecal) (Damaj, M.I. (322) 129)

μ-Opioid receptor; Regulation of mRNA; Etorphine; Receptor downregulation; Analgesia (Sehba, F. (339) 33)

Tongue protrusion
Reserpine; Oral dyskinesia; Dopamine; Tardive dyskinesia (Sussman, A.N. (337) 157)

Topical drug
FK506; Glucocorticosteroid; Immunosuppression; Local lymph node assay; Tacrolimus (Homey, B. (325) 199)

Topoisomerase I
Differentiation; U-937 cell (Shayo, C.C. (324) 129)

Toxicity
ACPC (1-aminocyclopropanecarboxylic acid); Neuroprotection; NMDA receptor; Neuronal injury; Glycine; Excitatory amino acid (Lin, Y. (318) 491)

Succinate dehydrogenase, inhibition; Catecholamine; Energy metabolism; Basal ganglia (Zeevalk, G.D. (320) 111)

Aconitum alkaloid; Na^+ channel; Antinociception (Friese, J. (337) 165)

Cocaine; Convulsion; Lethality; NMDA receptor (Matsumoto, R.R. (338) 233)

ω-Toxin
Ca^{2+} channel; Neuronal nicotinic receptor; Ca^{2+} channel antagonist; Chromaffin cell (Villarroya, M. (320) 249)

TP receptor
Pulmonary hypertension; Nitric oxide (NO); U-46619; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); SQ 29,548 (Valentin, J.-P. (317) 335)

Trachea
ANP (atrial natriuretic polypeptide); VIP (vasoactive intestinal polypeptide); K^+ channel; Levcromakalim; Ca^{2+} channel blocker; Isradipine; Smooth muscle, airway (Thirstrup, S. (319) 253)

Asthma; Drug combination; Interaction; Smooth muscle, airway; β_2-Adrenoceptor agonist; Methylxanthine; K^+ channel opener; Sodium nitroprusside; Dihydropyridine Ca^{2+} channel blocker (Thirstrup, S. (326) 191)

Ca^{2+}; Contraction; Econazole; Miconazole; SK&F 96365; Nifedipine (Li, L. (331) 221)

Edema; α-Trinositol; Capillary permeability; Skin (rat); Connective tissue; Inflammation; Anaphylaxis (Koller, M.-E. (331) 259)

Cocaine; Cl^- secretion; Short-circuit current; Gland cell (Chan, M.-H. (334) 281)

β_2-Adrenoceptor agonist; Plasma leakage; Substance P; Vascular permeability (Bowden, J.J. (338) 83)

Trachea bifurcation
Codeine; Larynx; Mechanical stimulation; Cough, codeine-resistant; C-fiber; A-fiber (Takahama, K. (329) 93)

Tracheal epithelial cell, guinea pig
Eosinophil; Neutrophil; Arachidonic acid (Prié, S. (317) 343)

Trachealis, bovine
SCA40; K^+-rich media; Electrophysiology; $^{86}Rb^+$ efflux; Phosphodiesterase isoenzyme (Pocock, T.M. (334) 75)

Tranilast
Hyperplasia, intimal; Balloon injury; Cholesterol, high (Fukuyama, J. (318) 327)

Muscle contraction; Restenosis; Angioplasty (Ihara, T. (329) 43)

Transcription
5-HT (5-hydroxytryptamine, serotonin) transporter; Tyrosine kinase inhibitor; Tyrosine phosphorylation; Choriocarcinoma cell, human (Prasad, P.D. (325) 85)

Transgenic rat
Hyperplasia; Smooth muscle, vascular; Cell culture; Nifedipine; Captopril; Losartan (Peiró, C. (324) 257)

Angiotensin II; Angiotensin AT_1 receptor; Contractile function; Cardiomyocyte, isolated (Rosenkranz, S. (330) 35)

Translocation
Norathyriol; Neutrophil, rat; Respiratory burst; Aggregation; Protein kinase C; Phorbol 12-myristate 13-acetate (Wang, J.-P. (336) 81)

Transmembrane action potential
S 16257; Bradycardic agent; Stereospecificity; Heart rate; QT interval (Thollon, C. (339) 43)

Transmitter release
Striatum; Hypoxia; Xanthine; Purine; Adenosine A_1 receptor (Jin, S. (329) 107)

Tremor
Tacrine; Cognex; Acetylcholine; Vacuous chew; Purposeless; Parkinson's disease; Alzheimer's disease (Cousins, M.S. (322) 137)

TRH (thyrotropin-releasing hormone)
Acid secretion; Gastric mucosal blood flow; Ketotifen; Mast cell; Mean arterial pressure; RX 77368; Vagus; Brain–gut (Király, Á. (334) 241)

Triacylglyceride
Epinephrine; Ethanol; Isolated hepatocyte; Piroxicam; Thiobarbituric acid-reactive substance (Saldaña-Balmori, Y. (317) 225)

Triamnopyridine
Flupirtine; hNT neuron; Bcl-2; Neuroprotection; Apoptosis; Glutathione (Perovic, S. (317) 157)

Tricyclic antidepressant
Antisense oligonucleotide; K^+ channel; mKv1.1; Analgesia; Antinociception; Clomipramine; Amitriptyline; (Mouse) (Galeotti, N. (330) 15)

Pain; Analgesia; C-fiber reflex; Clomipramine; Desipramine (Mestre, C. (335) 1)

Trigeminal nucleus caudalis
$5\text{-}HT_{1B/1D}$ receptor agonist; Rizatriptan; Migraine; Electrophysiology (Cumberbatch, M.J. (328) 37)

Triglyceride
GR79236; Insulin resistance; Lipolysis; Fructose; Non-insulin-dependent diabetes (NIDDM) (Qu, X. (338) 269)

Trigone
α_1-Adrenoceptor; Mesenteric artery; Prostate; Urethra; (Rabbit) (Van der Graaf, P.H. (327) 25)

Trimetazidine
Cardiomyopathy; Ca^{2+}; Hypertrophy; Ischemia; Verapamil (D'hahan, N. (328) 163)

α-Trinositol
Edema; Capillary permeability; Trachea; Skin (rat); Connective tissue; Inflammation; Anaphylaxis (Koller, M.-E. (331) 259)

Triphenylphosphonium compound
Levcromakalim; Quaternary ion; K^+ channel antagonist; Circumflex artery, right, pig; Tetraphenylphosphonium (Piekarska, A.E. (322) 37)

Triterpene
Inflammation; NO synthase, inducible; Pristimerin; RAW 264.7 macrophage (Dirsch, V.M. (336) 211)

Triterpenoids
Inflammation, chronic; Skin; 12-*O*-Tetradecanoylphorbol-13-acetate (Máñez, S. (334) 103)

Trivalent cation
ATP; Purinoceptor P_{2X}; PC12 cell; *Xenopus* oocyte (Nakazawa, K. (325) 237)

Tryptase
Microvascular leakage; Mast cell; Histamine; Heparin; Proteinase inhibitor; Histamine receptor antagonist (He, S. (328) 89)

Tuberomammillary nucleus
Histamine immunoreactivity; Vestibular nucleus; Unilateral vestibular neurectomy; Thioperamide; Betahistine; (Cat) (Tighilet, B. (330) 65)

Tubulointerstitial index
Anti-Thy1 nephritis; Cytokine; OPC15161; Matrix index; Superoxide radical (Hamada, N. (317) 123)

Tumor cell locomotion
Okadaic acid; Calyculin A; Phosphatase; Walker 256 carcinosarcoma cell; Vimentin (Niggli, V. (324) 99)

Two-kidney one-clip hypertensive rat
α_1-Adrenoceptor; Chloride ion; Niflumic acid; Mesenteric blood vessel (He, Y. (328) 191)

Two-way avoidance
Benzodiazepine withdrawal; Stress; GABA (γ-aminobutyric acid)-gated Cl^- flux; Forced swim; Carbamazepine (Martijena, I.D. (330) 101)

Type II cell
Cannabinoid; Lung; Ontogeny; Development; Steroid (Rice, W. (327) 227)

Tyrosine
RBL-2H3; Astemizole; Membrane; Protein; Phosphorylation; Ca^{2+}; Flux; Exocytosis (Fischer, M.J.E. (322) 97)

Sauvagine; Urotensin I; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Edema; Ca^{2+}; Inositol trisphosphate; CRF receptor; Skin; Phosphorylation (Kiang, J.G. (329) 237)

Tyrosine hydroxylase
Aromatic L-amino acid decarboxylase; Dopamine receptor; Striatum; Midbrain (Cho, S. (323) 149)

Aging; (−)-Deprenyl; IGF-I (insulin-like growth factor-I); (Rat) (De la Cruz, C.P. (327) 215)

Tyrosine kinase
Ca^{2+} channel antagonist; Protein kinase C; Calmodulin; Smooth muscle contraction (Sim, S.-S. (324) 205)

Genistein; Arrhythmia, ventricular; Preconditioning (Fatehi-Hassanabad, Z. (338) 67)

Tyrosine kinase inhibitor
5-HT (5-hydroxytryptamine, serotonin) transporter; Tyrosine phosphorylation; Transcription; Choriocarcinoma cell, human (Prasad, P.D. (325) 85)

Myogenic response; Pressure-induced contraction; Cerebral artery, rat; Herbimycin A; Genistein (Masunoto, N. (330) 55)

Tyrosine phosphorylation
5-HT (5-hydroxytryptamine, serotonin) transporter; Tyrosine kinase inhibitor; Transcription; Choriocarcinoma cell, human (Prasad, P.D. (325) 85)

Mesangial cell; Proliferation; Captopril; Angiotensin II-converting enzyme inhibitor; $pp60^{c\text{-}src}$ (Ruiz-Ginés, J.A. (336) 251)

Epiregulin; Growth factor; Cell proliferation; Epidermal growth factor; Epidermal growth factor receptor; Gastric cell (Sasaki, E. (338) 253)

Tyrphostin 23
Zooxanthellatoxin-A; Mitogen-activated protein kinase; Platelet aggregation (Rho, M.-C. (319) 375)

Tyrphostin
Lipopolysaccharide; Nitric oxide (NO) synthase, inducible; Aorta, rat; Genistein; Orthovanadate; Phenylarsine oxide (Duarte, J. (338) 25)

U-46619
Thromboxane; Smooth muscle, vascular; 8-epi-prostaglandin $F_{2\alpha}$; BMS-180291; SQ 29,548; Daltroban; BM-13505; SQ 30,741; AA-2414 (Zhang, R. (317) 91)

Pulmonary hypertension; Nitric oxide (NO); TP receptor; N^{ω}-Nitro-L-arginine methyl ester (L-NAME); SQ 29,548 (Valentin, J.-P. (317) 335)

Sulphonylurea; Levcromakalim; Thromboxane A_2; Structure-activity relationship; Coronary artery, pig (McPherson, G.A. (324) 193)

U-50,488
Morphine; Reward; Ontogeny; (Rat) (Bolanos, C.A. (317) 1)

U-101,958
Dopamine; Dopamine D_4-receptors; RBI-257 (Kula, N.S. (331) 333)

U-937 cell
Topoisomerase I; Differentiation (Shayo, C.C. (324) 129)

UDP
Nucleotide; $P2Y_6$ receptor (Robaye, B. (329) 231)

(+)-UH-232
Haloperidol; (+)-AJ76; (+)-PD 128907; (−)-Apomorphine; Discriminative stimulus effect; Dopamine D_3 receptor (Kleven, M.S. (321) 1)

U50,488H
Drug self-administration; Cocaine; Morphine; κ-Opioid receptor; (Rat); (Mouse) (Kuzmin, A.V. (321) 265)

Ulcer
Amylin; CGRP (calcitonin gene-related peptide), human; Capsaicin; Domperidone; Neostigmine (Clementi, G. (332) 209)

Ultrasonic vocalization
5-HT_{1A} autoreceptor; EMD 68843; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Fluoxetine; WAY 100635; Hypothermia; (Rat) (Bartoszyk, G.D. (322) 147)

5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; WAY-100635; *p*-Chlorophenylalanine; Hippocampus; Excitatory synaptic transmission; 5-HT_{1A} receptor; Excitatory postsynaptic potential; Anxiolytic (Xu, L. (323) 59)

Umbilical artery
5-HT_{2A} receptor; Inositol 1,4,5-triphosphate (Hu, X.-Q. (322) 107)

Umbilical vein
α_1-Adrenoceptor, subtype; Ca^{2+}; Uterine artery (Hu, X.-Q. (324) 67)

Umbilical vein, human
Des-Arg^9-bradykinin; Des-Arg^9-[Leu^8]bradykinin; Bradykinin B_1 receptor; Sensitization (Sardi, S.P. (321) 33)

Umbilical vein endothelial cell
Cationic amino acid transporter; Gene expression; TNF-α (tumor necrosis factor-α); Nitric oxide (NO); (Human) (Irie, K. (339) 289)

Umbilical vein endothelial cell, human
Neurotensin; Prostacyclin; Hematocrit (Schaeffer, P. (323) 215)

Uncompetitive
NMDA receptor; Calcium; Neuron; Neuroprotection; MK-801 (Black, M. (317) 377)

Unconditioned drug effect
Appetitive discrimination; Occasion setting; Midazolam; Amphetamine; Conditioned drug effect (Maes, J.H.R. (319) 5)

Unilateral vestibular neurectomy
Histamine immunoreactivity; Vestibular nucleus; Tuberomammillary nucleus; Thioperamide; Betahistine; (Cat) (Tighilet, B. (330) 65)

Unit activity
Dorsal lateral geniculate nucleus; Angiotensin; NMDA (*N*-methyl-D-aspartate); Kainate; Bicuculline; CGP 35348; Urethane; (Rat) (Albrecht, D. (332) 53)

Up-regulation
Dopamine D_2 receptor; Antipsychotic drug, atypical; 5-HT_{2A} receptor; Striatum (Ishikane, T. (321) 163)

Endothelin ET_A receptor; Endothelin ET_B receptor; Organ culture; Reverse transcription-polymerase chain reaction (Möller, S. (329) 69)

Uptake, quench flow
Bicuculline analogue, enantiomer; [^{14}C]GABA ([^{14}C]γ-aminobutyric acid); Cortex, rat (Kardos, J. (337) 83)

Uptake, stereoselective, active
Apomorphine; Enantiomer; Biodistribution (Sam, E. (329) 9)

UR-7280
Angiotensin AT_1 receptor; Angiotensin II; Binding; Losartan; Aorta, rabbit (De Arriba, A.F. (318) 341)

Ureter
Histamine receptor; Histamine H_1 receptor; Histamine H_2 receptor; 5-HT (5-hydroxytryptamine, serotonin); Prostaglandin; Noradrenaline (Dodel, R.C. (318) 395)

Urethane
Dorsal lateral geniculate nucleus; Angiotensin; NMDA (*N*-methyl-D-aspartate); Kainate; Bicuculline; CGP 35348; Unit activity; (Rat) (Albrecht, D. (332) 53)

Urethra
α_1-Adrenoceptor; Mesenteric artery; Prostate; Trigone; (Rabbit) (Van der Graaf, P.H. (327) 25)

Estrogen; Nitric oxide (NO); Nitric oxide (NO) synthase; (Rabbit) (Takahashi, W. (339) 165)

Urethra, dog
Capsaicin; Nitric oxide (NO); Smooth muscle relaxation (Nishizawa, S. (335) 211)

Uridine nucleotide receptor
UTP; Inositol trisphosphate (Communi, D. (317) 383)

Urinary bladder
5-HT (5-hydroxytryptamine, serotonin); 5-HT_3 receptor; Electrical field stimulation; (Rabbit) (Barras, M. (318) 425)

ATP; Ecto-ATPase; ARL 67156; Purinergic (Westfall, T.D. (329) 169)

P-4 (1-methyl-4-piperidyl diphenylpropoxyacetate hydrochloride); Antipollakiuric agent; Smooth muscle; Actomyosin ATPase activity; Calmodulin (Matsushima, S. (333) 93)

Urinary bladder contraction
Salivation; Muscarinic receptor subtype; Muscarinic receptor antagonist; (Guinea pig); (Cat); (Human) (Nilvebrant, L. (327) 195)

Urine formation
Endothelin-1; Endothelin ET_A receptor; DOCA (deoxycorticosterone acetate)-salt hypertension; Renal function (Matsumura, Y. (319) 65)

FK409; Nitric oxide (NO); N^G-Nitro-L-arginine; Renal function (Urabe, K. (321) 195)

Urotensin I
Sauvagine; Corticoliberin; CRF (corticotropin-releasing factor); Epithelium; Edema; Ca^{2+}; Inositol trisphosphate; CRF receptor; Skin; Tyrosine; Phosphorylation (Kiang, J.G. (329) 237)

Uterine artery
α_1-Adrenoceptor, subtype; Ca^{2+}; Umbilical vein (Hu, X.-Q. (324) 67)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Losartan; PD-123319; Pregnancy; (Sheep) (Burrell, J.H. (330) 257)

Uterus
Tachykinin receptor; Peptidase inhibitor; Oestrogen; SR 142801 (Fisher, L. (335) 221)

Opioid; Estradiol; Proliferation; Cell culture; (Rat) (Környei, J.L. (336) 65)

Uterus, rat
Tachykinin NK_3 receptor, expression; Polymerase chain reaction (Pinto, F.M. (324) 125)

Mn^{2+}; Ca^{2+} channel, receptor-operated (Magraner, J. (326) 211)

UTP
ATP; Purinoceptor; Pyrimidinoceptor; Stomach, rat; Suramin (Otsuguro, K.-i. (317) 97)

Uridine nucleotide receptor; Inositol trisphosphate (Communi, D. (317) 383)

Lipopolysaccharide; Arachidonic acid; Phospholipase A_2; Protein kinase; RAW 264.7 macrophage (Lin, W.W. (321) 121)

Coronary artery, canine; Vasoconstriction; Vasodilation; P2 purinoceptor; ATP; Suramin; Reactive blue 2 (Matsumoto, T. (334) 173)

UTP receptor
P_{2X} purinoceptor; Chorionic surface artery; Placenta, human, term; α,β-Methylene-ATP; Smooth muscle, vascular (Dobronyi, I. (320) 61)

Vacuous chew
Tacrine; Cognex; Acetylcholine; Purposeless; Tremor; Parkinson's disease; Alzheimer's disease (Cousins, M.S. (322) 137)

Vacuous chewing
Dopamine 'D_1-like' receptor; Dopamine 'D_2-like' receptor; D_1/D_2 interaction; LY 270411; BW 737C; SCH 23390; Grooming behavior; Myoclonic jerking; (Rat) (Deveney, A.M. (317) 175)

Dihydrexidine; Dopamine D_2 receptor; Locomotor activity; Sedation; Yawning (Smith, H.P. (323) 27)

Vagal bradycardia
Nociceptin; Blood pressure; Hypotension; Heart rate (Giuliani, S. (333) 177)

Vagus
Acid secretion; Gastric mucosal blood flow; Ketotifen; Mast cell; Mean arterial pressure; RX 77368; TRH (thyrotropin-releasing hormone); Brain–gut (Király, Á. (334) 241)

Vagus nerve
Vomiting; Capsaicin; Resiniferatoxin; Solitary nucleus; (Dog) (Shiroshita, Y. (339) 183)

Vagus nerve stimulation
Muscarinic M_2 receptor, prejunctional; Receptor dysfunction; Muscarinic receptor antagonist; Allergic reaction, early, late; Bronchial hyperresponsiveness; (Conscious, unrestrained guinea pig) (Ten Berge, R.E.J. (318) 131)

Valsartan
Spontaneously hypertensive rat (SHR); Glucose tolerance; Blood pressure; Angiotensin-converting enzyme inhibitor; Angiotensin AT_1 receptor antagonist (Chow, L. (319) 77)

Vanadyl sulphate
Endocrine pancreas; Insulin secretion; (Rat) (Cadène, A. (318) 145)

Vascular effect
Endothelin-1; Endothelin receptor antagonist; Bosentan; PD155080; Clearance; Half-life (Hemsén, A. (318) 369)

Vascular heterogeneity
Coronary artery, bovine; Glyceryl trinitrate; *S*-Nitroso-*N*-acetylpenicillamine; Sodium nitroprusside; Isoprenaline (De la Lande, I.S. (318) 65)

Vascular permeability
ABT-491; PAF (platelet-activating factor); PAF receptor antagonist; Ca^{2+} flux; Superoxide anion; Degranulation; Endotoxemia (Albert, D.H. (325) 69)

Nitric oxide (NO); Endotoxin; Nitric oxide (NO) synthase inhibitor; Microcirculation; Inflammation; Inducible nitric oxide (NO) synthase (László, F. (334) 99)

β-Adrenoceptor agonist; Isoproterenol; Clenbuterol; Mast cell; Allergic reaction (Inagaki, N. (336) 225)

β_2-Adrenoceptor agonist; Plasma leakage; Substance P; Trachea (Bowden, J.J. (338) 83)

Vascular resistance, renal
Endothelin-1; Endothelin ET_A receptor antagonist (Ignasiak, D.P. (321) 295)

Vascular smooth muscle
S-nitrosothiol (stereoisomer); Nitric oxide (NO); cGMP (Travis, M.D. (318) 47)

Vasculature
Insulin resistance; Fructose hypertension (Verma, S. (322) R1)

Cannabinoid; Anandamide (Calignano, A. (337) R1)

Vas deferens
Adrenergic transmission; Purinergic transmission; Contractile response; Circular muscle; Development; (Guinea pig) (Ren, L.-M. (318) 411)

Ca^{2+} channel; ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Conotoxin MVIIC; ω-Agatoxin IVA; Purinergic neurotransmission (Hirata, H. (321) 217)

Vas deferens, guinea-pig
ATP; Neurotransmission; Dopamine D_1 receptor; α_2-Adrenoceptor (Furukawa, T. (328) 229)

Vas deferens, mouse
Cannabinoids; Cannabinoid CB_1 receptors; Cannabinoid CB_2 receptors; SR141716A; Myenteric plexus-longitudinal muscle preparation, guinea-pig small intestine (Griffin, G. (339) 53)

Vas deferens, rat
Purinergic transmission; Noradrenergic transmission; Cromakalim; Prazosin; Suramin; Glibenclamide (Grana, E. (319) 57)

NS 1619; Charybdotoxin; Glibenclamide; K^+ channel, Ca^{2+}-activated; Ca^{2+} channel (Huang, Y. (325) 21)

Noradrenaline uptake inhibitor; Protriptyline; Amitriptyline; Xylamine; Electric field stimulation; Contraction (Huang, Y. (327) 41)

CGRP (calcitonin gene-related peptide); Electric field stimulation; Glibenclamide; K^+ channel, ATP-sensitive; Neurotransmission (Huang, Y. (327) 209)

Nitric oxide (NO); L-Arginine; Sodium nitroprusside; *N*-nitro-L-arginine methyl ester (L-NAME); (Neurotransmission) (Ventura, S. (334) 87)

Vasoconstriction
Capsaicin-sensitive; Resiniferatoxin; Saphenous nerve; Neuropeptide Y; Vasodilation; Laser-Doppler flowmetry (Pintér, E. (325) 57)

Vasodilation; Bradykinin; Bradykinin receptor; Mesenteric bed; B_2 knockout mice (Berthiaume, N. (333) 55)

Coronary artery, canine; Vasodilation; P2 purinoceptor; ATP; UTP; Suramin; Reactive blue 2 (Matsumoto, T. (334) 173)

Kidney; CNP (C-type natriuretic peptide); Angiotensin II; Norepinephrine; (Dog) (Yoshida, K. (338) 131)

Vasodilatation
Hepatic circulation; 8-Phenyltheophylline; ATP; Adenosine; (Rat) (Browse, D.J. (320) 139)

Nitric oxide (NO); Peroxynitrite; Sugar; L-Cysteine; Sodium nitrite; Methylene blue; Haemoglobin (Dowell, F.J. (338) 43)

Vasodilation
Nitric oxide (NO); CGRP (calcitonin gene-related peptide); Nitric oxide (NO) synthase containing nerve (Uchiyama, M. (321) 19)

Capsaicin-sensitive; Resiniferatoxin; Saphenous nerve; Neuropeptide Y; Vasoconstriction; Laser-Doppler flowmetry (Pintér, E. (325) 57)

Cyclopiazonic acid; Nitric oxide (NO); Endothelium; N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Rahimian, R. (327) 143)

Coronary artery; SIN-1 (3-morpholinosydnonimine); Nitric oxide (NO); K_{ATP} channel; Glibenclamide (Deka, D.K. (330) 157)

Vasoconstriction; Bradykinin; Bradykinin receptor; Mesenteric bed; B_2 knockout mice (Berthiaume, N. (333) 55)

Coronary artery, canine; Vasoconstriction; P2 purinoceptor; ATP; UTP; Suramin; Reactive blue 2 (Matsumoto, T. (334) 173)

Vasodilator
Na^+,K^+-ATPase; Na^+,K^+-ATPase, α-subunit; Hypertension; Spontaneously hypertensive rat (SHR); Ca^{2+} channel blocker (Liu, X. (327) 151)

Vasodilator nerve
Migraine; Flunarizine; Nitric oxide (NO) (Ayajiki, K. (329) 49)

Vasomotor control
Heme-L-lysinate; Chromium mesoporphyrin (Kozma, F. (323) R1)

Vasopressin
Smooth muscle cell, vascular; Ca^{2+}-permeable non-selective cation channel; Endothelin-1; Mg^{2+}, extracellular (Nakajima, T. (320) 81)

YM087; Vasopressin V_{1A} receptor; Vasopressin V_2 receptor; Non-peptide antagonist (Yatsu, T. (321) 225)

Quinpirole; Dopamine; Dopamine D_2 receptor; Rilmenidine; α-Methyldopa; Hydralazine; Sympathetic nervous system (Van den Buuse, M. (322) 191)

Oxytocin; Factor VIII (F-VIII); Antihemophilic factor; Blood clotting; Plasminogen activator; Neurohypophyseal hormone analog; Dose–response analysis; Time response; Non-monotonic profile (Neuenschwander, S. (323) 205)

Endothelin; Spontaneously hypertensive rat (SHR); Hemodynamics; Cardiac output; Radiotelemetry (Balakrishnan, S.M. (334) 55)

Vasopressin receptor antagonist, iodinated
Vasopressin V_2 receptor, human; Autoradiography (Ala, Y. (331) 285)

Vasopressin V_{1A} receptor
YM087; Vasopressin; Vasopressin V_2 receptor; Non-peptide antagonist (Yatsu, T. (321) 225)

Vasopressin V_2 receptor
YM087; Vasopressin; Vasopressin V_{1A} receptor; Non-peptide antagonist (Yatsu, T. (321) 225)

Vasopressin V_2 receptor, human
Vasopressin receptor antagonist, iodinated; Autoradiography (Ala, Y. (331) 285)

Vasorelaxation
Chelerythrine; Protein kinase C; Phosphodiesterase, cyclic nucleotide; SK&F 94120; Isoprenaline (Eckly-Michel, A.E. (324) 85)

Thoracic aorta; Norepinephrine; cAMP; cGMP; Ca^{2+} channel blocker (Cheng, Y.-W. (336) 23)

VCAM-1 (vascular cell adhesion molecule-1)
VLA-4 (very late antigen-4) integrin; SAO (Splanchnic artery occlusion shock); (Rat) (Squadrito, F. (318) 153)

Vein
Pain; Noradrenaline; Phentolamine; (Human) (Kindgen-Milles, D. (328) 41)

Venodilation
Cerebral vein; Histamine H_2 receptor; Endothelium; Nitric oxide (NO); Prostanoid (Monge, L. (338) 135)

Venodilator effect
Pranidipine (OPC-13340); Ca^{2+} channel antagonist; Circulatory filling pressure, mean; (Rat) (Hirano, T. (324) 201)

Venous resistance
Endothelin-1; Circulatory filling pressure, mean; Cardiac output; Arterial resistance, systemic; Venous tone, body (Palacios, B. (327) 183)

Venous tone, body
Endothelin-1; Circulatory filling pressure, mean; Cardiac output; Arterial resistance, systemic; Venous resistance (Palacios, B. (327) 183)

Ventral striatum
Microdialysis; Chronic transversal; Amphetamine, repeated; Dopamine release; Dopamine synthesis; Behavioral sensitization (Imperato, A. (317) 231)

Ventral tegmental area
Dopamine D_1 receptor; Medial prefrontal cortex; Substantia nigra (Dewar, K.M. (336) 155)

Imipramine; Dopamine D_2 autoreceptor; mRNA; (Rat) (Dziedzicka-Wasylewska, M. (337) 291)

Ventricular arrhythmia
Bradykinin; Icatibant; Cardiac pacing, rapid; Ischemic preconditioning (Kaszala, K. (328) 51)

Ventricular cell, guinea pig
Felodipine; Ca^{2+} channel, L-type; Voltage-dependent block; E-C (excitation-contraction) coupling (Kohmoto, O. (319) 355)

Ventricular function
Adenosine; Coronary artery disease; Lactate; Myocardial ischaemia (De Jonge, R. (337) 41)

Ventricular mass
Ion-selective microelectrode; Ca^{2+} level; Diastolic (Lopez, J.R. (339) 161)

Ventricular myocyte
Diltiazem; 1,4-Dihydropyridine; Ca^{2+} channel, L-type; Ca^{2+} channel antagonist; Cardiac myocyte; (Rat) (Kanda, S. (319) 101)

Semotiadil; Diltiazem; Amlodipine; Nifedipine; Ca^{2+} current (Koidl, B. (322) 243)

Benzothiazepine; Diltiazem; Verapamil; Ca^{2+} channel antagonist; Ca^{2+} channel, L-type (Kurokawa, J. (325) 229)

Ventricular pacing, rapid
Heart failure; Dorsal pedal artery; Saphenous vein; α_1-Adrenoceptor; 5-Methyl-urapidil (Forster, C. (318) 55)

Heart failure; Blood vessel; α_1-Adrenoceptor subtype; Chloroethylclonidine (Le Tran, Y. (336) 177)

Ventrolateral medulla, rostral
α_2-Adrenoceptor; Sympathetic nerve activity; Blood pressure (Vayssettes-Courchay, C. (320) 151)

Ventromedial tegmentum lesion
Talipexole; Bromocriptine; Dopamine D_2 receptor agonist; Anti-tremor effect; Parkinson's disease; (Cynomolgus monkey) (Kohno, Y. (319) 197)

Verapamil
Benzothiazepine; Diltiazem; Ca^{2+} channel antagonist; Ventricular myocyte; Ca^{2+} channel, L-type (Kurokawa, J. (325) 229)

Chemotherapeutic; P-glycoprotein; Ca^{2+} current (Nanaumi, K. (327) 239)

Cardiomyopathy; Ca^{2+}; Hypertrophy; Ischemia; Trimetazidine (D'hahan, N. (328) 163)

Veratridine
l-cis-Diltiazem; *d-cis*-Diltiazem; Ca^{2+} overload; Na^+ overload; Myocyte; (Rat) (Itogawa, E. (317) 401)

Vesamicol
AH5183; Alzheimer's disease; Acetylcholine transporter; σ binding site; SPECT (Single-photon emission computed tomography) (Custers, F.G.J. (338) 177)

Vesamicol receptor
Acetylcholine; Synaptic vesicle; Acetylcholine transporter, vesicular (Staley, J.K. (338) 159)

Vesicular monoamine transporter type-2 (VMAT2)
Dopamine transporter, neuronal membrane; Methamphetamine; Amphetamine; Dihydrotetrabenazine; WIN 35,428; Dopamine (Frey, K. (334) 273)

Vestibular nucleus
Histamine immunoreactivity; Tuberomammillary nucleus; Unilateral vestibular neurectomy; Thioperamide; Betahistine; (Cat) (Tighilet, B. (330) 65)

Viability
Ischaemia-reperfusion; Nitric oxide (NO); Skeletal muscle; Oedema; (Mouse) (Knight, K.R. (332) 273)

Vimentin
Okadaic acid; Calyculin A; Phosphatase; Tumor cell locomotion; Walker 256 carcinosarcoma cell (Niggli, V. (324) 99)

VIP (vasoactive intestinal peptide)
Peritoneal macrophage; Adenylyl cyclase; VIP receptor antagonist; VIP receptor; Propranolol; Isoproterenol; Neuroimmunobiology (Pozo, D. (321) 379)

Guanylin; Intestine; Ion transport; Na^+ and Cl^- unidirectional flux; STa (heat-stable enterotoxin of *Escherichia coli*) (Volant, K. (328) 217)

Peptide YY; Intestinal secretion; Intestinal nerve; α_2-Adrenoceptor; σ Receptor; (Rat) (Souli, A. (333) 87)

PACAP (pituitary adenylate cyclase-activating peptide); PACAP receptor; VIP receptor; Neuropeptide Y; Motor effect; Gastro-intestinal tract; Apamin (Ekblad, E. (334) 61)

PACAP (pituitary adenylate cyclase-activating polypeptide); Atrioventricular conduction; Parasympathetic nerve (Hirose, M. (338) 35)

VIP (vasoactive intestinal polypeptide)
ANP (atrial natriuretic polypeptide); K^+ channel; Levcromakalim; Ca^{2+} channel blocker; Isradipine; Trachea; Smooth muscle, airway (Thirstrup, S. (319) 253)

Ca^{2+}, internal; Endothelial cells; Ca^{2+} imaging; Fura-2 (Low, A.M. (339) 227)

VIP receptor
VIP (vasoactive intestinal peptide); Peritoneal macrophage; Adenylyl cyclase; VIP receptor antagonist; Propranolol; Isoproterenol; Neuroimmunobiology (Pozo, D. (321) 379)

PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal peptide); PACAP receptor; Neuropeptide Y; Motor effect; Gastro-intestinal tract; Apamin (Ekblad, E. (334) 61)

VIP receptor antagonist
VIP (vasoactive intestinal peptide); Peritoneal macrophage; Adenylyl cyclase; VIP receptor; Propranolol; Isoproterenol; Neuroimmunobiology (Pozo, D. (321) 379)

Visceral hyperalgesia
Intestinal distension; Visceral nociception; Mast cell; Tachykinin; Tachykinin NK_2 receptor (McLean, P.G. (337) 279)

Visceral hypersensitivity
5-HT_3 receptor antagonist; Colonic distension; (Rat) (Langlois, A. (318) 141)

Visceral nociception
Intestinal distension; Visceral hyperalgesia; Mast cell; Tachykinin; Tachykinin NK_2 receptor (McLean, P.G. (337) 279)

Visceral pain
Fedotozine; κ-Opioid receptor; μ-Opioid receptor; Colonic hypersensitivity; (Colonic distension) (Langlois, A. (324) 211)

Vitamin B
Culture; Cytotoxicity; Glutamate; Retina (Kaneda, K. (322) 259)

Vitamin C
D-Glucose oxidation; Endothelial cell; EDRF (endothelium-derived relaxing factor); Glutathione; Superoxide dismutase; Vitamin E (Graier, W.F. (322) 113)

Vitamin D
Glioma; Apoptosis; Noradrenaline (Canova, C. (319) 365)

Vitamin E
D-Glucose oxidation; Endothelial cell; EDRF (endothelium-derived relaxing factor); Glutathione; Superoxide dismutase; Vitamin C (Graier, W.F. (322) 113)

Lung cancer; K-*ras*; Proliferating cell nuclear antigen; Chemoprevention (Yano, T. (323) 99)

VLA-4 (very late antigen-4) integrin
VCAM-1 (vascular cell adhesion molecule-1); SAO (Splanchnic artery occlusion shock); (Rat) (Squadrito, F. (318) 153)

Vocalization threshold
Antinociception; Mononeuropathic rat; CCK_B receptor antagonist; L-365,260; Morphine; Naloxone; Struggle latency (Idänpään-Heikkilä, J.J. (325) 155)

Voltage clamp
Ca^{2+} channel; CP-0605; Smooth muscle, vascular; Electrophysiology; Ca^{2+} channel antagonist (Ohya, Y. (330) 93)

Voltage clamp, whole cell
β-Adrenoceptor; Heart, neonatal; Ca^{2+} current; G protein (Katsube, Y. (317) 391)

Voltage-dependent block
Felodipine; Ventricular cell, guinea pig; Ca^{2+} channel, L-type; E-C (excitation-contraction) coupling (Kohmoto, O. (319) 355)

Voltammetry, in vivo
Dopamine; Striatum; Dopamine D_2 receptor antagonist; Behavior; (Rat) (Horikawa, H.P.M. (326) 15)

Atipamezole; Medetomidine; Dopamine overflow; Dopamine metabolisms; Mouse (Yavich, L. (339) 113)

Vomiting
Radioligand binding; Oral bioavailability; $t_{1/2}$; Brain penetration; Retching; Nausea; Ondansetron (Singh, L. (321) 209)

Capsaicin; Resiniferatoxin; Solitary nucleus; Vagus nerve; (Dog) (Shiroshita, Y. (339) 183)

W-7
DY-9760e; Calmodulin antagonist; Cytotoxicity; Neuroprotection (Sugimura, M. (336) 99)

Walker 256 carcinosarcoma cell
Okadaic acid; Calyculin A; Phosphatase; Tumor cell locomotion; Vimentin (Niggli, V. (324) 99)

Washout
Nimodipine, chronic; Metrifonate, acute; Water maze; Passive avoidance; Motor test; Aged rat; Medial septum-lesioned rat (Riekkinen, M. (322) 1)

Water intake
Melatonin; Lipopolysaccharide; Fever; Nitric oxide (NO) (Nava, F. (331) 267)

Water maze
Nimodipine, chronic; Metrifonate, acute; Passive avoidance; Motor test; Washout; Aged rat; Medial septum-lesioned rat (Riekkinen, M. (322) 1)

Water-maze test
β-Amyloid peptide-(25–35); Amyloid-type amnesia (Delobette, S. (319) 1)

WAY100635
Spinal cord; Pain; Nociception; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (Gjerstad, J. (318) 315)

5-HT_{1A} receptor; Monoamine oxidase inhibitor; Dorsal raphe nucleus; Microdialysis; Extracellular recording (Sharp, T. (320) 15)

5-HT_{1A} autoreceptor; EMD 68843; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Fluoxetine; Hypothermia; Ultrasonic vocalization; (Rat) (Bartoszyk, G.D. (322) 147)

5-HT (5-hydroxytryptamine, serotonin); Ipsapirone; *p*-Chlorophenylalanine; Hippocampus; Excitatory synaptic transmission; 5-HT_{1A} receptor; Excitatory postsynaptic potential; Ultrasonic vocalization; Anxiolytic (Xu, L. (323) 59)

5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Flesinoxan; Anxiety; Geller-Seifter, conflict; (Rat) (King, C.M.F. (325) 121)

Flesinoxan; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor; Feedback regulation; Microdialysis; (Rat) (Bosker, F.J. (333) 147)

Spinal cord; Nociception; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; CP-93,129; Cyanopindolol (Gjerstad, J. (335) 127)

WB 4101
α_1-Adrenoceptor, subtype; Chloroethylclonidine; 5-Methylurapidil; BMY 7378; $^{86}Rb^+$, influx rate; Inositol 1,4,5-trisphosphate (Viko, H. (323) 269)

α_1-Adrenoceptor, subtype; Endogenous noradrenaline; Chlorethylclonidine; Positive inotropic action; Myocardium, rabbit (Hattori, Y. (329) 165)

Wernicke-Korsakoff syndrome
3-Methoxytyramine; Monoamine oxidase (Mousseau, D.D. (317) 263)

Western blot
Nitric oxide synthase, inducible (NO); Cyclooxygenase-2; Lipopolysaccharide; cAMP; Indomethacin; Cytotoxicity (Pang, L. (317) 151)

Wet-dog shake
Corticosterone; 5-HT_{1A} receptor; 5-HT_2 receptor; Body temperature; 5-HT (5-hydroxytryptamine, serotonin) syndrome (Takao, K. (333) 123)

Whole-cell current
Ondansetron; GABA (γ-aminobutyric acid); Patch-clamp; Seizure (Ye, J.H. (337) 87)

Whole-cell recording
Bladder detrusor, guinea pig; Patch-clamp; BK_{Ca} channel; Inside-out single channel recording; Open-state probability (Hu, S. (318) 461)

WIN 35,428
Vesicular monoamine transporter type-2 (VMAT2); Dopamine transporter, neuronal membrane; Methamphetamine; Amphetamine; Dihydrotetrabenazine; Dopamine (Frey, K. (334) 273)

WIN 35,428 binding
Dopamine transporter; Arachidonic acid; Protein kinase C; Parkinson's disease; Drug abuse (Reith, M.E.A. (324) 1)

WISH cell
Prostaglandin H synthase-2; Non-steroidal anti-inflammatory drug (Hulkower, K.I. (331) 79)

Wistar-Kyoto rat
Forced swimming test; Brown Norway rat; Sprague-Dawley rat; Imipramine; 5-HT_1 receptor; 5-HT_2 receptor; β-Adrenoceptor; Depression (Lahmame, A. (337) 115)

Withdrawal
5-HT (5-hydroxytryptamine, serotonin); Diazepam; 5-HT_{1A} receptor; Raphe nucleus, dorsal; Electrophysiological recording (Lanfumey, L. (323) 137)

Arachidonic acid; Opioid; Ileum (Capasso, A. (330) 199)

Working memory
D-Cycloserine; Glycine site; NMDA receptor; Acetylcholine; Hippocampus (Ohno, M. (318) 267)

Wortmannin
Phosphatidylinositol 3-kinase inhibitor; Anti-angiogenic activity; Angiogenesis, embryonic; Chorioallantoic membrane (Oikawa, T. (318) 93)

Neutrophils; Cell locomotion; Phosphatidylinositol 3-kinase; Actin, α-Actinin (Niggli, V. (335) 43)

Xanomeline
Muscarinic receptors; Alzheimer's disease (Christopoulos, A. (334) R3)

Xanthine
Striatum; Hypoxia; Purine; Transmitter release; Adenosine A_1 receptor (Jin, S. (329) 107)

***Xenopus* oocyte**
NMDA receptor; Glutamate receptor; Ligand-gated ion channel (Buller, A.L. (320) 87)

ATP; Purinoceptor P_{2X}; Ion channel; Site-directed mutagenesis (Nakazawa, K. (325) 101)

ATP; Purinoceptor P_{2X}; Trivalent cation; PC12 cell (Nakazawa, K. (325) 237)

$GABA_C$ receptor; GABA (γ-aminobutyric acid); $GABA_B$ receptor agonist; $GABA_B$ receptor antagonist; *trans*-4-Aminocrotonic acid; *cis*-4-Aminocrotonic acid (Chebib, M. (329) 223)

Dotarizine; 5-HT_2 receptor; Ca^{2+} channels; Coronary artery (Montiel, C. (332) 183)

Corymine; $GABA_A$ receptors; Glycine receptors (Leewanich, P. (332) 321)

Glutamate receptor; Allosteric antagonism; Ifenprodil; CP 101,606; Ro 25-6981; Haloperidol (Whittemore, E.R. (337) 197)

Halothane; Ethanol; Muscarinic receptor; Protein kinase C (Minami, K. (339) 237)

***Xenopus laevis* oocyte**
5-HT_3 receptor; Ligand-gated ion channel; N1E-115 mouse neuroblastoma cell; (Partial agonist); (Antagonist) (Van Hooft, J.A. (322) 229)

Xipamide
Diuretic; Amiloride; Cardiocyte; H9c2 heart cell line; Cell membrane; (Rat, newborn) (Taouil, K. (324) 289)

Xylamine
Noradrenaline uptake inhibitor; Protriptyline; Amitriptyline; Electric field stimulation; Contraction; Vas deferens, rat (Huang, Y. (327) 41)

Y-26763
K^+ channel opener; Glibenclamide; Cardioprotection; K^+ channel, ATP-sensitive (Rahman, F. (317) 293)

Myocardium, stunned; Ischemia; Reperfusion; ATP-sensitive K^+ channel (Fukunari, A. (323) 197)

Yawning
Dihydrexidine; Dopamine D_2 receptor; Locomotor activity; Sedation; Vacuous chewing (Smith, H.P. (323) 27)

NMDA (*N*-methyl-D-aspartate); Nitric oxide (NO); Dopamine; Oxytocin; Penile erection; Paraventricular nucleus of the hypothalamus; (Rat) (Melis, M.R. (328) 115)

YC-1
Smooth muscle tension; Guanylyl cyclase; Isoliquiritigenin; ODQ (Wegener, J.W. (323) 89)

YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole)
Tail bleeding time; Antithrombotic effect; Platelet aggregation; Profibrinolytic effect (Teng, C.-M. (320) 161)

Yeast-induced hyperthermia
Nimesulide; Cyclooxygenase-2; Antipyretic action; Hypothalamus; RT-PCR (reverse transcription and polymerase chain reaction) (Taniguchi, Y. (330) 221)

YM087
Vasopressin; Vasopressin V_{1A} receptor; Vasopressin V_2 receptor; Non-peptide antagonist (Yatsu, T. (321) 225)

YM358
Angiotensin II; Angiotensin AT_1 receptor antagonist; Losartan (Shibasaki, M. (335) 167)

Angiotensin II receptor antagonist; Antihypertensive activity (Shibasaki, M. (335) 175)

YM435
Dopamine D_1 receptor agonist; Renal vasodilator; Angiotensin II; Renal nerve stimulation; PAF (platelet-activating factor) (Yatsu, T. (322) 45)

YM992
Antidepressant; 5-HT (5-hydroxytryptamine, serotonin) re-uptake inhibition; 5-HT_{2A} receptor antagonistic activity; Tail suspension test; Olfactory bulbectomized rat (Takeuchi, H. (329) 27)

YM-60828
Argatroban; Heparin; Dalteparin; Arterio–venous shunt; Bleeding time (Sato, K. (339) 141)

Zaprinast
Glutamate release; Synaptosome; Nitric oxide (NO); cGMP; Protein kinase G (Sistiaga, A. (321) 247)

Memory; Nitric oxide (NO); cGMP; Blood pressure; 7-Nitroindazole; (Rat) (Prickaerts, J. (337) 125)

Zatebradine
Tachycardia; Respiratory resistance; cAMP (Yamazaki, K. (320) 21)

Zinc protoporphyrin IX
N^G-nitro-L-arginine; Nitric oxide (NO); Nitric oxide (NO) synthase; Carbon monoxide; Heme oxygenase (Seki, T. (331) 87)

Zn^{2+}
$P2X_2$ purinoceptor; pH dependence; Neuroamine; Adenosine; Cd^{2+} (Nakazawa, K. (337) 309)

Zn^{2+} inhibition
NMDA receptor, binding; MK-801; σ Receptor; Spinal cord; (Mouse) (Kovács, K.J. (324) 117)

Zooxanthellatoxin-A
Tyrphostin 23; Mitogen-activated protein kinase; Platelet aggregation (Rho, M.-C. (319) 375)

Zucker rat
Brown fat; α_1-Adrenoceptor agonist; α_2-Adrenoceptor antagonist; Imidazoline derivative; Obesity, drug therapy (Savontaus, E. (328) 207)

Zucker (*fa/fa*) rat
BRL 35135; β_3-adrenoceptor agonism; Insulin sensitivity; Non-esterified fatty acid; Euglycaemic hyperinsulinaemic clamp (Virtanen, K.A. (332) 215)

European Journal of Pharmacology

GENERAL INSTRUCTIONS

Complete instructions are given in the 'Notice to authors' (Vol. 341, No. 1, pages v–x) or available as reprint, free on request. The 'Notice' must be followed to the letter so that papers conform to the style of the *European Journal of Pharmacology*.

The original and 3 copies, complete with 4 sets of figures and tables should be sent to:

The Editorial Office, European Journal of Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands

Tel.: (31-30) 253-8833; Fax: (31-30) 253-9033

Acceptability of rapid communications will be decided by the editors, who usually will be advised by a member of the editorial board or by one of the consultants. Full-length manuscripts, short communications and short reviews are generally submitted to two referees who are chosen for their ability to evaluate the work. Authors may request that certain referees not be chosen. Members of the editorial board will usually be called upon for advice when there is disagreement among referees or between referees and authors, or when the editors believe that the manuscript has not received adequate consideration from the referees. In order to reduce mailing costs, manuscripts will not be returned to the authors. Only the decision of the editors, together with the advise of the referees will be sent to the author(s). When authors submit a revised manuscript, they should reply to the comments of the referees, indicating which comments they have incorporated and their reasons for disregarding any suggestions considered unacceptable. Revised manuscripts should be returned in duplicate to the editorial office. A revised manuscript should be received at the editorial office not later than 5 weeks (minor revision) or 10 weeks (extensive revision) after the editorial decision was postmarked to the author(s). Revised manuscripts received later than this will be processed as a new manuscript. Handwritten additions or corrections are not acceptable. Pages affected by revision must be retyped.

The final version of the manuscript should be sent on disk (see section 1.3) to the accepting editor together with the original and a copy of a printout of the reviewed and revised manuscript (see 'Electronic manuscripts' below). Manuscripts submitted by facsimile transmission will not be considered. Manuscripts should be typewritten or printed with double spacing (at least 6 mm between lines) and with wide margins (not more than 26 lines per page). The possibility that accepted manuscripts will be processed by electronic scanning makes it essential that the typing/printing be of the highest quality. A laser-type or similar quality printer or a high-quality typewriter with a black carbon ribbon should be used to ensure proper contrast for the original. A standard, at least 12-point (0.0138 inch), type face, neither distorted nor reduced or enlarged, is to be used. Manuscripts printed with low-quality printers will be returned for retyping with an acceptable type face. Manuscripts should be written in English. Accepted manuscripts will, if necessary, have English style and language corrected. Manuscripts with extensive changes will be returned to the authors for retyping. Submission of a paper in clear, grammatical English will, therefore, shorten publication time considerably.

1. Electronic manuscripts

Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. The preferred storage medium is a $5\frac{1}{4}$ or $3\frac{1}{2}$ inch disk in MS-DOS format, although other systems are welcome, e.g., NEC and Macintosh (in this case, save your file in the usual manner, do not use the option 'save in MS-DOS format'). Please do not split the article into separate files (title page as one file, text as another, etc.). Ensure that the letter 'l' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your wordprocessor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter α). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your wordprocessor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the wordprocessor format. If your wordprocessor features the option to save files 'in flat ASCII', please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and wordprocessing package used and label the disk with your name and the name of the file on the disk. After final acceptance, your disk plus one, final, printed and exactly matching version (as a printout) should be submitted together to the accepting editor. It is important that the file on disk and the printout are identical. Both will then be forwarded by the editor to Elsevier. Further information may be obtained from the Publisher.

2. Rapid communications

(a) Reports on exciting new results within the scope of the journal can be submitted for publication in the rapid communications section.

(b) A rapid communication should not exceed 700 words and should contain no or only one simple table or figure of not more than 8.4 cm = 1 column width.

(c) A maximum of 8 references may be used.

(d) The rapid communication should be typewritten, lines double spaced, with wide margins, without any subheadings, and preferably accompanied by a floppy disk (see section 1). The manuscript should be arranged in the following order: title (not exceeding 85 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done (all on 1 page); abstract (max. 75 words) and keywords (indexing terms, max. 3 items); text; acknowledgement(s); references; figure legend and figure; table (colour figures will delay publication). Name, full postal address, telephone, fax numbers, and e-mail address of author to whom correspondence is to be sent should be mentioned on the title page.

(e) Rapid communications have priority at the editorial office and publisher.

(f) All proofreading will be done by the editorial staff of the publisher; no proofs will be sent to the author(s).

(g) Upon acceptance of a rapid communication a reprint order form will be sent to the author(s).

3. Full-length manuscripts

(a) The manuscript should be arranged as follows. First page: title (not exceeding 85 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done; name, full postal address, telephone and telefax numbers of author to whom proofs and other correspondence should be sent. Next page (2): abstract and keywords (indexing terms: normally 3–6 items). Pages 3 to end: 1. Introduction; 2. Materials and methods; 3. Results; 4. Discussion; Acknowledgements; References; figure legends and figures; tables. Both sections and their subdivisions should be numbered (2.1., 2.2., 2.3., etc.).

(b) Abstract and keywords: an abstract not exceeding 150 words and stating what was done, what was found, and what was concluded should be typed on a separate sheet. Below the abstract, type 3–6 keywords or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, keywords should be selected from *Index Medicus* or *Excerpta Medica Index*. First category keywords (e.g., Hyperphagia; G-Strophantidin; Fiber shortening) will all be listed and cross-indexed. Second category keywords (e.g., Rat, Cold, Metabolite) will only be listed under the index entry for the first category keywords. If the editors feel that keywords should be adjusted to the standards of the journal this will be done without consultation of the author(s).

(c) Standard nomenclature should be used throughout. Avoid unnecessary abbreviations and symbols (see extensive 'Notice to authors', Vol. 319, No. 1, p. v). Words at the end of a line should not be divided. Use of hyphens, capital letters, numbers written or spelled out (e.g., 8 or eight) should be consistent throughout the manuscript.

(d) Legends of illustrations and footnotes should be typed on separate sheets, lines double spaced. Footnotes, to be numbered consecutively in superscript throughout the text, should be used as little as possible.
(e) Drugs: generic names should be used. Trade names may be mentioned in parentheses the first time the name of the drug appears in the text. The form of the drug used should be indicated.

4. Short communications should be prepared as described under 3, except for the following:
(a) The average length of a short communication should not exceed 4 pages in print (approx. 2000–2300 words including abstract, captions and references). A maximum of 2 illustrations (figures and tables) is allowed.
(b) An abstract of not more than 100 words should be provided and 3–6 keywords should be listed immediately below the abstract.
(c) All proofreading will be done by the editorial staff of the publisher; no proofs will be sent to the author(s).
(d) Upon acceptance of a short communication a reprint order form will be sent to the author(s).

5. References
References in the text to literature cited should be given by the name of the author(s), followed by the year of publication in parentheses, e.g.: Downie and Larsson (1990) or (Hicks et al., 1988, 1989; Seeman et al., 1990; Stoof and Kebabian, 1991a,b,c). For three or more authors the name of the first author followed by et al. should be used. Journal names should be abbreviated according to the *List of Serial Title Word Abbreviations* (available from the International Serials Data System, 20 Rue Bachaumont, 75002 Paris, France; ISBN 2-904938-02-8). References should be listed alphabetically. Citations of the literature in the list of references should include the full title of the article referred to. Personal communications and unpublished data should not appear in the list of references. Sample references:

Periodicals:
Paivio, A., Jansen, B., Becker, L.J., 1975. Comparisons through the mind's eye. Cognition 37, 635–647.
Strunk, W., White, E.B., 1979. The Elements of Style, third ed. MacMillan, New York, NY.
Gurman, A.S., Kniskern, D.P., 1981. Family therapy outcome research: knowns and unknowns. In: Gurman, A.S., Kniskern, D.P. (Eds.), Handbook of Family Therapy. Brunner/Maazel, New York, NY, pp. 742–775.

Order of references:
De Groat, W., 1990.
Maggi, C.A., 1988.
Maggi, C.A., Lecci, A., 1987.
Maggi, C.A., Meli, A., 1986.
Maggi, C.A., Santicoli, P., Meli, A., 1984.
Maggi, C.A., Giuliani, S., Patacchini, R., Rovero, P., Giachetti, A., Meli, A., 1989a.
Maggi, C.A., Patacchini, R., Rovero, P., Giachetti, A., Meli, A., 1989b.
Maggi, C.A., Giuliani, S., Patacchini, R., Santicoli, P., Giachetti, A., Meli, A., 1990.
Monsma Jr., F.J., 1989.
Van der Giessen, A., 1990.

6. Illustrations, graphs and tables (see Notice to authors, Vol. 319, No. 1, p. v)
(a) Either the original drawings plus 3 good photographs, or 4 good photographs of the drawings (on glossy paper and unmounted) or 4 high-quality computer printouts should be submitted. Illustrations may be submitted in electronic format as well, but must always be accompanied by reproducible paper printouts. Photocopies may not be used. The photographs should be of adequate definition and contrast. The number of illustrations should be limited to the essential.
(b) It is important to allow for reduction to fit a single column, 8.4 cm wide, or at most a double column, maximally 17.6 cm wide. Illustrations, especially photomicrographs, should be submitted in their final size (single or double column). When possible, all key symbols should be explained in the figures. The following symbols can be typeset and explained (as well as all lettering) in the legends: + × ■ □ ● ▲ ▼ ◀ ▶ ○ ◇ △ ▽ ▷ ◁ ⊕ ⊗ ⊖ ⊜ ⊛ * ★. All letters and numerals appearing in a particular illustration should be of the same size (approximately 1.4–2 mm height when reduced to 8.4 cm width).
(c) Graphs, electrocardiograms and oscillograms should be prepared by a skilled photographer so that the dark, cross-hatched background is eliminated, the faint portions of the graphs intensified, and a sharp print obtained. This process may be avoided by using blue-ruled instead of black-ruled recording paper for the originals. Kymograph records on sooted paper should be reversed photographically to ensure graphs in black on a white background.
(d) Drawings of complicated chemical structures should be prepared in the same way as graphs.
(e) A calibration bar should be drawn on the micrographs instead of giving a magnification rate in the figure legend.
(f) All illustrations should be referred to as figures and numbered in Arabic numerals (Fig. 1, 2, etc.).
(g) Legends to figures should make these comprehensible without reference to the text.
(h) Tables should be numbered separately in Arabic numerals (Table 1, 2, etc.).
(i) Colour reproduction of illustrations is available at cost. Original high-quality illustrations (preferably slides) should be well protected against possible damage during shipment. Detailed information regarding the use of colour may be obtained from the publisher, at the time of submission of the manuscript to the editors.

7. Proofs
One set of galley proofs will be sent to the author named on the title page (see section 3.). Proofs will usually be drawn on lower quality paper. Only printer's errors may be corrected; no changes in, or additions to, the edited manuscript will be allowed. Proofs should be returned within 48 hours to Elsevier Science B.V., Log-in Department, P.O. Box 2759, 1000 CT Amsterdam, The Netherlands, preferably by Fax ((31-20) 485-3239). If this period is exceeded no reminders will be sent, the manuscript will be read by the editorial staff of the publisher only and printed without the author's corrections. Authors of short and rapid communications will not receive galley proofs.

8. Page charges and reprints
There will be no page charge. Authors of a full-length paper will receive, together with the galley proofs, a reprint order form with must be completed and returned to the publisher with the proofs. Authors of short and rapid communications will receive a reprinted order form but no proofs; this order form should be mailed to the publisher by return post. Reprints ordered after the journal has been printed will cost considerably more than those ordered immediately.

© 1998 Elsevier Science B.V. All rights reserved

Printed in The Netherlands *Library of Congress Catalog Card Number 68-26539* Published weekly

EUROPEAN JOURNAL OF PHARMACOLOGY

Master Author and Keyword Indexes, Volumes 317–339, 1997

Cited in: Biological Abstracts – Chemical Abstracts – Current Contents/Life Sciences – Excerpta Medica (EMBASE) – Index Medicus – Pascal M – Reference Update – Unlisted Drugs – Current Awareness in Biological Sciences (CABS)

CONTENTS

Master author index to volumes 317–339 (1997) 1

Master keyword index to volumes 317–339 (1997) 47